

Title Page

Protocol Title:

A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects with Chronic Hepatitis B Infection

Short Title: Open-Label Study of AB-729, Nucleos(t)ide Analogue and Pegylated Interferon Alfa-2a in Subjects with Chronic Hepatitis B Infection

Protocol Number:

AB-729-201

Compound Number:

AB-729

Sponsor Name and Legal Registered Address:

at bottom of this page

Regulatory Agency Identifying Number(s):

US IND number: 155503


Approval Date of Protocol, Version 3.0: 17 June 2022



701 Veterans Circle
Warminster, PA 18974
Tel: 267-469-0914 Fax: 267-282-0411

The information contained in this document is confidential to Arbutus Biopharma Corporation and is not to be copied, disclosed, or otherwise distributed to any third party without the prior written consent of Arbutus Biopharma Corporation.

Sponsor Approval Signatures



June 17, 2022

Name: Gaston Picchio, PhD
Title: Chief Development Officer
Arbutus Biopharma Corporation

Date



June 17, 2022

Name: Karen Sims, MD, PhD
Title: Vice President, Clinical Development
Arbutus Biopharma Corporation

Date

Medical Monitor Name and Contact Information

Karen Sims, MD, PhD
Vice President, Clinical Development
Arbutus Biopharma Corporation
Mobile: 215-806-1962
ksims@arbutusbio.com

Table of Contents

Sponsor Approval Signatures	2
List of Figures.....	6
1. PROTOCOL SUMMARY.....	7
1.1. Synopsis	7
1.2. Schema.....	11
1.3. Schedule of Activities	12
2. INTRODUCTION.....	27
2.1. Background	27
2.2. Study Rationale	27
2.3. Benefit/Risk Assessment	29
3. OBJECTIVES AND ENDPOINTS.....	32
4. STUDY DESIGN.....	35
4.1. Overall Design	35
4.1.1. Number of Subjects	35
4.1.2. Treatment Groups and Duration.....	36
4.1.3. Data Monitoring Committee	36
4.2. Scientific Rationale for Study Design.....	36
4.3. Justification for Dose	38
4.4. Nucleos(t)ide Discontinuation Criteria	38
4.5. End of Study Definition	39
5. STUDY POPULATION.....	40
5.1. Inclusion Criteria	40
5.2. Exclusion Criteria	41
5.3. Lifestyle Considerations	44
5.3.1. Meals and Dietary Restrictions	44
5.3.2. Alcohol and Tobacco.....	44
5.3.3. Activity	44
5.4. Screen Failures.....	44
6. STUDY TREATMENT	46
6.1. Study Treatment(s) Administered.....	46
6.2. Preparation/Handling/Storage/Accountability	47
6.3. Measures to Minimize Bias: Randomization and Blinding	47
6.4. Study Treatment Compliance	48
6.5. Concomitant Therapy.....	48
6.5.1. Prohibited Medications.....	49
6.6. Dose Modification	50
6.6.1. AB-729	50

6.6.2. Peg-IFN α -2a	50
6.7. Intervention after the End of the Study	51
7. STUDY TREATMENT DISCONTINUATION AND SUBJECT DISCONTINUATION/WITHDRAWAL	52
7.1. Discontinuation of Study Treatment for Individual Subjects	52
7.2. Study Discontinuation Criteria	53
7.3. Procedures for Subject Discontinuation or Withdrawal from the Study	53
7.4. Lost to Follow-up.....	54
7.5. Replacement of Subjects.....	54
8. STUDY ASSESSMENTS AND PROCEDURES	55
8.1. Screening Assessments	55
8.2. Genetics.....	56
8.3. Immune Biomarkers.....	56
8.4. Pharmacodynamic and Virologic Assessments	56
8.5. Safety Assessments.....	57
8.5.1. Physical Examinations	57
8.5.2. Vital Signs	57
8.5.3. Electrocardiograms.....	57
8.5.4. Pregnancy Testing	57
8.5.5. Clinical Safety Laboratory Assessments	58
8.6. ALT Elevation Management.....	59
8.7. Adverse Events and Serious Adverse Events	60
8.7.1. Time Period and Frequency for Collecting AE and SAE Information	60
8.7.2. Method of Detecting AEs and SAEs	61
8.7.3. Follow-up of AEs and SAEs	61
8.7.4. Regulatory Reporting Requirements for SAEs	61
8.7.5. Pregnancy	62
8.8. Treatment of Overdose	62
8.9. Pharmacokinetic Assessments	63
8.10. Use of Residual Samples for Optional Future Research.....	63
8.11. Medical Resource Utilization and Health Economics	64
9. STATISTICAL CONSIDERATIONS.....	65
9.1. Statistical Hypotheses	65
9.2. Sample Size Determination.....	65
9.3. Populations for Analyses	65
9.4. Statistical Analyses	66
9.4.1. Safety Analyses	66
9.4.2. Immune Biomarkers	67

9.4.3. Pharmacodynamic and Efficacy Analyses	67
9.4.4. Pharmacokinetic Analyses	68
9.5. Interim Analyses	69
10. REFERENCES.....	70
11. APPENDICES FOR SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS	73
Appendix 1 Abbreviations and Trademarks	74
Appendix 2 Regulatory, Ethical, and Study Oversight Considerations.....	76
Appendix 3 Contraceptive Guidance and Collection of Pregnancy Information	80
Appendix 4 Clinical Laboratory Tests	85
Appendix 5 Immune and Inflammatory Genes for Pharmacogenomic Testing	88
Appendix 6 Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting.....	283
Appendix 7 Pharmacokinetic Sampling for AB-729 in Study AB-729-201	290
Appendix 8 Schedule of Activities for Early Termination (Lead-in Period only).....	291
Appendix 9 NA Retreatment Criteria and Follow up Schedule of Activities.....	293
Appendix 10 Resistance Monitoring Plan.....	295
Appendix 11 Protocol Amendment History	342
INVESTIGATOR SIGNATURE PAGE.....	352

List of Tables

Table 1. Schedule of Activities for 24 Week Lead-In Treatment Period (All Subjects)	12
Table 2. Schedule of Activities for Cohort A: Consolidation Treatment Period and NA-only Post-Treatment Follow-Up Periods 1 and 2.....	16
Table 3. Schedule of Activities for Cohort A: NA-Discontinuation Period (For Subjects who Qualify)	19
Table 4. Schedule of Activities for Cohort B: Consolidation Treatment Period and NA-only Post-Treatment Follow-Up Periods 1 and 2.....	21
Table 5. Schedule of Activities for Cohort B: NA-Discontinuation Period (For Subjects who Qualify)	25
Table 6. Tabular Summary of Study Treatment(s)	46
Table 7. Hematologic Adverse Reactions and Dose Adjustments for Peg-IFN α -2a.....	50
Table 8. ALT Elevations and Dose Adjustments for Peg-IFN α -2a	51
Table 9. Populations for Analysis	66
Table 10. Pharmacokinetic Parameters for AB-729	68
Table 11. Highly Effective Contraceptive Methods	82
Table 12. Protocol-Required Laboratory Assessments.....	86
Table 13. Schedule of Activities for Early Termination (Lead-in Period only)	291

Table 14. Schedule of Activities for Subjects who Restart NA Therapy	293
Table 15. Virological Assessments	296
Table 16. HBV Genotype Reference Sequences for Read Mapping	299

List of Figures

Figure 1. Schematic of Study AB-729-201	11
Figure 2. Mean (\pm SE) $\Delta\log_{10}$ HBsAg with Repeat Dosing of AB-729 in Virologically-Suppressed CHB Subjects.....	37
Figure 3. Overview of Bioinformatics Sequence Analysis Approach	298

1. PROTOCOL SUMMARY

1.1. Synopsis

Protocol Title: A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects with Chronic Hepatitis B Infection

Short Title: Open-Label Study of AB-729, Nucleos(t)ide Analogue and Pegylated Interferon Alfa-2a in Subjects with Chronic Hepatitis B Infection

Rationale:

AB-729 is a potent, selective, subcutaneously (SC) administered, *N*-Acetylgalactosamine (GalNAc) conjugated small interfering ribonucleic acid (siRNA) inhibitor of hepatitis B virus (HBV) that cleaves and degrades HBV RNA, resulting in downstream silencing of viral proteins, DNA replication and virion production. Development of therapeutic agents that target HBV protein expression, particularly HBV surface antigen (HBsAg), may provide a valuable addition to current approved therapies (nucleos[t]ide analogues [NA] and pegylated interferon alfa [Peg-IFN α]) and possibly increase current HBV cure rates. In an ongoing phase 1 study, AB-729 has been administered as either single or repeat doses to over 40 chronic hepatitis B (CHB) subjects on stable NA therapy. After a single dose of AB-729 60 mg, the mean HBsAg decline at Week 12 was $\sim 1.0 \log_{10}$ IU/mL (N=6), similar to the decline observed at Week 12 in subjects receiving repeat doses of AB-729 60 mg every 4 weeks (N=7) or every 8 weeks (N=7). However, subjects receiving AB-729 60 mg every 4 weeks or every 8 weeks continued to experience reductions in HBsAg beyond Week 12, with mean maximum $\Delta \log_{10}$ HBsAg of $-1.9 \log_{10}$ IU/mL and $-1.8 \log_{10}$ IU/mL, respectively. Furthermore, 10 of 14 subjects receiving AB-729 60 mg with either dosing interval have achieved HBsAg < 100 IU/mL (2 of whom reached < 10 IU/mL) to date, with treatment ongoing in both groups.

Recent data using a more sensitive HBV DNA assay suggest that ongoing viral replication occurs even in the context of stable NA use, which may continue to place patients at risk for liver-related morbidity and mortality. Current longitudinal data regarding the likelihood of achieving functional cure (defined as sustained HBV DNA suppression and HBsAg loss with or without hepatitis B surface antibody [HBsAb] seroconversion that is maintained > 6 months after discontinuation of antiviral therapy) in subjects who are receiving standard of care (SOC) therapy (NA or Peg-IFN α) suggests that the rate is quite low: $< 3\%$ for NA-treated subjects and $< 7\%$ for Peg-IFN α monotherapy after 48 weeks of therapy. Given the ongoing unmet medical need for novel therapeutic combinations to induce functional cure, this study will assess the safety and antiviral efficacy of the addition of AB-729 to ongoing SOC NA therapy in HBV DNA suppressed, hepatitis B virus e-antigen (HBeAg) negative, non-cirrhotic CHB subjects for 24 weeks to reduce HBsAg levels, followed by addition of Peg-IFN α -2a with or without continued AB-729 treatment for either 12 or 24 weeks as consolidation therapy to further decrease HBsAg levels and promote anti-HBV immune reawakening. Subjects will remain on NA therapy during the initial 24-week follow up period, and then may be eligible to discontinue NA treatment if stopping criteria are met. Upon NA discontinuation, the subject will enter a more intensive follow-up period for 48 weeks to monitor for potential rebound of viral markers

and safety events, as well as for sustained viral response and HBsAg loss. Subjects who remain on NA therapy will be followed for an additional 24 weeks (48 weeks total post-end of treatment).

Objectives and Endpoints

Primary Objective

The primary objective of the study is as follows:

Objective	Endpoint
<ul style="list-style-type: none"> To evaluate the safety and tolerability of AB-729 plus Peg-IFNα-2a in subjects with NA-suppressed CHB infection 	<ul style="list-style-type: none"> The frequency and severity of treatment emergent adverse events (TEAEs), discontinuations due to adverse events (AEs), and laboratory abnormalities after dosing with AB-729 plus Peg-IFNα-2a

Secondary Objectives

The secondary objectives of the study are as follows:

Objectives	Endpoints
Secondary	
<ul style="list-style-type: none"> To evaluate changes in HBsAg concentration and other virologic parameters during and following repeat doses of AB-729 plus Peg-IFNα-2a 	<ul style="list-style-type: none"> Change from baseline in HBsAg, HBV DNA, HBV RNA, HBsAb, hepatitis B virus e-antibody (HBeAb) and hepatitis B virus core-related antigen (HBcrAg) concentration at each timepoint Proportion of subjects with a change in HBsAg from baseline meeting response criteria (≥ 0.5, 1, 2, or 3 log₁₀ reduction; \leq lower limit of quantitation [LLOQ] or target not detected [TND]) Proportion of subjects with a change in HBV RNA from baseline meeting response criteria (≥ 0.5, 1, 2, or 3 log₁₀ reduction; \leq LLOQ or TND) Proportion of subjects with a change in HBcrAg from baseline meeting response criteria (≥ 0.5, 1, 2, or 3 log₁₀ reduction; \leq LLOQ or TND)
<ul style="list-style-type: none"> To evaluate the proportion of subjects with HBsAb seroconversion 	<ul style="list-style-type: none"> Proportion of subjects with HBsAb seroconversion at each timepoint

Objectives	Endpoints
Secondary	
<ul style="list-style-type: none"> To evaluate the proportion of subjects who meet NA therapy discontinuation criteria 	<ul style="list-style-type: none"> Proportion of subjects who are eligible to stop NA after Week 24 of follow up
<ul style="list-style-type: none"> To evaluate the proportion of subjects who discontinue NA therapy and subsequently restart NA therapy during the follow-up period 	<ul style="list-style-type: none"> Proportion of subjects who discontinue NA and subsequently restart NA therapy after meeting criteria
<ul style="list-style-type: none"> To evaluate the proportion of subjects who experience clinical and/or viral relapse in the follow-up period after discontinuing NA therapy 	<ul style="list-style-type: none"> Proportion of subjects who discontinue NA and subsequently meet protocol-defined clinical relapse criteria Proportion of subjects who discontinue NA and subsequently meet protocol-defined viral relapse criteria Proportion of subjects who have HBV DNA <LLOQ at each timepoint after discontinuation of NA therapy Proportion of subjects who have HBsAg <100 IU/mL or <10 IU/mL at each timepoint after discontinuation of NA therapy
<ul style="list-style-type: none"> To evaluate plasma concentrations of AB-729 	<ul style="list-style-type: none"> Post-dose plasma concentrations of AB-729 anti-sense (AS), AB-729 AS(N-1)3', and AB-729 AS(N-2)3' at selected timepoints

Overall Design:

This is a randomized, open label, multicenter Phase 2 study investigating the safety and antiviral activity of AB-729 in combination with ongoing NA therapy and short courses of Peg-IFN α -2a in subjects with CHB.

The study will enroll 40 stably NA-suppressed, HBeAg negative, non-cirrhotic CHB subjects. After a 24-week lead-in period of AB-729 60 mg SC every 8 weeks (Q8W) added to ongoing SOC NA, subjects will be randomized into one of 4 groups:

- A1: AB-729 + NA + weekly Peg-IFN α -2a for 24 weeks (N = 12)
- A2: NA + weekly Peg-IFN α -2a for 24 weeks (N = 12)
- B1: AB-729 + NA + weekly Peg-IFN α -2a for 12 weeks (N = 8)
- B2: NA + weekly Peg-IFN α -2a for 12 weeks (N = 8)

Treatment assignment will be stratified by HBsAg level at Week 24 (HBsAg \leq 100 IU/mL vs >100 IU/mL).

After completion of the assigned Peg-IFN α -2a treatment period, all subjects will remain on NA therapy for the initial 24-week follow up period, and then will discontinue NA treatment if the following criteria are met:

- Alanine aminotransferase (ALT) $<2 \times$ upper limit normal (ULN), and
- Undetectable HBV DNA, and
- At least one of the following:
 - HBsAg undetectable (via conventional assay) for at least 24 weeks after the last dose of AB-729
 - HBsAg <100 IU/mL at two consecutive visits at least 24 weeks after the last dose of AB-729
 - HBsAb positive for at least 24 weeks after the last dose of AB-729

If subjects stop NA therapy, they will enter a more intensive follow-up period for 48 weeks to monitor for potential rebound of viral markers and safety events as well as for sustained viral response and HBsAg loss. Subjects who remain on NA therapy will be followed for an additional 24 weeks.

Number of Subjects:

Approximately 80 subjects will be screened to achieve approximately 40 dosed subjects.

Safety Review Committee:

Safety will be continuously monitored by the Investigator, Sponsor's Medical Monitor, and study personnel.

A Data Monitoring Committee (DMC) will periodically review safety data from this study. The DMC will be a group of 3 independent members who will operate in accordance with a pre-specified charter and make recommendations to the Sponsor.

Treatment Groups and Duration:

All subjects will continue their ongoing SOC NA (either entecavir [ETV], tenofovir disoproxil fumarate [TDF] or equivalent, or tenofovir alafenamide [TAF]) and receive AB-729 60 mg SC Q8W (4 doses) for 24 weeks. Subjects will then be randomized into one of 4 groups:

- A1: AB-729 60 mg SC Q8 weeks (2 doses) + NA + Peg-IFN α -2a 180 mcg SC every week (QW) for 24 weeks (N = 12)
- A2: NA + Peg-IFN α -2a 180 mcg SC QW for 24 weeks (N = 12)
- B1: AB-729 60 mg SC Q8 weeks (1 dose) + NA + Peg-IFN α -2a 180 mcg SC QW for 12 weeks (N = 8)
- B2: NA + Peg-IFN α -2a 180 mcg SC QW for 12 weeks (N = 8)

Treatment assignment will be stratified by HBsAg level at Week 24 (HBsAg ≤ 100 IU/mL vs >100 IU/mL).


The study will be conducted for approximately 130 weeks as follows:

- The Screening Visit will occur within 45 days prior to the first dose of AB-729.
- Dose 1 of AB-729 will be administered on Day 1 and subjects will be confined to the clinic for a minimum of 6 hours on Day 1 for pharmacokinetic (PK) assessments.
- All subjects will return to the clinic for monthly visits through Week 24 (6 visits) as shown in [Table 1](#).
 - During the Week 24 visit, subjects will be confined to the clinic for a minimum of 6 hours for PK assessments.
- Subjects randomized to Cohorts A1 and A2 will have between 19 (through Week 100) and 32 (through Week 124) visits depending on whether they qualify for NA discontinuation. See [Table 2](#) and [Table 3](#) for details.
- Subjects randomized to Cohorts B1 and B2 will have between 16 (through Week 88) and 29 (through Week 112) visits depending on whether they qualify for NA discontinuation. See [Table 4](#) and [Table 5](#) for details.

1.2. Schema

The study design is represented schematically in [Figure 1](#).

Figure 1. Schematic of Study AB-729-201



Abbreviations: HBeAg- = hepatitis B virus e-antigen negative; IFN = interferon; NA = nucleos(t)ide analogue; Q8 = every 8.

1.3. Schedule of Activities

Table 1 summarizes the schedule of study-related activities for the 24 Week Lead-In Treatment period for all subjects; Table 2 is the Cohort A Consolidation Treatment period and NA-only Post-Treatment follow up (Periods 1 and 2); Table 3 is the Cohort A NA-discontinuation period (for subjects who qualify). Table 4 is the Cohort B Consolidation Treatment period and NA-only Post-Treatment follow-up (Periods 1 and 2), and Table 5 is the Cohort B NA-discontinuation period (for subjects who qualify).

All laboratory assessments including clinical laboratory tests (safety assessments), virology, biomarker and PBMC collections should be drawn pre-dose (AB-729 or Peg-IFN α -2a) when applicable. Additional details of the various laboratory tests are found in Appendix 4 Clinical Laboratory Tests, and Section 8.

Table 1. Schedule of Activities for 24 Week Lead-In Treatment Period (All Subjects)

Assessment	Screening Day -45 to Day -1 ^a	Lead-In Treatment Period ^{b,d}								Notes
		Baseline Day 1	Week 4	Week 8	Week 12	Week 16	Week 20	Week 24	Early Termination	
Written informed consent	X									
Review inclusion/exclusion criteria	X	X								
Demographics	X									
Height and BMI	X									
Weight	X									
Medical and medication history	X	X								
Concomitant medications	X	X	X	X	X	X	X	X	X	
Eye examination	X									Subjects must provide documentation of an eye examination including a retinal evaluation within 6 months prior to Day 1.
Physical examination	X	X	X	X	X	X	X	X	X	Complete PEs will be conducted at SCR> From Day 1, targeted PEs may be completed at any study visit based on any reported changes to the subject's health.
Vital signs	X	X	X	X	X	X	X	X	X	BP, HR, RR, and temp to be performed pre-dose, when applicable.

Assessment	Screening Day -45 to Day -1 ^a	Lead-In Treatment Period ^{b,d}								Notes
		Baseline Day 1	Week 4	Week 8	Week 12	Week 16	Week 20	Week 24	Early Termination	
ECG	X	X			X			X	X	Will be performed pre-dose, when applicable.
Clinical laboratory tests	X	X	X	X	X	X	X	X	X	Includes clinical chemistry (including fasting plasma glucose), hematology, coagulation tests, serology, and urine as specified in Appendix 4 , and are to be completed after an overnight fast of ≥ 8 hrs.
HbA1C	X									
TSH/Free T4	X									
AFP	X									
ANA, ASMA, anti-LKM1 serology	X									
Pregnancy test (females only)	X	X	X	X	X	X	X	X	X	Urine pregnancy test is required at SCR for all female subjects, and at subsequent study visits for WOCBP only. If the urine test is positive or not interpretable, a serum/plasma pregnancy test is to be conducted.
FSH (post-menopausal females only)	X									
Fibroscan [®]	X									Is only required if results from a previous study performed within 6 mos of Day 1 are not available. For subjects who do not have a Fibroscan [®] result, a prior liver biopsy (performed within 12 mos of Day 1) may be used to determine noncirrhotic status for the purposes of determining eligibility.
Liver ultrasound	X									Is only required if results from a previous study performed within 6 mos of Day 1 are not available.
HIV, HCV, HDV antibody	X									Positive antibody tests may reflex to a confirmatory PCR test.
Qualitative HBcAb IgM	X									
Qualitative HBeAg	X	X			X			X	X	
Quantitative HBsAg ^c	X	X	X	X	X	X	X	X	X	

Assessment	Screening Day -45 to Day -1 ^a	Lead-In Treatment Period ^{b,d}								Notes
		Baseline Day 1	Week 4	Week 8	Week 12	Week 16	Week 20	Week 24	Early Termination	
HBsAg Ultrasensitive ^c	X	X	X	X	X	X	X	X	X	To be assessed only if quantitative HBsAg result is <LLOQ
Quantitative HBsAb ^c		X			X			X	X	
Quantitative HBV DNA ^c	X	X	X	X	X	X	X	X	X	
Quantitative HBV RNA ^c		X	X	X	X	X	X	X	X	
Quantitative HBcrAg ^c		X	X	X	X	X	X	X	X	
Quantitative HBeAg ^c		X			X			X	X	To be assessed only if positive result obtained with HBeAg qualitative test
Qualitative HBeAb ^c		X			X			X	X	
HBsAg isoforms ^c		X	X	X	X	X	X	X	X	
HBsAg immune complex ^c		X			X			X	X	
Resistance Sample ^c	X	X	X	X	X	X	X	X	X	
HBV Genotype Sample		X								
IL28B GT		X								
Exploratory Immune genes SNP Sample		X								Will be stored and analyzed only if a non-response in HBsAg is observed.
miRNAs ^c		X			X			X	X	Will be stored and analyzed only if a HBsAg effect is observed
RNAi PD marker ^c		X	X	X	X	X	X	X	X	
Immune biomarker/cytokines sample ^c		X		X		X		X	X	Unscheduled samples will be collected in the event of any unexpected safety finding.
PBMCs ^c		X		X		X		X	X	Unscheduled samples will be collected in the event of any unexpected safety finding.
Randomization								X		Subjects will be randomized at the Week 24 visit into Cohort A (A1 or A2) or Cohort B (B1 or B1).
Drug dispensing/ accountability		X	X	X	X	X	X	X	X	Subjects will record all NA doses in a dosing diary, which will be reviewed at each study visit.
AB-729 dosing		X		X		X		X		Doses administered in the clinic only.

Assessment	Screening Day -45 to Day -1 ^a	Lead-In Treatment Period ^{b,d}								Notes
		Baseline Day 1	Week 4	Week 8	Week 12	Week 16	Week 20	Week 24	Early Termination	
Record AEs		X	X	X	X	X	X	X	X	Will be collected from the time of the start of study treatment through the last Post-Treatment F/U visit.
Record SAEs	X	X	X	X	X	X	X	X	X	Will be collected from the signing of the ICF through the last Post-Treatment F/U visit and followed until resolution of any event.
AB-729 PK sampling		X						X		Will be collected on Day 1 and at Week 24 according to the schedule provided in Appendix 7 . On PK collection days, subjects will remain in the clinic a minimum of 6 hours post-dose.

Abbreviations: AEs = adverse events; AFP = alpha-fetoprotein; BMI = body mass index; ANA = antinuclear antibody; anti-LKM1 = liver/kidney microsomal antibody type 1; ASMA = anti-smooth muscle antibody; BP = blood pressure; ECG = electrocardiogram; FSH = follicle stimulating hormone; F/U = follow up; HBcAb = hepatitis B core-related antibody; HBcrAg = hepatitis B virus core-related antigen; HBeAb = hepatitis B virus e-antibody; HBeAg = hepatitis B virus e-antigen; HBsAb = hepatitis B virus surface antibody; HBsAg = hepatitis B virus surface antigen; HBV = hepatitis B virus; HCV = hepatitis C virus; HDV = hepatitis D virus; HbA1C = hemoglobin A1C; HIV = human immunodeficiency virus; HR = heart rate; hrs = hours; ICF = informed consent form; IgM = immunoglobulin M; IL28B GT = interleukin 28B genotype; LFTs = liver function tests; miRNAs = micro RNAs; mos = months; NA = nucleos(t)ide analogue; PBMCs = peripheral blood mononuclear cells; PCR = polymerase chain reaction; PD = pharmacodynamic; PE = physical exam; PK = pharmacokinetic; RNAi = RNA interference; RR = respiration rate; SAE = serious adverse event; SCR = screening; SNP = single nucleotide polymorphism; temp = temperature; TSH = thyroid stimulating hormone; T4 = thyroxine; WOCBP = women of childbearing potential.

- a. If the Screening Visit is >45 days from Day 1 (up to a maximum of 60 days from Day 1), only the safety screening labs (hematology, chemistry including LFTs, and coagulation parameters) need be repeated for the subject to enroll.
- b. Visit windows are \pm 5 days.
- c. Samples are to be drawn pre-dose where applicable.
- d. If a subject discontinues on or before Week 28 (prior to peg-IFN α -2a treatment), they should complete an Early Termination visit. If they agree to remain in follow-up they should follow the schedule of activities for Early Termination (Lead-in Period only) [Table 13](#).

Table 2. Schedule of Activities for Cohort A: Consolidation Treatment Period and NA-only Post-Treatment Follow-Up Periods 1 and 2

Cohort A							
Assessment	Consolidation Treatment Period		Post-Treatment Follow-Up (NA only) Period 1		Post-Treatment Follow-Up (NA only) Period 2 ^c	Early Termination ^e	Notes
	Weeks 28, 30, 32, 34, 36, 38 ^a	Weeks 40, 44, 48, 52 ^b	Weeks 56, 60, 64, 68, 72 ^b	Weeks 75 and 76 ^a	Weeks 88 and 100 (EOS)		
Concomitant medications	X	X	X	X	X	X	
Physical examination	X	X	X	X	X	X	Targeted PEs may be completed at any study visit based on any reported changes to the subject's health.
Vital signs	X	X	X	X	X	X	BP, HR, RR, and temp to be performed pre-dose, when applicable.
ECG	X	X	X	X	X	X	Will be performed pre-dose, when applicable.
Clinical laboratory tests ^d	X*	X*	X*	X	X	X	Includes clinical chemistry, hematology, coagulation tests, serology, and urine as specified in Appendix 4 , and are to be completed after an overnight fast of ≥8 hrs. *TSH to be drawn only at selected visits (Weeks 28, 40, 52 and 64).
Pregnancy test (WOCBP only)	X*	X	X	X**	X	X	Urine pregnancy tests will be collected as indicated. If the urine test is positive or not interpretable, a serum/plasma pregnancy test is to be conducted. *Samples to be collected at Weeks 28, 32, 36. **Sample to be collected at Week 76.
Quantitative HBsAg ^d	X	X	X	X	X	X	
HBsAg Ultrasensitive ^d	X	X	X	X	X	X	To be assessed only if quantitative HBsAg result is <LLOQ
Quantitative HBsAb ^d	X	X	X	X	X	X	Samples to be collected at Weeks 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 72, 76, 88, 100.
Quantitative HBV DNA ^d	X	X	X	X	X	X	
Quantitative HBV RNA ^d	X	X	X	X	X	X	
Quantitative HBcrAg ^d	X	X	X	X	X	X	
Qualitative HBeAg ^d	X	X	X	X	X	X	Samples to be collected at Weeks 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 72, 76, 88, 100.

Cohort A							
Assessment	Consolidation Treatment Period		Post-Treatment Follow-Up (NA only) Period 1		Post-Treatment Follow-Up (NA only) Period 2 ^c	Early Termination ^e	Notes
	Weeks 28, 30, 32, 34, 36, 38 ^a	Weeks 40, 44, 48, 52 ^b	Weeks 56, 60, 64, 68, 72 ^b	Weeks 75 and 76 ^a	Weeks 88 and 100 (EOS)		
Quantitative HBeAg ^d	X	X	X	X	X	X	Samples to be collected at Weeks 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 72, 76, 88, 100. To be assessed only if positive result obtained with HBeAg qualitative test.
Qualitative HBeAb ^d	X	X	X	X	X	X	Samples to be collected at Weeks 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 72, 76, 88, 100.
HBsAg isoforms ^d	X	X	X	X	X	X	
HBsAg immune complex ^d	X	X	X	X	X	X	Samples to be collected at Weeks 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 72, 76, 88, 100.
Resistance Sample ^d	X	X	X	X	X	X	
miRNAs ^d	X	X	X	X	X	X	Will be stored and analyzed only if a HBsAg effect is observed. Samples to be collected at Weeks 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 72, 76, 88, 100.
RNAi PD marker ^d	X	X	X	X	X	X	
Immune biomarker/cytokines sample ^d	X*	X	X**	X***	X	X	Unscheduled samples will be collected in the event of any unexpected safety finding. *Collected at Week 28, 32 and 36. **Collected at Week 56, 60, 64, and 72. ***Collected at Week 76 only.
PBMCs ^d	X*	X	X**	X***	X	X	. Unscheduled samples will be collected in the event of any unexpected safety finding. * Collected at Week 28, 32 and 36. ** Collected at Week 56, 60, 64, and 72. ***Collected at Week 76 only.
Drug dispensing/accountability	X	X	X	X	X	X	Subjects will record all doses in a dosing diary, which will be reviewed at each study visit.
AB-729 dosing in the clinic (Cohort A1 only)	X	X					Weeks 32 and 40 only.

Cohort A							
Assessment	Consolidation Treatment Period		Post-Treatment Follow-Up (NA only) Period 1		Post-Treatment Follow-Up (NA only) Period 2 ^c	Early Termination ^e	Notes
	Weeks 28, 30, 32, 34, 36, 38 ^a	Weeks 40, 44, 48, 52 ^b	Weeks 56, 60, 64, 68, 72 ^b	Weeks 75 and 76 ^a	Weeks 88 and 100 (EOS)		
Peg-IFN α -2a dosing	X	X					First Peg-IFN α -2a dose to be administered in the clinic at Week 28 visit, and Peg-IFN α -2a administration will occur in the clinic on visit days. Remainder of Peg-IFN α -2a doses (odd numbered Weeks and Weeks 42, 46 and 50) to be self-administered with last dose at Week 51. Subjects will record all Peg-IFN α -2a doses in a dosing diary, which will be reviewed at each study visit.
Record AEs	X	X	X	X	X	X	Will be collected from the time of the start of study treatment through the last Post-Treatment F/U visit.
Record SAEs	X	X	X	X	X	X	Will be collected from the signing of the ICF through the last Post-Treatment F/U visit and followed until resolution of any event.
AB-729 PK sampling	X	X					Will be collected at Week 32 and Week 40 for Group A1 only according to the schedule provided in Appendix 7 . On PK collection days, subjects will remain in the clinic a minimum of 6 hrs post-dose.

Abbreviations: AEs = adverse events; BP = blood pressure; ECG = electrocardiogram; EOS = end of study; ET = Early Termination; F/U = follow up; HBcrAg = hepatitis B virus core-related antigen; HBeAb = hepatitis B virus e-antibody; HBeAg = hepatitis B virus e-antigen; HBsAb = hepatitis B virus surface antibody; HBsAg = hepatitis B virus surface antigen; HBV = hepatitis B virus; HR = heart rate; hrs = hours; ICF = informed consent form; miRNAs = micro RNAs; NA = nucleos(t)ide analogue; RNAi = RNA interference; PBMCs = peripheral blood mononuclear cells; Peg-IFN α -2a = pegylated interferon α -2a; PD = pharmacodynamic; PE = physical exam; PK = pharmacokinetic; RR = respiration rate; SAE = serious adverse event; temp = temperature; WOCBP = women of childbearing potential.

- Visit windows are \pm 3 days.
- Visit windows are \pm 5 days.
- Visit windows are \pm 7 days.
- Samples are to be drawn pre-dose where applicable.
- If a subject discontinues between Week 28 and 52, they should complete an Early Termination visit. If they agree to remain in follow-up they should enter the Post-Treatment FU (NA only) Periods 1 and 2 within 4 weeks of the ET visit. The subject may skip the Week 75 visit as they will not be eligible for NA discontinuation.

Table 3. Schedule of Activities for Cohort A: NA-Discontinuation Period (For Subjects who Qualify)

Assessment	Cohort A NA-Discontinuation Period ^a		Notes
	Weeks 78, 80, 82, 84, 86, 88 ^b	Weeks 92, 96, 100, 104, 108, 112, 116, 120, 124 (EOS) ^c	
Concomitant medications	X	X	
Physical examination	X	X	Targeted PEs may be completed at any study visit based on any reported changes to the subject's health.
Vital signs	X	X	BP, HR, RR, and temperature.
ECG	X	X	
Clinical laboratory tests	X	X	Includes clinical chemistry, hematology, coagulation tests, serology, and urine as specified in Appendix 4 , and are to be completed after an overnight fast of ≥8 hrs .
Pregnancy test (WOCBP only)	X*	X	Urine pregnancy tests will be collected as indicated. If the urine test is positive or not interpretable, a serum/plasma pregnancy test is to be conducted. *Samples to be collected at Weeks 80, 84, and 88.
Quantitative HBsAg	X	X	
HBsAg Ultrasensitive	X	X	To be assessed only if quantitative HBsAg result is <LLOQ
Quantitative HBsAb	X	X	Samples to be collected at Weeks 80, 84, 88, 92, 100, 112, 124.
Quantitative HBV DNA	X	X	
Quantitative HBV RNA	X	X	
Quantitative HBcrAg	X	X	
Qualitative HBeAg	X	X	
Quantitative HBeAg	X	X	To be assessed only if positive result obtained with HBeAg qualitative test.
Qualitative HBeAb	X	X	Samples to be collected at Weeks 80, 84, 88, 92, 100, 112, 124.
HBsAg isoforms	X	X	
HBsAg immune complex	X	X	Samples to be collected at Weeks 80, 84, 88, 92, 100, 112, 124.
Resistance Sample	X	X	
miRNAs	X	X	Will be stored and analyzed only if a HBsAg effect is observed. Samples to be collected at Weeks 80, 84, 88, 92, 100, 112, 124.

Assessment	Cohort A NA-Discontinuation Period ^a		Notes
	Weeks 78, 80, 82, 84, 86, 88 ^b	Weeks 92, 96, 100, 104, 108, 112, 116, 120, 124 (EOS) ^c	
RNAi PD marker	X	X	
Immune biomarker/cytokines sample	X*	X**	Unscheduled samples will be collected in the event of any unexpected safety finding. *Collected at Weeks 80, 84, and 88. **Collected at Weeks 92, 100, 112, and 124.
PBMCs	X*	X**	Unscheduled samples will be collected in the event of any unexpected safety finding. *Collected at Weeks 80, 84, and 88. **Collected at Weeks 92, 100, 112, and 124.
Record AEs	X	X	Will be collected from the time of the start of study treatment through the last Post-Treatment F/U visit.
Record SAEs	X	X	Will be collected from the signing of the ICF through the last Post-Treatment F/U visit and followed until resolution of any event.

Abbreviations: AEs = adverse events; BP = blood pressure; ECG = electrocardiogram; EOS = end of study; F/U = follow up; HBcrAg = hepatitis B virus core-related antigen; HBeAb = hepatitis B virus e-antibody; HBeAg = hepatitis B virus e-antigen; HBsAb = hepatitis B virus surface antibody; HBsAg = hepatitis B virus surface antigen; HBV = hepatitis B virus; HR = heart rate; hrs = hours; ICF = informed consent form; miRNAs = micro RNAs; NA = nucleos(t)ide analogue; PBMCs = peripheral blood mononuclear cells; PD = pharmacodynamic; PE = physical exam; PK = pharmacokinetic; RNAi = RNA interference; RR = respiration rate; SAE = serious adverse event; temp = temperature.

- Subjects who Early Terminate during this period should discuss restarting NA therapy and entering the NA Restart Follow-Up period (Table 14) or discuss alternative follow-up plans with the study Investigator.
- Visit windows are ± 3 days.
- Visit windows are ± 5 days.

Table 4. Schedule of Activities for Cohort B: Consolidation Treatment Period and NA-only Post-Treatment Follow-Up Periods 1 and 2

Cohort B						
Assessment	Consolidation Treatment Period ^a	Post-Treatment Follow-Up (NA only) Period 1		Post-Treatment Follow-Up (NA only) Period 2 ^c	Early Termination ^e	Notes
	Weeks 28, 30, 32, 34, 36, 38, 40	Weeks 44, 48, 52, 56, 60 ^b	Weeks 63 and 64 ^a	Weeks 76 and 88 (EOS)		
Concomitant medications	X	X	X	X	X	
Physical examination	X	X	X	X	X	Targeted PEs may be completed at any study visit based on any reported changes to the subject's health.
Vital signs	X	X	X	X	X	BP, HR, RR, and temp to be performed pre-dose, when applicable.
ECG	X	X	X	X	X	Will be performed pre-dose, when applicable.
Clinical laboratory tests ^d	X*	X*	X	X	X	Includes clinical chemistry, hematology, coagulation tests, serology, and urine as specified in Appendix 4 , and are to be completed after an overnight fast of ≥8 hrs. *TSH to be drawn only at selected visits (Weeks 28, 40, and 52)
Pregnancy test (WOCBP only)	X*	X	X**	X	X	Urine pregnancy tests will be collected as indicated. If the urine test is positive or not interpretable, a serum/plasma pregnancy test is to be conducted. * Samples to be collected at Weeks 28, 32, 36, and 40. **Sample to be collected at Week 64.
Quantitative HBsAg ^d	X	X	X	X	X	
HBsAg Ultrasensitive ^d	X	X	X	X	X	To be assessed only if quantitative HBsAg result is <LLOQ
Quantitative HBsAb ^d	X	X	X	X	X	Samples to be collected at Weeks 28, 32, 36, 40, 44, 48, 52, 60, 64, 76, and 88.
Quantitative HBV DNA ^d	X	X	X	X	X	

Cohort B						
Assessment	Consolidation Treatment Period ^a	Post-Treatment Follow-Up (NA only) Period 1		Post-Treatment Follow-Up (NA only) Period 2 ^c	Early Termination ^e	Notes
	Weeks 28, 30, 32, 34, 36, 38, 40	Weeks 44, 48, 52, 56, 60 ^b	Weeks 63 and 64 ^a	Weeks 76 and 88 (EOS)		
Quantitative HBV RNA ^d	X	X	X	X	X	
Quantitative HBcrAg ^d	X	X	X	X	X	
Qualitative HBeAg ^d	X	X	X	X	X	
Quantitative HBeAg ^d	X	X	X	X	X	To be assessed only if positive result obtained with HBeAg qualitative test.
Qualitative HBeAb ^d	X	X	X	X	X	Samples to be collected at Weeks 28, 32, 36, 40, 44, 48, 52, 60, 64, 76, and 88.
HBsAg isoforms ^d	X	X	X	X	X	
HBsAg immune complex ^d	X	X	X	X	X	Samples to be collected at Weeks 28, 32, 36, 40, 44, 48, 52, 60, 64, 76, and 88.
Resistance Sample ^d	X	X	X	X	X	
miRNAs ^d	X	X	X	X	X	Will be stored and analyzed only if a HBsAg effect is observed. Samples to be collected at Weeks 28, 32, 36, 40, 44, 48, 52, 60, 64, 76, and 88.
RNAi PD marker ^d	X	X	X	X	X	
Immune biomarker/cytokines sample ^d	X*	X	X**	X	X	Unscheduled samples will be collected in the event of any unexpected safety finding. *Collected at Weeks 28, 32, 36 and 40. **Collected at Week 64 only.
PBMCs ^d	X*	X	X**	X	X	Unscheduled samples will be collected in the event of any unexpected safety finding. *Collected at Week 28, 32,36, and 40. ** Collected at Week 64 only.
Drug dispensing/accountability	X	X	X	X	X	Subjects will record all NA doses in a dosing diary, which will be reviewed at each study visit.
AB-729 dosing in the clinic (Cohort B1 only)	X					Week 32 only.

Cohort B						
Assessment	Consolidation Treatment Period ^a	Post-Treatment Follow-Up (NA only) Period 1		Post-Treatment Follow-Up (NA only) Period 2 ^c	Early Termination ^e	Notes
	Weeks 28, 30, 32, 34, 36, 38, 40	Weeks 44, 48, 52, 56, 60 ^b	Weeks 63 and 64 ^a	Weeks 76 and 88 (EOS)		
Peg-IFN α -2a dosing	X					First Peg-IFN α -2a dose to be administered in the clinic at Week 28 visit, and Peg-IFN α -2a administration will occur in the clinic on visit days. Remainder of Peg-IFN α -2a doses (odd numbered Weeks) to be self-administered with last dose at Week 39. Subjects will record all Peg-IFN α -2a doses in a dosing diary, which will be reviewed at each study visit.
Record AEs	X	X	X	X	X	Will be collected from the time of the start of study treatment through the last Post-Treatment F/U visit.
Record SAEs	X	X	X	X	X	Will be collected from the signing of the ICF through the last Post-Treatment F/U visit and followed until resolution of any event.
AB-729 PK sampling	X					Will be collected at Week 32 for Group B1 only according to the schedule provided in Appendix 7 . At this visit, subjects will remain in the clinic for a minimum of 6 hrs post-dose.

Abbreviations: AEs = adverse events; BP = blood pressure; ECG = electrocardiogram; EOS = end of study; ET = early termination; F/U = follow up; HBcrAg = hepatitis B virus core-related antigen; HBeAb = hepatitis B virus e-antibody; HBeAg = hepatitis B virus e-antigen; HBsAb = hepatitis B virus surface antibody; HBsAg = hepatitis B virus surface antigen; HBV = hepatitis B virus; HR = heart rate; hrs = hours; ICF = informed consent form; miRNAs = micro RNAs; RNAi = RNA interference; NA = nucleos(t)ide analogue; PBMCs = peripheral blood mononuclear cells; PD = pharmacodynamic; PE = physical examination; Peg-IFN α -2a = pegylated interferon α -2a; PK = pharmacokinetic; RR = respiration rate; SAE = serious adverse event; temp = temperature; TSH = thyroid stimulating hormone; WOCBP = women of childbearing potential.

- Visit windows are \pm 3 days.
- Visit windows are \pm 5 days.
- Visit windows are \pm 7 days.
- Samples are to be drawn pre-dose where applicable.

- e. If a subject discontinues between Week 28 and 40, they should complete an Early Termination visit. If they agree to remain in follow-up they should enter the Post-Treatment FU (NA only) Periods 1 and 2 within 4 weeks of the ET visit. The subject may skip the Week 63 visit as they will not be eligible for NA discontinuation.

Table 5. Schedule of Activities for Cohort B: NA-Discontinuation Period (For Subjects who Qualify)

Assessment	Cohort B NA-Discontinuation Period a		Notes
	Weeks 66, 68, 70, 72, 74, 76 ^b	Weeks 80, 84, 88, 92, 96, 100, 104, 108, 112 (EOS) ^c	
Concomitant medications	X	X	
Physical examination	X	X	Targeted PEs may be completed at any study visit based on any reported changes to the subject's health.
Vital signs	X	X	BP, HR, RR, and temperature.
ECG	X	X	
Clinical laboratory tests	X	X	Includes clinical chemistry, hematology, coagulation tests, serology, and urine as specified in Appendix 4 , and are to be completed after an overnight fast of ≥ 8 hrs and, during the treatment period, should be drawn prior to dosing, when applicable.
Pregnancy test (WOCBP only)	X*	X	Urine pregnancy tests will be collected as indicated. If the urine test is positive or not interpretable, a serum/plasma pregnancy test is to be conducted. *Samples to be collected at Weeks 68, 72, and 76
Quantitative HBsAg	X	X	
HBsAg Ultrasensitive	X	X	To be assessed only if quantitative HBsAg result is $< \text{LLOQ}$
Quantitative HBsAb	X	X	Samples to be collected at Weeks 68, 72, 76, 80, 88, 100, 112.
Quantitative HBV DNA	X	X	
Quantitative HBV RNA	X	X	
Quantitative HBcrAg	X	X	
Qualitative HBeAg	X	X	
Quantitative HBeAg	X	X	To be assessed only if positive result obtained with HBeAg qualitative test
Qualitative HBeAb	X	X	Samples to be collected at Weeks 68, 72, 76, 80, 88, 100, 112.
HBsAg isoforms	X	X	
HBsAg immune complex	X	X	Samples to be collected at Weeks 68, 72, 76, 80, 88, 100, 112.
Resistance Sample	X	X	
miRNAs	X	X	Will be stored and analyzed only if a HBsAg effect is observed. Samples to be collected at Weeks 68, 72, 76, 80, 88, 100, 112.
RNAi PD marker	X	X	

Assessment	Cohort B NA-Discontinuation Period a		Notes
	Weeks 66, 68, 70, 72, 74, 76 ^b	Weeks 80, 84, 88, 92, 96, 100, 104, 108, 112 (EOS) ^c	
Immune biomarker/cytokines sample	X*	X**	Unscheduled samples will be collected in the event of any unexpected safety finding. *Collected at Weeks 68, 72, and 76. **Collected at Weeks 80, 88, 100 and 112.
PBMCs	X*	X**	Unscheduled samples will be collected in the event of any unexpected safety finding. *Collected at Weeks 68, 72, and 76. **Collected at Weeks 80, 88, 100 and 112.
Record AEs	X	X	Will be collected from the time of the start of study treatment through the last Post-Treatment F/U visit.
Record SAEs	X	X	Will be collected from the signing of the ICF through the last Post-Treatment F/U visit and followed until resolution of any event.

Abbreviations: AEs = adverse events; BP = blood pressure; ECG = electrocardiogram; EOS= end of study; F/U = follow up; HBcrAg = hepatitis B virus core-related antigen; HBeAb = hepatitis B virus e-antibody; HBeAg = hepatitis B virus e-antigen; HBsAb = hepatitis B virus surface antibody; HBsAg = hepatitis B virus surface antigen; HBV = hepatitis B virus; HR = heart rate; hrs = hours; ICF = informed consent form; miRNAs = micro RNAs; RNAi = RNA interference; PBMCs = peripheral blood mononuclear cells; PD = pharmacodynamic; PE = physical exam; PK = pharmacokinetic; RR = respiration rate; SAE = serious adverse event; temp = temperature.

- Subjects who Early Terminate during this period should discuss restarting NA therapy and entering the NA Restart Follow-Up period ([Table 14](#)) or discuss alternative follow-up plans with the study Investigator.
- Visit windows are ± 3 days.
- Visit windows are ± 5 days.

2. INTRODUCTION

Arbutus Biopharma Corporation (hereafter referred to as Arbutus) is developing AB-729, a potent, selective, SC administered, GalNAc-conjugated siRNA inhibitor of HBV that cleaves and degrades HBV RNA, resulting in downstream silencing of viral proteins, DNA replication and virion production. Development of therapeutic agents that target HBV protein expression, particularly HBsAg, may provide a valuable addition to current approved therapies (NA and Peg-IFN α) and possibly increase current HBV cure rates. In an ongoing phase 1 study, AB-729 has been administered, as either single or repeat doses, to over 40 chronic hepatitis B (CHB) subjects on stable NA therapy and had been well tolerated. After a single dose of AB-729 60 mg, the mean HBsAg decline at week 12 was $\sim 1.0 \log_{10}$ IU/mL (N=6), similar to the decline observed at Week 12 in subjects receiving repeat doses of AB-729 60 mg every 4 weeks (N=7) or every 8 weeks (N=7). However, subjects receiving AB-729 60 mg every 4 weeks or every 8 weeks continued to experience reductions in HBsAg beyond Week 12, with mean maximum $\Delta \log_{10}$ HBsAg of $-1.9 \log_{10}$ IU/mL and $-1.8 \log_{10}$ IU/mL, respectively. Furthermore, 10 of 14 subjects receiving AB-729 60 mg with either dosing interval have achieved HBsAg < 100 IU/mL (2 of whom reached < 10 IU/mL) to date, with treatment ongoing in both groups.

A summary of AB-729 preclinical and clinical data is presented in the Investigator's Brochure.[\[1\]](#)

2.1. Background

Hepatitis B is the world's most common serious liver infection, with an estimated 257 million individuals living with chronic hepatitis B (CHB) infection.[\[2\]](#) Unchecked, CHB can lead to liver cirrhosis and liver cancer. Despite the availability of an effective prophylactic HBV vaccine and interferon- and nucleos(t)ide analogue (NA)-based therapies, there remains an unmet medical need for novel, finite, and more efficacious CHB treatments that result in improved long-term outcomes, including an increased chance for functional cure (defined as sustained HBV DNA suppression and hepatitis B surface antigen [HBsAg] loss with or without hepatitis B virus surface antibody (HBsAb) seroconversion that is maintained > 6 months after discontinuation of antiviral therapy). Recognizing that monotherapy approaches are unlikely to be successful in promoting functional cure in subjects with CHB, AB-729 is being developed as a key component of a combination treatment strategy that includes NA therapy and potentially drugs with other mechanisms of action, such as direct acting antivirals and/or immunomodulators such as pegylated interferon alfa (PEG-IFN α).

2.2. Study Rationale

Recent data using a more sensitive HBV DNA assay suggest that ongoing viral replication occurs even in the context of stable NA use, which may continue to place patients at risk for liver-related morbidity and mortality.[\[3, 4\]](#) Current longitudinal data regarding the likelihood of achieving functional cure in subjects who are receiving SOC therapy (NA or Peg-IFN α) suggests that the rate is quite low: $< 3\%$ for NA-treated subjects and $< 7\%$ for Peg-IFN α -2a monotherapy after 48 weeks of therapy. An alternative and perhaps complementary approach to long-term suppression of the viral polymerase is to reduce the production of HBsAg and other viral

antigens, which are believed to contribute to host immune exhaustion, resulting in inadequate effective T-cell and B-cell responses to CHB infection.[5] By targeting HBsAg and other viral antigen production in addition to suppressing viral replication, a functional cure may be possible. This has been preliminarily explored via clinical trials using GalNAc-conjugated small inhibitory RNAs (siRNAs) and antisense oligonucleotide approaches to prevent the translation of viral messenger RNAs to viral proteins. While these approaches have demonstrated impressive and sustained declines in HBsAg when given in combination with stable NA therapy, none to date have led to on-treatment loss of HBsAg or HBsAb seroconversion even when another novel, direct acting antiviral such as a capsid inhibitor/capsid assembly modulator is added to the combination.[6-9]. Indeed, even suppression of HBsAg levels to <100 IU/mL or <10 IU/mL in a subset of subjects taking these combinations have been insufficient to promote reawakening of the immune system as manifested by ALT flares, HBsAg loss or HBsAb seroconversion. This suggests that profound inhibition of viral replication and/or antigen production alone may be insufficient to promote functional cure, and that addition of a therapeutic agent capable of boosting the host immune system may be required. Indeed, the only experimental regimen to induce notable levels of functional cure has been the combination of NA + nucleic acid polymers (NAPs) + Peg-IFN α , where rapid HBsAg declines were observed during the first 24 weeks of Peg-IFN α -2a treatment.[10]

Pegasys® (peginterferon alfa-2a, Peg-IFN α -2a) is approved for the treatment of CHB, and while the percentage of subjects who achieve functional cure when used as monotherapy for 48 weeks has been somewhat disappointing, in HBeAg positive patients who achieve HBeAg loss during therapy, HBsAg loss in the post-treatment period can reach 30%.[11] A multicenter trial examining combination therapy in treatment naïve or previously treated but off-therapy CHB subjects with tenofovir and Peg-IFN α -2a as dual therapy vs. each as monotherapy found that the combination arm was superior in regard to HBsAg loss at Week 24 post-treatment.[12] Given the known immunostimulatory and HBsAg lowering effects of Peg-IFN α -2a, consolidation with a short pulse of Peg-IFN α -2a therapy in the context of profound suppression of HBV antigens (HBsAg in particular) by AB-729 and of viral replication by a NA may promote immune reawakening and lead to functional cure.[13]

New data examining the role of discontinuing NA therapy in subjects with sustained suppression of HBV DNA to promote HBsAg loss and HBsAb seroconversion has also become available. Discontinuation of nucleos(t)ide analogue therapy in non-cirrhotic CHB-infected subjects has been endorsed in recent hepatology society guidelines in certain subsets of patients.[14-16] Given that HBsAg loss is infrequent during NA monotherapy, recent studies have examined the likelihood of sustained virologic suppression and/or HBsAg loss after NA discontinuation in non-cirrhotic, HBV DNA suppressed subjects with low HBsAg levels. Several recent reviews and meta-analyses suggest that low HBsAg in the context of NA-mediated suppression of HBV DNA may predict the likelihood of maintaining off-therapy virologic suppression and HBsAg loss after NA discontinuation, and that avoidance of premature re-treatment may promote better outcomes in terms of virologic remission. HBsAg thresholds of 100 IU/mL or less appear to be a good predictor of a favorable response to NA cessation in non-cirrhotic, HBeAg negative subjects.[17-21] In addition, there is interest in other biomarkers and prediction tools, such as HBV RNA levels, HBcrAg levels, and composite predictors such as SCALE-B [(35*HBsAg (log IU/mL) + 20*HBcrAg (log U/mL) + 2*age (years) + ALT (U/L) + 40 for tenofovir use]. A

low SCALE-B score (<260 points) may accurately predict a low risk of clinical flare and a higher chance of HBsAg seroclearance.[22-24]

Given the ongoing unmet medical need for novel therapeutic combinations to induce functional cure, this study will assess the safety and antiviral efficacy of the addition of AB-729 to ongoing SOC NA therapy in HBV DNA suppressed, HBeAg negative, non-cirrhotic CHB subjects for 24 weeks to reduce HBsAg levels, followed by addition of Peg-IFN α -2a with or without continued AB-729 treatment for either 12 or 24 weeks as consolidation therapy to further decrease HBsAg levels and promote anti-HBV immune reawakening. Subjects will then discontinue all treatment after completion of the Peg-IFN α -2a consolidation period and enter an intensive follow-up period for 6 months to monitor for potential rebound of viral markers and safety events. Additional follow up for up to a total of 96 weeks will assess for sustained viral response and HBsAg loss.

2.3. Benefit/Risk Assessment

Nonclinical safety pharmacology and Good Laboratory Practice (GLP) toxicology studies in both rat and cynomolgus monkey are described in the IB [1] and demonstrate adequate dose margins for the proposed dose of AB-729 (60 mg every 8 weeks) to be assessed in this study. In addition, preliminary data from the AB-729-001 study have shown an acceptable safety profile for repeat dosing of AB-729 60 or 90 mg every 4 – 12 weeks in NA-suppressed and treatment naïve or off-treatment CHB subjects for a dosing period of up to 48 weeks. The most common TEAEs have been related to the injection site, mostly single events of mild injection site pain, redness or pruritis, that have resolved. The most common laboratory abnormalities have been mild to moderate ALT elevations that have been asymptomatic and transient and have not been considered adverse events by the Investigators. No changes in total or direct bilirubin or markers of liver synthetic function have been observed in subjects with ALT changes. As noted above, all subjects receiving repeat doses of AB-729 have had declines in HBsAg of 1.0 log₁₀ IU/mL or more, with a majority of subjects reaching levels <100 IU/mL after 24 weeks of dosing. These HBsAg declines are sustained throughout the dosing period, and based on AB-729 single dose data, are anticipated to remain suppressed for weeks to months after the end of treatment. A detailed description of available clinical data is available in the IB.[25]

Peg-IFN α -2a is approved as monotherapy for the treatment of CHB, has a well-understood safety profile, and has been tested in combination with NA in many clinical trials.[11, 26, 27] As noted above, HBsAg thresholds of 100 IU/mL or less appear to be a good predictor of a favorable response to NA cessation in non-cirrhotic, HBeAg negative subjects. Given the known immunostimulatory and HBsAg-lowering effects of Peg-IFN α -2a, consolidation with a short pulse of Peg-IFN α -2a therapy in the context of profound suppression of HBV antigens (HBeAg and HBsAg in particular) may promote immune reawakening and lead to functional cure. Short courses of 12 – 24 weeks of Peg-IFN α -2a may also be better tolerated by subjects than a traditional 48-week course of therapy.

Discontinuation of NA therapy in non-cirrhotic CHB-infected subjects has been endorsed in recent hepatology society guidelines in certain subsets of patients.[14-16] In this study, subjects will be assessed for eligibility to stop NA therapy after the first 24 weeks of follow up. Those that meet the criteria described in Section 4.3 will enter an intensive follow-up period for 24 weeks to monitor for potential rebound of viral markers and safety events. Additional follow up for another 24 weeks (48 weeks total) will assess for sustained viral response and HBsAg loss and/or HBsAb seroconversion. Provided that only subjects who are non-cirrhotic and have minimal fibrosis are permitted to discontinue NAs (as reflected by this study population) and close monitoring is performed after NA discontinuation, the risk of hepatic decompensation is low.[21, 28-30] Re-initiation of NA therapy will be permitted should subjects meet ALT and/or HBV DNA criteria as outlined in Section 8.6. Given the addition of a long-acting HBsAg lowering agent (AB-729) with capacity to also reduce other HBV antigens and Peg-IFN α -2a to stable NA therapy, subjects should be better positioned to experience continued viral suppression and potentially HBsAg loss off-treatment.

AB-729 Drug Interaction Potential

Details regarding the disposition of AB-729 are provided in the IB.[1] AB-729 is metabolized by nucleases and is not expected to be a victim of cytochrome P450 (CYP)-mediated drug interactions. *In vitro* investigations of the drug interaction potential of structurally related GalNAc-conjugated antisense oligonucleotides demonstrated no significant inhibition or induction of the major CYP enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4), nor meaningful inhibition on either uptake transporters (organic cation transporter [OCT]1, organic anion transporter [OAT]P1B1/1B3, OAT1, OAT3, OCT2) or efflux transporters (P-glycoprotein [P-gp], breast cancer resistance protein [BCRP], bile salt export pump [BSEP]).[31] Thus, CYP- and transporter-mediated drug interactions with AB-729 are not anticipated.

Nucleos(t)ide Analogue Co-administration with AB-729 and Peg-IFN α -2a

Subjects will remain on their pre-study NA therapy (TAF, TDF or ETV) for the duration of the study treatment period and the first 24-week follow-up period. To date, the safety and PK profile of each of these NAs are well-characterized. Co-administration of AB-729 with TDF, TAF, or ETV is not expected to have a clinically meaningful impact on exposures to either AB-729 nor these NAs. As a result, there are no expectations that specific NA-associated AEs will be exacerbated or changes in efficacy will be observed during or after the administration of AB-729 to these subjects. In on-going clinical study AB-729-001, AB-729 90 mg Q8W and daily TDF are being assessed in CHB subjects who were HBV DNA+ (not taking NA therapy) at baseline. HBV DNA concentrations in these subjects reached unquantifiable levels by Week 16, consistent with the known HBV DNA profile of TDF monotherapy, and suggests that AB-729 does not impact NA efficacy when co-administered. NAs have been co-administered with Peg-IFN α -2a in many clinical trials and there have been no reports of exacerbation of NA-associated or Peg-IFN α -2a associated AEs during co-administration.[11, 26, 27]

Peg-IFN α -2a Co-administration with AB-729 and NAs

While Peg-IFN α -2a is associated with inhibition of CYP12 [32], this will not have any meaningful impact on exposures to either AB-729 or NAs when co-administered. Peg-IFN α -2a has been co-administered with NAs in many clinical trials and there have been no reports of exacerbation of NA-associated or Peg-IFN α -2a-associated AEs during co-administration. Different injection sites will be recommended for days when AB-729 dosing and Peg-IFN α -2a dosing coincide to minimize subject discomfort and to allow for observation and differentiation of potential injection-related AEs from either compound.

The adverse event profiles of TAF, TDF and ETV are well characterized, and there does not appear to be overlapping toxicity between these NAs and AB-729 based on available non-clinical and clinical data. Ongoing trials with HBV-specific GalNAc-siRNA compounds co-administered with NAs, including AB-729-001, have not revealed exacerbation of any class-associated safety signals attributable to additive or synergistic AE profiles.[1, 6-9] Combination treatment with GalNAc-siRNA compounds and Peg-IFN α -2a in CHB subjects on NAs is being investigated in several ongoing clinical trials, however data regarding safety are not yet available (NCT04412863, NCT04667104, NCT04439539). The adverse event profile of Peg-IFN α -2a includes flu-like symptoms (fever, headache, fatigue, myalgias, anorexia), alopecia, and cytopenias (neutropenia, thrombocytopenia). Of these, only headache has been observed as a related AE in the AB-729-001 program to date (in 2 subjects), and these AEs have not been commonly described in other HBV-specific GalNAc-siRNA programs. ALT elevations have been commonly noted during and after Peg-IFN α -2a therapy in CHB subjects, thus liver function tests will be monitored intensively during this study to allow appropriate dose modification of Peg-IFN α -2a therapy as indicated in the product label.[32] Mild to moderate asymptomatic ALT elevations have been observed in the repeat dosing cohorts of the AB-729-001 study, but none have been considered AEs and have improved with continued dosing of AB-729. The mechanism of these ALT elevations is unknown, but all have occurred in the setting of HBsAg declines and may reflect “beneficial” flares due to restoration of anti-HBV host immune responses in the context of rapid HBV antigen suppression.[33]

Routine safety laboratory testing (including hematology, chemistry, liver function tests, and urinalyses) and clinical assessments will be obtained frequently during the treatment and Follow-up periods to monitor for expected and unexpected AEs during AB-729, NA and Peg-IFN α -2a co-administration. Follow up clinic visits and laboratory testing schedules are more intense during and after changes in treatment strategy, such as during the addition of Peg-IFN α -2a and after NA discontinuation (in eligible subjects). The Investigator should refer to their country-specific approved product labels for additional information about TDF, TAF, ETV and Peg-IFN α -2a use in CHB.

3. OBJECTIVES AND ENDPOINTS

Objectives	Endpoints
Primary	
<ul style="list-style-type: none"> To evaluate the safety and tolerability of AB-729 plus Peg-IFNα-2a in subjects with NA-suppressed CHB infection 	<ul style="list-style-type: none"> The frequency and severity of TEAEs, discontinuations due to AEs, and laboratory abnormalities after dosing with AB-729 plus Peg-IFNα-2a
Secondary	
<ul style="list-style-type: none"> To evaluate changes in HBsAg concentration and other virologic parameters during and following repeat doses of AB-729 plus Peg-IFNα-2a 	<ul style="list-style-type: none"> Change from baseline in HBsAg, HBV DNA, HBV RNA, HBsAb, HBeAb and HBcrAg concentration at each timepoint Proportion of subjects with a change in HBsAg from baseline meeting response criteria (≥ 0.5, 1, 2, or 3 log₁₀ reduction; \leq LLOQ or TND) Proportion of subjects with a change in HBV RNA from baseline meeting response criteria (≥ 0.5, 1, 2, or 3 log₁₀ reduction; \leq LLOQ or TND) Proportion of subjects with a change in HBcrAg from baseline meeting response criteria (≥ 0.5, 1, 2, or 3 log₁₀ reduction; \leq LLOQ or TND)
<ul style="list-style-type: none"> To evaluate the proportion of subjects with HBsAb seroconversion 	<ul style="list-style-type: none"> Proportion of subjects with HBsAb seroconversion at each timepoint
<ul style="list-style-type: none"> To evaluate the proportion of subjects who meet NA therapy discontinuation criteria 	<ul style="list-style-type: none"> Proportion of subjects who are eligible to stop NA after Week 24 of follow up
<ul style="list-style-type: none"> To evaluate the proportion of subjects who discontinue NA therapy and subsequently restart NA therapy during the follow-up period 	<ul style="list-style-type: none"> Proportion of subjects who discontinue NA and subsequently restart NA therapy after meeting criteria
<ul style="list-style-type: none"> To evaluate the proportion of subjects who experience clinical and/or viral relapse in the follow-up period after discontinuing NA therapy 	<ul style="list-style-type: none"> Proportion of subjects who discontinue NA and subsequently meet protocol-defined clinical relapse criteria Proportion of subjects who discontinue NA and subsequently meet protocol-defined viral relapse criteria Proportion of subjects who have HBV DNA $<$ LLOQ at each timepoint after discontinuation of NA therapy

Objectives	Endpoints
	<ul style="list-style-type: none"> Proportion of subjects who have HBsAg <100 IU/mL or <10 IU/mL at each timepoint after discontinuation of NA therapy
<ul style="list-style-type: none"> To evaluate plasma concentrations of AB-729 	<ul style="list-style-type: none"> Post-dose plasma concentrations of AB-729 AS, AB-729 AS(N-1)3', and AB-729 AS(N-2)3' at selected timepoints
Tertiary/Exploratory	
<ul style="list-style-type: none"> To evaluate potential viral resistance to AB-729, as data permit 	<ul style="list-style-type: none"> Identification of AB-729 target site variants from sequencing of drug resistant HBV variants, if observed
<ul style="list-style-type: none"> To evaluate changes in the levels of HBsAg isoforms (small, middle, and large) 	<ul style="list-style-type: none"> Change from baseline in small, middle, and large isoforms of HBsAg
<ul style="list-style-type: none"> To evaluate changes in the levels of immune biomarkers with AB-729 treatment in lead-in period with AB-729 + Peg-IFNα-2a in consolidation period, as data permit To evaluate changes in the levels of immune biomarkers during and after treatment with AB-729 + Peg-IFNα-2a and NA + Peg-IFNα-2a, as data permit 	<ul style="list-style-type: none"> Change from baseline in immune-related protein levels (such as soluble programmed death-1 [sPD-1] and cytokines) and HBsAg immune complex levels Assessment of the relationship between immune-related protein levels, immune complex levels, and virologic responses
<ul style="list-style-type: none"> To profile HBV-specific immune function with AB-729 treatment in lead-in period with AB-729 + Peg-IFNα-2a in consolidation period, as data permit To profile HBV-specific immune function following treatment with AB-729 + Peg-IFNα-2a and NA + Peg-IFNα-2a, as data permit 	<ul style="list-style-type: none"> Assessment of the relationship between immunologic activity of peripheral blood mononuclear cells (PBMCs) and virologic response
<ul style="list-style-type: none"> To characterize interleukin (IL)28B genotype and explore potential correlation to virologic response, as data permit 	<ul style="list-style-type: none"> Assessment of the relationship between IL28B genotype and virologic response
<ul style="list-style-type: none"> To explore relationships between safety and/or pharmacodynamics (PD) with immune/inflammatory gene polymorphisms, as data permit 	<ul style="list-style-type: none"> Assessment of immune and inflammatory gene polymorphisms via allele-specific oligonucleotide array

Objectives	Endpoints
<ul style="list-style-type: none"> To monitor AB-729 RNA interference (RNAi) activity and explore correlation to virologic response, as data permit 	<ul style="list-style-type: none"> Detection of HBV RNA cleavage products in blood resulting from AB-729 RNAi activity Assessment of the relationship between detection of HBV RNA cleavage products and virologic responses
<ul style="list-style-type: none"> To evaluate changes in levels of HBV-related microRNAs (miRNAs) during and after treatment with AB-729, as data permit 	<ul style="list-style-type: none"> Change from baseline in selected potentially HBV-related miRNA levels Assessment of the relationship between HBV-related miRNAs and virologic responses
<ul style="list-style-type: none"> To assess the SCALE-B score in predicting post-treatment clinical relapse and HBsAg loss 	<ul style="list-style-type: none"> Assessment of SCALE-B score at end-of-treatment (EOT) Proportion of subjects who experience clinical relapse with SCALE-B scores of <260, 260 – 320, and >320 points Proportion of subjects who experience HBsAg loss with SCALE-B scores of <260, 260-320, and >320 points

4. STUDY DESIGN

4.1. Overall Design

This is a randomized, open label, multicenter Phase 2 study investigating the safety and antiviral activity of AB-729 in combination with ongoing NA therapy and short courses of Peg-IFN α -2a in subjects with CHB.

The study will enroll 40 stably NA-suppressed, HBeAg negative, non-cirrhotic CHB subjects. After a 24-week lead-in period of AB-729 60 mg SC every 8 weeks (Q8W) added to ongoing SOC NA, subjects will be randomized into one of 4 groups:

- A1: AB-729 + NA + weekly Peg-IFN α -2a for 24 weeks (N = 12)
- A2: NA + weekly Peg-IFN α -2a for 24 weeks (N = 12)
- B1: AB-729 + NA + weekly Peg-IFN α -2a for 12 weeks (N = 8)
- B2: NA + weekly Peg-IFN α -2a for 12 weeks (N = 8)

Treatment assignment will be stratified by HBsAg level at Week 24 (HBsAg \leq 100 IU/mL vs $>$ 100 IU/mL).

All subjects will remain on NA therapy for the initial 24-week follow up period, and then may be considered for NA discontinuation if the following criteria are met:

- ALT $<2 \times$ ULN, and
- Undetectable HBV DNA, and
- At least one of the following:
 - HBsAg undetectable (via conventional assay) for at least 24 weeks after the last dose of AB-729
 - HBsAg $<$ 100 IU/mL at two consecutive visits at least 24 weeks after the last dose of AB-729
 - HBsAb positive for at least 24 weeks after the last dose of AB-729

If subjects stop NA therapy, they will enter a more intensive follow-up period for 48 weeks to monitor for potential rebound of viral markers and safety events as well as for sustained viral response and HBsAg loss. Subjects who remain on NA therapy will be followed for an additional 24 weeks (48 weeks total post-end of treatment).

4.1.1. Number of Subjects

Approximately 80 subjects will be screened to achieve approximately 40 dosed subjects.

4.1.2. Treatment Groups and Duration

All subjects will continue their ongoing SOC NA (either ETV, TDF or equivalent, or TAF) and receive AB-729 60 mg SC Q8W (4 doses) for 24 weeks. Subjects will then be randomized into one of 4 groups:

- A1: AB-729 60 mg SC Q8 weeks (2 doses) + NA + Peg-IFN α -2a 180 mcg SC QW for 24 weeks (N = 12)
- A2: NA + Peg-IFN α -2a 180 mcg SC QW for 24 weeks (N = 12)
- B1: AB-729 60 mg SC Q8 weeks (1 dose) + NA + Peg-IFN α -2a 180 mcg SC QW for 12 weeks (N = 8)
- B2: NA + Peg-IFN α -2a 180 mcg SC QW for 12 weeks (N = 8)

Treatment assignment will be stratified by HBsAg level at Week 24 (HBsAg \leq 100 IU/mL vs $>$ 100 IU/mL).

The study will be conducted for approximately 130 weeks as follows:

- The Screening Visit will occur within 45 days prior to the first dose of AB-729.
- Dose 1 of AB-729 will be administered on Day 1 and subjects will be confined to the clinic for a minimum of 6 hours on Day 1 for PK assessments.
- All subjects will return to the clinic for monthly visits through Week 24 (6 visits) as shown in [Table 1](#).
 - During the Week 24 visit subjects will be confined to the clinic for a minimum of 6 hours for PK assessments
- Subjects randomized to Cohorts A1 and A2 will have between 19 (through Week 100) and 32 (through Week 124) visits depending on whether they qualify for NA discontinuation. See [Table 2](#) and [Table 3](#).
- Subjects randomized to Cohorts B1 and B2 will have between 16 (through Week 88) and 29 (through Week 112) visits depending on whether they qualify for NA discontinuation. See [Table 4](#) and [Table 5](#) for details.

4.1.3. Data Monitoring Committee


Safety will be continuously monitored by the Investigator, Sponsor's Medical Monitor, and study personnel.

A DMC will periodically review safety data from this study. The DMC will be a group of 3 independent members who will operate in accordance with a pre-specified charter and make recommendations to the Sponsor as needed.

4.2. Scientific Rationale for Study Design

With repeat dosing of AB-729 in CHB subjects at doses of 60 mg or 90 mg every 4 to every 12 weeks for up to 48 weeks, HBsAg declines were observed in all subjects, after which HBsAg response plateaued at approximately Week 20 with no additional meaningful decline in HBsAg with continued dosing of AB-729, regardless of the dose or dosing interval [Figure 2](#).

Figure 2. Mean (\pm SE) $\Delta\log_{10}$ HBsAg with Repeat Dosing of AB-729 in Virologically-Suppressed CHB Subjects



Abbreviations: CHB = chronic hepatitis B; HBsAg = hepatitis B virus surface antigen; Q4W = every 4 weeks; Q8W = every 8 weeks; Q12W = every 12 weeks; SE = standard error.

Note: subjects receiving AB-729 60 mg Q4W were switched to AB-729 60 mg Q12W following their Week 20 dose

It is unclear if continued dosing of AB-729 is necessary to maintain the plateau in HBsAg; thus subjects randomized to Cohorts A2 and B2 will receive their final dose of AB-729 at Week 24 (when the course of Peg-IFN α -2a is initiated), while subjects randomized to Cohorts A1 and B1 will continue dosing with AB-729 through Week 40 (Cohort A1) or Week 32 (Cohort B1) (concurrently with the course of Peg-IFN α -2a).

When used as monotherapy for CHB, the recommended treatment duration for Peg-IFN α -2a is 180 mcg weekly for 48 weeks.[32] However, the optimal duration of Peg-IFN α -2a therapy when used as an “add-on” in subjects on HBV DNA suppressive therapy (NAs) and on HBsAg-lowering therapy (AB-729) is not known. HBsAg response at 12 and 24 weeks of interferon monotherapy may predict sustained response after end of therapy for a traditional 48-week regimen [11, 12, 14, 34, 35], but there is limited data regarding outcomes after shorter courses of Peg-IFN α -2a therapy. In a study in CHB subjects examining two combination regimens of TDF plus Peg-IFN α -2a (TDF + Peg-IFN α -2a for 48 weeks and TDF for 48 weeks with Peg-IFN α -2a for the first 16 weeks) versus TDF alone for 120 weeks or Peg-IFN α -2a monotherapy for 48 weeks, the 16 week course of Peg-IFN α -2a + TDF performed as well as 48 weeks of Peg-IFN α -2a monotherapy, and the rates of sustained response (HBV DNA suppression) 24 weeks post-end of treatment was similar across all Peg-IFN α -2a-containing regimens, regardless of duration.[26] A more recent pilot study examined short course Peg-IFN α -2b monotherapy (median 16 weeks) in untreated CHB inactive carriers with low HBsAg (<20 IU/mL) and found a 94% rate of HBsAg loss and 31% rate of anti-HBs seroconversion during the treatment period that was

sustained 9 months post-end of treatment.[27] A shorter course of Peg-IFN α -2a may also be better tolerated than a full 48-week treatment course.

4.3. Justification for Dose

The ongoing Part 3 of Study AB-729-001 is assessing safety and virologic activity of AB-729 60 mg and 90 mg administered at varying dosing intervals: every 4 weeks and every 8 weeks for the 60 mg dose and every 8 weeks and every 12 weeks for the 90 mg dose. Figure 2 above displays the mean \pm standard error (SE) HBsAg decline with repeat dosing of AB-729 in virologically-suppressed CHB subjects. At Week 24, there is no meaningful difference ($p \geq 0.2$) in mean (SE) HBsAg decline between the four dosing regimens: -1.84 (0.16), -1.57 (0.09), -1.79 (0.22), -1.56 (0.25) with AB-729 60 mg Q4W (Q12W after Week 20), AB-729 60 mg Q8W, AB-729 90 mg Q8W, and AB-729 90 mg Q12W, respectively. Furthermore, HBsAg decline appears to plateau beyond Week 20, with continued dosing of AB-729 resulting in no meaningful additional decline regardless of dose or dosing interval. At Week 36, AB-729 60 mg Q4W (Q12W after Week 20) and 60 mg Q8W resulted in similar mean (SE) HBsAg declines ($p = 0.6$): -1.90 (0.18) and -1.78 (0.11, $N = 6$). Thus, the more conservative and convenient AB-729 60 mg Q8W dosing schedule will be assessed in this study.

In this study, the recommended dose of Peg-IFN α -2a for adults with CHB (180 mcg) will be administered subcutaneously for either 24 or 12 weeks depending on assignment to Cohort A or B, respectively (Section 4.2). Dose reduction is permitted for adverse events as described in Section 6.6 and the product label.[32]

4.4. Nucleos(t)ide Discontinuation Criteria

Discontinuation of NA therapy in non-cirrhotic CHB-infected subjects has been endorsed in recent hepatology society guidelines in certain subsets of patients.[14-16] These include HBeAg positive patients who achieve HBeAg loss, anti-HBe seroconversion, and HBV DNA suppression on stable NA therapy and receive consolidation therapy for 6 – 12 months (or longer). Subjects who are HBeAg negative and demonstrate HBsAg loss with or without anti-HBs seroconversion may also be considered for treatment discontinuation. However, given that HBsAg loss is infrequent during NA monotherapy, recent studies have examined the likelihood of sustained virologic suppression and/or HBsAg loss after NA discontinuation in non-cirrhotic, HBV DNA suppressed subjects with low HBsAg levels. These data suggest that on-treatment HBsAg levels at the time of NA discontinuation may predict the likelihood of HBsAg loss after treatment discontinuation. Several recent reviews and meta-analyses suggest that low HBsAg in the context of NA-mediated suppression of HBV DNA may predict the likelihood of maintaining off-therapy virologic suppression and HBsAg loss after NA discontinuation. HBsAg thresholds of 100 IU/mL or less appear to be a good predictor of a favorable response to NA cessation in non-cirrhotic, HBeAg negative subjects.[17-20]

Discontinuation of NA therapy will occur when the following criteria are met by individual subjects upon completion of the first 24 week follow up period:

- ALT $<2 \times$ ULN, and
- Undetectable HBV DNA, and
- At least one of the following:
 - HBsAg undetectable (via conventional assay) for at least 24 weeks after the last dose of AB-729
 - HBsAg <100 IU/mL at two consecutive visits at least 24 weeks after the last dose of AB-729
 - HBsAb positive for at least 24 weeks after the last dose of AB-729

Subjects who discontinue NA therapy will enter a more intensive follow up period to monitor for safety, evidence of clinical or virologic relapse, defined as follows:

Clinical relapse: HBV DNA >2000 IU/mL AND ALT $>2x$ baseline and $\geq 2 \times$ ULN, confirmed by repeat 4 weeks apart

Virologic relapse: HBV DNA > 2000 IU/ml confirmed by repeat 4 weeks apart

Resumption of NA therapy during the second follow-up period should occur if any of the following scenarios occur and after discussion with the Sponsor Medical Monitor:

- Persistent ALT elevations $\geq 2 \times$ baseline, AND $\geq 2 - 5 \times$ ULN, AND HBV DNA >2000 IU/mL for 12 weeks
- Persistent ALT elevations $\geq 2 \times$ baseline, AND $\geq 5 - 10 \times$ ULN, AND HBV DNA >2000 IU/mL for 4 weeks
- HBV DNA $> 20,000$ IU/mL regardless of ALT level, confirmed by repeat
- ALT $> 10 \times$ ULN confirmed by repeat
- ALT $>$ baseline and $>$ ULN, AND:
 - increased direct or total bilirubin $\geq 2 \times$ ULN and $\geq 2 \times$ baseline confirmed by repeat, OR
 - INR increase of ≥ 0.5 from baseline, confirmed by repeat.

Subjects who restart NA therapy will be assessed every 2 weeks until clinically stable (i.e. ALT and HBV DNA declining on 2 consecutive visits) and will be followed for 24 weeks total via unscheduled visits as needed prior to study discharge (see [Appendix 9](#)).

4.5. End of Study Definition

A subject is considered to have completed the study if s/he has completed all phases of the study including the final Post-Treatment Follow-up visit for the study Cohort in which the subject is enrolled.

The end of the study is defined as the date of the last visit of the last subject in the study, globally.

5. STUDY POPULATION

Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as protocol waivers or exemptions, is not permitted.

5.1. Inclusion Criteria

Subjects are eligible to be included in the study only if all the following criteria apply:

1. Subjects must be 18 (or other appropriate age of consent) to 60 years of age, inclusive, at the time of signing the informed consent.
2. Body mass index (BMI) ≥ 18 kg/m² and ≤ 38 kg/m².
3. Male or female subjects as follows:

a. Male subjects:

A male subject is eligible to participate if he does not have a female partner who is pregnant or who intends to become pregnant during the study. Male subjects must agree to use contraception as detailed in [Appendix 3](#) starting 4 weeks prior to the first dose of study drug, during the Lead-In Treatment Period, the Consolidation Treatment Period, and throughout the Post-Treatment Follow Up Period. If a subject discontinues the study early, they should continue to follow the contraceptive guidance for 6 months after the last dose of AB-729 study treatment or 28 days after the last dose of Peg-IFN α -2a, whichever is later, and refrain from donating sperm during this period. Male subjects should also be advised of the benefit for their female partners (who are woman of childbearing potential [WOCBP]) to use a highly effective method of contraception as detailed in [Appendix 3](#), as a condom may break or leak.

b. Female subjects:

A female subject is eligible to participate if she is not pregnant, not breastfeeding, does not intend to become pregnant during the study, and at least one of the following conditions applies:

- i. Not a WOCBP as defined in [Appendix 3](#).

OR

- ii. A WOCBP who agrees to follow the contraceptive guidance in [Appendix 3](#) starting 4 weeks prior to the first dose of study drug, during the Lead-In Treatment Period, the Consolidation Treatment Period, and throughout the Post-Treatment Follow Up Period. If a subject discontinues the study early, they should continue to follow the contraceptive guidance for 6 months after the last dose of AB-729 study treatment or 28 days after the last dose of Peg-IFN α -2a, whichever is later.

4. Documented chronic HBV infection via the following:

- a. Positive HBsAg, HBV DNA, or HBeAg at least 6 months prior to the Screening Visit (historical documentation must be provided), AND
- b. Negative serum immunoglobulin M (IgM) anti-hepatitis B core-related antibody (HBcAb) at the Screening Visit.

5. Subjects must be HBeAg-negative at the Screening Visit to participate.
6. HBV DNA must be <LLOQ at Screening.
7. HBsAg between 100 and 5,000 IU/mL (via conventional assay) at Screening.
8. Subjects must have been receiving either TAF, TDF (or equivalent), or ETV consistently for ≥ 12 months prior to Day 1 and are willing to continue with the same NA treatment through the final study visit (switching from TDF to TAF or vice versa at least 28 days prior to dosing Day 1 is permitted).
9. Liver ultrasound with absence of clinically significant abnormalities is required within 6 months prior to Day 1.
10. All subjects must have assessment of fibrosis demonstrating non-cirrhotic status available at Screening. Non-cirrhotic subjects are defined by a Fibroscan® result of ≤ 8.5 kPa within 6 months prior to Day 1.
11. Subjects must provide documentation of an eye examination including a retinal evaluation within 6 months prior to Day 1. Any abnormalities must be reviewed with the Sponsor Medical Monitor prior to Day 1.
12. Thyroid stimulating hormone (TSH) and free thyroxine (T4) levels within the normal laboratory reference range, or clinically euthyroid on a stable medication regimen.
13. Capable of giving signed informed consent, able to understand and comply with protocol requirements, instructions, and protocol-related restrictions, and likely to complete the study as planned.

5.2. Exclusion Criteria

A subject is not eligible for inclusion in this study if any of the following criteria apply during Screening:

Medical Status or History

1. Known co-infection with any of the following:
 - a. Human immunodeficiency virus (HIV),
 - b. Acute hepatitis A virus (HAV),
 - c. Hepatitis C virus (HCV),
 - d. Hepatitis D virus (HDV), OR
 - e. Acute hepatitis E virus (HEV).
2. Any known preexisting medical or psychiatric condition that could interfere with the subject's ability to provide informed consent or participate in study conduct, or that may confound study findings including, but not limited to:
 - a. History of any clinically significant medical condition associated with chronic liver disease (e.g., hemochromatosis, autoimmune hepatitis, Wilson's disease, α -1-

- antitrypsin deficiency, alcoholic liver disease, non-alcoholic steatohepatitis, or toxin exposures) that may affect the ability to respond to HBV therapy.
- b. Immunologically mediated (autoimmune) disease such as autoimmune hepatitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, scleroderma, multiple sclerosis, or sarcoidosis.
 - c. Significant immunosuppression from, but not limited to, immunodeficiency conditions such as common variable hypogammaglobulinemia or receipt of systemic immunosuppressive medications during the study or ≤ 2 months prior to the first dose of study treatment, including but not limited to: prednisone (>10 mg/day), azathioprine, methotrexate, and/or cyclosporine.
 - d. Current or history of any clinically significant cardiac abnormalities/dysfunction such as congestive heart failure, myocardial infarction ≤ 6 months prior to the Screening Visit, pulmonary hypertension, complex congenital heart disease, significant arrhythmia, and/or active cardiac ischemia. Additional cardiac exclusion criteria include:
 - i. A known history of marked prolongation of QT/QTc interval (e.g., repeated demonstration of a QTcF interval >450 msec for males or >470 msec for females).
 - ii. History of additional risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).
 - e. Current uncontrolled hypertension or past medical history of hypertensive crisis or hypertensive retinopathy.
 - f. Uncontrolled thyroid disease (hyper- or hypothyroidism), on or off medication.
 - g. Uncontrolled diabetes mellitus or subjects with a history of diabetic retinopathy.
 - h. Ocular disease including but not limited to retinopathy, macular edema, retinal artery or vein thrombosis, optic neuritis or retinal detachment. Documentation of an eye examination with retinal evaluation within 6 months of Day 1 must be provided.
 - i. History of cirrhosis at any time, or evidence of decompensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding esophageal varices, hepatorenal syndrome, liver transplantation and/or hepatic encephalopathy.
 - j. Liver ultrasound or other imaging with findings suggestive of hepatocellular carcinoma (HCC) at any time.
 - k. Clinically unstable medical condition ≤ 2 weeks prior to the first dose of study treatment.
 - l. Unstable or clinically severe psychiatric condition(s), including but not limited to severe depression, suicidal or homicidal ideation and/or attempt.
 - m. Epilepsy or central nervous system dysfunction

3. Evidence of active or suspected malignancy, or a history of malignancy ≤ 3 years prior to the Screening Visit (except adequately treated carcinoma in situ and basal cell carcinoma of the skin). Subjects under evaluation for malignancy are not eligible.
4. Any known or suspected hypersensitivity or previous severe reactions to any of the constituents of AB-729 or Peg-IFN α -2a, to biologics such as vaccines, or a history of previous severe hypersensitivity reactions (i.e., anaphylaxis, Stevens-Johnson Syndrome, toxic epidermal necrolysis).
5. Poor venous access that precludes the peripheral blood sampling required for this study.
6. Incapable of self-administration or assisted administration of Peg-IFN α -2a at home.

Findings/Diagnostic Assessments

7. QTcF interval >450 msec for males or >470 msec for females at Screening or Baseline (Day 1) Visit, confirmed by repeat reading.
8. ALT $>2 \times$ ULN of the laboratory reference range, confirmed by repeat.
9. Direct or total bilirubin $>1.5 \times$ ULN of the laboratory reference range, confirmed by repeat.
10. Serum albumin <3.2 g/dL, confirmed by repeat.
11. INR $>$ ULN of the laboratory reference range, confirmed by repeat.
12. Any of the following hematologic criteria, confirmed by repeat (growth factors may not be used to achieve study entry requirements):
 - a. Hemoglobin: <12 g/dL for females and <13 g/dL for males; OR
 - b. Neutrophils $<1500/\text{mm}^3$ (African descent: $<1200/\text{mm}^3$); OR
 - c. Platelets $<150,000/\text{mm}^3$.
13. Estimated creatinine clearance <60 mL/min, calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. The formula can be found at https://www.kidney.org/professionals/kdoqi/gfr_calculator/. Age, gender, race (non-black or black) and creatinine must be entered. Cystatin is to be left blank.
14. Poorly controlled diabetes mellitus with whole blood hemoglobin A1c (HbA1c) $\geq 7.5\%$ and/or Screening fasting plasma glucose of ≥ 126 mg/dL, confirmed by repeat.
15. Laboratory data (such as positive ANA plus positive ASMA and/or anti-LKM1, confirmed by repeat) and/or clinical signs or symptoms suggestive of autoimmune hepatitis.
16. Alpha fetoprotein (AFP) >10 ng/mL.

Medications, Substances, Lifestyle

17. Clinical diagnosis of substance abuse with alcohol, narcotics, or cocaine ≤ 12 months prior to the Screening Visit, except for those subjects monitored in an opioid substitution maintenance program.

18. Previous treatment with an experimental HBV-directed RNA-interference or antisense oligonucleotide product is exclusionary. History of any other prior experimental HBV treatment must be approved by the Sponsor Medical Monitor.
19. Previous serious adverse events or Grade 4 adverse events due to prior treatment with Peg-IFN α -2a are exclusionary.
20. Participation in any investigational drug, vaccine, or device study within 30 days before study treatment administration, or 90 days for a biologic study, or at any time during participation in the study.

5.3. Lifestyle Considerations

5.3.1. Meals and Dietary Restrictions

All laboratory safety assessments in the clinic should be conducted after subjects have fasted for a minimum of 8 hours. Subject must take their NA therapy with or without a meal as prescribed by the product labeling for their NA therapy.

5.3.2. Alcohol and Tobacco

Alcohol consumption is to be strongly discouraged. During the study, subjects should consume no more than an average of 2 standard drinks of alcohol daily.

The definition of a standard drink (as adapted from the National Institute on Alcohol Abuse and Alcoholism web site [36]) is defined as:

- 360 mL (12 fluid oz.) of regular beer,
- 240-270 mL (8-9 fluid oz.) of malt liquor,
- 150 mL (5 fluid oz.) of table wine,
- 90-120 mL (3-4 fluid oz.) of fortified wine,
- 60-90 mL (2-3 fluid oz.) of liqueur, or
- 45 mL (1.5 fluid oz.) of brandy, cognac, or 80-proof distilled spirits.

Subjects are discouraged from smoking, tobacco use, or use of nicotine-containing products for the entire duration of the study.

5.3.3. Activity

Strenuous exercise is strongly discouraged during the study from 96 hours before Day 1 dosing and for 96 hours prior to any clinic visit.

5.4. Screen Failures

Screen failures are defined as subjects who consent to participate in the clinical study but are not subsequently assigned to treatment. A minimal set of screen failure information is required to ensure transparent reporting of screen failure subjects to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, eligibility criteria,

and any serious adverse event (SAE). Subjects who have been deemed as screen failures may be rescreened for possible participant at a later date, if approved by the Sponsor.

6. STUDY TREATMENT

Study treatment is defined as any investigational intervention(s), marketed product(s), placebo, or medical device(s) intended to be administered to a study subject according to the study protocol.

6.1. Study Treatment(s) Administered

Table 6. Tabular Summary of Study Treatment(s)

Study Treatment Name:	AB-729	Tenofovir Disoproxil Fumarate (TDF)	Tenofovir Alafenamide (TAF)	Entecavir (ETV)	Pegylated interferon alfa-2a (Peg-IFNα-2a)
Dosage Formulation:	Sterile solution for injection	Tablet	Tablet	Tablet	Sterile solution for injection
Unit Dose Strength(s)/ Dosage Level(s):	180 mg/mL	300 mg TDF equivalent to 245 mg of tenofovir disoproxil	25 mg	0.5 and 1 mg	180 mcg/ 0.5mL in a pre-filled syringe
Route of Administration:	Subcutaneous injection	Oral	Oral	Oral	Subcutaneous injection
Dosing Instructions:	See Pharmacy Manual	See Pharmacy Manual	See Pharmacy Manual	See Pharmacy Manual	See Pharmacy Manual and Section 6.6
Packaging and Labeling:	AB-729 will be provided in vials and labeled as required per country requirement	To be sourced locally or to be provided by Sponsor and packaged/ labelled in accordance with local regulatory requirements	To be sourced locally or to be provided by Sponsor and packaged/ labelled in accordance with local regulatory requirements	To be sourced locally or to be provided by Sponsor and packaged/ labelled in accordance with local regulatory requirements	To be sourced locally or to be provided by Sponsor and packaged/ labelled in accordance with local regulatory requirements

Study Treatment Name:	AB-729	Tenofovir Disoproxil Fumarate (TDF)	Tenofovir Alafenamide (TAF)	Entecavir (ETV)	Pegylated interferon alfa-2a (Peg-IFNα-2a)
Storage:	Store under controlled refrigeration (2 – 8°C) and protect from light	Store at 20 – 25°C If provided locally, store according to package insert/label instructions	Store below 30°C If provided locally, store according to package insert/label instructions	Store at 20 – 25°C If provided locally, store according to package insert/label instructions	Store in the refrigerator at 2 – 8°C and protect from light If provided locally, store according to package insert/label instructions

See the Pharmacy Manual for further dosing instructions.

6.2. Preparation/Handling/Storage/Accountability

The investigator or designee must confirm appropriate temperature conditions have been maintained during transit for all study treatment received and any discrepancies are reported and resolved before use of the study treatment.

Only subjects enrolled in the study may receive study treatment and only authorized site staff may supply or administer study treatment. All study treatment must be stored in a secure, environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions with access limited to the investigator and authorized site staff when the study treatment is kept at the site.

The investigator, institution, or the head of the medical institution (where applicable) is responsible for study treatment accountability, reconciliation, and record maintenance (i.e., receipt, reconciliation, and final disposition records).

Further guidance and information for the final disposition of unused study treatments are provided in the Pharmacy Manual.

6.3. Measures to Minimize Bias: Randomization and Blinding

This is an open label study where after completion of a 24-week lead-in period of AB-729 60 mg SC Q8W added to ongoing SOC NA, subjects will be randomized into one of 4 groups (Cohort A1 or A2: Cohort B1 or B2). Treatment assignment will be stratified by HBsAg level at Week 24 (HBsAg \leq 100 IU/mL vs >100 IU/mL).

Each subject will be issued a unique randomization number. The randomization schedule will be generated by the clinical contract research organization (CRO) or by a statistician supporting the study and retained for the study. The randomization sequence along with the assigned study treatment for each number in the randomization sequence will be held confidentially. A manual

randomization process will be followed. A Pharmacist will assign the subjects to randomization numbers to be assigned sequentially from a master randomization schedule.

This study is open-label, so no formal blinding will be performed. However, virology data or other laboratory/analyte results that could bias the conduct of the study will not be reported to investigative sites or other personnel until the subject reaches the end of the first 24 week follow up period to evaluate if NA discontinuation criteria have been met.

6.4. Study Treatment Compliance

All doses of AB-729 will be administered at the study site by study staff members. Each dose administered will be recorded in the patient's Case Report Form (CRF).

Subjects will record all NA doses in a dosing diary, which will be reviewed at each study visit.

Peg-IFN α -2a will be administered weekly for 24 weeks (Cohorts A1 and A2) or 12 weeks (Cohorts B1 and B2). Subjects will record all self-administered Peg-IFN α -2a doses in a dosing diary, which will be reviewed at each study visit.

For Cohort A, the first Peg-IFN α -2a dose will be administered in the clinic at the Week 28 visit, and Peg-IFN α -2a administration will occur in the clinic on visit days (Weeks 30, 32, 34, 36, 38, 40, 44, 48). The remainder of Peg-IFN α -2a doses will be self-administered (Weeks 29, 31, 33, 35, 37, 39, 41, 42, 43, 45, 46, 47, 49, 50, 51). The last dose of Peg-IFN α -2a will be self-administered at Week 51.

For Cohort B, the first Peg-IFN α -2a dose will be administered in the clinic at the Week 28 visit, and Peg-IFN α -2a administration will occur in the clinic on visit days (Weeks 30, 32, 34, 36, 38). The remainder of Peg-IFN α -2a doses will be self-administered (Weeks 29, 31, 33, 35, 37, 39). The last dose of Peg-IFN α -2a will be self-administered at Week 39.

Subjects should take their dose of Peg-IFN α -2a on the same day and approximately same time each week. Subjects should also be advised that if they miss a dose, but remember within 2 days, to take their missed dose as soon as they remember and then to take their next dose on the day they normally do. If they remember when more than 2 days have passed, patients should be advised to consult their Study doctor. Subjects should also be advised to consult their Study doctor if the full dose is not received (e.g., leakage around the injection site).

For further details, see the Pharmacy Manual.

6.5. Concomitant Therapy

All medications or vaccines (including over-the-counter or prescription medicines, vitamins, and/or herbal supplements) taken by subjects at the time of enrollment (Screening) prior to first dose of study treatment through the last study visit, will be documented in the CRF as concomitant treatment. Any concomitant treatment given for any reason must be recorded on the CRF, including dosage, start and stop dates, and reason for use.

Any medication or vaccine (including over-the-counter or prescription medicines, vitamins, and/or herbal supplements) that the subject is receiving at the time of enrollment or receives during the study must be recorded along with:

- Reason for use
- Dates of administration including start and end dates
- Dosage information including dose and frequency

Regarding COVID-19 vaccination, the following timing of vaccine administration in relation to AB-729 and Peg-IFN α -2a dosing is suggested:

- When COVID-19 vaccination is anticipated AFTER an AB-729 dose, wait 72 hours prior to administering the COVID-19 vaccine administration when possible
- When AB-729 dosing is to occur AFTER COVID-19 vaccination, wait 7 days after vaccination prior to dosing AB-729 when possible
- Changes to the administration schedule of AB-729 outside of the allowed visit windows due to COVID-19 vaccination should be discussed with the Sponsor, and must be documented as COVID-19-related protocol deviations
- COVID-19 vaccination should be avoided during the period of Peg-IFN α -2a dosing due to the potential for overlapping side effects

The Sponsor's Medical Monitor and/or Clinical Pharmacologist should be contacted if there are any questions regarding concomitant or prior therapy.

The prescribing label, product monograph, or package insert of all ongoing concomitant medications used for the treatment of other medical conditions should be evaluated by the Investigator for continued administration during the subject's participation in the study. The medication list for each potential subject should be provided to the Sponsor's Medical Monitor and/or Clinical Pharmacologist for review as soon as possible after the Screening Visit to minimize the risk of unexpected drug interactions. Any medications added after the Screening Visit prior to the subject's randomization must be documented in the CRF and approved by the Sponsor's Medical Monitor and/or Clinical Pharmacologist.

Subjects must refrain from taking any new prescription or nonprescription drugs (including vitamins and dietary or herbal supplements) within 7 days or 5 half-lives (whichever is longer) before the start of study treatment until completion of the last Post-Treatment Follow-up visit, unless, in the opinion of the Investigator and Sponsor's Medical Monitor and/or Clinical Pharmacologist, the medication will not interfere with the study. Routine vaccinations should be avoided during the screening period.

6.5.1. Prohibited Medications

Investigational agents, with the exception of AB-729, are prohibited. Provisions regarding concomitant medications described in the respective Peg-IFN α -2a and NA package inserts must be followed during the study and throughout the follow-up period.

The Sponsor's Medical Monitor or Clinical Pharmacologist should be contacted if there are any questions regarding concomitant or prior therapy.

6.6. Dose Modification

6.6.1. AB-729

Modification of the AB-729 dose level or interval for a given subject is not allowed at any time.

6.6.2. Peg-IFN α -2a

Peg-IFN α -2a dose modifications may be made as follows after consultation with the Sponsor Medical Monitor according to the approved product label.[32] Following improvement of the neutropenia, thrombocytopenia, or ALT elevation, consider re-escalation of the dosage back to the previous dosage.

Hematologic adverse reactions and dose adjustments for Peg-IFN α -2a are outlined in [Table 7](#).

Table 7. Hematologic Adverse Reactions and Dose Adjustments for Peg-IFN α -2a

Laboratory Value	Recommended Peg-IFN α -2a Dosage Adjustment	Peg-IFN α -2a prefilled syringe (180 mcg/0.5 mL) volume to be injected ^a
Neutropenia		
ANC ≥ 500 but < 750 cells/mm ³	Reduce to 135 mcg SC weekly	Use 0.375 mL
ANC < 500 cells/mm ³	Hold doses until ANC ≥ 1000 cells/mm ³ then restart at 90 mcg SC weekly and monitor ANC.	Use 0.25 mL
Thrombocytopenia		
Platelets $\geq 25,000$ but $< 50,000$ cells/mm ³	Reduce to 90 mcg SC weekly	Use 0.25 mL
Platelets $< 25,000$ cells/mm ³	Discontinue treatment until resolved	N/A

Abbreviations: ANC = absolute neutrophil count; N/A = not applicable; Peg-IFN α -2a = pegylated interferon alfa 2a; SC = subcutaneous.

a. Syringe marked at 90 mcg, 135 mcg, and 180 mcg graduations.

Source: PEGASYS USPI [32]

ALT elevations and dose adjustments for Peg-IFN α -2a are outlined in [Table 8](#).

Table 8. ALT Elevations and Dose Adjustments for Peg-IFN α -2a

Laboratory Value	Recommended Peg-IFN α -2a Dosage Adjustment	Peg-IFN α -2a prefilled syringe (180 mcg/0.5 mL) volume to be injected ^a
ALT >2 \times baseline and 5 \times ULN but <10 \times ULN	Reduce to 135 mcg SC weekly or hold dose(s) until ALT elevation resolved	Use 0.375 mL
ALT >5 \times baseline and 10 \times ULN for \geq 2 weeks	Discontinue treatment until ALT elevation resolved	N/A

Abbreviations: ALT = alanine aminotransferase; N/A = not applicable; Peg-IFN α -2a = pegylated interferon alfa 2a; SC = subcutaneous; ULN = upper limit normal.

a. Syringe marked at 90 mcg, 135 mcg, and 180 mcg graduations.

Source: PEGASYS USPI [32]

Management of ALT elevations in the context of AB-729 treatment is discussed in Section 8.6 ALT Elevation Management.

Subjects who develop new ocular symptoms should receive a prompt and complete eye examination. Peg-IFN α -2a treatment discontinuation should be considered in patients who develop new or worsening ophthalmologic disorders as recommended in the approved product label and after discussion with the Sponsor Medical Monitor.

Subjects who develop Peg-IFN α -2a-related depression or worsening of existing depression while on treatment should be referred for psychiatric consultation and dose reduction of Peg-IFN α -2a should be considered as recommended in the approved product label.[32]

6.7. Intervention after the End of the Study

No study treatment will be provided to subjects enrolled in this study after the study follow up period has been completed. NAs will continue to be provided during the study follow up period for those who do not qualify for NA discontinuation.

7. STUDY TREATMENT DISCONTINUATION AND SUBJECT DISCONTINUATION/WITHDRAWAL

7.1. Discontinuation of Study Treatment for Individual Subjects

General Subject Discontinuation Criteria:

AB-729 study treatment will be discontinued for any subject who meets any of the following criteria:

- The subject requests to stop study treatment.
- Any AE, laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that continued participation in the study is not in the best interest of the subject
- Any Grade 3 or higher (Division of AIDS [DAIDS] Table for Grading the Severity of Adult and Pediatric Adverse Events)[37] AE or clinically significant laboratory abnormality (confirmed by repeat testing) considered related to AB-729, excluding ALT elevations (see Section 8.6 ALT Elevation Management)
- Pregnancy
- Termination of the study by the Sponsor
- Loss of ability to freely provide continuing consent because of imprisonment or incarceration for any reason, including for treatment of either a psychiatric or physical illness (e.g., infectious disease)
- Failure to comply with the dosing, evaluations, or other requirements of the study

Subjects may interrupt or discontinue Peg-IFN α -2a treatment due to Peg-IFN α -2a-related adverse events as indicated in Section 6.6 or the product label.[32] Subjects may continue dosing AB-729 and their NA and may remain in the study Consolidation Treatment Period if the Investigator and Sponsor Medical Monitor agree it is in the best interest of the subject.

Hepatic Discontinuation Criteria during the Treatment Period:

- Evidence of confirmed hepatic decompensation (Child Pugh Class B or C)
- Evidence of persistent ALT $\geq 5 \times$ baseline AND $\geq 10 \times$ ULN for ≥ 2 weeks without alternate cause
- ALT $\geq 2 \times$ baseline AND $\geq 5 \times$ ULN accompanied by changes in direct bilirubin $\geq 2 \times$ baseline, confirmed by repeat and without alternate cause
- Laboratory test(s) must be repeated as soon as possible and prior to the next study visit; the Sponsor's Medical Monitor should be informed of results for which discontinuation of the subject is considered. If the laboratory test results are confirmed and the Principal Investigator or Sub-Investigator assess that the above criteria have been met, the subject will discontinue study treatment.

Discontinuation from treatment does not mean discontinuation from the study. Subjects who prematurely discontinue their assigned treatment regimen should immediately undergo the assessments listed for the Early Termination visit and then continue scheduled follow-up assessments.

7.2. Study Discontinuation Criteria

Any of the following events reported will result in a halt of dosing and review of all accumulated safety data by the DMC:

- 2 or more subjects develop SAEs that are at least possibly related to AB-729
- 2 or more subjects develop severe laboratory abnormalities (DAIDS Grade 3 or greater) of the same character that are at least possibly related to AB-729, excluding ALT abnormalities
- 3 or more subjects who meet the hepatic discontinuation criterion of persistent ALT $\geq 5 \times$ baseline AND $\geq 10 \times$ ULN for ≥ 2 weeks without alternate cause
- 3 or more subjects who meet the hepatic discontinuation criterion of ALT $\geq 2 \times$ baseline AND $\geq 5 \times$ ULN accompanied by changes in direct bilirubin $\geq 2 \times$ baseline, confirmed by repeat and without alternate cause

FDA and relevant health authorities will be notified if study discontinuation criteria are met. If the DMC agrees to resume dosing, the minutes from the meeting, rationale, and supportive data will be submitted to the FDA and other relevant health authorities, as well as the Institutional Ethics Committee(s)/Institutional Review Board(s) (IEC[s]/IRB[s]) overseeing the study. IEC/IRB approval will be required before resuming dosing.

7.3. Procedures for Subject Discontinuation or Withdrawal from the Study

A subject may withdraw from the study at any time at his/her own request or may be withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons.

If the subject withdraws consent for disclosure of future information, the Sponsor may retain and continue to use any data collected before such a withdrawal of consent.

If a subject withdraws from the study, s/he may request destruction of any samples taken and not tested, and the Investigator must document this in the site's study records.

See the Schedule of Activities (Section 1.3) for data to be collected at the time of study discontinuation and follow-up and for any further evaluations that need to be completed.

Procedures for Discontinuation of Subjects:

If a subject discontinues prior to completion of the study, the reason for the discontinuation should be obtained. The date of the last dose of study medication and the date of the last assessment and/or contact should be obtained. This information should be documented in the appropriate section of the CRF. A follow-up contact (telephone or visit) should be arranged, as appropriate.

It is vital to obtain follow-up data on any subject withdrawn because of an AE. If a subject is discontinued due to an AE, the event will be followed until resolution or until the event becomes chronic, as assessed by the Investigator.

Discontinuation from study treatment and discontinuation from the overall study, including follow-up, will be collected as two separate events.

7.4. Lost to Follow-up

A subject will be considered lost to follow-up if s/he repeatedly fails to return for scheduled visits and is unable to be contacted by the study site.

For subjects lost to follow-up, a reasonable effort will be made to contact the subject in order to ascertain the reason(s) for stopping participation, while fully respecting the subject's rights.

7.5. Replacement of Subjects

Subjects who meet individual subject discontinuation rules for safety events assessed by the Investigator as related to AB-729 will not be replaced; however, subjects who discontinue for other safety-related findings may be replaced after discussion with the DMC. Other non-safety related reasons subjects may be replaced without DMC approval include non-compliance with the protocol or an inability to complete all required study visits and procedures (e.g., withdrawal of consent). Any replacements should be made in a timely manner and only after discussion between the Investigator(s) and the Sponsor's Medical Monitor.

8. STUDY ASSESSMENTS AND PROCEDURES

Refer to the tabular Schedule of Activities (Section 1.3) for the timing of assessments.

Adherence to the study design requirements, including those specified in the Schedule of Activities, is essential and required for study conduct.

The Investigator must document any deviation from the protocol procedures and notify the Sponsor or CRO.

Immediate safety concerns should be discussed with the Medical Monitor/Sponsor immediately upon occurrence or awareness, to determine if the subject should continue or discontinue study treatment.

8.1. Screening Assessments

A written informed consent form (ICF), signed and dated by both the subject and the Investigator (or authorized designee), must be obtained prior to screening assessments and before any study specific assessments and procedures are initiated. The ICF will be filed in the subject's medical record, with a copy given to the subject.

All screening evaluations must be completed and reviewed to confirm that potential subjects meet all eligibility criteria. The Investigator will maintain a screening log to record details of all subjects screened, and to confirm eligibility or record reasons for screening failure, as applicable.

Procedures conducted as part of a subject's routine clinical management (e.g., blood count) and obtained before signing of the ICF may be used for screening or baseline purposes, provided the procedures met the protocol-specified criteria and were performed within the time frame defined in the Schedule of Activities (Section 1.3).

After a subject has provided informed consent, the Investigator and other study personnel will determine if the subject is eligible for participation in the study.

Demographic data will include the following and will only be collected during Screening: age, gender, race, ethnicity, height (cm), and BMI.

A complete medical history will be collected during Screening and will be updated before the first study treatment. The medical history should include, but is not limited to chronic medical conditions, any prior HBV therapies, and concomitant medications.

A liver ultrasound to assess for HCC or other abnormalities will be performed if the subject has not had one performed (with documentation of results available) within 6 months of the Day 1 Visit. A Fibroscan® transient elastography assessment (to be read locally, if performed) will be used to assess cirrhosis status if the subject has not had one performed (with documentation of results available) within 6 months of the Day 1 Visit. If the subject had a liver biopsy within the prior 12 months, that result supersedes the Fibroscan® result. In addition, any prior liver biopsy demonstrating cirrhosis or a Metavir fibrosis score \geq F3 is exclusionary. Screening can begin 45 days prior to dosing to allow for a possible Fibroscan® or liver ultrasound, if needed, as specified in the inclusion criteria.

Subjects must provide documentation of an eye examination including a retinal evaluation within 6 months prior to Day 1. Any abnormalities must be reviewed with the Sponsor Medical Monitor prior to Day 1.

Laboratory testing will be performed per the Schedule of Assessments (Section 1.3) and as per Appendix 4 and the Study's PK/Laboratory Manual(s). Clinical safety laboratory abnormalities performed at the Screening assessment that may be exclusionary may be repeated once for confirmation (see Section 5.2).

8.2. Genetics

A pharmacogenomics blood sample for DNA isolation to examine potential polymorphisms in immune and inflammatory genes in humans and their possible associations with safety and/or PD data will be collected. A single exploratory blood sample for immune genes will be collected on Day 1. In the event of DNA extraction failure, a replacement genetic blood sample may be requested from the subject.

See Appendix 5 for a list of the genetic analyses that may be performed. Details on processes for collection and shipment and destruction of these samples can be found in the Laboratory Manual.

8.3. Immune Biomarkers

Immune biomarker samples for the measurement of soluble immune markers (such as sPD-1), immune complexes, and serum cytokines will be collected as described in the Schedule of Activities (Section 1.3). Cytokines to be examined include, but not limited to:

sCD40L, EGF, Eotaxin/CCL11, FGF-2, Flt-3 ligand, Fractalkine, G-CSF, GM-CSF, GRO, IFN- α 2, IFN- γ , IL-1 α , IL-1 β , IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17A, IP-10, MCP-1, MCP-3, MDC (CCL22), MIP-1 α , MIP-1 β , PDGF-AA, PDGF-AB/BB, RANTES, TGF- α , TNF- α , TNF- β , VEGF.

Samples will be collected for PBMC isolation, as described in the Schedule of Activities (Section 1.3) and laboratory manual. PBMC samples will be evaluated for changes in inflammatory immune response profile or HBV-specific T-cells and other immune cell phenotypes relative to baseline (pre-dose).

Details on processes for collection, shipment, and destruction of these samples can be found in the Study PK/Laboratory Manual.

8.4. Pharmacodynamic and Virologic Assessments

Samples will be collected for assessment of pre-existing or treatment-emergent resistance (via viral sequencing, see Resistance Monitoring Plan [Appendix 10] for details), HBV-related miRNA, RNAi PD marker, and HBV virologic markers (including HBV DNA, HBsAg, HBsAg isoforms, HBV RNA, HBcrAg, HBeAg, HBsAb, HBeAb), as described in the Schedule of Activities (Section 1.3). An ultrasensitive HBsAg sample will be collected for exploratory purposes should subjects reach <LLOQ on the standard HBsAg assay (see Section 1.3). Unused samples may be archived.

A single blood sample for analysis of the interleukin 28B (IL28B) genotype will be collected on Day 1 to determine a potential correlation with virologic responses.

Details on processes for collection, shipment, and destruction of these samples can be found in the Study Laboratory Manual.

8.5. Safety Assessments

Planned time points for all safety assessments are provided in the Schedule of Activities (Section 1.3).

8.5.1. Physical Examinations

Complete or targeted physical examinations will be conducted by the Investigator (or authorized designee) at each timepoint indicated in the Schedule of Activities (Section 1.3). A complete physical examination will include, at a minimum, assessments of the Cardiovascular, Respiratory, Gastrointestinal, Dermatologic and Neurological systems. A complete physical examination is required at Screening. A targeted physical examination can occur after Day 1 and will be based on any changes to the subject's health since the last visit.

8.5.2. Vital Signs

Vital signs to be measured at all applicable visits will include systolic/diastolic blood pressure, heart rate, respiratory rate, and temperature unless otherwise indicated. Blood pressure and heart rate measurements will be assessed using a completely automated device before dosing while the subject is seated or supine (unless an alternative position is medically required), however, the same position must be used at every visit and should be indicated in the CRF. Manual techniques will be used only if an automated device is not available. Blood pressure and heart rate measurements should be preceded by at least 5 minutes of rest for the subject in a quiet setting without distractions (e.g., television, cell phones).

8.5.3. Electrocardiograms

12-lead electrocardiograms (ECGs) will be obtained using an ECG machine that automatically calculates the heart rate and measures PR, RR, QRS, QT, and QTc (preferably QTcF) intervals at the timepoints indicated in Section 1.3. The Investigator or designee is responsible for reviewing the ECG to assess whether the ECG is within normal limits and to determine the clinical significance of the results. These assessments, including PR, RR, QRS, QT, and QTc/QTcF intervals, will be recorded on the CRF.

For any clinically significant abnormal results, the Investigator must contact the Sponsor's Medical Monitor to discuss continued participation of the subject in the study (e.g., ischemic ECG changes, wave/interval changes, or arrhythmia).

The investigator may repeat the ECG to verify the results of the original ECG.

8.5.4. Pregnancy Testing

For female subjects enrolled, a urine pregnancy test (and follicle stimulating hormone [FSH] test, if necessary to document postmenopausal status) will be performed to confirm eligibility at

Screening, and pregnancy tests will be repeated at the time points shown in the Schedule of Activities (Section 1.3). If a urine pregnancy test is positive or not interpretable, a serum/plasma pregnancy test will also be performed. Subjects who are pregnant are not eligible for study participation.

8.5.5. Clinical Safety Laboratory Assessments

See [Appendix 4](#) for the list of clinical laboratory tests to be performed. Refer to the Schedule of Activities Section 1.3) for details on the timing and frequency of each clinical laboratory test.

The Investigator must review the laboratory report, document this review, and record any clinically relevant changes occurring during the study in the AE section of the CRF. The laboratory reports must be filed with the source documents. Clinically significant abnormal laboratory values are those which are not associated with the underlying disease, unless judged by the Investigator to be more severe than expected for the subject's condition.

All laboratory values considered clinically significantly abnormal during participation in the study or during the protocol-defined Follow-up period after the last dose of study treatment, should be repeated until the values return to normal or baseline, or are no longer considered clinically significant by the Investigator or Sponsor's Medical Monitor.

- If such values do not return to normal/baseline within a period of time judged reasonable by the Investigator, the etiology should be identified and the Sponsor notified.
- All protocol-required laboratory assessments, as defined in [Appendix 4](#) must be conducted in accordance with the Study PK/Laboratory Manual(s) and the Schedule of Activities (Section 1.3).
- If laboratory values from non-protocol specified laboratory assessments performed at the institution's local laboratory, require a change in subject management or are considered clinically significant by the Investigator (e.g., SAE or AE), then the results from the local laboratory will be entered into the CRF.

The investigator may repeat the laboratory test or request additional tests to verify the results of the original laboratory tests.

8.5.5.1. Virology Screen

Screening tests for HIV, HCV, and HDV will be performed as indicated in the Schedule of Activities (Section 1.3) and in [Appendix 4](#). Refer to the Study Manual for further information, as applicable. Positive results may have to be reported to Public Health Authorities.

8.5.5.2. Clinical Chemistry, Hematology, and Urine Parameters

Detailed information regarding hematology and clinical chemistry testing is provided in the Schedule of Activities (Section 1.3) and in [Appendix 4](#).

Urinalysis will be performed by a dipstick test and reflex microscopic analysis.

Coagulation studies may include an evaluation of prothrombin time (PT) expressed as INR and activated partial thromboplastin time (aPTT) as indicated in [Appendix 4](#). Refer to the Study PK/Laboratory Manual(s) for further information, as applicable.

8.6. ALT Elevation Management

Subjects with ALT $\geq 2 \times$ baseline AND $\geq 5 \times$ ULN should be monitored for changes in hepatic function every 1 – 2 weeks via testing of ALT, aspartate aminotransaminase (AST), total and direct bilirubin, alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), serum albumin and international normalized ratio (INR). Unscheduled visits should be added when necessary. Subjects may continue treatment if there is no evidence of declining liver function or if a causal event (such as intercurrent illness, concomitant medication, etc.) is identified and there is no contraindication to continue treatment.

Subjects with persistent ALT elevations as noted above should also be tested for the following:

- HAV IgM
- HDV IgM/IgG and RNA by PCR
- HCV RNA by PCR
- HEV IgM
- Epstein-Barr virus (EBV) DNA by PCR
- Cytomegalovirus (CMV) DNA by PCR

Subjects with persistent ALT $\geq 5 \times$ baseline AND $\geq 10 \times$ ULN for ≥ 2 weeks OR ALT $\geq 2 \times$ baseline AND $\geq 5 \times$ ULN accompanied by changes in direct bilirubin $\geq 2 \times$ baseline without alternate cause, or symptoms of liver inflammation (such as jaundice, fatigue, nausea, vomiting, loss of appetite) should discontinue AB-729 treatment.

Subjects on Peg-IFN α -2a therapy:

- Subjects with confirmed ALT $\geq 2 \times$ baseline AND $\geq 5 \times$ ULN who are on Peg-IFN α -2a therapy may be considered for Peg-IFN α -2a dose reduction to 135 mcg.
- If persistent ALT $\geq 2 \times$ baseline AND $\geq 5 \times$ ULN is observed after reduction of Peg-IFN α -2a dosage, Peg-IFN α -2a treatment should be interrupted.
- If at any time direct bilirubin $\geq 2 \times$ baseline, treatment should be interrupted.
- See Section [6.6](#) for additional guidance.

Subjects in the Post-Treatment follow up period:

Subjects who have confirmed ALT elevations $\geq 2 \times$ baseline AND $\geq 2 \times$ ULN should be monitored for changes in hepatic function every 2 weeks via testing of ALT, AST, total and direct bilirubin, ALP, GGT, serum albumin and INR. Additional testing for HBV DNA, HBsAg, and HBeAg should also be performed. Unscheduled visits should be added when necessary, since subjects may only have scheduled visits on a bi-weekly or monthly during this period.

In addition, the following tests may be performed after confirmation of abnormalities and if warranted based on the results of HBV viral parameters noted above:

- HAV IgM
- HDV IgM/IgG and RNA
- HCV RNA by PCR
- HEV IgM
- EBV DNA by PCR
- CMV DNA by PCR

For subjects who discontinued NA therapy per protocol (see Section 4.4), resumption of NA therapy should occur if any of the following scenarios occur and after discussion with the Sponsor Medical Monitor:

- Persistent ALT elevations $\geq 2 \times$ baseline, AND $\geq 2 - 5 \times$ ULN, AND HBV DNA > 2000 IU/mL for 12 weeks
- Persistent ALT elevations $\geq 2 \times$ baseline, AND $\geq 5 - 10 \times$ ULN, AND HBV DNA > 2000 IU/mL for 4 weeks
- HBV DNA $> 20,000$ IU/mL regardless of ALT level, confirmed by repeat
- ALT $> 10 \times$ ULN, confirmed by repeat
- ALT $>$ baseline and $>$ ULN, AND:
 - increased direct or total bilirubin $\geq 2 \times$ ULN and $\geq 2 \times$ baseline confirmed by repeat, OR
 - INR increase of ≥ 0.5 from baseline, confirmed by repeat.

Subjects who restart NA therapy will be assessed every 2 weeks until clinically stable (i.e. ALT and HBV DNA declining on 2 consecutive visits) and will be followed for 24 weeks total via unscheduled visits as needed prior to study discharge (see Appendix 9).

8.7. Adverse Events and Serious Adverse Events

The definitions of an AE and SAE can be found in Appendix 6.

AEs may be reported by the subject. AEs can be spontaneously reported or elicited during examination or evaluation of a subject. To prevent reporting bias, subjects should not be questioned regarding the specific occurrence of one or more AEs.

The Investigator and any qualified designees are responsible for detecting, documenting, and recording events that meet the definition of an AE or SAE, and remain responsible for following up AEs that are serious, considered related to the study treatment or study procedures, or that caused the subject to discontinue the study treatment or study.

8.7.1. Time Period and Frequency for Collecting AE and SAE Information

All SAEs will be collected from the signing of the ICF until the last Post-Treatment Follow-up visit at all the time points specified in the Schedule of Activities (Section 1.3).

All AEs will be collected from the start of study treatment until the last Follow-up visit at all the time points specified in the Schedule of Activities (Section 1.3). Other medical occurrences that

begin after obtaining informed consent but before the start of study treatment will be recorded on the Medical History/Current Medical Conditions section of the CRF, not the AE section.

All SAEs will be recorded on the SAE Report Form and reported to the Sponsor or designee within 24 hours via email or fax, as indicated in [Appendix 6](#). The Investigator will submit any follow-up information with an updated SAE form, to the Sponsor or designee, within 24 hours of it being available.

Investigators are not obligated to actively seek AEs or SAEs after conclusion of study participation. However, if the Investigator learns of any SAE, including a death, at any time after a subject has been discharged from the study, and s/he considers the event to be reasonably related to the study treatment or study participation, the Investigator must promptly notify the Sponsor.

The method of recording, evaluating, and assessing causality of AEs and SAEs, and the procedures for completing and transmitting SAE reports, are provided in [Appendix 6](#).

8.7.2. Method of Detecting AEs and SAEs

Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and non-leading verbal questioning of the subject is the preferred method to inquire about AE occurrences.

8.7.3. Follow-up of AEs and SAEs

After the initial AE/SAE report, the Investigator is required to proactively follow each subject at subsequent visits/contacts. All AEs and SAEs documented at a previous site visit or contact, and are designated as ongoing, will be reviewed at subsequent visits/contacts.

The Sponsor may request that the Investigator perform, or arrange for, the conduct of supplemental measurements and/or evaluations, to elucidate, as fully as possible, the nature and/or causality of the AE or SAE. The Investigator is obligated to assist.

All SAEs and related AEs will be followed until resolution, stabilization, the event is otherwise explained, or the subject is lost to follow-up (as defined in [Section 7.4](#)). Further information on follow-up procedures for SAEs is given in [Appendix 6](#). Information regarding pregnancies is found in [Section 8.7.5](#).

8.7.4. Regulatory Reporting Requirements for SAEs

Prompt notification by the Investigator to the Sponsor of an SAE is essential, so that legal obligations and ethical responsibilities towards the safety of subjects and the safety of a study treatment under clinical investigation, are met.

The Sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study treatment under clinical investigation. The Sponsor or their designee will comply with country-specific regulatory requirements relating to safety reporting to the regulatory authority, IRB/IEC, and Investigators (see [Appendix 6](#)).

Investigator safety reports must be prepared for suspected unexpected serious adverse reactions (SUSARs) according to local regulatory requirements and Sponsor policy and be forwarded to Investigators as necessary.

An Investigator who receives an Investigator Safety Report describing SAEs or other specific safety information (e.g., summary or listing of SAEs) from the Sponsor, will review it and then file it, along with the IB, and will notify the IRB/IEC, if appropriate, according to local requirements.

8.7.5. Pregnancy

The Sponsor must be notified of any female subject that becomes pregnant while participating in the study, or of any pregnancy that occurs in the female partner of a male subject in the study. Pregnancy in a study subject should result in immediate discontinuation of study treatment.

Although pregnancy is a normal human experience and not technically an AE, all pregnancies must be followed to conclusion to determine outcomes for both mother and baby. This information is important for characterizing the investigational product safety profile. It is the responsibility of the Investigator or designee to report any pregnancy in a subject that occurs during the study. In the event of an early discontinuation, it is the responsibility of the Investigator or designee to report any pregnancy they are aware of in a subject that occurs within 6 months after the last dose of the investigational product.

For women who become pregnant after sexual intercourse with a study subject, a Pregnancy Follow-up Consent Form must be completed to permit follow-up of the woman to ascertain outcomes for both mother and baby. Such informed consent and follow-up are necessary during the study, or in the event the subject discontinues early and the Investigator becomes aware of a pregnancy, when the estimated date of conception falls within 6 months or less of the study subject's last study treatment exposure. Follow-up should be performed by the Investigator or designee in accordance with the schedule outlined on the Pregnancy Report Form.

If the pregnancy ends, the Investigator should notify the Sponsor and complete the Pregnancy Report Form. If necessary, other providers may be approached to ascertain pregnancy outcomes per the completed ICF. If the outcome of the pregnancy for either mother or child meets the criteria for an SAE (e.g., spontaneous abortion, fetal death, stillbirth, ectopic pregnancy, neonatal death, postpartum complications, or congenital anomaly including that in an aborted fetus), the Investigator should follow the procedures for reporting an SAE (see Section 8.7.4 and Appendix 6).

8.8. Treatment of Overdose

Overdose of AB-729 will not be reported as an AE/SAE unless it is an intentional overdose taken with possible suicidal/self-harming intent. Such overdoses should be reported regardless of sequelae.

The Sponsor does not recommend any specific treatment for an overdose other than supportive care.

In the event of a suspected overdose of AB-729, the Investigator should:

1. Contact the Sponsor's Medical Monitor immediately.
2. Closely monitor the subject for any AE/SAE and laboratory abnormalities for at least 7 days.
3. Obtain a plasma sample for PK analysis as soon as possible from the date of the last dose of study intervention, if requested by the Sponsor's Medical Monitor (determined on a case-by-case basis).
4. Document the quantity of the excess dose, as well as the duration of the overdose in the CRF.

Suspected overdose of NAs or Peg-IFN α -2a should be reported as per local regulatory guidelines for post-marketing adverse drug events.

8.9. Pharmacokinetic Assessments

Plasma samples will be collected at the time-points described in the Schedule of Activities (Section 1.3) and in [Appendix 7](#) and will be collected to achieve those measures detailed in Section 9.4.4. A window of ± 2 minutes for samples collected will be allowed for PK samples.

The actual time of sample collection will be documented. All instances of missed samples and sampling time deviations will be recorded and communicated to the Sponsor, prior to the sample analysis.

Additional details regarding PK sample collection and handling will be provided in the Study Laboratory Manual Kits for PK sample collection, including handling instructions, and all necessary materials for PK sample collection and storage, will be provided to each study site. It is critical that the sample handling instructions be followed exactly.

An intravenous catheter will be used for blood collection to avoid multiple skin punctures, when appropriate. Otherwise, blood samples will be collected by direct venipuncture.

8.10. Use of Residual Samples for Optional Future Research

In addition to the study-specific ICF to be signed by each subject participating in the study, a separate consent form, or a separate specific signature within the main ICF will be required to document a subject's agreement to allow the use of unused or residual biomarker, virologic, and/or PK samples collected as part of the protocol assessments for optional future research.

The specimens collected for optional future research will be used to increase knowledge and understanding of the biology of HBV and related diseases and to study the association of biomarkers with disease pathogenesis, progression and/or treatment outcomes, including efficacy, AEs, and the process of drug absorption and disposition.

These specimens may be used also to develop biomarker or diagnostic assays for HBV and establish the performance characteristics of these assays. The collection and analysis of optional future research specimens will facilitate the rational design of new pharmaceutical agents and the

development of diagnostic tests, which may allow for individualized drug therapy for patients in the future.

Samples will be securely stored by Arbutus or at an Arbutus-approved third party storage management facility for the period specified in the informed consent. Samples will be stored in a coded fashion, and no researcher will have access to the key. The key will be securely held by the Investigator at the clinical site such that there will be no direct ability for a researcher to connect a sample to a specific individual. Additional research samples will be retained for the maximum allowed by applicable law.

Further details of sample collection and processing will be provided to the site in the Study's Laboratory Manual.

8.11. Medical Resource Utilization and Health Economics

No Medical Resource Utilization or Health Economics parameters are evaluated in this study.

9. STATISTICAL CONSIDERATIONS

9.1. Statistical Hypotheses

No hypothesis will be formally tested in this study.

9.2. Sample Size Determination

Approximately 80 subjects will be screened to achieve approximately 40 dosed subjects, who are stably NA-suppressed, HBeAg negative, with non-cirrhotic CHB. After a 24-week lead-in period of AB-729 60 mg SC Q8W added to ongoing SOC NA, subjects will be randomized into one of 4 groups:

- A1: AB-729 + NA + weekly Peg-IFN α -2a for 24 weeks (N = 12)
- A2: NA + weekly Peg-IFN α -2a for 24 weeks (N = 12)
- B1: AB-729 + NA + weekly Peg-IFN α -2a for 12 weeks (N = 8)
- B2: NA + weekly Peg-IFN α -2a for 12 weeks (N = 8)

Treatment assignment will be stratified by HBsAg level at Week 24 (HBsAg ≤ 100 IU/mL vs >100 IU/mL).

The sample size for this study is based on clinical rather than statistical rationale. The sample size is considered adequate to support the planning and design of future studies.

9.3. Populations for Analyses

For purposes of analysis, the following populations are defined:

Table 9. Populations for Analysis

Population	Description
Safety Lead-in	All subjects who take at least 1 dose of study treatment in the Lead-in period
Randomized (intent-to-treat)	All subjects randomly assigned to study treatment
Safety	All subjects who take at least 1 dose of study treatment. Subjects' data will be analyzed according to the treatment they actually received.
Per Protocol	All subjects in the Safety Population who have no major protocol violations
PK	All subjects in the Safety Population with PK samples adequate for the calculation of PK parameters.

9.4. Statistical Analyses

The statistical analysis plan (SAP) will be developed and finalized before database lock and will describe the subject populations to be included in the analyses (see also [Table 9](#)), and procedures to account for missing, unused, and spurious data. This section is a summary of the planned statistical analyses of the primary, secondary, and exploratory endpoints.

In general, descriptive summaries will include n, mean, standard deviation, median, minimum, and maximum, for continuous variables, and n and percent for categorical variables. Summaries will present data by dose group and where appropriate, by assessment time. Geometric means, CV% and associated 95% confidence interval will be presented for PK parameters (except time of maximum observed plasma concentration [T_{max}]).

The data summaries will be provided by treatment period and treatment arm.

9.4.1. Safety Analyses

All safety analyses will be performed on the Safety and Safety Lead-in Population. Safety will be assessed based on AEs, clinical laboratory data, vital signs, ECG parameters, and physical examinations.

Number of doses administered and duration of exposure will be summarized, descriptively, by treatment period and treatment arm. Duration of exposure will be defined as the number of days from the first dose to the last.

9.4.1.1. Adverse Events

AEs will be coded to a Medical Dictionary for Regulatory Activities (MedDRA) preferred term and system organ classification. Any events reported after the initiation of study treatment and up to 12 weeks after the last dose of AB-729 or 28 days after the last dose of Peg-IFN α -2a, are defined as treatment-emergent. The occurrence of treatment-emergent AEs will be summarized using MedDRA preferred terms, system organ classifications, and severity. Separate summaries of treatment-emergent SAEs and AEs considered related to study treatment, and AEs leading to

study treatment discontinuation, will be generated. All AEs will be listed for individual subjects, showing both verbatim and preferred terms.

9.4.1.2. Clinical Laboratory Results

Laboratory abnormalities will be graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected Version 2.1 [37]. Any graded abnormality that occurs following the initiation of study treatment and represents at least a 1-grade increase from the baseline assessment, is defined as treatment-emergent. The number and percentage of subjects experiencing treatment-emergent graded toxicities will be summarized. Laboratory toxicity shifts from baseline to worst post-baseline assessments will be summarized.

Listings of the clinical laboratory test results will be provided. Abnormal laboratory values will be flagged in the listings.

9.4.1.3. Other Parameters

Descriptive summaries of vital signs, weight, ECG parameters, and clinical laboratory results will be presented.

Concomitant medications will be coded using the World Health Organization (WHO) drug dictionary and summarized.

9.4.2. **Immune Biomarkers**

The exploratory endpoints of soluble immune markers, immune complex levels, cytokines, inflammatory and HBV-specific immune markers on PBMCs may be reported separately from the clinical study report. The change from baseline in these markers (if applicable) will be summarized by treatment in tabular and graphic format using descriptive statistics.

The exploratory endpoint to examine potential polymorphisms in immune and inflammatory genes in humans may be reported separately from the clinical study report. Listings of polymorphisms (if applicable) will be summarized by treatment in tabular and graphic format using descriptive statistics.

9.4.3. **Pharmacodynamic and Efficacy Analyses**

The change from baseline in HBV DNA, HBV RNA, HBsAg, HBsAb, HBcrAg, HBeAg, and HBeAb will be summarized by treatment and visit in tabular and graphic format using descriptive statistics.

The proportion of subjects with HBsAg, HBV RNA and/or HBcrAg reduction of ≥ 0.5 , 1, 2, or 3 \log_{10} from baseline; \leq LLOQ or TND will be presented along with 95% exact binomial interval for each treatment group.

In addition to the descriptive statistics, treatment comparisons may be performed. The continuous variables, such as mean change from baseline, will be evaluated using a regression model with baseline values and stratification factor as covariates. The binary variables, such as the proportion of participants who meet the endpoint criterion, will be evaluated using a Cochran-Mantel-Haenszel test adjusting for the stratification factor. Details will be provided in the SAP.

The exploratory endpoints of HBsAg isoforms, RNAi PD marker levels, and HBV-related miRNAs may be reported separately from the clinical study report. The change from baseline in these markers (if applicable) will be summarized by treatment in tabular and graphic format using descriptive statistics.

9.4.4. Pharmacokinetic Analyses

Bioanalytical summary report(s) will include the analytical results, stability of the frozen samples, a summary of the standard curves and quality control samples, and results of the incurred sample reanalysis, if applicable. Residual plasma may be archived for exploratory metabolite analysis that would be reported separately from the clinical study report.

Pharmacokinetic analysis as defined in the SAP will be conducted using the PK population defined in Section 9.3. In the event of discrepancies between analyses described in the SAP and this clinical study protocol, the SAP will supersede the protocol.

- All samples will be analyzed and all concentrations listed.
- The listing of PK concentrations will be flagged for subjects who did not receive all doses and any other significant protocol deviations.
- Descriptive statistics will be performed for all time points available, with the exclusion of subjects who did not receive all doses or any other significant protocol deviations.
- Pharmacokinetic parameters will be derived where possible for all subjects. Data from subjects with incomplete profiles (missed blood draws, lost samples, samples unable to be quantified) may be used if PK parameters can be estimated using the remaining data points.
- Descriptive statistics will be performed on all parameters available, and any missing parameters will be flagged.
- Plasma PK parameters of AB-729 AS, AB-729 AS(N-1)3', and AB-729 AS(N-2)3' for each subject will be estimated over the sampling interval using non-compartmental analysis and summarized by treatment group using descriptive statistics. The plasma PK parameters that will be estimated, if feasible, are listed in the table below. Additional parameters may be analyzed, as appropriate.

Table 10. Pharmacokinetic Parameters for AB-729

Pharmacokinetic Parameter	Definition
C _{max}	Maximum observed plasma concentration
T _{max}	Time of maximum observed plasma concentration
AUC _{0-t}	Area under the concentration time- curve from the time of dosing to the last measurable concentration

Actual blood sampling times will be used for PK analysis. In all derivations of PK parameters, zero will be substituted for concentrations below the quantification limit (BQL) of the assay prior to the first quantifiable sample. Samples which are otherwise BQL will be treated as missing.

9.5. Interim Analyses

There are no formal interim analyses planned for this study, however, a DMC will periodically review safety data from this study.

10. REFERENCES

1. Arbutus Biopharma Corporation, *Investigator's Brochure for AB-729 Injection; Version 4.0*. 2021.
2. Organization., W.H., *Hepatitis B Factsheet*. Available at: <https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-b>, 2020.
3. Yuen, M., et al., *Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study*. Journal of Hepatology, 2020. **73(S1)**: p. S140.
4. Fung, S., et al., *Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-negative chronic hepatitis B infection*. Journal of Hepatology, 2020. **73(S1)**: p. S51.
5. Yuen, M.F., et al., *Hepatitis B virus infection*. Nat Rev Dis Primers, 2018. **4**: p. 18035.
6. Gane, E., et al., *Preliminary safety and antiviral activity of VIR-2218, an X-targeting HBV RNAi therapeutic, in chronic hepatitis B patients*. J Hepatol, 2020. **73**: p. S50-S51.
7. Gane, E., et al., *Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment*. J Hepatol, 2020. **73**: p. S20.
8. Yuen, M.F., et al, *First Clinical Experience with RNA Interference-based Triple Combination Therapy in Chronic Hepatitis B: JNJ-3989, JNJ-6379 and a Nucleos(t)ide Analogue*. Hepatol, 2019. **70(6)**: p. 1477A-1501A.
9. Yuen, M.F., et al, *HBV RNAi inhibitor RG6346 in phase 1b-2a trial was safe, well-tolerated, and resulted in substantial and durable reductions in serum HBsAg levels*. The Liver Meeting Digital Experience (The 71st AASLD Annual Meeting), 2020: p. Late Breaking Abstract L09.
10. Bazinet, M., et al., *Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy*. Gastroenterology, 2020. **158(8)**: p. 2180-2194.
11. Vigano, M., et al, *Treatment of hepatitis B: Is there still a role for interferon?* Liver International, 2018. **38**: p. 79-83.
12. Marcellin, P., et al., *Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B*. Aliment Pharmacol Ther, 2016. **44(9)**: p. 957-966.
13. Thimme, R. and M. Dandri, *Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B?* J Hepatol, 2013. **58(2)**: p. 205-9.
14. European Association for the Study of the Liver, *EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection*. J Hepatol, 2017. **67(2)**: p. 370-398.
15. Terrault, N.A., et al., *AASLD guidelines for treatment of chronic hepatitis B*. Hepatology, 2016. **63(1)**: p. 261-83.
16. Sarin, S.K., et al., *Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update*. Hepatol Int, 2016. **10(1)**: p. 1-98.
17. Liaw, Y.F., *Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection*. Nat Rev Gastroenterol Hepatol, 2019. **16(10)**: p. 631-641.

18. Papatheodoridi, M. and G. Papatheodoridis, *Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B*. Cells, 2020. **9**(2).
19. Chang, M.L., Y.F. Liaw, and S.J. Hadziyannis, *Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B*. Aliment Pharmacol Ther, 2015. **42**(3): p. 243-57.
20. Liu, J., et al., *The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation Among Asian Patients With Chronic Hepatitis B: A Systematic Review*. Hepatology, 2019. **70**(3): p. 1045-1055.
21. Jeng, W.J., et al., *Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B*. Hepatology, 2018. **68**(2): p. 425-434.
22. Hsu, Y.C., et al., *Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk*. Aliment Pharmacol Ther, 2019. **49**(1): p. 107-115.
23. Papatheodoridi, M., et al., *Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B*. J Viral Hepat, 2020. **27**(2): p. 118-126.
24. Sonneveld, M.J., et al., *Prediction of Sustained Response After Nucleo(s)ide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)*. Clin Gastroenterol Hepatol, 2020.
25. Agarwal, K., et al., *Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection*. J Hepatol, 2015. **62**(3): p. 533-40.
26. Marcellin, P., et al., *Combination of Tenofovir Disoproxil Fumarate and Peginterferon alpha-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B*. Gastroenterology, 2016. **150**(1): p. 134-144 e10.
27. Zeng QL, Y.Z., Shang J, Xu GH, Sun CY, Liu N, Li CX, Lv J, et al., *Short-term Peginterferon-Induced High Functional Cure Rate in Inactive Chronic Hepatitis B Virus Carriers With Low Surface Antigen Levels* Open Forum Infectious Diseases, 2020. **7**(6): p. <https://doi.org/10.1093/ofid/ofaa208>.
28. Assembly Biosciences, *Assembly Biosciences Provides Update on the Ongoing Phase 2 Extension Study of Vebicorvir in Patients with Chronic Hepatitis B Virus Infection*. <https://investor.assemblybio.com/node/10876/pdf>, 2020.
29. Liaw, Y.F., *Hepatitis B Flare After Cessation of Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B: To Retreat or Not to Retreat*. Hepatology, 2021. **73**(2): p. 843-852.
30. Papatheodoridis, G., et al., *Discontinuation of oral antivirals in chronic hepatitis B: A systematic review*. Hepatology, 2016. **63**(5): p. 1481-92.
31. Shemesh, C., et al., *Assessment of the Drug Interaction Potential of Unconjugated and GalNAc3-Conjugated 2'-MOE-ASOs*. Mol Ther Nucleic Acids, 2017. **9**: p. 34-47.
32. Hoffmann-La Roche Inc., *PEGASYS (peginterferon alfa-2a) injection, for subcutaneous use Prescribing Information*. 2021.
33. Chang, M.L. and Y.F. Liaw, *Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management*. J Hepatol, 2014. **61**(6): p. 1407-17.

34. Chuaypen, N., et al., *Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy*. Clin Microbiol Infect, 2018. **24**(3): p. 306 e7-306 e13.
35. Rijckborst, V., et al., *Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a*. J Hepatol, 2012. **56**(5): p. 1006-1011.
36. National Institutes of Health; National Institute of Alcohol Abuse and Alcoholism. *Rethinking Drinking; What's a "Standard" Drink Web Page*. April 2018.]; Available from: <https://www.rethinkingdrinking.niaaa.nih.gov/How-much-is-too-much/Is-your-drinking-pattern-risky/Whats-At-Risk-Or-Heavy-Drinking.aspx>.
37. United States Department of Health and Human Services - National Institutes of Health - National Institute of Allergy and Infectious Diseases Division of AIDS. *Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1*. July, 2017; Available from: [https://rsc.tech-res.com/docs/default-source/safety/division-of-aids-\(daids\)-table-for-grading-the-severity-of-adult-and-pediatric-adverse-events-corrected-v-2-1.pdf](https://rsc.tech-res.com/docs/default-source/safety/division-of-aids-(daids)-table-for-grading-the-severity-of-adult-and-pediatric-adverse-events-corrected-v-2-1.pdf).
38. CDER, *Guidance for Industry Technical Specifications Document: Submitting Next Generation Sequencing Data to the Division of Antiviral Products*. <https://www.fda.gov/media/129126/download>, 2019.

**11. APPENDICES FOR SUPPORTING DOCUMENTATION AND
OPERATIONAL CONSIDERATIONS**

Appendix 1 Abbreviations and Trademarks

Abbreviation	Definition
Arbutus	Arbutus Biopharma Corporation
AE	adverse event
AFP	alpha fetoprotein
ALT	alanine aminotransferase
aPTT	activated partial thromboplastin time
AS	anti-sense
AST	aspartate aminotransaminase
BMI	body mass index
BQL	below the quantification limit
CHB	chronic hepatitis B
CRF	case report form, electronic or paper
CRO	contract research organization
CYP	Cytochrome P450
DAIDS	Division of AIDS (acquired immunodeficiency syndrome)
DILI	drug induced liver injury
ECG	electrocardiogram
ETV	entecavir
FSH	follicle stimulating hormone
GalNAc	<i>N</i> -Acetylgalactosamine
GCP	Good Clinical Practice
HAV	hepatitis A virus
HBcAb	hepatitis B core antibody
HBcrAg	hepatitis B virus core related antigen
HBeAb	hepatitis B virus e-antibody
HBeAg	hepatitis B virus e-antigen
HBsAb	hepatitis B virus surface antibody
HBsAg	hepatitis B virus surface antigen
HBV	hepatitis B virus
HCC	hepatocellular carcinoma
HCV	hepatitis C virus
HDV	hepatitis D virus
HEV	hepatitis E virus
HIV	human immunodeficiency virus
HRT	hormonal replacement therapy
IB	Investigator's Brochure
ICF	informed consent form
ICH	International Council on Harmonisation
IEC	Institutional Ethics Committee
IFN α	interferon alpha

Abbreviation	Definition
IgM	immunoglobulin M
IL	interleukin
INR	international normalized ratio
IRB	institutional review board
IUD	intrauterine device
LLOQ	lower limit of quantification
MedDRA	Medical Dictionary for Regulatory Activities
miRNA	microRNAs
NA	nucleos(t)ide analogue
PBMC	peripheral blood mononuclear cells
PD	pharmacodynamic
Peg-IFN α	pegylated interferon alfa
PK	pharmacokinetic(s)
PT	prothrombin time
QTcF	QT interval corrected using Fridericia's formula
QW	every week
RNA	ribonucleic acid
SAE	serious adverse event
SAP	Statistical Analysis Plan
SC	subcutaneous
siRNA	small interfering ribonucleic acid
sPD-1	soluble programmed death-1
TAF	tenofovir alafenamide
TDF	tenofovir disoproxil fumarate
TEAE	treatment emergent adverse event
TND	target not detected
ULN	upper limit of normal
WOCBP	women of childbearing potential

Appendix 2 Regulatory, Ethical, and Study Oversight Considerations

Regulatory and Ethical Considerations

- This study will be conducted in accordance with the protocol and with the following:
 - Consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines
 - Applicable International Council on Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines
 - Applicable laws and regulations
- The protocol, protocol amendments, ICF, IB, and other relevant documents (e.g., subject recruitment materials) must be submitted to an IRB/IEC by the Investigator and reviewed and approved by the IRB/IEC before the study is initiated.
- Any amendments to the protocol will require IRB/IEC approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study subjects.
- The Investigator will be responsible for the following:
 - Providing written summaries of the status of the study to the IRB/IEC annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/IEC.
 - Notifying the IRB/IEC of SAEs or other significant safety findings as required by IRB/IEC procedures.
 - Providing oversight of the conduct of the study at the site and adherence to applicable requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies, and all other applicable local regulations.

Financial Disclosure

Investigators and Sub-Investigators must provide the Sponsor with sufficient, accurate financial information as requested to allow the Sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate regulatory authorities. Investigators are responsible for providing information on financial interests during the study and for 1 year after completion of the study.

Informed Consent Process

- The Investigator or his/her representative will explain the nature of the study to the subject and answer all questions regarding the study.
- Subjects must be informed that their participation is voluntary. Subjects will be required to sign a statement of informed consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA) or other privacy law requirements, where applicable, and the IRB/IEC or study center.
- The medical record must include a statement that written informed consent was obtained before the subject was enrolled in the study and the date the written consent was obtained. The authorized person obtaining the informed consent must also sign the ICF.
- Subjects must be re-consented to the most current version of the ICF(s) during their participation in the study.
- A copy of the ICF(s) must be provided to the subject.

A subject who is rescreened is not required to sign another ICF if the rescreening occurs within 60 days from the previous ICF signature date.

A separate ICF will be provided that addresses the use of remaining mandatory samples for optional exploratory research. The Investigator or authorized designee will explain to each subject the objectives of the exploratory research. Subjects will be told that they are free to refuse to participate and may withdraw their consent at any time and for any reason during the storage period. If a study subject refuses or withdraws consent to have their samples used for optional exploratory research, the samples will be destroyed accordingly as per local requirements. A signature on the separate, optional ICF will be required to document a subject's agreement to allow any remaining specimens to be used for exploratory research.

Data Protection

- Subjects will be assigned a unique identifier by the Sponsor. Any subject records or datasets that are transferred to the Sponsor will contain the identifier only; subject names or any information which would make the subject identifiable will not be transferred.
- The subject must be informed that his/her personal study-related data will be used by the Sponsor in accordance with local data protection law. The level of disclosure must also be explained to the subject.

- The subject must be informed that his/her medical records may be examined by Clinical Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory authorities.

Data Monitoring Committee Structure

The DMC will be a group of 3 independent members who will operate in accordance with a pre-specified charter and make recommendations to the Sponsor.

Data Quality Assurance

- All subject data relating to the study will be recorded on printed or electronic CRF(s) unless transmitted to the Sponsor or designee electronically (e.g., laboratory data). The Investigator is responsible for verifying that data entries are accurate and correct, and to confirm this by physically or electronically signing the CRF.
- The Investigator must maintain accurate documentation (source data) that supports the information entered in the CRF.
- The Investigator must permit study-related monitoring, audits, IRB/IEC review, and regulatory agency inspections and provide direct access to source data documents.
- The Sponsor or designee is responsible for the data management of this study including quality checking of the data.
- Study monitors will perform ongoing source data verification to confirm that data entered into the CRF by authorized site personnel are accurate, complete, and verifiable from source documents; that the safety and rights of subjects are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements.
- Records and documents, including signed ICFs, pertaining to the conduct of this study must be retained by the Investigator for 5 years after study completion unless local regulations or institutional policies require a longer retention period. No records may be destroyed during the retention period without the written approval of the Sponsor. No records may be transferred to another location or party without written notification to the Sponsor.

Source Documents

- Source documents provide evidence for the existence of the subject and substantiate the integrity of the data collected. Source documents are filed at the Investigator's site.

- Data reported on the CRF or entered in the eCRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The Investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available.

Study and Site Closure

The Sponsor or their designee reserves the right to close the study site or terminate the study at any time for any reason at the sole discretion of the Sponsor. Study sites will be closed upon study completion. A study site is considered closed when all required documents and study supplies have been collected and a study-site closure visit has been performed.

The Investigator may initiate study-site closure at any time, provided there is reasonable cause and sufficient notice is given in advance of the intended termination.

Reasons for the early closure of a study site by the Sponsor or Investigator may include but are not limited to:

- Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC or local Health Authorities, the Sponsor's procedures, or GCP guidelines
- Inadequate recruitment of subjects by the Investigator
- Discontinuation of further study treatment development.

Publication Policy

- The results of this study may be published or presented at scientific meetings. If this is foreseen, the Investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.
- The Sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating Investigator will be designated by mutual agreement.
- Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.

Appendix 3 Contraceptive Guidance and Collection of Pregnancy Information

Definitions:

Woman of Childbearing Potential (WOCBP)

A woman is considered fertile following menarche and until becoming post-menopausal unless permanently sterile (see below).

Women in the following categories are not considered WOCBP

1. Premenarchal
2. Premenopausal female with 1 of the following:
 - Documented hysterectomy
 - Documented bilateral salpingectomy
 - Documented bilateral oophorectomy

Note: Documentation can come from the site personnel's review of the subject's medical records, medical examination, or medical history interview.

3. Postmenopausal female
 - A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high FSH level in the postmenopausal range (>40 mIU/mL) may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.
 - Females on HRT and whose menopausal status is in doubt will be required to use one of the non- hormonal contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.

Contraception Guidance:

Male subjects

Male subjects with female partners of childbearing potential are eligible to participate if they agree to ONE of the following during the protocol-defined time frame in Section 5.1:

- Are abstinent from penile-vaginal intercourse as their usual and preferred lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent.

- Agree to use a male condom **plus** partner-use of a contraceptive method with a failure rate of <1% per year as described in [Table 11](#) when having penile-vaginal intercourse with a woman of childbearing potential who is not currently pregnant.

Male subjects with a pregnant partner are not eligible to enroll in this study.

Female subjects

Female subjects of childbearing potential are eligible to participate only if they agree to use a highly effective method of contraception consistently and correctly as described in Section 5.1. Female study subjects and female partners of male study subjects may use any of the highly effective methods shown in [Table 11](#).

Table 11. Highly Effective Contraceptive Methods

<p>Highly Effective Contraceptive Methods That Are User Dependent^a</p> <p><i>Failure rate of <1% per year when used consistently and correctly.</i></p> <p>Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:</p> <ul style="list-style-type: none"> • Oral • Intravaginal • Transdermal <p>Progestogen only hormonal contraception associated with inhibition of ovulation:</p> <ul style="list-style-type: none"> • Oral • Injectable <p>Sexual abstinence</p> <p><i>Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the subject.</i></p>
<p>Highly Effective Contraceptive Methods That Are User-Independent^b</p> <ul style="list-style-type: none"> • Implantable progestogen only hormonal contraception associated with inhibition of ovulation • Intrauterine device (IUD) • Intrauterine hormone-releasing system (IUS) • Bilateral tubal occlusion • Vasectomized partner: <i>A vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used.</i>

- a. Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent with local regulations regarding the use of contraceptive methods for subjects participating in clinical studies.
- b. User-independent methods do not require consistent interaction (between the user and the method) to assure their success rate.

Less effective contraceptive methods that are NOT permitted as the primary contraceptive method for use in this study include:

- Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action
- Male or female condom, with or without spermicide (male and female condoms used together do not constitute a highly effective method)
- Cervical cap, diaphragm or sponge with spermicide

Any of these methods above may be used as an additional method of contraception in addition to one of the highly effective methods in [Table 11](#) if required by local regulations.

Ineffective contraceptive methods that are NOT permitted for use in this study include:

- Periodic abstinence (calendar, symptothermal, post-ovulation methods)
- Withdrawal (coitus interruptus)
- Spermicides only
- Lactational amenorrhea method

Pregnancy Testing:

- WOCBP should only be included after a confirmed menstrual period and a negative urine pregnancy test.
- Additional pregnancy testing should be performed during the study period and after the last dose of study treatment as in Section 1.3, Schedule of Activities, and as required locally.
- Pregnancy testing will be performed whenever a menstrual cycle is missed or when pregnancy is otherwise suspected

Collection of Pregnancy Information:

Male subjects with partners who become pregnant

The Investigator will attempt to collect pregnancy information on any male subject's female partner who becomes pregnant while the male subject is in this study. This applies only to male subjects who receive active AB-729, if treatment assignment is known at the time the pregnancy is reported.

After obtaining the necessary signed informed consent from the pregnant female partner directly, the Investigator will record pregnancy information on the appropriate form and submit it to the Sponsor as soon as possible after learning of the partner's pregnancy. The female partner will also be followed to determine the outcome of the pregnancy. Information on the status of the mother and child will be forwarded to the Sponsor. Generally, the follow-up will be no longer than 6 to 8 weeks following the estimated delivery date. Any termination of the pregnancy will be reported regardless of fetal status (presence or absence of anomalies) or indication for the procedure.

Female subjects who become pregnant

The Investigator will collect pregnancy information on any female subject who becomes pregnant while participating in this study. Information will be recorded on the appropriate form and submitted to the Sponsor within 24 hours of learning of a subject's pregnancy. The subject will be followed to determine the outcome of the pregnancy. The Investigator will collect follow-up information on the subject and the neonate and the information will be forwarded to the Sponsor. Generally, follow-up will not be required for longer than 6 to 8 weeks beyond the

estimated delivery date. Any termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indication for the procedure.

While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or elective termination of a pregnancy will be reported as an AE or SAE. A spontaneous abortion is always considered to be an SAE and will be reported as such. Any post-study pregnancy-related SAE considered reasonably related to the study treatment by the Investigator will be reported to the Sponsor as described in Section 8.7.4. While the Investigator is not obligated to actively seek this information in former study subjects, he or she may learn of an SAE through spontaneous reporting.

Any female subject who becomes pregnant while participating in the study will discontinue study treatment and be withdrawn from the study.

Appendix 4 Clinical Laboratory Tests

Laboratory tests are to be completed after a fast of at least 8 hours (including refraining from ingestion of alcohol or caffeine-containing products) and, during the treatment period, should be drawn prior to dosing.

Local laboratory results are only required if the central laboratory results are not available in time for either study treatment administration and/or response evaluation. If a local sample is required, it is important that the sample for central analysis is obtained at the same time. Additionally, if the local laboratory results are used to make either a study treatment decision or response evaluation, the results must be entered into the CRF.

Additional tests may be performed at any time during the study as determined necessary by the investigator or required by local regulations.

Virology data or other laboratory/analyte results that could bias the conduct of the study will not be reported to investigative sites until the subject reaches the end of the first 24 week follow up period to evaluate if NA discontinuation criteria have been met.

Investigators must document their review of each laboratory safety report.

Table 12. Protocol-Required Laboratory Assessments

Laboratory Assessments	Parameters
Hematology	<div> <div> Platelet Count RBC Count Hemoglobin Hematocrit </div> <div> <u>WBC count with differential:</u> Neutrophil count Lymphocyte count Monocyte count Eosinophil count Basophil count </div> </div>
Clinical Chemistry	<div> <div> Sodium Potassium Glucose Chloride CO₂ BUN Creatinine Calcium Phosphorus Magnesium Uric acid Lactate dehydrogenase Lipase Albumin Total protein CPK </div> <div> <u>Liver Function Tests:</u> AST ALT Alkaline phosphatase Bilirubin (total and direct) GGT </div> </div>
Coagulation	PT / INR aPTT
Endocrine	TSH
Urine Parameters	<u>Urinalysis:</u> Specific gravity pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase by dipstick Microscopic examination (reflex if dipstick is abnormal)
Virology Tests	<div> <div> HBV Genotype <u>Quantitative tests:</u> HBsAb HBsAg HBsAg isoforms HBcrAg HBeAg HBV DNA HBV RNA Ultrasensitive HBsAg </div> <div> Resistance sample <u>Qualitative tests:</u> HBcAb IgM (screening only) HBeAg (screening only) HBeAb </div> </div>

Laboratory Assessments	Parameters
Biomarkers	HBV-related miRNAs Soluble immune biomarkers/immune complexes PBMCs
Genotype (24 Week Lead-In Period only)	IL28B Genotype
Pharmacogenomics (24 Week Lead-In Period only)	Exploratory immune genes SNP Sample
Other Screening Tests	FSH (as needed in postmenopausal females only) hCG pregnancy test (as needed for women of childbearing potential only) ^a Serology– HIV, HCV, and HDV antibody AFP, HbA _{1c} , and TSH/Free T4 ANA, ASMA, anti-LKM1 serology

Abbreviations: AFP = alpha fetoprotein; ALT = alanine aminotransferase; ANA = antinuclear antibody; anti-LKM1 = liver/kidney microsomal antibody type 1; aPTT = activated partial thromboplastin time; ASMA = anti-smooth muscle antibody; AST = aspartate aminotransferase; BUN = blood urea nitrogen; CO₂ = carbon dioxide; CPK = creatine phosphokinase; DNA = deoxyribonucleic acid; FSH = follicle stimulating hormone; GGT = gamma glutamyl transpeptidase; HbA_{1c} = whole blood hemoglobin A_{1c}; HBcAb = hepatitis B core antibody; HBV = hepatitis B virus; HBeAb = HBV e-antibody; HBeAg = HBV e antigen; HBsAb = HBV surface antibody; HBsAg = HBV surface antigen; HBcrAg = HBV core antigen; hCG = human chorionic gonadotropin; HCV = hepatitis C virus; HDV = hepatitis D virus; HIV = human immunodeficiency virus; IL28B = interleukin 28B; INR = international normalized ratio; miRNA = micro ribonucleic acid; PBMCs = peripheral blood mononuclear cells; PT = prothrombin time; RBC = red blood cells; RNA = ribonucleic acid; TSH = thyroid stimulating hormone; T4 = thyroxine; WBC = white blood cells.

- a. Local hCG pregnancy urine testing will be standard for the protocol unless serum/plasma testing is required by local regulation or IRB/IEC. See Schedule of Activities (Section 1.3) for required pregnancy testing throughout the study.

Appendix 5 Immune and Inflammatory Genes for Pharmacogenomic Testing

Immune and inflammatory genes for analysis will be tested via the [Affymetrix® GeneChip® Human Immune and Inflammation 9K SNP Kit](#):

http://tools.thermofisher.com/content/sfs/brochures/humanimmune_9k_snp_datasheet.pdf

Specific genes and polymorphisms are listed in the following [file](#):

http://www.affymetrix.com/Auth/support/technical/panelfiles/Immu-Inflammation9K_rev1.zip



Data Sheet

Affymetrix® GeneChip® Human Immune and Inflammation 9K SNP Kit

The Affymetrix GeneChip® Human Immune and Inflammation 9K SNP Kit contains over 9,000 SNPs in approximately 1,000 genes that have been implicated in, or are thought to be involved in, immune and inflammatory responses in humans. The 1,000 covered genes were selected in collaboration with leading researchers in the field. HapMap data from multiple populations were used to select SNPs to tag common (>5%) polymorphisms in these genes. In addition, the panel includes ~800 validated non-synonymous SNPs. The panel allows researchers engaged in studies of the immune system and inflammatory response to perform cost-effective genotyping. The Immune and Inflammation 9K SNP Kit is designed to work with the Affymetrix GeneChip® Scanner 3000 (with the Targeted Genotyping upgrade).

Features and Benefits

- A gene-focused approach to immune and inflammation studies has the potential to reduce genotyping and multiple testing costs.
- The use of tagging SNPs results in high genomic coverage for over 1,000 genes involved in immune and inflammation response.
- Tagging SNPs were selected using samples from multiple populations, resulting in a panel that is suitable for genotyping both Caucasian and non-Caucasian populations.
- The inclusion of potentially functional non-synonymous SNPs increases the possibility of directly detecting the causative variant.
- Significant associations can be linked directly to biological pathways and gene function.

Key Specifications

- Accuracy ≥ 99.25 percent
- Data Completeness ≥ 98 percent
- Repeatability ≥ 99.25 percent
- Quantity of genomic DNA required without amplification is 4.0 μ g
- Throughput of 48 samples per day (~0.5 million genotypes/day)
- SNPs selected from HapMap #17. SNP and gene annotations from Ensembl build 34 (dbSNP build 124)

Panel Design

Using Molecular Inversion Probe (MIP) technology, Affymetrix has developed an application-specific SNP genotyping panel for studying the immune system and inflammatory response. The panel is designed to cover over 1,000 candidate genes related to immunity and inflammation that were selected in collaboration with leading researchers in the field. The panel is suitable for studies in multiple ethnic populations. These studies can exploit the MIP technology's ability to develop large multiplex panels in a single assay to conduct affordable, large-scale genetic studies in two important areas: identifying the genes responsible for autoimmune diseases such as lupus, multiple sclerosis and rheumatoid arthritis; and collecting information on individual susceptibility to infectious disease or patient response to immunization, for example, measuring the genetic basis of patient response to the flu vaccine.

The panel is designed to cover ~1,000 genes (coverage of certain selected GO categories is shown in Figure 1). Tagging SNPs were selected to result in an r^2 coverage of ≥ 0.8 for all HapMap SNPs with MAF greater than 5 percent. These tagging SNPs were selected based on genotypes in the HapMap CEPH and Yoruban samples and covered SNPs from 5 kb upstream and 5 kb downstream of the gene. Additionally, 773 non-synonymous (amino acid-changing) SNPs were selected in these genes from the 20K panel (see the Affymetrix GeneChip® Human 20K cSNP Kit). The

average number of all types of SNPs per gene is 10. Following design and manufacture of MIP probes, conversion to working assays was very high (>92 percent), resulting in a panel of approximately 9,200 working assays.

Panel Performance

In actual studies using this panel, 88 DNA samples from 76 unique individuals (CEPH Utah HapMap samples plus one anonymous sample) were genotyped for a total of 824,729 genotypes. Accuracy, measured using Mendelian inheritance across 25 trios, was 99.90 percent. In addition, reviewing the SNPs that overlapped with reference genotypes generated in the HapMap project, concordance was measured with these genotypes as 99.71 percent. Repeatability, measured across six different individuals who were each genotyped two to eight times, was 99.95 percent. Data completeness, the average call rate across passed samples for passed SNPs, was measured on genotypes across the panel at 99.57 percent.

Figure 1: Representation of certain Gene Ontology (GO) categories for the ~1,000 genes represented on the Affymetrix GeneChip® Human Immune and Inflammation 9K SNP Kit. Note that many genes appear in multiple GO categories.





Figure 2: CEPH HapMap sample. Minor allele frequencies of the 9,200 SNPs that are present in the Affymetrix GeneChip® Human Immune and Inflammation 9K SNP Kit. SNPs with low minor allele frequencies in CEPH were either picked as tagging SNPs in the Yoruban HapMap samples (and hence were above 5% in that population) or are non-synonymous SNPs (the panel includes only nsSNPs validated as polymorphic in at least one HapMap population).



Notes:

Ordering Information

Affymetrix GeneChip® Human Immune and Inflammation 9K SNP Kit

900868 Contains enough reagents to process a total of 24 samples (including one control)

Affymetrix GeneChip® Universal 10K Tag Array

900604 (6 pack) Arrays have approximately 10K features on each array that can detect 10K SNPs using the Affymetrix GeneChip® DNA Analysis System incorporating MIP technology

900580 (96 pack)

To Order

North America

888-DNA-CHIP 888-362-2447

Europe

+44 (0) 1628 552550

Japan

+81-(0)3-5730-8200

AFFYMETRIX, INC.

3420 Central Expressway
Santa Clara, CA 95051 USA
Tel: 1-888-DNA-CHIP (1-888-362-2447)
Fax: 1-408-731-5441
sales@affymetrix.com
support@affymetrix.com

AFFYMETRIX UK Ltd

Voyager, Mercury Park,
Wycombe Lane, Wooburn Green,
High Wycombe HP10 0HH
United Kingdom
UK and Others Tel: +44 (0) 1628 552550
France Tel: 0800919505
Germany Tel: 01803001334
Fax: +44 (0) 1628 552585
saleseurope@affymetrix.com
supporteurope@affymetrix.com

AFFYMETRIX JAPAN K.K.

Mita NN Bldg., 16 F
4-1-23 Shiba, Minato-ku,
Tokyo 108-0014 Japan
Tel: +81-(0)3-5730-8200
Fax: +81-(0)3-5730-8201
salesjapan@affymetrix.com
supportjapan@affymetrix.com

www.affymetrix.com Please visit our web site for international distributor contact information.

For research use only. Not for use in diagnostic procedures.

Part No. 702189 Rev. 3
©2006 Affymetrix, Inc. All rights reserved. Affymetrix®, , GeneChip®, HuSNP®, GenFlex®, Flying Objective®, CustomExpress®, CustomSeq®, NetAffx®, Tools To Take You As Far As Your Vision®, The Way Ahead™, Powered by Affymetrix®, GeneChip-compatible™, and Command Console™ are trademarks of Affymetrix, Inc. All other trademarks are the property of their respective owners. Array products may be covered by one or more of the following patents and/or sold under license from Oxford Gene Technology: U.S. Patent Nos. 5,445,934; 5,700,637; 5,744,305; 5,945,334; 6,054,270; 6,140,044; 6,261,776; 6,291,183; 6,346,413; 6,399,365; 6,420,169; 6,551,817; 6,610,482; 6,733,977; and EP 619 321; 373 203 and other U.S. or foreign patents.

Number	Target	Id	TrueTag_10K_A	Tag	Id	Assay	Allele	Switched?	Assay	Id	External	Id	Map	Chromosome
Position	(bp)	Gene												
1	-	270	A/C	0	389095	rs1043730	Human	NCBI	Build	35	6	112008146	C6orf4	
3	-	921	A/C	0	389121	rs11141915	Human	NCBI	Build	35	9	87465348	DAPK1	
4	-	1297	A/C	0	389136	rs1165679	Human	NCBI	Build	35	12	102825705	TRA1	
5	-	1610	A/C	0	389153	rs1256061	Human	NCBI	Build	35	14	63773346	ESR2	
6	-	1939	A/C	0	389169	rs1322393	Human	NCBI	Build	35	6	137376639	IL20RA	
7	-	2567	A/C	0	389199	rs1713918	Human	NCBI	Build	35	7	2717428	CARD11	
10	-	2823	A/C	0	389213	rs1861759	Human	NCBI	Build	35	16	49303084	CARD15	
12	-	3185	A/C	0	389235	rs2052016	Human	NCBI	Build	35	7	156910465	PTPRN2	
13	-	3264	A/C	0	389240	rs2071555	Human	NCBI	Build	35	6	33013064	HLA-DMB	
18	-	4642	A/C	0	389298	rs2280148	Human	NCBI	Build	35	17	73865975	SOCS3	
19	-	5224	A/C	0	389327	rs2302821	Human	NCBI	Build	35	9	129581435	PTGES-ENSG00000198665	
20	-	5747	A/C	0	389356	rs25887	Human	NCBI	Build	35	5	131443960	CSF2	
21	-	6148	A/C	0	389378	rs3132453	Human	NCBI	Build	35	6	31712023	BAT3-BAT2	
22	-	6414	A/C	0	389398	rs3739070	Human	NCBI	Build	35	2	239088268	none	
23	-	6438	A/C	0	389400	rs3743249	Human	NCBI	Build	35	15	97322946	IGF1R-ENSG00000184474	
24	-	6727	A/C	1	389433	rs3802428	Human	NCBI	Build	35	9	34557200	CNTFR	
26	-	6999	A/C	0	389459	rs406231	Human	NCBI	Build	35	19	59442877	LILRB5-ENSG00000186152	
30	-	7502	A/C	0	389528	rs5743704	Human	NCBI	Build	35	4	154983556	TLR2	
31	-	7665	A/C	1	389564	rs6752445	Human	NCBI	Build	35	2	105930763	NCK2	
32	-	7705	A/C	0	389571	rs6961856	Human	NCBI	Build	35	7	157366332	PTPRN2	
33	-	7720	A/C	0	389575	rs706780	Human	NCBI	Build	35	10	6127032	IL2RA	
34	-	7721	A/C	0	389576	rs7079591	Human	NCBI	Build	35	10	133628642	BNIP3	
35	-	7859	A/C	0	389598	rs7543182	Human	NCBI	Build	35	1	71051994	PTGER3	
36	-	7891	A/C	0	389603	rs759171	Human	NCBI	Build	35	7	54860421	EGFR	
38	-	8208	A/C	0	389653	rs9282734	Human	NCBI	Build	35	7	45730209	IGFBP3	
39	-	8322	A/C	0	389675	rs9911257	Human	NCBI	Build	35	17	59365575	SCN4A-CD79B	
40	-	8432	A/C	1	389692	rs1042308	Human	NCBI	Build	35	6	33144831	HLA-DPA1	
42	-	8743	A/C	0	389760	rs13312727	Human	NCBI	Build	35	16	65745944	TRADD-ENSG00000180561	
43	-	8760	A/C	0	389765	rs14004	Human	NCBI	Build	35	6	32515687	HLA-DRA-HLA-DRA	
44	-	8805	A/C	0	389778	rs1610555	Human	NCBI	Build	35	18	65694127	CD226	
45	-	8813	A/C	0	389780	rs1638025	Human	NCBI	Build	35	7	156946842	PTPRN2	
47	-	8882	A/C	0	389796	rs1801033	Human	NCBI	Build	35	5	41235716	C6	
49	-	9119	A/C	1	389842	rs2227580	Human	NCBI	Build	35	10	75341362	C10orf55-PLAU	
51	-	9158	A/C	1	389851	rs2241715	Human	NCBI	Build	35	12	121217700		
ENSG00000176383-ENSG00000158113-DIABLO-ENSG00000197247														
52	-	9194	A/C	1	389856	rs2247584	Human	NCBI	Build	35	1	156072753	FCER1A-ENSG00000196266	
53	-	9320	A/C	0	389885	rs2304738	Human	NCBI	Build	35	18	75322195	NFATC1	
54	-	9350	A/C	0	389890	rs2335851	Human	NCBI	Build	35	7	157425076	PTPRN2	
55	-	9397	A/C	0	389894	rs2523809	Human	NCBI	Build	35	6	29957598	HLA-G	
56	-	9478	A/C	0	389911	rs2889982	Human	NCBI	Build	35	9	87528085	DAPK1	
57	-	9556	A/C	0	389926	rs3138038	Human	NCBI	Build	35	17	29671944	CCL8	
58	-	9598	A/C	0	389931	rs3212254	Human	NCBI	Build	35	14	23875303	RIPK3-ADCY4	
59	-	9655	A/C	1	389943	rs366510	Human	NCBI	Build	35	19	6648829	C3	
60	-	9719	A/C	0	389951	rs3741410	Human	NCBI	Build	35	11	48125240	PTPRJ	
61	-	9735	A/C	1	389953	rs3745376	Human	NCBI	Build	35	19	7739690	ENSG00000104938	
62	-	10017	A/C	0	389991	rs3806501	Human	NCBI	Build	35	2	136710801	ENSG00000121966	
63	-	10115	A/C	0	390011	rs3917148	Human	NCBI	Build	35	14	75516274	TGFB3	

64	-	10302	A/C	0	390035	rs436719	Human NCBI Build 35	1	193519401	CFHL1
65	-	10304	A/C	1	390036	rs4376721	Human NCBI Build 35	1	117434222	ENSG00000134258
66	-	10317	A/C	0	390038	rs446125	Human NCBI Build 35	20	42700679	ADA
67	-	10347	A/C	0	390043	rs4541741	Human NCBI Build 35	6	41772010	TFEB
68	-	10522	A/C	1	390069	rs4987768	Human NCBI Build 35	18	59055497	BCL2
70	-	10649	A/C	0	390092	rs6136	Human NCBI Build 35	1	166295609	SELP
71	-	10659	A/C	0	390094	rs6180	Human NCBI Build 35	5	42754996	GHR
72	-	10744	A/C	0	390105	rs6494457	Human NCBI Build 35	15	62050585	ENSG0000035664
76	-	10974	A/C	1	390140	rs7170924	Human NCBI Build 35	15	79370194	IL16
79	-	11088	A/C	1	390164	rs744690	Human NCBI Build 35	12	50727751	NR4A1
82	-	11352	A/C	0	390204	rs874627	Human NCBI Build 35	12	6804561	LEPREL2-CD4
83	-	11358	A/C	1	390207	rs8773	Human NCBI Build 35	9	90740262	SYK
84	-	11605	A/C	0	390243	rs9958610	Human NCBI Build 35	18	46395496	MAPK4
85	-	11621	A/C	1	390245	rs1002839	Human NCBI Build 35	7	38102637	TRGV9
86	-	11672	A/C	0	390252	rs1009950	Human NCBI Build 35	7	157035924	PTPRN2-ENSG00000197192
88	-	11849	A/C	0	390290	rs10845488	Human NCBI Build 35	12	12202634	LRP6-BCL2L14
89	-	11865	A/C	0	390296	rs10999108	Human NCBI Build 35	10	71481777	H2AFY2-AMID
90	-	11879	A/C	0	390300	rs11147439	Human NCBI Build 35	13	30223643	ALOX5AP
92	-	12003	A/C	0	390324	rs11621560	Human NCBI Build 35	14	101626496	HSPCA
93	-	12023	A/C	0	390328	rs11706098	Human NCBI Build 35	3	106854886	CBLB
94	-	12045	A/C	0	390333	rs11787222	Human NCBI Build 35	8	144175948	LY6E
95	-	12055	A/C	0	390335	rs1182136	Human NCBI Build 35	7	2739686	CARD11
96	-	12135	A/C	0	390348	rs1238706	Human NCBI Build 35	11	47999629	PTPRJ
97	-	12137	A/C	0	390349	rs12407446	Human NCBI Build 35	1	155050135	CD1A
98	-	12336	A/C	0	390383	rs13312735	Human NCBI Build 35	6	31664560	
ENSG00000096157-ENSG00000096224-LTB										
99	-	12345	A/C	0	390387	rs1377373	Human NCBI Build 35	7	157715025	PTPRN2
100	-	90	A/C	0	390451	rs1990384	Human NCBI Build 35	12	6213182	CD9
101	-	3367	A/C	0	390465	rs2071409	Human NCBI Build 35	17	53703229	LPO-MPO
102	-	4391	A/C	0	390473	rs2116941	Human NCBI Build 35	19	10195443	EDG5
103	-	4370	A/C	0	390477	rs2228059	Human NCBI Build 35	10	6042374	IL15RA
104	-	2281	A/C	0	390495	rs2238490	Human NCBI Build 35	16	24049697	PRKCB1
105	-	4928	A/C	0	390497	rs2241042	Human NCBI Build 35	22	15942253	IL17R
106	-	2721	A/C	0	390532	rs2287887	Human NCBI Build 35	19	7733955	ENSG00000104938
107	-	5881	A/C	0	390547	rs2293554	Human NCBI Build 35	2	201957093	CASP8
108	-	2738	A/C	0	390552	rs2298872	Human NCBI Build 35	1	195456899	PTPRC
110	-	5356	A/C	1	390676	rs3800313	Human NCBI Build 35	6	27318743	PRSS16
111	-	3348	A/C	0	390685	rs3809376	Human NCBI Build 35	13	30206722	ALOX5AP
112	-	3144	A/C	1	390705	rs3918245	Human NCBI Build 35	20	44070317	MMP9
113	-	5441	A/C	0	390726	rs4359426	Human NCBI Build 35	16	55950234	CCL22
115	-	1256	A/C	0	390813	rs657770	Human NCBI Build 35	17	44936149	NGFR
116	-	1670	A/C	1	390831	rs6922865	Human NCBI Build 35	6	36202166	MAPK13
117	-	5446	A/C	0	390877	rs7675460	Human NCBI Build 35	4	111078192	none
118	-	5780	A/C	0	390899	rs80579	Human NCBI Build 35	22	34864761	APOL3
119	-	2947	A/C	0	390926	rs859663	Human NCBI Build 35	1	169369112	ENSG00000117560
120	-	5061	A/C	0	390929	rs872580	Human NCBI Build 35	2	95144783	MAL
121	-	1683	A/C	0	390938	rs907800	Human NCBI Build 35	15	97140571	IGF1R
122	-	4161	A/C	1	390969	rs1014638	Human NCBI Build 35	3	39301287	CX3CR1
123	-	127	A/C	1	390989	rs10489683	Human NCBI Build 35	1	154622735	CD5L

124	-	4301	A/C	0	391007	rs1061147	Human NCBI Build 35	1	193385981	CFH
125	-	2843	A/C	1	391026	rs11239524	Human NCBI Build 35	10	45232777	ALOX5
126	-	651	A/C	1	391031	rs113378	Human NCBI Build 35	5	38952974	OSMR
127	-	202	A/C	1	391033	rs1138358	Human NCBI Build 35	15	78050400	BCL2A1
128	-	3351	A/C	0	391053	rs11959820	Human NCBI Build 35	5	149192703	PPARGC1B
129	-	4355	A/C	0	391091	rs1319869	Human NCBI Build 35	15	97030008	IGF1R
130	-	1316	A/C	1	391108	rs138696	Human NCBI Build 35	22	37444994	GTPBP1
131	-	2322	A/C	0	391118	rs1485888	Human NCBI Build 35	12	92728005	CRADD
133	-	1052	A/C	0	391162	rs1875324	Human NCBI Build 35	5	140002620	NDUFA2-IK-ENSG00000113119
134	-	5620	A/C	0	391164	rs1878806	Human NCBI Build 35	7	2794480	CARD11
135	-	777	A/C	1	391173	rs1977426	Human NCBI Build 35	10	6613473	PRKCQ
136	-	1450	A/C	0	391183	rs2015008	Human NCBI Build 35	5	142030683	FGF1
137	-	2200	A/C	0	391201	rs2074488	Human NCBI Build 35	6	31348410	HLA-C
138	-	4429	A/C	1	391215	rs2165627	Human NCBI Build 35	12	69270162	PTPRB
139	-	5361	A/C	0	391216	rs221259	Human NCBI Build 35	7	156835214	PTPRN2
140	-	3039	A/C	1	391227	rs2230112	Human NCBI Build 35	18	75272049	NFATC1
141	-	2989	A/C	0	391229	rs2234253	Human NCBI Build 35	6	41237083	ENSG00000095970
143	-	3762	A/C	0	391267	rs2281390	Human NCBI Build 35	6	33167647	HLA-DPB1-ENSG00000172899
144	-	330	A/C	0	391268	rs2282458	Human NCBI Build 35	4	185682809	IRF2
145	-	2007	A/C	0	391274	rs2288522	Human NCBI Build 35	19	60400287	BRSK1-PTPRH
147	-	1399	A/C	0	391309	rs2494493	Human NCBI Build 35	1	156623313	ENSG00000158714
148	-	5832	A/C	0	391322	rs2707210	Human NCBI Build 35	12	6772263	CD4
149	-	3747	A/C	1	391339	rs2848984	Human NCBI Build 35	11	77610375	GAB2
150	-	4506	A/C	1	391359	rs3128332	Human NCBI Build 35	1	2068759	PRKCZ
154	-	3013	A/C	1	391434	rs3801070	Human NCBI Build 35	7	2816823	CARD11
155	-	6166	A/C	0	391439	rs3808868	Human NCBI Build 35	9	34644142	GALT-ENSG00000137070
156	-	1536	A/C	1	391443	rs381406	Human NCBI Build 35	21	45128783	ITGB2
158	-	6322	A/C	0	391463	rs406113	Human NCBI Build 35	6	28591461	GPX6
159	-	4919	A/C	1	391467	rs4072932	Human NCBI Build 35	1	211111563	PTPN14-ENSG00000181931
161	-	1393	A/C	1	391501	rs4753827	Human NCBI Build 35	11	107392539	CUL5
162	-	4025	A/C	0	391519	rs4936429	Human NCBI Build 35	11	117715405	CD3G-CD3D
163	-	5990	A/C	0	391561	rs6107308	Human NCBI Build 35	20	3476101	ATRN
164	-	2667	A/C	0	391579	rs6478118	Human NCBI Build 35	9	114752700	TNFSF8
165	-	3898	A/C	0	391587	rs6621952	Human NCBI Build 35	X	104315589	IL1RAPL2
166	-	293	A/C	0	391593	rs6746073	Human NCBI Build 35	2	162970552	IFIH1
167	-	3708	A/C	1	391609	rs7192	Human NCBI Build 35	6	32519624	HLA-DRA-HLA-DRA
168	-	645	A/C	0	391617	rs730012	Human NCBI Build 35	5	179153244	MGAT4B-LTC4S
169	-	1258	A/C	0	391623	rs7502875	Human NCBI Build 35	17	43178226	TBX21
170	-	3038	A/C	1	391626	rs753993	Human NCBI Build 35	11	47306545	MADD-MYBPC3
171	-	5968	A/C	0	391628	rs755951	Human NCBI Build 35	8	27282707	PTK2B
172	-	5097	A/C	0	391672	rs838440	Human NCBI Build 35	2	232397516	PTMA
173	-	2820	A/C	0	391677	rs867228	Human NCBI Build 35	19	56941023	FPR1
174	-	736	A/C	0	391695	rs899178	Human NCBI Build 35	5	149110663	PPARGC1B
176	-	3188	A/C	0	391735	rs989902	Human NCBI Build 35	4	88063685	PTPN13
177	-	1456	A/C	0	391761	rs1046961	Human NCBI Build 35	6	32023593	C2-RDBP-BF
178	-	640	A/C	0	391777	rs10515638	Human NCBI Build 35	5	149132724	PPARGC1B
179	-	913	A/C	0	391782	rs1057027	Human NCBI Build 35	1	155815450	IFI16
180	-	2341	A/C	1	391786	rs10764735	Human NCBI Build 35	10	129715444	PTPRE
181	-	3867	A/C	0	391794	rs10889675	Human NCBI Build 35	1	67434237	IL23R

182	-	660	A/C	1	391795	rs10900213	Human NCBI Build 35	10	45224720	ALOX5
183	-	544	A/C	0	391806	rs11130350	Human NCBI Build 35	3	53190915	PRKCD
184	-	4509	A/C	0	391807	rs11135693	Human NCBI Build 35	8	22981099	TNFRSF10B
185	-	2056	A/C	0	391814	rs1143508	Human NCBI Build 35	19	60041047	KIR2DS1
187	-	796	A/C	1	391839	rs11980387	Human NCBI Build 35	7	121107521	PTPRZ1
188	-	6138	A/C	0	391847	rs12239356	Human NCBI Build 35	1	210946080	PTPN14
189	-	2327	A/C	1	391856	rs12551072	Human NCBI Build 35	9	87440062	DAPK1
190	-	6339	A/C	0	391870	rs131422	Human NCBI Build 35	22	22247979	IGLL1
191	-	485	A/C	0	391873	rs1323658	Human NCBI Build 35	10	6134360	IL2RA
192	-	2615	A/C	0	391875	rs1328111	Human NCBI Build 35	1	157539964	SLAMF7
193	-	4353	A/C	0	391877	rs13311	Human NCBI Build 35	12	111911372	OAS2
194	-	850	A/C	0	391913	rs1554999	Human NCBI Build 35	16	3055629	MMP25-ENSG00000008517
195	-	3286	A/C	0	391916	rs1569736	Human NCBI Build 35	20	49439729	NFATC2
196	-	4790	A/C	0	391920	rs1592639	Human NCBI Build 35	16	49357370	ENSG000000083799
197	-	17	A/C	0	391928	rs17088993	Human NCBI Build 35	8	23114165	TNFRSF10A-ENSG00000147457
198	-	1084	A/C	0	391948	rs1878673	Human NCBI Build 35	1	203372388	IL19-PIGR
199	-	1413	A/C	0	391960	rs1994251	Human NCBI Build 35	20	29750989	BCL2L1
200	-	233	A/C	0	391979	rs2064599	Human NCBI Build 35	6	47367642	TNFRSF21
201	-	3360	A/C	0	391991	rs2072324	Human NCBI Build 35	17	23141023	NOS2A
203	-	5527	A/C	0	392003	rs2182909	Human NCBI Build 35	1	204041501	CR2
204	-	4479	A/C	0	392004	rs2189480	Human NCBI Build 35	12	46550095	VDR
205	-	1819	A/C	0	392017	rs2232585	Human NCBI Build 35	20	36416102	LBP
206	-	3009	A/C	1	392037	rs2271700	Human NCBI Build 35	10	71519942	H2AFY2-AMID
207	-	1381	A/C	0	392062	rs2298432	Human NCBI Build 35	22	20447743	MAPK1
208	-	96	A/C	0	392074	rs2412559	Human NCBI Build 35	4	54992639	PDGFRA
210	-	1119	A/C	0	392114	rs2780816	Human NCBI Build 35	1	65014434	JAK1-ENSG00000162437
211	-	2827	A/C	0	392127	rs2867437	Human NCBI Build 35	20	40429991	PTPRT
212	-	1384	A/C	1	392129	rs2887640	Human NCBI Build 35	1	189759491	UCHL5-SSA2
214	-	6336	A/C	0	392160	rs310228	Human NCBI Build 35	1	65034253	JAK1
215	-	2358	A/C	0	392170	rs31564	Human NCBI Build 35	5	135258152	IL9
216	-	6252	A/C	0	392171	rs3172469	Human NCBI Build 35	3	188941790	BCL6
217	-	1836	A/C	0	392185	rs364685	Human NCBI Build 35	16	24059766	PRKCB1
218	-	1280	A/C	0	392206	rs3780136	Human NCBI Build 35	9	36835973	PAX5
219	-	5087	A/C	0	392236	rs3917422	Human NCBI Build 35	1	166430418	SELE
220	-	3565	A/C	1	392245	rs414634	Human NCBI Build 35	15	89157257	BLM
221	-	2123	A/C	1	392251	rs4251985	Human NCBI Build 35	2	113593644	IL1RN
222	-	6102	A/C	0	392254	rs4303974	Human NCBI Build 35	4	15052253	C1QTNF7
223	-	1149	A/C	1	392267	rs4592915	Human NCBI Build 35	20	36391335	BPI
224	-	6022	A/C	0	392269	rs4647575	Human NCBI Build 35	11	64863745	DPF2-ENSG00000197847
225	-	1494	A/C	0	392285	rs4769055	Human NCBI Build 35	13	30207830	ALOX5AP
226	-	3397	A/C	0	392315	rs501299	Human NCBI Build 35	1	43720927	PTPRF
227	-	2813	A/C	0	392321	rs534399	Human NCBI Build 35	1	193442724	CFH
228	-	5738	A/C	0	392323	rs5361	Human NCBI Build 35	1	166432718	SELE
229	-	4186	A/C	0	392340	rs598688	Human NCBI Build 35	3	61723039	PTPRG
230	-	4251	A/C	0	392351	rs612966	Human NCBI Build 35	9	21353126	ENSG00000120247
231	-	1690	A/C	0	392383	rs6723289	Human NCBI Build 35	2	112501871	MERTK
232	-	5117	A/C	0	392386	rs6742154	Human NCBI Build 35	2	68264166	ENSG00000115953
234	-	629	A/C	0	392423	rs7161192	Human NCBI Build 35	14	63706900	SYNE2-ESR2
235	-	1959	A/C	0	392425	rs7175052	Human NCBI Build 35	15	97125473	IGF1R

236	-	3636	A/C	1	392427	rs7184015	Human NCBI Build 35	15	89075579	BLM
237	-	5220	A/C	1	392441	rs737090	Human NCBI Build 35	20	36443038	LBP
238	-	4910	A/C	0	392463	rs7722480	Human NCBI Build 35	5	149762613	TCOF1-CD74
239	-	2226	A/C	0	392475	rs793816	Human NCBI Build 35	4	185729641	IRF2
240	-	5959	A/C	0	392479	rs8007516	Human NCBI Build 35	14	106096144	IGHA1
241	-	1644	A/C	0	392480	rs8030950	Human NCBI Build 35	15	97221544	IGF1R
242	-	3274	A/C	1	392488	rs8105558	Human NCBI Build 35	19	5224571	PTPRS
243	-	4821	A/C	0	392506	rs884399	Human NCBI Build 35	2	45894576	PRKCE
244	-	5403	A/C	0	392544	rs9831894	Human NCBI Build 35	3	123283177	CD86
245	-	2909	A/C	0	392546	rs9836430	Human NCBI Build 35	3	112792369	CD96-ZBED2
246	-	390	A/C	0	392549	rs9870965	Human NCBI Build 35	3	62048356	PTPRG
247	-	6184	A/C	1	392554	rs9944780	Human NCBI Build 35	18	12243275	CIDEA
248	-	931	A/C	0	392557	rs997476	Human NCBI Build 35	4	103899208	NFKB1
249	-	2066	A/C	1	392566	rs1019731	Human NCBI Build 35	12	101366892	IGF1
250	-	3609	A/C	0	392570	rs10401741	Human NCBI Build 35	19	18499405	FKBP8
251	-	3186	A/C	0	392572	rs10484322	Human NCBI Build 35	6	6210193	F13A1
253	-	1009	A/C	0	392607	rs10977207	Human NCBI Build 35	9	8559186	PTPRD
254	-	4101	A/C	0	392649	rs11885282	Human NCBI Build 35	2	152064567	TNFAIP6
255	-	1502	A/C	1	392690	rs1321389	Human NCBI Build 35	X	104398956	IL1RAPL2
256	-	2138	A/C	0	392710	rs1421125	Human NCBI Build 35	18	20311909	HRH4
257	-	4448	A/C	0	392741	rs1609785	Human NCBI Build 35	5	35187058	PRLR
258	-	1165	A/C	0	392758	rs17468739	Human NCBI Build 35	10	91055929	IFIT2-LIPA
259	-	1470	A/C	0	392789	rs1942956	Human NCBI Build 35	18	8091814	PTPRM
260	-	2020	A/C	0	392791	rs1957526	Human NCBI Build 35	14	24148754	GZMH
261	-	6109	A/C	0	392804	rs202566	Human NCBI Build 35	6	137506767	IL22RA2
262	-	1974	A/C	1	392822	rs2070729	Human NCBI Build 35	5	131847820	IRF1
263	-	920	A/C	1	392889	rs2305152	Human NCBI Build 35	2	113479694	IL1F6
264	-	2697	A/C	0	392893	rs2332673	Human NCBI Build 35	18	58949062	BCL2
265	-	5670	A/C	0	392894	rs2335230	Human NCBI Build 35	1	151402701	ADAR
267	-	3656	A/C	0	392910	rs2515402	Human NCBI Build 35	2	113536811	IL1F10-IL1F5
268	-	3269	A/C	0	392921	rs261582	Human NCBI Build 35	5	169141302	DOCK2
269	-	1409	A/C	0	392936	rs2755209	Human NCBI Build 35	13	40035804	FOXO1A
270	-	6216	A/C	0	392975	rs3138100	Human NCBI Build 35	1	155074144	CD1C
271	-	5135	A/C	0	392993	rs37364	Human NCBI Build 35	5	35108137	PRLR
272	-	4888	A/C	1	393006	rs3758161	Human NCBI Build 35	9	36891044	PAX5
273	-	3706	A/C	0	393011	rs3766941	Human NCBI Build 35	1	222381108	
ENSG00000196187-ENSG00000143787										
274	-	904	A/C	0	393013	rs3771300	Human NCBI Build 35	2	191661102	STAT1
275	-	51	A/C	0	393065	rs3885907	Human NCBI Build 35	13	30212455	ALOX5AP
276	-	5904	A/C	0	393068	rs3917010	Human NCBI Build 35	1	100902887	VCAM1
277	-	5731	A/C	1	393073	rs4082828	Human NCBI Build 35	3	52249782	PTK9L
278	-	6131	A/C	0	393074	rs409188	Human NCBI Build 35	2	32407122	CARD12
279	-	1572	A/C	1	393075	rs4092275	Human NCBI Build 35	11	76826352	PAK1
280	-	6230	A/C	0	393096	rs4396219	Human NCBI Build 35	10	97551931	ENTPD1
281	-	3652	A/C	1	393097	rs4399890	Human NCBI Build 35	3	61838038	PTPRG
282	-	5079	A/C	1	393104	rs4648099	Human NCBI Build 35	4	103886010	NFKB1
283	-	3800	A/C	1	393115	rs4763780	Human NCBI Build 35	12	12144858	BCL2L14
284	-	5003	A/C	0	393118	rs4781016	Human NCBI Build 35	16	10903900	MHC2TA
285	-	203	A/C	0	393123	rs4812405	Human NCBI Build 35	20	34709999	NDRG3-SLA2

286	-	1530	A/C	0	393144	rs4952794	Human NCBI Build 35	2	46066262	PRKCE
287	-	1158	A/C	0	393147	rs5030416	Human NCBI Build 35	11	36489064	TRAF6
289	-	813	A/C	0	393182	rs6065509	Human NCBI Build 35	20	40607519	PTPRT
290	-	4897	A/C	0	393185	rs6072672	Human NCBI Build 35	20	40328381	PTPRT
291	-	5649	A/C	0	393193	rs616096	Human NCBI Build 35	18	8296371	PTPRM
292	-	6515	A/C	0	393194	rs616130	Human NCBI Build 35	2	111628912	BCL2L11
293	-	1380	A/C	0	393205	rs6494454	Human NCBI Build 35	15	62020616	ENSG00000035664
294	-	2485	A/C	1	393210	rs652889	Human NCBI Build 35	3	61769094	PTPRG
295	-	438	A/C	1	393227	rs6706911	Human NCBI Build 35	2	239011854	none
296	-	5753	A/C	1	393258	rs7146672	Human NCBI Build 35	6	32024644	C2-RDBP-BF
297	-	1993	A/C	0	393263	rs7187854	Human NCBI Build 35	16	65165991	CKLF-ENSG00000140932
298	-	6059	A/C	0	393274	rs7384090	Human NCBI Build 35	7	157175714	PTPRN2-ENSG00000196201
299	-	5169	A/C	1	393276	rs739719	Human NCBI Build 35	5	131900764	IL5
300	-	4827	A/C	0	393286	rs754978	Human NCBI Build 35	2	75183451	TACR1
301	-	318	A/C	0	393288	rs7551550	Human NCBI Build 35	1	20183070	PLA2G2D
302	-	5513	A/C	0	393293	rs7595357	Human NCBI Build 35	2	239916590	HDAC4
303	-	1317	A/C	1	393299	rs7644602	Human NCBI Build 35	3	32295412	CKLFSF8
304	-	3760	A/C	1	393301	rs7650931	Human NCBI Build 35	3	33874954	PDCD6IP
305	-	4459	A/C	0	393326	rs7916444	Human NCBI Build 35	10	129613662	PTPRE
306	-	5607	A/C	0	393330	rs8027767	Human NCBI Build 35	15	97115026	IGF1R
307	-	3441	A/C	0	393337	rs8084	Human NCBI Build 35	6	32519013	HLA-DRA-HLA-DRA
308	-	6235	A/C	0	393360	rs909790	Human NCBI Build 35	6	6557196	LY86
310	-	3754	A/C	0	393385	rs9618106	Human NCBI Build 35	22	16625027	BID
311	-	786	A/C	0	393391	rs977785	Human NCBI Build 35	6	6533880	LY86-ENSG00000175753
312	-	4397	A/C	1	393396	rs9870937	Human NCBI Build 35	3	32341229	CKLFSF8
313	-	1060	A/C	0	393422	rs10402500	Human NCBI Build 35	19	44928529	CLC
314	-	2161	A/C	1	393432	rs10495098	Human NCBI Build 35	1	214904705	ENSG00000092969
315	-	2302	A/C	0	393452	rs10797666	Human NCBI Build 35	1	177750456	MR1
316	-	1049	A/C	0	393454	rs10801935	Human NCBI Build 35	1	117433929	ENSG00000134258
317	-	3514	A/C	0	393461	rs10882665	Human NCBI Build 35	10	97541718	ENTPD1
318	-	4999	A/C	0	393471	rs11096955	Human NCBI Build 35	4	38598673	TLR10
319	-	5098	A/C	0	393476	rs11167944	Human NCBI Build 35	5	146099155	PPP2R2B
320	-	1336	A/C	0	393504	rs1206382	Human NCBI Build 35	7	121296132	PTPRZ1
322	-	467	A/C	0	393521	rs12552580	Human NCBI Build 35	9	36951472	PAX5
323	-	4528	A/C	0	393549	rs1343413	Human NCBI Build 35	X	103859624	IL1RAPL2
324	-	1803	A/C	0	393578	rs1553297	Human NCBI Build 35	5	169421804	DOCK2
325	-	4123	A/C	1	393588	rs1607817	Human NCBI Build 35	12	116174906	NOS1
326	-	2468	A/C	1	393596	rs16858811	Human NCBI Build 35	2	218855349	IL8RA
327	-	5261	A/C	0	393626	rs1916880	Human NCBI Build 35	7	121137431	PTPRZ1
328	-	2236	A/C	0	393641	rs2024582	Human NCBI Build 35	20	49447188	NFATC2
330	-	3559	A/C	0	393647	rs2065137	Human NCBI Build 35	14	24141815	GZMH
331	-	4133	A/C	1	393651	rs2069709	Human NCBI Build 35	12	66839970	IFNG
332	-	3660	A/C	1	393662	rs2143004	Human NCBI Build 35	20	40148596	PTPRT
333	-	475	A/C	1	393664	rs2149380	Human NCBI Build 35	9	87524128	DAPK1
334	-	5770	A/C	0	393669	rs2192358	Human NCBI Build 35	4	15117201	C1QTNF7
335	-	1074	A/C	0	393701	rs2282055	Human NCBI Build 35	9	5445732	ENSG00000120217
336	-	5732	A/C	0	393705	rs2282799	Human NCBI Build 35	5	141971299	FGF1
337	-	2415	A/C	0	393727	rs231983	Human NCBI Build 35	3	173719142	TNFSF10
338	-	5765	A/C	0	393738	rs2501343	Human NCBI Build 35	1	156607649	ENSG00000158714

339	-	308	A/C	1	393762	rs2772548	Human NCBI Build 35	9	34660988	CCL27
340	-	1454	A/C	1	393783	rs2917887	Human NCBI Build 35	6	74589912	CD109
341	-	2129	A/C	0	393788	rs3017359	Human NCBI Build 35	18	58207709	TNFRSF11A
342	-	6149	A/C	1	393791	rs3024490	Human NCBI Build 35	1	203333706	PIGR-IL10
344	-	11	A/C	0	393800	rs3124236	Human NCBI Build 35	9	87441044	DAPK1
345	-	2324	A/C	0	393806	rs3135029	Human NCBI Build 35	6	33029752	HLA-DMA
346	-	2355	A/C	0	393827	rs3738900	Human NCBI Build 35	2	46152071	PRKCE
347	-	1961	A/C	0	393863	rs3793727	Human NCBI Build 35	10	6548383	PRKCQ
348	-	1406	A/C	0	393893	rs3926499	Human NCBI Build 35	4	87590083	MAPK10
349	-	2977	A/C	0	393894	rs3960965	Human NCBI Build 35	19	58481195	BIRC8-ENSG00000189348
350	-	334	A/C	0	393904	rs4308217	Human NCBI Build 35	3	123275877	CD86
351	-	259	A/C	0	393913	rs452159	Human NCBI Build 35	20	42704516	ADA
352	-	6119	A/C	1	393928	rs4713600	Human NCBI Build 35	6	32930836	PSMB9-TAP1
353	-	3554	A/C	0	393939	rs4798619	Human NCBI Build 35	18	8271595	PTPRM
355	-	3776	A/C	0	393999	rs642200	Human NCBI Build 35	2	45844500	PRKCE
357	-	2682	A/C	1	394022	rs665974	Human NCBI Build 35	3	61730878	PTPRG
358	-	695	A/C	0	394028	rs6688135	Human NCBI Build 35	1	240069515	AKT3
359	-	950	A/C	1	394039	rs6784733	Human NCBI Build 35	3	61568223	PTPRG
360	-	99	A/C	0	394041	rs6822209	Human NCBI Build 35	4	47941425	TXK
361	-	1095	A/C	0	394051	rs6911737	Human NCBI Build 35	6	30073480	HLA-G
362	-	253	A/C	0	394054	rs6921422	Human NCBI Build 35	6	21708502	SOX4
363	-	812	A/C	0	394084	rs7302663	Human NCBI Build 35	12	92707599	CRADD
364	-	3766	A/C	0	394086	rs7334	Human NCBI Build 35	7	55053061	EGFR
365	-	2097	A/C	1	394090	rs740058	Human NCBI Build 35	19	5239182	PTPRS
366	-	985	A/C	0	394110	rs7638209	Human NCBI Build 35	3	37777128	ITGA9
367	-	3931	A/C	0	394117	rs7756425	Human NCBI Build 35	6	47355111	TNFRSF21
368	-	2197	A/C	1	394121	rs7794256	Human NCBI Build 35	7	157705690	PTPRN2
369	-	250	A/C	1	394137	rs8067785	Human NCBI Build 35	17	11871706	MAP2K4
370	-	1235	A/C	0	394138	rs8083511	Human NCBI Build 35	18	58179635	TNFRSF11A
371	-	3014	A/C	0	394142	rs816353	Human NCBI Build 35	12	116147500	NOS1
372	-	6098	A/C	1	394144	rs835636	Human NCBI Build 35	3	138157198	ENSG00000174564
373	-	261	A/C	1	394146	rs872288	Human NCBI Build 35	2	46026676	PRKCE
374	-	79	A/C	0	394181	rs9491960	Human NCBI Build 35	6	128832480	PTPRK
375	-	1967	A/C	0	394191	rs974097	Human NCBI Build 35	5	146004319	PPP2R2B
377	-	2571	A/C	0	394203	rs987956	Human NCBI Build 35	3	126492754	ZNF148
378	-	2533	A/C	0	394251	rs10507213	Human NCBI Build 35	12	105632186	RFX4
379	-	6542	A/C	1	394259	rs10514919	Human NCBI Build 35	17	42697128	ITGB3
380	-	1134	A/C	0	394264	rs10518690	Human NCBI Build 35	15	64495859	MAP2K1
381	-	5804	A/C	0	394272	rs10800048	Human NCBI Build 35	1	161479066	PBX1
382	-	6434	A/C	1	394289	rs11243078	Human NCBI Build 35	6	6261801	F13A1
383	-	6463	A/C	0	394290	rs11247656	Human NCBI Build 35	1	27687201	G1P3
384	-	6476	A/C	0	394301	rs11637363	Human NCBI Build 35	15	79355028	IL16
385	-	6453	A/C	0	394312	rs1179249	Human NCBI Build 35	12	66931047	IL22
386	-	6404	A/C	0	394318	rs11924422	Human NCBI Build 35	3	30652488	TGFBR2
387	-	6482	A/C	1	394319	rs11947018	Human NCBI Build 35	4	87941002	PTPN13
388	-	6344	A/C	0	394325	rs12129883	Human NCBI Build 35	1	195407720	PTPRC
389	-	6486	A/C	0	394329	rs1224143	Human NCBI Build 35	13	107738749	TNFSF13B
390	-	6383	A/C	1	394332	rs12354	Human NCBI Build 35	12	6370366	LTBR
391	-	6443	A/C	0	394344	rs1257721	Human NCBI Build 35	11	56908725	PRG3-PRG2

393	-	6425	A/C	1	394358	rs1323578	Human NCBI Build 35	9	8503123	PTPRD
394	-	6343	A/C	0	394365	rs13332630	Human NCBI Build 35	16	11965059	TNFRSF17-ENSG00000122309
395	-	6583	A/C	0	394382	rs1425551	Human NCBI Build 35	4	185718207	IRF2
396	-	6586	A/C	0	394385	rs1455167	Human NCBI Build 35	2	138594899	HNMT
397	-	6599	A/C	0	394396	rs1517352	Human NCBI Build 35	2	191756970	STAT4
398	-	6607	A/C	0	394402	rs1569723	Human NCBI Build 35	20	44175471	ENSG00000101017
399	-	6640	A/C	0	394431	rs1867106	Human NCBI Build 35	4	78868935	CXCL13
401	-	6647	A/C	1	394437	rs1879188	Human NCBI Build 35	8	27249840	PTK2B
402	-	6650	A/C	1	394439	rs1884444	Human NCBI Build 35	1	67345833	IL23R
403	-	6683	A/C	0	394465	rs2019203	Human NCBI Build 35	17	34162198	PSMB3-ENSG00000056661
404	-	6704	A/C	1	394484	rs2072861	Human NCBI Build 35	22	35852862	IL2RB
405	-	6725	A/C	0	394501	rs2227553	Human NCBI Build 35	10	75339949	C10orf55-PLAU
406	-	6747	A/C	0	394519	rs2255094	Human NCBI Build 35	2	46143693	PRKCE
407	-	6792	A/C	0	394560	rs2466571	Human NCBI Build 35	1	204328441	MCP
408	-	6798	A/C	0	394566	rs2506	Human NCBI Build 35	10	54195515	MBL2
409	-	6837	A/C	0	394604	rs2789417	Human NCBI Build 35	1	156736184	SLAMF9
410	-	6848	A/C	0	394614	rs2894111	Human NCBI Build 35	10	71545067	H2AFY2-AMID
411	-	6874	A/C	0	394637	rs3176840	Human NCBI Build 35	1	155115191	CD1B
412	-	6886	A/C	1	394648	rs355971	Human NCBI Build 35	16	65228152	CKLFSF4
413	-	6912	A/C	0	394669	rs3768734	Human NCBI Build 35	2	46304366	PRKCE
414	-	6953	A/C	0	394707	rs3825084	Human NCBI Build 35	12	51880198	ITGB7
415	-	6956	A/C	1	394710	rs3847502	Human NCBI Build 35	11	47290261	MADD
416	-	6962	A/C	1	394715	rs3867257	Human NCBI Build 35	18	46400046	MAPK4
417	-	6988	A/C	1	394739	rs4366576	Human NCBI Build 35	13	27576488	FLT3-ENSG00000169793
418	-	6994	A/C	0	394745	rs4429172	Human NCBI Build 35	13	40087143	FOXO1A
419	-	6998	A/C	0	394748	rs4485556	Human NCBI Build 35	2	219982923	PTPRN-DNAJB2
421	-	7052	A/C	0	394796	rs495691	Human NCBI Build 35	3	106750190	ALCAM
423	-	7099	A/C	0	394837	rs644853	Human NCBI Build 35	1	152519290	DAP3-ENSG00000125459
424	-	7105	A/C	1	394842	rs6531925	Human NCBI Build 35	4	87621080	MAPK10
425	-	7116	A/C	0	394853	rs6679677	Human NCBI Build 35	8	22351173	SLC39A14-PPP3CC-PIWIL2
426	-	7127	A/C	0	394862	rs6748375	Human NCBI Build 35	2	46188173	PRKCE
427	-	7128	A/C	0	394863	rs6751349	Human NCBI Build 35	2	46088613	PRKCE
428	-	7146	A/C	0	394878	rs6953248	Human NCBI Build 35	7	38129655	TRGV9
429	-	7188	A/C	0	394914	rs748282	Human NCBI Build 35	8	27372897	PTK2B-CHRNA2
430	-	7236	A/C	0	394953	rs7869444	Human NCBI Build 35	9	8474298	PTPRD
432	-	7251	A/C	0	394964	rs797999	Human NCBI Build 35	1	117005805	CD2
433	-	7253	A/C	0	394966	rs8055243	Human NCBI Build 35	16	23926713	PRKCB1
434	-	7256	A/C	0	394969	rs8101249	Human NCBI Build 35	19	18362830	GDF15-LRRC25
435	-	7287	A/C	1	394995	rs9258170	Human NCBI Build 35	6	29797569	HLA-F
436	-	7289	A/C	0	394997	rs928040	Human NCBI Build 35	13	23086233	TNFRSF19
438	-	7299	A/C	1	395007	rs9393796	Human NCBI Build 35	6	27334944	PRSS16
439	-	7302	A/C	0	395010	rs9473040	Human NCBI Build 35	6	47331929	TNFRSF21
440	-	7336	A/C	0	395039	rs1006938	Human NCBI Build 35	19	54666198	FLT3LG-ALDH16A1
441	-	7347	A/C	0	395049	rs10212109	Human NCBI Build 35	3	191722173	IL1RAP
442	-	7390	A/C	1	395089	rs10497209	Human NCBI Build 35	2	160811093	ITGB6
443	-	7391	A/C	0	395090	rs10497212	Human NCBI Build 35	2	160790207	ITGB6
444	-	7400	A/C	1	395098	rs10510868	Human NCBI Build 35	3	61708638	PTPRG-ENSG00000168370
445	-	7406	A/C	0	395104	rs10516070	Human NCBI Build 35	5	169445438	DOCK2
446	-	7409	A/C	0	395107	rs10748663	Human NCBI Build 35	10	97937031	BLNK

447	-	7424	A/C	0	395121	rs10882671	Human NCBI Build 35	10	97574013	ENTPD1
448	-	7435	A/C	1	395129	rs11107487	Human NCBI Build 35	12	93157766	PLXNC1
449	-	7452	A/C	0	395141	rs1144942	Human NCBI Build 35	12	67485629	MDM2
450	-	7462	A/C	1	395151	rs11662719	Human NCBI Build 35	18	46437311	MAPK4
451	-	7466	A/C	1	395155	rs11767654	Human NCBI Build 35	7	157441419	PTPRN2
452	-	7473	A/C	0	395162	rs11954030	Human NCBI Build 35	5	169076225	DOCK2
453	-	7476	A/C	0	395164	rs12029239	Human NCBI Build 35	1	204461021	CD34
454	-	7482	A/C	1	395169	rs12085479	Human NCBI Build 35	1	50911137	FAF1
455	-	7536	A/C	1	395207	rs13293564	Human NCBI Build 35	9	35156763	UNC13B
456	-	7594	A/C	1	395253	rs16910239	Human NCBI Build 35	9	120805480	C5
457	-	7708	A/C	0	395345	rs2278278	Human NCBI Build 35	9	90688294	SYK
458	-	7717	A/C	1	395351	rs2289805	Human NCBI Build 35	10	49297918	MAPK8
460	-	7763	A/C	0	395384	rs259911	Human NCBI Build 35	5	169301496	DOCK2
461	-	7768	A/C	0	395389	rs262688	Human NCBI Build 35	19	45418176	
MAP3K10-ENSG00000105219-ENSG00000174521										
462	-	7775	A/C	1	395396	rs2670497	Human NCBI Build 35	15	97188764	IGF1R
463	-	7787	A/C	0	395405	rs2729722	Human NCBI Build 35	2	160491443	LY75
464	-	7834	A/C	0	395445	rs3212262	Human NCBI Build 35	11	117723064	CD3G-CD3D
465	-	7836	A/C	0	395447	rs322485	Human NCBI Build 35	5	145990005	PPP2R2B
466	-	7849	A/C	1	395460	rs37244	Human NCBI Build 35	5	76050867	F2R-ENSG00000183613
467	-	7883	A/C	0	395490	rs3773748	Human NCBI Build 35	3	139822605	FAIM
468	-	7930	A/C	0	395526	rs4140541	Human NCBI Build 35	6	128608712	PTPRK
469	-	7945	A/C	0	395537	rs4327896	Human NCBI Build 35	8	141926504	PTK2
470	-	7948	A/C	0	395539	rs4353657	Human NCBI Build 35	2	112477175	MERTK
471	-	7964	A/C	1	395554	rs4758635	Human NCBI Build 35	11	273928	NALP6
472	-	7969	A/C	0	395557	rs4766662	Human NCBI Build 35	12	111808419	OAS1
473	-	7982	A/C	0	395568	rs4906269	Human NCBI Build 35	14	102431770	TRAF3
474	-	7991	A/C	0	395577	rs4987752	Human NCBI Build 35	18	59068813	BCL2
475	-	8005	A/C	0	395590	rs5744081	Human NCBI Build 35	X	12698128	TLR8
476	-	8011	A/C	1	395596	rs5990	Human NCBI Build 35	1	193740254	F13B
477	-	8026	A/C	0	395608	rs637809	Human NCBI Build 35	18	7669794	PTPRM
478	-	8044	A/C	1	395625	rs6621930	Human NCBI Build 35	X	104168250	IL1RAPL2
480	-	8053	A/C	0	395633	rs6723629	Human NCBI Build 35	2	70979508	CD207
481	-	8074	A/C	1	395653	rs699244	Human NCBI Build 35	1	180257109	C1orf16-NCF2
482	-	8075	A/C	0	395654	rs6995333	Human NCBI Build 35	8	36863175	ENSG00000129699
483	-	8082	A/C	0	395661	rs7132188	Human NCBI Build 35	12	66898798	IL26
484	-	8083	A/C	0	395662	rs7137767	Human NCBI Build 35	12	21416873	IAPP-SLC01A2
485	-	8110	A/C	0	395684	rs751019	Human NCBI Build 35	8	27364502	PTK2B
486	-	8119	A/C	1	395693	rs7548449	Human NCBI Build 35	1	232356682	ENSG00000143669
487	-	8171	A/C	1	395735	rs854680	Human NCBI Build 35	17	31333164	CCL15-CCL16
488	-	8181	A/C	0	395744	rs903889	Human NCBI Build 35	7	45738235	IGFBP3
489	-	8191	A/C	1	395750	rs9284	Human NCBI Build 35	10	49313576	MAPK8
490	-	8197	A/C	0	395755	rs9311834	Human NCBI Build 35	3	62005889	PTPRG
491	-	8203	A/C	0	395759	rs935661	Human NCBI Build 35	2	45967008	PRKCE
492	-	8214	A/C	0	395768	rs953569	Human NCBI Build 35	5	156409978	HAVCR1
493	-	8246	A/C	0	395796	rs1017913	Human NCBI Build 35	3	106721305	ALCAM
494	-	8259	A/C	0	395805	rs10484879	Human NCBI Build 35	6	52159916	IL17
496	-	8269	A/C	0	395814	rs10496440	Human NCBI Build 35	2	112381230	MERTK
497	-	8270	A/C	0	395815	rs10501385	Human NCBI Build 35	11	59981058	MS4A1

498	-	8296	A/C	0	395835	rs10754573	Human NCBI Build 35	1	233003627	LGALS8
499	-	8329	A/C	0	395858	rs11065663	Human NCBI Build 35	12	109451606	ENSG00000196850
500	-	8369	A/C	0	395894	rs12137588	Human NCBI Build 35	1	161550453	PBX1
501	-	8376	A/C	0	395900	rs12421641	Human NCBI Build 35	11	36562795	RAG1
502	-	8403	A/C	0	395924	rs1320174	Human NCBI Build 35	3	61534065	PTPRG
503	-	8404	A/C	0	395925	rs1321168	Human NCBI Build 35	6	112177771	FYN
505	-	8431	A/C	0	395948	rs1471282	Human NCBI Build 35	15	61999328	ENSG00000035664
506	-	8448	A/C	0	395962	rs1557865	Human NCBI Build 35	12	111805318	OAS1
507	-	8454	A/C	1	395968	rs1592541	Human NCBI Build 35	16	45825500	ENSG00000129636
508	-	8468	A/C	0	395978	rs1699086	Human NCBI Build 35	11	104437736	CASP1
509	-	8471	A/C	0	395980	rs1727	Human NCBI Build 35 10	91056749	IFIT2-LIPA	
510	-	8479	A/C	0	395988	rs1788101	Human NCBI Build 35	18	65691348	CD226
511	-	8490	A/C	0	395994	rs1841958	Human NCBI Build 35	12	10453356	KLRC4
512	-	8525	A/C	0	396023	rs2046068	Human NCBI Build 35	12	66932242	IL22
513	-	8529	A/C	0	396026	rs206155	Human NCBI Build 35	20	41083768	PTPRT
514	-	8544	A/C	0	396038	rs2100071	Human NCBI Build 35	2	113541617	IL1F10-IL1F5
515	-	8579	A/C	0	396068	rs2271458	Human NCBI Build 35	1	207922451	TRAF5
516	-	8581	A/C	0	396070	rs2278346	Human NCBI Build 35	12	69216328	PTPRB
517	-	8583	A/C	0	396072	rs22824	Human NCBI Build 35 15	32014210	AVEN	
518	-	8649	A/C	0	396120	rs2701129	Human NCBI Build 35	12	50715744	NR4A1
519	-	8660	A/C	1	396130	rs2765814	Human NCBI Build 35	X	47249469	ELK1-PFC
520	-	8684	A/C	0	396146	rs3024358	Human NCBI Build 35	6	6212303	F13A1
521	-	8715	A/C	0	396170	rs3730091	Human NCBI Build 35	5	67625312	PIK3R1
522	-	8725	A/C	1	396177	rs3746821	Human NCBI Build 35	20	44188518	ENSG00000101017
523	-	8737	A/C	1	396188	rs3768748	Human NCBI Build 35	2	46263499	PRKCE
524	-	8752	A/C	0	396199	rs3792646	Human NCBI Build 35	5	40991410	C7
526	-	8773	A/C	0	396213	rs3846684	Human NCBI Build 35	5	156581710	ITK
527	-	8774	A/C	1	396214	rs3846755	Human NCBI Build 35	6	74461607	CD109
528	-	8778	A/C	0	396216	rs3858396	Human NCBI Build 35	11	107437602	CUL5
529	-	8786	A/C	1	396222	rs3917971	Human NCBI Build 35	1	36607757	CSF3R
530	-	8791	A/C	0	396225	rs405322	Human NCBI Build 35	16	24022987	PRKCB1
531	-	8793	A/C	0	396227	rs4132699	Human NCBI Build 35	9	89265981	SEMA4D
532	-	8810	A/C	1	396239	rs4444423	Human NCBI Build 35	18	46338134	MAPK4
533	-	8835	A/C	0	396257	rs4742100	Human NCBI Build 35	9	5460954	ENSG00000120217
534	-	8846	A/C	1	396265	rs4801	Human NCBI Build 35 5	140022144	IK-ENSG00000120314	
535	-	8858	A/C	0	396275	rs4925	Human NCBI Build 35 10	106012779	GSTO1	
536	-	8873	A/C	1	396289	rs512525	Human NCBI Build 35	1	157626816	CD244-ENSG00000198956
537	-	8877	A/C	0	396291	rs515299	Human NCBI Build 35	1	193438334	CFH
538	-	8900	A/C	0	396309	rs6101495	Human NCBI Build 35	20	34686388	SLA2
540	-	8933	A/C	0	396338	rs6728564	Human NCBI Build 35	2	45858760	PRKCE
541	-	8941	A/C	1	396345	rs6866324	Human NCBI Build 35	5	169382868	DOCK2
542	-	8943	A/C	0	396347	rs6879663	Human NCBI Build 35	5	169138890	DOCK2
543	-	8947	A/C	0	396350	rs6926332	Human NCBI Build 35	6	128527832	PTPRK
545	-	8977	A/C	0	396374	rs724985	Human NCBI Build 35	1	157390963	SLAMF1
546	-	8985	A/C	0	396381	rs7384313	Human NCBI Build 35	7	157598799	PTPRN2
547	-	8997	A/C	1	396391	rs7588807	Human NCBI Build 35	2	220264607	INHA-ENSG00000124006
548	-	9011	A/C	0	396403	rs7731963	Human NCBI Build 35	5	439014	AHRR
549	-	9019	A/C	0	396411	rs7871338	Human NCBI Build 35	9	5545023	PDCD1LG2
550	-	9024	A/C	0	396416	rs7922467	Human NCBI Build 35	10	129643702	PTPRE

551	-	9025	A/C	1	396417	rs7934770	Human NCBI Build 35	11	35169702	CD44
554	-	9050	A/C	0	396437	rs856084	Human NCBI Build 35	1	155728214	PYHIN1
555	-	9076	A/C	0	396452	rs9321111	Human NCBI Build 35	6	128466886	PTPRK
556	-	9079	A/C	0	396454	rs9325031	Human NCBI Build 35	5	146395360	PPP2R2B
557	-	9091	A/C	0	396465	rs958644	Human NCBI Build 35	12	69383756	PTPRR
559	-	9123	A/C	0	396489	rs1007555	Human NCBI Build 35	3	62174511	PTPRG
561	-	9134	A/C	1	396497	rs1030021	Human NCBI Build 35	2	102259996	IL1RL2
562	-	9141	A/C	0	396503	rs10489823	Human NCBI Build 35	1	154959459	CD1D-ENSG00000187213
563	-	9156	A/C	1	396514	rs10503573	Human NCBI Build 35	8	16047855	MSR1
564	-	9212	A/C	0	396560	rs11265544	Human NCBI Build 35	1	157819092	USF1-F11R
565	-	9219	A/C	0	396565	rs1147499	Human NCBI Build 35	7	121262271	PTPRZ1
566	-	9223	A/C	0	396567	rs11568849	Human NCBI Build 35	4	111192141	EGF
567	-	9226	A/C	1	396570	rs11581155	Human NCBI Build 35	1	50688327	FAF1
568	-	9236	A/C	0	396577	rs11721827	Human NCBI Build 35	4	187366286	TLR3
569	-	9240	A/C	0	396579	rs11748210	Human NCBI Build 35	5	146168608	PPP2R2B
570	-	9248	A/C	0	396587	rs12029576	Human NCBI Build 35	1	214947870	ENSG00000092969
571	-	9251	A/C	0	396590	rs12050807	Human NCBI Build 35	15	62091805	ENSG00000035664
572	-	9319	A/C	0	396643	rs1542313	Human NCBI Build 35	14	64069791	HSPA2
573	-	9324	A/C	0	396646	rs1558070	Human NCBI Build 35	7	30276726	CARD4
574	-	9346	A/C	0	396665	rs1887104	Human NCBI Build 35	14	59810079	PPM1A
575	-	9364	A/C	1	396681	rs2023671	Human NCBI Build 35	16	23757340	PRKCB1
576	-	9389	A/C	0	396704	rs208243	Human NCBI Build 35	20	40854450	PTPRT
577	-	9393	A/C	1	396708	rs2125062	Human NCBI Build 35	10	97970711	BLNK
578	-	9404	A/C	1	396716	rs2191311	Human NCBI Build 35	7	38108760	TRGV9
580	-	9427	A/C	0	396736	rs2303069	Human NCBI Build 35	5	147461278	SPINK5
581	-	9428	A/C	0	396737	rs2303070	Human NCBI Build 35	5	147480084	SPINK5
582	-	9433	A/C	0	396740	rs2308911	Human NCBI Build 35	6	33145558	HLA-DPA1
583	-	9461	A/C	0	396764	rs2683546	Human NCBI Build 35	10	71363704	COL13A1-AMID
584	-	9473	A/C	0	396773	rs2861304	Human NCBI Build 35	10	97947875	BLNK
585	-	9494	A/C	1	396787	rs3176882	Human NCBI Build 35	10	97613997	ENTPD1
586	-	9508	A/C	0	396799	rs353636	Human NCBI Build 35	11	35141306	CD44
587	-	9515	A/C	0	396804	rs3734099	Human NCBI Build 35	5	169055381	DOCK2
588	-	9533	A/C	0	396820	rs3773994	Human NCBI Build 35	3	191726419	IL1RAP
589	-	9537	A/C	0	396823	rs3775552	Human NCBI Build 35	4	185699336	IRF2
590	-	9540	A/C	0	396825	rs3782181	Human NCBI Build 35	12	87456029	KITLG
591	-	9547	A/C	0	396832	rs3794317	Human NCBI Build 35	12	8649861	AICDA
592	-	9555	A/C	1	396838	rs3819409	Human NCBI Build 35	6	135567089	MYB
593	-	9567	A/C	0	396848	rs3918227	Human NCBI Build 35	7	150138594	NOS3-NOS3AS
594	-	9569	A/C	1	396850	rs4251450	Human NCBI Build 35	12	42445458	ENSG00000198001
595	-	9571	A/C	0	396852	rs4262642	Human NCBI Build 35	10	129735537	PTPRE
596	-	9576	A/C	0	396856	rs4380159	Human NCBI Build 35	17	31562715	
ENSG00000187869-ENSG00000189315-ENSG00000197262										
598	-	9581	A/C	1	396861	rs4483927	Human NCBI Build 35	18	20298398	HRH4
600	-	9584	A/C	1	396864	rs4625350	Human NCBI Build 35	1	214931706	ENSG00000092969
601	-	9592	A/C	0	396870	rs4694178	Human NCBI Build 35	4	74977723	IL8
602	-	9603	A/C	0	396878	rs4804404	Human NCBI Build 35	19	7169382	INSR
603	-	9670	A/C	0	396932	rs629244	Human NCBI Build 35	10	6525665	PRKCQ
604	-	9698	A/C	0	396956	rs663273	Human NCBI Build 35	15	32048074	AVEN
605	-	9707	A/C	0	396965	rs6730511	Human NCBI Build 35	2	46206500	PRKCE

606	-	9709	A/C	0	396967	rs6741615	Human NCBI Build 35	2	102065189	IL1R2
607	-	9750	A/C	0	397002	rs7303577	Human NCBI Build 35	12	63160369	TBK1
608	-	9753	A/C	0	397005	rs732798	Human NCBI Build 35	16	23811451	PRKCB1
609	-	9768	A/C	0	397020	rs7566274	Human NCBI Build 35	2	191826425	STAT4
610	-	9769	A/C	0	397021	rs7589525	Human NCBI Build 35	2	102104909	IL1R2
611	-	9776	A/C	0	397027	rs7648198	Human NCBI Build 35	3	138154459	NCK1-ENSG00000174564
613	-	9783	A/C	0	397034	rs7713645	Human NCBI Build 35	5	67563082	PIK3R1
614	-	9794	A/C	0	397042	rs7806162	Human NCBI Build 35	7	142498642	CASP2-ENSG00000178826
616	-	9828	A/C	0	397067	rs871495	Human NCBI Build 35	9	87367170	DAPK1
618	-	9835	A/C	1	397074	rs9290936	Human NCBI Build 35	3	191735337	IL1RAP
619	-	9842	A/C	0	397081	rs9410327	Human NCBI Build 35	9	89345599	SEMA4D
620	-	9844	A/C	1	397083	rs9459835	Human NCBI Build 35	6	167387962	CCR6-ENSG00000187485
623	-	9864	A/C	1	397101	rs10225212	Human NCBI Build 35	7	121222626	PTPRZ1
624	-	9878	A/C	0	397113	rs10508903	Human NCBI Build 35	10	49311338	MAPK8
625	-	9879	A/C	0	397114	rs10512751	Human NCBI Build 35	5	40970589	C7
626	-	9880	A/C	0	397115	rs10513055	Human NCBI Build 35	3	139934050	PIK3CB
627	-	9888	A/C	0	397121	rs10797006	Human NCBI Build 35	1	155070911	CD1C
628	-	9911	A/C	0	397143	rs11205747	Human NCBI Build 35	1	50809306	FAF1
629	-	9923	A/C	0	397153	rs11739145	Human NCBI Build 35	5	35177946	PRLR
630	-	9950	A/C	0	397175	rs12244332	Human NCBI Build 35	10	106010130	GSTO1
631	-	9957	A/C	0	397180	rs12389812	Human NCBI Build 35	X	103743124	IL1RAPL2
632	-	9963	A/C	0	397186	rs12541118	Human NCBI Build 35	8	16077302	MSR1
633	-	9968	A/C	1	397191	rs12803	Human NCBI Build 35	2	157007433	NR4A2
634	-	9972	A/C	1	397195	rs13085295	Human NCBI Build 35	3	61935672	PTPRG
635	-	9978	A/C	0	397200	rs1339196	Human NCBI Build 35	6	128654826	PTPRK
636	-	9987	A/C	1	397208	rs1408077	Human NCBI Build 35	1	204192536	none
637	-	10033	A/C	0	397247	rs1883136	Human NCBI Build 35	6	112013716	C6orf4
638	-	10080	A/C	0	397286	rs2340988	Human NCBI Build 35	16	23891757	PRKCB1
639	-	10104	A/C	1	397305	rs259916	Human NCBI Build 35	5	169307427	DOCK2
640	-	10132	A/C	0	397328	rs3211834	Human NCBI Build 35	7	79924768	CD36
641	-	10133	A/C	1	397329	rs3211938	Human NCBI Build 35	7	79945100	CD36
642	-	10135	A/C	0	397331	rs351554	Human NCBI Build 35	8	16051766	MSR1
643	-	10159	A/C	0	397352	rs3799397	Human NCBI Build 35	6	136625205	ENSG0000029363
644	-	10172	A/C	0	397362	rs386406	Human NCBI Build 35	5	169165739	DOCK2
645	-	10173	A/C	0	397363	rs389883	Human NCBI Build 35	6	32055439	STK19-ENSG00000198209
646	-	10176	A/C	0	397366	rs4074459	Human NCBI Build 35	9	89264492	SEMA4D
647	-	10194	A/C	0	397383	rs4695357	Human NCBI Build 35	4	48040123	TEC
648	-	10209	A/C	0	397396	rs4896219	Human NCBI Build 35	6	137121235	MAP3K5
649	-	10233	A/C	1	397419	rs6051991	Human NCBI Build 35	20	3567384	ATRN
651	-	10236	A/C	1	397421	rs6102	Human NCBI Build 35	18	59721450	SERPINB2
652	-	10239	A/C	0	397424	rs627925	Human NCBI Build 35	3	106774924	ALCAM
653	-	10241	A/C	0	397426	rs630085	Human NCBI Build 35	18	8297219	PTPRM
654	-	10256	A/C	0	397436	rs6495403	Human NCBI Build 35	15	32042596	AVEN
656	-	10264	A/C	1	397443	rs6545835	Human NCBI Build 35	2	61024203	REL
657	-	10275	A/C	1	397453	rs6766943	Human NCBI Build 35	3	61809982	PTPRG
658	-	10293	A/C	0	397468	rs704853	Human NCBI Build 35	1	164200522	CD3Z
659	-	10308	A/C	0	397480	rs7244913	Human NCBI Build 35	18	8241524	PTPRM
660	-	10310	A/C	1	397482	rs7313141	Human NCBI Build 35	12	9913415	ENSG00000110852
661	-	10314	A/C	0	397485	rs7323925	Human NCBI Build 35	13	23115160	TNFRSF19

663	-	10352	A/C	0	397517	rs790632	Human NCBI Build 35	1	67390943	IL23R
664	-	10361	A/C	1	397525	rs8047161	Human NCBI Build 35	16	66771641	NFATC3
665	-	10390	A/C	0	397549	rs9402875	Human NCBI Build 35	6	137539711	IL22RA2
666	-	10394	A/C	0	397552	rs951012	Human NCBI Build 35	2	46309282	PRKCE
667	-	10420	A/C	0	397576	rs10494422	Human NCBI Build 35	1	161512673	PBX1
668	-	10429	A/C	0	397581	rs10506596	Human NCBI Build 35	12	69277604	PTPRB
669	-	10436	A/C	0	397587	rs10512203	Human NCBI Build 35	9	90738589	SYK
671	-	10476	A/C	0	397620	rs11779793	Human NCBI Build 35	8	23022145	TNFRSF10C-ENSG00000147457
672	-	10511	A/C	0	397652	rs13424615	Human NCBI Build 35	2	201835607	CFLAR
673	-	10514	A/C	0	397654	rs1343817	Human NCBI Build 35	1	111149171	CD53
674	-	10546	A/C	0	397682	rs1962113	Human NCBI Build 35	2	239844371	HDAC4
675	-	10549	A/C	0	397685	rs1997929	Human NCBI Build 35	X	103740526	IL1RAPL2
676	-	10560	A/C	0	397695	rs2069818	Human NCBI Build 35	5	131905423	IL5
677	-	10606	A/C	0	397729	rs2551402	Human NCBI Build 35	18	59141002	BCL2
678	-	10608	A/C	0	397731	rs2629396	Human NCBI Build 35	3	120731657	CD80
679	-	10614	A/C	0	397736	rs2687149	Human NCBI Build 35	3	61834305	PTPRG
680	-	10618	A/C	0	397740	rs2729726	Human NCBI Build 35	2	160493615	LY75
681	-	10619	A/C	0	397741	rs2758331	Human NCBI Build 35	6	160075481	SOD2
682	-	10630	A/C	1	397751	rs3093277	Human NCBI Build 35	7	76471089	FGL2-ENSG00000135205
684	-	10636	A/C	1	397757	rs340813	Human NCBI Build 35	3	30995500	IL5RA
685	-	10670	A/C	1	397783	rs3795542	Human NCBI Build 35	1	89446295	GBP5
686	-	10671	A/C	0	397784	rs3799207	Human NCBI Build 35	6	3025420	RIPK1
688	-	10687	A/C	0	397800	rs420444	Human NCBI Build 35	5	38893123	OSMR
689	-	10699	A/C	0	397810	rs4617959	Human NCBI Build 35	18	46336418	MAPK4
690	-	10703	A/C	0	397814	rs4655249	Human NCBI Build 35	1	210971379	PTPN14
691	-	10707	A/C	0	397817	rs4694890	Human NCBI Build 35	4	48067195	TEC
692	-	10731	A/C	1	397837	rs494800	Human NCBI Build 35	10	6562914	PRKCQ
693	-	10732	A/C	0	397838	rs4988406	Human NCBI Build 35	22	41842822	BIK-ENSG00000183614
694	-	10737	A/C	0	397841	rs539103	Human NCBI Build 35	10	6544259	PRKCQ
695	-	10756	A/C	0	397859	rs6072770	Human NCBI Build 35	20	40591121	PTPRT
696	-	10760	A/C	1	397862	rs629710	Human NCBI Build 35	11	64865809	DPF2-ENSG00000197847
697	-	10774	A/C	0	397875	rs6537798	Human NCBI Build 35	1	114063748	PTPN22-RSBN1
698	-	10775	A/C	1	397876	rs6544844	Human NCBI Build 35	2	45859483	PRKCE
699	-	10777	A/C	0	397878	rs6570087	Human NCBI Build 35	6	137048621	MAP3K5
700	-	10779	A/C	1	397880	rs6608190	Human NCBI Build 35	X	123221985	SH2D1A
701	-	10786	A/C	0	397887	rs6720948	Human NCBI Build 35	2	160500163	LY75
702	-	10807	A/C	0	397904	rs7026551	Human NCBI Build 35	9	120812687	C5
703	-	10821	A/C	0	397916	rs7393696	Human NCBI Build 35	10	45265696	ALOX5
704	-	10823	A/C	1	397918	rs7507039	Human NCBI Build 35	18	8227772	PTPRM
705	-	10830	A/C	0	397924	rs7597763	Human NCBI Build 35	2	233863899	INPP5D
707	-	10849	A/C	0	397942	rs8016917	Human NCBI Build 35	14	63639704	SYNE2-ESR2
708	-	10878	A/C	0	397965	rs9398863	Human NCBI Build 35	6	128362605	PTPRK
709	-	10884	A/C	0	397970	rs983884	Human NCBI Build 35	5	146219161	PPP2R2B
710	-	10890	A/C	1	397975	rs997997	Human NCBI Build 35	1	71198223	PTGER3
711	-	10898	A/C	0	397981	rs10103200	Human NCBI Build 35	8	141937570	PTK2
712	-	10902	A/C	1	397984	rs10124246	Human NCBI Build 35	9	34703129	CCL21
713	-	10908	A/C	0	397990	rs10252204	Human NCBI Build 35	7	76465451	FGL2-ENSG00000135205
714	-	10918	A/C	1	398000	rs10489630	Human NCBI Build 35	1	67374643	IL23R
715	-	10925	A/C	1	398004	rs10494418	Human NCBI Build 35	1	161324123	PBX1-ENSG00000197613

716	-	10944	A/C	0	398020	rs10826936	Human NCBI Build 35	10	31661748	TCF8
717	-	10978	A/C	0	398046	rs12198787	Human NCBI Build 35	6	31671207	ENSG00000096157
718	-	11021	A/C	0	398078	rs1507765	Human NCBI Build 35	1	203923641	DAF
719	-	11035	A/C	0	398090	rs1634522	Human NCBI Build 35	17	31462117	CCL4
720	-	11039	A/C	0	398094	rs1781785	Human NCBI Build 35	6	6174347	F13A1
721	-	11059	A/C	0	398108	rs1941031	Human NCBI Build 35	11	59992259	MS4A1
722	-	11070	A/C	1	398119	rs210428	Human NCBI Build 35	X	104746772	IL1RAPL2
723	-	11075	A/C	1	398122	rs2159777	Human NCBI Build 35	9	120862610	C5
724	-	11108	A/C	0	398149	rs250201	Human NCBI Build 35	5	142013492	FGF1
725	-	11114	A/C	0	398153	rs2670289	Human NCBI Build 35	3	120757276	CD80
726	-	11121	A/C	0	398159	rs2770144	Human NCBI Build 35	9	117554889	TLR4
727	-	11150	A/C	0	398186	rs3759273	Human NCBI Build 35	12	10349288	KLRD1
728	-	11161	A/C	1	398195	rs3821742	Human NCBI Build 35	3	191738117	IL1RAP
729	-	11166	A/C	0	398200	rs3917040	Human NCBI Build 35	1	100904956	VCAM1
730	-	11206	A/C	0	398234	rs4994772	Human NCBI Build 35	5	42703906	GHR
731	-	11218	A/C	0	398245	rs6072916	Human NCBI Build 35	20	41033425	PTPRT
732	-	11247	A/C	0	398268	rs6906871	Human NCBI Build 35	6	137003910	MAP3K5
733	-	11259	A/C	1	398277	rs7100081	Human NCBI Build 35	10	31686997	TCF8-ENSG00000196960
734	-	11277	A/C	0	398293	rs7520329	Human NCBI Build 35	1	24244217	IL28RA
735	-	11307	A/C	0	398318	rs854656	Human NCBI Build 35	17	31369774	CCL23
737	-	11350	A/C	0	398355	rs10283768	Human NCBI Build 35	9	35209714	UNC13B
738	-	11351	A/C	0	398356	rs1039337	Human NCBI Build 35	9	8377892	PTPRD
739	-	11367	A/C	0	398365	rs10508815	Human NCBI Build 35	10	35372627	CUL2
740	-	11390	A/C	0	398387	rs1147498	Human NCBI Build 35	7	121264473	PTPRZ1
742	-	11419	A/C	0	398409	rs12288787	Human NCBI Build 35	11	101703741	BIRC3
743	-	11422	A/C	0	398412	rs12692566	Human NCBI Build 35	2	160501934	LY75
744	-	11452	A/C	1	398439	rs2069762	Human NCBI Build 35	4	123735585	ENSG00000109471
745	-	11457	A/C	0	398444	rs2117515	Human NCBI Build 35	19	3993858	
PIAS4-ENSG00000178951-ENSG00000188205										
746	-	11461	A/C	1	398448	rs2176347	Human NCBI Build 35	2	45879884	PRKCE
748	-	11471	A/C	0	398457	rs2299939	Human NCBI Build 35	10	89647130	ENSG00000171862
749	-	11506	A/C	1	398486	rs319162	Human NCBI Build 35	5	146278814	PPP2R2B
750	-	11517	A/C	0	398495	rs3773976	Human NCBI Build 35	3	191769987	IL1RAP
751	-	11534	A/C	0	398510	rs4278155	Human NCBI Build 35	8	23052724	TNFRSF10D-ENSG00000147457
752	-	11536	A/C	0	398512	rs4352468	Human NCBI Build 35	4	87419542	MAPK10
753	-	11543	A/C	0	398518	rs4503638	Human NCBI Build 35	12	69534032	PTPRR
755	-	11611	A/C	0	398576	rs7552717	Human NCBI Build 35	1	161315999	PBX1
756	-	11638	A/C	1	398601	rs859005	Human NCBI Build 35	1	154961672	CD1D-ENSG00000187213
757	-	11675	A/C	0	398630	rs10492795	Human NCBI Build 35	16	23923602	PRKCB1
758	-	11679	A/C	0	398632	rs10497208	Human NCBI Build 35	2	160812428	ITGB6
759	-	11709	A/C	0	398657	rs13216847	Human NCBI Build 35	6	128867636	PTPRK
761	-	11756	A/C	0	398695	rs2305623	Human NCBI Build 35	3	133804960	NPHP3-CCRL1
763	-	11760	A/C	0	398699	rs2426295	Human NCBI Build 35	20	49448706	NFATC2
764	-	11762	A/C	0	398701	rs244693	Human NCBI Build 35	5	133483052	TCF7
765	-	11765	A/C	1	398703	rs2489870	Human NCBI Build 35	X	117647775	IL13RA1
766	-	11815	A/C	0	398741	rs4660123	Human NCBI Build 35	1	232377248	ENSG00000143669
767	-	11825	A/C	0	398748	rs493489	Human NCBI Build 35	1	71107203	PTGER3
768	-	11831	A/C	0	398753	rs501878	Human NCBI Build 35	10	6566503	PRKCQ
769	-	11836	A/C	0	398758	rs609039	Human NCBI Build 35	18	8393289	PTPRM

770	-	11844	A/C	0	398764	rs6488232	Human NCBI Build 35	12	9888578	KLRF1	
771	-	11881	A/C	0	398789	rs7467245	Human NCBI Build 35	9	8592246	PTPRD	
772	-	11891	A/C	0	398797	rs7771466	Human NCBI Build 35	6	52212068		IL17F
773	-	11895	A/C	0	398801	rs7864527	Human NCBI Build 35	9	8543569	PTPRD	
774	-	11929	A/C	0	398828	rs9847868	Human NCBI Build 35	3	191840234		IL1RAP
775	-	11934	A/C	1	398831	rs10099466	Human NCBI Build 35	8	38179548		BAG4
776	-	11941	A/C	0	398838	rs10511500	Human NCBI Build 35	9	8555802	PTPRD	
777	-	11950	A/C	1	398846	rs11018401	Human NCBI Build 35	10	129603531		PTPRE
778	-	11952	A/C	1	398848	rs11079772	Human NCBI Build 35	17	42748738		ITGB3
779	-	11971	A/C	1	398863	rs1396274	Human NCBI Build 35	3	62029636		PTPRG
780	-	11989	A/C	0	398875	rs1782322	Human NCBI Build 35	10	70156331		CCAR1
781	-	12002	A/C	1	398887	rs1982673	Human NCBI Build 35	18	58948995		BCL2
782	-	12011	A/C	0	398892	rs2155145	Human NCBI Build 35	11	71397267		NUMA1-IL18BP
783	-	12015	A/C	0	398896	rs2248202	Human NCBI Build 35	21	33525750		IFNAR2
784	-	12019	A/C	0	398900	rs2291270	Human NCBI Build 35	5	169078543		DOCK2
785	-	12020	A/C	1	398901	rs2296102	Human NCBI Build 35	9	8479105	PTPRD	
786	-	12022	A/C	0	398903	rs2300932	Human NCBI Build 35	9	120849990		C5
787	-	12028	A/C	0	398906	rs2330951	Human NCBI Build 35	7	54948551		EGFR
788	-	12032	A/C	0	398909	rs2387351	Human NCBI Build 35	13	27547457		FLT3
789	-	12080	A/C	1	398951	rs4701883	Human NCBI Build 35	5	10816656		DAP
790	-	12089	A/C	0	398957	rs534288	Human NCBI Build 35	2	45797660		PRKCE
791	-	12093	A/C	1	398961	rs6030289	Human NCBI Build 35	20	40563984		PTPRT
792	-	12098	A/C	1	398965	rs626748	Human NCBI Build 35	10	6556097	PRKCQ	
793	-	12112	A/C	0	398976	rs6964705	Human NCBI Build 35	7	54983846		EGFR
794	-	12124	A/C	0	398987	rs7543060	Human NCBI Build 35	1	232270439		ENSG00000143669
795	-	12142	A/C	0	399001	rs7912493	Human NCBI Build 35	10	71419026		AMID
796	-	12161	A/C	0	399019	rs942977	Human NCBI Build 35	1	71079485		PTGER3
797	-	12177	A/C	0	399034	rs10515921	Human NCBI Build 35	2	102439536		IL18R1
798	-	12189	A/C	0	399042	rs11209050	Human NCBI Build 35	1	67503757		IL12RB2
799	-	12207	A/C	1	399055	rs1531652	Human NCBI Build 35	8	16071566		MSR1
800	-	12223	A/C	0	399069	rs2270755	Human NCBI Build 35	11	22727498		GAS2
801	-	12234	A/C	0	399078	rs2624780	Human NCBI Build 35	1	143200719		CD160
802	-	12237	A/C	0	399080	rs2770145	Human NCBI Build 35	9	117554878		TLR4
803	-	12249	A/C	0	399091	rs3801382	Human NCBI Build 35	7	120592228		FAM3C
804	-	12276	A/C	0	399115	rs7260484	Human NCBI Build 35	19	5153825	PTPRS	
805	-	12306	A/C	0	399137	rs10061195	Human NCBI Build 35	5	122402132		PPIC
806	-	12311	A/C	0	399142	rs1337808	Human NCBI Build 35	9	8611368	PTPRD	
807	-	12318	A/C	0	399146	rs1543083	Human NCBI Build 35	9	8693025	PTPRD	
808	-	12333	A/C	0	399159	rs2077781	Human NCBI Build 35	18	59454958		SERPINB3
809	-	12350	A/C	0	399171	rs4468140	Human NCBI Build 35	1	158418543		ENSG00000132185
810	-	12360	A/C	0	399180	rs6786815	Human NCBI Build 35	3	106628025		ALCAM
811	-	12377	A/C	0	399192	rs858542	Human NCBI Build 35	1	164199440		CD3Z
812	-	12379	A/C	0	399194	rs9491931	Human NCBI Build 35	6	128614570		PTPRK
813	-	12384	A/C	0	399198	rs10082300	Human NCBI Build 35	1	195385041		PTPRC
815	-	12431	A/C	0	399237	rs9918557	Human NCBI Build 35	7	121143657		PTPRZ1
816	-	12435	A/C	0	399241	rs11585772	Human NCBI Build 35	1	51096811		FAF1
817	-	12436	A/C	0	399242	rs1478309	Human NCBI Build 35	12	10433012		KLRC4
818	-	12457	A/C	0	399259	rs661377	Human NCBI Build 35	20	3535698	ATRN	
819	-	12483	A/C	0	399279	rs2302474	Human NCBI Build 35	7	76912853		PTPN12

820	-	12486	A/C	1	399282	rs3863373	Human NCBI Build 35	12	69574663	PTPRR
821	-	12487	A/C	0	399283	rs5916911	Human NCBI Build 35	X	104478939	IL1RAPL2
822	-	12488	A/C	0	399284	rs612535	Human NCBI Build 35	15	32021107	AVEN
823	-	12496	A/C	0	399291	rs10878177	Human NCBI Build 35	12	63170028	TBK1
824	-	12504	A/C	1	399297	rs1190598	Human NCBI Build 35	14	101663201	HSPCA
826	-	223	A/G	1	389092	rs10421547	Human NCBI Build 35	19	47318047	POU2F2
827	-	242	A/G	0	389093	rs10424365	Human NCBI Build 35	19	19171527	RFKANK-ENSG00000184162
828	-	316	A/G	0	389097	rs10489990	Human NCBI Build 35	2	70974303	CD207
829	-	350	A/G	1	389099	rs1050382	Human NCBI Build 35	17	59753732	PECAM1
830	-	366	A/G	1	389100	rs1050998	Human NCBI Build 35	17	4585486	CXCL16-ENSG00000161920
831	-	418	A/G	0	389101	rs1051457	Human NCBI Build 35	Multiple	0	
KIR2DS2-ENSG00000167633-KIR2DS1-KIR3DS1-ENSG00000189013-KIR2DL4										
833	-	627	A/G	1	389111	rs10774910	Human NCBI Build 35	12	116137059	NOS1
834	-	719	A/G	1	389117	rs11039554	Human NCBI Build 35	11	48141731	PTPRJ
835	-	847	A/G	0	389120	rs11085100	Human NCBI Build 35	19	4762826	ENSG00000127666
836	-	993	A/G	0	389123	rs11230594	Human NCBI Build 35	11	60629048	CD5
837	-	998	A/G	0	389124	rs11247367	Human NCBI Build 35	15	97053799	IGF1R
838	-	1069	A/G	1	389127	rs1138294	Human NCBI Build 35	1	27372775	MAP3K6
841	-	1457	A/G	0	389145	rs11926063	Human NCBI Build 35	3	46238721	CCR3
842	-	1481	A/G	0	389147	rs12039194	Human NCBI Build 35	1	161268886	PBX1
844	-	1620	A/G	0	389154	rs12608511	Human NCBI Build 35	19	502374	GZMM
846	-	1771	A/G	0	389162	rs12738235	Human NCBI Build 35	1	3809402	DFFB
847	-	1811	A/G	0	389163	rs12755035	Human NCBI Build 35	1	2058523	PRKCZ
849	-	1912	A/G	1	389166	rs13007813	Human NCBI Build 35	2	45851558	PRKCE
851	-	2152	A/G	0	389177	rs13962	Human NCBI Build 35	1	155988600	FY-IGSF4B
853	-	2273	A/G	1	389184	rs1520811	Human NCBI Build 35	12	116227787	NOS1
854	-	2282	A/G	0	389185	rs1529835	Human NCBI Build 35	7	157141145	PTPRN2
855	-	2303	A/G	0	389186	rs1544766	Human NCBI Build 35	19	7712723	ENSG00000188197-ENSG00000090659
856	-	2323	A/G	1	389187	rs1550805	Human NCBI Build 35	5	67619563	PIK3R1
857	-	2400	A/G	0	389191	rs161021	Human NCBI Build 35	5	146189300	PPP2R2B
858	-	2416	A/G	0	389192	rs1654926	Human NCBI Build 35	3	138192622	ENSG00000174564
859	-	2489	A/G	0	389195	rs1687392	Human NCBI Build 35	9	114179510	ORM1-AKNA
860	-	2519	A/G	0	389197	rs16986309	Human NCBI Build 35	19	60401886	BRSK1-PTPRH
862	-	2845	A/G	0	389214	rs1862511	Human NCBI Build 35	19	6537268	TNFSF7
863	-	2880	A/G	0	389216	rs1892901	Human NCBI Build 35	11	65427469	FOSL1-ENSG00000197847
864	-	3193	A/G	1	389236	rs2066842	Human NCBI Build 35	16	49302125	CARD15
865	-	3201	A/G	0	389237	rs2070074	Human NCBI Build 35	9	34639442	GALT-ENSG00000137070
867	-	3285	A/G	0	389242	rs2072878	Human NCBI Build 35	22	49005516	MAPK12-MAPK11
868	-	3380	A/G	0	389245	rs2074800	Human NCBI Build 35	16	3665683	TRAP1
870	-	3489	A/G	1	389250	rs2076089	Human NCBI Build 35	22	41118728	ENSG00000167087
871	-	3527	A/G	0	389252	rs2082405	Human NCBI Build 35	5	146238789	PPP2R2B
872	-	3603	A/G	1	389254	rs2127679	Human NCBI Build 35	6	32926214	none
873	-	3650	A/G	0	389256	rs2161257	Human NCBI Build 35	5	149170190	PPARGC1B
878	-	4103	A/G	0	389278	rs2236660	Human NCBI Build 35	11	122438737	HSPA8
880	-	4130	A/G	0	389283	rs224205	Human NCBI Build 35	16	3236617	MEFV
881	-	4418	A/G	1	389293	rs2277619	Human NCBI Build 35	17	37629087	STAT5B
882	-	4481	A/G	0	389295	rs2278427	Human NCBI Build 35	19	60109543	NCR1
883	-	4700	A/G	0	389303	rs2284034	Human NCBI Build 35	22	35867262	IL2RB
884	-	4748	A/G	0	389305	rs2284553	Human NCBI Build 35	21	33698565	IFNGR2

885	-	4789	A/G	0	389306	rs2287074	Human	NCBI	Build	35	16	54084614	MMP2
886	-	4907	A/G	1	389307	rs2287720	Human	NCBI	Build	35	5	150395531	TNIP1
887	-	4922	A/G	0	389308	rs2287936	Human	NCBI	Build	35	7	150219719	
CENTG3-C7orf21-ENSG00000164896													
888	-	4942	A/G	0	389310	rs2288648	Human	NCBI	Build	35	12	56449006	
METTL1-ENSG00000123427-CYP27B1													
890	-	5005	A/G	0	389314	rs2289541	Human	NCBI	Build	35	17	75794003	CARD14-SGSH
892	-	5137	A/G	0	389322	rs2296140	Human	NCBI	Build	35	10	6038702	IL15RA
893	-	5170	A/G	0	389323	rs2297704	Human	NCBI	Build	35	1	110171884	CSF1
894	-	5228	A/G	0	389328	rs2303018	Human	NCBI	Build	35	5	150421931	TNIP1
898	-	5524	A/G	0	389340	rs2308503	Human	NCBI	Build	35	6	31430959	HLA-B
899	-	5535	A/G	0	389341	rs231458	Human	NCBI	Build	35	17	39350320	ENSG00000181763
901	-	5584	A/G	0	389345	rs241447	Human	NCBI	Build	35	6	32904729	TAP2
902	-	5654	A/G	0	389349	rs2512143	Human	NCBI	Build	35	11	117365792	IL10RA
903	-	5734	A/G	0	389355	rs258282	Human	NCBI	Build	35	16	2146592	RAB26-ENSG00000131653
905	-	5865	A/G	1	389360	rs2742973	Human	NCBI	Build	35	1	23598323	E2F2
907	-	5928	A/G	1	389365	rs2839685	Human	NCBI	Build	35	10	44201644	CXCL12
908	-	5932	A/G	0	389366	rs2844397	Human	NCBI	Build	35	3	37801726	ITGA9
909	-	5934	A/G	1	389367	rs2866111	Human	NCBI	Build	35	19	58998184	NALP12
910	-	5941	A/G	0	389368	rs2905517	Human	NCBI	Build	35	11	60524620	CD6
911	-	5970	A/G	1	389369	rs2963075	Human	NCBI	Build	35	5	146266754	PPP2R2B
912	-	6034	A/G	0	389372	rs2995090	Human	NCBI	Build	35	1	164163172	CD3Z
914	-	6058	A/G	0	389374	rs3059	Human	NCBI	Build	35	19	60564003	IL11-ENSG00000180024-C19orf16
916	-	6115	A/G	0	389376	rs312466	Human	NCBI	Build	35	17	6839945	ALOX12
919	-	6167	A/G	0	389381	rs317926	Human	NCBI	Build	35	19	11347514	EPOR-ENSG00000173928
921	-	6270	A/G	0	389388	rs334349	Human	NCBI	Build	35	9	98993942	TGFBR1
923	-	6305	A/G	0	389390	rs344560	Human	NCBI	Build	35	19	6616020	TNFSF14
924	-	6316	A/G	0	389392	rs353251	Human	NCBI	Build	35	5	148731378	IL17B-ENSG00000145882
925	-	6328	A/G	0	389394	rs355673	Human	NCBI	Build	35	4	78828683	CXCL13
931	-	6620	A/G	1	389414	rs3760874	Human	NCBI	Build	35	19	495315	GZMM-CDC34
932	-	6633	A/G	0	389416	rs3763959	Human	NCBI	Build	35	17	22981461	LGALS9
933	-	6648	A/G	0	389419	rs3774638	Human	NCBI	Build	35	3	45958891	CXCR6-FYC01
934	-	6660	A/G	0	389421	rs3782735	Human	NCBI	Build	35	12	6755337	LAG3
935	-	6671	A/G	0	389423	rs3786657	Human	NCBI	Build	35	19	14367632	CD97
936	-	6676	A/G	0	389425	rs3789933	Human	NCBI	Build	35	10	98004997	BLNK
937	-	6682	A/G	0	389426	rs3791417	Human	NCBI	Build	35	2	239770601	HDAC4
938	-	6691	A/G	0	389428	rs3792792	Human	NCBI	Build	35	5	150420699	TNIP1
940	-	6735	A/G	0	389435	rs3803800	Human	NCBI	Build	35	17	7403693	SEN3-TNFSF12
941	-	6766	A/G	0	389437	rs3804488	Human	NCBI	Build	35	6	6587594	LY86
943	-	6783	A/G	1	389440	rs3810194	Human	NCBI	Build	35	19	54719852	RCN3-FCGRT
944	-	6842	A/G	0	389442	rs3812501	Human	NCBI	Build	35	9	88853951	C9orf47-ENSG00000148082
945	-	6890	A/G	0	389448	rs3820729	Human	NCBI	Build	35	2	46304426	PRKCE
946	-	6936	A/G	0	389453	rs3886870	Human	NCBI	Build	35	2	45954129	PRKCE
947	-	6981	A/G	0	389457	rs3922668	Human	NCBI	Build	35	16	28900147	LAT-ENSG00000169682
948	-	7029	A/G	0	389463	rs4151031	Human	NCBI	Build	35	11	36552776	RAG1
949	-	7095	A/G	1	389470	rs4308977	Human	NCBI	Build	35	1	204035293	CR2
951	-	7154	A/G	0	389478	rs4524313	Human	NCBI	Build	35	3	32260790	CKLFSF8
952	-	7166	A/G	0	389479	rs4610634	Human	NCBI	Build	35	7	2852845	CARD11
954	-	7257	A/G	0	389496	rs4806608	Human	NCBI	Build	35	19	60087394	FCAR

955	-	7263	A/G	1	389497	rs4818232	Human NCBI Build 35	21	41613515	FAM3B
956	-	7269	A/G	0	389498	rs4819553	Human NCBI Build 35	22	15939461	IL17R
957	-	7271	A/G	0	389499	rs4822129	Human NCBI Build 35	22	41148414	ENSG00000167087
958	-	7306	A/G	0	389501	rs4852063	Human NCBI Build 35	2	240048996	HDAC4
962	-	7379	A/G	0	389508	rs4912870	Human NCBI Build 35	5	141995899	FGF1
963	-	7392	A/G	0	389510	rs4926	Human NCBI Build 35 11	57138565	SERPING1	
964	-	7421	A/G	1	389511	rs4947324	Human NCBI Build 35	6	31636109	ENSG00000168593
965	-	7438	A/G	0	389515	rs4987850	Human NCBI Build 35	18	58945496	BCL2
966	-	7440	A/G	0	389516	rs4997978	Human NCBI Build 35	7	157201346	
PTPRN2-ENSG00000196590-ENSG00000196201										
967	-	7444	A/G	1	389517	rs5030878	Human NCBI Build 35	19	56942028	FPR1
968	-	7449	A/G	0	389518	rs520639	Human NCBI Build 35	16	28415145	CLN3-IL27-ENSG00000184730
971	-	7520	A/G	0	389532	rs5746026	Human NCBI Build 35	1	12187328	TNFRSF1B
972	-	7530	A/G	1	389536	rs592373	Human NCBI Build 35	11	1847566	LSP1
973	-	7543	A/G	0	389538	rs6008259	Human NCBI Build 35	22	44954301	PPARA
974	-	7579	A/G	0	389544	rs6134	Human NCBI Build 35 1	166312442	SELP	
976	-	7601	A/G	0	389550	rs6431586	Human NCBI Build 35	2	233901635	INPP5D
977	-	7623	A/G	0	389553	rs6495560	Human NCBI Build 35	15	79394558	IL16-STARD5
978	-	7627	A/G	0	389555	rs6519065	Human NCBI Build 35	22	36231189	CARD10
979	-	7643	A/G	0	389559	rs667676	Human NCBI Build 35	1	43751309	PTPRF
982	-	7698	A/G	0	389570	rs6959334	Human NCBI Build 35	7	2798351	CARD11
984	-	7729	A/G	1	389577	rs7084584	Human NCBI Build 35	10	129659536	PTPRE
985	-	7732	A/G	0	389578	rs7125	Human NCBI Build 35 19	18149069	IFI30	
986	-	7737	A/G	0	389579	rs713016	Human NCBI Build 35	3	10253696	IRAK2
988	-	7742	A/G	0	389581	rs715147	Human NCBI Build 35	20	49488757	NFATC2
989	-	7759	A/G	0	389586	rs7250381	Human NCBI Build 35	19	12911201	CALR
990	-	7791	A/G	0	389591	rs7299659	Human NCBI Build 35	12	8587928	ENSG00000166523
991	-	7792	A/G	1	389592	rs737282	Human NCBI Build 35	1	204434036	CD34
992	-	7825	A/G	0	389596	rs7512943	Human NCBI Build 35	1	1373998	TLR5
993	-	7885	A/G	0	389602	rs7590833	Human NCBI Build 35	2	240019588	HDAC4
994	-	7893	A/G	0	389604	rs7604639	Human NCBI Build 35	2	112468159	MERTK
997	-	7929	A/G	1	389612	rs7832476	Human NCBI Build 35	8	79879472	IL7
998	-	7935	A/G	0	389614	rs7872802	Human NCBI Build 35	9	129595284	PTGES-ENSG00000198665
999	-	7947	A/G	1	389617	rs7968585	Human NCBI Build 35	12	46518360	VDR
1000	-	7970	A/G	0	389621	rs8057598	Human NCBI Build 35	16	65766756	
ENSG00000140939-ENSG00000196123										
1001	-	8003	A/G	1	389623	rs8065854	Human NCBI Build 35	17	59436418	ICAM2-ENSG00000159752
1002	-	8021	A/G	0	389625	rs8095870	Human NCBI Build 35	18	46457301	MAPK4
1006	-	8141	A/G	0	389638	rs884786	Human NCBI Build 35	12	120935902	BCL7A-ENSG00000197247
1011	-	8185	A/G	0	389647	rs908742	Human NCBI Build 35	1	2065418	PRKCZ
1013	-	8247	A/G	0	389659	rs9509350	Human NCBI Build 35	13	20189056	IL17D
1015	-	8268	A/G	0	389663	rs9612011	Human NCBI Build 35	22	41846448	BIK
1016	-	8295	A/G	0	389669	rs971545	Human NCBI Build 35	12	66877952	IL26
1017	-	8367	A/G	0	389683	rs10056437	Human NCBI Build 35	5	43426419	CCL28
1018	-	8386	A/G	0	389685	rs10163905	Human NCBI Build 35	18	8292207	PTPRM
1020	-	8418	A/G	0	389689	rs10402864	Human NCBI Build 35	11	606865	
IRF7-ENSG00000099834-ENSG00000070047										
1021	-	8425	A/G	0	389690	rs1041868	Human NCBI Build 35	21	33649200	IFNAR1
1023	-	8455	A/G	0	389695	rs1046089	Human NCBI Build 35	6	31710946	BAT3-BAT2

1024	-	8461	A/G	0	389697	rs1049033	Human NCBI Build 35	6	29905618	HLA-G
1027	-	8500	A/G	0	389706	rs107017	Human NCBI Build 35	22	22237277	IGLL1
1028	-	8511	A/G	0	389708	rs10764747	Human NCBI Build 35	10	129778717	PTPRE
1029	-	8539	A/G	0	389713	rs10941396	Human NCBI Build 35	5	38557462	LIFR
1030	-	8549	A/G	0	389715	rs10999147	Human NCBI Build 35	10	71550864	AMID
1031	-	8554	A/G	1	389717	rs11065898	Human NCBI Build 35	12	110325295	ENSG00000111252
1032	-	8556	A/G	0	389718	rs11068458	Human NCBI Build 35	12	116265462	NOS1
1034	-	8589	A/G	0	389722	rs1125331	Human NCBI Build 35	16	66785620	NFATC3
1035	-	8597	A/G	0	389725	rs1136448	Human NCBI Build 35	1	218301203	DUSP10
1037	-	8605	A/G	0	389727	rs1142882	Human NCBI Build 35	19	59941848	KIR2DS2-KIR2DS1-KIR2DL2
1038	-	8623	A/G	0	389731	rs11553464	Human NCBI Build 35	19	45413962	MAP3K10-ENSG00000174521
1040	-	8636	A/G	0	389734	rs11575936	Human NCBI Build 35	6	137582118	IFNGR1
1042	-	8676	A/G	0	389743	rs12023161	Human NCBI Build 35	1	43736952	PTPRF
1043	-	8700	A/G	0	389748	rs12229892	Human NCBI Build 35	12	111386113	PTPN11
1045	-	8713	A/G	0	389753	rs12624843	Human NCBI Build 35	20	36422510	LBP
1046	-	8719	A/G	0	389754	rs12762869	Human NCBI Build 35	10	101983702	CWF19L1-CHUK
1048	-	8735	A/G	0	389757	rs1319313	Human NCBI Build 35	7	105516474	PBEF1
1049	-	8738	A/G	1	389758	rs13239010	Human NCBI Build 35	7	157157142	PTPRN2-ENSG00000196201
1050	-	8739	A/G	0	389759	rs13265018	Human NCBI Build 35	8	22941965	TNFRSF10B
1051	-	8746	A/G	1	389761	rs13330462	Human NCBI Build 35	16	30272306	CD2BP2-ENSG00000169221
1053	-	8758	A/G	0	389764	rs135549	Human NCBI Build 35	22	44873827	PPARA
1054	-	8785	A/G	1	389772	rs1546159	Human NCBI Build 35	1	67500447	IL12RB2
1056	-	8807	A/G	1	389779	rs161704	Human NCBI Build 35	5	55242201	IL31RA
1057	-	8823	A/G	0	389783	rs1670377	Human NCBI Build 35	7	157744650	PTPRN2
1058	-	8824	A/G	0	389784	rs16986050	Human NCBI Build 35	19	60092982	FCAR
1059	-	8832	A/G	1	389786	rs170037	Human NCBI Build 35	5	149420837	CSF1R
1060	-	8845	A/G	1	389789	rs17697947	Human NCBI Build 35	19	10310514	ICAM3
1061	-	8876	A/G	1	389794	rs1800234	Human NCBI Build 35	22	44936399	PPARA
1062	-	8878	A/G	0	389795	rs1800781	Human NCBI Build 35	7	150130092	NOS3-NOS3AS
1063	-	8897	A/G	0	389799	rs1805749	Human NCBI Build 35	12	9036158	KLRG1
1064	-	8914	A/G	0	389802	rs1877563	Human NCBI Build 35	3	39279468	CX3CR1
1066	-	8971	A/G	0	389811	rs2020854	Human NCBI Build 35	12	55029634	STAT2
1068	-	9041	A/G	0	389819	rs2070765	Human NCBI Build 35	16	3006169	TNFRSF12A-CLDN9-CLDN6
1070	-	9060	A/G	0	389824	rs2075650	Human NCBI Build 35	19	50087459	TOMM40-ENSG00000130202
1072	-	9065	A/G	1	389828	rs210131	Human NCBI Build 35	6	33643444	BAK1
1073	-	9074	A/G	0	389832	rs2117341	Human NCBI Build 35	21	45126821	ITGB2
1075	-	9080	A/G	0	389834	rs2142831	Human NCBI Build 35	22	41125950	ENSG00000167087
1076	-	9094	A/G	0	389835	rs2148894	Human NCBI Build 35	10	129664053	PTPRE
1077	-	9128	A/G	0	389844	rs2229095	Human NCBI Build 35	17	35964748	CCR7
1078	-	9144	A/G	0	389848	rs2238640	Human NCBI Build 35	19	5212506	PTPRS
1079	-	9180	A/G	0	389854	rs2242499	Human NCBI Build 35	12	93152793	PLXNC1
1081	-	9204	A/G	0	389857	rs2252430	Human NCBI Build 35	6	36211899	MAPK13
1082	-	9206	A/G	1	389858	rs2256191	Human NCBI Build 35	14	63726608	SYNE2-ESR2
1084	-	9237	A/G	0	389868	rs2278275	Human NCBI Build 35	9	90686231	SYK
1085	-	9253	A/G	0	389871	rs2285452	Human NCBI Build 35	16	27368398	IL21R
1090	-	9332	A/G	0	389887	rs2307153	Human NCBI Build 35	1	67545664	IL12RB2
1092	-	9408	A/G	0	389897	rs270790	Human NCBI Build 35	Multiple	0	KIR2DS2-KIR2DS1
1093	-	9414	A/G	0	389898	rs270790	Human NCBI Build 35	Multiple	0	KIR2DS2-KIR2DS1
1094	-	9423	A/G	0	389899	rs2715434	Human NCBI Build 35	15	97207515	IGF1R

1096	-	9441	A/G	1	389903	rs2812325	Human NCBI Build 35	9	36826267	PAX5
1097	-	9451	A/G	0	389904	rs2834174	Human NCBI Build 35	21	33584987	IL10RB
1098	-	9455	A/G	0	389905	rs2838012	Human NCBI Build 35	21	41616740	FAM3B
1099	-	9464	A/G	0	389907	rs2838729	Human NCBI Build 35	21	45143845	ITGB2
1100	-	9472	A/G	1	389908	rs2838733	Human NCBI Build 35	21	45148159	ITGB2
1101	-	9475	A/G	0	389909	rs2861442	Human NCBI Build 35	10	44204965	CXCL12
1102	-	9485	A/G	0	389913	rs3002297	Human NCBI Build 35	1	210924456	PTPN14
1105	-	9513	A/G	0	389919	rs307823	Human NCBI Build 35	5	179984714	FLT4
1106	-	9521	A/G	0	389921	rs3091335	Human NCBI Build 35	5	131419497	IL3
1108	-	9548	A/G	1	389924	rs3097675	Human NCBI Build 35	6	33161618	HLA-DPB1
1109	-	9559	A/G	0	389927	rs31517	Human NCBI Build 35	5	135314928	LECT2-ENSG00000164616
1113	-	9646	A/G	0	389941	rs352692	Human NCBI Build 35	1	157499567	CD48
1114	-	9652	A/G	0	389942	rs36233	Human NCBI Build 35	16	2140883	RAB26-ENSG00000131653
1115	-	9658	A/G	0	389944	rs36686	Human NCBI Build 35	19	17783795	B3GNT3-INSL3
1116	-	9667	A/G	0	389945	rs367745	Human NCBI Build 35	3	11284274	APG7L-HRH1
1117	-	9671	A/G	0	389947	rs3740955	Human NCBI Build 35	11	36552176	RAG1
1118	-	9732	A/G	0	389952	rs3742509	Human NCBI Build 35	19	21965	KIR2DS2-KIR2DS1-KIR2DL2
1120	-	9791	A/G	0	389959	rs3759614	Human NCBI Build 35	14	22906941	IL17E-EFS
1121	-	9803	A/G	0	389964	rs3762681	Human NCBI Build 35	3	109294477	CD47
1122	-	9806	A/G	0	389965	rs3769824	Human NCBI Build 35	2	201948462	CASP8
1123	-	9808	A/G	0	389966	rs3771859	Human NCBI Build 35	2	75327225	TACR1
1124	-	9815	A/G	0	389968	rs3780891	Human NCBI Build 35	10	44198719	CXCL12
1125	-	9856	A/G	0	389971	rs3785529	Human NCBI Build 35	17	74484555	LGALS3BP
1126	-	9866	A/G	1	389972	rs3785930	Human NCBI Build 35	17	44941921	NGFR
1127	-	9872	A/G	0	389973	rs3785931	Human NCBI Build 35	17	44933117	NGFR
1128	-	9944	A/G	0	389983	rs3793829	Human NCBI Build 35	10	71353030	COL13A1-AMID
1129	-	9952	A/G	0	389984	rs3794764	Human NCBI Build 35	17	23135555	NOS2A
1130	-	9973	A/G	0	389986	rs3794901	Human NCBI Build 35	18	46505052	MAPK4
1131	-	9995	A/G	0	389988	rs3802813	Human NCBI Build 35	11	125667678	TIRAP
1132	-	10009	A/G	0	389989	rs3803036	Human NCBI Build 35	12	69425931	PTPRR
1133	-	10015	A/G	0	389990	rs3804277	Human NCBI Build 35	6	41353150	TREM1
1134	-	10020	A/G	0	389992	rs380731	Human NCBI Build 35	19	59451383	LILRB5
1135	-	10052	A/G	0	389995	rs3813200	Human NCBI Build 35	1	1191223	TNFRSF4-ENSG0000078808
1136	-	10060	A/G	0	389998	rs3816865	Human NCBI Build 35	19	11368855	EPOR
1137	-	10069	A/G	1	390000	rs3819495	Human NCBI Build 35	8	143920252	GML
1139	-	10094	A/G	0	390005	rs3826517	Human NCBI Build 35	17	4592073	CXCL16-ZMYND15
1140	-	10103	A/G	0	390007	rs3829264	Human NCBI Build 35	11	129269778	NFRKB
1141	-	10126	A/G	0	390012	rs3917651	Human NCBI Build 35	1	166331720	SELP
1143	-	10166	A/G	0	390017	rs4073472	Human NCBI Build 35	12	109639214	PPP1CC
1144	-	10228	A/G	0	390022	rs4148880	Human NCBI Build 35	6	32926752	PSMB9-TAP1
1145	-	10255	A/G	0	390028	rs4242389	Human NCBI Build 35	8	23028266	TNFRSF10C-ENSG00000147457
1146	-	10257	A/G	0	390029	rs4252303	Human NCBI Build 35	11	117365515	IL10RA
1148	-	10339	A/G	1	390041	rs451195	Human NCBI Build 35	5	122387539	PPIC
1149	-	10372	A/G	0	390047	rs4687163	Human NCBI Build 35	3	191824141	IL1RAP
1150	-	10373	A/G	1	390048	rs4700966	Human NCBI Build 35	5	179997709	FLT4
1151	-	10415	A/G	1	390052	rs4748153	Human NCBI Build 35	10	6646547	PRKCQ
1152	-	10427	A/G	0	390056	rs477461	Human NCBI Build 35	10	8160149	GATA3
1153	-	10435	A/G	0	390057	rs4776781	Human NCBI Build 35	15	62122857	ENSG0000035664
1154	-	10441	A/G	0	390059	rs4837404	Human NCBI Build 35	9	129585213	PTGES-ENSG00000198665

1155	-	10459	A/G	0	390061	rs4867569	Human NCBI Build 35	5	169037498	DOCK2
1156	-	10468	A/G	1	390063	rs4880043	Human NCBI Build 35	9	36940507	PAX5
1157	-	10489	A/G	0	390066	rs4952805	Human NCBI Build 35	2	46290275	PRKCE
1158	-	10505	A/G	1	390067	rs4987115	Human NCBI Build 35	6	33651671	BAK1
1160	-	10554	A/G	0	390073	rs5247	Human NCBI Build 35 14	24046414	CMA1	
1161	-	10564	A/G	0	390074	rs535937	Human NCBI Build 35	18	7563510	PTPRM
1163	-	10579	A/G	0	390081	rs5746025	Human NCBI Build 35	1	12187193	TNFRSF1B
1164	-	10584	A/G	0	390083	rs5747351	Human NCBI Build 35	22	16620929	BID
1165	-	10589	A/G	1	390084	rs5755074	Human NCBI Build 35	22	20445881	MAPK1
1166	-	10641	A/G	0	390089	rs6007662	Human NCBI Build 35	22	44941564	PPARA
1167	-	10644	A/G	0	390091	rs6076524	Human NCBI Build 35	20	3400447	ATRN
1169	-	10729	A/G	1	390102	rs6474036	Human NCBI Build 35	8	57070504	LYN
1170	-	10734	A/G	1	390103	rs6482644	Human NCBI Build 35	10	129715311	PTPRE
1171	-	10810	A/G	0	390112	rs655078	Human NCBI Build 35	18	7777550	PTPRM
1172	-	10843	A/G	0	390115	rs6716268	Human NCBI Build 35	2	45885787	PRKCE
1173	-	10862	A/G	0	390119	rs678060	Human NCBI Build 35	11	60637432	CD5
1174	-	10893	A/G	1	390124	rs6877489	Human NCBI Build 35	5	179610151	MAPK9
1178	-	10934	A/G	0	390130	rs6950296	Human NCBI Build 35	7	157519855	PTPRN2
1179	-	10942	A/G	0	390132	rs6973323	Human NCBI Build 35	7	76887696	PTPN12
1180	-	10955	A/G	0	390135	rs7045789	Human NCBI Build 35	9	89246470	SEMA4D
1182	-	10969	A/G	0	390137	rs7114162	Human NCBI Build 35	11	45873357	MAPK8IP1
1183	-	10979	A/G	0	390141	rs721336	Human NCBI Build 35	3	112772517	CD96
1185	-	10995	A/G	0	390146	rs7249222	Human NCBI Build 35	19	46435701	AXL
1186	-	11006	A/G	0	390148	rs7256574	Human NCBI Build 35	19	13969698	RFX1
1189	-	11026	A/G	0	390152	rs731170	Human NCBI Build 35	19	59868074	ENSG00000186818
1190	-	11029	A/G	0	390153	rs7312064	Human NCBI Build 35	12	7035688	C15
1191	-	11043	A/G	0	390155	rs7338903	Human NCBI Build 35	13	27534084	FLT3
1192	-	11048	A/G	0	390157	rs738095	Human NCBI Build 35	22	16630542	BID-ENSG00000185830
1193	-	11074	A/G	0	390161	rs742157	Human NCBI Build 35	22	41108328	ENSG00000167087
1194	-	11081	A/G	1	390163	rs7446531	Human NCBI Build 35	5	146091073	PPP2R2B
1196	-	11131	A/G	0	390171	rs7584409	Human NCBI Build 35	2	113458965	IL1F9
1197	-	11140	A/G	0	390172	rs7584458	Human NCBI Build 35	2	233875805	INPP5D
1200	-	11224	A/G	0	390184	rs7802866	Human NCBI Build 35	7	157192667	
PTPRN2-ENSG00000196590-ENSG00000196201										
1201	-	11225	A/G	0	390185	rs783833	Human NCBI Build 35	1	39904583	OXCT2-ENSG00000116985
1203	-	11250	A/G	0	390188	rs8034716	Human NCBI Build 35	15	79315689	IL16
1204	-	11255	A/G	0	390190	rs8072342	Human NCBI Build 35	17	59774925	PECAM1
1206	-	11291	A/G	0	390195	rs8177068	Human NCBI Build 35	X	47245247	PFC
1207	-	11311	A/G	1	390198	rs8179142	Human NCBI Build 35	12	107519814	SELPLG
1208	-	11335	A/G	0	390201	rs866066	Human NCBI Build 35	9	5440953	ENSG00000120217
1209	-	11336	A/G	0	390202	rs870020	Human NCBI Build 35	7	157104944	PTPRN2
1212	-	11393	A/G	1	390212	rs895437	Human NCBI Build 35	2	97808864	ZAP70
1213	-	11395	A/G	0	390213	rs897799	Human NCBI Build 35	19	23632665	
ENSG00000197372-ENSG00000196109-ENSG00000197360										
1214	-	11402	A/G	0	390215	rs908114	Human NCBI Build 35	5	424958	AHRR
1216	-	11423	A/G	0	390219	rs9264619	Human NCBI Build 35	6	31345781	HLA-C
1217	-	11484	A/G	0	390225	rs9332485	Human NCBI Build 35	1	166287240	F5-SELP
1218	-	11501	A/G	0	390228	rs9459836	Human NCBI Build 35	6	167389516	CCR6-ENSG00000187485
1219	-	11512	A/G	0	390229	rs9471966	Human NCBI Build 35	6	42999000	TNRC5-ENSG00000171611

1220	-	11524	A/G	0	390232	rs9620047	Human NCBI Build 35	22	41149537	ENSG00000167087
1221	-	11544	A/G	0	390234	rs9651076	Human NCBI Build 35	1	116755344	CD58
1224	-	11644	A/G	0	390246	rs1003694	Human NCBI Build 35	22	35863628	IL2RB
1225	-	11646	A/G	0	390247	rs1003887	Human NCBI Build 35	19	17788400	B3GNT3-INSL3
1226	-	11654	A/G	0	390248	rs10072977	Human NCBI Build 35	5	179999153	FLT4
1227	-	11667	A/G	0	390251	rs10097861	Human NCBI Build 35	8	27244435	PTK2B
1228	-	11673	A/G	0	390253	rs1013316	Human NCBI Build 35	16	24042613	PRKCB1
1229	-	11692	A/G	0	390256	rs1025299	Human NCBI Build 35	5	43426047	CCL28
1230	-	11694	A/G	1	390257	rs1033638	Human NCBI Build 35	1	11020983	MASP2-TARDBP
1231	-	11695	A/G	0	390258	rs103855	Human NCBI Build 35	2	108991235	EDAR
1232	-	11710	A/G	1	390261	rs10419832	Human NCBI Build 35	19	59541211	ENSG00000170858
1235	-	11766	A/G	0	390271	rs10500317	Human NCBI Build 35	19	59479826	ENSG00000131042
1236	-	11773	A/G	1	390273	rs1050483	Human NCBI Build 35	19	19164802	RFXANK-MEF2B
1237	-	11774	A/G	0	390274	rs1051006	Human NCBI Build 35	11	47263161	MADD
1238	-	11791	A/G	0	390276	rs1051792	Human NCBI Build 35	6	31486956	MICA
1239	-	11804	A/G	0	390278	rs1058240	Human NCBI Build 35	10	8156604	GATA3
1240	-	11807	A/G	0	390279	rs1061758	Human NCBI Build 35	9	34642330	GALT-ENSG00000137070
1242	-	11816	A/G	0	390283	rs10735810	Human NCBI Build 35	12	46559162	VDR
1244	-	11859	A/G	0	390294	rs10937615	Human NCBI Build 35	4	5141184	ENSG00000170891
1245	-	11876	A/G	1	390299	rs11136000	Human NCBI Build 35	8	27520436	CLU
1247	-	11913	A/G	0	390308	rs1131877	Human NCBI Build 35	14	102411802	TRAF3
1249	-	11977	A/G	0	390319	rs11575584	Human NCBI Build 35	9	34651994	CCL27-ENSG00000137070
1250	-	11979	A/G	0	390320	rs11577317	Human NCBI Build 35	1	43661986	PTPRF
1251	-	11983	A/G	0	390321	rs11580074	Human NCBI Build 35	1	43693577	PTPRF
1252	-	11987	A/G	0	390322	rs11587213	Human NCBI Build 35	1	157997948	NDUFS2-FCER1G
1253	-	11996	A/G	0	390323	rs11617870	Human NCBI Build 35	13	113289228	TFDP1-ENSG00000179951
1254	-	12030	A/G	0	390331	rs11722554	Human NCBI Build 35	4	5134955	ENSG00000170891
1257	-	12094	A/G	1	390341	rs12040633	Human NCBI Build 35	1	220271766	TP53BP2-CAPN2
1258	-	12144	A/G	0	390350	rs12410298	Human NCBI Build 35	1	143037007	ITGA10-ENSG00000198483
1259	-	12181	A/G	0	390352	rs12500797	Human NCBI Build 35	4	88049572	PTPN13
1260	-	12192	A/G	0	390356	rs12570165	Human NCBI Build 35	10	71481818	H2AFY2-AMID
1261	-	12193	A/G	0	390357	rs12594040	Human NCBI Build 35	15	97052574	IGF1R
1262	-	12220	A/G	0	390362	rs12625064	Human NCBI Build 35	20	49507278	NFATC2
1264	-	12291	A/G	0	390375	rs131421	Human NCBI Build 35	22	22245756	IGLL1
1265	-	12313	A/G	0	390378	rs1319107	Human NCBI Build 35	13	27534312	FLT3
1266	-	12340	A/G	1	390386	rs1374108	Human NCBI Build 35	18	7659072	PTPRM
1267	-	12362	A/G	0	390389	rs1432760	Human NCBI Build 35	5	146107761	PPP2R2B
1269	-	12371	A/G	1	390392	rs1484269	Human NCBI Build 35	6	41431514	ENSG00000096264
1270	-	12412	A/G	0	390398	rs1545130	Human NCBI Build 35	18	46474527	MAPK4
1271	-	12427	A/G	0	390402	rs1562302	Human NCBI Build 35	2	113526689	IL1F8
1272	-	12460	A/G	0	390407	rs1621828	Human NCBI Build 35	7	2717504	CARD11
1273	-	12469	A/G	0	390409	rs1642736	Human NCBI Build 35	3	10240057	IRAK2
1274	-	12476	A/G	0	390411	rs168259	Human NCBI Build 35	19	6546779	TNFSF7
1276	-	12513	A/G	0	390416	rs16938295	Human NCBI Build 35	9	21177357	IFNA4
1277	-	12525	A/G	0	390418	rs170359	Human NCBI Build 35	16	55953165	CCL22
1278	-	12529	A/G	0	390419	rs17059569	Human NCBI Build 35	3	58606361	FAM3D
1279	-	12536	A/G	0	390421	rs17121493	Human NCBI Build 35	11	117370056	IL10RA
1280	-	4137	A/G	0	390422	rs17152779	Human NCBI Build 35	11	58148114	CNTF
1281	-	3701	A/G	0	390425	rs17509489	Human NCBI Build 35	6	33144526	HLA-DPA1

1282	-	2891	A/G	0	390426	rs17572019	Human NCBI Build 35	5	149192664	PPARGC1B
1283	-	1759	A/G	0	390430	rs1788113	Human NCBI Build 35	18	65716830	CD226
1284	-	1472	A/G	0	390432	rs1800451	Human NCBI Build 35	10	54201232	MBL2
1285	-	1704	A/G	0	390434	rs1802323	Human NCBI Build 35	6	6599848	LY86
1286	-	63	A/G	0	390445	rs1882019	Human NCBI Build 35	12	102840134	TRA1
1287	-	210	A/G	0	390447	rs1974821	Human NCBI Build 35	19	56609547	SIGLEC10
1289	-	2826	A/G	0	390459	rs2066811	Human NCBI Build 35	12	55029264	STAT2
1290	-	5812	A/G	0	390463	rs2071214	Human NCBI Build 35	17	73731186	BIRC5-ENSG00000182802
1291	-	2602	A/G	0	390466	rs2071748	Human NCBI Build 35	22	34102172	HMOX1
1293	-	2308	A/G	0	390468	rs2074983	Human NCBI Build 35	19	5236570	PTPRS
1294	-	767	A/G	0	390471	rs2077422	Human NCBI Build 35	15	31978578	AVEN
1297	-	2160	A/G	0	390479	rs2228315	Human NCBI Build 35	12	107520364	SELPLG
1298	-	5496	A/G	0	390480	rs2230322	Human NCBI Build 35	3	46038333	XCR1
1299	-	5726	A/G	0	390488	rs2235937	Human NCBI Build 35	1	29452525	PTPRU
1300	-	1937	A/G	0	390496	rs2239179	Human NCBI Build 35	12	46544033	VDR
1301	-	4625	A/G	1	390500	rs2241270	Human NCBI Build 35	9	129594443	PTGES-ENSG00000198665
1302	-	2342	A/G	0	390502	rs2241598	Human NCBI Build 35	5	491564	AHRR-ENSG00000185509
1304	-	2343	A/G	0	390512	rs2269475	Human NCBI Build 35	6	31691910	AIF1-BAT2
1307	-	6114	A/G	0	390530	rs2286721	Human NCBI Build 35	19	60384935	BRSK1-PTPRH-SYT5
1308	-	4991	A/G	0	390534	rs2288419	Human NCBI Build 35	6	32259421	PBX2-AGER-RNF5
1309	-	4297	A/G	0	390539	rs2288817	Human NCBI Build 35	5	149767261	CD74
1310	-	5164	A/G	0	390540	rs2289863	Human NCBI Build 35	19	3979783	PIAS4
1311	-	3467	A/G	1	390541	rs2290065	Human NCBI Build 35	17	35969886	CCR7
1312	-	5309	A/G	0	390550	rs2296749	Human NCBI Build 35	6	33871105	MLN
1313	-	1162	A/G	0	390553	rs2300744	Human NCBI Build 35	1	39916018	ENSG00000116985
1314	-	4172	A/G	0	390558	rs2305743	Human NCBI Build 35	19	18054191	IL12RB1
1315	-	3487	A/G	0	390560	rs2341648	Human NCBI Build 35	16	45542876	DNAJA2
1317	-	6042	A/G	0	390571	rs2588325	Human NCBI Build 35	15	39656389	TYRO3
1318	-	6298	A/G	0	390572	rs260696	Human NCBI Build 35	2	109047603	EDAR
1319	-	4147	A/G	0	390584	rs2749812	Human NCBI Build 35	20	23010927	C1QR1
1320	-	2430	A/G	0	390585	rs2765493	Human NCBI Build 35	1	154611073	CD5L
1322	-	3986	A/G	1	390590	rs2820093	Human NCBI Build 35	1	111575348	ENSG00000134216
1324	-	864	A/G	1	390594	rs2838020	Human NCBI Build 35	21	41643746	FAM3B
1325	-	3438	A/G	0	390596	rs2852151	Human NCBI Build 35	18	12831176	PTPN2
1326	-	1897	A/G	0	390597	rs2855259	Human NCBI Build 35	X	100421623	BTB
1328	-	771	A/G	0	390599	rs2901872	Human NCBI Build 35	10	97556879	ENTPD1
1329	-	6561	A/G	1	390601	rs2905506	Human NCBI Build 35	11	60506624	CD6
1330	-	92	A/G	0	390603	rs2976230	Human NCBI Build 35	17	3577990	GSG2-ITGAE
1331	-	1047	A/G	1	390605	rs3024321	Human NCBI Build 35	6	6263125	F13A1
1332	-	5362	A/G	0	390607	rs3024630	Human NCBI Build 35	16	27273627	IL4R
1333	-	4721	A/G	1	390610	rs3087519	Human NCBI Build 35	16	10930709	MHC2TA-ENSG00000182108
1335	-	1190	A/G	0	390620	rs3176813	Human NCBI Build 35	9	34680811	CCL19
1336	-	2873	A/G	0	390624	rs3181034	Human NCBI Build 35	12	66833004	IFNG
1337	-	1436	A/G	0	390630	rs3218339	Human NCBI Build 35	22	35845711	IL2RB
1338	-	5549	A/G	0	390631	rs3219057	Human NCBI Build 35	1	222879951	PARP1
1339	-	2354	A/G	0	390632	rs322495	Human NCBI Build 35	5	145992613	PPP2R2B
1341	-	1929	A/G	0	390636	rs344596	Human NCBI Build 35	19	6545274	TNFSF7
1342	-	1922	A/G	0	390638	rs360059	Human NCBI Build 35	1	222383867	ENSG00000143787
1343	-	352	A/G	0	390640	rs3737058	Human NCBI Build 35	10	133634871	BNIP3

1344	-	5095	A/G	1	390642	rs3744948	Human NCBI Build 35	18	59073212	BCL2
1345	-	5900	A/G	0	390644	rs3746250	Human NCBI Build 35	19	40527422	CD22
1346	-	3139	A/G	1	390652	rs3757596	Human NCBI Build 35	7	75090425	CCL24
1347	-	5762	A/G	0	390656	rs3768738	Human NCBI Build 35	2	46275128	PRKCE
1348	-	49	A/G	1	390657	rs3771825	Human NCBI Build 35	2	75267135	TACR1
1349	-	4672	A/G	1	390659	rs377702	Human NCBI Build 35	19	50054507	ENSG00000130202
1350	-	4287	A/G	0	390660	rs3777909	Human NCBI Build 35	6	111987961	C6orf4
1352	-	6386	A/G	0	390663	rs3782377	Human NCBI Build 35	12	69230221	PTPRB
1354	-	6063	A/G	0	390667	rs3788332	Human NCBI Build 35	22	20496121	MAPK1
1355	-	3889	A/G	0	390668	rs3791373	Human NCBI Build 35	2	239741092	HDAC4
1356	-	3430	A/G	0	390672	rs3793815	Human NCBI Build 35	10	71377693	COL13A1-AMID
1357	-	4903	A/G	0	390674	rs3796878	Human NCBI Build 35	4	15461928	CD38
1358	-	6226	A/G	0	390678	rs3802814	Human NCBI Build 35	11	125667817	TIRAP
1359	-	2949	A/G	0	390679	rs3804279	Human NCBI Build 35	6	41813590	TFEB-PGC
1360	-	3970	A/G	1	390682	rs3806373	Human NCBI Build 35	1	117466101	ENSG00000134258
1361	-	3320	A/G	0	390683	rs3806932	Human NCBI Build 35	5	110433574	ENSG00000145777
1362	-	5560	A/G	0	390689	rs3818716	Human NCBI Build 35	17	16792559	TNFRSF13B-ENSG00000170160
1363	-	3951	A/G	0	390693	rs3822023	Human NCBI Build 35	4	886316	GAK
1364	-	4454	A/G	1	390698	rs3827760	Human NCBI Build 35	2	108972119	EDAR
1367	-	4768	A/G	1	390704	rs3917862	Human NCBI Build 35	1	166324771	SELP
1368	-	5739	A/G	1	390708	rs40401	Human NCBI Build 35	5	131424377	IL3
1370	-	2877	A/G	1	390711	rs4078338	Human NCBI Build 35	9	89276987	SEMA4D
1371	-	2285	A/G	0	390713	rs4149578	Human NCBI Build 35	12	6317698	TNFRSF1A
1372	-	2987	A/G	0	390718	rs4253449	Human NCBI Build 35	20	48243032	CEBPB
1375	-	4207	A/G	0	390740	rs4630612	Human NCBI Build 35	17	50852764	MMD
1376	-	2277	A/G	0	390743	rs4648072	Human NCBI Build 35	4	103875893	NFKB1
1377	-	5226	A/G	0	390746	rs4716515	Human NCBI Build 35	7	157260551	PTPRN2-ENSG00000196590
1378	-	2963	A/G	0	390747	rs4744510	Human NCBI Build 35	9	90678701	SYK
1379	-	6407	A/G	0	390748	rs4746936	Human NCBI Build 35	10	71369399	COL13A1-AMID
1380	-	5341	A/G	0	390749	rs4761587	Human NCBI Build 35	12	93054267	PLXNC1
1381	-	2382	A/G	0	390752	rs4803766	Human NCBI Build 35	19	50063008	ENSG00000130202
1382	-	5602	A/G	0	390754	rs4852013	Human NCBI Build 35	2	239719604	HDAC4
1383	-	6171	A/G	0	390756	rs4909090	Human NCBI Build 35	7	157855784	PTPRN2
1384	-	967	A/G	0	390757	rs4917728	Human NCBI Build 35	10	97989547	BLNK
1385	-	2552	A/G	0	390758	rs4939998	Human NCBI Build 35	18	46425665	MAPK4
1386	-	4299	A/G	0	390760	rs4952768	Human NCBI Build 35	2	45860238	PRKCE
1388	-	474	A/G	0	390765	rs5000605	Human NCBI Build 35	8	27351921	PTK2B
1389	-	5684	A/G	0	390766	rs5030390	Human NCBI Build 35	19	10243537	ICAM1
1390	-	3613	A/G	1	390767	rs5250	Human NCBI Build 35	14	24044461	CMA1
1391	-	3805	A/G	0	390769	rs5272	Human NCBI Build 35	1	183375494	PTGS2
1392	-	1031	A/G	0	390770	rs527790	Human NCBI Build 35	18	20314913	HRH4
1393	-	741	A/G	0	390776	rs5743899	Human NCBI Build 35	11	1280140	TOLLIP
1394	-	1689	A/G	1	390777	rs5744174	Human NCBI Build 35	1	1374616	TLR5
1395	-	134	A/G	1	390778	rs5744212	Human NCBI Build 35	20	36431086	LBP
1396	-	6040	A/G	0	390779	rs5746051	Human NCBI Build 35	1	12196238	TNFRSF1B
1397	-	5773	A/G	0	390782	rs5766743	Human NCBI Build 35	22	44927897	PPARA
1398	-	6046	A/G	0	390788	rs6050	Human NCBI Build 35	4	155865195	FGA
1399	-	5949	A/G	0	390792	rs6092	Human NCBI Build 35	7	100365152	SERPINE1
1400	-	490	A/G	1	390794	rs6111906	Human NCBI Build 35	20	1829734	PTPNS1

1402	-	5983	A/G	0	390803	rs637186	Human NCBI Build 35	11	60649182	CD5
1403	-	3670	A/G	0	390805	rs6426871	Human NCBI Build 35	1	161268656	PBX1
1404	-	954	A/G	0	390807	rs6476608	Human NCBI Build 35	9	37014438	PAX5
1405	-	4914	A/G	0	390811	rs6544864	Human NCBI Build 35	2	46074903	PRKCE
1406	-	164	A/G	0	390815	rs6587735	Human NCBI Build 35	1	150078600	PGLYRP3
1407	-	3976	A/G	0	390816	rs6602391	Human NCBI Build 35	10	6118038	IL2RA
1408	-	3966	A/G	0	390820	rs6746608	Human NCBI Build 35	2	111609215	BCL2L11
1409	-	5016	A/G	0	390830	rs6904029	Human NCBI Build 35	19	8034411	ELAVL1-CCL25-ENSG00000142449
1410	-	416	A/G	0	390832	rs700187	Human NCBI Build 35	5	39249372	FYB
1411	-	4458	A/G	0	390834	rs706765	Human NCBI Build 35	19	16874919	CPAMD8-F2RL3
1412	-	5859	A/G	0	390836	rs7118744	Human NCBI Build 35	11	127882690	ETS1
1413	-	5843	A/G	0	390844	rs7231887	Human NCBI Build 35	18	58182469	TNFRSF11A
1414	-	843	A/G	0	390845	rs724165	Human NCBI Build 35	14	23876069	RIPK3-ADCY4
1416	-	5852	A/G	0	390858	rs733498	Human NCBI Build 35	2	102102043	IL1R2
1417	-	3422	A/G	0	390859	rs7356932	Human NCBI Build 35	6	74574692	CD109
1420	-	1304	A/G	1	390865	rs7464769	Human NCBI Build 35	8	23063738	TNFRSF10D-ENSG00000147457
1421	-	1932	A/G	0	390867	rs749452	Human NCBI Build 35	18	7796676	PTPRM
1422	-	4667	A/G	1	390872	rs7561820	Human NCBI Build 35	2	46246784	PRKCE
1424	-	6001	A/G	1	390875	rs7652210	Human NCBI Build 35	3	32364379	CKLFSF8
1426	-	4814	A/G	1	390887	rs7810884	Human NCBI Build 35	7	157776402	PTPRN2
1427	-	2211	A/G	1	390889	rs7828258	Human NCBI Build 35	8	57030499	LYN
1428	-	3437	A/G	1	390893	rs7970004	Human NCBI Build 35	12	93167650	PLXNC1
1429	-	3757	A/G	0	390895	rs8012137	Human NCBI Build 35	14	24165785	GZMB
1431	-	2482	A/G	0	390898	rs805295	Human NCBI Build 35	19	71145	KIR2DS2-KIR3DS1-KIR2DL4
1432	-	1566	A/G	0	390900	rs8092336	Human NCBI Build 35	18	58187063	TNFRSF11A
1433	-	4572	A/G	0	390902	rs8096380	Human NCBI Build 35	18	59071461	BCL2
1434	-	15	A/G	0	390903	rs8102910	Human NCBI Build 35	19	40509554	CD22
1436	-	4608	A/G	0	390906	rs8108057	Human NCBI Build 35	19	44476402	IL29
1438	-	5960	A/G	0	390915	rs8177636	Human NCBI Build 35	10	6058600	IL15RA
1439	-	5897	A/G	1	390916	rs8177762	Human NCBI Build 35	10	6060197	IL15RA
1442	-	4286	A/G	0	390925	rs854684	Human NCBI Build 35	17	31336328	CCL15-CCL16
1443	-	4929	A/G	0	390928	rs872071	Human NCBI Build 35	6	356064	IRF4
1444	-	1821	A/G	0	390932	rs884328	Human NCBI Build 35	1	239980319	AKT3-SDCCAG8
1445	-	5619	A/G	0	390934	rs891087	Human NCBI Build 35	19	7135518	INSR
1446	-	4242	A/G	0	390936	rs901865	Human NCBI Build 35	3	11275707	HRH1
1447	-	3888	A/G	0	390941	rs929087	Human NCBI Build 35	1	169363714	ENSG00000117560
1448	-	2971	A/G	0	390954	rs9695221	Human NCBI Build 35	9	130689849	ABL1
1449	-	5028	A/G	0	390962	rs10042351	Human NCBI Build 35	5	169362758	DOCK2
1450	-	5099	A/G	0	390964	rs10046852	Human NCBI Build 35	9	33355563	NFX1
1451	-	240	A/G	1	390966	rs10101779	Human NCBI Build 35	8	27506452	CLU
1452	-	3848	A/G	0	390977	rs1042190	Human NCBI Build 35	6	33144977	HLA-DPA1
1453	-	5715	A/G	0	390978	rs10423648	Human NCBI Build 35	19	40530583	GPR40-CD22
1454	-	4079	A/G	0	390980	rs1044240	Human NCBI Build 35	3	106741551	ALCAM
1455	-	4051	A/G	0	390984	rs1048401	Human NCBI Build 35	1	89237987	GBP1
1456	-	781	A/G	0	390988	rs10489113	Human NCBI Build 35	4	103899404	NFKB1
1457	-	5679	A/G	0	390990	rs1048971	Human NCBI Build 35	1	204034717	CR2
1458	-	5518	A/G	0	390993	rs10494425	Human NCBI Build 35	1	161534361	PBX1
1459	-	3688	A/G	0	390996	rs1051488	Human NCBI Build 35	6	31430890	HLA-B
1460	-	1116	A/G	0	391001	rs1053023	Human NCBI Build 35	17	37719142	STAT5A-STAT3

1461	-	4028	A/G	0	391002	rs1056719	Human NCBI Build 35	9	87551577	DAPK1
1462	-	5156	A/G	0	391003	rs1058304	Human NCBI Build 35	1	239990898	AKT3-SDCCAG8
1463	-	4938	A/G	1	391004	rs1059442	Human NCBI Build 35	18	54567673	MALT1
1464	-	3233	A/G	0	391005	rs1059696	Human NCBI Build 35	10	45254443	ALOX5
1465	-	5321	A/G	0	391008	rs1061959	Human NCBI Build 35	9	21375192	IFNA2
1466	-	4569	A/G	1	391018	rs10918695	Human NCBI Build 35	1	164169611	CD3Z
1467	-	4655	A/G	0	391022	rs11117959	Human NCBI Build 35	1	204072914	none
1468	-	1085	A/G	0	391023	rs11120316	Human NCBI Build 35	1	210982586	PTPN14
1469	-	4402	A/G	0	391028	rs11265799	Human NCBI Build 35	9	89252025	SEMA4D
1471	-	4420	A/G	0	391037	rs11568943	Human NCBI Build 35	4	111240725	EGF
1473	-	5938	A/G	0	391050	rs11862806	Human NCBI Build 35	16	30271572	CD2BP2-ENSG00000169221
1474	-	5426	A/G	0	391055	rs11963915	Human NCBI Build 35	6	143133756	HIVEP2
1476	-	1645	A/G	0	391060	rs12075	Human NCBI Build 35	1	155988427	FY-IGSF4B
1477	-	2241	A/G	0	391061	rs12095738	Human NCBI Build 35	1	164211645	CD3Z
1478	-	2508	A/G	0	391062	rs12097758	Human NCBI Build 35	1	117288592	IGSF2
1479	-	4962	A/G	0	391065	rs12276572	Human NCBI Build 35	11	60628382	CD5
1480	-	1101	A/G	0	391070	rs12358294	Human NCBI Build 35	10	121414055	BAG3
1481	-	6310	A/G	0	391075	rs1255953	Human NCBI Build 35	14	63621441	SYNE2-ESR2
1482	-	414	A/G	0	391077	rs12609732	Human NCBI Build 35	9	35397431	
ENSG00000196186-ENSG00000179766-UNC13B										
1484	-	2516	A/G	0	391080	rs1266384	Human NCBI Build 35	1	233010098	LGALS8-ENSG00000182097
1485	-	2198	A/G	0	391083	rs12759925	Human NCBI Build 35	1	50846357	FAF1
1486	-	1669	A/G	1	391086	rs12975955	Human NCBI Build 35	19	5170803	PTPRS
1487	-	3227	A/G	0	391087	rs129988	Human NCBI Build 35	16	3703180	TRAP1
1488	-	5534	A/G	0	391088	rs131428	Human NCBI Build 35	22	22249985	IGLL1
1489	-	371	A/G	0	391090	rs131815	Human NCBI Build 35	19	8033331	ELAVL1-CCL25-ENSG00000142449
1490	-	4486	A/G	0	391102	rs1345441	Human NCBI Build 35	16	11587324	ENSG00000189067
1491	-	3736	A/G	0	391110	rs1389723	Human NCBI Build 35	1	111125553	CD53
1492	-	4461	A/G	0	391114	rs1411262	Human NCBI Build 35	9	5449419	ENSG00000120217
1493	-	3134	A/G	0	391115	rs1423417	Human NCBI Build 35	5	41175549	C6
1494	-	690	A/G	0	391117	rs1480158	Human NCBI Build 35	5	146398939	PPP2R2B
1495	-	1213	A/G	0	391119	rs1492354	Human NCBI Build 35	12	87450446	KITLG
1496	-	3470	A/G	0	391125	rs1533217	Human NCBI Build 35	1	207885486	TRAF5
1497	-	52	A/G	1	391129	rs1547904	Human NCBI Build 35	4	54987317	PDGFRA
1498	-	5769	A/G	0	391136	rs16938289	Human NCBI Build 35	Multiple	0	Unknown
1500	-	3937	A/G	0	391140	rs170360	Human NCBI Build 35	16	55955451	CCL22
1501	-	1181	A/G	0	391141	rs170361	Human NCBI Build 35	16	55972124	CX3CL1
1502	-	499	A/G	0	391145	rs1736924	Human NCBI Build 35	6	29800990	HLA-F
1503	-	1725	A/G	0	391149	rs1790942	Human NCBI Build 35	18	65692568	CD226
1504	-	1247	A/G	0	391160	rs1868388	Human NCBI Build 35	2	46044826	PRKCE
1505	-	3750	A/G	0	391161	rs1870584	Human NCBI Build 35	17	11988269	MAP2K4
1506	-	994	A/G	1	391163	rs1877840	Human NCBI Build 35	5	427748	AHRR
1507	-	3387	A/G	0	391166	rs1891467	Human NCBI Build 35	1	214968380	ENSG00000092969
1508	-	1685	A/G	0	391167	rs1893488	Human NCBI Build 35	18	46414555	MAPK4
1509	-	3572	A/G	0	391168	rs189586	Human NCBI Build 35	4	78839562	CXCL13
1510	-	2809	A/G	0	391172	rs1921	Human NCBI Build 35	1	989675	G1P2
1511	-	4234	A/G	0	391176	rs1981517	Human NCBI Build 35	12	110786302	ENSG00000089022
1512	-	4041	A/G	0	391180	rs1996664	Human NCBI Build 35	3	49853399	ENSG00000183763
1513	-	4165	A/G	0	391184	rs2024512	Human NCBI Build 35	2	75337278	TACR1

1514	-	4795	A/G	0	391187	rs2051625	Human NCBI Build 35	6	33395161	DAXX-ZNF297
1515	-	1743	A/G	1	391193	rs2069898	Human NCBI Build 35	2	127890457	PROC
1516	-	3938	A/G	1	391194	rs2070121	Human NCBI Build 35	6	32889532	HLA-DOB
1517	-	1453	A/G	0	391195	rs2070481	Human NCBI Build 35	3	37608552	ITGA9
1518	-	1303	A/G	0	391202	rs2075225	Human NCBI Build 35	2	70974721	CD207
1519	-	5999	A/G	0	391205	rs2098355	Human NCBI Build 35	2	201868422	CASP10
1520	-	153	A/G	0	391207	rs2105998	Human NCBI Build 35	14	106043053	IGHA1-ENSG00000198577
1521	-	5867	A/G	1	391208	rs2112705	Human NCBI Build 35	5	169057056	DOCK2
1522	-	2492	A/G	0	391211	rs2161369	Human NCBI Build 35	5	169331456	DOCK2
1525	-	3884	A/G	0	391219	rs2227506	Human NCBI Build 35	12	66929100	IL22
1526	-	332	A/G	0	391221	rs2227588	Human NCBI Build 35	1	170619100	SERPINC1
1527	-	382	A/G	1	391223	rs2228428	Human NCBI Build 35	3	32970932	CCR4
1528	-	6296	A/G	0	391226	rs2229857	Human NCBI Build 35	1	151387040	ADAR
1529	-	5057	A/G	0	391228	rs2232607	Human NCBI Build 35	20	36426747	LBP
1532	-	2817	A/G	0	391235	rs223812	Human NCBI Build 35	16	55961001	CX3CL1-CCL22
1533	-	2337	A/G	0	391236	rs2238136	Human NCBI Build 35	12	46563980	VDR
1534	-	3303	A/G	0	391238	rs2238494	Human NCBI Build 35	16	24106801	PRKCB1
1535	-	4876	A/G	0	391239	rs2239194	Human NCBI Build 35	12	110346499	
ENSG00000111252-ENSG00000196824										
1538	-	2549	A/G	1	391250	rs2266966	Human NCBI Build 35	22	20446108	MAPK1
1539	-	5834	A/G	0	391254	rs2271546	Human NCBI Build 35	19	46419037	AXL
1540	-	4336	A/G	1	391259	rs2273492	Human NCBI Build 35	20	61341667	BIRC7-C20orf58
1541	-	6519	A/G	0	391262	rs2275954	Human NCBI Build 35	20	36396081	BPI
1542	-	6169	A/G	0	391263	rs2276113	Human NCBI Build 35	11	101701229	BIRC3
1543	-	1802	A/G	1	391266	rs2280962	Human NCBI Build 35	X	70615762	ACRC-CXCR3
1544	-	478	A/G	0	391269	rs228271	Human NCBI Build 35	17	34160006	PSMB3-ENSG00000056661
1545	-	5308	A/G	0	391270	rs2283147	Human NCBI Build 35	11	2357859	ENSG00000110651
1546	-	4352	A/G	0	391272	rs2285097	Human NCBI Build 35	22	37946834	PDGFB
1547	-	4215	A/G	0	391273	rs2287155	Human NCBI Build 35	12	12132052	BCL2L14
1548	-	4737	A/G	0	391275	rs228956	Human NCBI Build 35	22	35857643	IL2RB
1550	-	836	A/G	1	391280	rs2297136	Human NCBI Build 35	9	5457955	ENSG00000120217
1551	-	2700	A/G	0	391282	rs230155	Human NCBI Build 35	20	40543335	PTPRT
1552	-	1551	A/G	0	391283	rs2301920	Human NCBI Build 35	7	2728338	CARD11
1554	-	2686	A/G	0	391286	rs2304234	Human NCBI Build 35	19	46440593	AXL
1556	-	172	A/G	0	391289	rs2306182	Human NCBI Build 35	12	10422001	KLRC4
1557	-	1196	A/G	0	391291	rs2308950	Human NCBI Build 35	1	15578812	CASP9
1558	-	4719	A/G	0	391294	rs2335832	Human NCBI Build 35	7	157491559	PTPRN2
1559	-	1124	A/G	0	391299	rs2402593	Human NCBI Build 35	7	121118551	PTPRZ1
1560	-	6000	A/G	0	391301	rs2425516	Human NCBI Build 35	20	40740014	PTPRT
1561	-	3366	A/G	0	391306	rs246844	Human NCBI Build 35	5	131429233	IL3
1562	-	4620	A/G	0	391308	rs2491244	Human NCBI Build 35	13	27497914	FLT3
1564	-	4926	A/G	0	391314	rs261051	Human NCBI Build 35	5	169263769	DOCK2
1565	-	4442	A/G	0	391315	rs2642196	Human NCBI Build 35	19	6668934	C3
1566	-	1327	A/G	0	391321	rs2704439	Human NCBI Build 35	4	47967014	TXK
1567	-	1160	A/G	0	391327	rs2729376	Human NCBI Build 35	11	57116992	SERPING1
1568	-	3243	A/G	0	391331	rs2789444	Human NCBI Build 35	1	161466115	PBX1
1570	-	260	A/G	0	391335	rs281501	Human NCBI Build 35	2	46329297	PRKCE
1571	-	5516	A/G	0	391338	rs2847297	Human NCBI Build 35	18	12787694	PTPN2
1572	-	4957	A/G	0	391342	rs2859136	Human NCBI Build 35	6	36217879	MAPK13

1573	-	1368	A/G	0	391347	rs294183	Human NCBI Build 35	1	22717404	C1QG
1574	-	3524	A/G	0	391348	rs2969970	Human NCBI Build 35	18	46357594	MAPK4
1575	-	6340	A/G	0	391351	rs2988003	Human NCBI Build 35	9	37008949	PAX5
1577	-	5030	A/G	0	391360	rs3128519	Human NCBI Build 35	9	87415759	DAPK1
1578	-	5255	A/G	0	391365	rs3181148	Human NCBI Build 35	10	6048036	IL15RA
1579	-	4895	A/G	0	391367	rs3188691	Human NCBI Build 35	5	147486776	SPINK5
1580	-	1266	A/G	0	391368	rs3213409	Human NCBI Build 35	19	17806696	INSL3
1582	-	5355	A/G	0	391370	rs324454	Human NCBI Build 35	5	55238308	IL31RA
1583	-	6031	A/G	0	391373	rs333947	Human NCBI Build 35	1	110182806	CSF1
1584	-	2782	A/G	1	391374	rs344595	Human NCBI Build 35	19	6544602	TNFSF7
1585	-	2444	A/G	1	391377	rs349155	Human NCBI Build 35	3	62055410	PTPRG
1586	-	5318	A/G	0	391378	rs353268	Human NCBI Build 35	5	148737396	IL17B
1588	-	4707	A/G	1	391382	rs361253	Human NCBI Build 35	3	138187266	ENSG00000174564
1589	-	5814	A/G	0	391383	rs3686	Human NCBI Build 35	2	75304634	TACR1
1590	-	4304	A/G	0	391386	rs3733673	Human NCBI Build 35	5	149437686	CSF1R
1591	-	3310	A/G	0	391387	rs3735126	Human NCBI Build 35	7	2732413	CARD11
1592	-	2804	A/G	0	391389	rs3737435	Human NCBI Build 35	21	44490033	DNMT3L-ENSG00000160223
1593	-	4800	A/G	0	391390	rs3738032	Human NCBI Build 35	1	151386492	ADAR
1594	-	1278	A/G	0	391393	rs3743582	Human NCBI Build 35	16	11557826	ENSG00000189067
1595	-	4824	A/G	0	391395	rs3748299	Human NCBI Build 35	12	15624936	PTPRO
1596	-	5785	A/G	1	391402	rs3754112	Human NCBI Build 35	1	117266463	IGSF2
1597	-	4902	A/G	1	391404	rs3756089	Human NCBI Build 35	4	185690941	IRF2
1598	-	1903	A/G	0	391413	rs3763404	Human NCBI Build 35	7	76810570	PTPN12
1599	-	477	A/G	0	391414	rs3764868	Human NCBI Build 35	17	59434446	ICAM2-ENSG00000159752
1600	-	4744	A/G	0	391419	rs3775113	Human NCBI Build 35	4	891153	GAK
1601	-	4201	A/G	0	391421	rs3780395	Human NCBI Build 35	9	5454552	ENSG00000120217
1603	-	841	A/G	0	391427	rs3795331	Human NCBI Build 35	1	156615756	ENSG00000158714
1604	-	6488	A/G	0	391432	rs3797390	Human NCBI Build 35	5	75942821	F2RL2-IQGAP2
1605	-	2778	A/G	0	391444	rs3817197	Human NCBI Build 35	11	1862750	LSP1-ENSG00000184682
1606	-	1166	A/G	0	391452	rs3858606	Human NCBI Build 35	12	92738353	CRADD
1607	-	5239	A/G	0	391454	rs3885423	Human NCBI Build 35	9	21065675	IFNB1
1609	-	156	A/G	0	391456	rs3917815	Human NCBI Build 35	1	166296904	SELP
1610	-	646	A/G	0	391457	rs3917907	Human NCBI Build 35	1	36618716	CSF3R
1611	-	524	A/G	0	391466	rs4072111	Human NCBI Build 35	15	79365194	IL16
1612	-	6103	A/G	1	391468	rs4073419	Human NCBI Build 35	1	156617164	ENSG00000158714
1613	-	3902	A/G	1	391471	rs4251961	Human NCBI Build 35	2	113590698	IL1RN
1614	-	641	A/G	0	391472	rs4252287	Human NCBI Build 35	11	117373848	IL10RA
1615	-	481	A/G	0	391473	rs4328074	Human NCBI Build 35	1	204035318	CR2
1616	-	4322	A/G	0	391474	rs4372467	Human NCBI Build 35	11	127888014	ETS1
1617	-	2898	A/G	0	391475	rs4426048	Human NCBI Build 35	10	71525603	H2AFY2-AMID
1618	-	5259	A/G	0	391485	rs4590335	Human NCBI Build 35	7	2777079	CARD11
1619	-	3819	A/G	0	391490	rs4653437	Human NCBI Build 35	1	222385650	ENSG00000143787
1620	-	3682	A/G	0	391491	rs4655344	Human NCBI Build 35	1	210989604	PTPN14
1622	-	3353	A/G	0	391494	rs4665162	Human NCBI Build 35	2	160885691	ITGB6
1623	-	2710	A/G	0	391496	rs4686467	Human NCBI Build 35	3	188944998	BCL6
1625	-	448	A/G	0	391503	rs4776764	Human NCBI Build 35	15	62108394	ENSG00000035664
1626	-	1660	A/G	0	391504	rs4781015	Human NCBI Build 35	16	10899453	MHC2TA
1627	-	5826	A/G	0	391507	rs4788103	Human NCBI Build 35	16	23903676	PRKCB1
1628	-	4868	A/G	0	391509	rs4806614	Human NCBI Build 35	19	60105668	NCR1

1629	-	4360	A/G	1	391516	rs4877369	Human NCBI Build 35	9	87554423	DAPK1
1630	-	4621	A/G	0	391517	rs4915154	Human NCBI Build 35	1	195403310	PTPRC
1631	-	5561	A/G	1	391518	rs4925663	Human NCBI Build 35	1	243940658	CIAS1-ENSG00000177535
1632	-	5813	A/G	0	391520	rs4940743	Human NCBI Build 35	18	54526838	MALT1
1633	-	1740	A/G	1	391532	rs540224	Human NCBI Build 35	1	157576443	LY9
1634	-	2789	A/G	0	391533	rs542413	Human NCBI Build 35	2	45833682	PRKCE
1635	-	4736	A/G	1	391537	rs5741804	Human NCBI Build 35	20	36385756	BPI
1636	-	3540	A/G	0	391539	rs5744077	Human NCBI Build 35	X	12696844	TLR8
1637	-	5134	A/G	0	391540	rs5744431	Human NCBI Build 35	5	139998877	IK-ENSG00000113119
1638	-	3347	A/G	1	391542	rs5746154	Human NCBI Build 35	3	12680048	RAF1-ENSG00000198383
1639	-	5122	A/G	0	391543	rs5848	Human NCBI Build 35 17	39785770	GRN-ENSG00000161682	
1640	-	3215	A/G	0	391544	rs590467	Human NCBI Build 35	10	6516741	PRKCQ
1641	-	5096	A/G	0	391545	rs5911814	Human NCBI Build 35	X	123200825	SH2D1A
1642	-	2305	A/G	0	391547	rs594942	Human NCBI Build 35	6	41144966	APOBEC2-NFYA-C6orf130
1643	-	1943	A/G	0	391548	rs5995720	Human NCBI Build 35	22	20924259	VPREB1
1644	-	2628	A/G	0	391549	rs5996577	Human NCBI Build 35	22	22245981	IGLL1
1646	-	2391	A/G	0	391551	rs6014705	Human NCBI Build 35	20	36378950	BPI
1647	-	6415	A/G	0	391554	rs6021275	Human NCBI Build 35	20	49588531	NFATC2
1648	-	5085	A/G	0	391557	rs6068	Human NCBI Build 35 17	4776894	SLC25A11-GP1BA	
1649	-	504	A/G	0	391559	rs6072686	Human NCBI Build 35	20	40387226	PTPRT
1650	-	3362	A/G	0	391563	rs6130274	Human NCBI Build 35	20	41047898	PTPRT
1651	-	2096	A/G	0	391564	rs6131	Human NCBI Build 35 1	166312543	SELP	
1653	-	1674	A/G	0	391567	rs6141	Human NCBI Build 35 3	185572968	POLR2H-THPO	
1654	-	4799	A/G	1	391568	rs615854	Human NCBI Build 35	3	61778468	PTPRG
1655	-	5221	A/G	0	391569	rs6195	Human NCBI Build 35 5	142759510	NR3C1	
1657	-	922	A/G	0	391574	rs645507	Human NCBI Build 35	1	232899301	EDARADD
1658	-	3158	A/G	0	391575	rs645574	Human NCBI Build 35	5	175040069	HRH2
1659	-	5587	A/G	1	391576	rs6459808	Human NCBI Build 35	7	157020656	PTPRN2-ENSG00000197192
1660	-	6201	A/G	0	391578	rs647571	Human NCBI Build 35	1	57131628	C8B
1661	-	2344	A/G	1	391584	rs6588391	Human NCBI Build 35	1	50837181	FAF1
1662	-	2870	A/G	0	391591	rs670804	Human NCBI Build 35	10	6530227	PRKCQ
1664	-	5956	A/G	0	391595	rs676913	Human NCBI Build 35	1	89349599	GBP2
1665	-	4772	A/G	0	391596	rs6835929	Human NCBI Build 35	4	111421696	EGF-ELOVL6
1666	-	2456	A/G	1	391602	rs703842	Human NCBI Build 35	6	32104579	TNXB-ENSG00000198209-C4A
1668	-	1440	A/G	0	391611	rs723527	Human NCBI Build 35	7	54909081	EGFR
1670	-	3829	A/G	0	391618	rs7312731	Human NCBI Build 35	12	9875867	KLRF1
1671	-	2151	A/G	0	391619	rs733618	Human NCBI Build 35	2	204556450	CTLA4
1672	-	3718	A/G	0	391622	rs7435825	Human NCBI Build 35	4	89260953	SPP1
1673	-	4911	A/G	1	391625	rs753974	Human NCBI Build 35	2	220266572	INHA
1674	-	2367	A/G	0	391627	rs754505	Human NCBI Build 35	18	75327356	NFATC1
1675	-	4256	A/G	0	391635	rs764324	Human NCBI Build 35	4	857696	GAK
1676	-	1672	A/G	0	391636	rs7703713	Human NCBI Build 35	5	42591688	GHR
1677	-	3037	A/G	0	391637	rs7710762	Human NCBI Build 35	5	39195219	FYB
1678	-	854	A/G	0	391644	rs7784964	Human NCBI Build 35	7	157237948	
PTPRN2-ENSG00000196590-ENSG00000196201										
1679	-	4558	A/G	0	391646	rs7812347	Human NCBI Build 35	8	27516102	CLU
1680	-	430	A/G	0	391647	rs7816586	Human NCBI Build 35	8	27425251	EPHX2
1681	-	3563	A/G	0	391652	rs7847158	Human NCBI Build 35	9	114639819	ENSG00000181634
1682	-	5064	A/G	0	391653	rs7850607	Human NCBI Build 35	9	36862314	PAX5

1683	-	6188	A/G	0	391656	rs7909843	Human NCBI Build 35	10	71503407	H2AFY2-AMID
1684	-	5647	A/G	0	391663	rs8106480	Human NCBI Build 35	16	65141119	ENSG00000184968-TK2-CKLF
1685	-	4139	A/G	0	391666	rs8138979	Human NCBI Build 35	22	22235300	IGLL1
1687	-	2854	A/G	0	391670	rs833069	Human NCBI Build 35	6	43850557	VEGF
1688	-	3904	A/G	0	391671	rs838437	Human NCBI Build 35	2	232405763	PTMA
1689	-	2074	A/G	0	391674	rs843462	Human NCBI Build 35	2	240055009	HDAC4
1690	-	2045	A/G	0	391675	rs854625	Human NCBI Build 35	17	31352574	CCL15
1691	-	4915	A/G	1	391681	rs870849	Human NCBI Build 35	12	6757281	LAG3
1692	-	4613	A/G	0	391682	rs872800	Human NCBI Build 35	1	65007469	JAK1-ENSG00000162437
1693	-	5652	A/G	0	391683	rs872914	Human NCBI Build 35	4	75083136	PF4V1
1694	-	3857	A/G	0	391684	rs873870	Human NCBI Build 35	19	19599554	EDG4-GMIP
1695	-	790	A/G	1	391686	rs877334	Human NCBI Build 35	22	41827205	BIK
1696	-	5290	A/G	0	391688	rs885720	Human NCBI Build 35	12	12139366	BCL2L14
1697	-	4408	A/G	0	391700	rs916811	Human NCBI Build 35	11	60520408	CD6
1698	-	1622	A/G	0	391704	rs925549	Human NCBI Build 35	4	123888598	IL21
1699	-	5072	A/G	0	391707	rs9273948	Human NCBI Build 35	6	32737793	HLA-DQB1
1701	-	6411	A/G	1	391711	rs9306198	Human NCBI Build 35	22	16584474	BCL2L13
1702	-	2715	A/G	0	391713	rs932269	Human NCBI Build 35	10	121429666	BAG3
1704	-	1232	A/G	0	391719	rs9410486	Human NCBI Build 35	9	89299225	SEMA4D
1705	-	5416	A/G	1	391726	rs9673386	Human NCBI Build 35	16	65167169	CKLF-ENSG00000140932
1706	-	4392	A/G	0	391734	rs9866555	Human NCBI Build 35	3	37711803	ITGA9
1707	-	3166	A/G	1	391736	rs9916903	Human NCBI Build 35	18	8317182	PTPRM
1708	-	22	A/G	0	391737	rs9917042	Human NCBI Build 35	19	14355473	CD97
1709	-	829	A/G	0	391738	rs999407	Human NCBI Build 35	7	157065893	PTPRN2-ENSG00000197192
1710	-	515	A/G	0	391743	rs1005511	Human NCBI Build 35	11	57123232	SERPING1
1711	-	46	A/G	1	391747	rs1010101	Human NCBI Build 35	5	149469303	CSF1R-PDGFRB
1712	-	2619	A/G	0	391748	rs1015793	Human NCBI Build 35	7	54888525	EGFR
1713	-	5569	A/G	0	391750	rs1021719	Human NCBI Build 35	9	8385913	PTPRD
1714	-	2311	A/G	0	391752	rs1023945	Human NCBI Build 35	1	143192159	CD160
1715	-	1355	A/G	1	391754	rs1027990	Human NCBI Build 35	8	56976863	LYN
1716	-	4477	A/G	0	391755	rs104000	Human NCBI Build 35	18	20305077	HRH4
1717	-	4954	A/G	1	391757	rs1042122	Human NCBI Build 35	19	54681236	FLT3LG-RPL13A
1718	-	3197	A/G	0	391759	rs10444436	Human NCBI Build 35	12	15580685	PTPRO
1719	-	3901	A/G	0	391762	rs10477307	Human NCBI Build 35	5	146063329	PPP2R2B
1721	-	5888	A/G	0	391776	rs1051455	Human NCBI Build 35	Multiple	0	Unknown
1722	-	6532	A/G	0	391778	rs10516142	Human NCBI Build 35	5	180003769	FLT4
1723	-	4164	A/G	1	391779	rs1051922	Human NCBI Build 35	9	21067716	IFNB1
1724	-	5632	A/G	0	391780	rs10519892	Human NCBI Build 35	15	32007977	AVEN
1725	-	5918	A/G	0	391783	rs10732305	Human NCBI Build 35	1	240052024	AKT3
1727	-	3415	A/G	0	391790	rs10846211	Human NCBI Build 35	12	15611516	PTPRO
1729	-	5942	A/G	1	391797	rs10902662	Human NCBI Build 35	1	27682536	G1P3
1730	-	4255	A/G	1	391802	rs10977146	Human NCBI Build 35	9	8465677	PTPRD
1731	-	1879	A/G	0	391808	rs11166998	Human NCBI Build 35	8	141880882	PTK2
1732	-	520	A/G	0	391809	rs1123425	Human NCBI Build 35	12	116248825	NOS1
1734	-	1550	A/G	0	391816	rs11465465	Human NCBI Build 35	X	48876916	FOXP3
1736	-	3497	A/G	1	391820	rs11546660	Human NCBI Build 35	11	57124043	SERPING1
1737	-	4710	A/G	0	391822	rs11569472	Human NCBI Build 35	19	6648563	C3
1738	-	2270	A/G	1	391823	rs11630556	Human NCBI Build 35	15	62073064	ENSG00000035664
1739	-	1780	A/G	1	391825	rs1165677	Human NCBI Build 35	12	102824611	TRA1

1740	-	4786	A/G	1	391826	rs11665084	Human NCBI Build 35	18	20310764	HRH4
1741	-	4776	A/G	0	391832	rs11766273	Human NCBI Build 35	7	22548903	IL6
1742	-	4692	A/G	0	391837	rs11870245	Human NCBI Build 35	17	70052531	ENSG00000167850
1743	-	5585	A/G	1	391841	rs1203127	Human NCBI Build 35	3	61957553	PTPRG
1744	-	2525	A/G	0	391842	rs1205171	Human NCBI Build 35	19	12772340	PRDX2
1745	-	3453	A/G	1	391843	rs12088508	Human NCBI Build 35	1	50853154	FAF1
1746	-	3358	A/G	0	391846	rs12217419	Human NCBI Build 35	10	31824722	TCF8
1747	-	2884	A/G	0	391848	rs12279604	Human NCBI Build 35	11	111121371	PPP2R1B
1748	-	297	A/G	0	391850	rs12443116	Human NCBI Build 35	15	89078880	BLM
1749	-	2882	A/G	0	391855	rs12526095	Human NCBI Build 35	6	137399102	IL20RA
1750	-	1774	A/G	0	391857	rs1255981	Human NCBI Build 35	14	63720721	SYNE2-ESR2
1752	-	5557	A/G	1	391860	rs1263550	Human NCBI Build 35	7	156969888	PTPRN2
1753	-	1293	A/G	0	391862	rs12678837	Human NCBI Build 35	8	23006334	TNFRSF10C
1754	-	5155	A/G	0	391865	rs12731981	Human NCBI Build 35	1	43473433	MPL
1755	-	5256	A/G	0	391869	rs13010627	Human NCBI Build 35	2	201899604	CASP10
1756	-	375	A/G	0	391881	rs1356495	Human NCBI Build 35	1	203481597	PIGR-ENSG00000162894
1757	-	5558	A/G	0	391882	rs1368981	Human NCBI Build 35	9	8686227	PTPRD
1758	-	2090	A/G	0	391885	rs1391868	Human NCBI Build 35	3	12654466	RAF1-ENSG00000198383
1760	-	1767	A/G	0	391889	rs1414272	Human NCBI Build 35	1	116827910	IGSF3-CD58
1761	-	1978	A/G	0	391891	rs1422812	Human NCBI Build 35	5	169001692	DOCK2
1762	-	5830	A/G	0	391893	rs1440997	Human NCBI Build 35	18	7888534	PTPRM
1763	-	1717	A/G	0	391894	rs1461496	Human NCBI Build 35	11	122434834	HSPA8
1764	-	4529	A/G	0	391898	rs1503849	Human NCBI Build 35	1	157493837	CD48
1765	-	5366	A/G	1	391900	rs1520812	Human NCBI Build 35	12	116214513	NOS1
1766	-	5492	A/G	0	391904	rs1533614	Human NCBI Build 35	11	45870228	MAPK8IP1
1767	-	634	A/G	1	391906	rs1538971	Human NCBI Build 35	1	158408052	ENSG00000132185
1768	-	1185	A/G	0	391907	rs1539964	Human NCBI Build 35	18	65776265	CD226
1770	-	4152	A/G	0	391915	rs1564858	Human NCBI Build 35	8	120014347	TNFRSF11B
1771	-	5858	A/G	0	391918	rs1587607	Human NCBI Build 35	5	35234219	PRLR
1772	-	5805	A/G	0	391921	rs161810	Human NCBI Build 35	1	7935063	TNFRSF9
1773	-	1300	A/G	1	391923	rs1654668	Human NCBI Build 35	19	59866025	ENSG00000186818
1774	-	1615	A/G	0	391924	rs1671160	Human NCBI Build 35	19	60120271	NCR1
1775	-	3087	A/G	1	391932	rs17608	Human NCBI Build 35	19	44917486	CLC
1776	-	2801	A/G	1	391933	rs17617321	Human NCBI Build 35	6	33014564	HLA-DMB
1777	-	2412	A/G	0	391935	rs1780335	Human NCBI Build 35	1	161291194	PBX1
1778	-	604	A/G	0	391938	rs179762	Human NCBI Build 35	16	27345472	IL21R
1779	-	1556	A/G	0	391940	rs1800792	Human NCBI Build 35	4	155892013	FGG
1780	-	3119	A/G	1	391941	rs1800794	Human NCBI Build 35	2	113259504	IL1A
1782	-	2325	A/G	0	391943	rs181396	Human NCBI Build 35	22	16598709	BID
1783	-	3313	A/G	1	391944	rs1858877	Human NCBI Build 35	15	89081147	BLM
1785	-	2210	A/G	0	391949	rs1917534	Human NCBI Build 35	1	164128929	CD3Z
1786	-	4539	A/G	0	391951	rs1941146	Human NCBI Build 35	18	7594556	PTPRM
1788	-	1519	A/G	1	391959	rs1991296	Human NCBI Build 35	12	105476024	RFX4
1789	-	5636	A/G	0	391962	rs2000494	Human NCBI Build 35	3	37646383	ITGA9
1790	-	5886	A/G	0	391964	rs2005701	Human NCBI Build 35	4	111355379	EGF-ELOVL6
1791	-	1246	A/G	1	391965	rs2009112	Human NCBI Build 35	1	214941924	ENSG00000092969
1792	-	5669	A/G	0	391966	rs2015469	Human NCBI Build 35	14	106158907	IGHA1
1793	-	4725	A/G	0	391970	rs2029253	Human NCBI Build 35	10	45211490	ALOX5
1794	-	4180	A/G	0	391971	rs2031214	Human NCBI Build 35	9	8415422	PTPRD

1795	-	974	A/G	0	391972	rs2042902	Human NCBI Build 35	19	7155470	INSR	
1796	-	4252	A/G	0	391976	rs2058372	Human NCBI Build 35	11	22763224	GAS2	
1797	-	5973	A/G	0	391980	rs2068223	Human NCBI Build 35	12	121240948	VPS33A-DIABLO	
1798	-	4913	A/G	0	391981	rs2069502	Human NCBI Build 35	6	32253685	AGPAT1-AGER-RNF5	
1799	-	3529	A/G	0	391982	rs2069700	Human NCBI Build 35	5	75949759	F2RL2-IQGAP2	
1800	-	1478	A/G	1	391984	rs2069835	Human NCBI Build 35	7	22541111	IL6-ENSG00000179428	
1801	-	4653	A/G	0	391987	rs2072045	Human NCBI Build 35	14	106184896	IGHA1	
1802	-	1180	A/G	0	391989	rs2072137	Human NCBI Build 35	12	111903641	OAS2	
1803	-	5132	A/G	0	391992	rs2072598	Human NCBI Build 35	19	15618528	CYP4F3	
1805	-	480	A/G	0	391997	rs2108411	Human NCBI Build 35	7	43439048	STK17A	
1807	-	5622	A/G	1	391999	rs2116211	Human NCBI Build 35	12	69246338	PTPRB	
1808	-	5242	A/G	0	392005	rs2191416	Human NCBI Build 35	16	3710730	TRAP1	
1809	-	3815	A/G	0	392012	rs2230523	Human NCBI Build 35	5	66515139	LY64	
1811	-	3520	A/G	1	392028	rs224329	Human NCBI Build 35	20	33482993	C20orf44-GDF5	
1812	-	1248	A/G	1	392035	rs2269714	Human NCBI Build 35	1	155037977	CD1A	
1813	-	1562	A/G	0	392039	rs2272298	Human NCBI Build 35	12	51868762	ITGB7-ENSG00000139651	
1814	-	2389	A/G	0	392040	rs2273962	Human NCBI Build 35	6	41426416	ENSG00000096264	
1815	-	5930	A/G	0	392042	rs2274593	Human NCBI Build 35	9	35388406	UNC13B-ENSG00000196186	
1816	-	4339	A/G	0	392044	rs2274619	Human NCBI Build 35	1	143022358	ITGA10	
1817	-	943	A/G	1	392048	rs228275	Human NCBI Build 35	17	34164351	PSMB3-ENSG00000056661	
1818	-	5056	A/G	1	392050	rs2284190	Human NCBI Build 35	6	32927495	PSMB9-TAP1	
1819	-	1829	A/G	1	392051	rs228832	Human NCBI Build 35	20	49493555	NFATC2	
1820	-	2560	A/G	0	392054	rs2290608	Human NCBI Build 35	3	3126759	IL5RA	
1821	-	618	A/G	0	392056	rs2291540	Human NCBI Build 35	3	62238087	PTPRG	
1822	-	3278	A/G	0	392058	rs2293347	Human NCBI Build 35	7	55043125	EGFR	
1823	-	5286	A/G	0	392059	rs2293348	Human NCBI Build 35	7	55040966	EGFR	
1824	-	361	A/G	0	392061	rs2297630	Human NCBI Build 35	10	44191554	CXCL12	
1825	-	5919	A/G	0	392066	rs2304240	Human NCBI Build 35	19	10310392	ICAM3	
1826	-	3775	A/G	0	392068	rs2307214	Human NCBI Build 35	17	6850562	ALOX12	
1827	-	3069	A/G	1	392072	rs2379609	Human NCBI Build 35	19	5187166	PTPRS	
1828	-	6088	A/G	1	392073	rs2381800	Human NCBI Build 35	9	8425110	PTPRD	
1829	-	2055	A/G	0	392080	rs2491218	Human NCBI Build 35	13	27502041	FLT3	
1830	-	5217	A/G	1	392081	rs249610	Human NCBI Build 35	5	133501596	TCF7	
1832	-	4033	A/G	0	392085	rs2524024	Human NCBI Build 35	6	29987508	HLA-G	
1833	-	1975	A/G	0	392086	rs253155	Human NCBI Build 35	12	9902102	ENSG00000110852	
1834	-	2982	A/G	0	392088	rs25680	Human NCBI Build 35	12	6424889	VAMP1-TNFRSF7	
1835	-	3785	A/G	0	392092	rs260633	Human NCBI Build 35	2	108984048	EDAR	
1836	-	3501	A/G	1	392094	rs261069	Human NCBI Build 35	5	169252884	DOCK2	
1837	-	1953	A/G	0	392096	rs2660	Human NCBI Build 35	12	111820162	OAS1	
1838	-	5710	A/G	1	392101	rs2667978	Human NCBI Build 35	8	57060505	LYN	
1839	-	5835	A/G	0	392102	rs2681404	Human NCBI Build 35	3	123261660	CD86	
1840	-	4406	A/G	0	392105	rs2717440	Human NCBI Build 35	12	69245373	PTPRB	
1841	-	4001	A/G	0	392107	rs2734985	Human NCBI Build 35	6	29926641	HLA-G	
1842	-	1187	A/G	0	392109	rs2745955	Human NCBI Build 35	1	204452736	CD34	
1843	-	3808	A/G	0	392110	rs2752572	Human NCBI Build 35	X	104338905	IL1RAPL2	
1844	-	4833	A/G	0	392112	rs2765503	Human NCBI Build 35	1	154619079	CD5L	
1845	-	5509	A/G	1	392118	rs281472	Human NCBI Build 35	2	46315488	PRKCE	
1846	-	2235	A/G	0	392123	rs2848713	Human NCBI Build 35	6	31492458	MICA	
1847	-	1663	A/G	0	392125	rs2853696	Human NCBI Build 35	5	158677238	IL12B	

1848	-	4438	A/G	1	392130	rs290211	Human	NCBI	Build	35	9	90675819	SYK
1849	-	5178	A/G	0	392135	rs2930049	Human	NCBI	Build	35	5	10752490	DAP-ENSG00000164236
1850	-	319	A/G	0	392136	rs2972393	Human	NCBI	Build	35	5	42532014	GHR
1851	-	4633	A/G	1	392144	rs3024523	Human	NCBI	Build	35	1	203431079	PIGR-IL20
1852	-	4918	A/G	0	392146	rs3024839	Human	NCBI	Build	35	2	191766488	STAT4
1853	-	526	A/G	0	392148	rs303211	Human	NCBI	Build	35	10	91152477	IFIT1
1854	-	2170	A/G	0	392149	rs304441	Human	NCBI	Build	35	10	91162281	IFIT5
1855	-	1075	A/G	1	392151	rs305080	Human	NCBI	Build	35	16	84499275	ENSG00000140968
1856	-	6136	A/G	1	392154	rs308526	Human	NCBI	Build	35	18	75377952	
ENSG00000186783-NFATC1-ENSG00000198275													
1857	-	1401	A/G	0	392168	rs3138156	Human	NCBI	Build	35	19	10539842	
AP1M2-ENSG00000129347-CDKN2D													
1858	-	6071	A/G	0	392169	rs3138512	Human	NCBI	Build	35	9	89452007	GADD45G
1859	-	3993	A/G	0	392174	rs3181350	Human	NCBI	Build	35	9	114773248	TNFSF8
1860	-	2598	A/G	1	392175	rs319166	Human	NCBI	Build	35	5	146273390	PPP2R2B
1861	-	2230	A/G	1	392176	rs3218614	Human	NCBI	Build	35	10	90758656	ENSG00000026103
1863	-	3620	A/G	0	392180	rs352143	Human	NCBI	Build	35	3	52239947	PTK9L
1864	-	1029	A/G	0	392182	rs355954	Human	NCBI	Build	35	16	65253955	CKLFSF4
1866	-	6153	A/G	0	392187	rs370655	Human	NCBI	Build	35	4	75268169	CXCL3
1867	-	4702	A/G	0	392188	rs3732378	Human	NCBI	Build	35	3	39282166	CX3CR1
1868	-	3965	A/G	1	392192	rs3739440	Human	NCBI	Build	35	9	37021074	PAX5
1869	-	1544	A/G	0	392197	rs3758483	Human	NCBI	Build	35	10	90738716	ENSG00000026103
1871	-	909	A/G	1	392201	rs3766730	Human	NCBI	Build	35	1	12174942	TNFRSF1B
1872	-	2631	A/G	1	392202	rs3769504	Human	NCBI	Build	35	2	105935610	NCK2
1873	-	1005	A/G	0	392204	rs3771156	Human	NCBI	Build	35	2	102495195	IL18RAP
1874	-	1170	A/G	1	392205	rs3771295	Human	NCBI	Build	35	2	128121090	GPR17-LIMS2
1875	-	2855	A/G	0	392208	rs378299	Human	NCBI	Build	35	21	44485771	DNMT3L-ENSG00000160223
1876	-	311	A/G	0	392212	rs3788979	Human	NCBI	Build	35	2	162726396	DPP4
1877	-	2204	A/G	0	392214	rs3791399	Human	NCBI	Build	35	2	239762015	HDAC4
1878	-	1950	A/G	0	392216	rs3794126	Human	NCBI	Build	35	11	35124117	CD44
1879	-	5875	A/G	0	392219	rs3795396	Human	NCBI	Build	35	1	150448498	SNAPAP-ILF2
1880	-	3407	A/G	1	392221	rs3809114	Human	NCBI	Build	35	12	56134906	INHBC-INHBE
1881	-	5637	A/G	0	392224	rs3812561	Human	NCBI	Build	35	9	136546713	SNAPC4-CARD9
1882	-	3076	A/G	0	392225	rs3813136	Human	NCBI	Build	35	19	15452333	ENSG00000161031
1883	-	196	A/G	0	392227	rs3819497	Human	NCBI	Build	35	8	143921054	GML
1885	-	2579	A/G	0	392233	rs3856848	Human	NCBI	Build	35	3	3122676	IL5RA
1886	-	3062	A/G	0	392234	rs3890760	Human	NCBI	Build	35	2	233880802	INPP5D
1888	-	3365	A/G	1	392237	rs3917724	Human	NCBI	Build	35	1	166313253	SELP
1889	-	4325	A/G	1	392241	rs4019759	Human	NCBI	Build	35	19	15610967	CYP4F3
1891	-	1127	A/G	0	392246	rs4148873	Human	NCBI	Build	35	6	32908390	TAP2
1892	-	844	A/G	0	392247	rs4149579	Human	NCBI	Build	35	12	6317618	TNFRSF1A
1893	-	5992	A/G	1	392249	rs4151032	Human	NCBI	Build	35	11	36553003	RAG1
1894	-	1532	A/G	0	392253	rs4280262	Human	NCBI	Build	35	16	11554993	ENSG00000189067
1895	-	835	A/G	0	392256	rs4329	Human	NCBI	Build	35	17	58917190	ACE
1896	-	4307	A/G	0	392257	rs4343	Human	NCBI	Build	35	17	58919763	ACE
1898	-	4932	A/G	0	392262	rs4495525	Human	NCBI	Build	35	9	89309064	SEMA4D
1899	-	2576	A/G	0	392265	rs4531696	Human	NCBI	Build	35	15	79346671	IL16
1900	-	3817	A/G	0	392276	rs4716857	Human	NCBI	Build	35	7	157265078	PTPRN2-ENSG00000196590
1902	-	397	A/G	0	392287	rs4786490	Human	NCBI	Build	35	16	4431191	DNAJA3

1904	-	5324	A/G	1	392290	rs4801891	Human NCBI Build 35	19	56946163	FPR1
1905	-	1758	A/G	0	392296	rs483404	Human NCBI Build 35	2	45841279	PRKCE
1906	-	6319	A/G	0	392298	rs4852038	Human NCBI Build 35	2	239922021	HDAC4
1907	-	2326	A/G	0	392299	rs4852054	Human NCBI Build 35	2	240016199	HDAC4
1908	-	662	A/G	0	392300	rs4853112	Human NCBI Build 35	2	75291261	TACR1
1909	-	2885	A/G	0	392301	rs48624	Human NCBI Build 35	5	145965968	PPP2R2B
1910	-	2540	A/G	0	392304	rs489286	Human NCBI Build 35	1	157535623	SLAMF7
1911	-	171	A/G	0	392307	rs4951522	Human NCBI Build 35	1	207915876	TRAF5
1912	-	1261	A/G	1	392309	rs4953260	Human NCBI Build 35	2	45945370	PRKCE
1913	-	4246	A/G	0	392310	rs4955145	Human NCBI Build 35	3	32373387	CKLFSF8
1914	-	3077	A/G	1	392311	rs497239	Human NCBI Build 35	6	32016740	C2
1915	-	5957	A/G	0	392313	rs4987721	Human NCBI Build 35	18	59105043	BCL2
1916	-	948	A/G	0	392316	rs5030674	Human NCBI Build 35	4	110973443	CASP6
1917	-	5733	A/G	1	392319	rs5273	Human NCBI Build 35	1	183375425	PTGS2
1918	-	1314	A/G	0	392324	rs555686	Human NCBI Build 35	1	203434507	PIGR-IL20
1919	-	2447	A/G	0	392328	rs5743542	Human NCBI Build 35	20	36397416	BPI
1921	-	5040	A/G	0	392334	rs583183	Human NCBI Build 35	5	146037641	PPP2R2B
1922	-	5409	A/G	0	392337	rs5939	Human NCBI Build 35	1	28160662	PTAFR
1923	-	2651	A/G	0	392346	rs609325	Human NCBI Build 35	5	146205371	PPP2R2B
1924	-	6342	A/G	0	392347	rs6093686	Human NCBI Build 35	20	40657250	PTPRT
1925	-	6535	A/G	0	392353	rs631465	Human NCBI Build 35	5	76164809	F2RL1-ENSG00000183613
1926	-	2145	A/G	1	392354	rs643552	Human NCBI Build 35	18	20306557	HRH4
1928	-	5265	A/G	0	392360	rs6506551	Human NCBI Build 35	18	8157050	PTPRM
1929	-	3421	A/G	0	392361	rs6512265	Human NCBI Build 35	19	18363835	GDF15-LRRC25
1930	-	5306	A/G	0	392362	rs6518661	Human NCBI Build 35	22	15962529	IL17R
1931	-	2269	A/G	0	392363	rs6518684	Human NCBI Build 35	22	28986262	OSM
1933	-	644	A/G	0	392380	rs6686208	Human NCBI Build 35	1	177759498	MR1
1934	-	5342	A/G	0	392381	rs6688383	Human NCBI Build 35	1	67367975	IL23R
1935	-	3630	A/G	0	392385	rs6736735	Human NCBI Build 35	2	97794951	ZAP70
1936	-	3015	A/G	1	392388	rs6756198	Human NCBI Build 35	2	68305835	
ENSG00000115953-ENSG00000115946										
1937	-	4179	A/G	0	392393	rs6802424	Human NCBI Build 35	3	61573768	PTPRG
1938	-	4444	A/G	0	392394	rs682082	Human NCBI Build 35	16	55965312	CX3CL1
1940	-	3680	A/G	0	392400	rs6895193	Human NCBI Build 35	5	35215350	PRLR
1941	-	4456	A/G	0	392401	rs6910730	Human NCBI Build 35	6	41354611	TREM1
1942	-	3644	A/G	1	392403	rs6928482	Human NCBI Build 35	6	32734227	HLA-DQB1
1943	-	5929	A/G	0	392409	rs703817	Human NCBI Build 35	12	55776095	NAB2-STAT6
1944	-	4882	A/G	0	392415	rs7071836	Human NCBI Build 35	10	97501027	ENTPD1
1945	-	5933	A/G	0	392416	rs7078870	Human NCBI Build 35	10	71484113	H2AFY2-AMID
1946	-	335	A/G	1	392418	rs7102920	Human NCBI Build 35	11	1874448	LSP1
1947	-	5204	A/G	0	392420	rs7105890	Human NCBI Build 35	11	35193310	CD44
1948	-	5088	A/G	0	392421	rs7115613	Human NCBI Build 35	11	127876651	ETS1
1950	-	114	A/G	0	392426	rs7176654	Human NCBI Build 35	15	71786059	SDFR1-ENSG00000103855
1951	-	5857	A/G	0	392428	rs718880	Human NCBI Build 35	7	38135239	TRGV9
1953	-	4424	A/G	0	392444	rs7409450	Human NCBI Build 35	19	59455781	LILRB5
1954	-	122	A/G	1	392446	rs741581	Human NCBI Build 35	5	149182978	PPARGC1B
1955	-	6549	A/G	0	392447	rs742153	Human NCBI Build 35	22	36221309	CARD10
1956	-	1294	A/G	1	392452	rs7512207	Human NCBI Build 35	1	240291033	AKT3
1957	-	3657	A/G	1	392456	rs755854	Human NCBI Build 35	1	117275624	IGSF2

1958	-	599	A/G	0	392457	rs7582320	Human NCBI Build 35	2	45900674	PRKCE
1959	-	3386	A/G	0	392460	rs7627178	Human NCBI Build 35	3	53856511	IL17RB-CHDH
1960	-	3578	A/G	0	392461	rs7697373	Human NCBI Build 35	4	15072198	C1QTNF7
1961	-	2663	A/G	0	392468	rs7796032	Human NCBI Build 35	7	157564205	PTPRN2
1962	-	1096	A/G	0	392473	rs789192	Human NCBI Build 35	1	180287948	NCF2
1963	-	6068	A/G	0	392474	rs7894368	Human NCBI Build 35	10	129668421	PTPRE
1964	-	5822	A/G	0	392482	rs80577	Human NCBI Build 35 22	34864352	APOL3	
1965	-	4718	A/G	1	392496	rs851027	Human NCBI Build 35	6	36098853	SLC26A8-MAPK14
1966	-	5163	A/G	0	392498	rs854477	Human NCBI Build 35	17	31427271	CCL4-CCL18
1967	-	5051	A/G	0	392499	rs871334	Human NCBI Build 35	15	97297272	IGF1R
1968	-	5779	A/G	1	392502	rs879732	Human NCBI Build 35	12	12131466	BCL2L14
1969	-	5514	A/G	0	392504	rs880770	Human NCBI Build 35	5	149135028	PPARGC1B
1970	-	2920	A/G	0	392507	rs884904	Human NCBI Build 35	7	55049691	EGFR
1971	-	2029	A/G	0	392510	rs888767	Human NCBI Build 35	19	37768455	PDCD5
1972	-	2609	A/G	0	392513	rs908263	Human NCBI Build 35	2	239999357	HDAC4
1974	-	1324	A/G	0	392516	rs910830	Human NCBI Build 35	20	41108091	PTPRT
1975	-	5108	A/G	0	392518	rs919594	Human NCBI Build 35	12	69223710	PTPRB
1976	-	2332	A/G	0	392519	rs922177	Human NCBI Build 35	15	62104673	ENSG00000035664
1977	-	5550	A/G	0	392520	rs9267522	Human NCBI Build 35	6	31711749	BAT3-BAT2
1978	-	4515	A/G	0	392524	rs928937	Human NCBI Build 35	19	40510449	CD22
1979	-	4274	A/G	0	392526	rs9328347	Human NCBI Build 35	6	6219946	F13A1
1980	-	1608	A/G	0	392532	rs9462739	Human NCBI Build 35	6	41788225	TFEB
1982	-	5153	A/G	1	392535	rs9605	Human NCBI Build 35 5	179595857	MAPK9	
1983	-	1412	A/G	0	392539	rs9706102	Human NCBI Build 35	12	109648111	PPP1CC
1984	-	2115	A/G	0	392542	rs9809422	Human NCBI Build 35	3	191846918	IL1RAP
1985	-	4904	A/G	0	392543	rs982872	Human NCBI Build 35	21	41653381	FAM3B-MX2
1986	-	3798	A/G	0	392547	rs9844687	Human NCBI Build 35	3	62013217	PTPRG
1987	-	4683	A/G	1	392551	rs9918252	Human NCBI Build 35	5	169124006	DOCK2
1988	-	1414	A/G	0	392552	rs9925126	Human NCBI Build 35	16	23945617	PRKCB1
1989	-	5655	A/G	1	392553	rs9943825	Human NCBI Build 35	12	93128140	PLXNC1
1991	-	684	A/G	0	392559	rs10052957	Human NCBI Build 35	5	142766894	NR3C1
1992	-	3097	A/G	0	392561	rs1010222	Human NCBI Build 35	19	12909608	CALR-FARSLA
1993	-	72	A/G	0	392565	rs10158752	Human NCBI Build 35	1	156614147	ENSG00000158714
1995	-	5782	A/G	0	392575	rs10489790	Human NCBI Build 35	1	233036242	LGALS8-ENSG00000119285
1996	-	5870	A/G	0	392576	rs10490573	Human NCBI Build 35	2	204408669	CD28
1999	-	3293	A/G	0	392588	rs1062827	Human NCBI Build 35	1	157779917	F11R
2000	-	2064	A/G	0	392591	rs10753265	Human NCBI Build 35	1	32933105	YARS
2001	-	3941	A/G	0	392594	rs10771927	Human NCBI Build 35	12	9650849	KLRB1
2002	-	4994	A/G	1	392595	rs10803124	Human NCBI Build 35	1	232372419	ENSG00000143669
2003	-	2051	A/G	0	392597	rs10846208	Human NCBI Build 35	12	15599517	PTPRO
2004	-	1801	A/G	0	392600	rs10861637	Human NCBI Build 35	12	105507190	RFX4
2005	-	6204	A/G	0	392606	rs10972201	Human NCBI Build 35	9	34697373	CCL21
2006	-	2988	A/G	0	392609	rs11066320	Human NCBI Build 35	12	111369135	PTPN11
2007	-	6393	A/G	0	392611	rs11097115	Human NCBI Build 35	4	87880573	PTPN13
2008	-	1145	A/G	1	392613	rs11154876	Human NCBI Build 35	6	136971712	MAP3K5
2009	-	1455	A/G	0	392616	rs11247653	Human NCBI Build 35	1	27673762	G1P3
2010	-	2017	A/G	0	392618	rs1126478	Human NCBI Build 35	3	46476217	LTF
2011	-	6412	A/G	0	392622	rs1138357	Human NCBI Build 35	15	78050461	BCL2A1
2012	-	3860	A/G	1	392628	rs11542001	Human NCBI Build 35	16	54077073	MMP2

2013	-	5624	A/G	0	392631	rs11575872	Human NCBI Build 35	21	44481202	ENSG00000160223
2014	-	5951	A/G	0	392632	rs11577442	Human NCBI Build 35	1	24198384	IL22RA1
2015	-	2472	A/G	0	392634	rs11631430	Human NCBI Build 35	15	79275425	IL16
2016	-	664	A/G	1	392637	rs11666779	Human NCBI Build 35	19	15436801	
ENSG00000161031-ENSG00000105122										
2019	-	4193	A/G	0	392653	rs12037013	Human NCBI Build 35	1	240110248	AKT3
2020	-	4576	A/G	1	392654	rs12070953	Human NCBI Build 35	1	243940427	CIAS1-ENSG00000177535
2021	-	6437	A/G	0	392655	rs12077177	Human NCBI Build 35	1	155069089	CD1C
2022	-	2214	A/G	1	392656	rs1209633	Human NCBI Build 35	7	121205784	PTPRZ1
2023	-	6261	A/G	0	392657	rs12146727	Human NCBI Build 35	12	7040597	C1S
2024	-	623	A/G	0	392658	rs12160838	Human NCBI Build 35	22	41118061	ENSG00000167087
2025	-	106	A/G	0	392664	rs12461754	Human NCBI Build 35	19	14381829	DDX39-CD97
2026	-	5415	A/G	0	392672	rs12638201	Human NCBI Build 35	3	45909283	LZTFL1-CCR9
2028	-	1563	A/G	0	392675	rs12665742	Human NCBI Build 35	6	32567275	HLA-DRB3-ENSG00000197080
2029	-	3092	A/G	0	392678	rs12723208	Human NCBI Build 35	1	207899289	TRAF5
2030	-	3617	A/G	0	392679	rs1282090	Human NCBI Build 35	3	112779804	CD96
2031	-	32	A/G	0	392680	rs12824	Human NCBI Build 35	9	35596738	ENSG00000196186-TESK1-CD72
2032	-	2368	A/G	0	392681	rs1293758	Human NCBI Build 35	12	111896307	OAS2
2033	-	946	A/G	0	392686	rs13179022	Human NCBI Build 35	5	141951465	FGF1
2036	-	5107	A/G	0	392692	rs13242	Human NCBI Build 35	16	2144836	RAB26-ENSG00000131653
2037	-	6503	A/G	0	392694	rs132661	Human NCBI Build 35	22	34886934	APOL3
2038	-	1312	A/G	0	392695	rs1327202	Human NCBI Build 35	6	112259108	FYN
2039	-	3199	A/G	0	392696	rs13306014	Human NCBI Build 35	1	71152073	PTGER3
2040	-	3279	A/G	1	392697	rs13361416	Human NCBI Build 35	5	39367543	C9
2042	-	6021	A/G	1	392705	rs1389623	Human NCBI Build 35	19	6635197	C3
2043	-	1112	A/G	0	392709	rs1420094	Human NCBI Build 35	2	102474205	IL18R1
2044	-	4815	A/G	0	392711	rs1425802	Human NCBI Build 35	11	35114977	CD44
2045	-	2708	A/G	1	392713	rs1436529	Human NCBI Build 35	4	87336261	MAPK10
2046	-	2600	A/G	0	392714	rs1441002	Human NCBI Build 35	18	7877531	PTPRM
2047	-	3333	A/G	1	392715	rs1455162	Human NCBI Build 35	2	138598783	HNMT
2048	-	3558	A/G	0	392718	rs1467143	Human NCBI Build 35	1	222307702	EPHX1
2049	-	3671	A/G	0	392719	rs1467558	Human NCBI Build 35	11	35186249	CD44
2050	-	5980	A/G	0	392721	rs1500323	Human NCBI Build 35	9	8360763	PTPRD
2051	-	575	A/G	0	392723	rs1503860	Human NCBI Build 35	1	157326529	CD84
2052	-	727	A/G	1	392724	rs1507760	Human NCBI Build 35	1	203897760	DAF
2053	-	4396	A/G	0	392725	rs151607	Human NCBI Build 35	1	157398779	SLAMF1
2054	-	5106	A/G	0	392729	rs1549599	Human NCBI Build 35	3	37506369	ITGA9
2055	-	2298	A/G	0	392730	rs1551747	Human NCBI Build 35	9	90740907	SYK
2056	-	2587	A/G	0	392731	rs1554338	Human NCBI Build 35	11	45863406	CRY2-MAPK8IP1
2058	-	1509	A/G	0	392734	rs1561798	Human NCBI Build 35	12	69251746	PTPRB
2059	-	5728	A/G	1	392737	rs1571878	Human NCBI Build 35	6	167511253	CCR6-ENSG00000187485
2060	-	3154	A/G	0	392739	rs1600877	Human NCBI Build 35	8	22434063	PPP3CC-PIWIL2
2061	-	3203	A/G	0	392740	rs160974	Human NCBI Build 35	5	146149704	PPP2R2B
2063	-	73	A/G	0	392745	rs1631484	Human NCBI Build 35	17	39346388	ENSG00000181763
2065	-	809	A/G	0	392754	rs17129772	Human NCBI Build 35	1	67498109	IL12RB2
2066	-	951	A/G	0	392763	rs17611	Human NCBI Build 35	9	120848754	C5
2067	-	3923	A/G	1	392766	rs1780352	Human NCBI Build 35	1	161394869	PBX1
2068	-	4163	A/G	0	392769	rs1799864	Human NCBI Build 35	Multiple	0	CCR2-CCR2
2069	-	5639	A/G	0	392770	rs1800620	Human NCBI Build 35	6	31652570	

ENSG00000196801-LTA-LTB-TNF

2070	-	3081	A/G	0	392773	rs1805723	Human	NCBI	Build	35	12	9033564	KLRG1
2071	-	1710	A/G	0	392775	rs1818545	Human	NCBI	Build	35	1	158008221	

ENSG00000158882-APOA2-NR1I3

2072	-	5775	A/G	1	392778	rs1870583	Human	NCBI	Build	35	17	11973669	MAP2K4
2073	-	2491	A/G	0	392781	rs1883815	Human	NCBI	Build	35	6	41786705	TFEB
2074	-	3759	A/G	0	392782	rs1893352	Human	NCBI	Build	35	11	125665897	TIRAP
2075	-	5262	A/G	0	392786	rs1927906	Human	NCBI	Build	35	9	117559669	TLR4
2076	-	4754	A/G	0	392790	rs1951133	Human	NCBI	Build	35	14	24044872	CMA1
2077	-	2208	A/G	0	392792	rs196325	Human	NCBI	Build	35	10	121418818	BAG3
2079	-	1129	A/G	0	392798	rs1984399	Human	NCBI	Build	35	20	40312545	PTPRT
2080	-	5498	A/G	0	392801	rs2007475	Human	NCBI	Build	35	7	41519797	INHBA
2081	-	2179	A/G	0	392803	rs2019724	Human	NCBI	Build	35	1	193406574	CFH
2082	-	3319	A/G	0	392806	rs2039475	Human	NCBI	Build	35	14	63678509	SYNE2-ESR2
2083	-	3493	A/G	0	392814	rs206683	Human	NCBI	Build	35	20	40985434	PTPRT
2084	-	3591	A/G	1	392816	rs2069824	Human	NCBI	Build	35	7	22538472	IL6-ENSG00000179428
2085	-	1839	A/G	0	392820	rs2070025	Human	NCBI	Build	35	4	155869429	FGA
2086	-	2012	A/G	1	392823	rs2070776	Human	NCBI	Build	35	17	59361230	CD79B
2088	-	4197	A/G	1	392829	rs2074227	Human	NCBI	Build	35	11	60533357	CD6
2089	-	1427	A/G	0	392830	rs2075642	Human	NCBI	Build	35	19	50069307	ENSG00000130202
2090	-	2429	A/G	0	392831	rs2076241	Human	NCBI	Build	35	20	40203338	PTPRT
2091	-	2312	A/G	0	392835	rs2177510	Human	NCBI	Build	35	7	121213033	PTPRZ1
2092	-	3978	A/G	0	392836	rs2185815	Human	NCBI	Build	35	1	117435673	ENSG00000134258
2093	-	4778	A/G	0	392837	rs2187668	Human	NCBI	Build	35	6	32713862	ENSG00000196735
2094	-	3448	A/G	1	392843	rs2230601	Human	NCBI	Build	35	18	8059868	PTPRM
2095	-	714	A/G	0	392844	rs2234167	Human	NCBI	Build	35	1	2522390	TNFRSF14
2096	-	5065	A/G	0	392845	rs2234355	Human	NCBI	Build	35	3	45962984	CXCR6-FYC01
2097	-	3675	A/G	0	392846	rs2235369	Human	NCBI	Build	35	6	14226484	CD83
2098	-	5844	A/G	0	392847	rs2236351	Human	NCBI	Build	35	14	23853254	LTB4R-ADCY4-CIDEB-LTB4R2
2099	-	538	A/G	0	392849	rs2237432	Human	NCBI	Build	35	7	41508274	INHBA
2100	-	4983	A/G	0	392853	rs2242148	Human	NCBI	Build	35	18	8351185	PTPRM
2101	-	1643	A/G	1	392858	rs2267131	Human	NCBI	Build	35	22	27515025	XBP1
2102	-	3674	A/G	0	392859	rs2267895	Human	NCBI	Build	35	1	204469458	CD34
2103	-	5424	A/G	0	392863	rs2270994	Human	NCBI	Build	35	11	48114445	PTPRJ
2104	-	6291	A/G	0	392868	rs2280201	Human	NCBI	Build	35	10	71550196	AMID
2105	-	4556	A/G	1	392869	rs2280574	Human	NCBI	Build	35	12	120955698	BCL7A-ENSG00000197247
2106	-	5936	A/G	0	392870	rs2281747	Human	NCBI	Build	35	9	8455598	PTPRD
2107	-	4176	A/G	0	392871	rs2282493	Human	NCBI	Build	35	11	117378439	IL10RA
2108	-	4841	A/G	1	392872	rs2284396	Human	NCBI	Build	35	12	12166202	LRP6-BCL2L14
2109	-	4275	A/G	1	392873	rs2286414	Human	NCBI	Build	35	7	156974496	PTPRN2-ENSG00000197787
2110	-	2350	A/G	0	392875	rs2286596	Human	NCBI	Build	35	12	6423316	VAMP1-TNFRSF7
2111	-	1557	A/G	0	392876	rs2287040	Human	NCBI	Build	35	2	102311498	IL1RL2
2112	-	3432	A/G	0	392878	rs2289866	Human	NCBI	Build	35	19	3964229	PIAS4
2113	-	1359	A/G	0	392880	rs2291119	Human	NCBI	Build	35	11	47254777	MADD
2114	-	5312	A/G	0	392884	rs2296449	Human	NCBI	Build	35	1	117290792	IGSF2
2115	-	558	A/G	1	392892	rs2308941	Human	NCBI	Build	35	1	15590024	CASP9
2116	-	4171	A/G	0	392895	rs235219	Human	NCBI	Build	35	1	12198621	TNFRSF1B
2117	-	2425	A/G	0	392896	rs2369724	Human	NCBI	Build	35	1	157388572	SLAMF1
2118	-	1923	A/G	0	392900	rs2394655	Human	NCBI	Build	35	10	71542141	H2AFY2-AMID

2119	-	5831	A/G	0	392901	rs2396971	Human NCBI Build 35	7	2810679	CARD11
2120	-	2118	A/G	0	392902	rs2426158	Human NCBI Build 35	20	48585691	PTPN1
2121	-	2376	A/G	0	392904	rs2448346	Human NCBI Build 35	10	62214927	CDC2
2122	-	1271	A/G	1	392905	rs2459449	Human NCBI Build 35	10	75339019	C10orf55-PLAU
2124	-	826	A/G	0	392911	rs2551640	Human NCBI Build 35	2	208233399	CREB1
2125	-	5681	A/G	0	392912	rs256962	Human NCBI Build 35	5	114970610	TICAM2
2126	-	3130	A/G	0	392913	rs2583840	Human NCBI Build 35	9	130647110	ABL1
2128	-	3160	A/G	0	392916	rs2589506	Human NCBI Build 35	4	87296871	MAPK10
2129	-	1092	A/G	0	392918	rs2609200	Human NCBI Build 35	4	75674327	AREG
2130	-	1391	A/G	0	392923	rs2661548	Human NCBI Build 35	4	47988702	TEC
2131	-	5885	A/G	0	392924	rs2673832	Human NCBI Build 35	10	89702453	ENSG00000171862
2132	-	1429	A/G	0	392927	rs2704405	Human NCBI Build 35	4	48075617	TEC
2133	-	1076	A/G	0	392929	rs27135	Human NCBI Build 35 5	76048599	F2R-ENSG00000183613	
2134	-	737	A/G	0	392934	rs2738047	Human NCBI Build 35	8	6715708	ENSG00000164825
2135	-	146	A/G	0	392938	rs2755217	Human NCBI Build 35	13	40061323	FOXO1A
2136	-	7	A/G	0	392941	rs2780820	Human NCBI Build 35	1	65021023	JAK1
2137	-	4650	A/G	1	392943	rs2838008	Human NCBI Build 35	21	41606914	FAM3B
2138	-	1363	A/G	1	392945	rs2844363	Human NCBI Build 35	3	37586864	ITGA9
2139	-	4230	A/G	1	392950	rs2894775	Human NCBI Build 35	7	2777656	CARD11
2141	-	3709	A/G	0	392956	rs2907749	Human NCBI Build 35	7	30258981	CARD4
2142	-	1202	A/G	0	392957	rs2918419	Human NCBI Build 35	5	142702546	NR3C1
2143	-	4066	A/G	0	392961	rs2994329	Human NCBI Build 35	1	239973962	AKT3-SDCCAG8
2144	-	750	A/G	1	392962	rs3013454	Human NCBI Build 35	1	210929078	PTPN14
2145	-	3131	A/G	0	392964	rs3020450	Human NCBI Build 35	14	63838055	ESR2
2146	-	105	A/G	0	392965	rs3024342	Human NCBI Build 35	6	6259642	F13A1
2147	-	3381	A/G	1	392969	rs3027001	Human NCBI Build 35	1	155982536	FY-IGSF4B
2148	-	70	A/G	0	392972	rs3128521	Human NCBI Build 35	9	87420816	DAPK1
2149	-	3975	A/G	0	392973	rs3136672	Human NCBI Build 35	3	46217789	CCR1
2150	-	2248	A/G	0	392974	rs3138056	Human NCBI Build 35	14	34938265	NFKBIA
2151	-	4968	A/G	0	392978	rs3176860	Human NCBI Build 35	1	100899240	VCAM1
2152	-	5635	A/G	0	392979	rs3176895	Human NCBI Build 35	10	97504178	ENTPD1
2153	-	6097	A/G	0	392980	rs3181291	Human NCBI Build 35	12	6211760	CD9
2154	-	5201	A/G	0	392981	rs3181362	Human NCBI Build 35	9	114746997	TNFSF8
2155	-	1696	A/G	0	392982	rs3194051	Human NCBI Build 35	5	35912031	IL7R
2156	-	3035	A/G	0	392983	rs320320	Human NCBI Build 35	1	240161227	AKT3
2157	-	3509	A/G	0	392987	rs32579	Human NCBI Build 35 5	149191041	PPARGC1B	
2158	-	4570	A/G	0	392994	rs3737361	Human NCBI Build 35	18	12821324	PTPN2
2159	-	5617	A/G	1	392995	rs3737791	Human NCBI Build 35	1	157328462	CD84
2160	-	565	A/G	0	392998	rs3741403	Human NCBI Build 35	1	203462227	IL24-PIGR-ENSG00000162894
2161	-	2202	A/G	0	392999	rs3746963	Human NCBI Build 35	21	44475925	ENSG00000160223
2162	-	1282	A/G	0	393003	rs3756090	Human NCBI Build 35	4	185697669	IRF2
2163	-	3767	A/G	0	393008	rs3759334	Human NCBI Build 35	12	6362269	LTBR
2164	-	1157	A/G	0	393010	rs3765258	Human NCBI Build 35	6	136985756	MAP3K5
2165	-	6089	A/G	0	393014	rs3771823	Human NCBI Build 35	2	75263603	TACR1
2166	-	2417	A/G	1	393015	rs3775568	Human NCBI Build 35	4	185736444	IRF2
2167	-	659	A/G	0	393016	rs3775572	Human NCBI Build 35	4	185744601	IRF2
2168	-	539	A/G	0	393017	rs3776418	Human NCBI Build 35	5	10761871	DAP-ENSG00000164236
2169	-	3055	A/G	0	393021	rs3782202	Human NCBI Build 35	12	116183100	NOS1
2170	-	1242	A/G	0	393022	rs3782415	Human NCBI Build 35	12	92470223	SOCS2

2171	-	5984	A/G	0	393024	rs3785872	Human NCBI Build 35	17	42727074	ITGB3
2172	-	5520	A/G	0	393029	rs3790567	Human NCBI Build 35	1	67534398	IL12RB2
2173	-	959	A/G	0	393031	rs3790722	Human NCBI Build 35	1	111147377	CD53
2174	-	5578	A/G	0	393037	rs3793828	Human NCBI Build 35	10	71353239	COL13A1-AMID
2175	-	2793	A/G	0	393040	rs3794700	Human NCBI Build 35	16	3658849	DNASE1-TRAP1
2176	-	3336	A/G	0	393045	rs380573	Human NCBI Build 35	19	59477405	ENSG00000131042
2177	-	5547	A/G	0	393047	rs3811047	Human NCBI Build 35	2	113387641	IL1F7
2178	-	4948	A/G	0	393048	rs3811066	Human NCBI Build 35	6	6540836	LY86-ENSG00000175753
2179	-	6219	A/G	1	393050	rs3816051	Human NCBI Build 35	19	60077416	FCAR
2182	-	5232	A/G	0	393066	rs3893319	Human NCBI Build 35	1	24251355	IL28RA
2183	-	3484	A/G	0	393067	rs3911592	Human NCBI Build 35	18	46436397	MAPK4
2184	-	3344	A/G	0	393070	rs3918003	Human NCBI Build 35	1	36600466	CSF3R-MRPS15
2185	-	5171	A/G	0	393072	rs3930521	Human NCBI Build 35	1	204178690	none
2186	-	2568	A/G	0	393077	rs4149576	Human NCBI Build 35	12	6319376	TNFRSF1A
2187	-	807	A/G	0	393082	rs4240205	Human NCBI Build 35	2	86968463	CD8B1-ENSG00000198012
2189	-	878	A/G	0	393091	rs4347211	Human NCBI Build 35	1	203366735	IL19-PIGR
2190	-	4361	A/G	1	393092	rs4347296	Human NCBI Build 35	10	129648261	PTPRE
2192	-	6145	A/G	1	393094	rs4390871	Human NCBI Build 35	3	37702098	ITGA9
2193	-	3761	A/G	1	393100	rs4535048	Human NCBI Build 35	2	112367636	MERTK
2194	-	496	A/G	0	393103	rs4646018	Human NCBI Build 35	1	15585680	CASP9
2195	-	6456	A/G	1	393105	rs4656698	Human NCBI Build 35	1	166419076	SELE
2196	-	4677	A/G	1	393106	rs4657618	Human NCBI Build 35	1	155785563	IFI16
2197	-	2101	A/G	0	393107	rs4675375	Human NCBI Build 35	2	204628236	ICOS
2198	-	4465	A/G	0	393108	rs4695356	Human NCBI Build 35	4	48031069	TEC
2199	-	4813	A/G	0	393109	rs4703500	Human NCBI Build 35	5	35146484	PRLR
2200	-	2008	A/G	0	393111	rs474600	Human NCBI Build 35	1	224892572	TRIM11-ENSG00000198504
2201	-	167	A/G	0	393112	rs4749926	Human NCBI Build 35	10	6125318	IL2RA
2202	-	5678	A/G	0	393113	rs4761470	Human NCBI Build 35	12	93185672	PLXNC1
2203	-	5207	A/G	0	393114	rs4761586	Human NCBI Build 35	12	93043383	PLXNC1
2204	-	4118	A/G	0	393117	rs477895	Human NCBI Build 35	11	63805488	BAD-ENSG00000173264
2205	-	3961	A/G	1	393119	rs4789907	Human NCBI Build 35	17	74475904	LGALS3BP
2206	-	116	A/G	0	393122	rs4810361	Human NCBI Build 35	20	40637385	PTPRT
2207	-	6269	A/G	0	393125	rs4839581	Human NCBI Build 35	1	111143130	CD53
2208	-	3089	A/G	1	393129	rs4852021	Human NCBI Build 35	2	239769939	HDAC4
2209	-	2364	A/G	0	393131	rs4867878	Human NCBI Build 35	5	169049910	DOCK2
2210	-	177	A/G	0	393132	rs4872058	Human NCBI Build 35	8	23045899	TNFRSF10D-ENSG00000147457
2211	-	1492	A/G	0	393134	rs4877365	Human NCBI Build 35	9	87385246	DAPK1
2212	-	1547	A/G	0	393139	rs4937334	Human NCBI Build 35	11	127840788	ETS1
2213	-	3254	A/G	0	393140	rs4939364	Human NCBI Build 35	11	59988901	MS4A1
2214	-	6365	A/G	0	393146	rs4987821	Human NCBI Build 35	18	58964195	BCL2
2215	-	4428	A/G	0	393149	rs506134	Human NCBI Build 35	2	45822601	PRKCE
2216	-	5862	A/G	0	393158	rs561712	Human NCBI Build 35	12	116214789	NOS1
2217	-	4545	A/G	0	393164	rs5743291	Human NCBI Build 35	16	49314777	CARD15
2218	-	3298	A/G	0	393169	rs591163	Human NCBI Build 35	11	125653642	TIRAP-ENSG00000110074
2219	-	1691	A/G	0	393171	rs5962983	Human NCBI Build 35	X	103847518	IL1RAPL2
2220	-	5666	A/G	0	393174	rs6021190	Human NCBI Build 35	20	49468360	NFATC2
2221	-	2968	A/G	0	393176	rs6024876	Human NCBI Build 35	20	36387124	BPI
2222	-	803	A/G	0	393183	rs6065532	Human NCBI Build 35	20	40828708	PTPRT
2223	-	5345	A/G	0	393189	rs611251	Human NCBI Build 35	19	54068898	PPP1R15A

2224	-	2455	A/G	0	393192	rs6132106	Human NCBI Build 35	20	1872127	PTPNS1	
2225	-	2545	A/G	0	393196	rs6266	Human NCBI Build 35	11	58148513	CNTF	
2226	-	1900	A/G	0	393197	rs629562	Human NCBI Build 35	18	7741789	PTPRM	
2227	-	4478	A/G	1	393198	rs631090	Human NCBI Build 35	1	22731709	C1QB	
2228	-	3426	A/G	0	393206	rs6496720	Human NCBI Build 35	15	89063091	BLM	
2229	-	453	A/G	0	393211	rs6530946	Human NCBI Build 35	8	16099299	MSR1	
2231	-	2165	A/G	0	393216	rs6550509	Human NCBI Build 35	3	37818821	ITGA9	
2232	-	3447	A/G	0	393218	rs657653	Human NCBI Build 35	3	61836554	PTPRG	
2233	-	5271	A/G	0	393219	rs6585241	Human NCBI Build 35	10	115476600	CASP7	
2234	-	2203	A/G	0	393220	rs6593210	Human NCBI Build 35	7	55028395	EGFR	
2235	-	851	A/G	1	393222	rs6602745	Human NCBI Build 35	10	6576558	PRKCQ	
2236	-	83	A/G	1	393224	rs6689084	Human NCBI Build 35	1	211035043	PTPN14	
2237	-	1321	A/G	1	393226	rs6704124	Human NCBI Build 35	1	157415321	SLAMF1	
2238	-	6111	A/G	0	393232	rs6740918	Human NCBI Build 35	2	233875035	INPP5D	
2239	-	289	A/G	0	393234	rs6773330	Human NCBI Build 35	3	30638918	TGFBR2	
2240	-	815	A/G	0	393235	rs677715	Human NCBI Build 35	1	204435679	CD34	
2241	-	1677	A/G	0	393240	rs6840615	Human NCBI Build 35	4	15383519	ENSG00000109743	
2242	-	5176	A/G	0	393243	rs6879285	Human NCBI Build 35	5	179965491	FLT4	
2243	-	3732	A/G	0	393244	rs6890267	Human NCBI Build 35	5	169434105	DOCK2	
2245	-	2669	A/G	0	393247	rs6939090	Human NCBI Build 35	6	3035499	RIPK1	
2246	-	4805	A/G	0	393249	rs6986526	Human NCBI Build 35	8	27325088	PTK2B	
2247	-	2871	A/G	0	393251	rs7021746	Human NCBI Build 35	9	91255816	NFIL3	
2249	-	343	A/G	0	393253	rs7081735	Human NCBI Build 35	10	129687046	PTPRE	
2250	-	6079	A/G	0	393254	rs7122335	Human NCBI Build 35	11	48063062	PTPRJ	
2252	-	3502	A/G	1	393256	rs7144366	Human NCBI Build 35	14	24173502	GZMB	
2253	-	6144	A/G	1	393257	rs7144688	Human NCBI Build 35	14	63683226	SYNE2-ESR2	
2254	-	2463	A/G	0	393261	rs7181961	Human NCBI Build 35	15	31955603	AVEN	
2255	-	6084	A/G	0	393267	rs726890	Human NCBI Build 35	7	101533194	ENSG00000160999	
2256	-	1204	A/G	1	393269	rs728373	Human NCBI Build 35	20	40278187	PTPRT	
2257	-	5677	A/G	1	393270	rs7288224	Human NCBI Build 35	22	30681914	YWHAH	
2258	-	162	A/G	0	393273	rs738149	Human NCBI Build 35	22	35654749	CSF2RB	
2259	-	3991	A/G	1	393275	rs738807	Human NCBI Build 35	22	22558799	MIF	
2260	-	3490	A/G	0	393279	rs747259	Human NCBI Build 35	10	97957259	BLNK	
2261	-	4190	A/G	0	393289	rs7560571	Human NCBI Build 35	2	95114648	MAL	
2262	-	4871	A/G	0	393291	rs7572482	Human NCBI Build 35	2	191840578	STAT4	
2263	-	620	A/G	0	393292	rs758518	Human NCBI Build 35	1	116793852	CD58	
2264	-	2195	A/G	0	393294	rs7618632	Human NCBI Build 35	3	106578283	ALCAM	
2265	-	4563	A/G	1	393300	rs7647165	Human NCBI Build 35	3	32357752	CKLFSF8	
2266	-	4573	A/G	0	393302	rs7653123	Human NCBI Build 35	3	120740376	CD80	
2267	-	4518	A/G	0	393303	rs766894	Human NCBI Build 35	11	119834068	ARHGEF12	
2268	-	6023	A/G	0	393304	rs7686588	Human NCBI Build 35	4	54975556	PDGFRA	
2269	-	1142	A/G	1	393305	rs7700286	Human NCBI Build 35	5	35219509	PRLR	
2270	-	4319	A/G	0	393306	rs7701546	Human NCBI Build 35	5	43258083	CCL28-ENSG00000177453	
2271	-	2383	A/G	0	393308	rs7715491	Human NCBI Build 35	5	40877519	CARD6	
2272	-	2335	A/G	0	393309	rs7718468	Human NCBI Build 35	5	35236793	PRLR	
2273	-	3146	A/G	0	393311	rs7734558	Human NCBI Build 35	5	35150368	PRLR	
2274	-	5571	A/G	1	393313	rs7748155	Human NCBI Build 35	6	128733046	PTPRK	
2275	-	389	A/G	0	393314	rs7748892	Human NCBI Build 35	6	137044971	MAP3K5	
2276	-	810	A/G	0	393315	rs7757906	Human NCBI Build 35	6	357741	IRF4	

2277	-	4056	A/G	0	393317	rs7786808	Human NCBI Build 35	7	157722582	PTPRN2
2278	-	1498	A/G	0	393318	rs7795387	Human NCBI Build 35	7	157570987	PTPRN2
2279	-	268	A/G	0	393321	rs7875727	Human NCBI Build 35	9	113417763	RGS3
2281	-	805	A/G	0	393324	rs7915235	Human NCBI Build 35	10	90769077	ENSG00000026103
2282	-	4447	A/G	1	393331	rs8048521	Human NCBI Build 35	16	11568203	ENSG00000189067
2283	-	2041	A/G	0	393332	rs8051519	Human NCBI Build 35	16	65267187	CKLFSF4
2284	-	2874	A/G	0	393338	rs8094332	Human NCBI Build 35	18	8247256	PTPRM
2285	-	3111	A/G	0	393345	rs831266	Human NCBI Build 35	9	33349575	NFX1
2286	-	1870	A/G	0	393347	rs843971	Human NCBI Build 35	1	150090496	PGLYRP3
2287	-	4803	A/G	0	393348	rs845552	Human NCBI Build 35	7	55019716	EGFR
2288	-	4508	A/G	0	393350	rs864104	Human NCBI Build 35	17	31349883	CCL15
2289	-	4306	A/G	1	393358	rs886562	Human NCBI Build 35	3	62057006	PTPRG
2290	-	2530	A/G	0	393359	rs887796	Human NCBI Build 35	22	15968239	IL17R
2291	-	368	A/G	1	393362	rs913836	Human NCBI Build 35	9	34654672	CCL27-ENSG00000137070
2292	-	4568	A/G	0	393366	rs926668	Human NCBI Build 35	20	49594865	NFATC2
2293	-	899	A/G	0	393368	rs9295385	Human NCBI Build 35	6	167418592	CCR6-ENSG00000187485
2294	-	591	A/G	0	393369	rs930214	Human NCBI Build 35	5	146173684	PPP2R2B
2295	-	696	A/G	1	393373	rs9376267	Human NCBI Build 35	6	137572724	IFNGR1
2296	-	1760	A/G	0	393374	rs9402833	Human NCBI Build 35	6	136972303	MAP3K5
2297	-	4597	A/G	0	393376	rs943842	Human NCBI Build 35	9	35385276	UNC13B-ENSG00000196186
2298	-	2317	A/G	0	393378	rs9446996	Human NCBI Build 35	6	74487216	CD109
2299	-	2314	A/G	0	393382	rs952331	Human NCBI Build 35	2	45877749	PRKCE
2300	-	4249	A/G	0	393384	rs959926	Human NCBI Build 35	12	105574104	RFX4
2302	-	1981	A/G	0	393394	rs9851992	Human NCBI Build 35	3	61520061	PTPRG
2303	-	131	A/G	0	393395	rs9854372	Human NCBI Build 35	3	37779857	ITGA9
2304	-	3307	A/G	0	393397	rs993247	Human NCBI Build 35	9	120864803	C5
2306	-	4338	A/G	0	393400	rs1001360	Human NCBI Build 35	1	161444976	PBX1
2307	-	3427	A/G	1	393402	rs10134463	Human NCBI Build 35	14	106111017	IGHA1
2308	-	429	A/G	0	393404	rs10148371	Human NCBI Build 35	14	54679171	LGALS3
2309	-	3247	A/G	0	393405	rs10149339	Human NCBI Build 35	14	22850062	BCL2L2
2310	-	590	A/G	0	393412	rs10271690	Human NCBI Build 35	7	157729297	PTPRN2
2311	-	5564	A/G	0	393420	rs1039336	Human NCBI Build 35	9	8366287	PTPRD
2312	-	945	A/G	1	393427	rs10484480	Human NCBI Build 35	6	112153017	FYN
2313	-	6566	A/G	0	393428	rs10488499	Human NCBI Build 35	7	76478717	FGL2-ENSG00000135205
2314	-	1528	A/G	0	393433	rs1049604	Human NCBI Build 35	15	50138181	MAPK6
2315	-	4630	A/G	0	393434	rs10500941	Human NCBI Build 35	11	22749706	GAS2
2316	-	1715	A/G	1	393435	rs1050208	Human NCBI Build 35	1	146576034	FCGR1A-ENSG00000185428
2317	-	3379	A/G	0	393438	rs10511935	Human NCBI Build 35	9	36866740	PAX5
2318	-	4745	A/G	0	393440	rs10513900	Human NCBI Build 35	18	8166865	PTPRM
2319	-	3628	A/G	0	393443	rs1057024	Human NCBI Build 35	1	155803320	IFI16
2320	-	5364	A/G	0	393444	rs1057756	Human NCBI Build 35	1	161383313	PBX1-ENSG00000197613
2321	-	2295	A/G	1	393448	rs10753419	Human NCBI Build 35	1	222810967	none
2322	-	4604	A/G	1	393450	rs10778176	Human NCBI Build 35	12	101365446	IGF1
2323	-	1088	A/G	0	393451	rs10779614	Human NCBI Build 35	1	210978309	PTPN14
2324	-	4844	A/G	0	393455	rs1080750	Human NCBI Build 35	9	34571525	CNTFR
2325	-	2729	A/G	0	393459	rs10859584	Human NCBI Build 35	12	92684312	CRADD
2326	-	5279	A/G	0	393467	rs11037416	Human NCBI Build 35	11	43310734	API5
2327	-	4413	A/G	1	393479	rs1124374	Human NCBI Build 35	3	37825081	ITGA9
2328	-	5958	A/G	0	393480	rs11244143	Human NCBI Build 35	9	130699665	ABL1

2329	-	2216	A/G	0	393483	rs11465716	Human NCBI Build 35	2	102520294	IL18RAP
2330	-	3079	A/G	0	393484	rs1147487	Human NCBI Build 35	7	121278669	PTPRZ1
2331	-	6056	A/G	0	393487	rs11587500	Human NCBI Build 35	1	24262186	IL28RA
2332	-	2403	A/G	1	393491	rs1169093	Human NCBI Build 35	12	120927640	BCL7A-ENSG00000197247
2334	-	639	A/G	0	393502	rs12005879	Human NCBI Build 35	9	130767203	ABL1
2335	-	228	A/G	0	393506	rs12092294	Human NCBI Build 35	1	193698510	CFHL5
2336	-	5404	A/G	0	393509	rs12248934	Human NCBI Build 35	10	35491604	CREM
2337	-	587	A/G	0	393512	rs12405767	Human NCBI Build 35	1	85458493	BCL10
2338	-	4254	A/G	0	393513	rs12412124	Human NCBI Build 35	10	72035136	PRF1
2339	-	5593	A/G	0	393517	rs12477946	Human NCBI Build 35	2	86955453	CD8B1
2340	-	29	A/G	0	393518	rs12490342	Human NCBI Build 35	3	62019276	PTPRG
2341	-	230	A/G	0	393519	rs12524093	Human NCBI Build 35	6	143118236	HIVEP2
2342	-	1070	A/G	0	393520	rs12528715	Human NCBI Build 35	6	128588870	PTPRK
2343	-	392	A/G	0	393525	rs12679874	Human NCBI Build 35	8	27286736	PTK2B
2344	-	4466	A/G	1	393526	rs12693932	Human NCBI Build 35	2	201918901	CASP10-CASP8
2345	-	4313	A/G	0	393528	rs1293344	Human NCBI Build 35	12	56430932	CDK4-MARCH9-SAS
2346	-	2565	A/G	0	393530	rs12956925	Human NCBI Build 35	18	58164620	TNFRSF11A
2347	-	5008	A/G	0	393531	rs12969413	Human NCBI Build 35	18	54542291	MALT1
2348	-	136	A/G	0	393539	rs131430	Human NCBI Build 35	22	22251688	IGLL1
2349	-	1377	A/G	0	393540	rs13203080	Human NCBI Build 35	6	136926504	MAP3K5
2350	-	1224	A/G	0	393541	rs1321646	Human NCBI Build 35	1	155108082	CD1B
2351	-	2938	A/G	0	393546	rs13376498	Human NCBI Build 35	1	152508127	DAP3-ENSG00000125459
2352	-	3184	A/G	0	393547	rs13425163	Human NCBI Build 35	2	201916544	CASP10
2353	-	5502	A/G	0	393548	rs13427084	Human NCBI Build 35	2	109041196	EDAR
2354	-	5246	A/G	0	393551	rs1359119	Human NCBI Build 35	9	8460749	PTPRD
2355	-	5429	A/G	0	393561	rs1425552	Human NCBI Build 35	4	185707720	IRF2
2356	-	4522	A/G	0	393564	rs1433048	Human NCBI Build 35	5	158688423	IL12B
2357	-	85	A/G	0	393568	rs1469348	Human NCBI Build 35	2	160526054	LY75
2358	-	6329	A/G	0	393570	rs1472971	Human NCBI Build 35	4	48101572	TEC
2359	-	6338	A/G	0	393574	rs1513103	Human NCBI Build 35	12	69388653	PTPRR
2360	-	183	A/G	0	393580	rs1553456	Human NCBI Build 35	1	157461469	CD48
2364	-	4615	A/G	0	393584	rs15677	Human NCBI Build 35	11	107482699	CUL5
2365	-	5895	A/G	1	393587	rs1583005	Human NCBI Build 35	5	140011721	NDUFA2-IK
2367	-	195	A/G	0	393598	rs16905649	Human NCBI Build 35	11	48105928	PTPRJ
2368	-	5701	A/G	1	393599	rs17012064	Human NCBI Build 35	4	88051171	PTPN13
2369	-	1319	A/G	1	393601	rs1736920	Human NCBI Build 35	6	29905152	HLA-G
2370	-	3114	A/G	0	393603	rs17615	Human NCBI Build 35	1	204034857	CR2
2371	-	5154	A/G	1	393604	rs176379	Human NCBI Build 35	20	40898608	PTPRT
2372	-	2259	A/G	0	393605	rs17705005	Human NCBI Build 35	5	147486786	SPINK5
2373	-	2336	A/G	0	393610	rs1800896	Human NCBI Build 35	1	203335292	PIGR-IL10
2374	-	6054	A/G	0	393613	rs1821429	Human NCBI Build 35	9	8705082	PTPRD
2375	-	262	A/G	1	393614	rs1860181	Human NCBI Build 35	17	29641700	CCL11
2376	-	1110	A/G	0	393615	rs1861046	Human NCBI Build 35	4	15074175	C1QTNF7
2377	-	6292	A/G	0	393616	rs1861245	Human NCBI Build 35	2	102425424	IL1RL1
2378	-	1517	A/G	1	393621	rs1883838	Human NCBI Build 35	20	44195303	ENSG00000101017
2379	-	1578	A/G	0	393628	rs1957074	Human NCBI Build 35	4	75063905	CXCL6
2380	-	2069	A/G	0	393629	rs198207	Human NCBI Build 35	16	24085634	PRKCB1
2381	-	4035	A/G	0	393633	rs1993703	Human NCBI Build 35	9	90668484	SYK
2382	-	2301	A/G	0	393634	rs2009257	Human NCBI Build 35	1	203465418	IL24-PIGR-ENSG00000162894

2383	-	288	A/G	1	393635	rs2009770	Human NCBI Build 35	18	7813730	PTPRM
2384	-	6253	A/G	0	393636	rs2011713	Human NCBI Build 35	17	34156699	ENSG00000056661
2385	-	748	A/G	1	393637	rs2012522	Human NCBI Build 35	5	149118304	PPARGC1B
2386	-	4323	A/G	0	393644	rs2050866	Human NCBI Build 35	9	113357794	RGS3
2387	-	2218	A/G	0	393645	rs2050887	Human NCBI Build 35	1	158418483	ENSG00000132185
2388	-	4643	A/G	1	393648	rs206650	Human NCBI Build 35	20	41006446	PTPRT
2389	-	401	A/G	0	393652	rs2069832	Human NCBI Build 35	7	22540673	IL6-ENSG00000179428
2391	-	2541	A/G	0	393659	rs2089511	Human NCBI Build 35	4	48017289	TEC
2392	-	530	A/G	1	393666	rs2169014	Human NCBI Build 35	18	8354598	PTPRM
2393	-	1416	A/G	0	393667	rs2171690	Human NCBI Build 35	1	161471757	PBX1
2394	-	75	A/G	0	393674	rs2230229	Human NCBI Build 35	8	23105237	TNFRSF10A-ENSG00000147457
2395	-	3707	A/G	0	393676	rs2230525	Human NCBI Build 35	5	66514382	LY64
2396	-	326	A/G	1	393678	rs2232340	Human NCBI Build 35	3	53866007	IL17RB
2397	-	6274	A/G	0	393682	rs2241005	Human NCBI Build 35	12	9639839	KLRB1
2398	-	5774	A/G	0	393690	rs2254595	Human NCBI Build 35	7	120601200	FAM3C
2399	-	2334	A/G	0	393691	rs2266969	Human NCBI Build 35	22	20498461	MAPK1
2400	-	60	A/G	0	393692	rs2267172	Human NCBI Build 35	22	30664336	YWHAH
2401	-	2858	A/G	0	393693	rs2268888	Human NCBI Build 35	2	162710957	DPP4
2402	-	1475	A/G	1	393697	rs2274620	Human NCBI Build 35	1	143016648	PEX11B-ITGA10
2403	-	2658	A/G	0	393699	rs2278329	Human NCBI Build 35	5	38957545	OSMR
2404	-	221	A/G	1	393700	rs2280234	Human NCBI Build 35	2	191675605	STAT1
2406	-	1056	A/G	0	393706	rs2288246	Human NCBI Build 35	4	185714666	IRF2
2407	-	1636	A/G	0	393710	rs2290149	Human NCBI Build 35	11	47302492	MADD
2408	-	2756	A/G	0	393711	rs2290182	Human NCBI Build 35	16	65171509	CKLF-ENSG00000140932
2409	-	118	A/G	0	393712	rs2290610	Human NCBI Build 35	3	3114957	IL5RA
2410	-	831	A/G	0	393722	rs2301333	Human NCBI Build 35	12	6751257	LAG3-PTMS
2411	-	3597	A/G	0	393724	rs2302463	Human NCBI Build 35	4	15389715	ENSG00000109743
2413	-	5553	A/G	0	393734	rs243866	Human NCBI Build 35	16	54069038	MMP2
2414	-	2816	A/G	0	393735	rs2456928	Human NCBI Build 35	4	47997063	TEC
2415	-	5931	A/G	0	393740	rs251406	Human NCBI Build 35	5	67572217	PIK3R1
2416	-	4377	A/G	1	393745	rs2564978	Human NCBI Build 35	1	203882811	DAF
2417	-	2875	A/G	1	393748	rs260682	Human NCBI Build 35	2	109068554	EDAR
2418	-	1174	A/G	1	393751	rs2636889	Human NCBI Build 35	9	114172664	ORM1
2419	-	3105	A/G	0	393753	rs2637988	Human NCBI Build 35	2	113593010	IL1RN
2420	-	2590	A/G	0	393763	rs2772560	Human NCBI Build 35	9	34685977	CCL19
2422	-	3622	A/G	1	393770	rs2820121	Human NCBI Build 35	1	155631048	MNDA
2423	-	3093	A/G	0	393772	rs2834213	Human NCBI Build 35	21	33714780	IFNGR2
2425	-	5847	A/G	1	393785	rs2970498	Human NCBI Build 35	7	30251296	CARD4
2427	-	988	A/G	0	393789	rs3024459	Human NCBI Build 35	6	6096818	F13A1
2428	-	61	A/G	0	393790	rs3024482	Human NCBI Build 35	6	6127664	F13A1
2429	-	2834	A/G	0	393792	rs3024498	Human NCBI Build 35	1	203329924	IL10
2430	-	1832	A/G	0	393793	rs3024585	Human NCBI Build 35	16	27267345	IL4R
2431	-	3629	A/G	1	393799	rs3118470	Human NCBI Build 35	10	6141719	IL2RA
2432	-	3503	A/G	0	393804	rs3128931	Human NCBI Build 35	6	33079686	HLA-DOA
2433	-	179	A/G	0	393808	rs313990	Human NCBI Build 35	1	28173834	PTAFR
2434	-	2768	A/G	0	393809	rs315721	Human NCBI Build 35	5	169647616	LCP2-ENSG00000198424
2435	-	3356	A/G	0	393811	rs3180825	Human NCBI Build 35	11	63766455	PPP1R14B-VEGFB-FKBP2
2436	-	3764	A/G	0	393813	rs3181192	Human NCBI Build 35	9	114774648	TNFSF8
2437	-	2109	A/G	0	393820	rs332292	Human NCBI Build 35	15	62088674	ENSG00000035664

2438	-	5754	A/G	0	393821	rs33368 Human NCBI Build 35	5	169277258	DOCK2
2439	-	3545	A/G	0	393830	rs3745550 Human NCBI Build 35	19	7066573 INSR	
2440	-	3964	A/G	0	393832	rs3749740 Human NCBI Build 35	5	39237656	FYB
2441	-	2433	A/G	1	393839	rs3755963 Human NCBI Build 35	4	884085 GAK	
2442	-	5598	A/G	0	393841	rs3756247 Human NCBI Build 35	4	15382735	ENSG00000109743
2444	-	5866	A/G	0	393844	rs3764541 Human NCBI Build 35	19	56963568	FPRL1
2445	-	1998	A/G	1	393851	rs3780282 Human NCBI Build 35	9	130773208	ABL1
2446	-	1431	A/G	0	393852	rs3780906 Human NCBI Build 35	10	45241988	ALOX5
2447	-	6147	A/G	0	393854	rs3782928 Human NCBI Build 35	12	7139817 C1RL-ENSG00000159403	
2448	-	5027	A/G	0	393855	rs3785087 Human NCBI Build 35	16	65147341	CKLF
2449	-	910	A/G	1	393856	rs3785142 Human NCBI Build 35	16	49344648	ENSG00000083799
2450	-	3907	A/G	0	393859	rs3791423 Human NCBI Build 35	2	239774941	HDAC4
2451	-	3434	A/G	0	393874	rs3817208 Human NCBI Build 35	9	8688875 PTPRD	
2452	-	252	A/G	0	393878	rs3845466 Human NCBI Build 35	1	180283417	NCF2
2454	-	2315	A/G	0	393883	rs386027 Human NCBI Build 35	21	41636669	FAM3B
2455	-	5052	A/G	1	393885	rs3896347 Human NCBI Build 35	3	32405606	ENSG00000153551
2457	-	4784	A/G	1	393887	rs3910815 Human NCBI Build 35	5	146091900	PPP2R2B
2458	-	4875	A/G	0	393888	rs3917201 Human NCBI Build 35	14	75499308	TGFB3
2459	-	3886	A/G	0	393891	rs3917836 Human NCBI Build 35	1	166292932	SELP
2460	-	862	A/G	0	393899	rs4151034 Human NCBI Build 35	11	36554089	RAG1
2461	-	1347	A/G	0	393902	rs4245234 Human NCBI Build 35	18	46396255	MAPK4
2462	-	5503	A/G	0	393907	rs436059 Human NCBI Build 35	19	4179071 ANKRD24-ENSG00000105246	
2464	-	5921	A/G	0	393916	rs460184 Human NCBI Build 35	1	193447994	CFH
2465	-	175	A/G	0	393921	rs4678985 Human NCBI Build 35	3	37663156	ITGA9
2466	-	2621	A/G	0	393923	rs4688014 Human NCBI Build 35	3	120733580	CD80
2467	-	3949	A/G	1	393926	rs4711668 Human NCBI Build 35	6	41354451	TREM1
2468	-	3244	A/G	0	393940	rs4804377 Human NCBI Build 35	19	7145976 INSR	
2469	-	5833	A/G	1	393941	rs4811184 Human NCBI Build 35	20	49558078	NFATC2
2470	-	187	A/G	0	393945	rs4845623 Human NCBI Build 35	1	151228850	IL6R
2471	-	2591	A/G	0	393946	rs4851526 Human NCBI Build 35	2	102076888	IL1R2
2472	-	3162	A/G	0	393951	rs490358 Human NCBI Build 35	11	56913981	PRG2
2473	-	840	A/G	0	393952	rs4909055 Human NCBI Build 35	7	157374819	PTPRN2
2474	-	1921	A/G	0	393954	rs4940742 Human NCBI Build 35	18	54517561	MALT1
2475	-	1642	A/G	1	393956	rs4953268 Human NCBI Build 35	2	45980945	PRKCE
2476	-	6373	A/G	0	393959	rs4953292 Human NCBI Build 35	2	46103634	PRKCE
2477	-	1339	A/G	0	393962	rs509749 Human NCBI Build 35	1	157606633	LY9
2478	-	2483	A/G	0	393963	rs510745 Human NCBI Build 35	10	6585110 PRKCQ	
2479	-	3121	A/G	0	393968	rs550672 Human NCBI Build 35	18	8123688 PTPRM	
2480	-	2091	A/G	1	393969	rs564601 Human NCBI Build 35	11	111099287	PPP2R1B-SNF1LK2
2482	-	2490	A/G	0	393974	rs5756708 Human NCBI Build 35	22	36228078	CARD10
2483	-	944	A/G	0	393975	rs588997 Human NCBI Build 35	6	33136695	HLA-DPA1
2484	-	2719	A/G	0	393976	rs589371 Human NCBI Build 35	18	7727601 PTPRM	
2485	-	1933	A/G	1	393977	rs5916936 Human NCBI Build 35	X	104688346	IL1RAPL2
2486	-	3216	A/G	0	393979	rs594771 Human NCBI Build 35	18	7753363 PTPRM	
2487	-	4343	A/G	0	393981	rs5962542 Human NCBI Build 35	X	104586648	IL1RAPL2
2489	-	3962	A/G	0	393995	rs6130039 Human NCBI Build 35	20	40179211	PTPRT
2490	-	3406	A/G	1	393997	rs614541 Human NCBI Build 35	9	21342862	IFNA6
2491	-	731	A/G	0	394001	rs6444552 Human NCBI Build 35	3	168916777	PDCD10
2492	-	2783	A/G	0	394005	rs6476454 Human NCBI Build 35	9	34570894	CNTFR

2493	-	5661	A/G	0	394006	rs6476479	Human NCBI Build 35	9	35208272	UNC13B
2494	-	3687	A/G	0	394017	rs657132	Human NCBI Build 35	18	20307272	HRH4
2495	-	1259	A/G	0	394020	rs6650771	Human NCBI Build 35	2	152834639	STAM2
2496	-	895	A/G	0	394031	rs6710189	Human NCBI Build 35	2	112506023	MERTK
2497	-	3739	A/G	0	394034	rs6717727	Human NCBI Build 35	2	239040157	none
2498	-	2465	A/G	0	394037	rs6742737	Human NCBI Build 35	2	46209565	PRKCE
2499	-	983	A/G	0	394038	rs677066	Human NCBI Build 35	1	204162386	none
2500	-	1686	A/G	1	394040	rs6785475	Human NCBI Build 35	3	61964985	PTPRG
2501	-	4068	A/G	0	394045	rs6865659	Human NCBI Build 35	5	149465965	CSF1R
2502	-	2065	A/G	0	394050	rs6896856	Human NCBI Build 35	5	39180975	FYB
2503	-	6465	A/G	0	394058	rs696743	Human NCBI Build 35	5	39243696	FYB
2504	-	117	A/G	0	394060	rs6982459	Human NCBI Build 35	8	23069864	TNFRSF10D-ENSG00000147457
2505	-	756	A/G	1	394061	rs699240	Human NCBI Build 35	1	180286106	NCF2
2506	-	5795	A/G	0	394063	rs700228	Human NCBI Build 35	5	39397612	C9
2507	-	5987	A/G	0	394065	rs7005909	Human NCBI Build 35	8	142052881	PTK2
2508	-	1445	A/G	0	394067	rs7032626	Human NCBI Build 35	9	36917364	PAX5
2509	-	1911	A/G	0	394069	rs706909	Human NCBI Build 35	6	112154982	FYN
2510	-	1790	A/G	0	394073	rs7156293	Human NCBI Build 35	14	75493336	TGFB3-KIAA0998
2511	-	3112	A/G	0	394074	rs7231577	Human NCBI Build 35	18	7568782	PTPRM
2512	-	1291	A/G	1	394075	rs723279	Human NCBI Build 35	18	66111294	SOCS6
2513	-	2027	A/G	1	394077	rs7248379	Human NCBI Build 35	19	47402429	ENSG00000160570
2514	-	734	A/G	1	394079	rs7251963	Human NCBI Build 35	19	7121241	INSR
2515	-	4141	A/G	0	394092	rs7419145	Human NCBI Build 35	1	157642371	CD244
2516	-	1598	A/G	0	394098	rs753733	Human NCBI Build 35	19	7675566	FCER2
2517	-	5000	A/G	1	394101	rs7555286	Human NCBI Build 35	1	157580322	LY9
2518	-	4106	A/G	0	394103	rs7558633	Human NCBI Build 35	2	45873257	PRKCE
2519	-	2596	A/G	0	394105	rs7578932	Human NCBI Build 35	2	162978555	IFIH1
2522	-	3781	A/G	0	394111	rs7651620	Human NCBI Build 35	3	11276532	HRH1
2523	-	1408	A/G	1	394113	rs769378	Human NCBI Build 35	4	87596943	MAPK10
2525	-	1032	A/G	1	394115	rs7724197	Human NCBI Build 35	5	39199660	FYB
2527	-	3561	A/G	0	394127	rs7941606	Human NCBI Build 35	11	127877378	ETS1
2528	-	77	A/G	0	394130	rs796051	Human NCBI Build 35	12	88243332	DUSP6
2529	-	6018	A/G	1	394132	rs8034284	Human NCBI Build 35	15	97313771	IGF1R
2530	-	760	A/G	0	394134	rs8050461	Human NCBI Build 35	16	11580966	ENSG00000189067
2531	-	1500	A/G	0	394135	rs8057341	Human NCBI Build 35	16	49295481	CARD15
2532	-	4213	A/G	0	394139	rs8087884	Human NCBI Build 35	18	7941041	PTPRM
2533	-	2421	A/G	0	394141	rs8138102	Human NCBI Build 35	22	44912271	PPARA
2534	-	4961	A/G	0	394143	rs8179390	Human NCBI Build 35	1	71206386	PTGER3
2535	-	3881	A/G	0	394145	rs858553	Human NCBI Build 35	1	164186803	CD3Z
2536	-	979	A/G	0	394148	rs880324	Human NCBI Build 35	20	49487597	NFATC2
2537	-	5976	A/G	0	394149	rs881878	Human NCBI Build 35	4	111193652	EGF
2538	-	2504	A/G	0	394150	rs884663	Human NCBI Build 35	15	97138749	IGF1R
2540	-	1264	A/G	1	394158	rs918498	Human NCBI Build 35	5	150439981	TNIP1
2542	-	229	A/G	0	394162	rs930067	Human NCBI Build 35	5	35163281	PRLR
2543	-	1001	A/G	0	394166	rs9349199	Human NCBI Build 35	6	41756676	TFEB
2544	-	1712	A/G	0	394171	rs9410476	Human NCBI Build 35	9	89255049	SEMA4D
2545	-	1172	A/G	0	394173	rs943451	Human NCBI Build 35	10	6661779	PRKCQ
2546	-	2610	A/G	0	394174	rs943452	Human NCBI Build 35	10	6655460	PRKCQ
2547	-	6251	A/G	1	394177	rs9459854	Human NCBI Build 35	6	167436293	CCR6-ENSG00000187485

2548	-	3431	A/G	0	394184	rs9553022	Human NCBI Build 35	13	23104628	TNFRSF19
2549	-	1479	A/G	0	394188	rs966645	Human NCBI Build 35	10	106000529	GSTO1
2550	-	2720	A/G	1	394189	rs9668031	Human NCBI Build 35	12	107516781	SEPLPG
2551	-	2775	A/G	0	394190	rs973767	Human NCBI Build 35	18	12810057	PTPN2
2552	-	1326	A/G	0	394192	rs9790107	Human NCBI Build 35	3	37683386	ITGA9
2553	-	4294	A/G	1	394197	rs9826860	Human NCBI Build 35	3	62162968	PTPRG
2554	-	3281	A/G	0	394199	rs9847419	Human NCBI Build 35	3	61760165	PTPRG
2555	-	2407	A/G	0	394204	rs9905566	Human NCBI Build 35	17	22992427	LGALS9
2556	-	693	A/G	1	394207	rs9969727	Human NCBI Build 35	9	89304388	SEMA4D
2557	-	3416	A/G	0	394211	rs10099598	Human NCBI Build 35	8	42262896	IKBKB
2558	-	2095	A/G	0	394212	rs10108011	Human NCBI Build 35	8	22376751	PPP3CC-PIWIL2
2559	-	2173	A/G	0	394213	rs10112856	Human NCBI Build 35	8	38168596	BAG4
2560	-	2451	A/G	1	394218	rs10159067	Human NCBI Build 35	1	177731008	MR1
2561	-	3270	A/G	0	394231	rs10471960	Human NCBI Build 35	5	55272131	IL6ST-ENSG00000176534
2562	-	997	A/G	0	394233	rs10483273	Human NCBI Build 35	14	21986886	ENSG00000166056
2563	-	142	A/G	0	394235	rs10484565	Human NCBI Build 35	6	32903010	TAP2
2564	-	165	A/G	0	394240	rs10490775	Human NCBI Build 35	3	62011764	PTPRG
2566	-	4740	A/G	0	394244	rs10494976	Human NCBI Build 35	1	211009188	PTPN14
2567	-	6207	A/G	0	394246	rs10499858	Human NCBI Build 35	7	79880497	CD36
2568	-	1040	A/G	0	394247	rs10500782	Human NCBI Build 35	11	13466762	PTH
2569	-	4111	A/G	0	394249	rs10502357	Human NCBI Build 35	18	7579318	PTPRM
2570	-	464	A/G	0	394256	rs1050975	Human NCBI Build 35	6	353012	IRF4
2571	-	185	A/G	1	394257	rs1051007	Human NCBI Build 35	17	4583562	CXCL16-ENSG00000161920
2572	-	1613	A/G	0	394258	rs10513797	Human NCBI Build 35	3	185575183	THPO
2575	-	1114	A/G	1	394267	rs1052371	Human NCBI Build 35	19	7063593	INSR
2576	-	3290	A/G	0	394277	rs10910843	Human NCBI Build 35	1	143180156	ZNF364-CD160
2577	-	6492	A/G	0	394279	rs10932201	Human NCBI Build 35	2	208251763	CREB1
2579	-	6382	A/G	0	394287	rs11212495	Human NCBI Build 35	11	107424109	CUL5
2580	-	6406	A/G	0	394292	rs11265416	Human NCBI Build 35	1	157284886	SLAMF6
2581	-	6354	A/G	0	394295	rs1135352	Human NCBI Build 35	1	210931214	PTPN14
2582	-	6459	A/G	0	394296	rs1141714	Human NCBI Build 35	1	218300756	DUSP10
2583	-	6431	A/G	0	394299	rs11574697	Human NCBI Build 35	4	110976509	CASP6
2584	-	6445	A/G	0	394300	rs11603079	Human NCBI Build 35	11	107433417	CUL5
2585	-	6460	A/G	0	394306	rs11696647	Human NCBI Build 35	20	3398635	ATRN
2586	-	6362	A/G	0	394308	rs11717869	Human NCBI Build 35	3	37736553	ITGA9
2587	-	6424	A/G	1	394321	rs11996401	Human NCBI Build 35	8	16007687	MSR1
2588	-	6402	A/G	0	394323	rs12065526	Human NCBI Build 35	1	243940448	CIAS1-ENSG00000177535
2589	-	6439	A/G	0	394326	rs12131585	Human NCBI Build 35	1	189766670	SSA2
2591	-	6389	A/G	1	394334	rs12410385	Human NCBI Build 35	1	143029436	ITGA10
2592	-	2534	A/G	0	394335	rs12418673	Human NCBI Build 35	11	107467742	CUL5
2593	-	6374	A/G	1	394341	rs12508721	Human NCBI Build 35	4	123902269	IL21
2594	-	6375	A/G	0	394346	rs12645462	Human NCBI Build 35	4	75064777	CXCL6
2595	-	6349	A/G	1	394349	rs12824240	Human NCBI Build 35	12	10501813	KLRC1
2596	-	6473	A/G	0	394350	rs12992554	Human NCBI Build 35	2	109048898	EDAR
2597	-	2709	A/G	0	394364	rs1332332	Human NCBI Build 35	10	91092418	IFIT3-LIPA
2598	-	6464	A/G	0	394367	rs1345975	Human NCBI Build 35	9	21129896	IFNW1
2599	-	4834	A/G	0	394369	rs13501	Human NCBI Build 35	6	32901501	TAP2
2600	-	6571	A/G	0	394372	rs1360165	Human NCBI Build 35	9	36991008	PAX5
2601	-	6572	A/G	0	394373	rs1361117	Human NCBI Build 35	9	8605045	PTPRD

2602	-	6573	A/G	0	394374	rs1361861	Human NCBI Build 35	X	103855883	IL1RAPL2
2603	-	6577	A/G	0	394377	rs1381548	Human NCBI Build 35	18	59108376	BCL2
2604	-	6578	A/G	1	394378	rs1409165	Human NCBI Build 35	1	71076126	PTGER3
2605	-	6580	A/G	1	394379	rs1410577	Human NCBI Build 35	9	87512615	DAPK1
2606	-	6582	A/G	0	394381	rs1422987	Human NCBI Build 35	5	147466552	SPINK5
2607	-	6587	A/G	0	394386	rs1457238	Human NCBI Build 35	2	160810969	ITGB6
2608	-	6591	A/G	0	394389	rs1483757	Human NCBI Build 35	12	116224260	NOS1
2609	-	6595	A/G	0	394393	rs1503190	Human NCBI Build 35	11	48074449	PTPRJ
2610	-	6596	A/G	0	394394	rs1511815	Human NCBI Build 35	4	75116466	CXCL1
2611	-	6601	A/G	1	394398	rs1541373	Human NCBI Build 35	4	110986498	CASP6
2613	-	6610	A/G	1	394405	rs163913	Human NCBI Build 35	19	6673635 C3	
2614	-	6611	A/G	0	394406	rs1641716	Human NCBI Build 35	12	12115985	BCL2L14
2615	-	6614	A/G	0	394409	rs169082	Human NCBI Build 35	5	169006634	DOCK2
2616	-	6616	A/G	1	394411	rs17020956	Human NCBI Build 35	1	203675876	C4BPA
2617	-	6621	A/G	0	394415	rs1718704	Human NCBI Build 35	3	61704728	PTPRG-ENSG00000168370
2618	-	6624	A/G	0	394417	rs1772180	Human NCBI Build 35	10	93587141	TNKS2
2619	-	6625	A/G	1	394418	rs1780330	Human NCBI Build 35	1	161434212	PBX1
2620	-	6627	A/G	1	394420	rs1780365	Human NCBI Build 35	1	161286944	PBX1
2622	-	6631	A/G	0	394424	rs1809216	Human NCBI Build 35	2	46903648	SOCSS5
2623	-	6632	A/G	0	394425	rs1831150	Human NCBI Build 35	1	204058833	none
2624	-	6634	A/G	0	394426	rs1838065	Human NCBI Build 35	10	54199263	MBL2
2625	-	6637	A/G	0	394428	rs1861594	Human NCBI Build 35	12	15552237	PTPRO
2626	-	6638	A/G	0	394429	rs1864972	Human NCBI Build 35	5	149489463	PDGFRB
2627	-	6644	A/G	1	394434	rs1874328	Human NCBI Build 35	7	128179055	IRF5
2628	-	6651	A/G	0	394440	rs1884565	Human NCBI Build 35	20	1825150 PTPNS1	
2629	-	6652	A/G	0	394441	rs1891150	Human NCBI Build 35	6	128805122	PTPRK
2630	-	6654	A/G	0	394443	rs1892802	Human NCBI Build 35	3	37572223	ITGA9
2633	-	6662	A/G	0	394449	rs1944055	Human NCBI Build 35	11	58099205	CNTF-LPXN
2634	-	6668	A/G	0	394455	rs1973522	Human NCBI Build 35	17	38092355	CNTNAP1-ENSG00000184451
2636	-	6674	A/G	0	394459	rs1993552	Human NCBI Build 35	6	6165028 F13A1	
2637	-	6679	A/G	0	394462	rs2000467	Human NCBI Build 35	22	22566087	MIF
2638	-	6681	A/G	0	394464	rs2017946	Human NCBI Build 35	18	8348871 PTPRM	
2639	-	6685	A/G	0	394467	rs2026742	Human NCBI Build 35	9	87392809	DAPK1
2640	-	6686	A/G	0	394468	rs2027311	Human NCBI Build 35	6	128676927	PTPRK
2641	-	6692	A/G	1	394472	rs2043136	Human NCBI Build 35	3	30695308	TGFBR2
2642	-	6693	A/G	1	394473	rs2048640	Human NCBI Build 35	15	97122498	IGF1R
2643	-	6694	A/G	0	394474	rs2051322	Human NCBI Build 35	18	65701566	CD226
2644	-	6703	A/G	0	394483	rs2071749	Human NCBI Build 35	22	34107967	HMOX1
2645	-	6714	A/G	0	394493	rs2125231	Human NCBI Build 35	1	240088340	AKT3
2646	-	6716	A/G	1	394494	rs2159776	Human NCBI Build 35	9	120835714	C5
2647	-	6717	A/G	0	394495	rs2179634	Human NCBI Build 35	1	204451462	CD34
2648	-	6723	A/G	0	394500	rs2227507	Human NCBI Build 35	12	66928914	IL22
2649	-	6729	A/G	0	394504	rs2232351	Human NCBI Build 35	3	53874239	IL17RB-ACTR8
2650	-	6730	A/G	0	394505	rs2232565	Human NCBI Build 35	12	47249288	LALBA
2651	-	6733	A/G	0	394507	rs2235133	Human NCBI Build 35	21	45145600	ITGB2
2652	-	6739	A/G	0	394512	rs2239695	Human NCBI Build 35	11	117718842	CD3G-CD3D
2653	-	6740	A/G	0	394513	rs2239907	Human NCBI Build 35	17	23749871	SARM1-ENSG00000076351
2654	-	6743	A/G	0	394515	rs2242656	Human NCBI Build 35	6	31722081	BAT3
2655	-	6750	A/G	1	394522	rs2268890	Human NCBI Build 35	2	162697999	DPP4

2656	-	6753	A/G	0	394525	rs2275472	Human NCBI Build 35	1	36603760	CSF3R-MRPS15
2657	-	6757	A/G	0	394529	rs2278345	Human NCBI Build 35	12	69221228	PTPRB
2658	-	6759	A/G	0	394531	rs2280375	Human NCBI Build 35	8	27373254	PTK2B-CHRNA2
2659	-	6768	A/G	0	394539	rs2300747	Human NCBI Build 35	1	116816257	CD58
2661	-	6771	A/G	0	394542	rs2303962	Human NCBI Build 35	12	69239723	PTPRB
2662	-	6775	A/G	1	394545	rs231779	Human NCBI Build 35	2	204559993	CTLA4
2663	-	6776	A/G	0	394546	rs2338873	Human NCBI Build 35	5	169641269	LCP2-ENSG00000198424
2664	-	6778	A/G	1	394547	rs233998	Human NCBI Build 35	3	173726448	TNFSF10
2665	-	6786	A/G	0	394554	rs2387356	Human NCBI Build 35	13	27568595	FLT3
2666	-	6789	A/G	1	394557	rs2426299	Human NCBI Build 35	20	49451402	NFATC2
2667	-	6790	A/G	0	394558	rs2427829	Human NCBI Build 35	1	156095084	FCER1A-ENSG00000196266
2668	-	6794	A/G	0	394562	rs2476601	Human NCBI Build 35	1	114089610	PTPN22
2669	-	6795	A/G	0	394563	rs2493163	Human NCBI Build 35	1	222438426	ENSG00000143768
2670	-	6799	A/G	0	394567	rs2509963	Human NCBI Build 35	11	61949507	SCGB1A1
2671	-	6801	A/G	1	394569	rs2524005	Human NCBI Build 35	6	30007656	HLA-G-ENSG00000181573
2673	-	6804	A/G	1	394572	rs253826	Human NCBI Build 35	12	15514784	PTPRO
2674	-	6807	A/G	0	394575	rs2546890	Human NCBI Build 35	5	158692478	IL12B
2675	-	6809	A/G	0	394577	rs256991	Human NCBI Build 35	5	114939814	TICAM2
2676	-	6811	A/G	0	394579	rs2584021	Human NCBI Build 35	12	69316000	PTPRB-PTPRR
2677	-	6813	A/G	0	394581	rs2602477	Human NCBI Build 35	11	76825118	PAK1
2678	-	6817	A/G	0	394585	rs261632	Human NCBI Build 35	5	169190568	DOCK2
2679	-	6819	A/G	0	394587	rs262838	Human NCBI Build 35	5	169107272	DOCK2
2680	-	6821	A/G	1	394589	rs2646076	Human NCBI Build 35	4	140974479	MGST2-ENSG00000170202
2681	-	6825	A/G	1	394593	rs2684792	Human NCBI Build 35	15	97305604	IGF1R
2682	-	6826	A/G	0	394594	rs2684796	Human NCBI Build 35	15	97300915	IGF1R
2683	-	6827	A/G	1	394595	rs2690271	Human NCBI Build 35	7	121199677	PTPRZ1
2684	-	6828	A/G	0	394596	rs2705881	Human NCBI Build 35	4	185947874	CASP3-ENSG00000164306
2685	-	6830	A/G	0	394598	rs2729749	Human NCBI Build 35	11	76776618	PAK1
2686	-	6832	A/G	1	394599	rs2740170	Human NCBI Build 35	1	222331532	EPHX1
2687	-	6835	A/G	0	394602	rs2772546	Human NCBI Build 35	9	34658546	CCL27
2688	-	6839	A/G	0	394606	rs2808428	Human NCBI Build 35	1	27680280	G1P3
2689	-	6843	A/G	0	394609	rs2853618	Human NCBI Build 35	1	233025074	LGALS8
2691	-	6849	A/G	1	394615	rs289834	Human NCBI Build 35	2	151957638	NMI
2692	-	6851	A/G	0	394617	rs290235	Human NCBI Build 35	9	90654953	SYK
2693	-	6863	A/G	0	394628	rs307805	Human NCBI Build 35	5	180010093	FLT4
2695	-	6867	A/G	0	394632	rs3118873	Human NCBI Build 35	9	87493880	DAPK1
2697	-	6875	A/G	1	394638	rs3181096	Human NCBI Build 35	2	204395598	CD28
2698	-	6882	A/G	0	394645	rs34022	Human NCBI Build 35	5	141984492	FGF1
2701	-	6897	A/G	0	394656	rs3746972	Human NCBI Build 35	21	45152263	ITGB2
2702	-	6899	A/G	0	394657	rs3747517	Human NCBI Build 35	2	162954331	IFIH1
2703	-	6901	A/G	1	394659	rs3750773	Human NCBI Build 35	10	71553498	AMID
2704	-	6907	A/G	0	394664	rs3755459	Human NCBI Build 35	2	75233258	TACR1
2705	-	6908	A/G	1	394665	rs3755463	Human NCBI Build 35	2	75236127	TACR1
2706	-	6911	A/G	0	394668	rs3766526	Human NCBI Build 35	1	143187681	CD160
2707	-	6915	A/G	0	394672	rs3771172	Human NCBI Build 35	2	102444330	IL18R1
2708	-	6918	A/G	0	394675	rs3775574	Human NCBI Build 35	4	185745215	IRF2
2709	-	6921	A/G	1	394678	rs3780286	Human NCBI Build 35	9	130762252	ABL1
2710	-	6922	A/G	0	394679	rs3782347	Human NCBI Build 35	12	64918183	IRAK3
2712	-	6928	A/G	0	394685	rs3787201	Human NCBI Build 35	20	49513738	NFATC2

2713	-	6930	A/G	0	394687	rs3790568	Human NCBI Build 35	1	67548081	IL12RB2
2714	-	6933	A/G	0	394689	rs3791578	Human NCBI Build 35	2	239853313	HDAC4
2715	-	6934	A/G	0	394690	rs3793647	Human NCBI Build 35	9	87548409	DAPK1
2716	-	6938	A/G	0	394693	rs3799924	Human NCBI Build 35	6	14236320	CD83
2717	-	6941	A/G	0	394695	rs3804476	Human NCBI Build 35	6	6570703 LY86	
2718	-	6942	A/G	0	394696	rs3804486	Human NCBI Build 35	6	6582994 LY86	
2720	-	6947	A/G	0	394701	rs3813948	Human NCBI Build 35	1	203658253	C4BPB
2722	-	6964	A/G	1	394717	rs3901648	Human NCBI Build 35	18	65695697	CD226
2723	-	6966	A/G	0	394718	rs3902966	Human NCBI Build 35	1	211017672	PTPN14
2725	-	6971	A/G	0	394723	rs3924547	Human NCBI Build 35	9	89292820	SEMA4D
2726	-	6979	A/G	0	394731	rs4129009	Human NCBI Build 35	4	38597455	TLR10
2727	-	6982	A/G	0	394733	rs4243449	Human NCBI Build 35	6	137064415	MAP3K5
2728	-	6986	A/G	1	394737	rs4321646	Human NCBI Build 35	4	38606530	TLR10
2729	-	6989	A/G	0	394740	rs4371263	Human NCBI Build 35	18	58154336	TNFRSF11A
2730	-	6993	A/G	1	394744	rs4426332	Human NCBI Build 35	15	97040118	IGF1R
2731	-	6995	A/G	0	394746	rs4439987	Human NCBI Build 35	2	75198761	TACR1
2732	-	6996	A/G	0	394747	rs4440115	Human NCBI Build 35	3	62106731	PTPRG
2733	-	7000	A/G	0	394749	rs4519913	Human NCBI Build 35	5	147452004	SPINK5
2734	-	7001	A/G	0	394750	rs452223	Human NCBI Build 35	5	156544071	ITK
2735	-	7002	A/G	1	394751	rs4543590	Human NCBI Build 35	8	141795016	PTK2
2737	-	7004	A/G	0	394753	rs4584412	Human NCBI Build 35	1	100893597	VCAM1
2738	-	7011	A/G	0	394758	rs4663882	Human NCBI Build 35	2	239052148	none
2739	-	7015	A/G	1	394762	rs4675374	Human NCBI Build 35	2	204628084	ICOS
2740	-	7017	A/G	0	394764	rs4689977	Human NCBI Build 35	4	5140568 ENSG00000170891	
2741	-	7028	A/G	0	394774	rs4778636	Human NCBI Build 35	15	79378694	IL16
2742	-	7033	A/G	0	394778	rs4798615	Human NCBI Build 35	18	8184433 PTPRM	
2743	-	7035	A/G	0	394780	rs4802131	Human NCBI Build 35	19	47293152	POU2F2
2744	-	7036	A/G	1	394781	rs4802863	Human NCBI Build 35	19	56960784	FPRL1
2745	-	7040	A/G	0	394784	rs4848908	Human NCBI Build 35	2	112439348	MERTK
2746	-	7044	A/G	0	394788	rs4879913	Human NCBI Build 35	7	150212954	
C7orf21-ENSG00000164896-SLC4A2										
2747	-	7046	A/G	0	394790	rs4894559	Human NCBI Build 35	3	173716071	TNFSF10
2748	-	7049	A/G	1	394793	rs4934540	Human NCBI Build 35	10	35514705	CREM
2749	-	7050	A/G	1	394794	rs4939992	Human NCBI Build 35	18	46406082	MAPK4
2750	-	7051	A/G	0	394795	rs4956404	Human NCBI Build 35	4	142981897	IL15
2751	-	7053	A/G	0	394797	rs4957018	Human NCBI Build 35	5	367011 AHRR	
2752	-	7056	A/G	0	394799	rs4961237	Human NCBI Build 35	8	141971675	PTK2
2753	-	7058	A/G	0	394801	rs4987852	Human NCBI Build 35	18	58944901	BCL2
2754	-	7059	A/G	0	394802	rs5021634	Human NCBI Build 35	2	109040875	EDAR
2755	-	7060	A/G	0	394803	rs5023688	Human NCBI Build 35	6	74553873	CD109
2756	-	7062	A/G	0	394805	rs5030552	Human NCBI Build 35	4	110976610	CASP6
2757	-	7071	A/G	0	394813	rs5750807	Human NCBI Build 35	22	20925466	VPREB1
2758	-	7076	A/G	0	394818	rs6030447	Human NCBI Build 35	20	40794378	PTPRT
2759	-	7084	A/G	0	394825	rs609412	Human NCBI Build 35	5	146205437	PPP2R2B
2760	-	7085	A/G	0	394826	rs6102934	Human NCBI Build 35	20	40667515	PTPRT
2761	-	7089	A/G	0	394829	rs615739	Human NCBI Build 35	1	89355665	GBP4-GBP2
2764	-	7100	A/G	0	394838	rs6459797	Human NCBI Build 35	7	156864582	PTPRN2
2765	-	7101	A/G	1	394839	rs6490812	Human NCBI Build 35	13	23101027	TNFRSF19
2766	-	7102	A/G	1	394840	rs6503691	Human NCBI Build 35	17	37647616	STAT5B

2767	-	7106	A/G	0	394843	rs6543518	Human NCBI Build 35	2	239880539	HDAC4
2768	-	7107	A/G	1	394844	rs658560	Human NCBI Build 35	11	104344432	CASP4
2769	-	7125	A/G	0	394861	rs6743144	Human NCBI Build 35	2	45938552	PRKCE
2770	-	7130	A/G	0	394864	rs6759058	Human NCBI Build 35	2	45912137	PRKCE
2771	-	7132	A/G	0	394866	rs6785764	Human NCBI Build 35	3	62196081	PTPRG
2772	-	7136	A/G	0	394870	rs6862038	Human NCBI Build 35	5	38632225	LIFR
2773	-	7137	A/G	0	394871	rs6874087	Human NCBI Build 35	5	149447856	CSF1R
2775	-	7145	A/G	0	394877	rs693293	Human NCBI Build 35	3	139891874	PIK3CB
2776	-	7148	A/G	0	394880	rs700221	Human NCBI Build 35	5	39392932	C9
2777	-	7149	A/G	0	394881	rs7017417	Human NCBI Build 35	8	27401222	EPHX2
2779	-	7153	A/G	0	394884	rs7046918	Human NCBI Build 35	9	8524385	PTPRD
2780	-	7155	A/G	0	394885	rs706128	Human NCBI Build 35	9	33301100	NFX1-ENSG00000086065
2781	-	7156	A/G	0	394886	rs706779	Human NCBI Build 35	10	6138830	IL2RA
2782	-	7163	A/G	0	394893	rs7190307	Human NCBI Build 35	16	66775837	NFATC3
2783	-	7164	A/G	0	394894	rs719250	Human NCBI Build 35	2	102082236	IL1R2
2784	-	7167	A/G	0	394896	rs7232952	Human NCBI Build 35	18	8237249	PTPRM
2785	-	7173	A/G	0	394900	rs726657	Human NCBI Build 35	9	114775890	TNFSF8
2786	-	7178	A/G	0	394905	rs7327579	Human NCBI Build 35	13	27513835	FLT3
2787	-	7180	A/G	0	394907	rs7357894	Human NCBI Build 35	X	123205534	SH2D1A
2788	-	7182	A/G	0	394909	rs737921	Human NCBI Build 35	22	28964768	LIF-ENSG00000185188
2789	-	7186	A/G	0	394912	rs743660	Human NCBI Build 35	Multiple	0	CCR2-CCR2
2790	-	7190	A/G	0	394915	rs7486905	Human NCBI Build 35	12	105662636	RFX4
2791	-	7193	A/G	1	394917	rs752252	Human NCBI Build 35	15	64512669	MAP2K1
2792	-	7194	A/G	0	394918	rs7527297	Human NCBI Build 35	1	195377263	PTPRC
2793	-	7195	A/G	0	394919	rs7543972	Human NCBI Build 35	1	210918181	PTPN14
2795	-	7202	A/G	0	394925	rs7578701	Human NCBI Build 35	2	239048220	none
2796	-	7208	A/G	0	394929	rs7604415	Human NCBI Build 35	2	46285180	PRKCE
2797	-	7213	A/G	0	394933	rs763317	Human NCBI Build 35	7	54869406	EGFR
2798	-	7217	A/G	0	394936	rs7651901	Human NCBI Build 35	3	106651945	ALCAM
2799	-	7219	A/G	1	394938	rs7677486	Human NCBI Build 35	4	185712001	IRF2
2800	-	7220	A/G	0	394939	rs7689036	Human NCBI Build 35	4	111411256	EGF-ELOVL6
2801	-	7227	A/G	0	394945	rs7748513	Human NCBI Build 35	6	41235950	ENSG00000095970
2802	-	7230	A/G	0	394948	rs7810832	Human NCBI Build 35	7	157329822	PTPRN2
2803	-	7232	A/G	0	394950	rs7842	Human NCBI Build 35	12	8102454	FOXJ2-C3AR1
2804	-	7238	A/G	0	394954	rs7870438	Human NCBI Build 35	9	8550363	PTPRD
2805	-	7243	A/G	0	394957	rs7916556	Human NCBI Build 35	10	6625420	PRKCQ
2806	-	7250	A/G	1	394963	rs7975614	Human NCBI Build 35	12	12224109	LRP6-BCL2L14
2807	-	7259	A/G	1	394971	rs8192111	Human NCBI Build 35	4	140982286	MGST2-ENSG00000170202
2809	-	7266	A/G	1	394977	rs861475	Human NCBI Build 35	1	204439783	CD34
2810	-	7275	A/G	0	394984	rs8832	Human NCBI Build 35	16	27283288	IL4R
2812	-	7284	A/G	0	394993	rs916346	Human NCBI Build 35	6	36196233	MAPK13
2813	-	7290	A/G	1	394998	rs9286999	Human NCBI Build 35	1	222801250	LIN9
2814	-	7292	A/G	0	395000	rs9302690	Human NCBI Build 35	16	56000469	CCL17
2815	-	7296	A/G	0	395004	rs935656	Human NCBI Build 35	2	45976508	PRKCE
2816	-	7298	A/G	0	395006	rs9387040	Human NCBI Build 35	6	112238271	FYN
2817	-	7300	A/G	0	395008	rs9402839	Human NCBI Build 35	6	137036903	MAP3K5
2818	-	7301	A/G	0	395009	rs940339	Human NCBI Build 35	2	228510767	CCL20-ENSG00000197218
2819	-	7304	A/G	0	395012	rs9491896	Human NCBI Build 35	6	128342642	PTPRK
2820	-	7305	A/G	1	395013	rs9491948	Human NCBI Build 35	6	128805163	PTPRK

2821	-	7309	A/G	1	395015	rs9501919	Human NCBI Build 35	6	3033939	RIPK1
2822	-	7314	A/G	1	395018	rs955155	Human NCBI Build 35	19	44421319	IL28B
2823	-	7315	A/G	0	395019	rs9607287	Human NCBI Build 35	22	20487979	MAPK1
2824	-	7322	A/G	0	395025	rs9827942	Human NCBI Build 35	3	61957110	PTPRG
2826	-	7328	A/G	0	395031	rs9874660	Human NCBI Build 35	3	61906393	PTPRG
2827	-	7330	A/G	1	395033	rs9914497	Human NCBI Build 35	17	38262971	AOC3
2828	-	7331	A/G	1	395034	rs9924831	Human NCBI Build 35	16	23848239	PRKCB1
2829	-	7335	A/G	1	395038	rs1006025	Human NCBI Build 35	9	114770755	TNFSF8
2830	-	7338	A/G	0	395041	rs1009897	Human NCBI Build 35	1	204451900	CD34
2831	-	7339	A/G	0	395042	rs1012049	Human NCBI Build 35	6	128572000	PTPRK
2832	-	7343	A/G	0	395046	rs1018199	Human NCBI Build 35	4	47927632	TXK
2833	-	7348	A/G	0	395050	rs1023532	Human NCBI Build 35	3	62016923	PTPRG
2834	-	7349	A/G	0	395051	rs10244108	Human NCBI Build 35	7	54926546	EGFR
2835	-	7354	A/G	1	395056	rs10284203	Human NCBI Build 35	X	123233685	SH2D1A
2836	-	7357	A/G	0	395059	rs1036200	Human NCBI Build 35	5	156464443	HAVCR2
2837	-	7359	A/G	0	395061	rs1036751	Human NCBI Build 35	8	79804461	IL7
2838	-	7361	A/G	0	395063	rs1040023	Human NCBI Build 35	12	69499744	PTPRR
2839	-	7366	A/G	0	395068	rs1043526	Human NCBI Build 35	5	67630080	PIK3R1
2840	-	7370	A/G	1	395072	rs10484479	Human NCBI Build 35	6	111983678	C6orf4
2841	-	7372	A/G	0	395074	rs10489268	Human NCBI Build 35	1	169893875	TNFSF4
2842	-	7374	A/G	0	395076	rs10489629	Human NCBI Build 35	1	67400370	IL23R
2843	-	7376	A/G	0	395078	rs10489637	Human NCBI Build 35	1	157465549	CD48
2844	-	7378	A/G	0	395079	rs10490570	Human NCBI Build 35	2	102286257	IL1RL2
2845	-	7380	A/G	0	395080	rs10490774	Human NCBI Build 35	3	62035910	PTPRG
2846	-	7382	A/G	0	395082	rs10491070	Human NCBI Build 35	10	97943276	BLNK
2847	-	7383	A/G	0	395083	rs10492796	Human NCBI Build 35	16	23997254	PRKCB1
2848	-	7384	A/G	1	395084	rs10494133	Human NCBI Build 35	1	111566730	ENSG00000134216
2850	-	7397	A/G	0	395095	rs10507036	Human NCBI Build 35	12	93165215	PLXNC1
2852	-	7407	A/G	0	395105	rs10516782	Human NCBI Build 35	4	88048177	PTPN13
2853	-	7410	A/G	0	395108	rs10752351	Human NCBI Build 35	10	6628023	PRKCQ
2854	-	7412	A/G	0	395110	rs10777585	Human NCBI Build 35	12	93089181	PLXNC1
2855	-	7415	A/G	1	395113	rs10823258	Human NCBI Build 35	10	70201223	CCAR1
2856	-	7418	A/G	0	395116	rs10846178	Human NCBI Build 35	12	15499132	PTPRO
2857	-	7422	A/G	0	395119	rs10861641	Human NCBI Build 35	12	105535514	RFX4
2858	-	7423	A/G	0	395120	rs10878791	Human NCBI Build 35	12	66895313	IL26
2859	-	7429	A/G	0	395125	rs10976946	Human NCBI Build 35	9	8310978	PTPRD
2860	-	7437	A/G	1	395131	rs11120309	Human NCBI Build 35	1	210959365	PTPN14
2861	-	7441	A/G	0	395133	rs11158528	Human NCBI Build 35	14	63629073	SYNE2-ESR2
2862	-	7442	A/G	0	395134	rs11167010	Human NCBI Build 35	8	142023392	PTK2
2863	-	7445	A/G	1	395136	rs11203109	Human NCBI Build 35	10	91147139	IFIT1
2864	-	7446	A/G	0	395137	rs1121276	Human NCBI Build 35	1	240036448	AKT3
2865	-	7447	A/G	0	395138	rs11237451	Human NCBI Build 35	11	77703107	GAB2
2866	-	7455	A/G	0	395144	rs1152888	Human NCBI Build 35	12	64891495	IRAK3
2867	-	7456	A/G	1	395145	rs11538	Human NCBI Build 35	22	16595385	BID
2868	-	7461	A/G	0	395150	rs11643240	Human NCBI Build 35	16	68193417	NFAT5
2869	-	7463	A/G	0	395152	rs11672983	Human NCBI Build 35	19	60074863	FCAR-KIR3DL2
2870	-	7470	A/G	0	395159	rs11814042	Human NCBI Build 35	10	115439466	CASP7
2871	-	7471	A/G	0	395160	rs11875184	Human NCBI Build 35	18	58980533	BCL2
2872	-	7475	A/G	1	395163	rs12001153	Human NCBI Build 35	9	21338719	IFNA6

2873	-	7480	A/G	0	395167	rs12064925	Human NCBI Build 35	1	157616921	CD244
2874	-	7483	A/G	0	395170	rs12090545	Human NCBI Build 35	1	50906005	FAF1
2875	-	7485	A/G	0	395171	rs120909	Human NCBI Build 35	16	23898407	PRKCB1
2876	-	7491	A/G	0	395176	rs12302585	Human NCBI Build 35	12	7045308	C1S
2877	-	7493	A/G	0	395177	rs12329487	Human NCBI Build 35	20	3532784	ATRN
2878	-	7494	A/G	1	395178	rs1234220	Human NCBI Build 35	10	89635453	ENSG00000171862
2879	-	7506	A/G	0	395185	rs1255986	Human NCBI Build 35	14	63724914	SYNE2-ESR2
2880	-	7510	A/G	0	395188	rs12564400	Human NCBI Build 35	1	3823275	DFFB
2881	-	7511	A/G	0	395189	rs12578067	Human NCBI Build 35	11	43285190	API5
2882	-	7512	A/G	0	395190	rs12633488	Human NCBI Build 35	3	106565233	ALCAM
2883	-	7528	A/G	0	395201	rs1321390	Human NCBI Build 35	X	104399171	IL1RAPL2
2884	-	7529	A/G	0	395202	rs1322067	Human NCBI Build 35	9	114740487	TNFSF8
2885	-	7534	A/G	0	395206	rs1329119	Human NCBI Build 35	1	89286047	GBP2-ENSG00000162644
2886	-	7537	A/G	0	395208	rs1329423	Human NCBI Build 35	1	193378044	CFH
2887	-	7540	A/G	0	395211	rs13329844	Human NCBI Build 35	16	68236336	NFAT5
2888	-	7542	A/G	0	395213	rs1348407	Human NCBI Build 35	18	7839169	PTPRM
2889	-	7545	A/G	0	395215	rs1352883	Human NCBI Build 35	3	62206359	PTPRG
2890	-	7546	A/G	0	395216	rs1362218	Human NCBI Build 35	7	157069931	PTPRN2-ENSG00000197192
2891	-	7551	A/G	0	395220	rs1388612	Human NCBI Build 35	3	62219484	PTPRG
2892	-	7557	A/G	1	395226	rs1439123	Human NCBI Build 35	12	97578784	APAF1
2893	-	7559	A/G	0	395228	rs1460753	Human NCBI Build 35	4	87580647	MAPK10
2894	-	7565	A/G	1	395234	rs1530549	Human NCBI Build 35	2	113533686	IL1F5
2895	-	7570	A/G	0	395238	rs1550134	Human NCBI Build 35	18	65699462	CD226
2896	-	7571	A/G	0	395239	rs1561560	Human NCBI Build 35	12	8654230	AICDA
2898	-	7575	A/G	0	395241	rs1571535	Human NCBI Build 35	9	89445288	GADD45G
2899	-	7577	A/G	0	395243	rs159279	Human NCBI Build 35	17	29716300	CCL1
2900	-	7580	A/G	0	395244	rs160971	Human NCBI Build 35	5	146195901	PPP2R2B
2901	-	7581	A/G	1	395245	rs161041	Human NCBI Build 35	5	146165144	PPP2R2B
2902	-	7595	A/G	0	395254	rs1697845	Human NCBI Build 35	5	75958260	F2RL2-IQGAP2
2903	-	7596	A/G	0	395255	rs17101661	Human NCBI Build 35	14	63634433	SYNE2-ESR2
2904	-	7598	A/G	0	395257	rs1742930	Human NCBI Build 35	6	6173405	F13A1
2905	-	7599	A/G	0	395258	rs174383	Human NCBI Build 35	6	112021393	C6orf4
2906	-	7600	A/G	0	395259	rs17610	Human NCBI Build 35	9	120816699	C5
2907	-	7602	A/G	0	395260	rs1768360	Human NCBI Build 35	6	128645054	PTPRK
2908	-	7603	A/G	0	395261	rs1781795	Human NCBI Build 35	6	6186280	F13A1
2909	-	7606	A/G	0	395263	rs1788234	Human NCBI Build 35	18	65717567	CD226
2910	-	7610	A/G	0	395266	rs1819814	Human NCBI Build 35	7	76820630	PTPN12
2911	-	7611	A/G	0	395267	rs1831281	Human NCBI Build 35	1	193412471	CFH
2912	-	7612	A/G	0	395268	rs1837559	Human NCBI Build 35	4	75324128	CXCL2
2913	-	7613	A/G	0	395269	rs1838066	Human NCBI Build 35	10	54199331	MBL2
2914	-	7615	A/G	0	395271	rs1867	Human NCBI Build 35	9	88849338	C9orf47
2915	-	7616	A/G	1	395272	rs1871047	Human NCBI Build 35	19	50043586	ENSG00000130202
2917	-	7621	A/G	1	395277	rs188334	Human NCBI Build 35	6	44330988	
HSPCB-NFKBIE-ENSG00000157593										
2918	-	7628	A/G	0	395281	rs1892174	Human NCBI Build 35	1	161379351	PBX1-ENSG00000197613
2920	-	7634	A/G	1	395286	rs1922452	Human NCBI Build 35	12	6766455	CD4
2921	-	7639	A/G	0	395289	rs1935780	Human NCBI Build 35	1	117450679	ENSG00000134258
2922	-	7644	A/G	0	395293	rs1999713	Human NCBI Build 35	1	110162219	CSF1
2924	-	7648	A/G	0	395296	rs2023906	Human NCBI Build 35	17	35967212	CCR7

2925	-	7650	A/G	0	395298	rs2034002	Human NCBI Build 35	4	77462353	SCARB2
2926	-	7653	A/G	0	395300	rs2040410	Human NCBI Build 35	6	32710676	ENSG00000196735
2927	-	7660	A/G	1	395305	rs2076249	Human NCBI Build 35	20	40177623	PTPR
2930	-	7670	A/G	0	395313	rs2127355	Human NCBI Build 35	10	62204222	CDC2
2931	-	7672	A/G	0	395315	rs216124	Human NCBI Build 35	5	149442202	CSF1R
2932	-	7673	A/G	0	395316	rs2184978	Human NCBI Build 35	9	8528919	PTPRD
2933	-	7676	A/G	1	395317	rs2200287	Human NCBI Build 35	13	42066660	TNFSF11
2934	-	7681	A/G	1	395321	rs2227617	Human NCBI Build 35	1	170605716	SERPINC1
2935	-	7683	A/G	0	395323	rs2227973	Human NCBI Build 35	11	36553889	RAG1
2937	-	7689	A/G	0	395328	rs2239182	Human NCBI Build 35	12	46541678	VDR
2938	-	7693	A/G	0	395332	rs2240184	Human NCBI Build 35	12	111907263	OAS2
2939	-	7694	A/G	1	395333	rs2241004	Human NCBI Build 35	9	120861692	C5
2940	-	7696	A/G	0	395335	rs2241716	Human NCBI Build 35	19	46545926	TGFB1-ENSG00000188054
2941	-	7699	A/G	0	395337	rs2249707	Human NCBI Build 35	1	156736032	SLAMF9
2942	-	7704	A/G	0	395342	rs2270777	Human NCBI Build 35	6	32259200	PBX2-AGER-RNF5
2943	-	7707	A/G	0	395344	rs2275913	Human NCBI Build 35	6	52158992	IL17
2944	-	7710	A/G	0	395347	rs2282659	Human NCBI Build 35	11	104402647	CASP1
2945	-	7712	A/G	0	395349	rs2284191	Human NCBI Build 35	6	33084632	HLA-DOA
2946	-	7718	A/G	0	395352	rs2291333	Human NCBI Build 35	12	93123526	PLXNC1
2947	-	7722	A/G	1	395354	rs2295663	Human NCBI Build 35	6	31777274	BAT5
2949	-	7724	A/G	0	395356	rs2296095	Human NCBI Build 35	9	8410902	PTPRD
2950	-	7725	A/G	1	395357	rs2297137	Human NCBI Build 35	9	5455732	ENSG00000120217
2951	-	7726	A/G	1	395358	rs2297301	Human NCBI Build 35	14	63713958	SYNE2-ESR2
2952	-	7733	A/G	0	395363	rs2304238	Human NCBI Build 35	19	10310202	ICAM3-ENSG00000161847
2953	-	7741	A/G	0	395369	rs2366684	Human NCBI Build 35	3	62099518	PTPRG
2954	-	7745	A/G	1	395372	rs2426309	Human NCBI Build 35	20	49469152	NFATC2
2955	-	7747	A/G	1	395374	rs243842	Human NCBI Build 35	16	54084923	MMP2
2956	-	7748	A/G	0	395375	rs2458439	Human NCBI Build 35	12	69495562	PTPRR
2957	-	7765	A/G	0	395386	rs2613310	Human NCBI Build 35	9	90710000	SYK
2958	-	7766	A/G	1	395387	rs2617170	Human NCBI Build 35	12	10452224	KLRC4
2959	-	7776	A/G	0	395397	rs2670509	Human NCBI Build 35	15	97202432	IGF1R
2960	-	7777	A/G	0	395398	rs2684941	Human NCBI Build 35	15	32119074	AVEN
2961	-	7782	A/G	0	395402	rs2715261	Human NCBI Build 35	3	123281267	CD86
2962	-	7786	A/G	1	395404	rs2725829	Human NCBI Build 35	11	76733434	PAK1
2963	-	7788	A/G	0	395406	rs2735024	Human NCBI Build 35	6	29900467	HLA-G
2964	-	7801	A/G	0	395416	rs2839664	Human NCBI Build 35	10	31831507	TCF8
2966	-	7806	A/G	0	395420	rs2869460	Human NCBI Build 35	4	77278993	CXCL9
2967	-	7811	A/G	0	395424	rs2894798	Human NCBI Build 35	6	52165609	IL17
2968	-	7812	A/G	0	395425	rs290238	Human NCBI Build 35	9	90654049	SYK
2969	-	7813	A/G	0	395426	rs2984921	Human NCBI Build 35	1	189283281	RGS1
2970	-	7815	A/G	0	395428	rs3007716	Human NCBI Build 35	1	222432352	ENSG00000143768
2971	-	7817	A/G	0	395430	rs3024530	Human NCBI Build 35	16	27258188	IL4R
2972	-	7822	A/G	0	395435	rs311309	Human NCBI Build 35	1	204023482	CR2
2973	-	7828	A/G	1	395440	rs315936	Human NCBI Build 35	2	113597178	IL1RN
2974	-	7831	A/G	0	395442	rs3181353	Human NCBI Build 35	9	114773054	TNFSF8
2975	-	7832	A/G	0	395443	rs3204850	Human NCBI Build 35	Multiple	0	CCRL2-ENSG00000188268
2976	-	7833	A/G	0	395444	rs3211821	Human NCBI Build 35	7	79923214	CD36
2977	-	7841	A/G	0	395452	rs34309	Human NCBI Build 35	5	67600139	PIK3R1
2978	-	7846	A/G	1	395457	rs355686	Human NCBI Build 35	4	78862551	CXCL13

2979	-	7848	A/G	1	395459	rs360722	Human NCBI Build 35	11	111531913	IL18
2980	-	7850	A/G	0	395461	rs3729740	Human NCBI Build 35	5	38532394	LIFR
2981	-	7855	A/G	1	395466	rs3741457	Human NCBI Build 35	12	87428718	KITLG
2982	-	7858	A/G	0	395469	rs3750050	Human NCBI Build 35	7	76901364	PTPN12
2983	-	7863	A/G	0	395472	rs3754573	Human NCBI Build 35	2	46238394	PRKCE
2984	-	7866	A/G	0	395475	rs3759992	Human NCBI Build 35	12	120919707	
BCL7A-ENSG00000180645-ENSG00000197247										
2985	-	7869	A/G	1	395477	rs3765892	Human NCBI Build 35	1	71192615	PTGER3
2986	-	7872	A/G	1	395479	rs3767364	Human NCBI Build 35	1	161522192	PBX1
2987	-	7875	A/G	1	395482	rs3768753	Human NCBI Build 35	2	46254430	PRKCE
2988	-	7877	A/G	1	395484	rs3769687	Human NCBI Build 35	2	204422011	CD28
2990	-	7882	A/G	0	395489	rs3773663	Human NCBI Build 35	3	30705876	TGFBR2
2991	-	7884	A/G	0	395491	rs3773777	Human NCBI Build 35	3	32513251	CKLFSF6
2992	-	7886	A/G	1	395492	rs3773965	Human NCBI Build 35	3	191789874	IL1RAP
2993	-	7888	A/G	0	395494	rs3775582	Human NCBI Build 35	4	185763636	IRF2
2995	-	7894	A/G	0	395498	rs3786153	Human NCBI Build 35	18	7945525	PTPRM
2996	-	7899	A/G	1	395503	rs3794110	Human NCBI Build 35	11	35148790	CD44
2997	-	7904	A/G	0	395507	rs3798309	Human NCBI Build 35	6	167393953	CCR6-ENSG00000187485
2998	-	7908	A/G	0	395510	rs3808816	Human NCBI Build 35	9	130775671	ABL1
2999	-	7910	A/G	0	395512	rs3820142	Human NCBI Build 35	1	150088398	PGLYRP3
3000	-	7912	A/G	0	395513	rs3824432	Human NCBI Build 35	9	5081675	JAK2
3001	-	7914	A/G	0	395514	rs3827731	Human NCBI Build 35	1	50699848	FAF1
3002	-	7916	A/G	0	395515	rs3827763	Human NCBI Build 35	2	113547520	IL1F10
3003	-	7917	A/G	0	395516	rs3851514	Human NCBI Build 35	6	6219569	F13A1
3004	-	7924	A/G	0	395522	rs4073699	Human NCBI Build 35	2	191804865	STAT4
3005	-	7927	A/G	0	395524	rs4075311	Human NCBI Build 35	10	97564645	ENTPD1
3006	-	7928	A/G	0	395525	rs4131744	Human NCBI Build 35	10	129725983	PTPRE
3007	-	7931	A/G	0	395527	rs4220	Human NCBI Build 35	4	155849364	FGB-FGA
3008	-	7934	A/G	1	395529	rs4242391	Human NCBI Build 35	8	23056128	TNFRSF10D-ENSG00000147457
3009	-	7940	A/G	0	395533	rs4251545	Human NCBI Build 35	12	42466562	ENSG00000198001
3010	-	7941	A/G	0	395534	rs4253662	Human NCBI Build 35	22	44893263	PPARA
3011	-	7943	A/G	0	395536	rs4273617	Human NCBI Build 35	5	42731228	GHR
3012	-	7946	A/G	1	395538	rs4330872	Human NCBI Build 35	1	24221676	IL28RA
3013	-	7954	A/G	0	395544	rs4602070	Human NCBI Build 35	17	3632715	ITGAE
3014	-	7955	A/G	0	395545	rs4623354	Human NCBI Build 35	7	157674632	PTPRN2
3015	-	7958	A/G	0	395548	rs4649932	Human NCBI Build 35	1	71060197	PTGER3
3016	-	7960	A/G	0	395550	rs4663886	Human NCBI Build 35	2	239072648	none
3017	-	7963	A/G	1	395553	rs4742097	Human NCBI Build 35	9	5445632	ENSG00000120217
3018	-	7968	A/G	0	395556	rs4764212	Human NCBI Build 35	12	15637310	PTPRO
3019	-	7972	A/G	0	395559	rs4788426	Human NCBI Build 35	16	23931809	PRKCB1
3020	-	7973	A/G	0	395560	rs4798592	Human NCBI Build 35	18	7737873	PTPRM
3021	-	7977	A/G	0	395564	rs4823613	Human NCBI Build 35	22	44918826	PPARA
3022	-	7978	A/G	1	395565	rs4866811	Human NCBI Build 35	5	43272945	CCL28-ENSG00000177453
3023	-	7983	A/G	0	395569	rs4932363	Human NCBI Build 35	15	89124105	BLM
3024	-	7985	A/G	0	395571	rs4941185	Human NCBI Build 35	18	58974534	BCL2
3025	-	7988	A/G	0	395574	rs4961287	Human NCBI Build 35	8	141775502	PTK2
3026	-	7990	A/G	0	395576	rs4969170	Human NCBI Build 35	17	73872133	SOC3
3029	-	7995	A/G	0	395581	rs503473	Human NCBI Build 35	11	119860440	ARHGEF12
3030	-	8001	A/G	0	395587	rs5743651	Human NCBI Build 35	6	6594866	LY86

3031	-	8002	A/G	1	395588	rs5743808	Human NCBI Build 35	4	38653302	TLR6
3032	-	8009	A/G	1	395594	rs591026	Human NCBI Build 35	4	75117475	CXCL1
3033	-	8010	A/G	0	395595	rs5917148	Human NCBI Build 35	X	103870686	IL1RAPL2
3034	-	8012	A/G	0	395597	rs6000152	Human NCBI Build 35	22	34862553	APOL3
3035	-	8013	A/G	0	395598	rs6003	Human NCBI Build 35	1	193762678	F13B
3036	-	8016	A/G	0	395600	rs6016864	Human NCBI Build 35	20	40724350	PTPRT
3037	-	8018	A/G	0	395602	rs6021266	Human NCBI Build 35	20	49572654	NFATC2
3038	-	8022	A/G	0	395605	rs6093669	Human NCBI Build 35	20	40579796	PTPRT
3039	-	8023	A/G	1	395606	rs616235	Human NCBI Build 35	5	76164277	F2RL1-ENSG00000183613
3041	-	8034	A/G	0	395615	rs6499245	Human NCBI Build 35	16	68296453	NQO1-NFAT5
3042	-	8036	A/G	0	395617	rs653760	Human NCBI Build 35	10	6580095	PRKCQ
3043	-	8037	A/G	0	395618	rs6542787	Human NCBI Build 35	2	109014883	EDAR
3044	-	8040	A/G	0	395621	rs6560006	Human NCBI Build 35	9	87412087	DAPK1
3046	-	8047	A/G	0	395628	rs6661173	Human NCBI Build 35	1	169891940	TNFSF4
3047	-	8052	A/G	0	395632	rs669822	Human NCBI Build 35	18	12853142	PTPN2
3048	-	8057	A/G	0	395637	rs6786121	Human NCBI Build 35	3	191728790	IL1RAP
3049	-	8060	A/G	0	395640	rs682808	Human NCBI Build 35	20	3531178	ATRN
3050	-	8061	A/G	0	395641	rs6831585	Human NCBI Build 35	4	15452450	CD38
3052	-	8064	A/G	0	395644	rs6876898	Human NCBI Build 35	5	156602625	ITK
3053	-	8069	A/G	0	395648	rs6910116	Human NCBI Build 35	6	112182621	FYN
3054	-	8071	A/G	1	395650	rs695161	Human NCBI Build 35	1	32412959	LCK
3055	-	8072	A/G	0	395651	rs6955367	Human NCBI Build 35	7	99605845	PILRB
3056	-	8073	A/G	0	395652	rs6956010	Human NCBI Build 35	7	100360470	SERPINE1
3057	-	8076	A/G	0	395655	rs700782	Human NCBI Build 35	9	27516047	IFNK-ENSG00000120162
3058	-	8079	A/G	0	395658	rs7046290	Human NCBI Build 35	9	87432131	DAPK1
3059	-	8081	A/G	0	395660	rs7117111	Human NCBI Build 35	11	107422297	CUL5
3060	-	8094	A/G	0	395671	rs7254060	Human NCBI Build 35	19	7234414	INSR
3061	-	8095	A/G	0	395672	rs7254487	Human NCBI Build 35	19	7220321	INSR
3062	-	8101	A/G	0	395677	rs7404793	Human NCBI Build 35	16	23779175	PRKCB1
3063	-	8107	A/G	0	395682	rs743393	Human NCBI Build 35	3	37718972	ITGA9
3064	-	8111	A/G	1	395685	rs751363	Human NCBI Build 35	12	69300126	PTPRB
3065	-	8112	A/G	0	395686	rs7514391	Human NCBI Build 35	1	78835115	IFI44
3066	-	8115	A/G	1	395689	rs7522611	Human NCBI Build 35	1	50969629	FAF1
3067	-	8117	A/G	0	395691	rs7535121	Human NCBI Build 35	1	161435182	PBX1
3068	-	8126	A/G	1	395698	rs7631771	Human NCBI Build 35	3	107020518	CBLB
3069	-	8128	A/G	0	395700	rs7641268	Human NCBI Build 35	3	62149572	PTPRG
3070	-	8129	A/G	1	395701	rs7648171	Human NCBI Build 35	3	106704936	ALCAM
3071	-	8130	A/G	0	395702	rs765429	Human NCBI Build 35	21	33581871	IL10RB
3072	-	8137	A/G	0	395708	rs7735889	Human NCBI Build 35	5	42597956	GHR
3073	-	8139	A/G	0	395710	rs7744	Human NCBI Build 35	3	38159025	MYD88
3074	-	8149	A/G	0	395717	rs7895774	Human NCBI Build 35	10	6550540	PRKCQ
3075	-	8166	A/G	1	395730	rs8136691	Human NCBI Build 35	22	20482215	MAPK1
3076	-	8167	A/G	1	395731	rs8136902	Human NCBI Build 35	22	20490111	MAPK1
3077	-	8169	A/G	1	395733	rs821806	Human NCBI Build 35	2	239044325	none
3078	-	8170	A/G	0	395734	rs8264	Human NCBI Build 35	5	41018537	C7
3079	-	8176	A/G	1	395740	rs880263	Human NCBI Build 35	18	20296661	HRH4
3080	-	8193	A/G	0	395752	rs9300321	Human NCBI Build 35	12	111874526	OAS2-OAS3
3081	-	8196	A/G	0	395754	rs9305079	Human NCBI Build 35	19	16452464	CALR3
3082	-	8198	A/G	0	395756	rs9313479	Human NCBI Build 35	5	169380429	DOCK2

3083	-	8199	A/G	0	395757	rs9314347	Human NCBI Build 35	8	27375722	PTK2B-CHRNA2
3084	-	8205	A/G	0	395761	rs9385769	Human NCBI Build 35	6	136988333	MAP3K5
3085	-	8209	A/G	1	395764	rs9427663	Human NCBI Build 35	1	193685654	CFHL5
3086	-	8218	A/G	1	395771	rs960930	Human NCBI Build 35	7	121180188	PTPRZ1
3087	-	8219	A/G	0	395772	rs9640663	Human NCBI Build 35	7	76892472	PTPN12
3088	-	8220	A/G	0	395773	rs965225	Human NCBI Build 35	4	185692046	IRF2
3089	-	8223	A/G	0	395776	rs981954	Human NCBI Build 35	3	112741026	CD96
3090	-	8227	A/G	1	395779	rs9863159	Human NCBI Build 35	3	61631014	PTPRG
3091	-	8230	A/G	0	395782	rs9877410	Human NCBI Build 35	3	32406070	ENSG00000153551
3092	-	8235	A/G	0	395785	rs9914239	Human NCBI Build 35	17	23734040	SARM1
3093	-	8237	A/G	0	395787	rs9971686	Human NCBI Build 35	12	8644606	AICDA
3094	-	8238	A/G	0	395788	rs1001793	Human NCBI Build 35	8	22956894	TNFRSF10B
3095	-	8243	A/G	0	395793	rs1006588	Human NCBI Build 35	3	61915896	PTPRG
3096	-	8250	A/G	0	395798	rs1026916	Human NCBI Build 35	17	37783361	STAT3
3097	-	8260	A/G	0	395806	rs10488630	Human NCBI Build 35	7	128187899	IRF5-TNPO3
3098	-	8261	A/G	0	395807	rs10488810	Human NCBI Build 35	11	35169954	CD44
3099	-	8262	A/G	0	395808	rs10489114	Human NCBI Build 35	4	103868581	NFKB1
3100	-	8263	A/G	0	395809	rs10489789	Human NCBI Build 35	1	233006218	LGALS8
3101	-	8265	A/G	0	395811	rs10491361	Human NCBI Build 35	5	149188961	PPARGC1B
3102	-	8274	A/G	0	395818	rs10503575	Human NCBI Build 35	8	16026250	MSR1
3103	-	8275	A/G	1	395819	rs10506598	Human NCBI Build 35	12	69302206	PTPRB
3104	-	8279	A/G	0	395822	rs1050783	Human NCBI Build 35	6	6090691	F13A1
3105	-	8281	A/G	1	395823	rs10508307	Human NCBI Build 35	10	6537313	PRKCQ
3106	-	8290	A/G	1	395830	rs10513983	Human NCBI Build 35	18	65703318	CD226
3107	-	8292	A/G	0	395832	rs10516778	Human NCBI Build 35	4	87993230	PTPN13
3108	-	8293	A/G	1	395833	rs1055740	Human NCBI Build 35	11	63756105	
DNAJC4-VEGFB-ENSG00000149761										
3109	-	8302	A/G	0	395839	rs10779455	Human NCBI Build 35	1	218295082	DUSP10
3110	-	8305	A/G	0	395842	rs10800120	Human NCBI Build 35	1	162336968	MGST3
3111	-	8307	A/G	0	395843	rs10838810	Human NCBI Build 35	11	48135462	PTPRJ
3112	-	8308	A/G	0	395844	rs10852259	Human NCBI Build 35	16	23975815	PRKCB1
3113	-	8310	A/G	0	395845	rs10859685	Human NCBI Build 35	12	93097105	PLXNC1
3114	-	8311	A/G	0	395846	rs10863651	Human NCBI Build 35	1	218297588	DUSP10
3117	-	8321	A/G	0	395855	rs10964871	Human NCBI Build 35	9	21153761	IFNA21
3118	-	8327	A/G	0	395857	rs10977266	Human NCBI Build 35	9	8719721	PTPRD
3119	-	8331	A/G	1	395859	rs11074858	Human NCBI Build 35	16	27336738	IL21R
3120	-	8332	A/G	0	395860	rs11075728	Human NCBI Build 35	16	68169083	NFAT5
3121	-	8333	A/G	0	395861	rs11081370	Human NCBI Build 35	18	8231986	PTPRM
3122	-	8334	A/G	0	395862	rs11107500	Human NCBI Build 35	12	93200108	PLXNC1-ENSG00000173588
3123	-	8335	A/G	0	395863	rs11130874	Human NCBI Build 35	3	62039809	PTPRG
3124	-	8336	A/G	1	395864	rs11152377	Human NCBI Build 35	18	59123426	BCL2
3125	-	8341	A/G	1	395869	rs11244	Human NCBI Build 35	6	32888702	HLA-DOB
3126	-	8343	A/G	0	395871	rs1147489	Human NCBI Build 35	7	121273084	PTPRZ1
3127	-	8344	A/G	0	395872	rs1147504	Human NCBI Build 35	7	121247349	PTPRZ1
3128	-	8348	A/G	0	395876	rs11615170	Human NCBI Build 35	12	69255848	PTPRB
3129	-	8351	A/G	0	395879	rs11722146	Human NCBI Build 35	4	103881822	NFKB1
3130	-	8356	A/G	1	395884	rs1177614	Human NCBI Build 35	3	10201144	IRAK2
3131	-	8357	A/G	0	395885	rs11785606	Human NCBI Build 35	8	27294743	PTK2B
3132	-	8359	A/G	0	395887	rs1196474	Human NCBI Build 35	7	121236311	PTPRZ1

3133	-	8370	A/G	0	395895	rs12165104	Human NCBI Build 35	18	58201621	TNFRSF11A
3134	-	8372	A/G	1	395896	rs12172554	Human NCBI Build 35	22	20519629	MAPK1
3135	-	8373	A/G	0	395897	rs12244380	Human NCBI Build 35	10	6093380	IL2RA
3136	-	8375	A/G	0	395899	rs1234313	Human NCBI Build 35	1	169897904	TNFSF4
3137	-	8379	A/G	0	395903	rs12473955	Human NCBI Build 35	2	162984032	IFIH1
3138	-	8383	A/G	0	395907	rs12570061	Human NCBI Build 35	10	31720584	TCF8
3139	-	8385	A/G	0	395909	rs12625871	Human NCBI Build 35	20	40208063	PTPRT
3140	-	8388	A/G	1	395910	rs12637323	Human NCBI Build 35	3	61843282	PTPRG
3141	-	8392	A/G	0	395914	rs12708653	Human NCBI Build 35	16	23751012	PRKCB1
3142	-	8408	A/G	1	395929	rs13296	Human NCBI Build 35 6	44326098	HSPCB-ENSG00000157593	
3143	-	8409	A/G	0	395930	rs13353326	Human NCBI Build 35	19	59409113	ENSG00000186152
3144	-	8412	A/G	0	395932	rs1339195	Human NCBI Build 35	6	128681100	PTPRK
3145	-	8413	A/G	0	395933	rs1344307	Human NCBI Build 35	7	54912097	EGFR
3146	-	8416	A/G	0	395936	rs1397706	Human NCBI Build 35	2	160554512	LY75
3149	-	8422	A/G	0	395941	rs1420089	Human NCBI Build 35	2	102396907	IL1RL1
3150	-	8423	A/G	0	395942	rs1428467	Human NCBI Build 35	5	66525614	LY64
3151	-	8424	A/G	0	395943	rs1434265	Human NCBI Build 35	9	8683432	PTPRD
3152	-	8428	A/G	0	395945	rs1463162	Human NCBI Build 35	2	46092974	PRKCE
3153	-	8437	A/G	0	395952	rs1489595	Human NCBI Build 35	15	66164180	PIAS1
3154	-	8438	A/G	0	395953	rs1494558	Human NCBI Build 35	5	35896825	IL7R
3155	-	8441	A/G	0	395956	rs1532533	Human NCBI Build 35	3	12610706	RAF1
3156	-	8443	A/G	0	395958	rs1542480	Human NCBI Build 35	12	15440261	PTPRO
3157	-	8444	A/G	0	395959	rs1544570	Human NCBI Build 35	11	22782135	GAS2
3158	-	8452	A/G	0	395966	rs1567810	Human NCBI Build 35	15	97096569	IGF1R
3159	-	8453	A/G	0	395967	rs1580252	Human NCBI Build 35	12	15493688	PTPRO
3160	-	8456	A/G	0	395969	rs1597097	Human NCBI Build 35	12	9911534	ENSG00000110852
3161	-	8460	A/G	0	395972	rs1619450	Human NCBI Build 35	9	91248710	NFIL3
3163	-	8467	A/G	0	395977	rs1695144	Human NCBI Build 35	12	67510209	MDM2
3164	-	8469	A/G	0	395979	rs17130	Human NCBI Build 35 19	5205970	PTPRS	
3165	-	8473	A/G	0	395982	rs1733133	Human NCBI Build 35	7	157764666	PTPRN2
3166	-	8475	A/G	0	395984	rs174400	Human NCBI Build 35	6	112029672	C6orf4
3167	-	8476	A/G	1	395985	rs177820	Human NCBI Build 35	19	60021713	
ENSG00000167633-KIR2DS1-ENSG00000189013										
3168	-	8486	A/G	0	395991	rs181272	Human NCBI Build 35	4	75268399	CXCL3
3169	-	8487	A/G	0	395992	rs1818813	Human NCBI Build 35	18	59464783	SERPINB3
3170	-	8492	A/G	0	395996	rs1849465	Human NCBI Build 35	12	69487509	PTPRR
3171	-	8495	A/G	0	395999	rs1864615	Human NCBI Build 35	3	30674786	TGFBR2
3172	-	8499	A/G	0	396002	rs1878803	Human NCBI Build 35	7	2760035	CARD11
3173	-	8503	A/G	1	396005	rs1890120	Human NCBI Build 35	1	220332872	TP53BP2
3174	-	8513	A/G	1	396013	rs194682	Human NCBI Build 35	6	33022591	HLA-DMA
3175	-	8517	A/G	0	396016	rs1982612	Human NCBI Build 35	1	220328619	TP53BP2
3176	-	8520	A/G	1	396019	rs2001763	Human NCBI Build 35	7	157548897	PTPRN2
3177	-	8521	A/G	0	396020	rs2004231	Human NCBI Build 35	15	61982822	ENSG0000035664
3178	-	8523	A/G	0	396022	rs2044750	Human NCBI Build 35	18	75372976	
ENSG00000186783-NFATC1-ENSG00000198275										
3179	-	8530	A/G	0	396027	rs2064700	Human NCBI Build 35	6	112248601	FYN
3180	-	8536	A/G	0	396032	rs2072493	Human NCBI Build 35	1	1374687	TLR5
3181	-	8538	A/G	0	396034	rs208179	Human NCBI Build 35	20	40866540	PTPRT
3182	-	8542	A/G	0	396036	rs209474	Human NCBI Build 35	6	33032562	HLA-DMA

3183	-	8543	A/G	1	396037	rs2096987	Human NCBI Build 35	18	65771673	CD226
3184	-	8547	A/G	1	396041	rs2120585	Human NCBI Build 35	3	106885434	CBLB
3185	-	8552	A/G	0	396044	rs2164747	Human NCBI Build 35	12	102847303	TRA1
3186	-	8553	A/G	0	396045	rs2169643	Human NCBI Build 35	3	112372664	PVRL3
3187	-	8557	A/G	0	396047	rs2204204	Human NCBI Build 35	2	45817597	PRKCE
3188	-	8558	A/G	0	396048	rs2206593	Human NCBI Build 35	1	183374086	PTGS2
3189	-	8559	A/G	0	396049	rs221275	Human NCBI Build 35	7	156845667	PTPRN2
3190	-	8562	A/G	0	396052	rs2227513	Human NCBI Build 35	12	66933606	IL22
3191	-	8563	A/G	0	396053	rs2227606	Human NCBI Build 35	1	170612779	SERPINC1
3192	-	8564	A/G	0	396054	rs2227744	Human NCBI Build 35	5	76046105	F2R-ENSG00000183613
3193	-	8572	A/G	0	396062	rs2241054	Human NCBI Build 35	7	55014188	EGFR
3194	-	8575	A/G	1	396065	rs2253849	Human NCBI Build 35	12	10494937	KLRC1
3196	-	8582	A/G	0	396071	rs2282079	Human NCBI Build 35	9	37026247	PAX5
3197	-	8588	A/G	0	396075	rs2286806	Human NCBI Build 35	17	50840185	MMD
3198	-	8590	A/G	1	396076	rs2287047	Human NCBI Build 35	2	102232572	IL1R1
3199	-	8594	A/G	1	396078	rs2289244	Human NCBI Build 35	3	32374185	CKLFSF8
3200	-	8596	A/G	0	396080	rs2294696	Human NCBI Build 35	14	23684201	ISGF3G-PSME2-C14orf122
3201	-	8599	A/G	0	396082	rs2296618	Human NCBI Build 35	1	195397889	PTPRC
3202	-	8602	A/G	1	396084	rs2301756	Human NCBI Build 35	12	111353496	PTPN11
3203	-	8608	A/G	0	396089	rs2322608	Human NCBI Build 35	8	27261694	PTK2B-ENSG00000197825
3204	-	8612	A/G	0	396091	rs2338833	Human NCBI Build 35	5	169444641	DOCK2
3205	-	8615	A/G	1	396094	rs2351311	Human NCBI Build 35	6	74507496	CD109
3206	-	8616	A/G	0	396095	rs2358820	Human NCBI Build 35	1	117423953	ENSG00000134258
3207	-	8618	A/G	0	396096	rs2366461	Human NCBI Build 35	3	61883005	PTPRG
3208	-	8619	A/G	0	396097	rs2374767	Human NCBI Build 35	12	9634325	KLRB1
3209	-	8620	A/G	0	396098	rs2400478	Human NCBI Build 35	5	147491059	SPINK5
3210	-	8621	A/G	0	396099	rs246856	Human NCBI Build 35	5	156564700	ITK
3211	-	8632	A/G	0	396107	rs2542170	Human NCBI Build 35	18	12790820	PTPN2
3212	-	8633	A/G	1	396108	rs25776	Human NCBI Build 35	5	156605803	ITK
3213	-	8637	A/G	1	396111	rs262866	Human NCBI Build 35	5	169094222	DOCK2
3214	-	8645	A/G	1	396116	rs2681400	Human NCBI Build 35	3	123320067	CD86
3215	-	8646	A/G	0	396117	rs2681415	Human NCBI Build 35	3	123298305	CD86
3216	-	8648	A/G	0	396119	rs2700179	Human NCBI Build 35	3	61794896	PTPRG
3217	-	8650	A/G	1	396121	rs2701858	Human NCBI Build 35	13	40036389	FOXO1A
3219	-	8653	A/G	0	396124	rs2717418	Human NCBI Build 35	12	69259863	PTPRB
3220	-	8657	A/G	0	396127	rs2736726	Human NCBI Build 35	7	30292270	CARD4
3222	-	8661	A/G	0	396131	rs2792248	Human NCBI Build 35	1	161356920	PBX1-ENSG00000197613
3223	-	8664	A/G	0	396133	rs2834202	Human NCBI Build 35	21	33652824	IFNAR1
3224	-	8665	A/G	0	396134	rs2839975	Human NCBI Build 35	18	46516418	MAPK4
3225	-	8675	A/G	1	396141	rs2962089	Human NCBI Build 35	5	35168107	PRLR
3226	-	8680	A/G	1	396144	rs3002303	Human NCBI Build 35	1	210928246	PTPN14
3227	-	8682	A/G	0	396145	rs3013739	Human NCBI Build 35	9	37021876	PAX5
3229	-	8690	A/G	0	396152	rs3130050	Human NCBI Build 35	6	31726740	BAT3-APOM
3230	-	8692	A/G	1	396154	rs3134883	Human NCBI Build 35	10	6140731	IL2RA
3231	-	8696	A/G	0	396157	rs3181033	Human NCBI Build 35	12	66842399	IFNG
3232	-	8697	A/G	0	396158	rs3181123	Human NCBI Build 35	10	97597065	ENTPD1
3233	-	8702	A/G	0	396161	rs318699	Human NCBI Build 35	19	11362240	EPOR
3235	-	8706	A/G	0	396163	rs3212243	Human NCBI Build 35	14	23880210	RIPK3
3236	-	8708	A/G	1	396165	rs3218611	Human NCBI Build 35	10	90764093	ENSG00000026103

3237	-	8709	A/G	0	396166	rs3218619	Human NCBI Build 35	10	90752781	ENSG00000026103
3238	-	8716	A/G	0	396171	rs3731714	Human NCBI Build 35	2	201886326	CASP10
3241	-	8728	A/G	0	396180	rs3750490	Human NCBI Build 35	9	8623097	PTPRD
3242	-	8729	A/G	0	396181	rs3754559	Human NCBI Build 35	2	46320797	PRKCE
3243	-	8734	A/G	0	396186	rs3765187	Human NCBI Build 35	7	79930654	CD36
3244	-	8736	A/G	0	396187	rs3768648	Human NCBI Build 35	2	152828920	STAM2
3245	-	8740	A/G	0	396189	rs3768757	Human NCBI Build 35	2	46236517	PRKCE
3246	-	8744	A/G	0	396192	rs3773480	Human NCBI Build 35	3	15033960	NR2C2
3247	-	8747	A/G	1	396194	rs3773989	Human NCBI Build 35	3	191748131	IL1RAP
3249	-	8755	A/G	0	396201	rs3796508	Human NCBI Build 35	4	38652682	TLR6
3250	-	8761	A/G	0	396204	rs3806603	Human NCBI Build 35	2	160587315	LY75
3252	-	8764	A/G	1	396207	rs3818361	Human NCBI Build 35	1	204173363	none
3253	-	8768	A/G	0	396209	rs3822288	Human NCBI Build 35	4	111212148	EGF
3255	-	8771	A/G	0	396211	rs3825264	Human NCBI Build 35	12	97627208	APAF1-ENSG00000185046
3256	-	8772	A/G	0	396212	rs3826878	Human NCBI Build 35	19	60069023	KIR3DL2
3257	-	8777	A/G	0	396215	rs3852876	Human NCBI Build 35	19	7190555	INSR
3258	-	8780	A/G	0	396217	rs3867263	Human NCBI Build 35	18	59482590	SERPINB3
3259	-	8784	A/G	0	396221	rs3917854	Human NCBI Build 35	1	166290693	F5-SELP
3260	-	8796	A/G	0	396230	rs4151659	Human NCBI Build 35	6	32026443	RDBP-BF
3261	-	8797	A/G	0	396231	rs4267553	Human NCBI Build 35	2	46071680	PRKCE
3262	-	8799	A/G	1	396233	rs4311	Human NCBI Build 35	17	58914495	ACE
3265	-	8819	A/G	0	396245	rs4538475	Human NCBI Build 35	4	15414206	ENSG00000109743
3266	-	8820	A/G	0	396246	rs4541169	Human NCBI Build 35	18	66148264	SOC6
3267	-	8821	A/G	0	396247	rs4552686	Human NCBI Build 35	5	146370958	PPP2R2B
3268	-	8836	A/G	1	396258	rs4742533	Human NCBI Build 35	9	8728267	PTPRD
3269	-	8838	A/G	0	396260	rs4750531	Human NCBI Build 35	10	6574390	PRKCQ
3270	-	8842	A/G	1	396262	rs4780355	Human NCBI Build 35	16	11255359	SOC1
3271	-	8848	A/G	0	396266	rs4802070	Human NCBI Build 35	16	21573817	
IGSF6-ENSG00000197006-ENSG00000158482-ENSG00000169246										
3272	-	8854	A/G	1	396272	rs4859596	Human NCBI Build 35	4	77313572	CXCL11-ENSG00000169253
3273	-	8856	A/G	0	396274	rs4909144	Human NCBI Build 35	7	157540713	PTPRN2
3274	-	8861	A/G	0	396278	rs4939641	Human NCBI Build 35	18	46414902	MAPK4
3275	-	8862	A/G	1	396279	rs4941210	Human NCBI Build 35	18	59473023	SERPINB3
3276	-	8864	A/G	0	396281	rs4968723	Human NCBI Build 35	17	59770666	PECAM1
3277	-	8865	A/G	1	396282	rs4986791	Human NCBI Build 35	9	117555156	TLR4
3278	-	8866	A/G	0	396283	rs4987233	Human NCBI Build 35	9	117555159	TLR4
3279	-	8867	A/G	1	396284	rs4987774	Human NCBI Build 35	18	59043342	BCL2
3280	-	8880	A/G	0	396293	rs5486	Human NCBI Build 35	12	21423367	IAPP-SLC01A2
3281	-	8888	A/G	0	396298	rs5745308	Human NCBI Build 35	5	10731281	DAP-ENSG00000164236
3282	-	8891	A/G	0	396301	rs583911	Human NCBI Build 35	3	161193092	IL12A
3283	-	8894	A/G	0	396304	rs5980901	Human NCBI Build 35	X	69160595	IGBP1
3284	-	8896	A/G	0	396306	rs6030388	Human NCBI Build 35	20	40696797	PTPRT
3285	-	8898	A/G	0	396307	rs6035103	Human NCBI Build 35	20	1869450	PTPNS1
3286	-	8899	A/G	0	396308	rs6065522	Human NCBI Build 35	20	40730408	PTPRT
3287	-	8904	A/G	0	396312	rs619957	Human NCBI Build 35	18	8068390	PTPRM
3288	-	8906	A/G	0	396313	rs6214	Human NCBI Build 35	12	101296036	IGF1
3289	-	8907	A/G	0	396314	rs6219	Human NCBI Build 35	12	101292659	IGF1
3290	-	8908	A/G	0	396315	rs632941	Human NCBI Build 35	9	21378712	IFNA2
3291	-	8909	A/G	0	396316	rs634492	Human NCBI Build 35	10	6575438	PRKCQ

3292	-	8910	A/G	0	396317	rs6434435	Human NCBI Build 35	2	191779370	STAT4
3293	-	8911	A/G	0	396318	rs647080	Human NCBI Build 35	11	111114384	PPP2R1B
3294	-	8913	A/G	0	396320	rs6506523	Human NCBI Build 35	18	7657575	PTPRM
3295	-	8916	A/G	1	396322	rs6523834	Human NCBI Build 35	X	104369992	IL1RAPL2
3296	-	8919	A/G	0	396325	rs6547705	Human NCBI Build 35	2	86955974	CD8B1
3297	-	8925	A/G	0	396331	rs6670721	Human NCBI Build 35	1	157349634	CD84
3298	-	8926	A/G	0	396332	rs6680396	Human NCBI Build 35	1	193364127	CFH
3299	-	8930	A/G	0	396336	rs6710007	Human NCBI Build 35	2	113497161	IL1F6-IL1F8
3300	-	8934	A/G	0	396339	rs6729724	Human NCBI Build 35	2	162945818	IFIH1
3301	-	8937	A/G	0	396342	rs6755308	Human NCBI Build 35	2	46141918	PRKCE
3302	-	8938	A/G	0	396343	rs6780883	Human NCBI Build 35	3	37639603	ITGA9
3303	-	8942	A/G	0	396346	rs6878981	Human NCBI Build 35	5	35118836	PRLR
3304	-	8946	A/G	1	396349	rs6923217	Human NCBI Build 35	6	112263790	FYN
3305	-	8952	A/G	0	396355	rs6993266	Human NCBI Build 35	8	141831841	PTK2
3306	-	8960	A/G	0	396360	rs706349	Human NCBI Build 35	4	140957912	MGST2
3307	-	8962	A/G	1	396362	rs7072496	Human NCBI Build 35	10	6648319	PRKCQ
3308	-	8964	A/G	0	396363	rs7076228	Human NCBI Build 35	10	129660744	PTPRE
3309	-	8965	A/G	0	396364	rs7085243	Human NCBI Build 35	10	129693110	PTPRE
3311	-	8967	A/G	0	396366	rs7116578	Human NCBI Build 35	11	127893983	ETS1
3312	-	8980	A/G	0	396377	rs7302224	Human NCBI Build 35	12	92748182	CRADD
3313	-	8983	A/G	0	396379	rs7329483	Human NCBI Build 35	13	23140801	TNFRSF19
3314	-	8984	A/G	1	396380	rs7379862	Human NCBI Build 35	5	146335458	PPP2R2B
3315	-	8991	A/G	0	396385	rs7541092	Human NCBI Build 35	1	71074493	PTGER3
3316	-	8996	A/G	0	396390	rs7583529	Human NCBI Build 35	2	201813744	CFLAR
3317	-	8999	A/G	0	396393	rs7621740	Human NCBI Build 35	3	62250653	PTPRG
3318	-	9001	A/G	0	396394	rs7626795	Human NCBI Build 35	3	191833163	IL1RAP
3319	-	9002	A/G	0	396395	rs7628250	Human NCBI Build 35	3	191791229	IL1RAP
3320	-	9005	A/G	1	396397	rs7655371	Human NCBI Build 35	4	185700088	IRF2
3321	-	9009	A/G	0	396401	rs7723693	Human NCBI Build 35	5	359032	AHRR
3322	-	9013	A/G	0	396405	rs7761076	Human NCBI Build 35	6	128457032	PTPRK
3323	-	9016	A/G	0	396408	rs7789066	Human NCBI Build 35	7	105521703	PBEF1
3324	-	9023	A/G	0	396415	rs791587	Human NCBI Build 35	10	6128705	IL2RA
3325	-	9026	A/G	1	396418	rs7937334	Human NCBI Build 35	11	117696484	CD3E
3327	-	9031	A/G	0	396423	rs8055756	Human NCBI Build 35	16	68206154	NFAT5
3328	-	9035	A/G	0	396426	rs8069645	Human NCBI Build 35	17	37748428	STAT3
3329	-	9037	A/G	0	396428	rs8094315	Human NCBI Build 35	18	59087027	BCL2
3330	-	9047	A/G	0	396434	rs832501	Human NCBI Build 35	12	93179798	PLXNC1
3331	-	9049	A/G	0	396436	rs853362	Human NCBI Build 35	6	14246406	CD83
3332	-	9056	A/G	0	396442	rs888206	Human NCBI Build 35	17	50823212	MMD
3334	-	9066	A/G	0	396446	rs894768	Human NCBI Build 35	18	46477656	MAPK4
3336	-	9072	A/G	1	396450	rs9277489	Human NCBI Build 35	6	33161920	HLA-DPB1
3337	-	9075	A/G	0	396451	rs9290939	Human NCBI Build 35	3	191816578	IL1RAP
3338	-	9081	A/G	1	396455	rs935653	Human NCBI Build 35	2	46000195	PRKCE
3339	-	9082	A/G	1	396456	rs9381034	Human NCBI Build 35	6	41157486	NFYA
3340	-	9086	A/G	1	396460	rs9402011	Human NCBI Build 35	6	128347581	PTPRK
3341	-	9089	A/G	1	396463	rs944461	Human NCBI Build 35	14	63774893	ESR2
3343	-	9092	A/G	0	396466	rs9610	Human NCBI Build 35	11	117377296	IL10RA
3344	-	9098	A/G	1	396470	rs972769	Human NCBI Build 35	12	69419738	PTPRR
3345	-	9101	A/G	0	396473	rs9823898	Human NCBI Build 35	3	61561983	PTPRG

3346	-	9117	A/G	0	396484	rs9993323	Human NCBI Build 35	4	111298310	EGF
3347	-	9132	A/G	1	396495	rs1019855	Human NCBI Build 35	3	30672665	TGFBR2
3348	-	9137	A/G	0	396499	rs1041429	Human NCBI Build 35	21	33621779	IFNAR1
3349	-	9140	A/G	0	396502	rs10488137	Human NCBI Build 35	7	54887036	EGFR
3350	-	9147	A/G	0	396506	rs10493822	Human NCBI Build 35	1	89241701	GBP1
3351	-	9151	A/G	0	396509	rs10494979	Human NCBI Build 35	1	211046606	PTPN14
3352	-	9162	A/G	0	396518	rs10510697	Human NCBI Build 35	3	37831653	ITGA9
3353	-	9166	A/G	0	396522	rs10512765	Human NCBI Build 35	5	41247884	C6
3355	-	9174	A/G	0	396529	rs1052653	Human NCBI Build 35	20	49438061	NFATC2
3356	-	9175	A/G	1	396530	rs1060612	Human NCBI Build 35	9	8689017	PTPRD
3357	-	9177	A/G	0	396532	rs10745657	Human NCBI Build 35	12	92475969	SOCS2
3358	-	9178	A/G	0	396533	rs10745679	Human NCBI Build 35	12	93091455	PLXNC1
3359	-	9179	A/G	1	396534	rs10759930	Human NCBI Build 35	9	117541175	TLR4
3360	-	9182	A/G	0	396536	rs10866820	Human NCBI Build 35	8	23033115	TNFRSF10C-ENSG00000147457
3362	-	9195	A/G	0	396547	rs10972434	Human NCBI Build 35	9	35319331	UNC13B-ENSG00000196186
3363	-	9196	A/G	0	396548	rs10977110	Human NCBI Build 35	9	8435066	PTPRD
3364	-	9198	A/G	0	396550	rs10999064	Human NCBI Build 35	10	71412707	AMID
3366	-	9202	A/G	0	396554	rs11107202	Human NCBI Build 35	12	92719152	CRADD
3367	-	9207	A/G	0	396557	rs11210887	Human NCBI Build 35	1	43745112	PTPRF
3368	-	9211	A/G	0	396559	rs11242867	Human NCBI Build 35	6	360406	IRF4
3369	-	9213	A/G	1	396561	rs1135314	Human NCBI Build 35	9	136534299	GPSM1-CARD9
3370	-	9225	A/G	0	396569	rs11576837	Human NCBI Build 35	1	157816947	F11R
3371	-	9227	A/G	1	396571	rs11585301	Human NCBI Build 35	1	50833060	FAF1
3372	-	9234	A/G	0	396575	rs11710163	Human NCBI Build 35	3	12671288	RAF1-ENSG00000198383
3373	-	9239	A/G	0	396578	rs11740247	Human NCBI Build 35	5	149113927	PPARGC1B
3374	-	9242	A/G	0	396581	rs11831659	Human NCBI Build 35	12	110318398	ENSG00000111252
3375	-	9250	A/G	0	396589	rs12034383	Human NCBI Build 35	1	204191990	none
3376	-	9254	A/G	0	396591	rs12067513	Human NCBI Build 35	1	51022083	FAF1
3377	-	9255	A/G	0	396592	rs12109339	Human NCBI Build 35	5	142009538	FGF1
3378	-	9260	A/G	0	396596	rs12153009	Human NCBI Build 35	5	42589636	GHR
3379	-	9265	A/G	0	396600	rs12269665	Human NCBI Build 35	10	70204957	CCAR1
3380	-	9270	A/G	0	396603	rs12330015	Human NCBI Build 35	22	44910797	PPARA
3381	-	9280	A/G	1	396609	rs1256114	Human NCBI Build 35	14	63879758	ESR2
3382	-	9286	A/G	0	396615	rs12691940	Human NCBI Build 35	2	138584750	HNMT
3383	-	9292	A/G	1	396620	rs1327475	Human NCBI Build 35	6	137578148	IFNGR1
3384	-	9298	A/G	0	396626	rs1383169	Human NCBI Build 35	5	146414993	PPP2R2B
3386	-	9311	A/G	0	396635	rs1470315	Human NCBI Build 35	15	62001337	ENSG00000035664
3387	-	9313	A/G	1	396637	rs1472441	Human NCBI Build 35	1	210915647	PTPN14
3388	-	9314	A/G	1	396638	rs1477437	Human NCBI Build 35	15	31964079	AVEN
3389	-	9315	A/G	0	396639	rs1491963	Human NCBI Build 35	3	62208809	PTPRG
3390	-	9321	A/G	0	396644	rs1552323	Human NCBI Build 35	20	3398811	ATRN
3391	-	9335	A/G	1	396656	rs17782078	Human NCBI Build 35	20	3489382	ATRN
3392	-	9341	A/G	0	396661	rs1867195	Human NCBI Build 35	3	107030866	CBLB
3393	-	9344	A/G	1	396663	rs1875239	Human NCBI Build 35	9	8397583	PTPRD
3394	-	9345	A/G	0	396664	rs187875	Human NCBI Build 35	5	39351502	C9
3395	-	9354	A/G	0	396671	rs195996	Human NCBI Build 35	16	23862011	PRKCB1
3396	-	9356	A/G	1	396673	rs196290	Human NCBI Build 35	10	121398061	BAG3
3397	-	9357	A/G	0	396674	rs1980283	Human NCBI Build 35	3	61763660	PTPRG
3399	-	9363	A/G	0	396680	rs2000220	Human NCBI Build 35	1	214976031	ENSG00000092969

3400	-	9368	A/G	0	396684	rs2028373	Human NCBI Build 35	12	8648748	AICDA	
3402	-	9372	A/G	0	396688	rs2040710	Human NCBI Build 35	4	111352396	EGF-ELOVL6	
3403	-	9375	A/G	1	396691	rs2050066	Human NCBI Build 35	1	71167156	PTGER3	
3404	-	9377	A/G	0	396693	rs2063979	Human NCBI Build 35	17	31327679	CCL16	
3405	-	9378	A/G	1	396694	rs2064236	Human NCBI Build 35	6	6584424	LY86	
3406	-	9379	A/G	0	396695	rs206640	Human NCBI Build 35	20	40993939	PTPRT	
3407	-	9380	A/G	0	396696	rs2066445	Human NCBI Build 35	1	67493996	IL12RB2	
3408	-	9382	A/G	0	396698	rs2066805	Human NCBI Build 35	2	191688407	STAT1	
3409	-	9385	A/G	0	396700	rs2069882	Human NCBI Build 35	5	135257532	IL9	
3410	-	9386	A/G	0	396701	rs2070845	Human NCBI Build 35	10	91056055	IFIT2-LIPA	
3411	-	9390	A/G	0	396705	rs2088578	Human NCBI Build 35	12	67484379	MDM2	
3412	-	9391	A/G	0	396706	rs2090414	Human NCBI Build 35	2	45864072	PRKCE	
3413	-	9392	A/G	0	396707	rs210941	Human NCBI Build 35	6	135578189	MYB	
3414	-	9395	A/G	0	396710	rs2155753	Human NCBI Build 35	18	8362783	PTPRM	
3415	-	9396	A/G	0	396711	rs2165587	Human NCBI Build 35	4	77472628	SCARB2	
3416	-	9401	A/G	0	396714	rs2176046	Human NCBI Build 35	2	240031867	HDAC4	
3417	-	9409	A/G	0	396720	rs2227492	Human NCBI Build 35	12	66932404	IL22	
3418	-	9411	A/G	1	396722	rs2232350	Human NCBI Build 35	3	53874218	IL17RB-ACTR8	
3419	-	9413	A/G	0	396724	rs2240825	Human NCBI Build 35	7	38061510	TRGV9	
3420	-	9415	A/G	0	396725	rs2242352	Human NCBI Build 35	3	62256476	PTPRG	
3421	-	9416	A/G	0	396726	rs2243051	Human NCBI Build 35	5	76161558	F2RL1-ENSG00000183613	
3423	-	9421	A/G	1	396731	rs2283548	Human NCBI Build 35	16	24086743	PRKCB1	
3424	-	9424	A/G	0	396733	rs2295616	Human NCBI Build 35	1	157523230	SLAMF7	
3425	-	9425	A/G	0	396734	rs2295758	Human NCBI Build 35	11	35192701	CD44	
3426	-	9426	A/G	1	396735	rs2300168	Human NCBI Build 35	1	71185812	PTGER3	
3427	-	9434	A/G	0	396741	rs2322283	Human NCBI Build 35	17	11935225	MAP2K4	
3428	-	9445	A/G	0	396750	rs2490879	Human NCBI Build 35	1	159503598	ENSG00000132196	
3429	-	9448	A/G	0	396753	rs2517896	Human NCBI Build 35	6	29908121	HLA-G	
3431	-	9459	A/G	0	396762	rs2640726	Human NCBI Build 35	8	27461726	EPHX2	
3432	-	9460	A/G	0	396763	rs267939	Human NCBI Build 35	5	10805315	DAP	
3433	-	9463	A/G	0	396765	rs2689774	Human NCBI Build 35	2	73991188	STAMBP	
3434	-	9467	A/G	1	396768	rs2764850	Human NCBI Build 35	1	117262665	IGSF2	
3435	-	9479	A/G	0	396776	rs30079	Human NCBI Build 35	5	169205188	DOCK2	
3436	-	9482	A/G	0	396779	rs3096085	Human NCBI Build 35	5	146026611	PPP2R2B	
3437	-	9491	A/G	0	396785	rs31562	Human NCBI Build 35	5	135264193	IL9	
3438	-	9509	A/G	0	396800	rs364418	Human NCBI Build 35	18	7803239	PTPRM	
3439	-	9511	A/G	0	396801	rs364640	Human NCBI Build 35	5	39157265	FYB	
3440	-	9514	A/G	0	396803	rs3730520	Human NCBI Build 35	12	67495278	MDM2	
3441	-	9516	A/G	1	396805	rs373496	Human NCBI Build 35	16	11967664	TNFRSF17-ENSG00000122309	
3442	-	9524	A/G	1	396811	rs3758841	Human NCBI Build 35	11	101708061	BIRC3	
3443	-	9525	A/G	0	396812	rs3762999	Human NCBI Build 35	5	150449619	TNIP1	
3445	-	9527	A/G	0	396814	rs3768235	Human NCBI Build 35	1	85445395	BCL10	
3446	-	9528	A/G	1	396815	rs3769827	Human NCBI Build 35	2	201928191	CASP8	
3447	-	9529	A/G	0	396816	rs3771185	Human NCBI Build 35	2	102299025	IL1RL2	
3448	-	9530	A/G	0	396817	rs3771811	Human NCBI Build 35	2	75231314	TACR1	
3449	-	9532	A/G	0	396819	rs3772556	Human NCBI Build 35	3	106731901	ALCAM	
3450	-	9542	A/G	0	396827	rs3785404	Human NCBI Build 35	16	23774158	PRKCB1	
3451	-	9552	A/G	1	396835	rs3804474	Human NCBI Build 35	6	6566507	LY86	
3452	-	9553	A/G	0	396836	rs3811633	Human NCBI Build 35	2	112471111	MERTK	

3453	-	9554	A/G	0	396837	rs3811635	Human NCBI Build 35	2	112471232	MERTK
3454	-	9558	A/G	0	396840	rs3851976	Human NCBI Build 35	2	201912775	CASP10
3455	-	9564	A/G	0	396845	rs3906652	Human NCBI Build 35	5	146071967	PPP2R2B
3456	-	9572	A/G	1	396853	rs4268128	Human NCBI Build 35	8	22993801	TNFRSF10C
3457	-	9575	A/G	1	396855	rs4363056	Human NCBI Build 35	6	137039312	MAP3K5
3458	-	9580	A/G	1	396860	rs4473484	Human NCBI Build 35	22	16495404	BCL2L13
3459	-	9586	A/G	0	396865	rs4674259	Human NCBI Build 35	2	218816511	IL8RB
3460	-	9589	A/G	0	396867	rs4680367	Human NCBI Build 35	3	158648825	PTX3-VEPH1
3461	-	9591	A/G	1	396869	rs4693761	Human NCBI Build 35	4	87568650	MAPK10
3462	-	9593	A/G	0	396871	rs4716860	Human NCBI Build 35	7	157273969	PTPRN2
3463	-	9594	A/G	0	396872	rs4744505	Human NCBI Build 35	9	90659552	SYK
3464	-	9597	A/G	0	396875	rs4766500	Human NCBI Build 35	12	109456511	ENSG00000196850
3465	-	9605	A/G	0	396880	rs4812652	Human NCBI Build 35	20	40860242	PTPRT
3467	-	9615	A/G	0	396887	rs4879877	Human NCBI Build 35	9	35171291	UNC13B
3468	-	9616	A/G	0	396888	rs4880019	Human NCBI Build 35	9	36853450	PAX5
3469	-	9620	A/G	0	396890	rs4909289	Human NCBI Build 35	7	157454380	PTPRN2
3470	-	9624	A/G	1	396894	rs4959377	Human NCBI Build 35	6	6225287 F13A1	
3471	-	9628	A/G	0	396897	rs4987739	Human NCBI Build 35	18	59090714	BCL2
3472	-	9634	A/G	0	396902	rs570613	Human NCBI Build 35	10	8146508 GATA3	
3473	-	9637	A/G	0	396905	rs5743831	Human NCBI Build 35	4	38649980	TLR6
3475	-	9644	A/G	0	396912	rs587585	Human NCBI Build 35	1	22703624	C1QA
3478	-	9648	A/G	0	396915	rs5987840	Human NCBI Build 35	X	114064714	IL13RA2
3479	-	9662	A/G	0	396926	rs6098	Human NCBI Build 35	18	59715374	SERPINB2
3480	-	9663	A/G	0	396927	rs6100	Human NCBI Build 35	18	59720625	SERPINB2
3481	-	9665	A/G	1	396929	rs6102985	Human NCBI Build 35	20	40736940	PTPRT
3482	-	9674	A/G	0	396935	rs636624	Human NCBI Build 35	3	61714824	PTPRG
3483	-	9676	A/G	1	396937	rs6418240	Human NCBI Build 35	X	104369452	IL1RAPL2
3484	-	9687	A/G	0	396945	rs6459830	Human NCBI Build 35	7	157334204	PTPRN2
3485	-	9691	A/G	1	396949	rs6538486	Human NCBI Build 35	12	93078458	PLXNC1
3486	-	9692	A/G	1	396950	rs6555810	Human NCBI Build 35	5	156390564	HAVCR1
3487	-	9695	A/G	0	396953	rs6570288	Human NCBI Build 35	6	139181282	ENSG00000118519
3488	-	9701	A/G	0	396959	rs6687162	Human NCBI Build 35	1	211066795	PTPN14
3489	-	9703	A/G	0	396961	rs6689237	Human NCBI Build 35	1	157305343	SLAMF6
3490	-	9710	A/G	1	396968	rs6741642	Human NCBI Build 35	2	46846559	SOCS5
3491	-	9711	A/G	0	396969	rs675469	Human NCBI Build 35	9	33343212	NFX1
3492	-	9713	A/G	1	396971	rs6792467	Human NCBI Build 35	3	37752372	ITGA9
3493	-	9715	A/G	0	396973	rs6804441	Human NCBI Build 35	3	120743634	CD80
3494	-	9716	A/G	0	396974	rs6808749	Human NCBI Build 35	3	61635667	PTPRG
3495	-	9720	A/G	0	396977	rs683031	Human NCBI Build 35	1	232921460	EDARADD
3496	-	9721	A/G	0	396978	rs6873234	Human NCBI Build 35	5	169232546	DOCK2
3497	-	9723	A/G	1	396980	rs6912975	Human NCBI Build 35	6	112201031	FYN
3498	-	9724	A/G	1	396981	rs6918969	Human NCBI Build 35	6	41157873	NFYA
3499	-	9725	A/G	0	396982	rs6930478	Human NCBI Build 35	6	143112456	HIVEP2
3500	-	9726	A/G	0	396983	rs6934113	Human NCBI Build 35	6	112274302	FYN
3501	-	9733	A/G	0	396989	rs706908	Human NCBI Build 35	6	112154149	FYN
3502	-	9734	A/G	0	396990	rs7101128	Human NCBI Build 35	10	31808975	TCF8
3504	-	9747	A/G	0	397000	rs725787	Human NCBI Build 35	8	27321393	PTK2B
3505	-	9748	A/G	1	397001	rs7259148	Human NCBI Build 35	19	59023873	NALP12
3506	-	9759	A/G	0	397011	rs749067	Human NCBI Build 35	11	47274733	MADD

3507	-	9763	A/G	0	397015	rs7535374	Human NCBI Build 35	1	50678918	FAF1
3508	-	9770	A/G	0	397022	rs759160	Human NCBI Build 35	7	54955651	EGFR
3509	-	9772	A/G	0	397024	rs7601754	Human NCBI Build 35	2	191765957	STAT4
3510	-	9773	A/G	0	397025	rs7617041	Human NCBI Build 35	3	12684167	RAF1-ENSG00000198383
3511	-	9777	A/G	1	397028	rs7656613	Human NCBI Build 35	4	54982771	PDGFRA
3512	-	9778	A/G	0	397029	rs7658893	Human NCBI Build 35	4	38604986	TLR10
3513	-	9781	A/G	0	397032	rs7693779	Human NCBI Build 35	4	48027080	TEC
3515	-	9786	A/G	0	397036	rs7729932	Human NCBI Build 35	5	35204127	PRLR
3516	-	9787	A/G	0	397037	rs7735431	Human NCBI Build 35	5	169134305	DOCK2
3517	-	9788	A/G	0	397038	rs7757672	Human NCBI Build 35	6	36193303	MAPK13
3518	-	9789	A/G	0	397039	rs775833	Human NCBI Build 35	19	60118110	NCR1
3519	-	9818	A/G	0	397058	rs8090864	Human NCBI Build 35	18	75265044	NFATC1
3520	-	9822	A/G	0	397061	rs8109165	Human NCBI Build 35	19	58484854	BIRC8-ENSG00000189348
3521	-	9823	A/G	0	397062	rs8119377	Human NCBI Build 35	20	34660287	TGIF2-SLA2
3522	-	9824	A/G	1	397063	rs8178405	Human NCBI Build 35	17	53699204	LPO-MPO
3523	-	9825	A/G	0	397064	rs849877	Human NCBI Build 35	6	22406678	PRL
3524	-	9831	A/G	0	397070	rs8919	Human NCBI Build 35 22	16587611	BID-BCL2L13	
3525	-	9834	A/G	0	397073	rs928799	Human NCBI Build 35	3	37525386	ITGA9
3526	-	9837	A/G	0	397076	rs9314349	Human NCBI Build 35	8	27530121	CLU
3527	-	9846	A/G	0	397085	rs956084	Human NCBI Build 35	1	50623368	FAF1
3528	-	9848	A/G	0	397087	rs9669800	Human NCBI Build 35	12	109485227	ENSG00000196850
3529	-	9849	A/G	0	397088	rs976168	Human NCBI Build 35	18	8210827	PTPRM
3530	-	9857	A/G	0	397094	rs996924	Human NCBI Build 35	9	8308231	PTPRD
3531	-	9860	A/G	0	397097	rs10150297	Human NCBI Build 35	14	59800263	PPM1A
3532	-	9865	A/G	1	397102	rs1031116	Human NCBI Build 35	18	7851456	PTPRM
3533	-	9869	A/G	0	397105	rs10485163	Human NCBI Build 35	6	128858581	PTPRK
3534	-	9871	A/G	0	397107	rs10491538	Human NCBI Build 35	9	120800037	C5
3535	-	9875	A/G	1	397110	rs10494935	Human NCBI Build 35	1	207901170	TRAF5
3536	-	9877	A/G	1	397112	rs10501158	Human NCBI Build 35	11	36582180	RAG1-ENSG00000166352
3537	-	9892	A/G	1	397125	rs10850109	Human NCBI Build 35	12	111876888	OAS2-OAS3
3538	-	9893	A/G	0	397126	rs10857565	Human NCBI Build 35	10	49289799	MAPK8
3540	-	9896	A/G	0	397129	rs10933819	Human NCBI Build 35	3	106736335	ALCAM
3541	-	9898	A/G	0	397131	rs10971482	Human NCBI Build 35	9	33350125	NFX1
3542	-	9900	A/G	0	397133	rs11074594	Human NCBI Build 35	16	23880872	PRKCB1
3543	-	9901	A/G	1	397134	rs11080606	Human NCBI Build 35	18	12857969	PTPN2
3544	-	9902	A/G	0	397135	rs11120218	Human NCBI Build 35	1	203666846	C4BPA
3545	-	9905	A/G	1	397138	rs11129562	Human NCBI Build 35	3	33831892	PDCD6IP
3546	-	9907	A/G	0	397139	rs11130854	Human NCBI Build 35	3	61786047	PTPRG
3547	-	9908	A/G	0	397140	rs1116084	Human NCBI Build 35	8	22451254	PPP3CC
3548	-	9910	A/G	0	397142	rs11196422	Human NCBI Build 35	10	115433080	CASP7
3549	-	9913	A/G	0	397144	rs11243069	Human NCBI Build 35	6	6235002	F13A1
3550	-	9915	A/G	0	397146	rs11466655	Human NCBI Build 35	4	38598636	TLR10
3551	-	9917	A/G	1	397147	rs11466657	Human NCBI Build 35	4	38598360	TLR10
3552	-	9924	A/G	0	397154	rs11739243	Human NCBI Build 35	5	42563695	GHR
3553	-	9929	A/G	0	397157	rs11831354	Human NCBI Build 35	12	15604976	PTPRO
3554	-	9930	A/G	0	397158	rs11862517	Human NCBI Build 35	16	45915052	ENSG00000129636
3555	-	9933	A/G	0	397161	rs1187873	Human NCBI Build 35	14	54570004	SOCS4
3556	-	9937	A/G	0	397164	rs1206499	Human NCBI Build 35	7	121156158	PTPRZ1
3557	-	9939	A/G	1	397166	rs12104442	Human NCBI Build 35	2	201839462	CFLAR

3558	-	9941	A/G	0	397167	rs12116153	Human NCBI Build 35	X	104524008	IL1RAPL2
3559	-	9942	A/G	1	397168	rs12117799	Human NCBI Build 35	1	114030646	PTPN22-RSBN1
3560	-	9945	A/G	0	397170	rs12124113	Human NCBI Build 35	1	240230407	AKT3
3561	-	9956	A/G	0	397179	rs1234213	Human NCBI Build 35	10	89679301	ENSG00000171862
3562	-	9958	A/G	0	397181	rs12392726	Human NCBI Build 35	X	104488412	IL1RAPL2
3564	-	9960	A/G	0	397183	rs12456376	Human NCBI Build 35	18	7952217	PTPRM
3565	-	9970	A/G	1	397193	rs13074062	Human NCBI Build 35	3	61648392	PTPRG
3566	-	9975	A/G	0	397197	rs1329120	Human NCBI Build 35	1	89296586	GBP2
3567	-	9980	A/G	1	397201	rs13405631	Human NCBI Build 35	2	102287138	IL1RL2
3568	-	9982	A/G	0	397203	rs1358748	Human NCBI Build 35	1	67348921	IL23R
3569	-	9983	A/G	0	397204	rs1363576	Human NCBI Build 35	5	169332702	DOCK2
3570	-	9985	A/G	0	397206	rs1398868	Human NCBI Build 35	1	51031367	FAF1
3571	-	9986	A/G	0	397207	rs1405938	Human NCBI Build 35	4	185931767	CASP3
3572	-	9991	A/G	0	397212	rs1461035	Human NCBI Build 35	12	15537139	PTPRO
3573	-	9992	A/G	0	397213	rs1461155	Human NCBI Build 35	3	99731422	GPR15
3574	-	10001	A/G	0	397221	rs1559018	Human NCBI Build 35	3	191779785	IL1RAP
3575	-	10004	A/G	0	397224	rs1599796	Human NCBI Build 35	3	120726624	CD80-C3orf1
3576	-	10011	A/G	0	397230	rs1686191	Human NCBI Build 35	1	161392362	PBX1
3577	-	10012	A/G	0	397231	rs17006436	Human NCBI Build 35	2	70971766	CD207
3579	-	10021	A/G	0	397237	rs1788114	Human NCBI Build 35	18	65714952	CD226
3580	-	10025	A/G	1	397241	rs1827355	Human NCBI Build 35	5	38961921	OSMR
3581	-	10029	A/G	0	397245	rs1867192	Human NCBI Build 35	3	107050936	CBLB
3582	-	10032	A/G	1	397246	rs1877724	Human NCBI Build 35	1	222320090	EPHX1
3583	-	10035	A/G	0	397249	rs1921622	Human NCBI Build 35	2	102424585	IL1RL1
3584	-	10038	A/G	0	397252	rs1946131	Human NCBI Build 35	2	102420447	IL1RL1
3585	-	10039	A/G	0	397253	rs1956922	Human NCBI Build 35	14	24048014	CMA1
3586	-	10041	A/G	0	397255	rs2029087	Human NCBI Build 35	2	46082013	PRKCE
3588	-	10044	A/G	1	397258	rs2065979	Human NCBI Build 35	20	33231351	PROCR
3589	-	10045	A/G	0	397259	rs2069837	Human NCBI Build 35	7	22541267	IL6-ENSG00000179428
3590	-	10046	A/G	0	397260	rs2070782	Human NCBI Build 35	17	59785865	PECAM1
3591	-	10048	A/G	1	397262	rs2072473	Human NCBI Build 35	2	102101013	IL1R2
3592	-	10056	A/G	1	397268	rs2172708	Human NCBI Build 35	1	151372868	ADAR
3593	-	10063	A/G	0	397273	rs2240853	Human NCBI Build 35	7	38147937	TRGV9-ENSG00000198117
3594	-	10067	A/G	0	397276	rs2276002	Human NCBI Build 35	3	37793624	ITGA9
3595	-	10074	A/G	0	397281	rs2293445	Human NCBI Build 35	12	47685129	PRKAG1
3596	-	10079	A/G	0	397285	rs2307148	Human NCBI Build 35	1	67528793	IL12RB2
3597	-	10084	A/G	1	397289	rs2377422	Human NCBI Build 35	12	8172175	ENSG00000111729
3598	-	10085	A/G	0	397290	rs238736	Human NCBI Build 35	20	3410333	ATRN
3599	-	10090	A/G	0	397295	rs2448343	Human NCBI Build 35	10	62209650	CDC2
3600	-	10092	A/G	0	397297	rs2476599	Human NCBI Build 35	1	114075501	PTPN22
3601	-	10096	A/G	0	397299	rs2517892	Human NCBI Build 35	6	29909453	HLA-G
3602	-	10099	A/G	0	397302	rs25800	Human NCBI Build 35	5	156616669	ITK
3603	-	10100	A/G	0	397303	rs2583764	Human NCBI Build 35	8	79826355	IL7
3604	-	10105	A/G	0	397306	rs262865	Human NCBI Build 35	5	169094611	DOCK2
3605	-	10108	A/G	0	397308	rs267533	Human NCBI Build 35	3	37564877	ITGA9
3606	-	10110	A/G	0	397309	rs267944	Human NCBI Build 35	5	10801231	DAP
3607	-	10111	A/G	0	397310	rs2681417	Human NCBI Build 35	3	123307887	CD86
3608	-	10113	A/G	0	397311	rs2684761	Human NCBI Build 35	15	97181893	IGF1R
3609	-	10116	A/G	0	397313	rs2729747	Human NCBI Build 35	11	76776127	PAK1

3610	-	10117	A/G	0	397314	rs2869461	Human NCBI Build 35	4	77278072	CXCL9
3611	-	10122	A/G	1	397319	rs3027623	Human NCBI Build 35	X	100437283	BTk
3612	-	10123	A/G	0	397320	rs3027651	Human NCBI Build 35	X	100408128	TIMM8A-BTK
3613	-	10128	A/G	1	397324	rs3124237	Human NCBI Build 35	9	87447772	DAPK1
3614	-	10134	A/G	1	397330	rs337442	Human NCBI Build 35	11	22699044	GAS2
3615	-	10136	A/G	0	397332	rs3730089	Human NCBI Build 35	5	67623904	PIK3R1
3616	-	10144	A/G	0	397338	rs3750779	Human NCBI Build 35	10	71382508	COL13A1-AMID
3617	-	10145	A/G	0	397339	rs3750919	Human NCBI Build 35	11	1249407	TOLLIP
3618	-	10146	A/G	0	397340	rs3755867	Human NCBI Build 35	4	103883867	NFKB1
3620	-	10148	A/G	0	397342	rs3764240	Human NCBI Build 35	6	74586795	CD109
3621	-	10150	A/G	0	397344	rs3771882	Human NCBI Build 35	2	151952474	NMI
3622	-	10152	A/G	1	397346	rs3774956	Human NCBI Build 35	4	103865719	NFKB1
3623	-	10153	A/G	0	397347	rs3775291	Human NCBI Build 35	4	187379223	TLR3
3624	-	10155	A/G	1	397349	rs3794318	Human NCBI Build 35	12	8649810	AICDA
3625	-	10168	A/G	0	397359	rs3847356	Human NCBI Build 35	10	71498843	H2AFY2-AMID
3626	-	10174	A/G	0	397364	rs3924111	Human NCBI Build 35	4	38620382	TLR1
3627	-	10177	A/G	0	397367	rs412394	Human NCBI Build 35	12	69209460	PTPRB
3628	-	10180	A/G	0	397369	rs4133139	Human NCBI Build 35	4	87377083	MAPK10
3629	-	10181	A/G	0	397370	rs4253655	Human NCBI Build 35	22	44889690	PPARA
3630	-	10182	A/G	0	397371	rs4253754	Human NCBI Build 35	22	44935663	PPARA
3631	-	10183	A/G	0	397372	rs4257674	Human NCBI Build 35	4	77302864	CXCL10
3632	-	10184	A/G	0	397373	rs4262243	Human NCBI Build 35	7	38072440	TRGV9
3633	-	10191	A/G	1	397380	rs4510947	Human NCBI Build 35	9	36844541	PAX5
3634	-	10193	A/G	1	397382	rs4648037	Human NCBI Build 35	4	103861972	NFKB1
3635	-	10198	A/G	0	397387	rs4807651	Human NCBI Build 35	19	4773855	ENSG00000127666
3636	-	10200	A/G	1	397388	rs4810482	Human NCBI Build 35	20	44067957	MMP9
3637	-	10202	A/G	1	397390	rs4812677	Human NCBI Build 35	20	41215113	PTPRT
3638	-	10204	A/G	0	397391	rs4845384	Human NCBI Build 35	1	151400742	ADAR
3639	-	10207	A/G	0	397394	rs4880052	Human NCBI Build 35	9	37026285	PAX5
3640	-	10210	A/G	0	397397	rs489832	Human NCBI Build 35	15	32065199	AVEN
3641	-	10214	A/G	0	397401	rs4940003	Human NCBI Build 35	18	46474150	MAPK4
3642	-	10215	A/G	0	397402	rs4948878	Human NCBI Build 35	10	44194827	CXCL12
3643	-	10216	A/G	0	397403	rs4956405	Human NCBI Build 35	4	142985254	IL15
3644	-	10219	A/G	0	397406	rs527342	Human NCBI Build 35	1	157535137	SLAMF7
3645	-	10222	A/G	1	397409	rs535351	Human NCBI Build 35	1	89438613	GBP5
3646	-	10225	A/G	1	397412	rs5743815	Human NCBI Build 35	4	38652381	TLR6
3649	-	10242	A/G	1	397427	rs636006	Human NCBI Build 35	3	32426349	ENSG00000153551
3650	-	10245	A/G	0	397429	rs6417047	Human NCBI Build 35	18	8264246	PTPRM
3651	-	10250	A/G	1	397433	rs6445998	Human NCBI Build 35	3	58626893	FAM3D
3652	-	10253	A/G	0	397434	rs6472812	Human NCBI Build 35	8	75079638	LY96
3653	-	10259	A/G	0	397438	rs650652	Human NCBI Build 35	10	6580729	PRKCQ
3654	-	10261	A/G	0	397440	rs6533489	Human NCBI Build 35	4	111318669	EGF
3655	-	10265	A/G	1	397444	rs6546952	Human NCBI Build 35	2	75213418	TACR1
3656	-	10274	A/G	0	397452	rs6693492	Human NCBI Build 35	1	211074373	PTPN14
3657	-	10276	A/G	0	397454	rs6783508	Human NCBI Build 35	3	138102264	NCK1-ENSG00000181882
3658	-	10280	A/G	0	397457	rs6804472	Human NCBI Build 35	3	106691352	ALCAM
3659	-	10281	A/G	0	397458	rs6805169	Human NCBI Build 35	3	61911116	PTPRG
3660	-	10284	A/G	0	397460	rs6829390	Human NCBI Build 35	4	48039914	TEC
3661	-	10285	A/G	0	397461	rs6838095	Human NCBI Build 35	4	89266615	SPP1

3663	-	10289	A/G	0	397464	rs696758	Human NCBI Build 35	5	39366973	C9
3664	-	10290	A/G	0	397465	rs6993386	Human NCBI Build 35	8	79816700	IL7
3667	-	10298	A/G	0	397472	rs7124085	Human NCBI Build 35	11	59996299	MS4A1
3668	-	10299	A/G	0	397473	rs7142474	Human NCBI Build 35	14	22855445	BCL2L2-ENSG00000100836
3669	-	10300	A/G	0	397474	rs714373	Human NCBI Build 35	6	47337585	TNFRSF21
3671	-	10312	A/G	0	397484	rs732111	Human NCBI Build 35	5	460230	AHRR
3672	-	10318	A/G	0	397488	rs744038	Human NCBI Build 35	4	185727562	IRF2
3673	-	10321	A/G	1	397491	rs7543272	Human NCBI Build 35	1	50781123	FAF1
3674	-	10329	A/G	0	397497	rs7624400	Human NCBI Build 35	3	106921496	CBLB
3675	-	10333	A/G	0	397501	rs7655579	Human NCBI Build 35	4	111223312	EGF
3676	-	10334	A/G	0	397502	rs7659024	Human NCBI Build 35	4	155878535	FGG
3677	-	10345	A/G	0	397511	rs7783685	Human NCBI Build 35	7	76895741	PTPN12
3679	-	10351	A/G	0	397516	rs7854120	Human NCBI Build 35	9	89332138	SEMA4D
3680	-	10355	A/G	0	397520	rs7947433	Human NCBI Build 35	11	35173390	CD44
3681	-	10356	A/G	0	397521	rs7957426	Human NCBI Build 35	12	6786167	CD4
3682	-	10366	A/G	0	397529	rs8106553	Human NCBI Build 35	17	31664281	
ENSG00000187869-ENSG00000189315-ENSG00000197262										
3683	-	10368	A/G	0	397530	rs8107911	Human NCBI Build 35	19	6657041	C3
3684	-	10369	A/G	0	397531	rs8177600	Human NCBI Build 35	10	6065069	IL15RA
3686	-	10374	A/G	0	397534	rs872211	Human NCBI Build 35	3	62158661	PTPRG
3687	-	10377	A/G	1	397536	rs891848	Human NCBI Build 35	15	64485226	MAP2K1
3688	-	10380	A/G	0	397539	rs916329	Human NCBI Build 35	20	40445935	PTPRT
3689	-	10383	A/G	0	397542	rs9311832	Human NCBI Build 35	3	61963338	PTPRG
3690	-	10388	A/G	1	397547	rs9376263	Human NCBI Build 35	6	137531319	IL22RA2
3691	-	10389	A/G	0	397548	rs9395241	Human NCBI Build 35	6	47308970	TNFRSF21
3692	-	10399	A/G	0	397556	rs9932414	Human NCBI Build 35	16	66777470	NFATC3
3693	-	10400	A/G	0	397557	rs9959983	Human NCBI Build 35	18	59011951	BCL2
3694	-	10402	A/G	0	397559	rs1006026	Human NCBI Build 35	9	114770824	TNFSF8
3695	-	10408	A/G	0	397565	rs1020161	Human NCBI Build 35	18	66129836	SOCS6
3696	-	10412	A/G	0	397569	rs10399783	Human NCBI Build 35	1	50639432	FAF1
3697	-	10416	A/G	0	397572	rs10489445	Human NCBI Build 35	1	29476362	PTPRU
3698	-	10428	A/G	1	397580	rs10506481	Human NCBI Build 35	12	64930378	IRAK3
3699	-	10430	A/G	0	397582	rs10506616	Human NCBI Build 35	12	69597373	PTPRR
3700	-	10433	A/G	0	397585	rs10510696	Human NCBI Build 35	3	37654551	ITGA9
3701	-	10444	A/G	0	397593	rs10800041	Human NCBI Build 35	1	161382817	PBX1-ENSG00000197613
3702	-	10445	A/G	0	397594	rs10815895	Human NCBI Build 35	9	8504456	PTPRD
3703	-	10453	A/G	0	397602	rs11097100	Human NCBI Build 35	4	87465921	MAPK10
3704	-	10454	A/G	0	397603	rs11098047	Human NCBI Build 35	4	111071568	none
3705	-	10455	A/G	1	397604	rs11107162	Human NCBI Build 35	12	92592402	CRADD
3706	-	10458	A/G	0	397606	rs11118516	Human NCBI Build 35	1	204317735	MCP
3707	-	10462	A/G	0	397608	rs11153311	Human NCBI Build 35	6	112116018	FYN
3708	-	10464	A/G	0	397610	rs1125819	Human NCBI Build 35	4	111394006	EGF-ELOVL6
3709	-	10465	A/G	0	397611	rs11465635	Human NCBI Build 35	2	102456601	IL18R1
3711	-	10474	A/G	0	397618	rs11671053	Human NCBI Build 35	17	31562690	
ENSG00000187869-ENSG00000189315-ENSG00000197262										
3712	-	10477	A/G	0	397621	rs11780669	Human NCBI Build 35	8	16018641	MSR1
3713	-	10478	A/G	0	397622	rs11860257	Human NCBI Build 35	16	46003798	ENSG00000129636
3714	-	10479	A/G	0	397623	rs11864698	Human NCBI Build 35	16	49355708	ENSG00000083799
3715	-	10480	A/G	0	397624	rs11876772	Human NCBI Build 35	18	58968686	BCL2

3716	-	10482	A/G	0	397625	rs1204682	Human NCBI Build 35	1	204465401	CD34
3717	-	10487	A/G	0	397630	rs1217407	Human NCBI Build 35	1	114105790	PTPN22
3718	-	10490	A/G	0	397632	rs1222158	Human NCBI Build 35	1	220295436	TP53BP2
3719	-	10494	A/G	0	397636	rs12451415	Human NCBI Build 35	17	11947505	MAP2K4
3720	-	10495	A/G	0	397637	rs12556235	Human NCBI Build 35	X	103990675	IL1RAPL2
3721	-	10497	A/G	0	397639	rs12582133	Human NCBI Build 35	12	92578096	CRADD
3722	-	10498	A/G	0	397640	rs12582135	Human NCBI Build 35	12	92578164	CRADD
3723	-	10499	A/G	0	397641	rs12641958	Human NCBI Build 35	4	155826176	PLRG1-FGA
3724	-	10500	A/G	0	397642	rs12677679	Human NCBI Build 35	8	22967018	TNFRSF10B
3725	-	10502	A/G	0	397644	rs12954459	Human NCBI Build 35	18	8241933	PTPRM
3726	-	10504	A/G	0	397646	rs13027171	Human NCBI Build 35	2	112403219	MERTK
3727	-	10515	A/G	0	397655	rs1353983	Human NCBI Build 35	9	8308948	PTPRD
3728	-	10516	A/G	1	397656	rs1359850	Human NCBI Build 35	10	129675326	PTPRE
3729	-	10517	A/G	1	397657	rs1362567	Human NCBI Build 35	16	45782194	ENSG00000129636
3730	-	10519	A/G	0	397659	rs1375063	Human NCBI Build 35	8	142033089	PTK2
3731	-	10520	A/G	0	397660	rs140522	Human NCBI Build 35	22	49261410	ECGF1
3732	-	10521	A/G	0	397661	rs1437137	Human NCBI Build 35	16	68262239	NFAT5
3734	-	10532	A/G	0	397669	rs1615504	Human NCBI Build 35	18	65677624	CD226
3735	-	10533	A/G	0	397670	rs169111	Human NCBI Build 35	3	37490537	ITGA9
3736	-	10534	A/G	0	397671	rs17258982	Human NCBI Build 35	1	204041759	CR2
3737	-	10538	A/G	0	397675	rs1773542	Human NCBI Build 35	1	164164607	CD3Z
3738	-	10545	A/G	1	397681	rs1905045	Human NCBI Build 35	8	75062568	LY96-ENSG00000175606
3739	-	10548	A/G	1	397684	rs197505	Human NCBI Build 35	6	143140569	HIVEP2
3740	-	10553	A/G	0	397689	rs2026432	Human NCBI Build 35	10	6547609	PRKCQ
3741	-	10559	A/G	1	397694	rs2069705	Human NCBI Build 35	12	66841278	IFNG
3742	-	10563	A/G	0	397698	rs2130791	Human NCBI Build 35	10	71461357	AMID
3743	-	10576	A/G	0	397706	rs2237042	Human NCBI Build 35	4	111199624	EGF
3744	-	10580	A/G	1	397707	rs2250647	Human NCBI Build 35	11	76747394	PAK1
3745	-	10582	A/G	1	397709	rs2272986	Human NCBI Build 35	6	41145756	NFYA-C6orf130
3746	-	10586	A/G	0	397711	rs2274393	Human NCBI Build 35	6	6127604	F13A1
3747	-	10588	A/G	1	397713	rs2277025	Human NCBI Build 35	5	156392673	HAVCR1
3748	-	10591	A/G	0	397715	rs2286404	Human NCBI Build 35	6	30081599	HLA-G
3749	-	10594	A/G	0	397718	rs2305011	Human NCBI Build 35	11	119843250	ARHGEF12
3750	-	10601	A/G	0	397725	rs2426159	Human NCBI Build 35	20	48606586	PTPN1
3753	-	10623	A/G	1	397744	rs2834211	Human NCBI Build 35	21	33711678	IFNGR2
3754	-	10624	A/G	0	397745	rs2844477	Human NCBI Build 35	6	31686751	AIF1
3755	-	10628	A/G	1	397749	rs3024422	Human NCBI Build 35	6	6156418	F13A1
3756	-	10629	A/G	1	397750	rs3091434	Human NCBI Build 35	20	40761935	PTPRT
3758	-	10634	A/G	1	397755	rs3176787	Human NCBI Build 35	12	9804401	CD69
3759	-	10635	A/G	0	397756	rs334782	Human NCBI Build 35	3	3123458	IL5RA
3760	-	10640	A/G	1	397760	rs351584	Human NCBI Build 35	8	16096972	MSR1
3761	-	10647	A/G	1	397764	rs360720	Human NCBI Build 35	11	111527154	IL18
3762	-	10651	A/G	0	397767	rs3740593	Human NCBI Build 35	10	70171916	CCAR1
3763	-	10658	A/G	1	397773	rs3757165	Human NCBI Build 35	6	137157712	MAP3K5
3764	-	10661	A/G	0	397775	rs3761957	Human NCBI Build 35	1	154626826	CD5L
3765	-	10662	A/G	0	397776	rs3764383	Human NCBI Build 35	17	73720446	BIRC5
3766	-	10663	A/G	1	397777	rs3771810	Human NCBI Build 35	2	75219308	TACR1
3767	-	10666	A/G	0	397779	rs3782379	Human NCBI Build 35	12	69228676	PTPRB
3768	-	10667	A/G	0	397780	rs3783516	Human NCBI Build 35	2	113261909	IL1A

3769	-	10668	A/G	0	397781	rs3788935	Human NCBI Build 35	X	12682316	TLR8
3770	-	10669	A/G	0	397782	rs3793729	Human NCBI Build 35	10	6562512	PRKCQ
3771	-	10673	A/G	1	397786	rs3808391	Human NCBI Build 35	8	56953203	LYN
3772	-	10677	A/G	1	397790	rs3829864	Human NCBI Build 35	12	66906983	IL26
3773	-	10678	A/G	0	397791	rs3867381	Human NCBI Build 35	3	32390118	CKLFSF8
3774	-	10679	A/G	0	397792	rs3892225	Human NCBI Build 35	1	214941692	ENSG00000092969
3775	-	10686	A/G	1	397799	rs419939	Human NCBI Build 35	5	114954320	TICAM2
3776	-	10689	A/G	0	397802	rs4235078	Human NCBI Build 35	4	87386497	MAPK10
3777	-	10696	A/G	0	397807	rs4385221	Human NCBI Build 35	5	169390179	DOCK2
3778	-	10697	A/G	0	397808	rs4501465	Human NCBI Build 35	6	33148285	HLA-DPB1-HLA-DPA1
3779	-	10701	A/G	0	397812	rs4632862	Human NCBI Build 35	6	74553730	CD109
3780	-	10702	A/G	0	397813	rs4647311	Human NCBI Build 35	7	142510820	CASP2
3781	-	10704	A/G	0	397815	rs4659455	Human NCBI Build 35	1	232949864	EDARADD
3782	-	10711	A/G	0	397820	rs4750565	Human NCBI Build 35	10	6608207	PRKCQ
3783	-	10713	A/G	0	397822	rs4771218	Human NCBI Build 35	13	27553311	FLT3
3784	-	10716	A/G	0	397825	rs4795095	Human NCBI Build 35	17	31221413	CCL5-ENSG00000172653
3785	-	10718	A/G	1	397827	rs4844573	Human NCBI Build 35	1	203693295	C4BPA
3786	-	10720	A/G	1	397829	rs485922	Human NCBI Build 35	3	106746314	ALCAM
3787	-	10723	A/G	0	397832	rs4880042	Human NCBI Build 35	9	36940301	PAX5
3788	-	10733	A/G	0	397839	rs507879	Human NCBI Build 35	11	104383137	CASP5
3789	-	10740	A/G	1	397844	rs5742692	Human NCBI Build 35	12	101302065	IGF1
3790	-	10745	A/G	0	397848	rs5917188	Human NCBI Build 35	X	104036235	IL1RAPL2
3791	-	10750	A/G	0	397853	rs6013202	Human NCBI Build 35	20	49552854	NFATC2
3792	-	10754	A/G	0	397857	rs607175	Human NCBI Build 35	6	52220925	IL17F
3793	-	10755	A/G	0	397858	rs6072687	Human NCBI Build 35	20	40389307	PTPRT
3794	-	10757	A/G	0	397860	rs6072949	Human NCBI Build 35	20	41080347	PTPRT
3795	-	10761	A/G	1	397863	rs6429238	Human NCBI Build 35	1	232180781	ENSG00000143669
3796	-	10764	A/G	0	397866	rs6441948	Human NCBI Build 35	3	46270781	CCR3
3797	-	10767	A/G	0	397869	rs6488507	Human NCBI Build 35	12	12248167	LRP6-BCL2L14
3798	-	10769	A/G	1	397871	rs6500552	Human NCBI Build 35	16	3699394	TRAP1
3799	-	10781	A/G	0	397882	rs6616577	Human NCBI Build 35	X	104288722	IL1RAPL2
3801	-	10791	A/G	1	397891	rs6764799	Human NCBI Build 35	3	106876990	CBLB
3802	-	10794	A/G	0	397894	rs6867398	Human NCBI Build 35	5	179644666	MAPK9
3803	-	10797	A/G	1	397896	rs6897932	Human NCBI Build 35	5	35910332	IL7R
3804	-	10800	A/G	0	397897	rs6910587	Human NCBI Build 35	6	128615234	PTPRK
3805	-	10803	A/G	0	397900	rs696365	Human NCBI Build 35	3	109243490	CD47
3806	-	10808	A/G	0	397905	rs7051841	Human NCBI Build 35	X	104772152	IL1RAPL2
3807	-	10813	A/G	1	397909	rs7157967	Human NCBI Build 35	14	101655966	HSPCA
3808	-	10816	A/G	1	397911	rs7261303	Human NCBI Build 35	20	40851971	PTPRT
3810	-	10829	A/G	0	397923	rs7545135	Human NCBI Build 35	1	157339600	CD84
3811	-	10831	A/G	0	397925	rs7621905	Human NCBI Build 35	3	106661546	ALCAM
3812	-	10835	A/G	0	397929	rs7659704	Human NCBI Build 35	4	140984730	MGST2
3813	-	10839	A/G	1	397933	rs7707913	Human NCBI Build 35	5	42620609	GHR
3814	-	10841	A/G	0	397935	rs7772036	Human NCBI Build 35	6	112167492	FYN
3816	-	10846	A/G	0	397939	rs7957299	Human NCBI Build 35	12	109465031	ENSG00000196850
3817	-	10851	A/G	0	397944	rs8053982	Human NCBI Build 35	16	68237872	NFAT5
3819	-	10856	A/G	0	397947	rs845551	Human NCBI Build 35	7	55011492	EGFR
3820	-	10857	A/G	1	397948	rs849876	Human NCBI Build 35	6	22407617	PRL
3821	-	10859	A/G	0	397949	rs851006	Human NCBI Build 35	6	36173163	MAPK13-MAPK14

3822	-	10863	A/G	1	397952	rs875530	Human NCBI Build 35	18	7764104	PTPRM	
3823	-	10865	A/G	0	397953	rs888161	Human NCBI Build 35	12	15636521	PTPRO	
3824	-	10867	A/G	0	397955	rs9288918	Human NCBI Build 35	3	112296769	PVRL3	
3825	-	10873	A/G	1	397960	rs9323444	Human NCBI Build 35	14	63635335	SYNE2-ESR2	
3826	-	10875	A/G	0	397962	rs932589	Human NCBI Build 35	6	137124831	MAP3K5	
3827	-	10883	A/G	0	397969	rs961734	Human NCBI Build 35	4	15106303	C1QTNF7	
3828	-	10885	A/G	1	397971	rs984654	Human NCBI Build 35	7	54918365	EGFR	
3829	-	10899	A/G	0	397982	rs1010799	Human NCBI Build 35	X	104452551	IL1RAPL2-ENSG00000181819	
3830	-	10903	A/G	0	397985	rs10126067	Human NCBI Build 35	X	104519944	IL1RAPL2	
3831	-	10909	A/G	0	397991	rs10260982	Human NCBI Build 35	7	157735146	PTPRN2	
3832	-	10912	A/G	0	397994	rs10452184	Human NCBI Build 35	4	111346552	EGF-ELOVL6	
3833	-	10913	A/G	0	397995	rs10457506	Human NCBI Build 35	6	128533696	PTPRK	
3834	-	10914	A/G	1	397996	rs10465613	Human NCBI Build 35	1	232295427	ENSG00000143669	
3835	-	10919	A/G	0	398001	rs10489681	Human NCBI Build 35	1	154533082	SPAP1	
3836	-	10927	A/G	0	398006	rs10495930	Human NCBI Build 35	2	46284326	PRKCE	
3837	-	10928	A/G	0	398007	rs10498474	Human NCBI Build 35	14	54680607	DLG7-LGALS3	
3838	-	10929	A/G	0	398008	rs10506599	Human NCBI Build 35	12	69309150	PTPRB	
3839	-	10931	A/G	0	398010	rs10511504	Human NCBI Build 35	9	8583619	PTPRD	
3840	-	10935	A/G	0	398013	rs1058157	Human NCBI Build 35	2	46899926	SOCSS5	
3841	-	10937	A/G	0	398015	rs10745836	Human NCBI Build 35	12	97597643	APAF1	
3842	-	10939	A/G	0	398017	rs10797007	Human NCBI Build 35	1	155108702	CD1B	
3843	-	10940	A/G	0	398018	rs10797887	Human NCBI Build 35	1	180276351	NCF2	
3845	-	10956	A/G	0	398029	rs11066323	Human NCBI Build 35	12	111386081	PTPN11	
3846	-	10959	A/G	0	398032	rs11097118	Human NCBI Build 35	4	88046447	PTPN13	
3847	-	10977	A/G	0	398045	rs12156709	Human NCBI Build 35	X	104462758	IL1RAPL2-ENSG00000181819	
3848	-	10985	A/G	0	398050	rs12443784	Human NCBI Build 35	16	23768338	PRKCB1	
3849	-	10986	A/G	0	398051	rs1246409	Human NCBI Build 35	4	75685457	AREG	
3850	-	10988	A/G	0	398053	rs1263549	Human NCBI Build 35	7	156969471	PTPRN2	
3851	-	10994	A/G	0	398057	rs12746642	Human NCBI Build 35	1	50831790	FAF1	
3853	-	11000	A/G	0	398061	rs131843	Human NCBI Build 35	22	35661909	CSF2RB	
3854	-	11003	A/G	0	398064	rs13288123	Human NCBI Build 35	9	36924760	PAX5	
3856	-	11008	A/G	0	398068	rs1344632	Human NCBI Build 35	2	160510938	LY75	
3857	-	11011	A/G	0	398070	rs1389830	Human NCBI Build 35	5	35899776	IL7R	
3858	-	11013	A/G	0	398072	rs1409981	Human NCBI Build 35	1	71064891	PTGER3	
3859	-	11015	A/G	1	398074	rs1441000	Human NCBI Build 35	18	7816503	PTPRM	
3860	-	11016	A/G	0	398075	rs1469857	Human NCBI Build 35	18	65679994	CD226	
3861	-	11022	A/G	0	398079	rs1513256	Human NCBI Build 35	3	39292440	CX3CR1	
3863	-	11031	A/G	0	398086	rs1555793	Human NCBI Build 35	1	117269273	IGSF2	
3864	-	11034	A/G	0	398089	rs1634320	Human NCBI Build 35	X	12656678	TLR7	
3865	-	11041	A/G	0	398096	rs1796235	Human NCBI Build 35	18	75377844		
ENSG00000186783-NFATC1-ENSG00000198275											
3866	-	11045	A/G	1	398098	rs1835538	Human NCBI Build 35	3	30630485	TGFBR2	
3868	-	11054	A/G	0	398103	rs1867005	Human NCBI Build 35	12	69264491	PTPRB	
3869	-	11067	A/G	0	398116	rs2043055	Human NCBI Build 35	11	111536834	BCDO2-IL18	
3870	-	11076	A/G	0	398123	rs2162356	Human NCBI Build 35	3	37542900	ITGA9	
3871	-	11082	A/G	0	398127	rs2237094	Human NCBI Build 35	6	36116122	MAPK14	
3872	-	11083	A/G	0	398128	rs2240982	Human NCBI Build 35	7	120606826	FAM3C	
3873	-	11085	A/G	0	398130	rs2243266	Human NCBI Build 35	5	132041688	IL4	
3874	-	11090	A/G	1	398133	rs2256595	Human NCBI Build 35	5	38518261	LIFR	

3875	-	11092	A/G	1	398135	rs2270628	Human NCBI Build 35	7	45722810	IGFBP3
3876	-	11098	A/G	0	398140	rs2288403	Human NCBI Build 35	11	129243199	NFRKB
3877	-	11101	A/G	0	398143	rs2300291	Human NCBI Build 35	12	15626949	PTPRO
3879	-	11103	A/G	0	398145	rs2301220	Human NCBI Build 35	6	33146744	HLA-DPB1-HLA-DPA1
3880	-	11107	A/G	0	398148	rs2392545	Human NCBI Build 35	7	38116237	TRGV9
3881	-	11110	A/G	0	398150	rs2535707	Human NCBI Build 35	22	16556423	BCL2L13
3882	-	11111	A/G	0	398151	rs256996	Human NCBI Build 35	5	114943989	TICAM2
3883	-	11120	A/G	1	398158	rs2737532	Human NCBI Build 35	8	7260460	DEFB4
3884	-	11122	A/G	0	398160	rs2800795	Human NCBI Build 35	1	161461836	PBX1
3885	-	11125	A/G	0	398163	rs2820187	Human NCBI Build 35	1	155716325	PYHIN1
3886	-	11126	A/G	1	398164	rs2839661	Human NCBI Build 35	10	31787684	TCF8
3887	-	11130	A/G	0	398168	rs3000466	Human NCBI Build 35	1	71220983	PTGER3
3888	-	11132	A/G	0	398169	rs3012519	Human NCBI Build 35	6	74593230	CD109
3889	-	11133	A/G	1	398170	rs3092215	Human NCBI Build 35	20	41118917	PTPRT
3890	-	11135	A/G	1	398172	rs3095943	Human NCBI Build 35	5	179621162	MAPK9-ENSG00000183279
3891	-	11136	A/G	0	398173	rs3104233	Human NCBI Build 35	5	54439714	GZMA-ENSG00000164287
3892	-	11137	A/G	1	398174	rs3110234	Human NCBI Build 35	5	38521822	LIFR
3893	-	11138	A/G	0	398175	rs3181175	Human NCBI Build 35	11	104380471	CASP5
3894	-	11142	A/G	1	398178	rs353642	Human NCBI Build 35	11	35139236	CD44
3895	-	11143	A/G	0	398179	rs370643	Human NCBI Build 35	5	146042020	PPP2R2B
3896	-	11144	A/G	0	398180	rs3733625	Human NCBI Build 35	4	111290608	EGF
3897	-	11149	A/G	1	398185	rs3754098	Human NCBI Build 35	1	195390513	PTPRC
3898	-	11152	A/G	0	398187	rs3764880	Human NCBI Build 35	X	12684483	TLR8
3899	-	11155	A/G	0	398190	rs3767371	Human NCBI Build 35	1	161504298	PBX1
3900	-	11156	A/G	1	398191	rs3791244	Human NCBI Build 35	2	138565497	HNMT
3901	-	11162	A/G	1	398196	rs3823098	Human NCBI Build 35	6	3057254	RIPK1
3902	-	11173	A/G	1	398206	rs4240530	Human NCBI Build 35	1	111565623	ENSG00000134216
3903	-	11190	A/G	0	398221	rs4761230	Human NCBI Build 35	12	69351449	PTPRR
3904	-	11194	A/G	0	398225	rs4821402	Human NCBI Build 35	22	20539300	MAPK1
3905	-	11200	A/G	0	398229	rs4876872	Human NCBI Build 35	8	120038338	TNFRSF11B
3906	-	11202	A/G	0	398230	rs4952779	Human NCBI Build 35	2	45972026	PRKCE
3907	-	11203	A/G	1	398231	rs4953299	Human NCBI Build 35	2	46148860	PRKCE
3908	-	11207	A/G	0	398235	rs516224	Human NCBI Build 35	4	75115182	CXCL1
3909	-	11208	A/G	0	398236	rs527589	Human NCBI Build 35	11	76832287	PAK1
3910	-	11209	A/G	0	398237	rs543410	Human NCBI Build 35	7	157210246	
PTPRN2-ENSG00000196590-ENSG00000196201										
3911	-	11217	A/G	0	398244	rs6072765	Human NCBI Build 35	20	40561846	PTPRT
3912	-	11219	A/G	0	398246	rs614004	Human NCBI Build 35	3	32430085	ENSG00000153551
3913	-	11227	A/G	0	398250	rs6437591	Human NCBI Build 35	3	106664570	ALCAM
3914	-	11228	A/G	1	398251	rs6438537	Human NCBI Build 35	3	120760536	CD80
3915	-	11234	A/G	0	398257	rs6518660	Human NCBI Build 35	22	15950354	IL17R
3916	-	11239	A/G	0	398260	rs6578143	Human NCBI Build 35	8	141980049	PTK2
3917	-	11240	A/G	0	398261	rs6581568	Human NCBI Build 35	12	63167820	TBK1
3918	-	11242	A/G	0	398263	rs6700734	Human NCBI Build 35	1	169362468	ENSG00000117560
3919	-	11244	A/G	0	398265	rs6752770	Human NCBI Build 35	2	191799069	STAT4
3920	-	11248	A/G	0	398269	rs6923822	Human NCBI Build 35	6	128881163	PTPRK
3921	-	11249	A/G	0	398270	rs696737	Human NCBI Build 35	5	39231180	FYB
3922	-	11252	A/G	1	398271	rs6970138	Human NCBI Build 35	7	156926466	PTPRN2
3923	-	11253	A/G	0	398272	rs7008498	Human NCBI Build 35	8	141946210	PTK2

3924	-	11256	A/G	0	398274	rs7032710	Human NCBI Build 35	9	34694054	CCL21
3925	-	11260	A/G	0	398278	rs7129006	Human NCBI Build 35	11	22760288	GAS2
3926	-	11264	A/G	0	398281	rs717450	Human NCBI Build 35	1	165283850	XCL1
3927	-	11265	A/G	0	398282	rs7213162	Human NCBI Build 35	17	50844598	MMD
3928	-	11268	A/G	0	398285	rs7302972	Human NCBI Build 35	12	93185075	PLXNC1
3929	-	11270	A/G	0	398286	rs7303928	Human NCBI Build 35	12	69283974	PTPRB
3930	-	11271	A/G	0	398287	rs730688	Human NCBI Build 35	5	179637509	MAPK9
3931	-	11273	A/G	0	398289	rs7338328	Human NCBI Build 35	13	23057525	TNFRSF19
3932	-	11276	A/G	0	398292	rs7513873	Human NCBI Build 35	1	155616946	MNDA
3933	-	11280	A/G	0	398295	rs7591613	Human NCBI Build 35	2	46871282	SOC5
3934	-	11281	A/G	0	398296	rs7613548	Human NCBI Build 35	3	45901573	LZTFL1-CCR9
3935	-	11282	A/G	0	398297	rs7624627	Human NCBI Build 35	3	32271509	CKLFSF8
3936	-	11284	A/G	0	398298	rs7630364	Human NCBI Build 35	3	61876832	PTPRG
3937	-	11292	A/G	0	398305	rs7843858	Human NCBI Build 35	8	75062462	LY96-ENSG00000175606
3938	-	11296	A/G	0	398309	rs7952910	Human NCBI Build 35	12	93111019	PLXNC1
3939	-	11298	A/G	1	398310	rs8025474	Human NCBI Build 35	15	66173577	PIAS1
3940	-	11301	A/G	1	398313	rs8069177	Human NCBI Build 35	17	59783168	PECAM1
3941	-	11302	A/G	1	398314	rs8072536	Human NCBI Build 35	17	7893795	ALOX15B
3942	-	11308	A/G	0	398319	rs856055	Human NCBI Build 35	1	155814666	IFI16
3943	-	11314	A/G	1	398323	rs864537	Human NCBI Build 35	1	164143042	CD3Z
3944	-	11315	A/G	0	398324	rs876435	Human NCBI Build 35	8	22929478	TNFRSF10B-RHOBTB2
3946	-	11318	A/G	0	398327	rs9200	Human NCBI Build 35	5	41178363	C6
3947	-	11320	A/G	0	398329	rs928180	Human NCBI Build 35	9	98977287	TGFBR1
3948	-	11328	A/G	0	398336	rs947889	Human NCBI Build 35	11	117379741	IL10RA
3949	-	11332	A/G	0	398340	rs977214	Human NCBI Build 35	1	71138281	PTGER3
3950	-	11334	A/G	0	398342	rs9804300	Human NCBI Build 35	10	71443571	AMID
3951	-	11338	A/G	0	398344	rs9848900	Human NCBI Build 35	3	123314187	CD86
3952	-	11340	A/G	0	398346	rs9947567	Human NCBI Build 35	18	46411572	MAPK4
3953	-	11345	A/G	0	398351	rs997766	Human NCBI Build 35	6	74563697	CD109
3954	-	11353	A/G	0	398357	rs1043654	Human NCBI Build 35	11	129275136	PRDM10-NFRKB
3955	-	11357	A/G	0	398359	rs10483723	Human NCBI Build 35	14	59828848	PPM1A
3956	-	11359	A/G	0	398360	rs10490779	Human NCBI Build 35	3	61986334	PTPRG
3957	-	11362	A/G	0	398361	rs10494344	Human NCBI Build 35	1	157285413	SLAMF6
3958	-	11364	A/G	0	398362	rs10497711	Human NCBI Build 35	2	191839427	STAT4
3959	-	11368	A/G	0	398366	rs10510872	Human NCBI Build 35	3	62066133	PTPRG
3960	-	11369	A/G	0	398367	rs10512630	Human NCBI Build 35	5	35246477	PRLR
3961	-	11371	A/G	0	398369	rs10513931	Human NCBI Build 35	18	59720443	SERPINB2
3962	-	11372	A/G	0	398370	rs10515521	Human NCBI Build 35	5	142720359	NR3C1
3963	-	11373	A/G	0	398371	rs10797094	Human NCBI Build 35	1	157995745	NDUFS2-FCER1G
3964	-	11374	A/G	0	398372	rs10814231	Human NCBI Build 35	9	35351044	UNC13B-ENSG00000196186
3965	-	11382	A/G	1	398380	rs11107185	Human NCBI Build 35	12	92688399	CRADD
3966	-	11387	A/G	0	398384	rs11265452	Human NCBI Build 35	1	157407311	SLAMF1
3967	-	11388	A/G	0	398385	rs11265455	Human NCBI Build 35	1	157433224	SLAMF1
3968	-	11389	A/G	1	398386	rs11466004	Human NCBI Build 35	8	75103829	LY96
3969	-	11392	A/G	0	398389	rs11646540	Human NCBI Build 35	16	24031685	PRKCB1
3970	-	11394	A/G	0	398390	rs11804922	Human NCBI Build 35	1	89308704	GBP2
3971	-	11396	A/G	0	398391	rs11807930	Human NCBI Build 35	1	157795330	F11R
3972	-	11397	A/G	0	398392	rs1181332	Human NCBI Build 35	12	12253186	LRP6-BCL2L14
3973	-	11400	A/G	0	398395	rs11930396	Human NCBI Build 35	4	88088417	PTPN13

3974	-	11405	A/G	0	398397	rs1196512	Human	NCBI	Build	35	7	121217117	PTPRZ1
3975	-	11409	A/G	0	398401	rs12085435	Human	NCBI	Build	35	1	57127331	C8B
3976	-	11441	A/G	0	398428	rs1894445	Human	NCBI	Build	35	X	103909567	IL1RAPL2
3977	-	11442	A/G	0	398429	rs1937271	Human	NCBI	Build	35	X	117642009	IL13RA1
3978	-	11444	A/G	0	398431	rs1978498	Human	NCBI	Build	35	15	31990960	AVEN
3979	-	11448	A/G	0	398435	rs2040790	Human	NCBI	Build	35	16	27340236	IL21R
3980	-	11449	A/G	1	398436	rs2054592	Human	NCBI	Build	35	4	88030624	PTPN13
3981	-	11451	A/G	0	398438	rs2069716	Human	NCBI	Build	35	12	66837082	IFNG
3982	-	11455	A/G	0	398442	rs2072540	Human	NCBI	Build	35	12	15568619	PTPRO
3983	-	11456	A/G	0	398443	rs208202	Human	NCBI	Build	35	20	40958123	PTPRT
3984	-	11458	A/G	0	398445	rs212703	Human	NCBI	Build	35	2	32358264	CARD12-SLC30A6
3985	-	11459	A/G	0	398446	rs2140904	Human	NCBI	Build	35	19	59587	
KIR2DS2-KIR2DS1-ENSG00000189013-KIR2DL4													
3986	-	11463	A/G	0	398450	rs220060	Human	NCBI	Build	35	10	31843522	TCF8
3987	-	11464	A/G	1	398451	rs2253017	Human	NCBI	Build	35	13	20198909	IL17D-ENSG00000150456
3988	-	11468	A/G	1	398454	rs2288287	Human	NCBI	Build	35	18	59706274	SERPINB2
3989	-	11475	A/G	0	398460	rs2307049	Human	NCBI	Build	35	4	54971082	PDGFRA
3990	-	11476	A/G	0	398461	rs2326173	Human	NCBI	Build	35	6	3020552	RIPK1
3991	-	11478	A/G	0	398463	rs2439732	Human	NCBI	Build	35	12	69301398	PTPRB
3992	-	11480	A/G	0	398465	rs2482357	Human	NCBI	Build	35	9	91259533	NFIL3
3993	-	11481	A/G	0	398466	rs2494251	Human	NCBI	Build	35	1	156094224	FCER1A-ENSG00000196266
3994	-	11482	A/G	0	398467	rs251409	Human	NCBI	Build	35	5	67609219	PIK3R1
3995	-	11485	A/G	0	398468	rs2536167	Human	NCBI	Build	35	7	120596139	FAM3C
3996	-	11486	A/G	0	398469	rs2551928	Human	NCBI	Build	35	2	208291284	CREB1
3997	-	11487	A/G	0	398470	rs260326	Human	NCBI	Build	35	5	39241949	FYB
3998	-	11488	A/G	0	398471	rs2603751	Human	NCBI	Build	35	12	50739549	NR4A1
4000	-	11492	A/G	0	398475	rs2834168	Human	NCBI	Build	35	21	33572661	IL10RB
4001	-	11494	A/G	1	398476	rs2849382	Human	NCBI	Build	35	18	59127173	BCL2
4002	-	11496	A/G	0	398477	rs2850724	Human	NCBI	Build	35	18	75263701	NFATC1
4003	-	11499	A/G	1	398480	rs2921177	Human	NCBI	Build	35	5	41247610	C6
4004	-	11500	A/G	1	398481	rs2972391	Human	NCBI	Build	35	5	42525886	GHR
4006	-	11518	A/G	0	398496	rs3774968	Human	NCBI	Build	35	4	103888305	NFKB1
4007	-	11520	A/G	1	398498	rs3780144	Human	NCBI	Build	35	9	36877241	PAX5
4008	-	11525	A/G	0	398501	rs3805226	Human	NCBI	Build	35	5	41009762	C7
4009	-	11526	A/G	0	398502	rs3809088	Human	NCBI	Build	35	11	59977996	MS4A1
4010	-	11527	A/G	1	398503	rs3824761	Human	NCBI	Build	35	10	129620017	PTPRE
4011	-	11528	A/G	1	398504	rs392715	Human	NCBI	Build	35	16	24023323	PRKCB1
4012	-	11531	A/G	0	398507	rs4129472	Human	NCBI	Build	35	5	42558929	GHR
4013	-	11533	A/G	1	398509	rs4246122	Human	NCBI	Build	35	8	141794982	PTK2
4014	-	11535	A/G	0	398511	rs4301489	Human	NCBI	Build	35	8	141961639	PTK2
4015	-	11546	A/G	0	398520	rs4655345	Human	NCBI	Build	35	1	210997099	PTPN14
4016	-	11548	A/G	0	398522	rs4660	Human	NCBI	Build	35	4	89261184	SPP1
4017	-	11555	A/G	1	398525	rs4833095	Human	NCBI	Build	35	4	38622276	TLR1
4018	-	11557	A/G	0	398527	rs4953245	Human	NCBI	Build	35	2	45888404	PRKCE
4019	-	11559	A/G	0	398529	rs4957381	Human	NCBI	Build	35	5	41267570	C6
4020	-	11560	A/G	0	398530	rs4978115	Human	NCBI	Build	35	9	21397604	IFNA8
4021	-	11561	A/G	0	398531	rs4986790	Human	NCBI	Build	35	9	117554856	TLR4
4022	-	11562	A/G	0	398532	rs521153	Human	NCBI	Build	35	10	6605105	PRKCQ
4023	-	11563	A/G	1	398533	rs541670	Human	NCBI	Build	35	10	6586156	PRKCQ

4024	-	11564	A/G	0	398534	rs552582	Human NCBI Build 35	4	75220893	PPBP
4025	-	11565	A/G	1	398535	rs5693	Human NCBI Build 35 1	71186803	PTGER3	
4026	-	11566	A/G	0	398536	rs5743224	Human NCBI Build 35	11	43300481	API5
4027	-	11567	A/G	0	398537	rs5743740	Human NCBI Build 35	X	12651617	TLR7
4028	-	11572	A/G	1	398541	rs6060563	Human NCBI Build 35	20	29712464	BCL2L1
4029	-	11573	A/G	0	398542	rs639342	Human NCBI Build 35	5	76148625	F2RL1-ENSG00000183613
4030	-	11574	A/G	0	398543	rs6428681	Human NCBI Build 35	1	117423389	ENSG00000134258
4031	-	11577	A/G	0	398546	rs650877	Human NCBI Build 35	1	204137188	none
4032	-	11584	A/G	0	398551	rs6652922	Human NCBI Build 35	X	104467049	IL1RAPL2
4033	-	11585	A/G	0	398552	rs6660836	Human NCBI Build 35	1	67539347	IL12RB2
4034	-	11588	A/G	1	398555	rs6696162	Human NCBI Build 35	1	195413835	PTPRC
4036	-	11597	A/G	0	398563	rs7018682	Human NCBI Build 35	9	87357564	DAPK1
4037	-	11602	A/G	1	398568	rs7247086	Human NCBI Build 35	19	44477859	IL29
4038	-	11604	A/G	0	398570	rs7338164	Human NCBI Build 35	13	23098266	TNFRSF19
4040	-	11608	A/G	0	398573	rs747745	Human NCBI Build 35	22	41828045	BIK
4041	-	11610	A/G	0	398575	rs7533471	Human NCBI Build 35	1	151414409	ADAR
4042	-	11615	A/G	0	398579	rs7643445	Human NCBI Build 35	3	61778834	PTPRG
4043	-	11616	A/G	0	398580	rs7650510	Human NCBI Build 35	3	191845818	IL1RAP
4044	-	11618	A/G	0	398582	rs7707666	Human NCBI Build 35	5	122401816	PPIC
4045	-	11620	A/G	0	398584	rs7726237	Human NCBI Build 35	5	40724309	PTGER4
4046	-	11628	A/G	1	398591	rs7903344	Human NCBI Build 35	10	101967873	CHUK
4049	-	11640	A/G	0	398603	rs8705	Human NCBI Build 35 11	127834123	ETS1	
4051	-	11643	A/G	0	398606	rs920027	Human NCBI Build 35	7	157282184	PTPRN2
4053	-	11648	A/G	0	398609	rs9308316	Human NCBI Build 35	12	102822676	TRA1
4054	-	11653	A/G	0	398614	rs9372889	Human NCBI Build 35	6	128732163	PTPRK
4055	-	11656	A/G	0	398616	rs953311	Human NCBI Build 35	3	62066716	PTPRG
4056	-	11657	A/G	0	398617	rs9641678	Human NCBI Build 35	7	121131955	PTPRZ1
4057	-	11659	A/G	0	398618	rs973491	Human NCBI Build 35	2	46842427	SOCS5
4058	-	11664	A/G	0	398622	rs9949799	Human NCBI Build 35	18	7920834	PTPRM
4061	-	11677	A/G	0	398631	rs10493152	Human NCBI Build 35	1	50840798	FAF1
4062	-	11682	A/G	0	398635	rs10518758	Human NCBI Build 35	15	66254147	PIAS1
4063	-	11683	A/G	0	398636	rs1053954	Human NCBI Build 35	1	1373939	TLR5
4064	-	11687	A/G	1	398640	rs10927059	Human NCBI Build 35	1	240178120	AKT3
4065	-	11689	A/G	0	398642	rs11015999	Human NCBI Build 35	10	129674463	PTPRE
4066	-	11690	A/G	0	398643	rs1122832	Human NCBI Build 35	11	127861069	ETS1
4067	-	11691	A/G	0	398644	rs1135547	Human NCBI Build 35	2	68271157	ENSG00000115953
4068	-	11693	A/G	0	398645	rs11466651	Human NCBI Build 35	4	38598886	TLR10
4069	-	11702	A/G	0	398651	rs12078019	Human NCBI Build 35	1	232281630	ENSG00000143669
4071	-	11708	A/G	0	398656	rs1293773	Human NCBI Build 35	12	111883271	OAS2
4072	-	11712	A/G	0	398658	rs1421094	Human NCBI Build 35	5	39391348	C9
4074	-	11721	A/G	0	398665	rs16981016	Human NCBI Build 35	22	16540575	BCL2L13
4075	-	11722	A/G	0	398666	rs1770557	Human NCBI Build 35	1	161321299	PBX1
4076	-	11723	A/G	0	398667	rs1822454	Human NCBI Build 35	18	7848157	PTPRM
4077	-	11726	A/G	0	398669	rs1860516	Human NCBI Build 35	7	38099217	TRGV9
4078	-	11728	A/G	0	398671	rs187115	Human NCBI Build 35	11	35132735	CD44
4079	-	11732	A/G	0	398674	rs1944423	Human NCBI Build 35	18	59141498	BCL2
4080	-	11733	A/G	0	398675	rs196002	Human NCBI Build 35	16	23870738	PRKCB1
4081	-	11735	A/G	1	398677	rs1993684	Human NCBI Build 35	15	62081215	ENSG00000035664
4082	-	11740	A/G	0	398680	rs2011442	Human NCBI Build 35	3	126442524	ZNF148

4083	-	11741	A/G	0	398681	rs20513 Human NCBI Build 35	9	8352155	PTPRD	
4084	-	11748	A/G	0	398688	rs2268241 Human NCBI Build 35	21	33702920	IFNGR2	
4085	-	11757	A/G	0	398696	rs235523 Human NCBI Build 35	20	3547516	ATRN	
4086	-	11761	A/G	0	398700	rs243840 Human NCBI Build 35	16	54085660	MMP2	
4087	-	11771	A/G	1	398707	rs2668017 Human NCBI Build 35	8	57032420	LYN	
4088	-	11775	A/G	0	398709	rs2717425 Human NCBI Build 35	12	69302908	PTPRB	
4089	-	11778	A/G	1	398711	rs2731198 Human NCBI Build 35	14	106144017	IGHA1	
4091	-	11784	A/G	0	398717	rs3118846 Human NCBI Build 35	9	87486381	DAPK1	
4092	-	11787	A/G	0	398720	rs334355 Human NCBI Build 35	9	98988841	TGFBR1	
4093	-	11789	A/G	1	398722	rs355687 Human NCBI Build 35	4	78862757	CXCL13	
4094	-	11798	A/G	1	398729	rs3771886 Human NCBI Build 35	2	151964030	NMI	
4095	-	11799	A/G	0	398730	rs3773643 Human NCBI Build 35	3	30685247	TGFBR2	
4096	-	11801	A/G	0	398732	rs3776526 Human NCBI Build 35	5	39389479	C9	
4097	-	11803	A/G	0	398734	rs3796947 Human NCBI Build 35	4	111228369	EGF	
4098	-	11806	A/G	0	398736	rs3847294 Human NCBI Build 35	9	8406157	PTPRD	
4099	-	11809	A/G	1	398737	rs4041435 Human NCBI Build 35	15	32049212	AVEN	
4100	-	11813	A/G	0	398739	rs4253623 Human NCBI Build 35	22	44870625	PPARA	
4101	-	11821	A/G	0	398745	rs4740363 Human NCBI Build 35	9	130658738	ABL1	
4102	-	11824	A/G	0	398747	rs4879879 Human NCBI Build 35	9	35171433	UNC13B	
4103	-	11829	A/G	1	398751	rs4966882 Human NCBI Build 35	16	45982329	ENSG00000129636	
4104	-	11832	A/G	0	398754	rs547584 Human NCBI Build 35	11	104319097	CASP4	
4105	-	11838	A/G	0	398760	rs6437589 Human NCBI Build 35	3	106636468	ALCAM	
4106	-	11840	A/G	0	398761	rs6441284 Human NCBI Build 35	3	161200970	IL12A	
4107	-	11845	A/G	0	398765	rs649641 Human NCBI Build 35	1	89324951	GBP2	
4108	-	11847	A/G	1	398766	rs6510975 Human NCBI Build 35	19	7217878	INSR	
4109	-	11848	A/G	0	398767	rs656264 Human NCBI Build 35	3	61819864	PTPRG	
4110	-	11850	A/G	0	398768	rs6578132 Human NCBI Build 35	8	141831740	PTK2	
4112	-	11854	A/G	0	398770	rs6728881 Human NCBI Build 35	2	46880367	SOC5	
4113	-	11856	A/G	1	398772	rs6813526 Human NCBI Build 35	4	89251414	SPP1	
4114	-	11867	A/G	0	398779	rs7021906 Human NCBI Build 35	9	21294057	IFNA5	
4115	-	11868	A/G	0	398780	rs7094015 Human NCBI Build 35	10	70199831	CCAR1	
4116	-	11882	A/G	0	398790	rs751554 Human NCBI Build 35	3	106620533	ALCAM	
4117	-	11884	A/G	0	398791	rs7548864 Human NCBI Build 35	1	156080328	FCER1A-ENSG00000196266	
4118	-	11886	A/G	1	398793	rs759162 Human NCBI Build 35	7	55002382	EGFR	
4120	-	11890	A/G	0	398796	rs7755 Human NCBI Build 35	7	79950922	CD36	
4121	-	11894	A/G	1	398800	rs7856797 Human NCBI Build 35	9	8401848	PTPRD	
4122	-	11897	A/G	0	398803	rs8101605 Human NCBI Build 35	19	59840299	ENSG00000104972	
4123	-	11899	A/G	0	398804	rs8191997 Human NCBI Build 35	4	140942636	MGST2	
4124	-	11904	A/G	0	398807	rs870790 Human NCBI Build 35	2	240052260	HDAC4	
4125	-	11905	A/G	0	398808	rs873826 Human NCBI Build 35	2	162743578	DPP4	
4126	-	11920	A/G	0	398820	rs9446986 Human NCBI Build 35	6	74467070	CD109	
4127	-	11922	A/G	0	398822	rs954443 Human NCBI Build 35	15	79285850	IL16	
4128	-	11925	A/G	0	398824	rs9788441 Human NCBI Build 35	14	63866179	ESR2	
4129	-	11926	A/G	0	398825	rs9813017 Human NCBI Build 35	3	33868991	PDCD6IP	
4130	-	11933	A/G	1	398830	rs10014383 Human NCBI Build 35	4	111205923	EGF	
4131	-	11936	A/G	0	398833	rs1028018 Human NCBI Build 35	9	8649757	PTPRD	
4132	-	11937	A/G	0	398834	rs1038522 Human NCBI Build 35	3	106711276	ALCAM	
4133	-	11939	A/G	0	398836	rs10494447 Human NCBI Build 35	1	162357768	MGST3	
4134	-	11942	A/G	0	398839	rs10512647 Human NCBI Build 35	3	126537059	ZNF148	

4135	-	11945	A/G	0	398841	rs10754726	Human NCBI Build 35	1	232201060	ENSG00000143669
4136	-	11948	A/G	1	398844	rs10868626	Human NCBI Build 35	9	87399940	DAPK1
4137	-	11949	A/G	0	398845	rs10941232	Human NCBI Build 35	5	35090396	PRLR
4138	-	11959	A/G	0	398853	rs11568778	Human NCBI Build 35	9	98979965	TGFBR1
4139	-	11960	A/G	0	398854	rs11601450	Human NCBI Build 35	11	43298055	API5
4140	-	11961	A/G	0	398855	rs11788376	Human NCBI Build 35	9	33362396	NFX1
4141	-	11965	A/G	0	398857	rs12038282	Human NCBI Build 35	1	161265865	PBX1
4142	-	11967	A/G	0	398859	rs12660741	Human NCBI Build 35	6	31484968	MICA
4143	-	11968	A/G	0	398860	rs12690718	Human NCBI Build 35	7	157515036	PTPRN2
4144	-	11969	A/G	0	398861	rs132649	Human NCBI Build 35	22	34877681	APOL3
4145	-	11970	A/G	0	398862	rs13429625	Human NCBI Build 35	2	201915067	CASP10
4146	-	11973	A/G	0	398864	rs1440999	Human NCBI Build 35	18	7816623	PTPRM
4147	-	11975	A/G	0	398865	rs1450656	Human NCBI Build 35	5	40985754	C7
4148	-	11976	A/G	0	398866	rs1479397	Human NCBI Build 35	3	61917856	PTPRG
4149	-	11978	A/G	0	398867	rs1489598	Human NCBI Build 35	15	66136947	PIAS1
4150	-	11985	A/G	0	398872	rs162293	Human NCBI Build 35	6	167420582	CCR6-ENSG00000187485
4151	-	11986	A/G	0	398873	rs173969	Human NCBI Build 35	5	40877713	CARD6
4152	-	11994	A/G	0	398880	rs1862917	Human NCBI Build 35	15	31997834	AVEN
4153	-	12001	A/G	0	398886	rs197459	Human NCBI Build 35	6	143125671	HIVEP2
4154	-	12004	A/G	1	398888	rs1998517	Human NCBI Build 35	9	8502133	PTPRD
4155	-	12009	A/G	0	398891	rs2073362	Human NCBI Build 35	21	33542671	IFNAR2
4156	-	12012	A/G	0	398893	rs2175797	Human NCBI Build 35	15	97205052	IGF1R
4157	-	12014	A/G	0	398895	rs2227503	Human NCBI Build 35	12	66929965	IL22
4158	-	12031	A/G	0	398908	rs2361832	Human NCBI Build 35	3	191742739	IL1RAP
4159	-	12035	A/G	0	398912	rs253810	Human NCBI Build 35	12	15507811	PTPRO
4160	-	12039	A/G	0	398915	rs2715274	Human NCBI Build 35	3	123264413	CD86
4161	-	12040	A/G	0	398916	rs2877260	Human NCBI Build 35	7	54945838	EGFR
4162	-	12041	A/G	0	398917	rs2940922	Human NCBI Build 35	5	42498980	GHR
4163	-	12042	A/G	0	398918	rs3092951	Human NCBI Build 35	X	135452706	ENSG00000102245
4164	-	12044	A/G	0	398920	rs3134054	Human NCBI Build 35	8	120018292	TNFRSF11B
4165	-	12048	A/G	0	398923	rs358501	Human NCBI Build 35	5	39141351	FYB-ENSG00000182977
4166	-	12051	A/G	1	398925	rs3745469	Human NCBI Build 35	19	54868983	BCL2L12-HRMT1L2
4167	-	12056	A/G	0	398929	rs3795171	Human NCBI Build 35	X	69134624	IGBP1
4168	-	12066	A/G	0	398939	rs438408	Human NCBI Build 35	2	32407046	CARD12
4169	-	12069	A/G	0	398941	rs451197	Human NCBI Build 35	5	145985029	PPP2R2B
4170	-	12071	A/G	0	398943	rs4587810	Human NCBI Build 35	12	69588056	PTPRR
4171	-	12077	A/G	1	398949	rs4687150	Human NCBI Build 35	3	191763586	IL1RAP
4172	-	12084	A/G	0	398953	rs4760933	Human NCBI Build 35	12	69430025	PTPRR
4173	-	12088	A/G	0	398956	rs4879876	Human NCBI Build 35	9	35161905	UNC13B
4174	-	12097	A/G	0	398964	rs617881	Human NCBI Build 35	9	21373193	IFNA2
4176	-	12103	A/G	0	398970	rs6736093	Human NCBI Build 35	2	112371473	MERTK
4177	-	12105	A/G	0	398971	rs6745660	Human NCBI Build 35	2	198175042	HSPD1
4178	-	12111	A/G	1	398975	rs6947766	Human NCBI Build 35	7	105504617	PBEF1
4179	-	12114	A/G	1	398978	rs7037673	Human NCBI Build 35	9	120820038	C5
4180	-	12115	A/G	1	398979	rs707994	Human NCBI Build 35	6	36129239	MAPK13-MAPK14
4181	-	12118	A/G	0	398982	rs7132930	Human NCBI Build 35	12	9028555	KLRG1
4182	-	12120	A/G	0	398984	rs721953	Human NCBI Build 35	X	104604601	IL1RAPL2
4183	-	12123	A/G	0	398986	rs741344	Human NCBI Build 35	12	66883353	IL26
4184	-	12125	A/G	0	398988	rs757918	Human NCBI Build 35	2	102071817	IL1R2

4185	-	12128	A/G	1	398990	rs7629011	Human NCBI Build 35	3	15029818	NR2C2
4186	-	12130	A/G	0	398991	rs763362	Human NCBI Build 35	18	65682777	CD226
4187	-	12131	A/G	0	398992	rs7636237	Human NCBI Build 35	3	139926486	PIK3CB
4188	-	12133	A/G	0	398994	rs7748777	Human NCBI Build 35	6	41241784	ENSG00000095970
4189	-	12136	A/G	0	398996	rs7829816	Human NCBI Build 35	8	57011940	LYN
4191	-	12141	A/G	1	399000	rs7899726	Human NCBI Build 35	10	71474655	AMID
4192	-	12143	A/G	0	399002	rs7922218	Human NCBI Build 35	10	101965380	CHUK
4194	-	12151	A/G	0	399009	rs842647	Human NCBI Build 35	2	61031122	REL
4195	-	12152	A/G	0	399010	rs852982	Human NCBI Build 35	5	142685614	NR3C1
4196	-	12153	A/G	1	399011	rs856135	Human NCBI Build 35	1	155762578	PYHIN1
4197	-	12154	A/G	0	399012	rs900699	Human NCBI Build 35	11	47996210	PTPRJ
4198	-	12155	A/G	0	399013	rs920191	Human NCBI Build 35	16	68246621	NFAT5
4199	-	12158	A/G	0	399016	rs9308910	Human NCBI Build 35	2	239947952	HDAC4
4200	-	12163	A/G	0	399021	rs9877268	Human NCBI Build 35	3	191768524	IL1RAP
4201	-	12172	A/G	0	399029	rs1034504	Human NCBI Build 35	12	15406094	PTPRO
4202	-	12175	A/G	1	399032	rs10489871	Human NCBI Build 35	1	189283333	RGS1
4203	-	12176	A/G	0	399033	rs10512750	Human NCBI Build 35	5	40967571	C7
4204	-	12179	A/G	0	399036	rs1065248	Human NCBI Build 35	2	68370428	ENSG00000115953
4205	-	12186	A/G	0	399040	rs1101991	Human NCBI Build 35	1	155806341	IFI16
4206	-	12188	A/G	0	399041	rs11167783	Human NCBI Build 35	5	142024758	FGF1
4207	-	12190	A/G	0	399043	rs12286658	Human NCBI Build 35	11	36584045	RAG1-ENSG00000166352
4208	-	12194	A/G	0	399045	rs12430855	Human NCBI Build 35	13	27560007	FLT3
4209	-	12196	A/G	0	399047	rs12671484	Human NCBI Build 35	7	45720395	IGFBP3
4210	-	12198	A/G	1	399049	rs1339189	Human NCBI Build 35	6	128689308	PTPRK
4211	-	12209	A/G	0	399057	rs1567747	Human NCBI Build 35	12	69469962	PTPRR
4212	-	12210	A/G	0	399058	rs1634484	Human NCBI Build 35	17	31432267	CCL4
4213	-	12211	A/G	0	399059	rs16870908	Human NCBI Build 35	6	32898067	TAP2
4214	-	12213	A/G	1	399061	rs1738290	Human NCBI Build 35	6	128639388	PTPRK
4215	-	12215	A/G	0	399062	rs1806584	Human NCBI Build 35	2	208291776	CREB1
4216	-	12216	A/G	0	399063	rs1833773	Human NCBI Build 35	5	146029704	PPP2R2B
4217	-	12222	A/G	0	399068	rs2137347	Human NCBI Build 35	9	8668766	PTPRD
4218	-	12230	A/G	0	399074	rs2338192	Human NCBI Build 35	14	105831373	IGHA1
4219	-	12231	A/G	1	399075	rs2340690	Human NCBI Build 35	2	198186392	HSPD1-ENSG00000115541
4220	-	12232	A/G	1	399076	rs2440861	Human NCBI Build 35	10	49275145	MAPK8
4221	-	12240	A/G	1	399083	rs289831	Human NCBI Build 35	2	151961022	NMI
4223	-	12243	A/G	0	399086	rs3176789	Human NCBI Build 35	12	9803997	CD69
4224	-	12248	A/G	0	399090	rs3774934	Human NCBI Build 35	4	103784661	NFKB1
4226	-	12258	A/G	0	399100	rs4678971	Human NCBI Build 35	3	37609737	ITGA9
4227	-	12260	A/G	0	399102	rs4985694	Human NCBI Build 35	17	16802057	TNFRSF13B
4228	-	12263	A/G	1	399104	rs571589	Human NCBI Build 35	11	104450117	CASP1
4229	-	12264	A/G	1	399105	rs582169	Human NCBI Build 35	1	232925025	EDARADD
4230	-	12265	A/G	0	399106	rs599683	Human NCBI Build 35	1	89354355	GBP2
4231	-	12270	A/G	1	399111	rs7040603	Human NCBI Build 35	9	120887774	C5
4232	-	12271	A/G	1	399112	rs7043072	Human NCBI Build 35	9	8599905	PTPRD
4233	-	12273	A/G	1	399114	rs7259857	Human NCBI Build 35	19	6532715	TNFSF7
4234	-	12282	A/G	0	399118	rs7530034	Human NCBI Build 35	1	154535783	SPAP1
4235	-	12284	A/G	1	399119	rs7537126	Human NCBI Build 35	1	169753006	TNFSF18
4236	-	12290	A/G	0	399124	rs797598	Human NCBI Build 35	12	9904173	ENSG00000110852
4237	-	12295	A/G	0	399128	rs842619	Human NCBI Build 35	2	61057990	REL

4238	-	12300	A/G	1	399132	rs9491970	Human NCBI Build 35	6	128860720	PTPRK
4239	-	12303	A/G	1	399135	rs9933843	Human NCBI Build 35	16	30811180	BCL7C-CTF1
4240	-	12305	A/G	0	399136	rs9946837	Human NCBI Build 35	18	54522999	MALT1
4241	-	12307	A/G	0	399138	rs10777538	Human NCBI Build 35	12	92635752	CRADD
4242	-	12310	A/G	0	399141	rs12085302	Human NCBI Build 35	1	50719857	FAF1
4243	-	12314	A/G	1	399144	rs1370483	Human NCBI Build 35	18	46482966	MAPK4
4244	-	12319	A/G	0	399147	rs1563573	Human NCBI Build 35	2	160859662	ITGB6
4245	-	12323	A/G	0	399151	rs1930781	Human NCBI Build 35	9	120767388	TRAF1
4246	-	12327	A/G	0	399154	rs1944050	Human NCBI Build 35	11	58107715	CNTF
4247	-	12328	A/G	0	399155	rs1967432	Human NCBI Build 35	12	10496212	KLRC1
4248	-	12330	A/G	1	399157	rs2058769	Human NCBI Build 35	16	45905281	ENSG00000129636
4249	-	12337	A/G	0	399162	rs260077	Human NCBI Build 35	5	39236937	FYB
4250	-	12343	A/G	0	399165	rs3739632	Human NCBI Build 35	9	21337828	IFNA6
4251	-	12355	A/G	0	399175	rs5917132	Human NCBI Build 35	X	103783714	IL1RAPL2
4252	-	12357	A/G	0	399177	rs6151582	Human NCBI Build 35	15	57743845	BNIP2
4253	-	12358	A/G	0	399178	rs6512050	Human NCBI Build 35	19	15634915	CYP4F3
4254	-	12361	A/G	0	399181	rs6868807	Human NCBI Build 35	5	146381715	PPP2R2B
4255	-	12364	A/G	1	399183	rs718011	Human NCBI Build 35	11	36477991	TRAF6
4256	-	12366	A/G	1	399185	rs730691	Human NCBI Build 35	5	158688805	IL12B
4257	-	12367	A/G	0	399186	rs7318	Human NCBI Build 35	5	38971439	OSMR-ENSG00000164327
4258	-	12368	A/G	1	399187	rs7746783	Human NCBI Build 35	6	128472199	PTPRK
4259	-	12374	A/G	1	399189	rs7965985	Human NCBI Build 35	12	97561605	APAF1
4260	-	12375	A/G	0	399190	rs8177603	Human NCBI Build 35	10	6064714	IL15RA
4261	-	12380	A/G	0	399195	rs9850093	Human NCBI Build 35	3	112323283	PVRL3
4262	-	12382	A/G	0	399196	rs993893	Human NCBI Build 35	12	15472628	PTPRO
4263	-	12388	A/G	0	399202	rs11205750	Human NCBI Build 35	1	50825552	FAF1
4264	-	12391	A/G	0	399205	rs1206482	Human NCBI Build 35	7	121143779	PTPRZ1
4265	-	12393	A/G	0	399207	rs12760951	Human NCBI Build 35	1	50721566	FAF1
4266	-	12394	A/G	0	399208	rs13358091	Human NCBI Build 35	5	41265034	C6
4267	-	12396	A/G	0	399209	rs173702	Human NCBI Build 35	5	67575723	PIK3R1
4268	-	12401	A/G	0	399214	rs2062343	Human NCBI Build 35	18	66118723	SOCS6
4270	-	12413	A/G	0	399223	rs3138106	Human NCBI Build 35	1	155076452	CD1C
4271	-	12414	A/G	1	399224	rs37250	Human NCBI Build 35	5	76055072	F2R-ENSG00000183613
4272	-	12419	A/G	0	399229	rs6778167	Human NCBI Build 35	3	3120403	IL5RA
4273	-	12430	A/G	0	399236	rs959	Human NCBI Build 35	1	71030282	PTGER3
4274	-	12432	A/G	1	399238	rs10128757	Human NCBI Build 35	12	63147641	TBK1
4275	-	12433	A/G	0	399239	rs1062225	Human NCBI Build 35	10	49313232	MAPK8
4276	-	12437	A/G	0	399243	rs2059691	Human NCBI Build 35	2	179127391	PRKRA
4277	-	12444	A/G	0	399249	rs2301035	Human NCBI Build 35	3	106913775	CBLB
4278	-	12445	A/G	0	399250	rs230511	Human NCBI Build 35	4	103831958	NFKB1
4279	-	12446	A/G	1	399251	rs2381796	Human NCBI Build 35	9	8415122	PTPRD
4280	-	12447	A/G	0	399252	rs3176793	Human NCBI Build 35	12	9801987	CD69
4281	-	12452	A/G	0	399256	rs6512227	Human NCBI Build 35	19	17824564	INSL3
4282	-	12462	A/G	1	399263	rs7671905	Human NCBI Build 35	4	111080490	none
4284	-	12466	A/G	0	399266	rs9842772	Human NCBI Build 35	3	106735892	ALCAM
4285	-	12471	A/G	0	399270	rs10777125	Human NCBI Build 35	12	87418303	KITLG
4286	-	12473	A/G	1	399271	rs10879181	Human NCBI Build 35	12	69375298	PTPRR
4287	-	12475	A/G	0	399273	rs1152597	Human NCBI Build 35	14	63741932	SYNE2-ESR2
4288	-	12485	A/G	0	399281	rs3747158	Human NCBI Build 35	22	30667530	YWHAH

4289	-	12489	A/G	0	399285	rs6510263	Human NCBI Build 35	19	37759207	PDCD5
4290	-	12491	A/G	0	399287	rs7538011	Human NCBI Build 35	1	240029385	AKT3
4291	-	12492	A/G	0	399288	rs7798065	Human NCBI Build 35	7	54883920	EGFR
4292	-	12493	A/G	0	399289	rs791589	Human NCBI Build 35	10	6129577	IL2RA
4293	-	12497	A/G	0	399292	rs1593971	Human NCBI Build 35	5	43449201	CCL28
4294	-	12499	A/G	0	399293	rs2007448	Human NCBI Build 35	9	21186356	ENSG00000137026
4295	-	12501	A/G	0	399294	rs2672744	Human NCBI Build 35	5	464047	AHRR
4296	-	12503	A/G	0	399296	rs9610355	Human NCBI Build 35	22	20488187	MAPK1
4298	-	68	A/T	0	389086	rs10127175	Human NCBI Build 35	X	152805019	IRAK1-MECP2
4299	-	537	A/T	0	389106	rs1064116	Human NCBI Build 35	17	37728870	STAT3
4300	-	564	A/T	0	389107	rs1065552	Human NCBI Build 35	14	105565290	IGHA1
4301	-	1920	A/T	1	389167	rs130653	Human NCBI Build 35	22	37967240	PDGFB
4302	-	2927	A/T	0	389219	rs1899823	Human NCBI Build 35	3	58614902	FAM3D
4303	-	5274	A/T	1	389332	rs2304633	Human NCBI Build 35	16	4436974	DNAJA3
4304	-	6003	A/T	0	389370	rs2970803	Human NCBI Build 35	12	12517572	DUSP16
4305	-	6489	A/T	0	389406	rs3745419	Human NCBI Build 35	19	59539902	ENSG00000170858
4306	-	7093	A/T	1	389469	rs4295944	Human NCBI Build 35	10	71556271	AMID
4307	-	7172	A/T	0	389481	rs4657374	Human NCBI Build 35	1	161492276	PBX1
4308	-	7185	A/T	0	389482	rs4698803	Human NCBI Build 35	4	111272031	EGF
4310	-	7223	A/T	0	389490	rs4788115	Human NCBI Build 35	16	28905612	LAT-ENSG00000169682
4312	-	7535	A/T	0	389537	rs5983	Human NCBI Build 35	6	6112832	F13A1
4313	-	7592	A/T	0	389549	rs6425795	Human NCBI Build 35	1	32387192	LCK-ENSG00000183615
4316	-	7762	A/T	0	389587	rs7251953	Human NCBI Build 35	19	37764549	PDCD5
4318	-	7926	A/T	0	389611	rs7804688	Human NCBI Build 35	7	54964307	EGFR
4319	-	7949	A/T	0	389618	rs8005080	Human NCBI Build 35	14	101613610	HSPCA
4321	-	8125	A/T	0	389636	rs875890	Human NCBI Build 35	3	45920291	LZTFL1-CCR9
4322	-	8231	A/T	0	389657	rs943445	Human NCBI Build 35	10	6619068	PRKCQ
4324	-	8309	A/T	0	389673	rs9857232	Human NCBI Build 35	3	126577192	ZNF148
4326	-	8360	A/T	0	389681	rs10033543	Human NCBI Build 35	4	15019047	C1QTNF7
4327	-	8515	A/T	0	389709	rs1077861	Human NCBI Build 35	16	49317048	CARD15
4328	-	8526	A/T	0	389711	rs10865408	Human NCBI Build 35	2	75315445	TACR1
4329	-	8551	A/T	0	389716	rs11016033	Human NCBI Build 35	10	129730527	PTPRE
4330	-	8629	A/T	1	389732	rs11569017	Human NCBI Build 35	4	111259715	EGF
4331	-	8955	A/T	0	389807	rs1899941	Human NCBI Build 35	5	38627302	LIFR
4332	-	8963	A/T	0	389809	rs1997664	Human NCBI Build 35	1	166305824	SELP
4333	-	9070	A/T	1	389830	rs2109134	Human NCBI Build 35	X	12686843	TLR8
4334	-	9105	A/T	0	389838	rs2226772	Human NCBI Build 35	11	63026471	LGALS12-ENSG00000184999
4335	-	9216	A/T	0	389861	rs2269059	Human NCBI Build 35	9	120762026	TRAF1
4336	-	9252	A/T	1	389870	rs2281819	Human NCBI Build 35	6	33879651	MLN
4337	-	9432	A/T	0	389901	rs2738182	Human NCBI Build 35	8	6723179	ENSG00000164825
4339	-	10736	A/T	0	390104	rs6482655	Human NCBI Build 35	10	129775124	PTPRE
4340	-	11269	A/T	1	390192	rs8095534	Human NCBI Build 35	18	75365708	NFATC1-ENSG00000186783
4341	-	11305	A/T	0	390197	rs8177688	Human NCBI Build 35	10	6047555	IL15RA
4342	-	11493	A/T	0	390226	rs9372309	Human NCBI Build 35	6	112154291	FYN
4343	-	11898	A/T	0	390303	rs11210885	Human NCBI Build 35	1	43734193	PTPRF
4344	-	12010	A/T	0	390327	rs11703495	Human NCBI Build 35	22	44913855	PPARA
4345	-	12025	A/T	0	390329	rs11716821	Human NCBI Build 35	3	33856542	PDCD6IP
4347	-	12182	A/T	0	390353	rs12530380	Human NCBI Build 35	14	23685275	ISGF3G-PSME2-C14orf122
4348	-	12224	A/T	0	390363	rs12629000	Human NCBI Build 35	3	138126269	NCK1

4349	-	12283	A/T	1	390373	rs1293755	Human NCBI Build 35	12	111898170	OAS2
4350	-	12373	A/T	0	390393	rs1501643	Human NCBI Build 35	5	169369531	DOCK2
4351	-	12381	A/T	0	390394	rs1520810	Human NCBI Build 35	12	116227909	NOS1
4352	-	5332	A/T	0	390423	rs1719152	Human NCBI Build 35	17	31456777	CCL4
4353	-	5759	A/T	0	390428	rs17617333	Human NCBI Build 35	6	33014630	HLA-DMB
4355	-	5310	A/T	0	390518	rs2274602	Human NCBI Build 35	9	87542934	DAPK1
4356	-	4901	A/T	0	390573	rs26128	Human NCBI Build 35	5	149201427	PPARGC1B
4358	-	1926	A/T	0	390612	rs3091236	Human NCBI Build 35	16	27352689	IL21R
4359	-	3702	A/T	1	390661	rs3780159	Human NCBI Build 35	9	36932563	PAX5
4360	-	6105	A/T	1	390680	rs3805215	Human NCBI Build 35	5	40996380	C7
4362	-	2995	A/T	0	390712	rs411103	Human NCBI Build 35	16	24137704	PRKCB1
4363	-	3587	A/T	0	390715	rs4151667	Human NCBI Build 35	6	32022003	C2-BF
4364	-	6154	A/T	0	390728	rs4419163	Human NCBI Build 35	19	59019380	NALP12
4365	-	4162	A/T	0	390732	rs4459610	Human NCBI Build 35	17	58938452	ACE
4366	-	5808	A/T	0	390735	rs4488661	Human NCBI Build 35	2	86964810	CD8B1-ENSG00000198012
4367	-	532	A/T	0	390772	rs5491	Human NCBI Build 35	19	10246540	ICAM1
4368	-	128	A/T	1	390795	rs6123041	Human NCBI Build 35	20	49537264	NFATC2
4369	-	2144	A/T	1	390822	rs6796045	Human NCBI Build 35	3	38164164	MYD88
4370	-	4949	A/T	0	390838	rs7153640	Human NCBI Build 35	14	23876972	RIPK3-ADCY4
4371	-	3440	A/T	0	390842	rs722796	Human NCBI Build 35	6	128775386	PTPRK
4372	-	1486	A/T	0	390874	rs7611117	Human NCBI Build 35	3	62114124	PTPRG
4373	-	5809	A/T	0	390909	rs8112310	Human NCBI Build 35	19	7710320	ENSG00000188197-ENSG00000090659
4375	-	635	A/T	0	390939	rs914929	Human NCBI Build 35	9	90702934	SYK
4376	-	5143	A/T	0	390948	rs954439	Human NCBI Build 35	10	91056440	IFIT2-LIPA
4377	-	9	A/T	0	390987	rs10488141	Human NCBI Build 35	7	54969553	EGFR
4378	-	6035	A/T	1	391000	rs1052231	Human NCBI Build 35	1	164131732	CD3Z
4379	-	6075	A/T	0	391057	rs1203126	Human NCBI Build 35	3	61958163	PTPRG
4381	-	509	A/T	0	391094	rs132618	Human NCBI Build 35	22	34862000	APOL3
4382	-	1681	A/T	0	391103	rs1347251	Human NCBI Build 35	1	150082257	PGLYRP3
4383	-	4203	A/T	1	391139	rs170211	Human NCBI Build 35	17	3589186	ITGAE
4384	-	3640	A/T	0	391143	rs17110944	Human NCBI Build 35	5	149495590	PDGFRB
4385	-	4086	A/T	0	391152	rs1802461	Human NCBI Build 35	1	150446773	SNAPAP-ILF2
4386	-	2420	A/T	0	391154	rs181410	Human NCBI Build 35	22	16611990	BID
4387	-	3586	A/T	0	391159	rs1860184	Human NCBI Build 35	17	29637245	CCL11
4388	-	1935	A/T	1	391178	rs1986546	Human NCBI Build 35	9	36867591	PAX5
4389	-	3063	A/T	1	391181	rs1997865	Human NCBI Build 35	1	29464497	PTPRU
4390	-	3318	A/T	0	391188	rs2062011	Human NCBI Build 35	18	59027094	BCL2
4391	-	4714	A/T	0	391204	rs2095858	Human NCBI Build 35	9	35606583	CD72-ENSG00000196186
4393	-	1207	A/T	0	391253	rs2270401	Human NCBI Build 35	17	35429782	THRAP4-CSF3
4395	-	3425	A/T	0	391312	rs2523765	Human NCBI Build 35	6	29925085	HLA-G
4396	-	4119	A/T	0	391317	rs2661889	Human NCBI Build 35	3	62043452	PTPRG
4398	-	5923	A/T	0	391406	rs3758164	Human NCBI Build 35	9	36901732	PAX5
4399	-	2520	A/T	0	391410	rs375867	Human NCBI Build 35	19	44916673	CLC
4400	-	3803	A/T	0	391412	rs3761977	Human NCBI Build 35	6	36204425	MAPK13
4401	-	2032	A/T	0	391445	rs3819268	Human NCBI Build 35	6	31487038	MICA
4402	-	440	A/T	0	391633	rs7609752	Human NCBI Build 35	3	58608301	FAM3D
4404	-	300	A/T	0	391691	rs892145	Human NCBI Build 35	19	15447672	ENSG00000161031
4406	-	3363	A/T	0	391705	rs9260794	Human NCBI Build 35	22	49249752	SC02-ECGF1-ENSG00000025770
4407	-	3150	A/T	0	391729	rs9824147	Human NCBI Build 35	3	138100696	NCK1-ENSG00000181882

4408	-	3560	A/T	0	391730	rs9831477	Human NCBI Build 35	3	30668526	TGFBR2
4410	-	2726	A/T	1	391774	rs10509571	Human NCBI Build 35	10	91082538	IFIT3-LIPA
4411	-	4082	A/T	0	391812	rs1130480	Human NCBI Build 35	19	60040966	KIR2DS1
4412	-	3322	A/T	0	391852	rs12457042	Human NCBI Build 35	18	58144433	TNFRSF11A
4413	-	2133	A/T	1	391874	rs132642	Human NCBI Build 35	22	34869637	APOL3
4414	-	1561	A/T	0	391884	rs1388604	Human NCBI Build 35	3	46251882	CCR3
4415	-	3213	A/T	0	391895	rs1465693	Human NCBI Build 35	5	149461515	CSF1R
4416	-	3519	A/T	0	391896	rs1473037	Human NCBI Build 35	6	344079	IRF4
4417	-	98	A/T	0	391911	rs1553970	Human NCBI Build 35	3	112805801	CD96
4418	-	5194	A/T	0	391917	rs158689	Human NCBI Build 35	9	90737316	SYK
4419	-	6065	A/T	0	391950	rs1930361	Human NCBI Build 35	9	35256881	UNC13B-ENSG00000196186
4420	-	2791	A/T	0	391955	rs196009	Human NCBI Build 35	16	23885450	PRKCB1
4421	-	2262	A/T	0	391967	rs2015620	Human NCBI Build 35	16	3063562	ENSG00000008517
4422	-	3132	A/T	0	391968	rs2024301	Human NCBI Build 35	12	8169448	ENSG00000111729
4423	-	5210	A/T	0	392032	rs2267966	Human NCBI Build 35	19	60385056	BRSK1-PTPRH-SYT5
4424	-	1370	A/T	0	392060	rs2294019	Human NCBI Build 35	X	48859468	CXorf37-FOXP3
4425	-	1203	A/T	0	392091	rs2595200	Human NCBI Build 35	2	46099890	PRKCE
4427	-	4289	A/T	0	392137	rs2987902	Human NCBI Build 35	9	130739800	ABL1
4428	-	2493	A/T	1	392153	rs307810	Human NCBI Build 35	5	180003855	FLT4
4429	-	2284	A/T	1	392191	rs3736863	Human NCBI Build 35	10	6054209	IL15RA
4430	-	5421	A/T	1	392230	rs3826946	Human NCBI Build 35	19	801199	PRTN3-ELA2
4431	-	5744	A/T	0	392238	rs3923647	Human NCBI Build 35	4	38622105	TLR1
4432	-	3026	A/T	0	392242	rs404733	Human NCBI Build 35	19	18030997	IL12RB1
4433	-	5850	A/T	0	392279	rs4750934	Human NCBI Build 35	10	129746866	PTPRE
4434	-	2139	A/T	1	392286	rs4776700	Human NCBI Build 35	15	62057914	ENSG00000035664
4435	-	431	A/T	1	392331	rs5744054	Human NCBI Build 35	X	12692378	TLR8
4436	-	4404	A/T	0	392375	rs6662947	Human NCBI Build 35	1	211087554	PTPN14
4438	-	5062	A/T	0	392459	rs761376	Human NCBI Build 35	20	49480278	NFATC2
4439	-	1709	A/T	1	392462	rs7707145	Human NCBI Build 35	5	35240339	PRLR
4440	-	16	A/T	0	392476	rs7939734	Human NCBI Build 35	11	69732593	FADD
4441	-	3161	A/T	0	392481	rs8034167	Human NCBI Build 35	15	50127514	MAPK6
4442	-	1315	A/T	1	392491	rs8177676	Human NCBI Build 35	10	6050633	IL15RA
4443	-	1884	A/T	0	392505	rs884195	Human NCBI Build 35	10	71556666	AMID
4444	-	3619	A/T	0	392660	rs12325842	Human NCBI Build 35	17	11935497	MAP2K4
4445	-	2528	A/T	1	392661	rs12391546	Human NCBI Build 35	X	104300791	IL1RAPL2
4446	-	3143	A/T	0	392670	rs1261990	Human NCBI Build 35	10	79237800	DLG5
4447	-	3880	A/T	0	392684	rs13068778	Human NCBI Build 35	3	62216246	PTPRG
4448	-	5841	A/T	0	392726	rs1522986	Human NCBI Build 35	2	45855977	PRKCE
4449	-	5829	A/T	1	392742	rs1609800	Human NCBI Build 35	20	36411924	LBP
4450	-	5185	A/T	0	392750	rs16931745	Human NCBI Build 35	9	114632712	ENSG00000181634
4451	-	4291	A/T	0	392755	rs1719153	Human NCBI Build 35	17	31457342	CCL4
4452	-	1886	A/T	0	392784	rs1907699	Human NCBI Build 35	12	87392445	KITLG
4453	-	5197	A/T	1	392794	rs196344	Human NCBI Build 35	10	121409299	BAG3
4454	-	4124	A/T	1	392817	rs2069860	Human NCBI Build 35	7	22544278	IL6-ENSG00000179428
4455	-	1344	A/T	1	392930	rs2719248	Human NCBI Build 35	8	57076081	LYN
4456	-	1234	A/T	0	392955	rs2906933	Human NCBI Build 35	7	156950225	PTPRN2
4457	-	4077	A/T	0	392958	rs2957125	Human NCBI Build 35	18	58209322	TNFRSF11A
4458	-	1845	A/T	0	392989	rs371388	Human NCBI Build 35	5	146042260	PPP2R2B
4460	-	5807	A/T	1	393069	rs3917332	Human NCBI Build 35	2	102255042	IL1R1

4461	-	2359	A/T	0	393095	rs4394131	Human NCBI Build 35	5	42670911	GHR
4462	-	5697	A/T	0	393101	rs4602441	Human NCBI Build 35	4	5130067	ENSG00000170891
4464	-	5245	A/T	0	393229	rs6711238	Human NCBI Build 35	2	73996172	STAMPB
4465	-	5147	A/T	0	393239	rs6802213	Human NCBI Build 35	3	58631039	FAM3D
4466	-	4637	A/T	1	393325	rs791590	Human NCBI Build 35	10	6130328	IL2RA
4467	-	2799	A/T	1	393393	rs9819529	Human NCBI Build 35	3	112846973	CD96
4468	-	1711	A/T	0	393418	rs1035140	Human NCBI Build 35	2	201977997	ALS2CR12-CASP8
4469	-	2702	A/T	1	393429	rs10488809	Human NCBI Build 35	11	35152987	CD44
4470	-	6264	A/T	0	393475	rs1116195	Human NCBI Build 35	16	54066374	MMP2
4471	-	5077	A/T	0	393478	rs11196431	Human NCBI Build 35	10	115442433	CASP7
4472	-	3804	A/T	0	393522	rs12583006	Human NCBI Build 35	13	107735453	TNFSF13B
4473	-	1682	A/T	0	393524	rs12670590	Human NCBI Build 35	7	157438534	PTPRN2
4474	-	2205	A/T	0	393534	rs13006529	Human NCBI Build 35	2	201907965	CASP10
4475	-	4654	A/T	0	393545	rs13355609	Human NCBI Build 35	5	169234172	DOCK2
4476	-	4143	A/T	0	393550	rs1352545	Human NCBI Build 35	1	161440156	PBX1
4477	-	5663	A/T	1	393555	rs1385504	Human NCBI Build 35	8	120035514	TNFRSF11B
4478	-	1504	A/T	0	393560	rs1422430	Human NCBI Build 35	5	149151333	PPARGC1B
4479	-	2640	A/T	0	393573	rs1507924	Human NCBI Build 35	4	47910215	TXK
4480	-	1221	A/T	1	393593	rs1669300	Human NCBI Build 35	12	56118705	INHBC-ENSG00000198357
4481	-	4873	A/T	0	393594	rs1670796	Human NCBI Build 35	5	43262550	CCL28-ENSG00000177453
4482	-	1463	A/T	0	393606	rs1780367	Human NCBI Build 35	1	161406389	PBX1
4483	-	4695	A/T	0	393608	rs1796419	Human NCBI Build 35	12	119944359	OASL
4485	-	744	A/T	0	393642	rs2027908	Human NCBI Build 35	14	105999045	IGHA1
4486	-	1688	A/T	0	393650	rs2069658	Human NCBI Build 35	5	75953058	F2RL2-IQGAP2
4487	-	188	A/T	0	393670	rs2204886	Human NCBI Build 35	12	105630557	RFX4
4489	-	3508	A/T	1	393689	rs2253923	Human NCBI Build 35	21	33634289	IFNAR1
4490	-	3317	A/T	0	393707	rs2288377	Human NCBI Build 35	12	101377229	IGF1
4491	-	3400	A/T	0	393719	rs2295614	Human NCBI Build 35	1	157430204	SLAMF1
4492	-	1876	A/T	0	393737	rs2491395	Human NCBI Build 35	1	203690118	C4BPA
4494	-	1199	A/T	0	393750	rs2624252	Human NCBI Build 35	5	169288893	DOCK2
4495	-	6080	A/T	1	393765	rs2791743	Human NCBI Build 35	9	130670331	ABL1
4496	-	3241	A/T	0	393780	rs2857597	Human NCBI Build 35	6	31692979	AIF1-BAT2
4497	-	5840	A/T	1	393781	rs2870953	Human NCBI Build 35	12	66830897	IFNG
4498	-	321	A/T	1	393794	rs3024861	Human NCBI Build 35	2	191750112	STAT4
4499	-	1483	A/T	0	393810	rs3176778	Human NCBI Build 35	12	9806156	CD69
4500	-	6185	A/T	0	393814	rs319155	Human NCBI Build 35	5	146199797	PPP2R2B
4501	-	6014	A/T	0	393837	rs3753663	Human NCBI Build 35	1	222342024	EPHX1-ENSG00000196187
4502	-	295	A/T	0	393875	rs3820702	Human NCBI Build 35	2	152806361	STAM2
4503	-	3828	A/T	1	393881	rs3851491	Human NCBI Build 35	5	146085232	PPP2R2B
4504	-	6295	A/T	0	393909	rs441019	Human NCBI Build 35	21	45126457	ITGB2
4505	-	442	A/T	0	393920	rs4655541	Human NCBI Build 35	1	67554920	IL12RB2
4506	-	243	A/T	0	393944	rs4836834	Human NCBI Build 35	9	120745455	TRAF1
4507	-	1895	A/T	0	393983	rs597414	Human NCBI Build 35	15	32008784	AVEN
4508	-	53	A/T	0	393988	rs6030483	Human NCBI Build 35	20	40872779	PTPRT
4509	-	6357	A/T	1	394004	rs6465749	Human NCBI Build 35	7	76827502	PTPN12
4510	-	6095	A/T	0	394012	rs6550503	Human NCBI Build 35	3	37747677	ITGA9
4511	-	4023	A/T	0	394013	rs6554163	Human NCBI Build 35	4	54943487	PDGFRA
4512	-	213	A/T	1	394043	rs683916	Human NCBI Build 35	1	57137495	C8B
4513	-	6403	A/T	0	394072	rs7139068	Human NCBI Build 35	12	51883359	ITGB7

4514	-	2488	A/T	0	394083	rs7300723	Human NCBI Build 35	12	69248128	PTPRB
4515	-	5935	A/T	0	394097	rs7515774	Human NCBI Build 35	1	20182940	PLA2G2D
4516	-	4756	A/T	0	394168	rs939269	Human NCBI Build 35	8	27237373	PTK2B
4517	-	1133	A/T	0	394172	rs9429944	Human NCBI Build 35	1	204058702	none
4518	-	6272	A/T	0	394175	rs943841	Human NCBI Build 35	9	35343838	UNC13B-ENSG00000196186
4519	-	4691	A/T	0	394180	rs9491958	Human NCBI Build 35	6	128831093	PTPRK
4520	-	1919	A/T	0	394220	rs10203477	Human NCBI Build 35	2	61016636	REL
4521	-	3373	A/T	1	394238	rs10489269	Human NCBI Build 35	1	169891720	TNFSF4
4522	-	1958	A/T	1	394250	rs10507030	Human NCBI Build 35	12	93050428	PLXNC1
4524	-	916	A/T	0	394254	rs10509570	Human NCBI Build 35	10	91082211	IFIT3-LIPA
4525	-	3795	A/T	0	394255	rs10509686	Human NCBI Build 35	10	97567736	ENTPD1
4526	-	3634	A/T	0	394266	rs1052248	Human NCBI Build 35	1	152476399	
ENSG00000163374-ENSG00000125459-DAP3										
4527	-	1762	A/T	0	394274	rs10860869	Human NCBI Build 35	12	101367519	IGF1
4528	-	6358	A/T	0	394282	rs10999152	Human NCBI Build 35	10	71563139	AMID-TYSND1
4529	-	6369	A/T	1	394316	rs1182844	Human NCBI Build 35	12	66927799	IL22
4530	-	6405	A/T	0	394322	rs12004215	Human NCBI Build 35	9	8347036	PTPRD
4531	-	6387	A/T	0	394328	rs12233096	Human NCBI Build 35	2	239743297	HDAC4
4532	-	6487	A/T	0	394370	rs1351887	Human NCBI Build 35	18	66105008	SOCS6
4533	-	6612	A/T	1	394407	rs16839100	Human NCBI Build 35	1	154551555	SPAP1
4534	-	6643	A/T	0	394433	rs1867819	Human NCBI Build 35	2	46874390	SOCS5
4535	-	6689	A/T	1	394470	rs2033008	Human NCBI Build 35	2	105961103	NCK2
4536	-	6720	A/T	1	394498	rs2182912	Human NCBI Build 35	1	204048739	CR2
4537	-	6726	A/T	0	394502	rs2227648	Human NCBI Build 35	7	100365608	SERPINE1
4538	-	6732	A/T	0	394506	rs2234237	Human NCBI Build 35	6	41358444	TREM1
4539	-	6749	A/T	0	394521	rs2267574	Human NCBI Build 35	19	40516983	CD22
4540	-	6752	A/T	0	394524	rs2273865	Human NCBI Build 35	1	233032341	LGALS8
4541	-	6788	A/T	0	394556	rs2420034	Human NCBI Build 35	3	168937707	SERPINI1-PDCD10
4542	-	6853	A/T	0	394619	rs2987763	Human NCBI Build 35	1	150099107	PGLYRP3
4543	-	6855	A/T	0	394621	rs3024477	Human NCBI Build 35	6	6196119	F13A1
4544	-	6858	A/T	0	394624	rs3024904	Human NCBI Build 35	2	191720708	STAT4
4545	-	6869	A/T	0	394633	rs31225	Human NCBI Build 35	5	156556665	ITK
4546	-	6880	A/T	1	394643	rs334809	Human NCBI Build 35	3	3105221	IL5RA
4547	-	6891	A/T	1	394651	rs3734576	Human NCBI Build 35	6	27331446	PRSS16
4548	-	6916	A/T	0	394673	rs3771175	Human NCBI Build 35	2	102418728	IL1RL1
4549	-	6949	A/T	0	394703	rs3817655	Human NCBI Build 35	17	31223754	CCL5-ENSG00000172653
4550	-	6954	A/T	0	394708	rs3829318	Human NCBI Build 35	12	9899497	ENSG00000110852
4551	-	6960	A/T	0	394713	rs3858393	Human NCBI Build 35	11	107403687	CUL5
4552	-	6980	A/T	0	394732	rs4145212	Human NCBI Build 35	13	107758189	TNFSF13B
4553	-	7019	A/T	0	394766	rs4704739	Human NCBI Build 35	5	156559935	ITK
4554	-	7022	A/T	1	394768	rs4716531	Human NCBI Build 35	7	157305090	PTPRN2
4555	-	7027	A/T	0	394773	rs4775999	Human NCBI Build 35	15	50149097	MAPK6
4556	-	7041	A/T	0	394785	rs4867906	Human NCBI Build 35	5	169338200	DOCK2
4557	-	7066	A/T	0	394809	rs5743310	Human NCBI Build 35	4	187365542	TLR3
4558	-	7078	A/T	0	394819	rs6030541	Human NCBI Build 35	20	40944245	PTPRT
4559	-	7086	A/T	0	394827	rs6103805	Human NCBI Build 35	20	42717105	ADA-ENSG00000132832
4560	-	7118	A/T	0	394855	rs670717	Human NCBI Build 35	20	3542089	ATRN
4561	-	7147	A/T	0	394879	rs6985298	Human NCBI Build 35	8	57085771	LYN
4562	-	7168	A/T	0	394897	rs7241152	Human NCBI Build 35	18	59481353	SERPINB3

4563	-	7169	A/T	1	394898	rs7243090	Human NCBI Build 35	18	12263032	CIDEA
4564	-	7175	A/T	0	394902	rs7306360	Human NCBI Build 35	12	88247383	DUSP6
4565	-	7205	A/T	0	394927	rs7584870	Human NCBI Build 35	2	46885051	SOC5
4566	-	7207	A/T	1	394928	rs7593128	Human NCBI Build 35	2	46156831	PRKCE
4567	-	7221	A/T	0	394940	rs7716557	Human NCBI Build 35	5	146060345	PPP2R2B
4569	-	7245	A/T	1	394959	rs7932247	Human NCBI Build 35	11	60637242	CD5
4570	-	7270	A/T	1	394980	rs870139	Human NCBI Build 35	2	46300553	PRKCE
4571	-	7274	A/T	0	394983	rs879574	Human NCBI Build 35	22	15962859	IL17R
4572	-	7283	A/T	1	394992	rs914960	Human NCBI Build 35	1	65006724	JAK1-ENSG00000162437
4573	-	7318	A/T	0	395021	rs9676009	Human NCBI Build 35	18	7898746	PTPRM
4574	-	7319	A/T	0	395022	rs9727516	Human NCBI Build 35	1	193697762	CFHL5
4575	-	7327	A/T	0	395030	rs987106	Human NCBI Build 35	5	35911350	IL7R
4576	-	7341	A/T	1	395044	rs1015408	Human NCBI Build 35	16	24117863	PRKCB1
4577	-	7355	A/T	0	395057	rs1034072	Human NCBI Build 35	9	5078903	JAK2
4578	-	7365	A/T	0	395067	rs10425745	Human NCBI Build 35	19	15030836	CASP14
4579	-	7369	A/T	1	395071	rs1046690	Human NCBI Build 35	1	207934896	TRAF5
4580	-	7399	A/T	0	395097	rs1051070	Human NCBI Build 35	10	90764752	ENSG00000026103
4581	-	7403	A/T	0	395101	rs10513902	Human NCBI Build 35	18	8040297	PTPRM
4582	-	7419	A/T	0	395117	rs10846191	Human NCBI Build 35	12	15576343	PTPRO
4583	-	7459	A/T	0	395148	rs11632978	Human NCBI Build 35	15	79387565	IL16-STARD5
4584	-	7486	A/T	1	395172	rs12098571	Human NCBI Build 35	10	101945191	CHUK
4585	-	7503	A/T	0	395183	rs12488997	Human NCBI Build 35	3	32510032	CKLFSF6
4586	-	7513	A/T	0	395191	rs1265811	Human NCBI Build 35	1	157473434	CD48-ENSG00000198811
4587	-	7576	A/T	1	395242	rs1587608	Human NCBI Build 35	5	35254746	PRLR
4588	-	7588	A/T	1	395250	rs16839277	Human NCBI Build 35	1	154618723	CD5L
4590	-	7647	A/T	0	395295	rs2019727	Human NCBI Build 35	1	193406371	CFH
4591	-	7703	A/T	1	395341	rs2267575	Human NCBI Build 35	19	40517045	CD22
4592	-	7734	A/T	0	395364	rs2305013	Human NCBI Build 35	11	119845270	ARHGEF12
4593	-	7799	A/T	0	395414	rs2834190	Human NCBI Build 35	21	33614881	IFNAR1
4594	-	7820	A/T	0	395433	rs3092663	Human NCBI Build 35	20	40749570	PTPRT
4595	-	7823	A/T	0	395436	rs3115966	Human NCBI Build 35	2	204415841	CD28
4596	-	7827	A/T	0	395439	rs3136556	Human NCBI Build 35	5	54436285	GZMA
4598	-	7839	A/T	0	395450	rs33388	Human NCBI Build 35	5	142677488	NR3C1
4599	-	7853	A/T	1	395464	rs3733264	Human NCBI Build 35	1	157329615	CD84
4601	-	7867	A/T	0	395476	rs3763364	Human NCBI Build 35	6	32915498	TAP2-PSMB8
4602	-	7921	A/T	1	395519	rs3911403	Human NCBI Build 35	3	158644829	PTX3-VEPH1
4603	-	7980	A/T	1	395566	rs4871998	Human NCBI Build 35	8	22364095	PPP3CC-PIWIL2
4604	-	7987	A/T	0	395573	rs4952778	Human NCBI Build 35	2	45949705	PRKCE
4605	-	7989	A/T	0	395575	rs4968683	Human NCBI Build 35	17	59441987	ICAM2
4606	-	8028	A/T	0	395610	rs6445226	Human NCBI Build 35	3	61563017	PTPRG
4607	-	8049	A/T	0	395630	rs6670	Human NCBI Build 35	7	45725494	IGFBP3
4608	-	8077	A/T	1	395656	rs7019398	Human NCBI Build 35	9	8496677	PTPRD
4610	-	8097	A/T	0	395674	rs7323196	Human NCBI Build 35	13	113321253	TFDP1-ENSG00000179951
4611	-	8133	A/T	0	395704	rs7698675	Human NCBI Build 35	4	142952324	IL15
4612	-	8140	A/T	0	395711	rs7784413	Human NCBI Build 35	7	157741323	PTPRN2
4613	-	8177	A/T	0	395741	rs888284	Human NCBI Build 35	2	162959995	IFIH1
4614	-	8234	A/T	1	395784	rs989305	Human NCBI Build 35	3	109282155	CD47
4615	-	8240	A/T	0	395790	rs10018756	Human NCBI Build 35	4	15400061	ENSG00000109743
4616	-	8271	A/T	0	395816	rs10502366	Human NCBI Build 35	18	7981006	PTPRM

4617	-	8291	A/T	0	395831	rs10516069	Human NCBI Build 35	5	169272957	DOCK2
4618	-	8303	A/T	0	395840	rs10788928	Human NCBI Build 35	1	50680118	FAF1
4619	-	8320	A/T	0	395854	rs10908848	Human NCBI Build 35	1	150458953	ILF2
4620	-	8414	A/T	0	395934	rs1360166	Human NCBI Build 35	9	36990782	PAX5
4621	-	8430	A/T	0	395947	rs1468220	Human NCBI Build 35	4	111352821	EGF-ELOVL6
4622	-	8449	A/T	0	395963	rs1562654	Human NCBI Build 35	2	46108616	PRKCE
4623	-	8477	A/T	0	395986	rs1780615	Human NCBI Build 35	20	36404533	LBP
4624	-	8512	A/T	0	396012	rs1937956	Human NCBI Build 35	1	117399167	ENSG00000134258
4625	-	8531	A/T	1	396028	rs2069680	Human NCBI Build 35	5	75950612	F2RL2-IQGAP2
4626	-	8533	A/T	0	396030	rs2070802	Human NCBI Build 35	9	34546453	CNTFR
4627	-	8573	A/T	0	396063	rs2241599	Human NCBI Build 35	5	491454	AHRR-ENSG00000185509
4628	-	8606	A/T	1	396087	rs231774	Human NCBI Build 35	2	204557729	CTLA4
4629	-	8613	A/T	1	396092	rs2342910	Human NCBI Build 35	2	152036311	TNFAIP6
4630	-	8614	A/T	1	396093	rs2344706	Human NCBI Build 35	6	112105713	FYN
4631	-	8628	A/T	1	396105	rs250737	Human NCBI Build 35	5	76069058	F2R-ENSG00000183613
4632	-	8635	A/T	0	396110	rs261056	Human NCBI Build 35	5	169260198	DOCK2
4633	-	8673	A/T	0	396140	rs291085	Human NCBI Build 35	1	203484148	PIGR-ENSG00000162894
4634	-	8687	A/T	0	396149	rs3024979	Human NCBI Build 35	12	55774560	NAB2-STAT6
4635	-	8691	A/T	0	396153	rs3130660	Human NCBI Build 35	11	63762868	DNAJC4-VEGFB-FKBP2
4636	-	8695	A/T	1	396156	rs3176792	Human NCBI Build 35	12	9802354	CD69
4639	-	8781	A/T	0	396218	rs3917210	Human NCBI Build 35	14	75497533	TGFB3
4640	-	8788	A/T	1	396223	rs3936073	Human NCBI Build 35	1	24217460	IL22RA1
4641	-	8822	A/T	1	396248	rs4557544	Human NCBI Build 35	6	128529290	PTPRK
4642	-	8869	A/T	0	396286	rs5030593	Human NCBI Build 35	4	110969709	CASP6-ENSG0000005059
4643	-	8883	A/T	0	396295	rs5673	Human NCBI Build 35	1	71189862	PTGER3
4645	-	8948	A/T	0	396351	rs6940	Human NCBI Build 35	1	155837741	IFI16
4646	-	8951	A/T	1	396354	rs699002	Human NCBI Build 35	1	32919777	YARS
4647	-	8976	A/T	1	396373	rs723858	Human NCBI Build 35	1	169749920	TNFSF18
4648	-	9007	A/T	1	396399	rs7667268	Human NCBI Build 35	4	185765225	IRF2
4649	-	9020	A/T	1	396412	rs7893137	Human NCBI Build 35	10	71542953	H2AFY2-AMID
4650	-	9040	A/T	0	396430	rs809909	Human NCBI Build 35	4	185699759	IRF2
4651	-	9048	A/T	0	396435	rs835648	Human NCBI Build 35	3	138154202	NCK1
4652	-	9055	A/T	1	396441	rs881086	Human NCBI Build 35	1	67558133	IL12RB2
4653	-	9085	A/T	0	396459	rs9389621	Human NCBI Build 35	6	139183494	ENSG00000118519
4654	-	9099	A/T	1	396471	rs9752570	Human NCBI Build 35	2	61043680	REL
4655	-	9111	A/T	0	396480	rs9862773	Human NCBI Build 35	3	61673615	PTPRG
4656	-	9113	A/T	0	396481	rs9946840	Human NCBI Build 35	18	54530171	MALT1
4657	-	9114	A/T	0	396482	rs995380	Human NCBI Build 35	3	61996341	PTPRG
4658	-	9168	A/T	0	396524	rs10512825	Human NCBI Build 35	5	43344947	HMGCS1-CCL28
4659	-	9183	A/T	1	396537	rs10872493	Human NCBI Build 35	6	139189114	ENSG00000118519
4660	-	9193	A/T	0	396546	rs10972406	Human NCBI Build 35	9	35242022	UNC13B-ENSG00000196186
4662	-	9247	A/T	0	396586	rs12001779	Human NCBI Build 35	9	5529866	PDCD1LG2
4663	-	9259	A/T	0	396595	rs12127827	Human NCBI Build 35	1	211091809	PTPN14-ENSG00000181931
4664	-	9262	A/T	1	396597	rs12189718	Human NCBI Build 35	6	128457177	PTPRK
4665	-	9291	A/T	0	396619	rs1320961	Human NCBI Build 35	6	135539945	MYB
4666	-	9371	A/T	0	396687	rs2036892	Human NCBI Build 35	18	75269524	NFATC1
4667	-	9373	A/T	0	396689	rs2046408	Human NCBI Build 35	8	16085930	MSR1
4668	-	9388	A/T	0	396703	rs2076082	Human NCBI Build 35	20	40510165	PTPRT
4669	-	9400	A/T	0	396713	rs2175595	Human NCBI Build 35	9	8598381	PTPRD

4670	-	9435	A/T	0	396742	rs2330875	Human NCBI Build 35	7	43398352	STK17A
4673	-	9439	A/T	0	396745	rs2358818	Human NCBI Build 35	1	117414430	ENSG00000134258
4674	-	9444	A/T	1	396749	rs2476491	Human NCBI Build 35	10	6135416	IL2RA
4675	-	9452	A/T	0	396756	rs2583762	Human NCBI Build 35	8	79860038	IL7
4676	-	9476	A/T	1	396775	rs2930193	Human NCBI Build 35	11	48006224	PTPRJ
4677	-	9493	A/T	0	396786	rs315938	Human NCBI Build 35	2	113612276	IL1RN
4678	-	9502	A/T	1	396794	rs337453	Human NCBI Build 35	11	22707169	GAS2
4679	-	9549	A/T	0	396833	rs3796502	Human NCBI Build 35	1	157465803	CD48
4680	-	9578	A/T	0	396858	rs4434423	Human NCBI Build 35	5	40713439	PTGER4
4681	-	9599	A/T	0	396876	rs4785963	Human NCBI Build 35	16	4424397	DNAJA3
4682	-	9606	A/T	1	396881	rs4812672	Human NCBI Build 35	20	41194805	PTPRT
4683	-	9611	A/T	1	396885	rs4851524	Human NCBI Build 35	2	102073120	IL1R2
4685	-	9668	A/T	0	396931	rs624052	Human NCBI Build 35	1	232895912	EDARADD
4686	-	9688	A/T	0	396946	rs6459852	Human NCBI Build 35	7	157486972	PTPRN2
4687	-	9690	A/T	0	396948	rs6523840	Human NCBI Build 35	X	104419026	IL1RAPL2
4688	-	9699	A/T	0	396957	rs6656559	Human NCBI Build 35	1	211014978	PTPN14
4689	-	9706	A/T	0	396964	rs6699729	Human NCBI Build 35	1	151395969	ADAR
4690	-	9717	A/T	1	396975	rs681383	Human NCBI Build 35	18	8313984	PTPRM
4691	-	9730	A/T	0	396987	rs7043371	Human NCBI Build 35	9	5030203	JAK2-ENSG00000183276
4694	-	9809	A/T	0	397051	rs8031	Human NCBI Build 35	6	160071051	SOD2
4695	-	9811	A/T	0	397053	rs8060893	Human NCBI Build 35	16	66749109	NFATC3
4696	-	9833	A/T	1	397072	rs927335	Human NCBI Build 35	11	35207094	CD44
4697	-	9845	A/T	0	397084	rs9471474	Human NCBI Build 35	6	41166295	NFYA
4698	-	9897	A/T	1	397130	rs10940491	Human NCBI Build 35	5	55214809	IL31RA
4700	-	9967	A/T	1	397190	rs12715309	Human NCBI Build 35	3	38161421	MYD88
4701	-	9969	A/T	0	397192	rs12996772	Human NCBI Build 35	2	102405719	IL1RL1
4702	-	9984	A/T	0	397205	rs1380840	Human NCBI Build 35	15	62054718	ENSG00000035664
4703	-	9999	A/T	0	397219	rs1513644	Human NCBI Build 35	15	97127653	IGF1R
4704	-	10010	A/T	0	397229	rs164222	Human NCBI Build 35	3	32459914	ENSG00000153551
4705	-	10016	A/T	1	397234	rs1742919	Human NCBI Build 35	6	6181206	F13A1
4706	-	10028	A/T	0	397244	rs1866260	Human NCBI Build 35	3	32337429	CKLFSF8
4707	-	10034	A/T	0	397248	rs188589	Human NCBI Build 35	10	91175572	IFIT5
4708	-	10107	A/T	0	397307	rs264846	Human NCBI Build 35	5	169059316	DOCK2
4710	-	10131	A/T	0	397327	rs3210509	Human NCBI Build 35	10	129771768	PTPRE
4711	-	10143	A/T	1	397337	rs3748557	Human NCBI Build 35	1	193678526	CFHL5
4712	-	10154	A/T	1	397348	rs3783615	Human NCBI Build 35	1	100915786	VCAM1
4713	-	10158	A/T	0	397351	rs3797629	Human NCBI Build 35	5	146179107	PPP2R2B
4714	-	10161	A/T	0	397354	rs3801267	Human NCBI Build 35	7	105512873	PBEF1
4715	-	10188	A/T	0	397377	rs4413571	Human NCBI Build 35	5	41223714	C6
4716	-	10205	A/T	0	397392	rs4855616	Human NCBI Build 35	3	109256330	CD47
4717	-	10206	A/T	0	397393	rs4879540	Human NCBI Build 35	9	27517479	IFNK-ENSG00000120162
4718	-	10217	A/T	0	397404	rs4961303	Human NCBI Build 35	8	142019502	PTK2
4719	-	10291	A/T	0	397466	rs7030931	Human NCBI Build 35	9	8680155	PTPRD
4720	-	10322	A/T	0	397492	rs7546211	Human NCBI Build 35	1	154554310	SPAP1
4722	-	10350	A/T	0	397515	rs7852996	Human NCBI Build 35	9	5559860	PDCD1LG2
4723	-	10364	A/T	0	397527	rs8093327	Human NCBI Build 35	18	7862839	PTPRM-ENSG00000197286
4724	-	10381	A/T	0	397540	rs926328	Human NCBI Build 35	22	41830763	BIK
4726	-	10418	A/T	1	397574	rs10490830	Human NCBI Build 35	3	106931760	CBLB
4727	-	10423	A/T	0	397577	rs10500262	Human NCBI Build 35	19	37768813	PDCD5

4728	-	10442	A/T	1	397591	rs10737620	Human NCBI Build 35	1	189789628	SSA2
4729	-	10448	A/T	0	397597	rs10859678	Human NCBI Build 35	12	93040863	PLXNC1
4730	-	10456	A/T	0	397605	rs11113060	Human NCBI Build 35	12	105515338	RFX4
4731	-	10469	A/T	1	397614	rs11606407	Human NCBI Build 35	11	104335737	CASP4
4732	-	10472	A/T	0	397617	rs11665570	Human NCBI Build 35	18	46489323	MAPK4
4733	-	10475	A/T	0	397619	rs11744523	Human NCBI Build 35	5	55311673	IL6ST
4734	-	10484	A/T	0	397627	rs12089272	Human NCBI Build 35	1	155609978	MNDA
4736	-	10493	A/T	0	397635	rs12394678	Human NCBI Build 35	X	104292565	IL1RAPL2
4737	-	10508	A/T	1	397649	rs1326279	Human NCBI Build 35	1	195382170	PTPRC
4739	-	10529	A/T	0	397666	rs1537320	Human NCBI Build 35	10	6551759	PRKCQ
4741	-	10653	A/T	0	397769	rs3743673	Human NCBI Build 35	16	68268812	NFAT5
4742	-	10681	A/T	1	397794	rs3918241	Human NCBI Build 35	20	44069142	MMP9
4743	-	10691	A/T	0	397804	rs428191	Human NCBI Build 35	5	114975013	TICAM2
4744	-	10700	A/T	0	397811	rs4624606	Human NCBI Build 35	3	191836948	IL1RAP
4745	-	10721	A/T	0	397830	rs4859583	Human NCBI Build 35	4	77298299	CXCL10
4746	-	10752	A/T	0	397855	rs6030544	Human NCBI Build 35	20	40948508	PTPRT
4747	-	10778	A/T	0	397879	rs6581951	Human NCBI Build 35	12	69330855	PTPRR
4748	-	10780	A/T	0	397881	rs661139	Human NCBI Build 35	11	119741084	ARHGEF12
4749	-	10783	A/T	0	397884	rs6699717	Human NCBI Build 35	1	232147891	ENSG00000143669
4750	-	10804	A/T	0	397901	rs7014131	Human NCBI Build 35	8	23064551	TNFRSF10D-ENSG00000147457
4751	-	10822	A/T	0	397917	rs7435363	Human NCBI Build 35	4	87402818	MAPK10
4752	-	10828	A/T	0	397922	rs7542678	Human NCBI Build 35	1	117285715	IGSF2
4753	-	10866	A/T	0	397954	rs900402	Human NCBI Build 35	6	6099936	F13A1
4754	-	10881	A/T	0	397968	rs9610496	Human NCBI Build 35	22	20544003	MAPK1
4755	-	10895	A/T	1	397979	rs1004489	Human NCBI Build 35	9	8723398	PTPRD
4756	-	10900	A/T	0	397983	rs1012334	Human NCBI Build 35	21	33635621	IFNAR1
4757	-	10946	A/T	0	398022	rs10889680	Human NCBI Build 35	1	67480614	IL12RB2
4758	-	10958	A/T	0	398031	rs11079041	Human NCBI Build 35	17	37667605	STAT5B
4759	-	10963	A/T	0	398035	rs112461	Human NCBI Build 35	5	35099049	PRLR
4760	-	10970	A/T	0	398041	rs1205955	Human NCBI Build 35	6	22400955	PRL
4761	-	10992	A/T	0	398056	rs12732056	Human NCBI Build 35	1	100918704	VCAM1
4762	-	11033	A/T	0	398088	rs163308	Human NCBI Build 35	5	156551670	ITK
4763	-	11040	A/T	1	398095	rs179008	Human NCBI Build 35	X	12663316	TLR7
4764	-	11057	A/T	1	398106	rs1915092	Human NCBI Build 35	3	123306065	CD86
4765	-	11060	A/T	0	398109	rs1944419	Human NCBI Build 35	18	59075593	BCL2
4766	-	11062	A/T	1	398111	rs1978270	Human NCBI Build 35	9	120842230	C5
4767	-	11063	A/T	0	398112	rs1995759	Human NCBI Build 35	3	62066254	PTPRG
4768	-	11064	A/T	0	398113	rs2021742	Human NCBI Build 35	7	156881147	PTPRN2
4769	-	11069	A/T	0	398118	rs2059020	Human NCBI Build 35	3	191740326	IL1RAP
4770	-	11078	A/T	0	398124	rs2178899	Human NCBI Build 35	6	31714735	BAT3-BAT2
4771	-	11093	A/T	0	398136	rs2274368	Human NCBI Build 35	1	195409077	PTPRC
4772	-	11115	A/T	1	398154	rs2683053	Human NCBI Build 35	19	15627470	CYP4F3
4773	-	11117	A/T	0	398156	rs2711288	Human NCBI Build 35	2	46124940	PRKCE
4774	-	11123	A/T	0	398161	rs2800806	Human NCBI Build 35	1	161376104	PBX1-ENSG00000197613
4775	-	11127	A/T	1	398165	rs2849377	Human NCBI Build 35	18	59122624	BCL2
4776	-	11134	A/T	0	398171	rs3093986	Human NCBI Build 35	6	31601400	ATP6V1G2-ENSG00000189327
4777	-	11148	A/T	1	398184	rs3753395	Human NCBI Build 35	1	193418309	CFH
4778	-	11168	A/T	0	398202	rs393548	Human NCBI Build 35	19	18058744	IL12RB1
4779	-	11171	A/T	0	398204	rs4132490	Human NCBI Build 35	4	87438815	MAPK10

4781	-	11183	A/T	1	398215	rs4688283	Human	NCBI	Build	35	3	62025041	PTPRG
4782	-	11187	A/T	1	398218	rs4698784	Human	NCBI	Build	35	4	111026865	none
4783	-	11189	A/T	0	398220	rs4716803	Human	NCBI	Build	35	7	157235442	
PTPRN2-ENSG00000196590-ENSG00000196201													
4784	-	11192	A/T	0	398223	rs4767078	Human	NCBI	Build	35	12	110757462	ENSG00000089022
4785	-	11197	A/T	1	398227	rs4852052	Human	NCBI	Build	35	2	240008917	HDAC4
4786	-	11212	A/T	0	398240	rs579007	Human	NCBI	Build	35	2	45806770	PRKCE
4787	-	11285	A/T	0	398299	rs7653045	Human	NCBI	Build	35	3	46239316	CCR3
4788	-	11299	A/T	0	398311	rs8040800	Human	NCBI	Build	35	15	79308500	IL16
4789	-	11306	A/T	0	398317	rs8177664	Human	NCBI	Build	35	10	6053311	IL15RA
4790	-	11341	A/T	0	398347	rs9951224	Human	NCBI	Build	35	18	75385918	
ENSG00000186783-NFATC1-ENSG00000198662													
4791	-	11342	A/T	0	398348	rs995336	Human	NCBI	Build	35	9	8303393	PTPRD
4792	-	11344	A/T	0	398350	rs997049	Human	NCBI	Build	35	2	102240951	IL1R1
4793	-	11365	A/T	0	398363	rs10499138	Human	NCBI	Build	35	6	128533875	PTPRK
4794	-	11366	A/T	0	398364	rs10506954	Human	NCBI	Build	35	12	87427220	KITLG
4795	-	11384	A/T	0	398382	rs11120349	Human	NCBI	Build	35	1	211106908	PTPN14-ENSG00000181931
4796	-	11385	A/T	0	398383	rs1115132	Human	NCBI	Build	35	1	111138550	CD53
4797	-	11414	A/T	1	398405	rs12116432	Human	NCBI	Build	35	1	50661745	FAF1
4798	-	11421	A/T	1	398411	rs12610136	Human	NCBI	Build	35	19	44937352	CLC
4799	-	11425	A/T	0	398414	rs12854780	Human	NCBI	Build	35	X	104226505	IL1RAPL2
4800	-	11430	A/T	1	398419	rs1466998	Human	NCBI	Build	35	4	47938328	TXK
4801	-	11439	A/T	0	398426	rs1734953	Human	NCBI	Build	35	17	31364274	CCL23
4802	-	11443	A/T	0	398430	rs197481	Human	NCBI	Build	35	6	143111893	HIVEP2
4803	-	11466	A/T	0	398452	rs2271411	Human	NCBI	Build	35	12	121225881	DIABLO
4804	-	11497	A/T	1	398478	rs2859358	Human	NCBI	Build	35	6	28580800	GPX6
4805	-	11502	A/T	0	398482	rs3024921	Human	NCBI	Build	35	2	191768778	STAT4
4806	-	11515	A/T	0	398493	rs3772555	Human	NCBI	Build	35	3	106739814	ALCAM
4807	-	11545	A/T	1	398519	rs4516847	Human	NCBI	Build	35	5	122391446	PPIC
4808	-	11575	A/T	0	398544	rs646910	Human	NCBI	Build	35	11	102214732	MMP3
4809	-	11583	A/T	0	398550	rs6621956	Human	NCBI	Build	35	X	104333784	IL1RAPL2
4810	-	11590	A/T	0	398557	rs6848178	Human	NCBI	Build	35	4	111023775	none
4812	-	11619	A/T	0	398583	rs7724855	Human	NCBI	Build	35	5	149771734	CD74
4813	-	11626	A/T	1	398589	rs7839697	Human	NCBI	Build	35	8	141883847	PTK2
4814	-	11636	A/T	1	398599	rs856071	Human	NCBI	Build	35	1	155743574	PYHIN1
4815	-	11637	A/T	0	398600	rs857868	Human	NCBI	Build	35	1	155622688	MNDA
4816	-	11651	A/T	0	398612	rs933213	Human	NCBI	Build	35	X	103841819	IL1RAPL2
4817	-	11662	A/T	0	398620	rs988343	Human	NCBI	Build	35	12	69452460	PTPRR
4818	-	11697	A/T	0	398647	rs11664594	Human	NCBI	Build	35	18	58169186	TNFRSF11A
4819	-	11698	A/T	0	398648	rs11855356	Human	NCBI	Build	35	15	31943944	AVEN-ENSG00000198838
4820	-	11699	A/T	0	398649	rs11957616	Human	NCBI	Build	35	5	42565953	GHR
4821	-	11704	A/T	0	398653	rs12369297	Human	NCBI	Build	35	12	97552539	APAF1
4822	-	11705	A/T	0	398654	rs12686188	Human	NCBI	Build	35	9	8656150	PTPRD
4823	-	11713	A/T	1	398659	rs1438548	Human	NCBI	Build	35	3	106582337	ALCAM
4824	-	11714	A/T	1	398660	rs1454372	Human	NCBI	Build	35	11	63755816	
DNAJC4-VEGFB-ENSG00000149761													
4825	-	11716	A/T	0	398661	rs1471628	Human	NCBI	Build	35	1	143196101	CD160
4826	-	11719	A/T	1	398663	rs1634321	Human	NCBI	Build	35	X	12654982	TLR7
4827	-	11730	A/T	0	398673	rs1935031	Human	NCBI	Build	35	10	93579311	TNKS2

4828	-	11745	A/T	0	398685	rs2237054	Human NCBI Build 35	4	111268793	EGF
4830	-	11750	A/T	0	398690	rs2271381	Human NCBI Build 35	2	160568547	LY75
4831	-	11768	A/T	1	398704	rs261040	Human NCBI Build 35	5	169214742	DOCK2
4832	-	11769	A/T	0	398705	rs2628481	Human NCBI Build 35	20	3458636	ATRN
4833	-	11772	A/T	0	398708	rs2697185	Human NCBI Build 35	7	120634907	FAM3C
4834	-	11783	A/T	1	398716	rs2919935	Human NCBI Build 35	8	79846503	IL7
4835	-	11790	A/T	1	398723	rs3737977	Human NCBI Build 35	1	215004723	ENSG00000092969
4836	-	11796	A/T	0	398727	rs3758169	Human NCBI Build 35	9	36937083	PAX5
4837	-	11835	A/T	0	398757	rs5962458	Human NCBI Build 35	X	104106887	IL1RAPL2
4838	-	11861	A/T	1	398775	rs6908372	Human NCBI Build 35	6	36138226	MAPK13-MAPK14
4839	-	11866	A/T	0	398778	rs6988146	Human NCBI Build 35	8	23142031	TNFRSF10A-ENSG00000147457
4840	-	11870	A/T	0	398782	rs7099684	Human NCBI Build 35	10	45217161	ALOX5
4841	-	11923	A/T	1	398823	rs9784290	Human NCBI Build 35	3	61757078	PTPRG
4843	-	11982	A/T	0	398870	rs1558068	Human NCBI Build 35	7	30276603	CARD4
4844	-	11984	A/T	0	398871	rs1585476	Human NCBI Build 35	12	15422375	PTPRO
4845	-	11988	A/T	1	398874	rs174405	Human NCBI Build 35	6	112036915	C6orf4
4846	-	12013	A/T	1	398894	rs2213340	Human NCBI Build 35	X	104059271	IL1RAPL2
4847	-	12052	A/T	0	398926	rs3775170	Human NCBI Build 35	4	87306898	MAPK10
4848	-	12054	A/T	0	398928	rs3794347	Human NCBI Build 35	13	23113236	TNFRSF19
4849	-	12058	A/T	0	398931	rs3805716	Human NCBI Build 35	5	41197246	C6
4850	-	12060	A/T	0	398933	rs3817263	Human NCBI Build 35	15	97084585	IGF1R
4851	-	12072	A/T	0	398944	rs4625820	Human NCBI Build 35	18	54514474	MALT1-ENSG00000182288
4852	-	12073	A/T	0	398945	rs4656933	Human NCBI Build 35	1	157595634	LY9
4853	-	12074	A/T	0	398946	rs4657368	Human NCBI Build 35	1	161362741	PBX1-ENSG00000197613
4854	-	12102	A/T	0	398969	rs6688275	Human NCBI Build 35	1	177758984	MR1
4855	-	12140	A/T	1	398999	rs7886148	Human NCBI Build 35	X	104417799	IL1RAPL2
4856	-	12145	A/T	0	399003	rs793811	Human NCBI Build 35	4	185731822	IRF2
4857	-	12146	A/T	0	399004	rs7965431	Human NCBI Build 35	12	69584546	PTPRR
4859	-	12150	A/T	0	399008	rs8046314	Human NCBI Build 35	16	68255423	NFAT5
4860	-	12159	A/T	0	399017	rs9328379	Human NCBI Build 35	6	6552691	LY86
4861	-	12168	A/T	0	399026	rs10004195	Human NCBI Build 35	4	38607290	TLR10
4862	-	12200	A/T	0	399050	rs1373197	Human NCBI Build 35	2	68366054	ENSG00000115953
4863	-	12208	A/T	1	399056	rs1539035	Human NCBI Build 35	20	41176863	PTPRT
4864	-	12219	A/T	1	399066	rs1903361	Human NCBI Build 35	4	87453153	MAPK10
4865	-	12226	A/T	0	399071	rs2297960	Human NCBI Build 35	10	93594580	TNKS2
4866	-	12280	A/T	1	399117	rs7442554	Human NCBI Build 35	4	15097595	C1QTNF7
4867	-	12285	A/T	0	399120	rs7753357	Human NCBI Build 35	6	137042251	MAP3K5
4868	-	12287	A/T	0	399121	rs7851161	Human NCBI Build 35	9	35234061	UNC13B-ENSG00000196186
4869	-	12301	A/T	0	399133	rs951134	Human NCBI Build 35	5	395195	AHRR
4870	-	12302	A/T	0	399134	rs9606603	Human NCBI Build 35	22	15936067	IL17R
4871	-	12326	A/T	0	399153	rs1942951	Human NCBI Build 35	18	8037305	PTPRM
4872	-	12342	A/T	0	399164	rs2796825	Human NCBI Build 35	1	214920163	ENSG00000092969
4873	-	12348	A/T	0	399169	rs4341967	Human NCBI Build 35	2	191809792	STAT4
4874	-	12359	A/T	0	399179	rs6680709	Human NCBI Build 35	1	157305129	SLAMF6
4875	-	12372	A/T	1	399188	rs790824	Human NCBI Build 35	5	114973260	TICAM2
4877	-	12424	A/T	0	399232	rs7574608	Human NCBI Build 35	2	191735370	STAT4
4878	-	12442	A/T	0	399247	rs2285460	Human NCBI Build 35	15	89098460	BLM
4879	-	12448	A/T	0	399253	rs3783722	Human NCBI Build 35	14	64067719	HSPA2
4880	-	12449	A/T	0	399254	rs4601580	Human NCBI Build 35	1	151207490	IL6R

4881	-	12470	A/T	0	399269	rs10772570	Human NCBI Build 35	12	12534637	DUSP16
4882	-	12474	A/T	0	399272	rs11048414	Human NCBI Build 35	12	9036574	KLRG1
4883	-	12479	A/T	0	399276	rs1541985	Human NCBI Build 35	12	92576605	CRADD
4884	-	12508	A/T	0	399301	rs6847635	Human NCBI Build 35	4	87513369	MAPK10
4885	-	27	C/G	0	389084	rs10031983	Human NCBI Build 35	4	77315250	CXCL11-ENSG00000169253
4886	-	670	C/G	0	389114	rs10971451	Human NCBI Build 35	9	33239364	BAG1-SPINK4
4887	-	1348	C/G	0	389139	rs11721999	Human NCBI Build 35	4	185752371	IRF2
4889	-	1624	C/G	0	389155	rs12635458	Human NCBI Build 35	3	42866620	CCBP2
4890	-	2184	C/G	0	389179	rs1471962	Human NCBI Build 35	3	45924191	LZTFL1-CCR9
4894	-	4092	C/G	1	389276	rs2235831	Human NCBI Build 35	6	42991889	ENSG00000171611
4896	-	4591	C/G	0	389297	rs2278699	Human NCBI Build 35	2	97814768	ZAP70
4897	-	5039	C/G	0	389318	rs2293152	Human NCBI Build 35	17	37735055	STAT3
4898	-	5093	C/G	1	389321	rs2295979	Human NCBI Build 35	14	23694581	ISGF3G
4899	-	5303	C/G	0	389334	rs2305846	Human NCBI Build 35	10	97977134	BLNK
4902	-	5692	C/G	0	389351	rs2532498	Human NCBI Build 35	11	111542594	BCD02-IL18-TEX12
4905	-	6194	C/G	0	389383	rs3181254	Human NCBI Build 35	14	23871165	RIPK3-ADCY4
4906	-	6255	C/G	0	389387	rs332289	Human NCBI Build 35	15	62095422	ENSG00000035664
4907	-	6330	C/G	0	389395	rs355958	Human NCBI Build 35	16	65246064	CKLFSF4
4908	-	6635	C/G	1	389417	rs3765014	Human NCBI Build 35	19	60112736	NCR1
4909	-	6658	C/G	0	389420	rs3776078	Human NCBI Build 35	5	149504372	PDGFRB
4910	-	6669	C/G	1	389422	rs3786187	Human NCBI Build 35	18	75302598	NFATC1
4911	-	6687	C/G	0	389427	rs3791517	Human NCBI Build 35	2	239820555	HDAC4
4912	-	6741	C/G	0	389436	rs3804252	Human NCBI Build 35	5	169649516	LCP2-ENSG00000198424
4913	-	6895	C/G	0	389449	rs3821817	Human NCBI Build 35	3	188939606	BCL6
4914	-	6932	C/G	0	389452	rs386014	Human NCBI Build 35	6	30002608	HLA-G-ENSG00000181573
4915	-	6997	C/G	0	389458	rs401502	Human NCBI Build 35	19	18041413	IL12RB1
4918	-	7237	C/G	0	389492	rs4797312	Human NCBI Build 35	18	8357640	PTPRM
4919	-	7239	C/G	1	389493	rs4803763	Human NCBI Build 35	19	50049131	ENSG00000130202
4920	-	7389	C/G	0	389509	rs4914	Human NCBI Build 35	5	139991652	CD14-1K
4921	-	7490	C/G	1	389523	rs557806	Human NCBI Build 35	19	54069054	PPP1R15A
4922	-	7492	C/G	0	389524	rs562056	Human NCBI Build 35	1	39894714	PPIE-ENSG00000116985
4923	-	7566	C/G	0	389540	rs608694	Human NCBI Build 35	10	6608621	PRKCQ
4924	-	7572	C/G	0	389541	rs6090321	Human NCBI Build 35	20	61338938	BIRC7-C20orf58
4925	-	7574	C/G	0	389542	rs6101573	Human NCBI Build 35	20	34696948	SLA2
4927	-	7629	C/G	0	389556	rs6538494	Human NCBI Build 35	12	93171601	PLXNC1
4929	-	7870	C/G	1	389601	rs758512	Human NCBI Build 35	19	5241884	PTPRS
4930	-	7913	C/G	0	389608	rs7746553	Human NCBI Build 35	6	32003952	C2
4936	-	8215	C/G	0	389655	rs936906	Human NCBI Build 35	7	2806443	CARD11
4937	-	8273	C/G	1	389664	rs9646629	Human NCBI Build 35	18	58202179	TNFRSF11A
4938	-	8286	C/G	1	389667	rs967886	Human NCBI Build 35	19	16468233	CALR3-ENSG00000105072
4939	-	8298	C/G	0	389670	rs975484	Human NCBI Build 35	19	54872078	BCL2L12-HRMT1L2
4940	-	8400	C/G	1	389687	rs10261447	Human NCBI Build 35	7	157449881	PTPRN2
4941	-	8480	C/G	0	389700	rs1051456	Human NCBI Build 35	Multiple	0	
KIR2DS2-KIR2DS1-ENSG00000189013-KIR2DL4										
4942	-	8484	C/G	0	389702	rs1057401	Human NCBI Build 35	12	107188475	CMKLR1
4943	-	8485	C/G	1	389703	rs1059519	Human NCBI Build 35	19	18358024	GDF15-LRRC25
4944	-	8505	C/G	0	389707	rs10754555	Human NCBI Build 35	1	243910684	CIAS1
4945	-	8663	C/G	0	389739	rs11878811	Human NCBI Build 35	19	47286323	POU2F2
4946	-	8674	C/G	1	389742	rs11986840	Human NCBI Build 35	8	23125663	TNFRSF10A-ENSG00000147457

4947	-	8701	C/G	1	389749	rs12272556	Human NCBI Build 35	11	63030696	LGALS12-ENSG00000184999
4948	-	8765	C/G	0	389766	rs1413519	Human NCBI Build 35	10	44202567	CXCL12
4949	-	8779	C/G	0	389771	rs1536874	Human NCBI Build 35	9	36984299	PAX5
4950	-	8830	C/G	0	389785	rs17003048	Human NCBI Build 35	22	41129942	ENSG00000167087
4951	-	8839	C/G	1	389787	rs17208187	Human NCBI Build 35	22	49251998	SCO2-ECGF1-ENSG00000025770
4955	-	8982	C/G	0	389812	rs2040399	Human NCBI Build 35	22	37939817	PDGFB
4957	-	9034	C/G	0	389817	rs2067085	Human NCBI Build 35	16	49291360	CARD15
4961	-	9498	C/G	0	389916	rs3024941	Human NCBI Build 35	12	55792056	STAT6
4963	-	9632	C/G	0	389940	rs352677	Human NCBI Build 35	1	157488417	CD48
4964	-	9681	C/G	0	389950	rs3741404	Human NCBI Build 35	1	203463304	IL24-PIGR-ENSG00000162894
4965	-	9739	C/G	0	389954	rs3749228	Human NCBI Build 35	3	185582044	CHRD-THPO
4966	-	9749	C/G	1	389956	rs3754562	Human NCBI Build 35	2	46307898	PRKCE
4967	-	9820	C/G	1	389969	rs3782554	Human NCBI Build 35	12	66903288	IL26
4968	-	9912	C/G	0	389977	rs3788284	Human NCBI Build 35	22	16626657	BID
4969	-	9927	C/G	0	389980	rs3792633	Human NCBI Build 35	5	40965153	C7
4970	-	9979	C/G	0	389987	rs3795299	Human NCBI Build 35	1	24192774	IL22RA1
4971	-	10055	C/G	0	389996	rs3813800	Human NCBI Build 35	1	27381616	MAP3K6-FCN3
4973	-	10112	C/G	1	390010	rs3894049	Human NCBI Build 35	18	75392406	
ENSG00000186783-NFATC1-ENSG00000198662										
4974	-	10277	C/G	1	390031	rs427224	Human NCBI Build 35	20	42710276	ADA
4976	-	10439	C/G	1	390058	rs4822127	Human NCBI Build 35	22	41140254	ENSG00000167087
4977	-	10461	C/G	0	390062	rs4871857	Human NCBI Build 35	8	23115269	TNFRSF10A-ENSG00000147457
4978	-	10572	C/G	1	390077	rs5743287	Human NCBI Build 35	16	49311654	CARD15
4980	-	10622	C/G	0	390087	rs5995440	Human NCBI Build 35	22	36244364	CARD10
4982	-	10855	C/G	0	390117	rs6763439	Human NCBI Build 35	3	58618493	FAM3D
4983	-	10868	C/G	0	390121	rs680578	Human NCBI Build 35	1	232962715	EDARADD
4984	-	10887	C/G	0	390123	rs68734	Human NCBI Build 35	18	75266979	NFATC1
4985	-	10896	C/G	0	390125	rs6884561	Human NCBI Build 35	5	169405343	DOCK2
4986	-	10920	C/G	1	390127	rs6926628	Human NCBI Build 35	6	33025476	HLA-DMA
4987	-	10941	C/G	0	390131	rs6957176	Human NCBI Build 35	7	54875494	EGFR
4989	-	11077	C/G	1	390162	rs744120	Human NCBI Build 35	17	73719119	BIRC5
4990	-	11089	C/G	0	390165	rs7455546	Human NCBI Build 35	7	157353794	PTPRN2
4991	-	11096	C/G	0	390166	rs748224	Human NCBI Build 35	2	108998554	EDAR
4992	-	11109	C/G	0	390168	rs7542609	Human NCBI Build 35	1	39905271	OXCT2-ENSG00000116985
4993	-	11118	C/G	0	390170	rs7569134	Human NCBI Build 35	2	233888533	INPP5D
4994	-	11201	C/G	0	390180	rs7649466	Human NCBI Build 35	3	107070535	CBLB
4995	-	11434	C/G	1	390221	rs9273655	Human NCBI Build 35	6	32737187	HLA-DQB1
4997	-	11514	C/G	1	390230	rs948198	Human NCBI Build 35	18	7648973	PTPRM
4999	-	11706	C/G	0	390260	rs10413063	Human NCBI Build 35	19	5167283	PTPRS
5000	-	11900	C/G	0	390304	rs1124882	Human NCBI Build 35	9	34544227	CNTFR
5001	-	11902	C/G	0	390305	rs11265489	Human NCBI Build 35	1	157590621	LY9
5002	-	11930	C/G	0	390310	rs1136103	Human NCBI Build 35	5	149752473	TCOF1-CD74
5003	-	11963	C/G	0	390316	rs11569422	Human NCBI Build 35	19	6662070	C3
5004	-	12129	C/G	0	390347	rs12373018	Human NCBI Build 35	16	3661774	TRAP1
5005	-	12187	C/G	0	390355	rs12551429	Human NCBI Build 35	9	34566465	CNTFR
5006	-	12214	C/G	1	390361	rs12617336	Human NCBI Build 35	2	162674819	DPP4-SLC4A10
5007	-	12278	C/G	0	390370	rs12722015	Human NCBI Build 35	6	33156462	HLA-DPB1
5009	-	12325	C/G	1	390381	rs1327466	Human NCBI Build 35	1	71086128	PTGER3
5011	-	12404	C/G	1	390396	rs1539042	Human NCBI Build 35	10	93613997	TNKS2

5012	-	12410	C/G	0	390397	rs1544094	Human NCBI Build 35	9	37027317	PAX5
5013	-	12421	C/G	0	390399	rs1547550	Human NCBI Build 35	2	191671231	STAT1
5014	-	12425	C/G	0	390401	rs1556385	Human NCBI Build 35	9	88853059	C9orf47-ENSG00000148082
5015	-	2921	C/G	0	390435	rs1802498	Human NCBI Build 35	19	19173496	RFXANK-ENSG00000184162
5016	-	541	C/G	0	390437	rs1807382	Human NCBI Build 35	18	46508173	MAPK4
5017	-	6510	C/G	0	390442	rs1870660	Human NCBI Build 35	9	90677560	SYK
5018	-	6117	C/G	0	390457	rs2065583	Human NCBI Build 35	9	90672117	SYK
5019	-	1402	C/G	0	390493	rs223818	Human NCBI Build 35	16	55952259	CCL22
5020	-	1080	C/G	0	390498	rs2241145	Human NCBI Build 35	16	54079701	MMP2
5021	-	1208	C/G	0	390504	rs2243525	Human NCBI Build 35	1	233032903	LGALS8
5022	-	1120	C/G	0	390507	rs2250889	Human NCBI Build 35	20	44075813	MMP9
5023	-	4389	C/G	0	390508	rs2252673	Human NCBI Build 35	19	7101418	INSR
5024	-	4049	C/G	0	390513	rs2269715	Human NCBI Build 35	1	155038092	CD1A
5025	-	4205	C/G	0	390520	rs2276839	Human NCBI Build 35	3	53857943	IL17RB-CHDH
5026	-	1570	C/G	0	390523	rs2279785	Human NCBI Build 35	2	95112132	MAL
5027	-	4566	C/G	0	390526	rs2282001	Human NCBI Build 35	9	35367772	UNC13B-ENSG00000196186
5028	-	1678	C/G	1	390529	rs2286598	Human NCBI Build 35	12	6422777	VAMP1-TNFRSF7
5029	-	5727	C/G	0	390543	rs2290891	Human NCBI Build 35	9	90715825	SYK
5030	-	5675	C/G	1	390551	rs2298565	Human NCBI Build 35	21	44467824	ENSG00000160223
5031	-	4432	C/G	0	390556	rs2304207	Human NCBI Build 35	19	54859538	BCL2L12-IRF3
5032	-	3181	C/G	0	390557	rs2304225	Human NCBI Build 35	19	60077774	FCAR
5034	-	5529	C/G	0	390577	rs2672725	Human NCBI Build 35	5	487981	AHRR
5035	-	5909	C/G	0	390589	rs281432	Human NCBI Build 35	19	10251658	ICAM1
5036	-	6355	C/G	0	390606	rs3024608	Human NCBI Build 35	16	27271187	IL4R
5037	-	1107	C/G	0	390611	rs3088307	Human NCBI Build 35	2	191654918	STAT1-GLS
5039	-	3236	C/G	0	390622	rs317921	Human NCBI Build 35	19	11367099	EPOR
5041	-	4376	C/G	0	390629	rs3213546	Human NCBI Build 35	12	119933936	OASL
5042	-	277	C/G	1	390637	rs356969	Human NCBI Build 35	6	30085124	HLA-G
5043	-	2887	C/G	1	390648	rs3752371	Human NCBI Build 35	7	157430739	PTPRN2
5044	-	193	C/G	0	390649	rs3753348	Human NCBI Build 35	11	818916	ENSG00000177685-CD151-PNPLA2
5045	-	1067	C/G	0	390655	rs3764542	Human NCBI Build 35	19	56949485	FPR1
5046	-	168	C/G	0	390658	rs3775544	Human NCBI Build 35	4	185686125	IRF2
5047	-	1468	C/G	0	390664	rs3783613	Human NCBI Build 35	1	100908808	VCAM1
5048	-	2975	C/G	0	390681	rs3805434	Human NCBI Build 35	5	150400532	TNIP1
5049	-	5772	C/G	0	390694	rs3824448	Human NCBI Build 35	9	5498986	PDCD1LG2
5050	-	5425	C/G	0	390699	rs3829156	Human NCBI Build 35	10	133639376	BNIP3
5051	-	5423	C/G	1	390706	rs401090	Human NCBI Build 35	15	62118530	ENSG00000035664
5052	-	502	C/G	0	390716	rs419304	Human NCBI Build 35	19	59467161	ENSG00000131042
5053	-	5229	C/G	1	390734	rs4469075	Human NCBI Build 35	4	111048190	none
5054	-	1323	C/G	1	390739	rs4621902	Human NCBI Build 35	9	36853033	PAX5
5055	-	1236	C/G	1	390741	rs464286	Human NCBI Build 35	3	10226340	IRAK2
5056	-	1779	C/G	0	390761	rs4966038	Human NCBI Build 35	15	97264155	IGF1R
5057	-	4808	C/G	0	390790	rs6072702	Human NCBI Build 35	20	40428098	PTPRT
5058	-	5589	C/G	0	390799	rs622502	Human NCBI Build 35	3	50620797	MAPKAPK3-CISH
5059	-	1068	C/G	0	390801	rs630516	Human NCBI Build 35	10	6546953	PRKCQ
5060	-	5103	C/G	0	390804	rs641018	Human NCBI Build 35	12	6433071	VAMP1-TAPBPL-TNFRSF7
5061	-	4150	C/G	0	390806	rs6429354	Human NCBI Build 35	1	232308207	ENSG00000143669
5062	-	3436	C/G	0	390825	rs6845941	Human NCBI Build 35	4	48008863	TEC
5063	-	6083	C/G	0	390835	rs7100666	Human NCBI Build 35	10	129756439	PTPRE

5064	-	4749	C/G	0	390841	rs7207019	Human NCBI Build 35	17	59777169	PECAM1
5065	-	3733	C/G	0	390846	rs7242726	Human NCBI Build 35	18	75310556	NFATC1
5067	-	1353	C/G	0	390852	rs726173	Human NCBI Build 35	4	78786674	CXCL13
5069	-	5435	C/G	1	390905	rs8105483	Human NCBI Build 35	19	7715283	ENSG00000188197-ENSG00000090659
5070	-	5577	C/G	1	390912	rs816357	Human NCBI Build 35	12	116145486	NOS1
5073	-	3528	C/G	1	390920	rs832518	Human NCBI Build 35	12	93142614	PLXNC1
5074	-	3820	C/G	1	390931	rs882643	Human NCBI Build 35	22	15966377	IL17R
5075	-	3157	C/G	0	390937	rs907423	Human NCBI Build 35	8	57046172	LYN
5076	-	3478	C/G	0	390944	rs9405191	Human NCBI Build 35	6	3031952	RIPK1
5077	-	220	C/G	0	390946	rs944343	Human NCBI Build 35	9	113440525	RGS3
5078	-	5528	C/G	0	390975	rs10406301	Human NCBI Build 35	19	60041080	KIR2DS1
5080	-	800	C/G	0	391010	rs10757190	Human NCBI Build 35	9	21134920	IFNW1
5082	-	5828	C/G	0	391025	rs11229062	Human NCBI Build 35	11	57123993	SERPING1
5083	-	4115	C/G	0	391038	rs11568992	Human NCBI Build 35	4	111254856	EGF
5084	-	2990	C/G	0	391042	rs11602147	Human NCBI Build 35	11	101695376	BIRC3
5085	-	238	C/G	0	391051	rs11912524	Human NCBI Build 35	22	41104963	ENSG00000167087
5086	-	816	C/G	1	391052	rs11936921	Human NCBI Build 35	4	111031557	none
5087	-	2853	C/G	0	391054	rs11963191	Human NCBI Build 35	6	41799644	TFEB
5088	-	5673	C/G	1	391063	rs12123849	Human NCBI Build 35	16	65754639	
ENSG00000102878-FBXL8-TRADD										
5089	-	1025	C/G	1	391069	rs1235005	Human NCBI Build 35	1	114129479	PTPN22
5090	-	3684	C/G	1	391076	rs12569232	Human NCBI Build 35	1	207941459	TRAF5
5092	-	1362	C/G	0	391111	rs13926	Human NCBI Build 35	16	3664466	TRAP1
5093	-	6266	C/G	0	391126	rs1534880	Human NCBI Build 35	22	35653611	CSF2RB
5094	-	3472	C/G	0	391130	rs1553318	Human NCBI Build 35	5	156411901	HAVCR1
5095	-	6263	C/G	0	391144	rs1713239	Human NCBI Build 35	1	203425870	PIGR-IL20
5096	-	3896	C/G	0	391189	rs2066807	Human NCBI Build 35	12	55026949	STAT2
5097	-	199	C/G	0	391191	rs2066845	Human NCBI Build 35	16	49314041	CARD15
5098	-	5168	C/G	0	391197	rs2071888	Human NCBI Build 35	6	33380833	TAPBP
5099	-	3796	C/G	0	391206	rs210133	Human NCBI Build 35	6	33644775	BAK1
5100	-	5437	C/G	1	391209	rs2127569	Human NCBI Build 35	5	146323120	PPP2R2B
5101	-	4371	C/G	0	391225	rs2229070	Human NCBI Build 35	9	130789583	ABL1
5102	-	942	C/G	0	391233	rs2237269	Human NCBI Build 35	6	137008312	MAP3K5
5103	-	4580	C/G	0	391256	rs2272301	Human NCBI Build 35	12	51874619	ITGB7
5104	-	5142	C/G	0	391276	rs2289743	Human NCBI Build 35	15	39647990	TYRO3
5105	-	5748	C/G	0	391318	rs2664026	Human NCBI Build 35	4	48058789	TEC
5106	-	4015	C/G	0	391325	rs2717701	Human NCBI Build 35	14	23678987	PSME1-PSME2-C14orf122
5107	-	514	C/G	0	391330	rs2770151	Human NCBI Build 35	9	35296487	UNC13B-ENSG00000196186
5108	-	408	C/G	0	391333	rs2793380	Human NCBI Build 35	1	222895712	PARP1
5110	-	5586	C/G	0	391349	rs2978872	Human NCBI Build 35	8	6718140	ENSG00000164825
5111	-	5955	C/G	0	391355	rs3027031	Human NCBI Build 35	1	155991346	FY
5112	-	5868	C/G	0	391357	rs3095754	Human NCBI Build 35	9	87479790	DAPK1
5113	-	4431	C/G	0	391372	rs326346	Human NCBI Build 35	3	109288243	CD47
5114	-	5633	C/G	0	391380	rs355968	Human NCBI Build 35	16	65232063	CKLFSF4
5116	-	3309	C/G	0	391416	rs3769501	Human NCBI Build 35	2	105938324	NCK2
5117	-	3844	C/G	0	391431	rs3797135	Human NCBI Build 35	5	10782757	DAP-ENSG00000164236
5118	-	3242	C/G	0	391436	rs3803796	Human NCBI Build 35	17	7395252	TNFSF12
5119	-	699	C/G	1	391447	rs3822257	Human NCBI Build 35	4	15461285	CD38
5120	-	2256	C/G	0	391451	rs3851806	Human NCBI Build 35	17	42705918	ITGB3

5121	-	4046	C/G	0	391458	rs3917991	Human NCBI Build 35	1	36603898	CSF3R-MRPS15
5122	-	5618	C/G	0	391464	rs4064	Human NCBI Build 35 10	90741360	ENSG00000026103	
5123	-	4849	C/G	0	391469	rs4103200	Human NCBI Build 35	17	37760591	STAT3
5124	-	3046	C/G	0	391470	rs4149573	Human NCBI Build 35	12	6319645	TNFRSF1A
5125	-	1367	C/G	0	391479	rs4479591	Human NCBI Build 35	3	62157696	PTPRG
5126	-	1936	C/G	0	391480	rs448461	Human NCBI Build 35	19	59434550	ENSG00000186152
5127	-	476	C/G	0	391482	rs4519167	Human NCBI Build 35	12	7133338	C1RL-ENSG00000159403
5128	-	6308	C/G	1	391508	rs4806131	Human NCBI Build 35	19	40531882	GPR40-CD22
5129	-	3304	C/G	1	391525	rs4968200	Human NCBI Build 35	17	7389181	TNFSF12
5130	-	3124	C/G	0	391541	rs5744463	Human NCBI Build 35	5	66528168	LY64
5134	-	3879	C/G	0	391613	rs7247025	Human NCBI Build 35	19	59474139	ENSG00000131042
5135	-	5500	C/G	1	391614	rs7294695	Human NCBI Build 35	12	12214885	LRP6-BCL2L14
5136	-	4595	C/G	0	391615	rs7296859	Human NCBI Build 35	12	6764425	CD4
5137	-	4271	C/G	0	391624	rs751751	Human NCBI Build 35	3	61922409	PTPRG
5138	-	5708	C/G	0	391631	rs760456	Human NCBI Build 35	21	45153843	ITGB2
5139	-	2935	C/G	0	391639	rs7732671	Human NCBI Build 35	5	149192436	PPARGC1B
5140	-	5573	C/G	1	391649	rs7828483	Human NCBI Build 35	8	57055442	LYN
5141	-	5432	C/G	1	391658	rs793777	Human NCBI Build 35	4	185689562	IRF2
5142	-	5996	C/G	1	391680	rs869487	Human NCBI Build 35	9	35605896	CD72-ENSG00000196186
5143	-	166	C/G	0	391692	rs893320	Human NCBI Build 35	18	46424976	MAPK4
5144	-	1617	C/G	1	391706	rs927010	Human NCBI Build 35	6	112254016	FYN
5147	-	4140	C/G	0	391722	rs9504858	Human NCBI Build 35	6	6536464	LY86-ENSG00000175753
5148	-	1913	C/G	1	391745	rs1009847	Human NCBI Build 35	18	65702132	CD226
5149	-	245	C/G	1	391746	rs1009978	Human NCBI Build 35	14	54672814	LGALS3
5150	-	5791	C/G	0	391753	rs10241548	Human NCBI Build 35	7	76847345	PTPN12
5151	-	6061	C/G	0	391789	rs10845554	Human NCBI Build 35	12	12524217	DUSP16
5152	-	5554	C/G	0	391793	rs10875910	Human NCBI Build 35	12	47688660	PRKAG1
5153	-	1835	C/G	0	391796	rs10900215	Human NCBI Build 35	10	45227460	ALOX5
5154	-	1471	C/G	1	391811	rs11265919	Human NCBI Build 35	9	89337070	SEMA4D
5155	-	5714	C/G	0	391830	rs11742812	Human NCBI Build 35	5	156567922	ITK
5156	-	3992	C/G	1	391833	rs11778416	Human NCBI Build 35	8	23010250	TNFRSF10C
5157	-	1425	C/G	1	391838	rs11965188	Human NCBI Build 35	6	167389882	CCR6-ENSG00000187485
5158	-	940	C/G	0	391840	rs11993993	Human NCBI Build 35	8	23007870	TNFRSF10C
5159	-	3772	C/G	0	391861	rs12659166	Human NCBI Build 35	5	149087137	PPARGC1B
5160	-	1955	C/G	1	391905	rs1535094	Human NCBI Build 35	14	22849474	BCL2L2
5161	-	6133	C/G	1	391910	rs1548216	Human NCBI Build 35	7	22543013	IL6-ENSG00000179428
5162	-	4965	C/G	0	391914	rs1564360	Human NCBI Build 35	12	15375037	PTPRO
5163	-	6141	C/G	0	391957	rs1978237	Human NCBI Build 35	19	5160641	PTPRS
5164	-	4536	C/G	0	391990	rs2072138	Human NCBI Build 35	12	111887613	OAS2
5167	-	5947	C/G	0	392023	rs2240844	Human NCBI Build 35	7	38131342	TRGV9
5168	-	2116	C/G	1	392024	rs2241393	Human NCBI Build 35	19	6636304	C3
5169	-	3589	C/G	0	392026	rs2243158	Human NCBI Build 35	1	203396036	IL19-PIGR
5170	-	4661	C/G	0	392027	rs2243200	Human NCBI Build 35	5	132025315	IL13
5171	-	3984	C/G	0	392031	rs2267153	Human NCBI Build 35	22	28968163	LIF-ENSG00000185188
5172	-	5337	C/G	0	392033	rs2268013	Human NCBI Build 35	12	6196175	CD9
5173	-	3120	C/G	0	392036	rs2271316	Human NCBI Build 35	11	36568666	ENSG00000166352-RAG2-RAG1
5174	-	5352	C/G	0	392046	rs2278773	Human NCBI Build 35	2	46324073	PRKCE
5175	-	738	C/G	0	392053	rs2289924	Human NCBI Build 35	5	38921110	OSMR
5176	-	4992	C/G	0	392079	rs2489878	Human NCBI Build 35	X	117700645	IL13RA1

5177	-	5711	C/G	0	392084	rs251464	Human NCBI Build 35	5	149176427	PPARGC1B
5178	-	2023	C/G	1	392087	rs2551416	Human NCBI Build 35	15	31975878	AVEN
5179	-	5861	C/G	0	392089	rs2587074	Human NCBI Build 35	22	16544529	BCL2L13
5180	-	630	C/G	1	392090	rs2594491	Human NCBI Build 35	2	46319991	PRKCE
5181	-	1813	C/G	0	392095	rs2647395	Human NCBI Build 35	1	85440685	BCL10-ENSG00000162642
5182	-	511	C/G	0	392103	rs2701896	Human NCBI Build 35	13	40025892	FOXO1A
5183	-	135	C/G	0	392106	rs2734318	Human NCBI Build 35	Multiple	0	Unknown
5184	-	4782	C/G	0	392128	rs2871865	Human NCBI Build 35	15	97012419	IGF1R
5185	-	5737	C/G	0	392139	rs3007420	Human NCBI Build 35	1	6464089	TNFRSF25-ENSG00000162401
5186	-	860	C/G	1	392147	rs3024957	Human NCBI Build 35	12	55784302	STAT6
5187	-	3221	C/G	0	392178	rs347160	Human NCBI Build 35	3	32437397	ENSG00000153551
5188	-	1002	C/G	0	392198	rs3760396	Human NCBI Build 35	17	29605554	CCL2
5189	-	2983	C/G	1	392210	rs3787193	Human NCBI Build 35	20	49543352	NFATC2
5191	-	5810	C/G	0	392226	rs3815763	Human NCBI Build 35	5	54365760	GZMK
5192	-	488	C/G	0	392240	rs39999	Human NCBI Build 35	16	68211197	NFAT5
5193	-	5662	C/G	0	392273	rs4694891	Human NCBI Build 35	4	48097376	TEC
5195	-	2278	C/G	0	392281	rs475896	Human NCBI Build 35	19	7737429	ENSG00000104938
5196	-	5686	C/G	0	392293	rs4804130	Human NCBI Build 35	19	10272029	ICAM5
5197	-	2752	C/G	0	392294	rs4804195	Human NCBI Build 35	19	7205944	INSR
5198	-	5180	C/G	0	392318	rs523104	Human NCBI Build 35	11	104374918	CASP5
5199	-	573	C/G	0	392343	rs603151	Human NCBI Build 35	1	12182557	TNFRSF1B
5200	-	3721	C/G	0	392352	rs617180	Human NCBI Build 35	1	20184619	PLA2G2D
5201	-	4670	C/G	0	392355	rs6459806	Human NCBI Build 35	7	157009959	PTPRN2-ENSG00000197192
5202	-	1273	C/G	0	392366	rs6550234	Human NCBI Build 35	3	33888230	PDCD6IP
5203	-	675	C/G	0	392374	rs665691	Human NCBI Build 35	1	22705660	C1QA
5204	-	4883	C/G	0	392408	rs7028425	Human NCBI Build 35	17	23720043	SARM1-ENSG00000126656-VTN
5205	-	1200	C/G	0	392412	rs7058624	Human NCBI Build 35	X	103720533	IL1RAPL2
5206	-	1817	C/G	0	392414	rs706115	Human NCBI Build 35	9	33243605	BAG1
5207	-	1665	C/G	0	392431	rs7209750	Human NCBI Build 35	17	3622085	ITGAE
5208	-	409	C/G	1	392449	rs745723	Human NCBI Build 35	2	120828986	INHBB
5210	-	4260	C/G	0	392503	rs8800090	Human NCBI Build 35	19	19601729	EDG4-GMIP
5211	-	3663	C/G	0	392509	rs886557	Human NCBI Build 35	3	62042996	PTPRG
5212	-	5755	C/G	0	392515	rs910829	Human NCBI Build 35	20	41107922	PTPRT
5213	-	1658	C/G	0	392517	rs919092	Human NCBI Build 35	12	105490577	RFX4
5214	-	1512	C/G	0	392521	rs927374	Human NCBI Build 35	9	114758924	TNFSF8
5215	-	5443	C/G	0	392522	rs928114	Human NCBI Build 35	9	87408360	DAPK1
5216	-	884	C/G	0	392523	rs928149	Human NCBI Build 35	9	34658159	CCL27
5217	-	2679	C/G	1	392536	rs962253	Human NCBI Build 35	15	97157356	IGF1R
5218	-	6120	C/G	0	392541	rs976249	Human NCBI Build 35	20	40777020	PTPRT
5219	-	5615	C/G	1	392555	rs9956729	Human NCBI Build 35	18	7917343	PTPRM
5221	-	3810	C/G	0	392589	rs1063499	Human NCBI Build 35	5	40991318	C7
5222	-	2849	C/G	0	392590	rs1063560	Human NCBI Build 35	5	55307842	IL6ST
5224	-	941	C/G	1	392633	rs11582143	Human NCBI Build 35	1	207905371	TRAF5
5225	-	506	C/G	0	392636	rs11651728	Human NCBI Build 35	17	3640149	ITGAE
5226	-	5325	C/G	1	392663	rs12461559	Human NCBI Build 35	19	12778100	RNASEH2A-PRDX2
5228	-	4308	C/G	0	392682	rs13055337	Human NCBI Build 35	22	41109558	ENSG00000167087
5230	-	5672	C/G	0	392685	rs1316873	Human NCBI Build 35	2	95120520	MAL
5231	-	4969	C/G	1	392699	rs1341022	Human NCBI Build 35	20	36365965	BPI
5233	-	5199	C/G	0	392707	rs1400317	Human NCBI Build 35	2	112378945	MERTK

5234	-	2544	C/G	0	392722	rs1500331	Human NCBI Build 35	9	8382759	PTPRD
5235	-	6067	C/G	0	392746	rs1638745	Human NCBI Build 35	7	157034271	PTPRN2-ENSG00000197192
5236	-	648	C/G	1	392756	rs17226367	Human NCBI Build 35	12	69212131	PTPRB
5237	-	5351	C/G	1	392761	rs1759388	Human NCBI Build 35	1	232916538	EDARADD
5238	-	2515	C/G	0	392765	rs17718987	Human NCBI Build 35	2	70972591	CD207
5239	-	2521	C/G	0	392774	rs1807999	Human NCBI Build 35	18	59053152	BCL2
5240	-	3324	C/G	0	392777	rs1848502	Human NCBI Build 35	5	54358233	GZMK
5241	-	4363	C/G	0	392785	rs1922290	Human NCBI Build 35	2	102287286	IL1RL2
5242	-	263	C/G	0	392797	rs1983526	Human NCBI Build 35	12	10499280	KLRC1
5243	-	1962	C/G	0	392825	rs2071170	Human NCBI Build 35	16	10878128	MHC2TA
5244	-	691	C/G	0	392832	rs2134230	Human NCBI Build 35	5	156389535	HAVCR1
5245	-	753	C/G	0	392834	rs2173710	Human NCBI Build 35	9	8392501	PTPRD
5246	-	5292	C/G	0	392841	rs2213419	Human NCBI Build 35	X	104294136	IL1RAPL2
5247	-	1925	C/G	0	392850	rs2237436	Human NCBI Build 35	7	41504171	INHBA
5248	-	18	C/G	1	392852	rs2238335	Human NCBI Build 35	15	89091370	BLM
5250	-	4635	C/G	0	392883	rs2295266	Human NCBI Build 35	6	47333335	TNFRSF21
5251	-	871	C/G	1	392887	rs2302859	Human NCBI Build 35	3	10236689	IRAK2
5252	-	5020	C/G	0	392891	rs2308655	Human NCBI Build 35	6	31345141	HLA-C
5253	-	6325	C/G	0	392909	rs2494250	Human NCBI Build 35	1	156091324	FCER1A-ENSG00000196266
5254	-	2264	C/G	0	392925	rs2683571	Human NCBI Build 35	10	71360481	COL13A1-AMID
5255	-	883	C/G	1	392928	rs2704415	Human NCBI Build 35	4	48044397	TEC
5256	-	2575	C/G	0	392944	rs2838017	Human NCBI Build 35	21	41640437	FAM3B
5257	-	4724	C/G	1	392963	rs3018183	Human NCBI Build 35	9	36972745	PAX5
5258	-	5263	C/G	0	392968	rs3024548	Human NCBI Build 35	16	27262032	IL4R
5259	-	1571	C/G	0	392970	rs3092948	Human NCBI Build 35	X	135453281	ENSG00000102245
5260	-	3704	C/G	1	392992	rs3731898	Human NCBI Build 35	2	219975292	PTPRN-DNAJB2
5261	-	5855	C/G	1	392997	rs3740633	Human NCBI Build 35	11	63039796	LGALS12-ENSG00000184999
5262	-	5148	C/G	0	393002	rs3755833	Human NCBI Build 35	3	37839415	ITGA9
5263	-	398	C/G	0	393005	rs3756405	Human NCBI Build 35	5	10752771	DAP-ENSG00000164236
5264	-	624	C/G	0	393018	rs3776541	Human NCBI Build 35	5	39326562	C9
5265	-	3085	C/G	0	393026	rs3787190	Human NCBI Build 35	20	49553323	NFATC2
5266	-	1804	C/G	0	393028	rs3788518	Human NCBI Build 35	22	34867989	APOL3
5267	-	686	C/G	0	393032	rs3791226	Human NCBI Build 35	2	138602724	HNMT
5268	-	3404	C/G	1	393043	rs3801158	Human NCBI Build 35	7	41512381	INHBA
5269	-	2839	C/G	0	393044	rs3801268	Human NCBI Build 35	7	105492581	PBEF1
5270	-	3638	C/G	0	393054	rs3827632	Human NCBI Build 35	6	41361305	TREM1
5271	-	5100	C/G	1	393080	rs420931	Human NCBI Build 35	8	16088316	MSR1
5272	-	94	C/G	0	393081	rs4234463	Human NCBI Build 35	3	46476846	LTF
5273	-	6158	C/G	1	393084	rs4252552	Human NCBI Build 35	19	60570333	IL11-ENSG00000180024
5274	-	3742	C/G	1	393126	rs4846476	Human NCBI Build 35	1	214914623	ENSG00000092969
5275	-	379	C/G	0	393133	rs4872085	Human NCBI Build 35	8	23131433	TNFRSF10A-ENSG00000147457
5276	-	6280	C/G	0	393136	rs4891786	Human NCBI Build 35	18	65722590	CD226
5277	-	1018	C/G	0	393150	rs519113	Human NCBI Build 35	19	50068124	ENSG00000130202
5278	-	2473	C/G	1	393157	rs558832	Human NCBI Build 35	20	40966014	PTPRT
5279	-	5189	C/G	1	393170	rs5956646	Human NCBI Build 35	X	123213773	SH2D1A
5280	-	4562	C/G	0	393181	rs6060843	Human NCBI Build 35	20	29760708	BCL2L1
5281	-	1952	C/G	1	393188	rs6081084	Human NCBI Build 35	20	1827449	PTPNS1
5282	-	6231	C/G	0	393201	rs6453253	Human NCBI Build 35	5	76170533	F2RL1-ENSG00000183613
5283	-	3929	C/G	1	393202	rs6474030	Human NCBI Build 35	8	56980702	LYN

5284	-	3222	C/G	1	393215	rs6550507	Human NCBI Build 35	3	37764386	ITGA9
5285	-	437	C/G	0	393223	rs6661764	Human NCBI Build 35	1	204196780	none
5286	-	1724	C/G	1	393228	rs6710535	Human NCBI Build 35	2	127907190	PROC
5287	-	2363	C/G	0	393231	rs6736233	Human NCBI Build 35	2	201944480	CASP8
5288	-	4116	C/G	1	393233	rs6741949	Human NCBI Build 35	2	162735730	DPP4
5289	-	5136	C/G	0	393238	rs6796131	Human NCBI Build 35	3	191794834	IL1RAP
5290	-	180	C/G	0	393260	rs7169463	Human NCBI Build 35	15	64532983	MAP2K1
5291	-	4552	C/G	0	393262	rs7183706	Human NCBI Build 35	15	97092712	IGF1R
5292	-	2388	C/G	0	393307	rs7705216	Human NCBI Build 35	5	35229426	PRLR
5293	-	2662	C/G	0	393319	rs7855263	Human NCBI Build 35	9	89315012	SEMA4D
5294	-	2237	C/G	1	393323	rs7896632	Human NCBI Build 35	10	71507697	H2AFY2-AMID
5295	-	4982	C/G	0	393328	rs797558	Human NCBI Build 35	6	136635428	ENSG0000029363
5297	-	4892	C/G	1	393342	rs8121056	Human NCBI Build 35	20	40983729	PTPRT
5298	-	5327	C/G	0	393343	rs816361	Human NCBI Build 35	12	116117851	NOS1
5299	-	4657	C/G	1	393346	rs831631	Human NCBI Build 35	11	33698141	CD59
5300	-	4502	C/G	0	393351	rs866484	Human NCBI Build 35	1	155799550	IFI16
5301	-	235	C/G	0	393352	rs867375	Human NCBI Build 35	9	113404964	RGS3
5302	-	1422	C/G	1	393372	rs9331888	Human NCBI Build 35	8	27524779	CLU
5303	-	636	C/G	1	393375	rs9426418	Human NCBI Build 35	1	29474452	PTPRU
5304	-	5264	C/G	0	393388	rs966065	Human NCBI Build 35	1	165278832	XCL1
5305	-	1909	C/G	0	393426	rs10482810	Human NCBI Build 35	1	214995927	ENSG0000092969
5306	-	6331	C/G	0	393437	rs10510874	Human NCBI Build 35	3	62088101	ID2B-PTPRG
5308	-	5257	C/G	1	393457	rs10845472	Human NCBI Build 35	12	12129422	BCL2L14
5309	-	3579	C/G	0	393463	rs10921307	Human NCBI Build 35	1	189771038	SSA2
5310	-	3107	C/G	1	393468	rs1105238	Human NCBI Build 35	1	158413319	ENSG00000132185
5311	-	4071	C/G	0	393474	rs11152370	Human NCBI Build 35	18	58986489	BCL2
5312	-	821	C/G	0	393482	rs1142881	Human NCBI Build 35	19	19523	KIR2DS2-KIR2DS1-KIR2DL2
5313	-	1090	C/G	0	393492	rs1169670	Human NCBI Build 35	3	10198607	IRAK2
5314	-	6220	C/G	0	393503	rs12063780	Human NCBI Build 35	1	203663689	C4BPB-C4BPA
5315	-	5532	C/G	0	393507	rs12099964	Human NCBI Build 35	12	92750261	CRADD
5316	-	5252	C/G	0	393510	rs12255504	Human NCBI Build 35	10	91082169	IFIT3-LIPA
5317	-	4959	C/G	0	393511	rs1234314	Human NCBI Build 35	1	169909049	TNFSF4
5319	-	1859	C/G	0	393536	rs130654	Human NCBI Build 35	22	37967154	PDGFB
5320	-	4611	C/G	0	393537	rs13084656	Human NCBI Build 35	3	46255198	CCR3
5321	-	6076	C/G	0	393542	rs1324969	Human NCBI Build 35	13	23124318	TNFRSF19
5322	-	570	C/G	0	393556	rs1389834	Human NCBI Build 35	5	35916144	IL7R
5323	-	2732	C/G	1	393562	rs1427804	Human NCBI Build 35	3	42845562	CCBP2
5324	-	608	C/G	0	393566	rs1460834	Human NCBI Build 35	9	90649615	SYK
5325	-	4767	C/G	0	393571	rs1473418	Human NCBI Build 35	18	59137529	BCL2
5326	-	5508	C/G	0	393586	rs1572382	Human NCBI Build 35	1	157358233	CD84
5327	-	6181	C/G	0	393611	rs1800947	Human NCBI Build 35	1	156496511	CRP
5328	-	4387	C/G	0	393617	rs1867539	Human NCBI Build 35	5	41254463	C6
5329	-	2148	C/G	0	393618	rs1872529	Human NCBI Build 35	12	92700147	CRADD
5330	-	3442	C/G	0	393625	rs1909752	Human NCBI Build 35	9	8361974	PTPRD
5331	-	4390	C/G	0	393631	rs1988743	Human NCBI Build 35	3	191750602	IL1RAP
5332	-	788	C/G	0	393663	rs2146372	Human NCBI Build 35	1	170601226	SERPINC1
5333	-	5044	C/G	0	393681	rs2237062	Human NCBI Build 35	5	134940463	CXCL14
5334	-	2352	C/G	1	393702	rs228229	Human NCBI Build 35	17	34153747	ENSG0000056661
5335	-	875	C/G	1	393709	rs2289278	Human NCBI Build 35	5	110437047	ENSG00000145777

5336	-	2399	C/G	1	393716	rs2292863	Human NCBI Build 35	17	42724129	ITGB3
5337	-	67	C/G	1	393725	rs2306580	Human NCBI Build 35	17	37745206	STAT3
5338	-	5917	C/G	1	393729	rs2345631	Human NCBI Build 35	2	46139576	PRKCE
5339	-	1777	C/G	0	393731	rs2366216	Human NCBI Build 35	3	61540127	PTPRG
5340	-	8	C/G	0	393732	rs2416806	Human NCBI Build 35	9	120769846	TRAF1
5341	-	507	C/G	0	393733	rs2422666	Human NCBI Build 35	20	1851108	PTPNS1
5342	-	5281	C/G	0	393758	rs2719240	Human NCBI Build 35	8	57032602	LYN
5343	-	576	C/G	0	393768	rs2806878	Human NCBI Build 35	1	117286563	IGSF2
5344	-	102	C/G	0	393771	rs28305	Human NCBI Build 35 5	35080055		AGXT2-PRLR
5345	-	395	C/G	0	393773	rs2838023	Human NCBI Build 35	21	41645369	FAM3B
5346	-	6249	C/G	0	393777	rs2853699	Human NCBI Build 35	3	39348906	CCR8
5347	-	5449	C/G	0	393778	rs2855534	Human NCBI Build 35	12	6768782	CD4
5348	-	896	C/G	0	393824	rs344548	Human NCBI Build 35	19	6636817	C3
5349	-	1007	C/G	0	393829	rs3745150	Human NCBI Build 35	19	50077599	ENSG00000130202
5350	-	5979	C/G	1	393836	rs3753383	Human NCBI Build 35	1	157412725	SLAMF1
5351	-	3020	C/G	0	393838	rs3755286	Human NCBI Build 35	2	102302359	IL1RL2
5352	-	2636	C/G	0	393853	rs3782905	Human NCBI Build 35	12	46552434	VDR
5353	-	394	C/G	0	393860	rs3792231	Human NCBI Build 35	2	196856534	STK17B
5354	-	4500	C/G	0	393865	rs3794345	Human NCBI Build 35	13	23127046	TNFRSF19
5355	-	5215	C/G	0	393870	rs3805433	Human NCBI Build 35	5	150415673	TNIP1
5356	-	3985	C/G	0	393896	rs4082516	Human NCBI Build 35	10	71374662	COL13A1-AMID
5357	-	3906	C/G	0	393915	rs4572808	Human NCBI Build 35	3	32292718	CKLFSF8
5358	-	2124	C/G	0	393919	rs4647297	Human NCBI Build 35	7	142508198	CASP2
5359	-	143	C/G	1	393922	rs4682857	Human NCBI Build 35	3	42834803	CCBP2
5360	-	1212	C/G	1	393934	rs4750457	Human NCBI Build 35	10	6522285	PRKCQ
5361	-	1073	C/G	0	393948	rs4865998	Human NCBI Build 35	5	55239647	IL31RA
5362	-	960	C/G	0	393957	rs4953273	Human NCBI Build 35	2	45994521	PRKCE
5363	-	4664	C/G	0	393967	rs540303	Human NCBI Build 35	19	7743645	ENSG00000104938
5364	-	3136	C/G	0	393978	rs5935438	Human NCBI Build 35	X	12672679	TLR7
5365	-	5925	C/G	0	393985	rs5992807	Human NCBI Build 35	22	16585376	BCL2L13
5366	-	3455	C/G	0	393992	rs6067807	Human NCBI Build 35	20	49574300	NFATC2
5367	-	4574	C/G	0	394018	rs6592775	Human NCBI Build 35	11	77794695	GAB2
5370	-	1865	C/G	0	394044	rs6862588	Human NCBI Build 35	5	43434787	CCL28
5371	-	2190	C/G	0	394047	rs6879798	Human NCBI Build 35	5	169439532	DOCK2
5372	-	1671	C/G	0	394056	rs6940707	Human NCBI Build 35	6	137534102	IL22RA2
5373	-	3073	C/G	0	394062	rs700188	Human NCBI Build 35	5	39251822	FYB
5375	-	2672	C/G	1	394066	rs7027504	Human NCBI Build 35	9	36863881	PAX5
5376	-	4379	C/G	0	394070	rs7079777	Human NCBI Build 35	10	71424484	AMID
5377	-	1082	C/G	0	394089	rs737994	Human NCBI Build 35	22	16485654	ATP6V1E1-BCL2L13
5378	-	870	C/G	0	394104	rs7571586	Human NCBI Build 35	2	201965444	CASP8
5379	-	1361	C/G	0	394125	rs7895188	Human NCBI Build 35	10	79293384	DLG5
5380	-	3691	C/G	0	394157	rs910684	Human NCBI Build 35	6	112290151	FYN
5381	-	1342	C/G	0	394163	rs930507	Human NCBI Build 35	10	54198272	MBL2
5382	-	5066	C/G	0	394165	rs9321563	Human NCBI Build 35	6	136981080	MAP3K5
5383	-	1144	C/G	1	394167	rs9367269	Human NCBI Build 35	6	47311307	TNFRSF21
5385	-	2764	C/G	0	394186	rs9579648	Human NCBI Build 35	13	30225032	ALOX5AP
5386	-	1523	C/G	0	394202	rs9867325	Human NCBI Build 35	3	138101607	NCK1-ENSG00000181882
5387	-	4818	C/G	0	394206	rs9965844	Human NCBI Build 35	18	59029944	BCL2
5388	-	1081	C/G	0	394210	rs10093	Human NCBI Build 35 6	32821000		HLA-DQA2

5389	-	4848	C/G	0	394226	rs1036095	Human NCBI Build 35	3	30637332	TGFBR2
5390	-	5641	C/G	0	394232	rs1047275	Human NCBI Build 35	8	22936107	TNFRSF10B-RHOBTB2
5391	-	1017	C/G	0	394236	rs10485085	Human NCBI Build 35	6	6546338	LY86
5392	-	3712	C/G	0	394248	rs10501127	Human NCBI Build 35	11	33698233	CD59
5393	-	103	C/G	0	394253	rs10508198	Human NCBI Build 35	13	107740789	TNFSF13B
5394	-	6314	C/G	0	394262	rs10516773	Human NCBI Build 35	4	87589325	MAPK10
5395	-	2030	C/G	0	394268	rs1055333	Human NCBI Build 35	2	239706228	HDAC4
5396	-	980	C/G	0	394273	rs10815925	Human NCBI Build 35	9	8702601	PTPRD
5397	-	4701	C/G	0	394275	rs10878175	Human NCBI Build 35	12	63153605	TBK1
5398	-	1970	C/G	1	394278	rs10918054	Human NCBI Build 35	1	161359570	PBX1-ENSG00000197613
5399	-	6448	C/G	0	394302	rs11640219	Human NCBI Build 35	16	23982020	PRKCB1
5400	-	6457	C/G	1	394304	rs1168648	Human NCBI Build 35	12	64899302	IRAK3
5401	-	6418	C/G	0	394307	rs11701402	Human NCBI Build 35	21	33549644	IFNAR2
5402	-	6408	C/G	0	394313	rs1179251	Human NCBI Build 35	12	66931318	IL22
5403	-	6366	C/G	1	394314	rs11809371	Human NCBI Build 35	1	32424207	LCK-HDAC1
5404	-	6435	C/G	0	394336	rs12440176	Human NCBI Build 35	15	64501432	MAP2K1
5406	-	6376	C/G	0	394354	rs1316500	Human NCBI Build 35	3	61555080	PTPRG
5407	-	6452	C/G	0	394360	rs1326274	Human NCBI Build 35	1	195360279	PTPRC
5408	-	6346	C/G	0	394361	rs13262930	Human NCBI Build 35	8	27422318	EPHX2
5409	-	6570	C/G	0	394371	rs135547	Human NCBI Build 35	22	44874169	PPARA
5410	-	6584	C/G	0	394383	rs1434249	Human NCBI Build 35	9	8726751	PTPRD
5411	-	6590	C/G	0	394388	rs1469870	Human NCBI Build 35	4	87317075	MAPK10
5412	-	6592	C/G	0	394390	rs1485332	Human NCBI Build 35	3	120757611	CD80
5413	-	6597	C/G	0	394395	rs1513323	Human NCBI Build 35	3	112768809	CD96
5414	-	6605	C/G	1	394401	rs1569171	Human NCBI Build 35	11	48037828	PTPRJ
5415	-	6617	C/G	0	394412	rs17130717	Human NCBI Build 35	1	89236678	GBP1
5417	-	6655	C/G	0	394444	rs1894408	Human NCBI Build 35	6	32894811	TAP2-HLA-DOB
5418	-	6663	C/G	0	394450	rs1956870	Human NCBI Build 35	14	59833852	PPM1A
5419	-	6665	C/G	0	394452	rs1957075	Human NCBI Build 35	4	75064002	CXCL6
5420	-	6713	C/G	0	394492	rs210950	Human NCBI Build 35	6	135573144	MYB
5421	-	6718	C/G	0	394496	rs2179694	Human NCBI Build 35	6	128405416	PTPRK
5422	-	6738	C/G	0	394511	rs2239170	Human NCBI Build 35	12	7044190	C1S
5424	-	6758	C/G	1	394530	rs2279627	Human NCBI Build 35	19	6614594	TNFSF14
5425	-	6767	C/G	0	394538	rs2293045	Human NCBI Build 35	12	116125330	NOS1
5426	-	6780	C/G	0	394549	rs235328	Human NCBI Build 35	21	45138385	ITGB2
5427	-	6784	C/G	0	394552	rs2381801	Human NCBI Build 35	9	8425297	PTPRD
5428	-	6808	C/G	0	394576	rs2567135	Human NCBI Build 35	12	69232010	PTPRB
5429	-	6814	C/G	0	394582	rs260595	Human NCBI Build 35	2	108992076	EDAR
5430	-	6815	C/G	1	394583	rs260704	Human NCBI Build 35	2	109028631	EDAR
5432	-	6847	C/G	1	394613	rs2879125	Human NCBI Build 35	14	105832365	IGHA1
5433	-	6900	C/G	0	394658	rs3748669	Human NCBI Build 35	1	203468010	IL24-PIGR-ENSG00000162894
5434	-	6910	C/G	1	394667	rs3766	Human NCBI Build 35	16	30276092	CD2BP2-ENSG00000169221
5435	-	6919	C/G	0	394676	rs3776038	Human NCBI Build 35	5	54359983	GZMK
5436	-	6923	C/G	0	394680	rs3782558	Human NCBI Build 35	12	97608261	APAF1
5437	-	6924	C/G	0	394681	rs3783546	Human NCBI Build 35	2	113251061	IL1A
5438	-	6927	C/G	0	394684	rs3786989	Human NCBI Build 35	19	3555004	TBXA2R-ENSG00000179740
5439	-	6929	C/G	0	394686	rs3789903	Human NCBI Build 35	9	90700046	SYK
5440	-	6963	C/G	0	394716	rs389512	Human NCBI Build 35	6	32055573	STK19-ENSG00000198209
5441	-	6968	C/G	0	394720	rs3910551	Human NCBI Build 35	3	106659325	ALCAM

5442	-	6973	C/G	0	394725	rs40529 Human NCBI Build 35	5	35084329	AGXT2-PRLR
5443	-	6992	C/G	0	394743	rs4421828 Human NCBI Build 35	12	12580363	DUSP16
5444	-	7025	C/G	1	394771	rs4752904 Human NCBI Build 35	11	48122843	PTPRJ
5446	-	7072	C/G	0	394814	rs582213 Human NCBI Build 35	2	45787677	PRKCE
5447	-	7096	C/G	0	394834	rs641714 Human NCBI Build 35	1	57107771	C8B
5448	-	7113	C/G	1	394850	rs6670514 Human NCBI Build 35	1	218281060	DUSP10
5451	-	7124	C/G	0	394860	rs6733162 Human NCBI Build 35	2	162739005	DPP4
5452	-	7133	C/G	0	394867	rs6787175 Human NCBI Build 35	3	106899111	CBLB
5453	-	7135	C/G	0	394869	rs6861799 Human NCBI Build 35	5	169019097	DOCK2
5454	-	7157	C/G	0	394887	rs7071431 Human NCBI Build 35	10	31704635	TCF8
5455	-	7160	C/G	0	394890	rs7144549 Human NCBI Build 35	14	21991042	ENSG00000166056
5456	-	7177	C/G	0	394904	rs731465 Human NCBI Build 35	3	30711173	TGFBR2
5457	-	7187	C/G	1	394913	rs744170 Human NCBI Build 35	12	12518925	DUSP16
5458	-	7198	C/G	0	394921	rs7563114 Human NCBI Build 35	2	45867375	PRKCE
5459	-	7199	C/G	0	394922	rs757368 Human NCBI Build 35	21	41651461	FAM3B-MX2
5461	-	7211	C/G	0	394932	rs7617704 Human NCBI Build 35	3	15021103	NR2C2
5462	-	7216	C/G	0	394935	rs7640434 Human NCBI Build 35	3	61542154	PTPRG
5463	-	7224	C/G	0	394942	rs7729828 Human NCBI Build 35	5	146036640	PPP2R2B
5464	-	7231	C/G	0	394949	rs7831367 Human NCBI Build 35	8	56973233	LYN
5465	-	7242	C/G	0	394956	rs7910038 Human NCBI Build 35	10	6571202	PRKCQ
5466	-	7255	C/G	1	394968	rs8092455 Human NCBI Build 35	18	8222982	PTPRM
5467	-	7303	C/G	0	395011	rs9487724 Human NCBI Build 35	6	112232146	FYN
5468	-	7334	C/G	0	395037	rs10054727 Human NCBI Build 35	5	145946971	PPP2R2B
5469	-	7340	C/G	0	395043	rs10126835 Human NCBI Build 35	X	104546987	IL1RAPL2
5471	-	7353	C/G	0	395055	rs1027989 Human NCBI Build 35	8	56976975	LYN
5472	-	7358	C/G	0	395060	rs1036203 Human NCBI Build 35	5	146310435	PPP2R2B
5473	-	7368	C/G	0	395070	rs10463313 Human NCBI Build 35	5	150442333	TNIP1
5474	-	7387	C/G	0	395087	rs10497094 Human NCBI Build 35	2	152801510	STAM2
5475	-	7394	C/G	0	395092	rs10501320 Human NCBI Build 35	11	47250375	NR1H3-MADD
5476	-	7414	C/G	0	395112	rs10815162 Human NCBI Build 35	9	5112291	JAK2
5477	-	7432	C/G	1	395127	rs11070875 Human NCBI Build 35	15	50120160	MAPK6
5478	-	7448	C/G	0	395139	rs11247361 Human NCBI Build 35	15	97024915	IGF1R
5479	-	7457	C/G	0	395146	rs11568911 Human NCBI Build 35	4	111223864	EGF
5481	-	7478	C/G	1	395165	rs12052026 Human NCBI Build 35	18	54490707	MALT1
5482	-	7479	C/G	0	395166	rs1206486 Human NCBI Build 35	7	121146345	PTPRZ1
5483	-	7488	C/G	0	395174	rs12136558 Human NCBI Build 35	1	220336731	TP53BP2
5485	-	7495	C/G	0	395179	rs12357281 Human NCBI Build 35	10	89690651	ENSG00000171862
5486	-	7498	C/G	0	395180	rs12439162 Human NCBI Build 35	15	79281397	IL16
5487	-	7501	C/G	1	395182	rs12477409 Human NCBI Build 35	2	46239611	PRKCE
5488	-	7509	C/G	1	395187	rs1256116 Human NCBI Build 35	14	63877636	ESR2
5490	-	7531	C/G	0	395203	rs1323585 Human NCBI Build 35	9	8428004	PTPRD
5491	-	7532	C/G	1	395204	rs132638 Human NCBI Build 35	22	34868221	APOL3
5492	-	7553	C/G	0	395222	rs1407970 Human NCBI Build 35	9	8510995	PTPRD
5493	-	7555	C/G	0	395224	rs1424855 Human NCBI Build 35	9	21068815	IFNB1
5494	-	7558	C/G	0	395227	rs1446522 Human NCBI Build 35	2	113543734	IL1F10
5495	-	7568	C/G	0	395236	rs1538192 Human NCBI Build 35	9	8499506	PTPRD
5496	-	7586	C/G	0	395248	rs1638756 Human NCBI Build 35	7	157051843	PTPRN2-ENSG00000197192
5497	-	7604	C/G	0	395262	rs1782316 Human NCBI Build 35	10	70183951	CCAR1
5498	-	7622	C/G	0	395278	rs1888001 Human NCBI Build 35	13	20183906	IL17D

5499	-	7631	C/G	0	395283	rs1892408	Human NCBI Build 35	1	117401964	ENSG00000134258
5500	-	7655	C/G	0	395302	rs2070745	Human NCBI Build 35	19	56941759	FPR1
5501	-	7656	C/G	0	395303	rs2071594	Human NCBI Build 35	6	31620699	ATP6V1G2-ENSG00000168593
5502	-	7664	C/G	0	395309	rs2105851	Human NCBI Build 35	X	103910181	IL1RAPL2
5503	-	7671	C/G	0	395314	rs2127566	Human NCBI Build 35	8	16067655	MSR1
5504	-	7685	C/G	0	395325	rs2232599	Human NCBI Build 35	20	36425886	LBP
5505	-	7692	C/G	0	395331	rs2239339	Human NCBI Build 35	16	24137386	PRKCB1
5506	-	7700	C/G	0	395338	rs2255798	Human NCBI Build 35	6	31629281	ENSG00000168593
5507	-	7754	C/G	1	395378	rs2507758	Human NCBI Build 35	11	58115297	CNTF
5508	-	7755	C/G	0	395379	rs2518968	Human NCBI Build 35	15	89108414	BLM
5509	-	7770	C/G	0	395391	rs2633298	Human NCBI Build 35	10	75336345	C10orf55-PLAU
5510	-	7779	C/G	0	395400	rs2687506	Human NCBI Build 35	17	31324140	CCL16
5511	-	7781	C/G	0	395401	rs2701652	Human NCBI Build 35	12	64867144	IRAK3
5512	-	7797	C/G	0	395412	rs2796814	Human NCBI Build 35	1	214949976	ENSG00000092969
5514	-	7818	C/G	0	395431	rs3024936	Human NCBI Build 35	2	191720882	STAT4
5515	-	7837	C/G	0	395448	rs332278	Human NCBI Build 35	15	62103455	ENSG00000035664
5516	-	7840	C/G	0	395451	rs33391	Human NCBI Build 35	5	142660439	NR3C1
5517	-	7851	C/G	0	395462	rs3729961	Human NCBI Build 35	5	55287688	IL6ST
5518	-	7852	C/G	0	395463	rs3732127	Human NCBI Build 35	2	102472268	IL18R1
5519	-	7856	C/G	0	395467	rs3747531	Human NCBI Build 35	8	16057019	MSR1
5520	-	7860	C/G	1	395470	rs3753305	Human NCBI Build 35	1	166285716	F5-SELP
5521	-	7876	C/G	0	395483	rs3768758	Human NCBI Build 35	2	46231653	PRKCE
5522	-	7923	C/G	0	395521	rs3951216	Human NCBI Build 35	2	160536552	LY75
5523	-	7932	C/G	1	395528	rs4233305	Human NCBI Build 35	1	211037662	PTPN14
5524	-	7938	C/G	0	395532	rs4251535	Human NCBI Build 35	12	42465477	ENSG00000198001
5525	-	7952	C/G	0	395542	rs4505816	Human NCBI Build 35	4	15021312	C1QTNF7
5526	-	8008	C/G	1	395593	rs588969	Human NCBI Build 35	2	45795248	PRKCE
5527	-	8024	C/G	0	395607	rs631744	Human NCBI Build 35	11	111145830	PPP2R1B
5528	-	8078	C/G	0	395657	rs7026505	Human NCBI Build 35	9	36988416	PAX5
5529	-	8080	C/G	0	395659	rs7111171	Human NCBI Build 35	11	43295234	API5
5530	-	8090	C/G	0	395667	rs721619	Human NCBI Build 35	8	27437913	EPHX2
5531	-	8091	C/G	0	395668	rs721930	Human NCBI Build 35	22	15960362	IL17R
5533	-	8105	C/G	1	395681	rs7425883	Human NCBI Build 35	2	97790039	ZAP70
5534	-	8120	C/G	0	395694	rs7582694	Human NCBI Build 35	2	191795626	STAT4
5535	-	8134	C/G	0	395705	rs7705698	Human NCBI Build 35	5	169361082	DOCK2
5536	-	8135	C/G	0	395706	rs7720983	Human NCBI Build 35	5	41260297	C6
5537	-	8151	C/G	0	395718	rs7896426	Human NCBI Build 35	10	129778263	PTPRE
5538	-	8154	C/G	0	395720	rs7958746	Human NCBI Build 35	12	69459379	PTPRR
5539	-	8160	C/G	0	395725	rs8043545	Human NCBI Build 35	16	10889846	MHC2TA
5540	-	8161	C/G	0	395726	rs8051750	Human NCBI Build 35	16	23978645	PRKCB1
5541	-	8178	C/G	1	395742	rs888331	Human NCBI Build 35	9	87442763	DAPK1
5542	-	8180	C/G	0	395743	rs8946	Human NCBI Build 35	10	121427002	BAG3
5543	-	8206	C/G	0	395762	rs9393795	Human NCBI Build 35	6	27325698	PRSS16
5544	-	8216	C/G	1	395769	rs953870	Human NCBI Build 35	4	15503770	CD38
5545	-	8221	C/G	0	395774	rs9754221	Human NCBI Build 35	21	33539154	IFNAR2
5546	-	8228	C/G	0	395780	rs986468	Human NCBI Build 35	X	104316305	IL1RAPL2
5547	-	8239	C/G	0	395789	rs10018161	Human NCBI Build 35	4	15023064	C1QTNF7
5548	-	8242	C/G	0	395792	rs1005216	Human NCBI Build 35	12	15582907	PTPRO
5549	-	8251	C/G	1	395799	rs1034068	Human NCBI Build 35	13	23128811	TNFRSF19

5550	-	8255	C/G	0	395802	rs10440852	Human NCBI Build 35	6	112263713	FYN
5551	-	8276	C/G	1	395820	rs10506603	Human NCBI Build 35	12	69367960	PTPRR
5552	-	8283	C/G	0	395825	rs10509638	Human NCBI Build 35	10	93577805	TNKS2
5553	-	8325	C/G	0	395856	rs10977171	Human NCBI Build 35	9	8508052	PTPRD
5555	-	8352	C/G	0	395880	rs11733056	Human NCBI Build 35	4	15644408	PROM1-ENSG00000137441
5556	-	8364	C/G	1	395891	rs12051064	Human NCBI Build 35	16	45748097	ENSG00000129636
5557	-	8382	C/G	0	395906	rs12551333	Human NCBI Build 35	9	5447171	ENSG00000120217
5558	-	8420	C/G	0	395939	rs1409164	Human NCBI Build 35	1	71157924	PTGER3
5559	-	8429	C/G	0	395946	rs1467199	Human NCBI Build 35	2	191706008	STAT1
5560	-	8442	C/G	0	395957	rs1542153	Human NCBI Build 35	10	49317564	MAPK8
5561	-	8446	C/G	0	395960	rs1546518	Human NCBI Build 35	8	56987448	LYN
5562	-	8463	C/G	1	395973	rs1641727	Human NCBI Build 35	12	12137192	BCL2L14
5563	-	8481	C/G	0	395989	rs179016	Human NCBI Build 35	X	12654099	TLR7
5565	-	8567	C/G	1	396057	rs2231461	Human NCBI Build 35	11	33688121	CD59
5566	-	8586	C/G	0	396074	rs2286692	Human NCBI Build 35	7	38124908	TRGV9
5567	-	8591	C/G	0	396077	rs2288718	Human NCBI Build 35	12	97601392	APAF1
5568	-	8634	C/G	1	396109	rs2587076	Human NCBI Build 35	22	16546790	BCL2L13
5569	-	8642	C/G	0	396113	rs2646035	Human NCBI Build 35	4	140979423	MGST2-ENSG00000170202
5570	-	8658	C/G	0	396128	rs2736956	Human NCBI Build 35	7	38127240	TRGV9
5571	-	8669	C/G	0	396137	rs2891157	Human NCBI Build 35	9	21158306	IFNA21
5572	-	8678	C/G	1	396142	rs2962098	Human NCBI Build 35	5	35171405	PRLR
5573	-	8699	C/G	1	396160	rs3181320	Human NCBI Build 35	11	104384838	CASP5
5575	-	8730	C/G	0	396182	rs3756824	Human NCBI Build 35	6	22406716	PRL
5576	-	8790	C/G	0	396224	rs40493	Human NCBI Build 35	3	61949989	PTPRG
5577	-	8794	C/G	0	396228	rs4140521	Human NCBI Build 35	20	40302648	PTPRT
5578	-	8798	C/G	0	396232	rs4298142	Human NCBI Build 35	4	111083352	none
5579	-	8802	C/G	0	396234	rs431144	Human NCBI Build 35	19	11359174	EPOR
5580	-	8806	C/G	0	396236	rs4333080	Human NCBI Build 35	3	61688697	PTPRG
5581	-	8827	C/G	1	396251	rs4652813	Human NCBI Build 35	1	180266201	NCF2
5583	-	8833	C/G	0	396255	rs4698373	Human NCBI Build 35	4	15045231	C1QTNF7
5584	-	8863	C/G	1	396280	rs4960181	Human NCBI Build 35	6	6214297	F13A1
5585	-	8868	C/G	0	396285	rs5022713	Human NCBI Build 35	2	162749990	DPP4
5586	-	8879	C/G	0	396292	rs5246	Human NCBI Build 35	14	24046475	CMA1
5587	-	8903	C/G	0	396311	rs617687	Human NCBI Build 35	2	45803629	PRKCE
5588	-	8920	C/G	0	396326	rs657267	Human NCBI Build 35	3	61696545	PTPRG
5589	-	8924	C/G	0	396330	rs6665568	Human NCBI Build 35	1	232259576	ENSG00000143669
5590	-	8936	C/G	1	396341	rs6755148	Human NCBI Build 35	2	138551360	HNMT
5591	-	8940	C/G	0	396344	rs6847178	Human NCBI Build 35	4	15458194	CD38
5592	-	8959	C/G	0	396359	rs7034304	Human NCBI Build 35	9	8430001	PTPRD
5593	-	8968	C/G	1	396367	rs7148835	Human NCBI Build 35	14	105786485	IGHA1
5594	-	8973	C/G	0	396370	rs721231	Human NCBI Build 35	1	154563784	SPAP1
5595	-	8981	C/G	0	396378	rs7306834	Human NCBI Build 35	12	69455955	PTPRR
5598	-	9033	C/G	0	396425	rs8069300	Human NCBI Build 35	17	11924957	MAP2K4
5599	-	9051	C/G	0	396438	rs867231	Human NCBI Build 35	8	27523309	CLU
5601	-	9063	C/G	0	396445	rs894541	Human NCBI Build 35	3	106991341	CLLB
5602	-	9077	C/G	0	396453	rs9323445	Human NCBI Build 35	14	63640579	SYNE2-ESR2
5603	-	9095	C/G	1	396468	rs9684244	Human NCBI Build 35	4	185731394	IRF2
5604	-	9108	C/G	0	396478	rs9845906	Human NCBI Build 35	3	53205364	PRKCD
5605	-	9110	C/G	0	396479	rs9849171	Human NCBI Build 35	3	12597623	MKRN2-RAF1

5606	-	9115	C/G	0	396483	rs9965384	Human NCBI Build 35	18	7872689	PTPRM	
5607	-	9142	C/G	0	396504	rs10489870	Human NCBI Build 35	1	189272177	RGS1	
5608	-	9152	C/G	0	396510	rs10494981	Human NCBI Build 35	1	211110370	PTPN14-ENSG00000181931	
5609	-	9154	C/G	0	396512	rs10500942	Human NCBI Build 35	11	22756149	GAS2	
5610	-	9169	C/G	0	396525	rs10513855	Human NCBI Build 35	3	191792855	IL1RAP	
5611	-	9173	C/G	0	396528	rs10519899	Human NCBI Build 35	15	32061196	AVEN	
5612	-	9232	C/G	1	396574	rs11706397	Human NCBI Build 35	3	32347400	CKLFSF8	
5613	-	9235	C/G	1	396576	rs11710250	Human NCBI Build 35	3	61633955	PTPRG	
5615	-	9245	C/G	0	396584	rs11910627	Human NCBI Build 35	21	33721220	IFNGR2	
5616	-	9266	C/G	0	396601	rs12306153	Human NCBI Build 35	12	69551049	PTPRR	
5617	-	9279	C/G	1	396608	rs1256054	Human NCBI Build 35	14	63786066	ESR2	
5618	-	9366	C/G	0	396682	rs2024252	Human NCBI Build 35	7	121177152	PTPRZ1	
5619	-	9394	C/G	0	396709	rs2145362	Human NCBI Build 35	6	36137133	MAPK13-MAPK14	
5620	-	9402	C/G	1	396715	rs2189693	Human NCBI Build 35	3	61943483	PTPRG	
5622	-	9465	C/G	0	396766	rs2708943	Human NCBI Build 35	2	113390940	IL1F7	
5623	-	9488	C/G	0	396782	rs3124740	Human NCBI Build 35	10	115459615	CASP7	
5624	-	9505	C/G	0	396797	rs344550	Human NCBI Build 35	19	6633953	C3	
5626	-	9544	C/G	0	396829	rs3793730	Human NCBI Build 35	10	6562704	PRKCQ	
5627	-	9546	C/G	0	396831	rs3794316	Human NCBI Build 35	12	8649925	AICDA	
5628	-	9557	C/G	0	396839	rs3822530	Human NCBI Build 35	5	75942679	F2RL2-IQGAP2	
5629	-	9565	C/G	0	396846	rs3917312	Human NCBI Build 35	2	102248700	IL1R1	
5631	-	9595	C/G	0	396873	rs4755453	Human NCBI Build 35	11	36487220	TRAF6	
5632	-	9596	C/G	0	396874	rs4764022	Human NCBI Build 35	12	9885256	KLRF1	
5633	-	9626	C/G	0	396895	rs4966012	Human NCBI Build 35	15	97043671	IGF1R	
5634	-	9629	C/G	1	396898	rs5020833	Human NCBI Build 35	3	30645429	TGFBR2	
5635	-	9660	C/G	0	396924	rs6087709	Human NCBI Build 35	20	33481358	C20orf44-GDF5	
5636	-	9673	C/G	1	396934	rs632591	Human NCBI Build 35	15	32079927	AVEN	
5637	-	9686	C/G	0	396944	rs645725	Human NCBI Build 35	X	69138253	IGBP1	
5638	-	9693	C/G	0	396951	rs6557638	Human NCBI Build 35	8	23129747	TNFRSF10A-ENSG00000147457	
5639	-	9704	C/G	0	396962	rs6689267	Human NCBI Build 35	1	218294877	DUSP10	
5640	-	9705	C/G	0	396963	rs6692113	Human NCBI Build 35	1	50944520	FAF1	
5641	-	9756	C/G	0	397008	rs7430	Human NCBI Build 35	8	22454359	PPP3CC	
5642	-	9760	C/G	0	397012	rs7506022	Human NCBI Build 35	18	54561109	MALT1	
5643	-	9761	C/G	0	397013	rs7515174	Human NCBI Build 35	1	158290004	FCGR2A	
5644	-	9766	C/G	0	397018	rs7542681	Human NCBI Build 35	1	116822384	CD58	
5647	-	9790	C/G	0	397040	rs7758689	Human NCBI Build 35	6	128433973	PTPRK	
5648	-	9793	C/G	0	397041	rs7758826	Human NCBI Build 35	6	128734935	PTPRK	
5649	-	9804	C/G	0	397048	rs7971682	Human NCBI Build 35	12	92583307	CRADD	
5650	-	9816	C/G	0	397056	rs8084922	Human NCBI Build 35	18	59081501	BCL2	
5651	-	9847	C/G	0	397086	rs965892	Human NCBI Build 35	9	90709344	SYK	
5652	-	9853	C/G	1	397092	rs9921290	Human NCBI Build 35	16	11545689	ENSG00000189067	
5653	-	9891	C/G	0	397124	rs10846197	Human NCBI Build 35	12	15586403	PTPRO	
5654	-	9938	C/G	0	397165	rs12078434	Human NCBI Build 35	1	51105666	FAF1	
5655	-	9955	C/G	0	397178	rs12340211	Human NCBI Build 35	9	8521036	PTPRD	
5656	-	9966	C/G	0	397189	rs12590378	Human NCBI Build 35	14	63648640	SYNE2-ESR2	
5657	-	9974	C/G	0	397196	rs132615	Human NCBI Build 35	22	34856822	APOL3	
5658	-	10008	C/G	0	397228	rs1641721	Human NCBI Build 35	12	12122205	BCL2L14	
5659	-	10022	C/G	0	397238	rs1790930	Human NCBI Build 35	18	65713657	CD226	
5660	-	10026	C/G	0	397242	rs1860129	Human NCBI Build 35	4	111243947	EGF	

5661	-	10066	C/G	0	397275	rs2260863	Human NCBI Build 35	1	222326509	EPHX1
5662	-	10165	C/G	0	397357	rs3816724	Human NCBI Build 35	11	47268621	MADD
5664	-	10208	C/G	1	397395	rs4894831	Human NCBI Build 35	3	106633384	ALCAM
5665	-	10226	C/G	0	397413	rs5917151	Human NCBI Build 35	X	103875956	IL1RAPL2
5666	-	10230	C/G	0	397416	rs603723	Human NCBI Build 35	3	139861668	PIK3CB
5667	-	10237	C/G	0	397422	rs612242	Human NCBI Build 35	6	52211119	IL17F
5668	-	10243	C/G	1	397428	rs641701	Human NCBI Build 35	6	52209124	IL17F
5669	-	10272	C/G	0	397450	rs6669994	Human NCBI Build 35	1	195369914	PTPRC
5672	-	10332	C/G	0	397500	rs7636125	Human NCBI Build 35	3	39280438	CX3CR1
5673	-	10337	C/G	0	397505	rs7731414	Human NCBI Build 35	5	55284965	IL6ST
5674	-	10378	C/G	0	397537	rs900464	Human NCBI Build 35	5	169052785	DOCK2
5676	-	10396	C/G	0	397553	rs957707	Human NCBI Build 35	4	75687988	AREG
5677	-	10434	C/G	0	397586	rs10511505	Human NCBI Build 35	9	8611568	PTPRD
5678	-	10450	C/G	0	397599	rs10972389	Human NCBI Build 35	9	35220125	UNC13B-ENSG00000196186
5679	-	10451	C/G	1	397600	rs11066051	Human NCBI Build 35	12	110764480	ENSG00000089022
5680	-	10507	C/G	0	397648	rs13114920	Human NCBI Build 35	4	15111543	C1QTNF7
5681	-	10530	C/G	0	397667	rs1587059	Human NCBI Build 35	5	35086265	AGXT2-PRLR
5682	-	10540	C/G	0	397677	rs1788228	Human NCBI Build 35	18	65692298	CD226
5683	-	10541	C/G	0	397678	rs1863596	Human NCBI Build 35	3	37539918	ITGA9
5685	-	10547	C/G	0	397683	rs1967327	Human NCBI Build 35	2	179139866	PRKRA
5686	-	10551	C/G	0	397687	rs2019733	Human NCBI Build 35	3	37506274	ITGA9
5687	-	10552	C/G	0	397688	rs2021847	Human NCBI Build 35	16	24136004	PRKCB1
5688	-	10562	C/G	0	397697	rs212715	Human NCBI Build 35	2	32372537	CARD12
5689	-	10568	C/G	0	397701	rs2182756	Human NCBI Build 35	10	129591465	PTPRE
5690	-	10609	C/G	0	397732	rs2667985	Human NCBI Build 35	8	57042912	LYN
5691	-	10621	C/G	0	397743	rs2801822	Human NCBI Build 35	10	79258540	DLG5
5692	-	10633	C/G	1	397754	rs3136615	Human NCBI Build 35	10	6045516	IL15RA
5693	-	10692	C/G	0	397805	rs428253	Human NCBI Build 35	19	4180913	ENSG00000105246
5694	-	10741	C/G	1	397845	rs5743712	Human NCBI Build 35	X	12644643	TLR7
5695	-	10746	C/G	0	397849	rs5963015	Human NCBI Build 35	X	104038738	IL1RAPL2
5696	-	10765	C/G	1	397867	rs6445229	Human NCBI Build 35	3	61591841	PTPRG
5697	-	10766	C/G	0	397868	rs647934	Human NCBI Build 35	10	6574734	PRKCQ
5698	-	10773	C/G	0	397874	rs6533496	Human NCBI Build 35	4	111415244	EGF-ELOVL6
5699	-	10776	C/G	0	397877	rs6557627	Human NCBI Build 35	8	23112116	TNFRSF10A-ENSG00000147457
5700	-	10790	C/G	0	397890	rs6764212	Human NCBI Build 35	3	106575608	ALCAM
5701	-	10801	C/G	0	397898	rs6933029	Human NCBI Build 35	6	128563920	PTPRK
5702	-	10811	C/G	0	397907	rs7076748	Human NCBI Build 35	10	104140132	NFKB2
5703	-	10815	C/G	1	397910	rs717310	Human NCBI Build 35	19	15027568	CASP14
5704	-	10847	C/G	0	397940	rs7976467	Human NCBI Build 35	12	111350661	PTPN11
5705	-	10930	C/G	0	398009	rs10509984	Human NCBI Build 35	10	115457298	CASP7
5706	-	10936	C/G	0	398014	rs1061966	Human NCBI Build 35	10	71388730	COL13A1-AMID
5707	-	10945	C/G	0	398021	rs10888692	Human NCBI Build 35	1	50703494	FAF1
5709	-	11084	C/G	0	398129	rs2241344	Human NCBI Build 35	3	191765647	IL1RAP
5710	-	11095	C/G	1	398138	rs2279318	Human NCBI Build 35	5	169063452	DOCK2
5711	-	11141	C/G	1	398177	rs353635	Human NCBI Build 35	11	35141399	CD44
5712	-	11164	C/G	0	398198	rs384116	Human NCBI Build 35	19	59488531	ENSG00000170866
5713	-	11165	C/G	0	398199	rs3892360	Human NCBI Build 35	13	40082078	FOXO1A
5714	-	11172	C/G	0	398205	rs4237940	Human NCBI Build 35	12	12603961	DUSP16
5715	-	11178	C/G	1	398210	rs4465173	Human NCBI Build 35	1	211097093	PTPN14-ENSG00000181931

5716	-	11179	C/G	0	398211	rs4522587	Human NCBI Build 35	2	204637129	ICOS
5717	-	11233	C/G	0	398256	rs6502541	Human NCBI Build 35	17	16802955	TNFRSF13B
5718	-	11243	C/G	0	398264	rs6701673	Human NCBI Build 35	1	89237833	GBP1
5719	-	11245	C/G	0	398266	rs6757431	Human NCBI Build 35	2	75239853	TACR1
5720	-	11263	C/G	1	398280	rs7171540	Human NCBI Build 35	15	79340587	IL16
5721	-	11304	C/G	0	398316	rs8086340	Human NCBI Build 35	18	58157958	TNFRSF11A
5722	-	11316	C/G	0	398325	rs881393	Human NCBI Build 35	1	32925738	YARS
5723	-	11330	C/G	0	398338	rs9690115	Human NCBI Build 35	7	43393423	STK17A
5724	-	11370	C/G	0	398368	rs10512766	Human NCBI Build 35	5	41249092	C6
5725	-	11398	C/G	1	398393	rs1184257	Human NCBI Build 35	12	15502093	PTPRO
5726	-	11416	C/G	1	398407	rs12247408	Human NCBI Build 35	10	31651653	TCF8
5727	-	11420	C/G	0	398410	rs12321761	Human NCBI Build 35	12	66892769	IL26
5728	-	11424	C/G	0	398413	rs12695389	Human NCBI Build 35	3	120720843	CD80-C3orf1
5729	-	11428	C/G	0	398417	rs1385502	Human NCBI Build 35	8	120031480	TNFRSF11B
5730	-	11431	C/G	0	398420	rs1477844	Human NCBI Build 35	3	112312521	PVRL3
5731	-	11435	C/G	0	398422	rs1578275	Human NCBI Build 35	1	240006483	AKT3
5732	-	11445	C/G	0	398432	rs1993554	Human NCBI Build 35	6	6232215	F13A1
5733	-	11470	C/G	0	398456	rs2296096	Human NCBI Build 35	9	8439502	PTPRD
5734	-	11473	C/G	0	398459	rs2305010	Human NCBI Build 35	11	119835359	ARHGEF12
5735	-	11503	C/G	0	398483	rs3111515	Human NCBI Build 35	5	179627958	MAPK9
5736	-	11504	C/G	0	398484	rs3138114	Human NCBI Build 35	2	228505842	CCL20-ENSG00000197218
5737	-	11519	C/G	0	398497	rs3779062	Human NCBI Build 35	7	43436663	STK17A
5738	-	11521	C/G	0	398499	rs3781871	Human NCBI Build 35	11	107405917	CUL5
5740	-	11538	C/G	0	398514	rs4434006	Human NCBI Build 35	2	112445042	MERTK
5741	-	11591	C/G	0	398558	rs6898743	Human NCBI Build 35	5	42638249	GHR
5743	-	11609	C/G	0	398574	rs7525160	Human NCBI Build 35	1	204056809	none
5744	-	11612	C/G	0	398577	rs7590838	Human NCBI Build 35	2	68297167	
ENSG00000115953-ENSG00000115946										
5745	-	11617	C/G	0	398581	rs7659613	Human NCBI Build 35	4	155873021	FGA
5746	-	11622	C/G	1	398585	rs7743537	Human NCBI Build 35	6	128760029	PTPRK
5747	-	11633	C/G	0	398596	rs8066564	Human NCBI Build 35	17	11958170	MAP2K4
5748	-	11668	C/G	0	398625	rs1027154	Human NCBI Build 35	15	66191347	PIAS1
5749	-	11671	C/G	0	398628	rs1039422	Human NCBI Build 35	5	38905866	OSMR
5750	-	11674	C/G	0	398629	rs10491068	Human NCBI Build 35	10	97946892	BLNK
5751	-	11686	C/G	1	398639	rs10918072	Human NCBI Build 35	1	161510232	PBX1
5752	-	11688	C/G	1	398641	rs10971466	Human NCBI Build 35	9	33296972	NFX1-ENSG00000086065
5753	-	11718	C/G	0	398662	rs151544	Human NCBI Build 35	20	3432548	ATRN
5754	-	11725	C/G	0	398668	rs1822821	Human NCBI Build 35	5	41240418	C6
5755	-	11749	C/G	0	398689	rs2270573	Human NCBI Build 35	11	43297005	API5
5756	-	11754	C/G	0	398694	rs2291229	Human NCBI Build 35	5	169220956	DOCK2
5757	-	11786	C/G	1	398719	rs3181226	Human NCBI Build 35	5	158673108	IL12B
5758	-	11792	C/G	0	398724	rs3739442	Human NCBI Build 35	9	37022224	PAX5
5759	-	11817	C/G	0	398742	rs4674261	Human NCBI Build 35	2	218830515	IL8RB
5760	-	11833	C/G	0	398755	rs5743611	Human NCBI Build 35	4	38622780	TLR1
5761	-	11864	C/G	0	398777	rs6985838	Human NCBI Build 35	8	141870370	PTK2
5762	-	11908	C/G	0	398810	rs886116	Human NCBI Build 35	16	23885388	PRKCB1
5763	-	11909	C/G	1	398811	rs891401	Human NCBI Build 35	8	27437111	EPHX2
5764	-	11919	C/G	0	398819	rs9324916	Human NCBI Build 35	5	142702853	NR3C1
5765	-	11932	C/G	0	398829	rs986612	Human NCBI Build 35	3	61990202	PTPRG

5766	-	11981	C/G	0	398869	rs1547091	Human NCBI Build 35	6	137358277	IL20RA
5767	-	11990	C/G	1	398876	rs1787	Human NCBI Build 35 17	11935595	MAP2K4	
5768	-	11992	C/G	0	398878	rs1838341	Human NCBI Build 35	12	42447140	ENSG00000198001
5769	-	12000	C/G	0	398885	rs197455	Human NCBI Build 35	6	143130855	HIVEP2
5770	-	12016	C/G	1	398897	rs2276008	Human NCBI Build 35	22	20438590	MAPK1
5771	-	12017	C/G	0	398898	rs2284348	Human NCBI Build 35	12	6192123	CD9
5772	-	12021	C/G	0	398902	rs2296123	Human NCBI Build 35	10	6538805	PRKCQ
5773	-	12034	C/G	0	398911	rs2489154	Human NCBI Build 35	1	232260095	ENSG00000143669
5774	-	12046	C/G	1	398921	rs3176847	Human NCBI Build 35	1	155110768	CD1B
5775	-	12065	C/G	0	398938	rs4367401	Human NCBI Build 35	6	128708096	PTPRK
5776	-	12116	C/G	0	398980	rs7116603	Human NCBI Build 35	11	104342367	CASP4
5777	-	12119	C/G	0	398983	rs7150731	Human NCBI Build 35	14	106141273	IGHA1
5778	-	12156	C/G	0	399014	rs9291322	Human NCBI Build 35	4	48104970	TEC
5779	-	12157	C/G	0	399015	rs9308681	Human NCBI Build 35	2	113497566	IL1F6-IL1F8
5780	-	12166	C/G	0	399024	rs9924767	Human NCBI Build 35	16	66769625	NFATC3
5781	-	12174	C/G	0	399031	rs1041322	Human NCBI Build 35	9	87338913	DAPK1
5782	-	12178	C/G	0	399035	rs10516799	Human NCBI Build 35	4	89260372	SPP1
5783	-	12206	C/G	0	399054	rs1500500	Human NCBI Build 35	4	78818427	CXCL13
5784	-	12217	C/G	0	399064	rs1836225	Human NCBI Build 35	9	8726622	PTPRD
5785	-	12225	C/G	0	399070	rs2296600	Human NCBI Build 35	10	90760419	ENSG00000026103
5786	-	12247	C/G	0	399089	rs3730541	Human NCBI Build 35	12	67499922	MDM2
5787	-	12272	C/G	0	399113	rs7165875	Human NCBI Build 35	15	97254098	IGF1R
5788	-	12277	C/G	0	399116	rs727766	Human NCBI Build 35	7	121151992	PTPRZ1
5789	-	12297	C/G	0	399129	rs877572	Human NCBI Build 35	3	30701436	TGFBR2
5791	-	12351	C/G	0	399172	rs4853117	Human NCBI Build 35	2	75323014	TACR1
5792	-	12363	C/G	0	399182	rs6920032	Human NCBI Build 35	6	47302720	TNFRSF21
5793	-	12376	C/G	0	399191	rs852980	Human NCBI Build 35	5	142681049	NR3C1
5794	-	12383	C/G	0	399197	rs10006715	Human NCBI Build 35	4	111312615	EGF
5795	-	12387	C/G	0	399201	rs10863358	Human NCBI Build 35	1	204079266	none
5796	-	12389	C/G	1	399203	rs11814794	Human NCBI Build 35	10	62219848	CDC2
5797	-	12418	C/G	1	399228	rs6497710	Human NCBI Build 35	16	23920602	PRKCB1
5798	-	12422	C/G	0	399231	rs726510	Human NCBI Build 35	18	59064040	BCL2
5799	-	12443	C/G	1	399248	rs2287293	Human NCBI Build 35	2	162962234	IFIH1
5800	-	12455	C/G	0	399258	rs6555182	Human NCBI Build 35	5	390232	AHRR
5801	-	30	C/T	0	389085	rs1009316	Human NCBI Build 35	19	54150382	BAX
5802	-	149	C/T	1	389088	rs1016666	Human NCBI Build 35	5	134936301	CXCL14
5803	-	178	C/T	0	389089	rs10404456	Human NCBI Build 35	19	52504740	C5R1
5805	-	200	C/T	0	389091	rs1042057	Human NCBI Build 35	15	39657537	TYRO3
5806	-	258	C/T	0	389094	rs10431155	Human NCBI Build 35	11	77799626	GAB2
5807	-	274	C/T	0	389096	rs1047657	Human NCBI Build 35	18	66143664	SOCS6
5810	-	492	C/T	1	389103	rs1057149	Human NCBI Build 35	6	32922920	TAP1-PSMB8
5812	-	510	C/T	0	389105	rs1061662	Human NCBI Build 35	20	42676959	ADA-PKIG
5815	-	656	C/T	0	389113	rs10949695	Human NCBI Build 35	7	157360421	PTPRN2
5816	-	682	C/T	0	389115	rs10975163	Human NCBI Build 35	9	5524424	PDCD1LG2
5817	-	708	C/T	0	389116	rs1102290	Human NCBI Build 35	1	155611987	MNDA
5820	-	981	C/T	1	389122	rs11218941	Human NCBI Build 35	11	122437619	HSPA8
5822	-	1062	C/T	0	389126	rs1132975	Human NCBI Build 35	14	104293082	
ENSG00000184990-ENSG00000179627										
5823	-	1103	C/T	0	389129	rs11466023	Human NCBI Build 35	16	3239587	MEFV

5824	-	1135	C/T	1	389130	rs11466024	Human NCBI Build 35	16	3239469	MEFV	
5825	-	1198	C/T	1	389132	rs11574439	Human NCBI Build 35	Multiple	0		CCRL2-ENSG00000188268
5826	-	1230	C/T	0	389134	rs11575594	Human NCBI Build 35	9	34652048		CCL27-ENSG00000137070
5827	-	1334	C/T	0	389137	rs11673144	Human NCBI Build 35	19	59978462		KIR2DS1-ENSG00000188705
5828	-	1341	C/T	0	389138	rs11706450	Human NCBI Build 35	3	10252866		IRAK2
5829	-	1371	C/T	0	389140	rs11769443	Human NCBI Build 35	7	38130315		TRGV9
5830	-	1407	C/T	0	389141	rs1182137	Human NCBI Build 35	7	2739379	CARD11	
5832	-	1449	C/T	1	389144	rs11882361	Human NCBI Build 35	11	601919		
IRF7-ENSG0000099834-ENSG0000070047											
5833	-	1474	C/T	0	389146	rs1202	Human NCBI Build 35	4	87293587	MAPK10	
5834	-	1559	C/T	0	389151	rs1248657	Human NCBI Build 35	10	79299133		DLG5
5835	-	1639	C/T	1	389156	rs1263566	Human NCBI Build 35	7	156955409		PTPRN2
5836	-	1650	C/T	0	389157	rs12657050	Human NCBI Build 35	5	67615332		PIK3R1
5837	-	1744	C/T	0	389159	rs12721516	Human NCBI Build 35	1	110178772		CSF1
5838	-	1748	C/T	0	389160	rs12722106	Human NCBI Build 35	6	32742260		HLA-DQB1
5839	-	1894	C/T	0	389165	rs1290618	Human NCBI Build 35	19	15613137		CYP4F3
5840	-	1930	C/T	1	389168	rs13209	Human NCBI Build 35	16	3016000		
TNFRSF12A-ENSG00000162069-ENSG00000131652-HCFC1R1											
5842	-	2019	C/T	0	389172	rs13339140	Human NCBI Build 35	17	31664256		
ENSG00000187869-ENSG00000189315-ENSG00000197262											
5843	-	2026	C/T	0	389173	rs13345243	Human NCBI Build 35	19	13969267		RFX1
5844	-	2081	C/T	0	389174	rs13345720	Human NCBI Build 35	19	12778686		RNASEH2A-PRDX2
5845	-	2134	C/T	0	389175	rs13374168	Human NCBI Build 35	1	232164738		ENSG00000143669
5846	-	2146	C/T	0	389176	rs1375688	Human NCBI Build 35	11	47283793		MADD
5847	-	2154	C/T	1	389178	rs1466731	Human NCBI Build 35	1	151387893		ADAR
5849	-	2234	C/T	0	389181	rs1487562	Human NCBI Build 35	10	45248828		ALOX5
5850	-	2246	C/T	0	389182	rs1503185	Human NCBI Build 35	11	48103198		PTPRJ
5851	-	2345	C/T	0	389188	rs1554669	Human NCBI Build 35	1	164147449		CD3Z
5852	-	2370	C/T	1	389189	rs1560117	Human NCBI Build 35	19	18373932		LRRC25
5854	-	2427	C/T	0	389193	rs166507	Human NCBI Build 35	3	37543534		ITGA9
5856	-	2553	C/T	1	389198	rs17054374	Human NCBI Build 35	5	156582533		ITK
5857	-	2634	C/T	0	389200	rs1719493	Human NCBI Build 35	17	70053308		ENSG00000167850
5858	-	2645	C/T	1	389201	rs17719289	Human NCBI Build 35	19	40524663		CD22
5859	-	2655	C/T	0	389202	rs1773554	Human NCBI Build 35	1	164217984		CD3Z-ENSG00000198352
5860	-	2744	C/T	0	389206	rs1805015	Human NCBI Build 35	16	27281681		IL4R
5863	-	2814	C/T	1	389212	rs183835	Human NCBI Build 35	3	37500856		ITGA9
5866	-	2970	C/T	0	389221	rs1947195	Human NCBI Build 35	2	45996976		PRKCE
5867	-	3021	C/T	0	389222	rs196336	Human NCBI Build 35	10	121404226		BAG3
5868	-	3044	C/T	0	389224	rs1979672	Human NCBI Build 35	3	46249113		CCR3
5869	-	3053	C/T	0	389226	rs2003604	Human NCBI Build 35	5	149186133		PPARGC1B
5870	-	3061	C/T	1	389227	rs2015524	Human NCBI Build 35	22	36218920		CARD10
5873	-	3103	C/T	0	389230	rs2043494	Human NCBI Build 35	7	157266282		PTPRN2-ENSG00000196590
5874	-	3109	C/T	1	389231	rs2043496	Human NCBI Build 35	7	157268531		PTPRN2-ENSG00000196590
5875	-	3126	C/T	0	389232	rs2044693	Human NCBI Build 35	2	68296748		
ENSG00000115953-ENSG00000115946											
5876	-	3142	C/T	0	389233	rs2045571	Human NCBI Build 35	1	158374936		FCGR2B
5877	-	3175	C/T	1	389234	rs2050523	Human NCBI Build 35	1	157284917		SLAMF6
5879	-	3282	C/T	0	389241	rs2072446	Human NCBI Build 35	17	44942818		NGFR
5880	-	3289	C/T	1	389243	rs2073438	Human NCBI Build 35	17	6840800	ALOX12	

5882	-	3420	C/T	0	389247	rs2075106	Human	NCBI	Build	35	7	55027634	EGFR
5883	-	3477	C/T	0	389249	rs2075769	Human	NCBI	Build	35	Multiple	0	
KIR2DS2-KIR2DS1-ENSG00000189013-KIR2DL4													
5884	-	3590	C/T	0	389253	rs2089910	Human	NCBI	Build	35	11	1830980	LSP1
5885	-	3607	C/T	1	389255	rs2144494	Human	NCBI	Build	35	9	21177146	
ENSG00000137026-IFNA17-IFNA4													
5886	-	3672	C/T	0	389258	rs220475	Human	NCBI	Build	35	17	3607499	ITGAE
5887	-	3699	C/T	0	389261	rs2227434	Human	NCBI	Build	35	4	155844748	FGB-FGA
5889	-	3792	C/T	0	389263	rs2228014	Human	NCBI	Build	35	2	136706816	ENSG00000121966
5890	-	3801	C/T	1	389264	rs2228065	Human	NCBI	Build	35	10	45240512	ALOX5
5893	-	3845	C/T	1	389267	rs2229357	Human	NCBI	Build	35	12	56129978	INHBC
5894	-	3874	C/T	0	389269	rs2229653	Human	NCBI	Build	35	16	29582615	SPN-ENSG00000198106
5895	-	4005	C/T	0	389272	rs2233299	Human	NCBI	Build	35	5	150405660	TNIP1
5896	-	4008	C/T	0	389273	rs2233455	Human	NCBI	Build	35	17	28664	
ENSG00000187869-ENSG00000189315-ENSG00000197262													
5897	-	4034	C/T	0	389274	rs2235334	Human	NCBI	Build	35	22	36228751	CARD10
5900	-	4125	C/T	0	389282	rs2241500	Human	NCBI	Build	35	4	185704201	IRF2
5901	-	4149	C/T	0	389284	rs2242107	Human	NCBI	Build	35	12	50723758	NR4A1
5902	-	4155	C/T	0	389285	rs2242653	Human	NCBI	Build	35	19	131493	KIR2DS2-KIR2DS1-KIR2DL2
5903	-	4228	C/T	0	389286	rs2243072	Human	NCBI	Build	35	5	76150825	F2RL1-ENSG00000183613
5905	-	4320	C/T	0	389290	rs2275422	Human	NCBI	Build	35	7	150211956	
C7orf21-ENSG00000164896-SLC4A2													
5906	-	4357	C/T	1	389291	rs227653	Human	NCBI	Build	35	20	24878085	CST7
5908	-	4450	C/T	1	389294	rs2277998	Human	NCBI	Build	35	19	7737628	ENSG00000104938
5909	-	4645	C/T	0	389299	rs2280328	Human	NCBI	Build	35	11	45887943	PEX16-MAPK8IP1
5910	-	4678	C/T	0	389300	rs2280378	Human	NCBI	Build	35	16	84510246	ENSG00000140968
5911	-	4688	C/T	0	389301	rs2281820	Human	NCBI	Build	35	6	33876875	MLN
5913	-	4734	C/T	1	389304	rs2284035	Human	NCBI	Build	35	22	35869102	IL2RB
5916	-	5024	C/T	0	389316	rs2291667	Human	NCBI	Build	35	19	6620986	TNFSF14
5917	-	5038	C/T	0	389317	rs2292151	Human	NCBI	Build	35	19	4767719	ENSG00000127666
5918	-	5068	C/T	1	389320	rs2295418	Human	NCBI	Build	35	1	222432120	ENSG00000143768
5919	-	5190	C/T	1	389324	rs2302365	Human	NCBI	Build	35	12	6754505	LAG3-PTMS
5920	-	5198	C/T	0	389325	rs2302465	Human	NCBI	Build	35	4	15385461	ENSG00000109743
5921	-	5205	C/T	1	389326	rs2302612	Human	NCBI	Build	35	2	102310226	IL1RL2
5922	-	5296	C/T	0	389333	rs2304973	Human	NCBI	Build	35	17	4588971	CXCL16-ZMYND15
5924	-	5582	C/T	0	389344	rs2373929	Human	NCBI	Build	35	7	150152460	NOS3-NOS3AS
5925	-	5591	C/T	1	389346	rs246747	Human	NCBI	Build	35	5	156577517	ITK
5927	-	5706	C/T	0	389352	rs2532502	Human	NCBI	Build	35	12	6427453	VAMP1-TAPBPL-TNFRSF7
5928	-	5721	C/T	0	389354	rs2581731	Human	NCBI	Build	35	18	75353222	NFATC1-ENSG00000186783
5929	-	5797	C/T	0	389358	rs2684790	Human	NCBI	Build	35	15	97309063	IGF1R
5930	-	5839	C/T	0	389359	rs2701124	Human	NCBI	Build	35	12	50734424	NR4A1
5931	-	5890	C/T	0	389361	rs2779248	Human	NCBI	Build	35	17	23151959	NOS2A
5932	-	5912	C/T	0	389363	rs2785172	Human	NCBI	Build	35	11	35119978	CD44
5933	-	5924	C/T	0	389364	rs2838727	Human	NCBI	Build	35	21	45140335	ITGB2
5934	-	6165	C/T	1	389380	rs3176829	Human	NCBI	Build	35	17	77868542	SECTM1-CD7
5935	-	6174	C/T	0	389382	rs3181049	Human	NCBI	Build	35	19	10302117	ICAM3-ENSG00000161847
5936	-	6197	C/T	0	389384	rs3184504	Human	NCBI	Build	35	12	110347328	
ENSG00000111252-ENSG00000196824													
5937	-	6320	C/T	0	389393	rs353274	Human	NCBI	Build	35	5	148743536	IL17B

5938	-	6400	C/T	0	389397	rs3732380	Human NCBI Build 35	3	39282566	CX3CR1
5942	-	6462	C/T	0	389404	rs3744166	Human NCBI Build 35	17	74482474	LGALS3BP
5943	-	6483	C/T	0	389405	rs3744508	Human NCBI Build 35	17	29637007	CCL11
5945	-	6602	C/T	1	389412	rs3751601	Human NCBI Build 35	15	50191508	BCL2L10
5949	-	6707	C/T	1	389429	rs3792860	Human NCBI Build 35	5	38927654	OSMR
5950	-	6715	C/T	0	389430	rs3795300	Human NCBI Build 35	1	24192520	IL22RA1
5952	-	6731	C/T	1	389434	rs3803477	Human NCBI Build 35	15	97073811	IGF1R
5955	-	6872	C/T	0	389445	rs3815261	Human NCBI Build 35	7	75087238	CCL24
5956	-	6883	C/T	1	389446	rs3815362	Human NCBI Build 35	11	63790131	PLCB3-BAD
5957	-	6887	C/T	1	389447	rs3817578	Human NCBI Build 35	2	201962101	CASP8
5958	-	6898	C/T	0	389450	rs3826705	Human NCBI Build 35	19	47329072	POU2F2
5959	-	6902	C/T	0	389451	rs383369	Human NCBI Build 35	19	59475942	ENSG00000131042
5961	-	6957	C/T	1	389455	rs3918020	Human NCBI Build 35	1	36604501	CSF3R
5963	-	7010	C/T	1	389461	rs4113763	Human NCBI Build 35	Multiple	0	Unknown
5964	-	7020	C/T	0	389462	rs4144246	Human NCBI Build 35	7	157113307	PTPRN2
5965	-	7038	C/T	1	389464	rs4151033	Human NCBI Build 35	11	36554068	RAG1
5967	-	7103	C/T	0	389471	rs4327927	Human NCBI Build 35	9	113418696	RGS3
5970	-	7129	C/T	0	389474	rs4395980	Human NCBI Build 35	9	34538009	CNTFR
5971	-	7141	C/T	0	389476	rs4486393	Human NCBI Build 35	1	24208869	IL22RA1
5973	-	7197	C/T	1	389485	rs4764622	Human NCBI Build 35	12	6749463	LAG3-PTMS
5974	-	7203	C/T	0	389486	rs4764884	Human NCBI Build 35	12	101322066	IGF1
5975	-	7212	C/T	1	389488	rs4786494	Human NCBI Build 35	16	4446233	DNAJA3
5977	-	7235	C/T	1	389491	rs4792147	Human NCBI Build 35	17	7892544	ALOX15B
5978	-	7241	C/T	0	389494	rs4804127	Human NCBI Build 35	19	10207723	EDG5
5979	-	7246	C/T	1	389495	rs4804806	Human NCBI Build 35	19	7722625	ENSG00000090659
5980	-	7285	C/T	0	389500	rs4851522	Human NCBI Build 35	2	102069346	IL1R2
5982	-	7428	C/T	0	389512	rs4958436	Human NCBI Build 35	5	150423022	TNIP1
5983	-	7431	C/T	0	389513	rs4964475	Human NCBI Build 35	12	105528826	RFX4
5984	-	7434	C/T	1	389514	rs4966042	Human NCBI Build 35	15	97281626	IGF1R
5985	-	7451	C/T	0	389519	rs522073	Human NCBI Build 35	11	60635238	CD5
5986	-	7474	C/T	0	389520	rs537	Human NCBI Build 35	15	64573353	MAP2K1-SNAPC5
5988	-	7499	C/T	1	389527	rs5743673	Human NCBI Build 35	6	30817425	FLOT1-DDR1-IER3
5989	-	7505	C/T	0	389529	rs5744065	Human NCBI Build 35	X	12694276	TLR8
5990	-	7508	C/T	0	389530	rs5744068	Human NCBI Build 35	X	12694715	TLR8
5991	-	7514	C/T	0	389531	rs5744478	Human NCBI Build 35	5	66525321	LY64
5992	-	7523	C/T	0	389533	rs5746220	Human NCBI Build 35	3	12616718	RAF1
5993	-	7524	C/T	1	389534	rs587759	Human NCBI Build 35	5	131420379	IL3
5994	-	7526	C/T	0	389535	rs5918	Human NCBI Build 35	17	42715729	ITGB3
5995	-	7549	C/T	1	389539	rs6081106	Human NCBI Build 35	20	1834624	PTPNS1
5997	-	7589	C/T	1	389547	rs633429	Human NCBI Build 35	3	61703801	PTPRG-ENSG00000168370
5998	-	7590	C/T	0	389548	rs6413500	Human NCBI Build 35	16	27281334	IL4R
5999	-	7605	C/T	1	389551	rs6459831	Human NCBI Build 35	7	157339623	PTPRN2
6000	-	7635	C/T	0	389557	rs6557609	Human NCBI Build 35	8	22937797	TNFRSF10B-RHOBTB2
6001	-	7637	C/T	0	389558	rs660442	Human NCBI Build 35	11	63799573	BAD
6002	-	7646	C/T	1	389560	rs6712557	Human NCBI Build 35	2	46221476	PRKCE
6003	-	7652	C/T	0	389561	rs6732336	Human NCBI Build 35	2	109000371	EDAR
6004	-	7657	C/T	0	389562	rs6732673	Human NCBI Build 35	2	239935458	HDAC4
6005	-	7674	C/T	0	389566	rs6873253	Human NCBI Build 35	5	169343200	DOCK2
6006	-	7675	C/T	0	389567	rs6873777	Human NCBI Build 35	5	156421481	HAVCR1

6009	-	7749	C/T	0	389582	rs7168753	Human NCBI Build 35	15	62070678	ENSG00000035664
6010	-	7752	C/T	1	389583	rs7197779	Human NCBI Build 35	16	10910428	MHC2TA
6014	-	7783	C/T	1	389589	rs727852	Human NCBI Build 35	10	97980573	BLNK
6015	-	7785	C/T	0	389590	rs7287930	Human NCBI Build 35	22	41130622	ENSG00000167087
6016	-	7795	C/T	0	389593	rs741737	Human NCBI Build 35	11	278505	NALP6-ENSG00000142102
6019	-	7830	C/T	0	389597	rs7525979	Human NCBI Build 35	1	243913449	CIAS1
6020	-	7903	C/T	0	389605	rs7608582	Human NCBI Build 35	2	240056128	HDAC4
6024	-	8015	C/T	0	389624	rs8068433	Human NCBI Build 35	17	75780051	CARD14
6025	-	8065	C/T	1	389629	rs8108207	Human NCBI Build 35	19	18570768	CRLF1
6026	-	8084	C/T	0	389630	rs8110570	Human NCBI Build 35	19	5220458	PTPRS
6027	-	8087	C/T	1	389631	rs8113562	Human NCBI Build 35	19	3965065	PIAS4
6028	-	8106	C/T	0	389633	rs8179181	Human NCBI Build 35	19	46530046	TGFB1
6029	-	8109	C/T	0	389634	rs870034	Human NCBI Build 35	12	93142563	PLXNC1
6030	-	8123	C/T	0	389635	rs872848	Human NCBI Build 35	5	455321	AHRR
6032	-	8148	C/T	0	389640	rs885821	Human NCBI Build 35	10	72028661	PRF1
6033	-	8157	C/T	0	389643	rs892488	Human NCBI Build 35	1	43716835	PTPRF
6035	-	8187	C/T	1	389648	rs909564	Human NCBI Build 35	22	37451008	UNC84B-GTPBP1
6036	-	8188	C/T	0	389649	rs9247	Human NCBI Build 35	2	233895301	INPP5D
6039	-	8258	C/T	0	389662	rs9608859	Human NCBI Build 35	22	28991831	OSM
6040	-	8280	C/T	0	389666	rs9671376	Human NCBI Build 35	14	102439916	TRAF3
6041	-	8289	C/T	1	389668	rs968457	Human NCBI Build 35	19	41086674	
ENSG00000167604-TYROBP-HCST										
6042	-	8306	C/T	0	389672	rs982870	Human NCBI Build 35	21	41653135	FAM3B-MX2
6043	-	8316	C/T	0	389674	rs9899183	Human NCBI Build 35	17	7393701	TNFSF12
6044	-	8324	C/T	0	389677	rs10000856	Human NCBI Build 35	4	185721352	IRF2
6045	-	8326	C/T	0	389678	rs1000137	Human NCBI Build 35	7	157143628	PTPRN2
6046	-	8328	C/T	0	389679	rs1000294	Human NCBI Build 35	8	23136080	TNFRSF10A-ENSG00000147457
6047	-	8410	C/T	0	389688	rs1034917	Human NCBI Build 35	19	5225384	PTPRS
6050	-	8457	C/T	0	389696	rs1046276	Human NCBI Build 35	16	30822127	CTF1
6051	-	8462	C/T	1	389698	rs10507275	Human NCBI Build 35	12	115757224	HRK-ENSG00000135119
6054	-	8524	C/T	1	389710	rs10781522	Human NCBI Build 35	9	137090890	C9orf86-TRAF2
6056	-	8541	C/T	0	389714	rs109836	Human NCBI Build 35	6	143132956	HIVEP2
6057	-	8587	C/T	0	389721	rs11221322	Human NCBI Build 35	11	127852003	ETS1
6058	-	8592	C/T	0	389723	rs1127732	Human NCBI Build 35	3	33880570	PDCD6IP
6060	-	8609	C/T	0	389728	rs11465412	Human NCBI Build 35	19	7712070	ENSG00000188197-ENSG00000090659
6061	-	8611	C/T	0	389729	rs1150253	Human NCBI Build 35	1	203459990	IL24-PIGR
6062	-	8617	C/T	0	389730	rs1152918	Human NCBI Build 35	12	64922569	IRAK3
6063	-	8641	C/T	0	389737	rs11717574	Human NCBI Build 35	3	52243286	PTK9L
6064	-	8655	C/T	0	389738	rs11844715	Human NCBI Build 35	14	21989421	ENSG00000166056
6065	-	8668	C/T	0	389740	rs1190584	Human NCBI Build 35	14	101679346	WDR20-HSPCA
6067	-	8677	C/T	1	389744	rs12090237	Human NCBI Build 35	1	151202814	IL6R
6068	-	8681	C/T	1	389745	rs12093834	Human NCBI Build 35	1	117280542	IGSF2
6070	-	8693	C/T	0	389747	rs12144158	Human NCBI Build 35	1	156740980	SLAMF9
6073	-	8720	C/T	0	389755	rs1283155	Human NCBI Build 35	12	50726016	NR4A1
6075	-	8770	C/T	0	389768	rs1491961	Human NCBI Build 35	3	46225352	CCR3-CCR1
6076	-	8775	C/T	0	389769	rs1516629	Human NCBI Build 35	2	112375010	MERTK
6077	-	8776	C/T	0	389770	rs1516640	Human NCBI Build 35	2	112391089	MERTK
6078	-	8787	C/T	0	389773	rs1548731	Human NCBI Build 35	X	12687604	TLR8
6080	-	8817	C/T	0	389782	rs1670340	Human NCBI Build 35	7	157770498	PTPRN2

6081	-	8841	C/T	1	389788	rs1724120	Human NCBI Build 35	2	96231205	DUSP2
6082	-	8847	C/T	0	389790	rs17776004	Human NCBI Build 35	19	40512515	CD22
6083	-	8874	C/T	1	389793	rs1800204	Human NCBI Build 35	22	44934689	PPARA
6085	-	8905	C/T	0	389801	rs1861457	Human NCBI Build 35	2	75234922	TACR1
6086	-	8939	C/T	1	389804	rs1882248	Human NCBI Build 35	7	157819899	PTPRN2
6087	-	8953	C/T	0	389806	rs1893490	Human NCBI Build 35	18	46449799	MAPK4
6088	-	8989	C/T	0	389814	rs2056131	Human NCBI Build 35	17	42688742	ITGB3
6089	-	9000	C/T	0	389815	rs2066815	Human NCBI Build 35	12	55029311	STAT2
6090	-	9038	C/T	1	389818	rs2070600	Human NCBI Build 35	19	18101127	PIK3R2-IL12RB1-MAST3
6091	-	9043	C/T	0	389820	rs2071863	Human NCBI Build 35	6	36215150	MAPK13
6092	-	9058	C/T	0	389823	rs2075598	Human NCBI Build 35	14	54674106	LGALS3
6094	-	9064	C/T	0	389827	rs2097465	Human NCBI Build 35	22	34876416	APOL3
6096	-	9096	C/T	1	389836	rs216123	Human NCBI Build 35	5	149440746	CSF1R
6097	-	9102	C/T	0	389837	rs216128	Human NCBI Build 35	5	149409402	CSF1R-ENSG00000113716
6098	-	9112	C/T	0	389840	rs2227478	Human NCBI Build 35	12	66934889	IL22
6099	-	9116	C/T	0	389841	rs2227564	Human NCBI Build 35	10	75343107	C10orf55-PLAU
6100	-	9125	C/T	1	389843	rs2227723	Human NCBI Build 35	1	6457696	TNFRSF25-ENSG00000162401-ESPN
6101	-	9130	C/T	1	389845	rs2229113	Human NCBI Build 35	11	117374880	IL10RA
6104	-	9171	C/T	0	389853	rs224218	Human NCBI Build 35	16	3241898	MEFV
6105	-	9210	C/T	1	389860	rs2256817	Human NCBI Build 35	21	44539814	PFKL-AIRE
6106	-	9218	C/T	1	389862	rs2271694	Human NCBI Build 35	10	71544790	H2AFY2-AMID
6108	-	9229	C/T	0	389866	rs2274616	Human NCBI Build 35	1	143025126	ITGA10
6109	-	9233	C/T	1	389867	rs2274756	Human NCBI Build 35	20	44076518	MMP9
6110	-	9238	C/T	0	389869	rs2281388	Human NCBI Build 35	6	33168096	HLA-DPB1-ENSG00000172899
6111	-	9261	C/T	0	389873	rs2288288	Human NCBI Build 35	18	59705946	SERPINB2
6112	-	9268	C/T	1	389874	rs228945	Human NCBI Build 35	22	35850380	IL2RB
6113	-	9275	C/T	1	389877	rs2290890	Human NCBI Build 35	9	90716570	SYK
6115	-	9278	C/T	1	389879	rs2293054	Human NCBI Build 35	12	116164434	NOS1
6116	-	9305	C/T	1	389883	rs2304194	Human NCBI Build 35	19	3920505	DAPK3
6117	-	9309	C/T	0	389884	rs2304594	Human NCBI Build 35	3	32465898	ENSG00000153551
6119	-	9342	C/T	1	389889	rs2335534	Human NCBI Build 35	19	54706789	FCGRT
6120	-	9365	C/T	0	389892	rs243849	Human NCBI Build 35	16	54081206	MMP2
6121	-	9384	C/T	0	389893	rs2494523	Human NCBI Build 35	1	156611379	ENSG00000158714
6122	-	9399	C/T	0	389895	rs254987	Human NCBI Build 35	5	55229086	IL31RA
6123	-	9403	C/T	1	389896	rs2664538	Human NCBI Build 35	20	44073632	MMP9
6124	-	9437	C/T	0	389902	rs2782640	Human NCBI Build 35	1	43678126	PTPRF
6126	-	9507	C/T	0	389917	rs3025010	Human NCBI Build 35	6	43855555	VEGF
6127	-	9518	C/T	1	389920	rs3087554	Human NCBI Build 35	8	27511359	CLU
6128	-	9536	C/T	1	389922	rs3093002	Human NCBI Build 35	6	167524471	CCR6-ENSG00000187485
6129	-	9550	C/T	0	389925	rs3130062	Human NCBI Build 35	6	31633891	ENSG00000168593
6130	-	9574	C/T	1	389928	rs3176839	Human NCBI Build 35	17	77861274	CD7
6131	-	9585	C/T	0	389929	rs3179249	Human NCBI Build 35	6	30020259	HLA-A-HLA-G
6132	-	9602	C/T	1	389933	rs3218170	Human NCBI Build 35	1	23592835	E2F2
6134	-	9625	C/T	0	389939	rs352162	Human NCBI Build 35	3	52228009	ALAS1-PTK9L
6136	-	9679	C/T	0	389948	rs3741089	Human NCBI Build 35	11	56913014	PRG2
6137	-	9680	C/T	1	389949	rs3741240	Human NCBI Build 35	11	61943118	SCGB1A1
6139	-	9775	C/T	0	389957	rs3757598	Human NCBI Build 35	7	75090028	CCL24
6140	-	9792	C/T	0	389960	rs3760071	Human NCBI Build 35	16	55949490	CCL22
6141	-	9797	C/T	0	389962	rs3761820	Human NCBI Build 35	9	113346258	RGS3

6143	-	9813	C/T	0	389967	rs3780377	Human NCBI Build 35	9	5100899	JAK2-ENSG00000185192
6144	-	9854	C/T	0	389970	rs3783384	Human NCBI Build 35	14	102421583	TRAF3
6145	-	9882	C/T	1	389974	rs3786540	Human NCBI Build 35	19	47305035	POU2F2
6147	-	9925	C/T	0	389979	rs3791446	Human NCBI Build 35	2	239781604	HDAC4
6148	-	9934	C/T	0	389981	rs3792789	Human NCBI Build 35	5	150426161	TNIP1
6149	-	9940	C/T	0	389982	rs3793345	Human NCBI Build 35	7	45730918	IGFBP3
6152	-	10031	C/T	1	389994	rs3812564	Human NCBI Build 35	9	136547027	SNAPC4-CARD9
6153	-	10059	C/T	1	389997	rs3815716	Human NCBI Build 35	19	14383768	DDX39-CD97
6154	-	10071	C/T	0	390001	rs3819545	Human NCBI Build 35	12	46551273	VDR
6155	-	10081	C/T	1	390003	rs382410	Human NCBI Build 35	19	18029674	IL12RB1
6156	-	10093	C/T	0	390004	rs3824433	Human NCBI Build 35	9	5103577	JAK2-ENSG00000185192
6157	-	10101	C/T	0	390006	rs3829223	Human NCBI Build 35	11	1256982	TOLLIP
6159	-	10137	C/T	1	390013	rs3917718	Human NCBI Build 35	1	166314536	SELP
6160	-	10141	C/T	0	390014	rs3918211	Human NCBI Build 35	7	150148555	NOS3-NOS3AS
6161	-	10156	C/T	0	390015	rs396127	Human NCBI Build 35	18	75351626	NFATC1-ENSG00000186783
6163	-	10178	C/T	0	390019	rs4096393	Human NCBI Build 35	10	71387426	COL13A1-AMID
6164	-	10199	C/T	1	390020	rs4147359	Human NCBI Build 35	10	6148445	IL2RA
6165	-	10203	C/T	0	390021	rs4148876	Human NCBI Build 35	6	32904771	TAP2
6166	-	10235	C/T	0	390023	rs4149577	Human NCBI Build 35	12	6317783	TNFRSF1A
6167	-	10244	C/T	1	390024	rs4149584	Human NCBI Build 35	12	6312904	TNFRSF1A-ENSG0000008323
6168	-	10247	C/T	0	390025	rs4149637	Human NCBI Build 35	12	6313262	TNFRSF1A
6169	-	10251	C/T	0	390026	rs4150832	Human NCBI Build 35	13	113343955	TFDP1-ENSG00000179951
6171	-	10282	C/T	0	390032	rs4309	Human NCBI Build 35	17	58913655	ACE
6172	-	10287	C/T	1	390033	rs4318	Human NCBI Build 35	17	58916105	ACE
6173	-	10296	C/T	0	390034	rs4357599	Human NCBI Build 35	10	6606981	PRKCQ
6174	-	10313	C/T	0	390037	rs4460370	Human NCBI Build 35	8	22943553	TNFRSF10B
6177	-	10340	C/T	0	390042	rs4537545	Human NCBI Build 35	1	151231952	IL6R
6178	-	10357	C/T	0	390044	rs4544037	Human NCBI Build 35	11	117727272	CD3G
6179	-	10362	C/T	0	390045	rs4663873	Human NCBI Build 35	2	239007204	none
6180	-	10367	C/T	0	390046	rs4683233	Human NCBI Build 35	3	46476272	LTF
6181	-	10375	C/T	0	390049	rs4705381	Human NCBI Build 35	5	149160176	PPARGC1B
6182	-	10392	C/T	0	390050	rs4716762	Human NCBI Build 35	7	156903415	PTPRN2
6183	-	10395	C/T	0	390051	rs4716810	Human NCBI Build 35	7	157207352	
PTPRN2-ENSG00000196590-ENSG00000196201										
6184	-	10421	C/T	1	390053	rs4761	Human NCBI Build 35	14	23711366	REC8L1-ISGF3G
6185	-	10422	C/T	0	390054	rs4770467	Human NCBI Build 35	13	23081145	TNFRSF19
6186	-	10457	C/T	1	390060	rs48625	Human NCBI Build 35	5	145966063	PPP2R2B
6187	-	10473	C/T	1	390064	rs4909082	Human NCBI Build 35	7	157701558	PTPRN2
6188	-	10481	C/T	0	390065	rs4926322	Human NCBI Build 35	12	121215925	
ENSG00000176383-ENSG00000158113-DIABLO-ENSG00000197247										
6189	-	10513	C/T	0	390068	rs4987202	Human NCBI Build 35	19	12920626	CALR-RAD23A
6190	-	10524	C/T	0	390070	rs5030737	Human NCBI Build 35	10	54201248	MBL2
6191	-	10566	C/T	0	390075	rs558705	Human NCBI Build 35	19	7738183	ENSG00000104938
6192	-	10569	C/T	1	390076	rs5741809	Human NCBI Build 35	20	36389440	BPI
6193	-	10574	C/T	0	390078	rs5743867	Human NCBI Build 35	11	1284927	TOLLIP
6194	-	10583	C/T	0	390082	rs574610	Human NCBI Build 35	1	157610757	LY9-CD244
6195	-	10604	C/T	0	390085	rs5763918	Human NCBI Build 35	22	28985738	OSM
6196	-	10612	C/T	0	390086	rs5919	Human NCBI Build 35	17	42719539	ITGB3
6197	-	10639	C/T	0	390088	rs5996088	Human NCBI Build 35	22	40648413	TNFRSF13C

6198	-	10642	C/T	0	390090	rs6072794	Human NCBI Build 35	20	40623391	PTPRT
6199	-	10657	C/T	0	390093	rs614230	Human NCBI Build 35	16	55976787	CX3CL1
6200	-	10664	C/T	0	390095	rs628325	Human NCBI Build 35	11	76814368	PAK1
6201	-	10695	C/T	0	390097	rs633	Human NCBI Build 35 X	152795075	IRAK1	
6202	-	10706	C/T	0	390098	rs635269	Human NCBI Build 35	18	8398431	PTPRM
6203	-	10708	C/T	0	390099	rs637489	Human NCBI Build 35	1	232935570	EDARADD
6204	-	10726	C/T	0	390100	rs6436131	Human NCBI Build 35	2	219977363	PTPRN-DNAJB2
6205	-	10759	C/T	0	390106	rs6500550	Human NCBI Build 35	16	3686242	TRAP1
6207	-	10798	C/T	0	390110	rs6512255	Human NCBI Build 35	19	18254682	JUND
6208	-	10799	C/T	0	390111	rs6517154	Human NCBI Build 35	21	33530550	IFNAR2
6210	-	10864	C/T	0	390120	rs6796546	Human NCBI Build 35	3	37837722	ITGA9
6211	-	10882	C/T	0	390122	rs6829466	Human NCBI Build 35	4	87928361	PTPN13
6212	-	10949	C/T	1	390133	rs702398	Human NCBI Build 35	6	30047656	HCG9-HLA-G-ENSG00000197640
6214	-	10981	C/T	0	390142	rs7224934	Human NCBI Build 35	17	74488629	LGALS3BP
6215	-	10984	C/T	1	390143	rs7235803	Human NCBI Build 35	18	58151359	TNFRSF11A
6216	-	10993	C/T	0	390145	rs724710	Human NCBI Build 35	2	111623922	BCL2L11
6217	-	10998	C/T	0	390147	rs7254645	Human NCBI Build 35	19	59467201	ENSG00000131042
6218	-	11018	C/T	0	390151	rs7298918	Human NCBI Build 35	12	93113480	PLXNC1
6219	-	11042	C/T	0	390154	rs7325214	Human NCBI Build 35	13	113284925	TFDP1-ENSG00000179951
6220	-	11051	C/T	0	390158	rs738304	Human NCBI Build 35	22	36226677	CARD10
6221	-	11053	C/T	1	390159	rs738806	Human NCBI Build 35	22	22558726	MIF
6222	-	11106	C/T	0	390167	rs749948	Human NCBI Build 35	3	32363005	CKLFSF8
6223	-	11159	C/T	1	390174	rs760427	Human NCBI Build 35	21	44540419	PFKL-AIRE
6224	-	11169	C/T	0	390175	rs7611844	Human NCBI Build 35	3	37517329	ITGA9
6225	-	11185	C/T	0	390177	rs7627359	Human NCBI Build 35	3	62136655	PTPRG
6226	-	11196	C/T	0	390178	rs763096	Human NCBI Build 35	6	36208647	MAPK13
6227	-	11199	C/T	1	390179	rs7631600	Human NCBI Build 35	3	37812222	ITGA9
6228	-	11215	C/T	0	390181	rs7690305	Human NCBI Build 35	4	15642235	PROM1-ENSG00000137441
6229	-	11222	C/T	0	390183	rs7756525	Human NCBI Build 35	6	41783718	TFEB
6230	-	11237	C/T	0	390186	rs7901803	Human NCBI Build 35	10	6047423	IL15RA
6231	-	11261	C/T	0	390191	rs8078865	Human NCBI Build 35	17	7896039	ALOX15B
6232	-	11297	C/T	0	390196	rs8177399	Human NCBI Build 35	11	125666036	TIRAP
6233	-	11312	C/T	1	390199	rs8192917	Human NCBI Build 35	14	24172000	GZMB
6235	-	11354	C/T	0	390205	rs875727	Human NCBI Build 35	1	71085759	PTGER3
6236	-	11361	C/T	0	390209	rs880365	Human NCBI Build 35	16	84516863	ENSG00000140968
6239	-	11403	C/T	0	390216	rs916019	Human NCBI Build 35	19	17816093	INSL3
6240	-	11417	C/T	0	390218	rs919495	Human NCBI Build 35	8	27306738	PTK2B
6242	-	11465	C/T	0	390222	rs928150	Human NCBI Build 35	9	34675940	CCL19
6243	-	11483	C/T	1	390224	rs931273	Human NCBI Build 35	13	42076583	TNFSF11
6244	-	11522	C/T	0	390231	rs957644	Human NCBI Build 35	1	162347815	MGST3
6245	-	11552	C/T	0	390237	rs9669553	Human NCBI Build 35	12	115778069	HRK
6246	-	11554	C/T	0	390238	rs969802	Human NCBI Build 35	12	105481506	RFX4
6247	-	11568	C/T	0	390239	rs9898394	Human NCBI Build 35	17	39789391	GRN-ENSG00000161682
6248	-	11581	C/T	1	390241	rs9945652	Human NCBI Build 35	18	46458881	MAPK4
6249	-	11658	C/T	1	390249	rs1007888	Human NCBI Build 35	22	22565655	MIF
6250	-	11661	C/T	0	390250	rs10079250	Human NCBI Build 35	5	149430325	CSF1R
6251	-	11676	C/T	0	390254	rs1017875	Human NCBI Build 35	11	47955794	PTPRJ
6252	-	11678	C/T	0	390255	rs10234067	Human NCBI Build 35	7	157614018	PTPRN2
6253	-	11711	C/T	1	390262	rs1042178	Human NCBI Build 35	6	33145500	HLA-DPA1

6254	-	11715	C/T	0	390263	rs1042311	Human NCBI Build 35	22	44948299	PPARA
6255	-	11724	C/T	0	390265	rs1044531	Human NCBI Build 35	9	114178204	ORM1-AKNA
6256	-	11731	C/T	0	390266	rs10448290	Human NCBI Build 35	9	129589920	PTGES-ENSG00000198665
6257	-	11736	C/T	0	390267	rs1047266	Human NCBI Build 35	8	22956646	TNFRSF10B
6258	-	11739	C/T	1	390268	rs10494975	Human NCBI Build 35	1	210992026	PTPN14
6259	-	11767	C/T	1	390272	rs10503078	Human NCBI Build 35	18	58951168	BCL2
6260	-	11777	C/T	0	390275	rs10510873	Human NCBI Build 35	3	62181279	PTPRG
6263	-	11812	C/T	0	390282	rs10734565	Human NCBI Build 35	11	48128369	PTPRJ
6264	-	11820	C/T	0	390284	rs10753646	Human NCBI Build 35	1	161476547	PBX1
6265	-	11826	C/T	1	390286	rs10774580	Human NCBI Build 35	12	119939143	OASL
6266	-	11842	C/T	0	390288	rs10802189	Human NCBI Build 35	1	116768772	CD58
6267	-	11846	C/T	0	390289	rs10836343	Human NCBI Build 35	11	35201463	CD44
6268	-	11851	C/T	0	390291	rs10859589	Human NCBI Build 35	12	92704990	CRADD
6270	-	11857	C/T	0	390293	rs10897270	Human NCBI Build 35	11	61939583	SCGB1A1
6271	-	11872	C/T	0	390298	rs11123718	Human NCBI Build 35	2	109015554	EDAR
6272	-	11907	C/T	0	390306	rs1130371	Human NCBI Build 35	17	31440650	CCL4-CCL3
6273	-	11924	C/T	1	390309	rs1132610	Human NCBI Build 35	19	59414062	ENSG00000186152
6275	-	11955	C/T	0	390313	rs11539433	Human NCBI Build 35	12	51872522	ITGB7-ENSG00000139651
6277	-	12007	C/T	0	390326	rs11669206	Human NCBI Build 35	19	56969769	FPRL1
6278	-	12037	C/T	0	390332	rs11750344	Human NCBI Build 35	5	142009931	FGF1
6279	-	12079	C/T	0	390337	rs11838267	Human NCBI Build 35	12	7046133	C15
6280	-	12081	C/T	0	390338	rs11862958	Human NCBI Build 35	16	11962692	TNFRSF17-ENSG00000122309
6281	-	12087	C/T	0	390340	rs12003046	Human NCBI Build 35	9	130771180	ABL1
6282	-	12104	C/T	0	390342	rs12085877	Human NCBI Build 35	1	11021953	MASP2-TARDBP
6283	-	12106	C/T	1	390343	rs12094291	Human NCBI Build 35	1	39895139	PPIE-ENSG00000116985
6284	-	12110	C/T	0	390344	rs12248686	Human NCBI Build 35	10	129598039	PTPRE
6287	-	12183	C/T	0	390354	rs1253629	Human NCBI Build 35	1	232941560	EDARADD
6290	-	12204	C/T	0	390360	rs12613243	Human NCBI Build 35	2	111613737	BCL2L11
6291	-	12228	C/T	1	390364	rs1263542	Human NCBI Build 35	7	156920584	PTPRN2
6292	-	12235	C/T	0	390365	rs1263560	Human NCBI Build 35	7	156914992	PTPRN2
6293	-	12246	C/T	1	390366	rs12638646	Human NCBI Build 35	3	106604904	ALCAM
6294	-	12261	C/T	0	390367	rs12674036	Human NCBI Build 35	7	54857571	EGFR
6295	-	12274	C/T	1	390368	rs12675846	Human NCBI Build 35	8	57010099	LYN
6297	-	12281	C/T	0	390372	rs1293747	Human NCBI Build 35	12	111907565	OAS2
6298	-	12286	C/T	0	390374	rs13083280	Human NCBI Build 35	3	58615588	FAM3D
6299	-	12296	C/T	1	390376	rs1317140	Human NCBI Build 35	3	49853656	ENSG00000183763
6300	-	12304	C/T	0	390377	rs1317681	Human NCBI Build 35	1	214963597	ENSG00000092969
6301	-	12315	C/T	0	390379	rs13202921	Human NCBI Build 35	6	41795344	TFEB
6302	-	12331	C/T	0	390382	rs13296822	Human NCBI Build 35	9	21403703	IFNA8
6303	-	12339	C/T	0	390385	rs1359781	Human NCBI Build 35	6	33870082	MLN
6304	-	12352	C/T	1	390388	rs140174	Human NCBI Build 35	22	22247537	IGLL1
6305	-	12369	C/T	0	390390	rs1433097	Human NCBI Build 35	19	60110270	NCR1
6306	-	12423	C/T	0	390400	rs1552227	Human NCBI Build 35	12	116241755	NOS1
6307	-	12438	C/T	0	390403	rs1567102	Human NCBI Build 35	1	20189779	PLA2G2D
6308	-	12450	C/T	0	390404	rs1594	Human NCBI Build 35	2	201851127	CFLAR
6309	-	12456	C/T	0	390406	rs1621289	Human NCBI Build 35	6	112090872	FYN
6310	-	12465	C/T	0	390408	rs1636167	Human NCBI Build 35	7	2745313	CARD11
6311	-	12472	C/T	1	390410	rs16822692	Human NCBI Build 35	Multiple	0	HLA-DRB4-HLA-DRB5
6312	-	12481	C/T	0	390412	rs16829204	Human NCBI Build 35	1	24199994	IL22RA1

6313	-	12498	C/T	0	390414	rs169098	Human NCBI Build 35	6	143116393	HIVEP2
6314	-	12517	C/T	0	390417	rs170208	Human NCBI Build 35	17	3576447	GSG2-ITGAE
6315	-	888	C/T	0	390424	rs174827	Human NCBI Build 35	16	24122750	PRKCB1
6316	-	5222	C/T	0	390427	rs17583782	Human NCBI Build 35	6	33014694	HLA-DMB
6317	-	1385	C/T	0	390429	rs17765882	Human NCBI Build 35	Multiple	0	CCR5-CCR5
6318	-	1010	C/T	0	390431	rs1799811	Human NCBI Build 35	11	67110155	GSTP1
6320	-	3612	C/T	0	390436	rs1803630	Human NCBI Build 35	1	89232426	GBP1
6321	-	2683	C/T	1	390438	rs1807782	Human NCBI Build 35	2	102491665	IL18RAP
6322	-	2974	C/T	1	390439	rs181388	Human NCBI Build 35	22	16595721	BID
6324	-	4541	C/T	0	390443	rs187116	Human NCBI Build 35	11	35122376	CD44
6325	-	5231	C/T	0	390444	rs1879417	Human NCBI Build 35	12	116266235	NOS1
6326	-	2629	C/T	0	390449	rs1982632	Human NCBI Build 35	19	14000004	RLN3-IL27RA
6327	-	5428	C/T	0	390450	rs1983163	Human NCBI Build 35	3	62092506	PTPRG
6328	-	433	C/T	0	390452	rs1997502	Human NCBI Build 35	2	102302767	IL1RL2
6330	-	3756	C/T	1	390455	rs2055905	Human NCBI Build 35	8	57091259	LYN
6331	-	5450	C/T	0	390456	rs2061846	Human NCBI Build 35	4	842314	GAK
6332	-	4802	C/T	1	390460	rs2069683	Human NCBI Build 35	5	75949540	F2RL2-IQGAP2
6333	-	542	C/T	0	390461	rs2069916	Human NCBI Build 35	2	127894645	PROC
6334	-	5953	C/T	1	390462	rs2070946	Human NCBI Build 35	21	45165625	ITGB2
6335	-	3642	C/T	1	390464	rs2071222	Human NCBI Build 35	X	100423517	BTB
6337	-	4659	C/T	1	390470	rs2077171	Human NCBI Build 35	12	116219222	NOS1
6338	-	479	C/T	1	390474	rs2144493	Human NCBI Build 35	14	23844457	CIDEB-LTB4R2
6339	-	2950	C/T	0	390475	rs221310	Human NCBI Build 35	20	34706192	SLA2
6340	-	3211	C/T	1	390476	rs2227491	Human NCBI Build 35	12	66932788	IL22
6341	-	1395	C/T	1	390481	rs2230748	Human NCBI Build 35	19	14373489	CD97
6342	-	6173	C/T	0	390482	rs2231375	Human NCBI Build 35	1	143185738	CD160
6343	-	2652	C/T	0	390483	rs2232580	Human NCBI Build 35	20	36408359	LBP
6344	-	3526	C/T	0	390484	rs2233083	Human NCBI Build 35	17	19227056	MFAP4-MAPK7
6345	-	5964	C/T	0	390485	rs2234697	Human NCBI Build 35	1	222323310	EPHX1
6346	-	4980	C/T	0	390486	rs2234962	Human NCBI Build 35	10	121419623	BAG3
6347	-	3935	C/T	0	390487	rs2235330	Human NCBI Build 35	22	35864213	IL2RB
6349	-	5223	C/T	0	390491	rs2237863	Human NCBI Build 35	11	2369373	ENSG00000110651
6350	-	5781	C/T	0	390492	rs2237997	Human NCBI Build 35	11	60528666	CD6
6351	-	3745	C/T	0	390494	rs223828	Human NCBI Build 35	16	56004915	CCL17
6352	-	1423	C/T	1	390501	rs2241385	Human NCBI Build 35	19	59541378	ENSG00000170858
6353	-	3187	C/T	1	390503	rs2241647	Human NCBI Build 35	15	31947278	AVEN-ENSG00000198838
6354	-	527	C/T	0	390505	rs2244445	Human NCBI Build 35	5	169034177	DOCK2
6355	-	5645	C/T	1	390506	rs2244507	Human NCBI Build 35	2	128117321	GPR17-LIMS2
6356	-	5076	C/T	0	390509	rs2259693	Human NCBI Build 35	12	119920715	OASL-ENSG00000157895
6357	-	5967	C/T	0	390511	rs2268139	Human NCBI Build 35	12	15549363	PTPRO
6358	-	703	C/T	0	390514	rs2269911	Human NCBI Build 35	14	23678082	PSME1-PSME2-C14orf122
6359	-	5879	C/T	1	390515	rs2272990	Human NCBI Build 35	6	3022140	RIPK1
6360	-	3232	C/T	0	390517	rs2274064	Human NCBI Build 35	1	180274044	NCF2
6361	-	2212	C/T	0	390519	rs227656	Human NCBI Build 35	20	24879722	CST7
6362	-	1882	C/T	0	390522	rs2279374	Human NCBI Build 35	11	77615335	GAB2
6363	-	2872	C/T	1	390524	rs2280573	Human NCBI Build 35	12	120955318	BCL7A-ENSG00000197247
6364	-	4067	C/T	1	390525	rs2280714	Human NCBI Build 35	7	128188676	IRF5-TNPO3
6365	-	211	C/T	0	390527	rs2282851	Human NCBI Build 35	6	33388287	TAPBP-ZNF297
6366	-	846	C/T	0	390528	rs2283540	Human NCBI Build 35	16	24038271	PRKCB1

6367	-	3096	C/T	0	390531	rs2287848	Human NCBI Build 35	19	6647342	C3	
6368	-	4446	C/T	0	390533	rs228838	Human NCBI Build 35	20	49502108	NFATC2	
6370	-	894	C/T	1	390536	rs2288502	Human NCBI Build 35	5	156582630	ITK	
6372	-	6368	C/T	0	390538	rs2288518	Human NCBI Build 35	19	60401833	BRSK1-PTPRH	
6373	-	723	C/T	0	390542	rs2290882	Human NCBI Build 35	4	87607915	MAPK10	
6375	-	1447	C/T	0	390545	rs2293048	Human NCBI Build 35	12	116127545	NOS1	
6376	-	3813	C/T	1	390546	rs2293055	Human NCBI Build 35	12	116164604	NOS1	
6377	-	1782	C/T	1	390548	rs2295298	Human NCBI Build 35	14	23913460	NFATC4	
6378	-	5129	C/T	1	390554	rs2302008	Human NCBI Build 35	7	75043844	CCL26	
6379	-	4372	C/T	1	390555	rs2303942	Human NCBI Build 35	1	6458767	TNFRSF25-ENSG00000162401-ESPN	
6380	-	6019	C/T	0	390559	rs2335160	Human NCBI Build 35	7	157849769	PTPRN2	
6382	-	5179	C/T	0	390562	rs235422	Human NCBI Build 35	X	48298151	WAS	
6383	-	5227	C/T	1	390563	rs237554	Human NCBI Build 35	19	6637659	C3	
6384	-	5616	C/T	0	390564	rs238722	Human NCBI Build 35	20	3419971	ATRN	
6385	-	1206	C/T	0	390565	rs2394654	Human NCBI Build 35	10	71540120	H2AFY2-AMID	
6387	-	3911	C/T	0	390570	rs2532500	Human NCBI Build 35	11	111542224	BCD02-IL18-TEX12	
6388	-	1369	C/T	0	390574	rs261606	Human NCBI Build 35	5	169154677	DOCK2	
6389	-	5817	C/T	1	390575	rs264875	Human NCBI Build 35	5	169007204	DOCK2	
6390	-	5777	C/T	0	390579	rs2715259	Human NCBI Build 35	3	123310414	CD86	
6391	-	3482	C/T	0	390580	rs273266	Human NCBI Build 35	19	18144501	PIK3R2-IFI30	
6393	-	2524	C/T	0	390582	rs2741108	Human NCBI Build 35	8	6711986	ENSG00000164825	
6394	-	5991	C/T	1	390587	rs2789426	Human NCBI Build 35	1	156741132	SLAMF9	
6395	-	3814	C/T	0	390588	rs2800784	Human NCBI Build 35	1	161315491	PBX1	
6396	-	5588	C/T	0	390592	rs2834160	Human NCBI Build 35	21	33541983	IFNAR2	
6398	-	5104	C/T	1	390595	rs2842185	Human NCBI Build 35	1	43688824	PTPRF	
6399	-	6078	C/T	1	390602	rs291338	Human NCBI Build 35	2	239886216	HDAC4	
6400	-	3946	C/T	0	390604	rs3016173	Human NCBI Build 35	11	60547415	CD6	
6401	-	936	C/T	0	390608	rs3024974	Human NCBI Build 35	12	55779012	NAB2-STAT6	
6402	-	5304	C/T	0	390609	rs307803	Human NCBI Build 35	5	179952001	SCGB3A1	
6404	-	4626	C/T	0	390615	rs3112982	Human NCBI Build 35	2	95137741	MAL	
6405	-	804	C/T	0	390616	rs3136620	Human NCBI Build 35	10	6041448	IL15RA	
6406	-	4227	C/T	1	390617	rs3136655	Human NCBI Build 35	2	201975095		
ALS2CR12-CASP8-ENSG00000196709											
6407	-	3831	C/T	0	390621	rs317913	Human NCBI Build 35	19	11371314	EPOR	
6408	-	4070	C/T	0	390623	rs3181029	Human NCBI Build 35	1	155033038	CD1A	
6409	-	4457	C/T	0	390625	rs3181163	Human NCBI Build 35	19	15027162	CASP14	
6410	-	1954	C/T	0	390628	rs3213545	Human NCBI Build 35	12	119934057	OASL	
6411	-	4966	C/T	0	390633	rs324011	Human NCBI Build 35	12	55788449	STAT6	
6412	-	3082	C/T	0	390639	rs366542	Human NCBI Build 35	22	16632936	BID-ENSG00000185830	
6413	-	3451	C/T	1	390645	rs3748800	Human NCBI Build 35	1	43727236	PTPRF	
6415	-	732	C/T	1	390647	rs3751093	Human NCBI Build 35	17	22982431	LGALS9	
6416	-	768	C/T	0	390650	rs3754806	Human NCBI Build 35	2	105945900	NCK2	
6418	-	4002	C/T	1	390654	rs3764384	Human NCBI Build 35	17	73719323	BIRC5	
6419	-	5874	C/T	0	390669	rs3791500	Human NCBI Build 35	2	239811799	HDAC4	
6420	-	5161	C/T	0	390670	rs3793656	Human NCBI Build 35	9	87488091	DAPK1	
6421	-	3512	C/T	0	390671	rs3793726	Human NCBI Build 35	10	6545937	PRKCQ	
6422	-	3553	C/T	0	390677	rs38025	Human NCBI Build 35	16	3703735	TRAP1	
6423	-	4128	C/T	0	390684	rs3808814	Human NCBI Build 35	9	130787339	ABL1	
6424	-	244	C/T	0	390687	rs3812562	Human NCBI Build 35	9	136546812	SNAPC4-CARD9	

6425	-	469	C/T	0	390688	rs3817624	Human NCBI Build 35	19	41090739	TYROBP-HCST
6426	-	4989	C/T	1	390690	rs3818822	Human NCBI Build 35	1	111569250	ENSG00000134216
6427	-	2862	C/T	0	390692	rs3821982	Human NCBI Build 35	4	77452969	SCARB2
6428	-	459	C/T	0	390696	rs3826261	Human NCBI Build 35	16	23784676	PRKCB1
6429	-	3789	C/T	0	390697	rs3827730	Human NCBI Build 35	1	50649869	FAF1
6430	-	755	C/T	0	390701	rs3858340	Human NCBI Build 35	10	121426276	BAG3
6433	-	1647	C/T	1	390710	rs4075783	Human NCBI Build 35	5	42623665	GHR
6434	-	3538	C/T	1	390714	rs4151118	Human NCBI Build 35	16	56008835	CCL17
6435	-	6146	C/T	0	390719	rs4253772	Human NCBI Build 35	22	44948122	PPARA
6438	-	4386	C/T	0	390722	rs4303637	Human NCBI Build 35	18	58182743	TNFRSF11A
6439	-	1546	C/T	1	390724	rs4322490	Human NCBI Build 35	12	8180493	ENSG00000173245-ENSG00000111729
6440	-	4798	C/T	0	390725	rs4348467	Human NCBI Build 35	8	57013973	LYN
6441	-	5551	C/T	1	390727	rs441810	Human NCBI Build 35	21	41620777	FAM3B
6442	-	1216	C/T	0	390729	rs4419597	Human NCBI Build 35	5	42701861	GHR
6443	-	3690	C/T	1	390730	rs4445746	Human NCBI Build 35	13	30239435	ALOX5AP
6444	-	5815	C/T	0	390731	rs4452124	Human NCBI Build 35	2	204625203	ICOS
6445	-	5863	C/T	0	390733	rs4461142	Human NCBI Build 35	17	58931780	ACE
6446	-	3605	C/T	1	390736	rs4488761	Human NCBI Build 35	22	16584167	BCL2L13
6447	-	5086	C/T	0	390742	rs4647587	Human NCBI Build 35	11	64868551	DPF2-ENSG00000197847
6449	-	5313	C/T	0	390745	rs4705086	Human NCBI Build 35	5	149101960	PPARGC1B
6450	-	4836	C/T	1	390750	rs4774147	Human NCBI Build 35	14	106064161	IGHA1-ENSG00000198577
6451	-	3209	C/T	0	390751	rs4787664	Human NCBI Build 35	16	23958740	PRKCB1
6452	-	3779	C/T	1	390753	rs4804773	Human NCBI Build 35	19	7669248	FCER2
6453	-	1048	C/T	0	390755	rs4865908	Human NCBI Build 35	5	54351785	GZMK
6454	-	6033	C/T	0	390759	rs4945884	Human NCBI Build 35	6	112002553	C6orf4
6456	-	6304	C/T	0	390764	rs4985783	Human NCBI Build 35	17	16798512	TNFRSF13B-ENSG00000170160
6457	-	3086	C/T	0	390768	rs525731	Human NCBI Build 35	3	37546831	ITGA9
6458	-	6242	C/T	1	390773	rs5497	Human NCBI Build 35	19	10256468	ICAM1-ICAM4
6459	-	4337	C/T	0	390774	rs554277	Human NCBI Build 35	11	56919210	PRG2
6460	-	6126	C/T	0	390775	rs5694	Human NCBI Build 35	1	71152046	PTGER3
6461	-	5298	C/T	0	390780	rs5751435	Human NCBI Build 35	22	41837654	BIK-ENSG00000183614
6462	-	4108	C/T	1	390781	rs5755720	Human NCBI Build 35	22	34111427	HMOX1
6463	-	2831	C/T	0	390783	rs584507	Human NCBI Build 35	10	6571756	PRKCQ
6464	-	2986	C/T	1	390784	rs5917	Human NCBI Build 35	17	42716952	ITGB3
6466	-	5295	C/T	0	390786	rs6002542	Human NCBI Build 35	22	40643060	TNFRSF13C
6467	-	6048	C/T	1	390787	rs6025169	Human NCBI Build 35	20	36423881	LBP
6468	-	1245	C/T	1	390789	rs605470	Human NCBI Build 35	18	8400522	PTPRM
6469	-	4247	C/T	0	390791	rs6087	Human NCBI Build 35	1	43472956	MPL
6470	-	4921	C/T	0	390802	rs634346	Human NCBI Build 35	20	3535204	ATRN
6471	-	2942	C/T	0	390808	rs6509940	Human NCBI Build 35	19	60575691	IL11-ENSG00000160472
6472	-	225	C/T	0	390809	rs6510827	Human NCBI Build 35	19	4781628	ENSG00000127666
6473	-	5969	C/T	0	390810	rs6532114	Human NCBI Build 35	4	77315153	CXCL11-ENSG00000169253
6474	-	2807	C/T	0	390812	rs6546875	Human NCBI Build 35	2	73975328	STAMPB
6475	-	6156	C/T	0	390821	rs6761387	Human NCBI Build 35	2	218822059	IL8RB
6476	-	3994	C/T	0	390823	rs6802485	Human NCBI Build 35	3	173721072	TNFSF10
6478	-	6004	C/T	1	390827	rs6859	Human NCBI Build 35	19	50073874	ENSG00000130202
6479	-	3500	C/T	0	390828	rs686606	Human NCBI Build 35	2	239837349	HDAC4
6480	-	720	C/T	0	390829	rs6899226	Human NCBI Build 35	5	446377	AHRR
6481	-	742	C/T	1	390837	rs7140558	Human NCBI Build 35	14	103088404	BAG5

6483	-	2924	C/T	1	390840	rs7200798	Human NCBI Build 35	16	23761361	PRKCB1
6484	-	4819	C/T	0	390847	rs7250623	Human NCBI Build 35	19	18568973	CRLF1-ENSG00000006015
6485	-	5541	C/T	0	390850	rs7259347	Human NCBI Build 35	19	60084567	FCAR
6486	-	2979	C/T	0	390853	rs728116	Human NCBI Build 35	19	16472978	CALR3-ENSG00000105072
6487	-	4593	C/T	1	390854	rs7283236	Human NCBI Build 35	21	45177740	ITGB2-C21orf67
6488	-	2279	C/T	0	390855	rs7289754	Human NCBI Build 35	22	20920813	VPREB1
6489	-	3580	C/T	1	390857	rs7298369	Human NCBI Build 35	12	15507526	PTPRO
6490	-	5302	C/T	1	390861	rs739439	Human NCBI Build 35	17	23747949	SARM1-ENSG00000076351
6491	-	6112	C/T	0	390863	rs7404928	Human NCBI Build 35	16	23796341	PRKCB1
6492	-	5043	C/T	1	390864	rs746414	Human NCBI Build 35	20	40143469	PTPRT
6493	-	1906	C/T	1	390866	rs748025	Human NCBI Build 35	3	58590090	FAM3D-ENSG00000168309
6494	-	947	C/T	0	390868	rs751141	Human NCBI Build 35	8	27429782	EPHX2
6495	-	353	C/T	0	390869	rs7533482	Human NCBI Build 35	1	211061666	PTPN14
6496	-	4452	C/T	0	390870	rs7550231	Human NCBI Build 35	1	2519079	TNFRSF14
6497	-	5787	C/T	0	390871	rs7550930	Human NCBI Build 35	1	29415179	PTPRU
6498	-	419	C/T	0	390876	rs7673587	Human NCBI Build 35	4	155838039	FGB-FGA
6500	-	104	C/T	0	390881	rs7705243	Human NCBI Build 35	5	35155303	PRLR
6501	-	4709	C/T	0	390882	rs7710717	Human NCBI Build 35	5	43349699	HMGCS1-CCL28
6502	-	4362	C/T	0	390883	rs7730004	Human NCBI Build 35	5	43226790	CCL28-ENSG00000177453
6503	-	5017	C/T	0	390884	rs7739011	Human NCBI Build 35	6	3057529	RIPK1
6504	-	4359	C/T	0	390885	rs7801395	Human NCBI Build 35	7	157789903	PTPRN2
6506	-	6092	C/T	0	390890	rs7839010	Human NCBI Build 35	8	57035138	LYN
6507	-	5689	C/T	0	390891	rs7864799	Human NCBI Build 35	9	130681633	ABL1
6508	-	5173	C/T	0	390892	rs7869402	Human NCBI Build 35	9	117557586	TLR4
6509	-	886	C/T	0	390894	rs797775	Human NCBI Build 35	12	6181421	CD9
6510	-	3003	C/T	0	390897	rs8048821	Human NCBI Build 35	16	23886863	PRKCB1
6511	-	5314	C/T	0	390901	rs8096108	Human NCBI Build 35	18	46476874	MAPK4
6513	-	2063	C/T	0	390910	rs8119002	Human NCBI Build 35	20	40505704	PTPRT
6514	-	966	C/T	0	390911	rs8139063	Human NCBI Build 35	22	41138251	ENSG00000167087
6515	-	4906	C/T	1	390913	rs8176919	Human NCBI Build 35	16	3646698	DNASE1-TRAP1
6516	-	5338	C/T	1	390918	rs8190315	Human NCBI Build 35	22	16601318	BID
6517	-	3412	C/T	1	390921	rs842	Human NCBI Build 35	11	33687982	CD59
6518	-	5786	C/T	0	390922	rs84458	Human NCBI Build 35	22	35849708	IL2RB
6519	-	2446	C/T	0	390927	rs867923	Human NCBI Build 35	7	157030650	PTPRN2-ENSG00000197192
6520	-	2240	C/T	0	390930	rs875643	Human NCBI Build 35	22	22558552	MIF
6521	-	3777	C/T	0	390933	rs885838	Human NCBI Build 35	3	185579280	CHRD-THPO
6522	-	876	C/T	0	390935	rs899202	Human NCBI Build 35	19	43971421	LGALS7
6523	-	5230	C/T	0	390942	rs9308908	Human NCBI Build 35	2	239732433	HDAC4
6524	-	2599	C/T	0	390943	rs9331940	Human NCBI Build 35	8	27512047	CLU
6525	-	4075	C/T	0	390945	rs942198	Human NCBI Build 35	10	6103022	IL2RA
6526	-	2386	C/T	1	390947	rs94872	Human NCBI Build 35	1	203475240	PIGR-ENSG00000162894
6527	-	6127	C/T	0	390950	rs960173	Human NCBI Build 35	19	8024000	ELAVL1-CCL25
6528	-	5213	C/T	1	390951	rs960274	Human NCBI Build 35	9	35393745	
ENSG00000196186-ENSG00000179766-UNC13B										
6529	-	5032	C/T	0	390953	rs9648003	Human NCBI Build 35	7	2789042	CARD11
6530	-	4114	C/T	1	390955	rs9814648	Human NCBI Build 35	3	3130229	IL5RA
6531	-	982	C/T	0	390956	rs9846152	Human NCBI Build 35	3	106715506	ALCAM
6532	-	1375	C/T	0	390957	rs9892152	Human NCBI Build 35	17	59755697	PECAM1
6533	-	4587	C/T	0	390958	rs9921806	Human NCBI Build 35	16	30040261	MAPK3

6534	-	3350	C/T	0	390959	rs1001099	Human NCBI Build 35	7	157302148	PTPRN2
6535	-	1121	C/T	1	390960	rs10025405	Human NCBI Build 35	4	187381955	TLR3
6536	-	3012	C/T	0	390961	rs10033900	Human NCBI Build 35	4	111016671	none
6537	-	5725	C/T	0	390963	rs10045011	Human NCBI Build 35	5	39211126	FYB
6538	-	4997	C/T	0	390965	rs1007394	Human NCBI Build 35	9	87522179	DAPK1
6539	-	3917	C/T	0	390967	rs1010425	Human NCBI Build 35	19	56612425	SIGLEC10
6540	-	5297	C/T	0	390970	rs10180086	Human NCBI Build 35	2	112502122	MERTK
6541	-	766	C/T	0	390971	rs1021479	Human NCBI Build 35	16	84514915	ENSG00000140968
6543	-	1015	C/T	0	390973	rs1027241	Human NCBI Build 35	3	46287543	CCR3
6544	-	4859	C/T	0	390974	rs10283368	Human NCBI Build 35	8	141748999	PTK2
6545	-	5555	C/T	0	390979	rs1043261	Human NCBI Build 35	3	53874316	IL17RB-ACTR8
6546	-	6125	C/T	1	390981	rs10450761	Human NCBI Build 35	12	105545899	RFX4
6547	-	2866	C/T	0	390983	rs10481676	Human NCBI Build 35	9	113352235	RGS3
6548	-	6303	C/T	0	390985	rs10485685	Human NCBI Build 35	20	40201234	PTPRT
6549	-	6051	C/T	0	390986	rs1048691	Human NCBI Build 35	12	56439215	CYP27B1-MARCH9
6550	-	647	C/T	0	390991	rs10490341	Human NCBI Build 35	2	45835995	PRKCE
6552	-	2964	C/T	1	390994	rs10495928	Human NCBI Build 35	2	46264817	PRKCE
6553	-	6186	C/T	0	390995	rs10510750	Human NCBI Build 35	3	46249890	CCR3
6554	-	5907	C/T	0	390997	rs1051741	Human NCBI Build 35	1	222338964	EPHX1-ENSG00000196187
6555	-	830	C/T	1	390998	rs1051788	Human NCBI Build 35	6	31581979	MICB
6556	-	4733	C/T	0	391006	rs1060712	Human NCBI Build 35	12	92716580	CRADD
6557	-	5896	C/T	0	391009	rs1063478	Human NCBI Build 35	6	33025522	HLA-DMA
6559	-	4634	C/T	0	391013	rs10797888	Human NCBI Build 35	1	180278689	NCF2
6560	-	3627	C/T	0	391014	rs10859600	Human NCBI Build 35	12	92742628	CRADD
6561	-	491	C/T	0	391015	rs10860861	Human NCBI Build 35	12	101288036	IGF1
6562	-	4326	C/T	0	391016	rs10897141	Human NCBI Build 35	11	60653915	CD5-ENSG00000167987
6563	-	5651	C/T	1	391019	rs10947964	Human NCBI Build 35	6	41419799	ENSG00000096264
6565	-	4422	C/T	0	391021	rs11064419	Human NCBI Build 35	12	6795555	CD4
6566	-	5131	C/T	0	391027	rs11244139	Human NCBI Build 35	9	130690353	ABL1
6568	-	1426	C/T	0	391030	rs1131445	Human NCBI Build 35	15	79388837	IL16-STARD5
6569	-	4492	C/T	0	391032	rs1136410	Human NCBI Build 35	1	222862037	PARP1
6570	-	5397	C/T	0	391034	rs11480	Human NCBI Build 35	X	1545298	SLC25A6-IL3RA
6571	-	4472	C/T	0	391036	rs11567806	Human NCBI Build 35	12	8103642	FOXJ2-C3AR1
6572	-	3843	C/T	0	391039	rs11569046	Human NCBI Build 35	4	111266537	EGF
6575	-	342	C/T	1	391044	rs11655622	Human NCBI Build 35	17	38258273	AOC3-AOC2
6576	-	4940	C/T	1	391046	rs11666735	Human NCBI Build 35	19	60088725	FCAR
6577	-	5995	C/T	1	391048	rs11746	Human NCBI Build 35	1	158414794	ENSG00000132185
6578	-	1350	C/T	0	391049	rs11775256	Human NCBI Build 35	8	23107430	TNFRSF10A-ENSG00000147457
6579	-	3078	C/T	0	391058	rs12042283	Human NCBI Build 35	1	203363174	IL19-PIGR
6580	-	3610	C/T	0	391059	rs1205817	Human NCBI Build 35	19	47295616	POU2F2
6581	-	4927	C/T	1	391064	rs12164028	Human NCBI Build 35	6	136971628	MAP3K5
6582	-	614	C/T	1	391066	rs1228034	Human NCBI Build 35	11	47987216	PTPRJ
6583	-	3068	C/T	0	391067	rs12280601	Human NCBI Build 35	11	48151061	PTPRJ
6584	-	173	C/T	0	391068	rs1234224	Human NCBI Build 35	10	89665276	ENSG00000171862
6586	-	4947	C/T	0	391074	rs12479626	Human NCBI Build 35	20	49525600	NFATC2
6587	-	705	C/T	0	391079	rs1264456	Human NCBI Build 35	6	30570063	HLA-E
6588	-	1827	C/T	0	391081	rs12674047	Human NCBI Build 35	7	157794184	PTPRN2
6589	-	5191	C/T	1	391082	rs12735793	Human NCBI Build 35	1	29457592	PTPRU
6590	-	5608	C/T	1	391084	rs12867405	Human NCBI Build 35	13	113331064	TFDP1-ENSG00000179951

6591	-	2901	C/T	1	391085	rs12917279	Human NCBI Build 35	15	64526140	MAP2K1
6592	-	4765	C/T	0	391089	rs131429	Human NCBI Build 35	22	22250333	IGLL1
6593	-	5444	C/T	1	391092	rs1320473	Human NCBI Build 35	9	36957063	PAX5
6594	-	1035	C/T	0	391093	rs1325793	Human NCBI Build 35	13	42084421	TNFSF11
6595	-	3947	C/T	0	391095	rs13306020	Human NCBI Build 35	1	71190130	PTGER3
6596	-	893	C/T	0	391096	rs13306091	Human NCBI Build 35	17	58920067	ACE
6597	-	1178	C/T	0	391097	rs13306581	Human NCBI Build 35	1	180268015	NCF2
6598	-	3763	C/T	0	391098	rs1333630	Human NCBI Build 35	9	90660737	SYK
6599	-	5112	C/T	0	391099	rs1333633	Human NCBI Build 35	9	90647127	SYK
6600	-	3711	C/T	0	391100	rs13373917	Human NCBI Build 35	1	232164800	ENSG00000143669
6601	-	3	C/T	0	391101	rs1342852	Human NCBI Build 35	4	185681266	IRF2
6602	-	2182	C/T	1	391104	rs1353939	Human NCBI Build 35	12	116138073	NOS1
6603	-	5146	C/T	0	391105	rs1374280	Human NCBI Build 35	2	113512897	IL1F8
6604	-	5729	C/T	0	391107	rs1381547	Human NCBI Build 35	18	59108319	BCL2
6605	-	3393	C/T	0	391109	rs1388613	Human NCBI Build 35	3	62219610	PTPRG
6606	-	2120	C/T	0	391113	rs1403197	Human NCBI Build 35	3	61663681	PTPRG
6607	-	1054	C/T	0	391116	rs143383	Human NCBI Build 35	20	33489397	C20orf44-GDF5
6608	-	3106	C/T	0	391120	rs1494555	Human NCBI Build 35	5	35906947	IL7R
6609	-	1372	C/T	0	391121	rs1500325	Human NCBI Build 35	9	8369838	PTPRD
6610	-	540	C/T	0	391122	rs1500327	Human NCBI Build 35	9	8380467	PTPRD
6611	-	407	C/T	0	391123	rs1513102	Human NCBI Build 35	12	69400329	PTPRR
6612	-	3997	C/T	1	391124	rs1519552	Human NCBI Build 35	4	142933628	IL15
6613	-	5986	C/T	0	391127	rs1535045	Human NCBI Build 35	20	44181506	ENSG00000101017
6614	-	3897	C/T	0	391128	rs1546519	Human NCBI Build 35	8	56987112	LYN
6615	-	3016	C/T	0	391131	rs1553458	Human NCBI Build 35	1	157358006	CD84
6616	-	1006	C/T	0	391132	rs1558622	Human NCBI Build 35	2	102388665	IL1RL1
6617	-	452	C/T	1	391133	rs157580	Human NCBI Build 35	19	50087106	TOMM40-ENSG00000130202
6619	-	3928	C/T	1	391138	rs170209	Human NCBI Build 35	17	3582394	ITGAE
6620	-	267	C/T	0	391146	rs1739640	Human NCBI Build 35	20	36435348	LBP
6623	-	3722	C/T	0	391151	rs1800561	Human NCBI Build 35	4	15502827	CD38
6624	-	1123	C/T	1	391155	rs183374	Human NCBI Build 35	18	75376955	
ENSG00000186783-NFATC1-ENSG00000198275										
6625	-	4622	C/T	0	391156	rs1855025	Human NCBI Build 35	6	167508005	CCR6-ENSG00000187485
6626	-	2647	C/T	0	391157	rs1858584	Human NCBI Build 35	6	41802750	TFEB
6627	-	3051	C/T	0	391158	rs1859206	Human NCBI Build 35	11	60495408	CD6
6628	-	579	C/T	0	391165	rs1887402	Human NCBI Build 35	1	43705178	PTPRF
6629	-	3725	C/T	1	391169	rs1903860	Human NCBI Build 35	10	89610190	ENSG00000171862
6630	-	466	C/T	0	391170	rs1915992	Human NCBI Build 35	3	61675009	PTPRG
6631	-	1329	C/T	1	391171	rs1916886	Human NCBI Build 35	7	121124507	PTPRZ1
6632	-	4039	C/T	1	391174	rs1979469	Human NCBI Build 35	4	111418502	EGF-ELOVL6
6633	-	610	C/T	1	391175	rs1980131	Human NCBI Build 35	11	36554310	RAG1
6634	-	1680	C/T	0	391177	rs198178	Human NCBI Build 35	16	24128125	PRKCB1
6635	-	3694	C/T	0	391179	rs1992116	Human NCBI Build 35	16	54085392	MMP2
6637	-	3329	C/T	0	391185	rs2028827	Human NCBI Build 35	19	3975020	PIAS4
6638	-	1553	C/T	0	391186	rs2041992	Human NCBI Build 35	19	51216311	PGLYRP1-ENSG00000104983
6639	-	2930	C/T	0	391190	rs206684	Human NCBI Build 35	20	40988095	PTPRT
6640	-	791	C/T	0	391192	rs2066852	Human NCBI Build 35	16	49385019	ENSG00000083799
6641	-	6271	C/T	0	391196	rs2071369	Human NCBI Build 35	17	35425831	THRAP4-CSF3
6642	-	3301	C/T	1	391199	rs2072685	Human NCBI Build 35	17	7890159	ALOX15B

6643	-	5605	C/T	0	391200	rs2072797	Human NCBI Build 35	22	37458707	UNC84B-GTPBP1
6644	-	2684	C/T	0	391203	rs2075937	Human NCBI Build 35	22	35654582	CSF2RB
6645	-	97	C/T	0	391210	rs2158354	Human NCBI Build 35	21	41632045	FAM3B
6646	-	2956	C/T	1	391212	rs216143	Human NCBI Build 35	5	149424340	CSF1R
6647	-	4610	C/T	0	391217	rs221309	Human NCBI Build 35	20	34708087	SLA2
6648	-	6123	C/T	0	391222	rs2228058	Human NCBI Build 35	5	40717011	PTGER4
6649	-	5849	C/T	0	391230	rs2234255	Human NCBI Build 35	6	41235521	ENSG00000095970
6650	-	3942	C/T	0	391240	rs2239752	Human NCBI Build 35	3	50620417	MAPKAPK3-CISH
6651	-	3869	C/T	1	391241	rs2241749	Human NCBI Build 35	1	2145727	
PRKCZ-ENSG00000162585-ENSG00000182873										
6652	-	5971	C/T	0	391242	rs2241806	Human NCBI Build 35	3	53876651	IL17RB-ACTR8
6653	-	1746	C/T	0	391243	rs2242221	Human NCBI Build 35	5	179968924	FLT4
6655	-	3521	C/T	0	391246	rs2246618	Human NCBI Build 35	6	31586965	MICB
6656	-	5348	C/T	0	391248	rs2253557	Human NCBI Build 35	15	62235418	SNX22-PPIB
6657	-	6082	C/T	1	391249	rs2254210	Human NCBI Build 35	12	46559981	VDR
6658	-	2373	C/T	1	391251	rs2268894	Human NCBI Build 35	2	162681655	DPP4
6659	-	2372	C/T	0	391255	rs2271593	Human NCBI Build 35	2	219994112	PTPRN-DNAJB2
6660	-	1990	C/T	0	391257	rs2272606	Human NCBI Build 35	17	3603908	ITGAE
6661	-	6189	C/T	1	391258	rs2272736	Human NCBI Build 35	8	42296320	IKBKB
6662	-	5323	C/T	1	391260	rs2274037	Human NCBI Build 35	10	6102114	IL2RA
6663	-	1403	C/T	0	391261	rs2274787	Human NCBI Build 35	1	152514216	DAP3-ENSG00000125459
6664	-	5212	C/T	1	391264	rs2277989	Human NCBI Build 35	19	7667812	FCER2
6665	-	2514	C/T	0	391265	rs2279178	Human NCBI Build 35	4	896477	GAK
6667	-	793	C/T	1	391278	rs2294097	Human NCBI Build 35	8	42267051	IKBKB
6668	-	2864	C/T	0	391279	rs2295603	Human NCBI Build 35	6	27328869	PRSS16
6669	-	1558	C/T	0	391281	rs2298988	Human NCBI Build 35	4	111248504	EGF
6671	-	5247	C/T	0	391288	rs2305060	Human NCBI Build 35	5	41239101	C6
6673	-	2113	C/T	0	391292	rs2317385	Human NCBI Build 35	17	42684681	ITGB3
6674	-	28	C/T	0	391293	rs2333200	Human NCBI Build 35	3	126564384	ZNF148
6675	-	443	C/T	0	391295	rs235214	Human NCBI Build 35	1	12205769	TNFRSF1B
6676	-	2461	C/T	0	391296	rs2361356	Human NCBI Build 35	12	93054969	PLXNC1
6677	-	5965	C/T	0	391297	rs2378755	Human NCBI Build 35	9	87550462	DAPK1
6678	-	1223	C/T	0	391300	rs2405004	Human NCBI Build 35	1	51126152	FAF1
6679	-	50	C/T	0	391302	rs243324	Human NCBI Build 35	16	11262471	SOCS1
6680	-	2330	C/T	0	391303	rs244079	Human NCBI Build 35	20	42684005	ADA-PKIG
6681	-	1548	C/T	0	391304	rs244082	Human NCBI Build 35	20	42678605	ADA-PKIG
6682	-	2107	C/T	0	391311	rs2495626	Human NCBI Build 35	X	117640800	IL13RA1
6683	-	3982	C/T	0	391316	rs264839	Human NCBI Build 35	5	169066133	DOCK2
6684	-	3052	C/T	0	391319	rs2668021	Human NCBI Build 35	8	57036101	LYN
6685	-	1222	C/T	0	391320	rs2684777	Human NCBI Build 35	15	97214217	IGF1R
6686	-	2426	C/T	1	391323	rs2711295	Human NCBI Build 35	2	46084547	PRKCE
6687	-	2976	C/T	0	391324	rs2717445	Human NCBI Build 35	12	69322140	PTPRB-PTPRR
6688	-	3280	C/T	1	391326	rs2723192	Human NCBI Build 35	2	113392612	IL1F7
6689	-	4863	C/T	0	391328	rs273493	Human NCBI Build 35	6	31783744	C6orf21-BAT5-LY6G6E
6690	-	5877	C/T	0	391329	rs2736182	Human NCBI Build 35	6	31691291	AIF1
6691	-	2457	C/T	0	391334	rs2794520	Human NCBI Build 35	1	156491889	CRP
6692	-	5216	C/T	1	391336	rs2834195	Human NCBI Build 35	21	33642183	IFNAR1
6693	-	3471	C/T	0	391337	rs2839657	Human NCBI Build 35	10	31695774	TCF8-ENSG00000196960
6694	-	2462	C/T	0	391340	rs2853218	Human NCBI Build 35	20	3468496	ATRN

6695	-	3206	C/T	1	391341	rs2853950	Human NCBI Build 35	6	31344154	HLA-C
6696	-	5631	C/T	0	391343	rs2890795	Human NCBI Build 35	9	8437732	PTPRD
6697	-	1146	C/T	0	391346	rs2907684	Human NCBI Build 35	7	157038893	PTPRN2-ENSG00000197192
6698	-	3433	C/T	0	391350	rs2979302	Human NCBI Build 35	8	22415101	PPP3CC-PIWIL2
6699	-	285	C/T	1	391352	rs2995054	Human NCBI Build 35	1	164220542	CD3Z-ENSG00000198352
6700	-	1905	C/T	0	391353	rs3013445	Human NCBI Build 35	1	210947053	PTPN14
6701	-	4138	C/T	1	391354	rs3025033	Human NCBI Build 35	6	43859053	VEGF
6702	-	4248	C/T	0	391358	rs3097408	Human NCBI Build 35	4	75111607	CXCL1
6703	-	6077	C/T	0	391361	rs3136560	Human NCBI Build 35	12	9807813	CD69
6704	-	4775	C/T	1	391363	rs3138045	Human NCBI Build 35	14	34947472	NFKBIA
6705	-	5092	C/T	1	391366	rs3181215	Human NCBI Build 35	17	24101458	TRAF4
6706	-	5537	C/T	0	391375	rs348337	Human NCBI Build 35	19	6481656	TNFSF9
6707	-	3394	C/T	0	391376	rs348389	Human NCBI Build 35	19	6486637	TNFSF9
6708	-	1219	C/T	0	391384	rs372402	Human NCBI Build 35	5	148732213	IL17B-ENSG00000145882
6709	-	4212	C/T	0	391385	rs3731920	Human NCBI Build 35	2	220259550	INHA-ENSG00000124006
6710	-	6195	C/T	1	391391	rs3741434	Human NCBI Build 35	12	51891611	ITGB7-RARG
6711	-	4909	C/T	0	391392	rs3743262	Human NCBI Build 35	15	97282996	IGF1R
6712	-	996	C/T	0	391394	rs3745902	Human NCBI Build 35	19	60069820	KIR3DL2
6714	-	5894	C/T	0	391398	rs3750782	Human NCBI Build 35	10	71367235	COL13A1-AMID
6715	-	4693	C/T	1	391399	rs3751031	Human NCBI Build 35	11	35117652	CD44
6716	-	5289	C/T	0	391400	rs3751364	Human NCBI Build 35	13	23132517	TNFRSF19
6717	-	5162	C/T	0	391405	rs3756419	Human NCBI Build 35	5	38527160	LIFR
6718	-	3996	C/T	0	391407	rs3758167	Human NCBI Build 35	9	36933128	PAX5
6719	-	323	C/T	0	391408	rs3758270	Human NCBI Build 35	9	33253674	BAG1-ENSG0000086065
6720	-	6135	C/T	1	391409	rs3758562	Human NCBI Build 35	10	72032086	PRF1
6721	-	6009	C/T	0	391411	rs3761432	Human NCBI Build 35	22	30662740	YWHAH-C22orf24
6722	-	1276	C/T	0	391417	rs3769825	Human NCBI Build 35	2	201936886	CASP8
6723	-	2060	C/T	1	391418	rs3773977	Human NCBI Build 35	3	191769911	IL1RAP
6724	-	3858	C/T	0	391420	rs3780160	Human NCBI Build 35	9	36932624	PAX5
6725	-	712	C/T	0	391422	rs3782518	Human NCBI Build 35	12	107191477	CMKLR1
6726	-	4990	C/T	0	391424	rs3785383	Human NCBI Build 35	16	23954069	PRKCB1
6727	-	1871	C/T	1	391426	rs3791507	Human NCBI Build 35	2	239815159	HDAC4
6728	-	6025	C/T	0	391430	rs3797126	Human NCBI Build 35	5	10760870	DAP-ENSG00000164236
6729	-	3461	C/T	0	391433	rs3798315	Human NCBI Build 35	6	167515120	CCR6-ENSG00000187485
6730	-	1357	C/T	0	391435	rs3802604	Human NCBI Build 35	10	8142278	GATA3
6731	-	1233	C/T	0	391437	rs3804100	Human NCBI Build 35	4	154983014	TLR2
6732	-	3314	C/T	0	391440	rs3811450	Human NCBI Build 35	1	151364105	CHRNA2-ADAR
6733	-	4134	C/T	0	391441	rs3812066	Human NCBI Build 35	5	179641502	MAPK9
6734	-	2943	C/T	0	391446	rs3820733	Human NCBI Build 35	2	46154625	PRKCE
6735	-	1188	C/T	0	391448	rs3822356	Human NCBI Build 35	6	30051046	HCG9-HLA-G-ENSG00000197640
6736	-	3328	C/T	0	391449	rs3825103	Human NCBI Build 35	12	116203229	NOS1
6737	-	5125	C/T	1	391450	rs3847355	Human NCBI Build 35	10	71395026	AMID
6738	-	1026	C/T	1	391453	rs3866740	Human NCBI Build 35	14	63688789	SYNE2-ESR2
6741	-	5764	C/T	0	391461	rs3921115	Human NCBI Build 35	20	40442750	PTPRT
6742	-	5730	C/T	0	391465	rs4065	Human NCBI Build 35	10	75346470	C10orf55-PLAU
6743	-	3973	C/T	0	391476	rs4428488	Human NCBI Build 35	6	41778747	TFEB
6744	-	5187	C/T	0	391478	rs4446102	Human NCBI Build 35	2	45909518	PRKCE
6745	-	2969	C/T	0	391481	rs4489498	Human NCBI Build 35	1	24257361	IL28RA
6746	-	3255	C/T	0	391483	rs4525555	Human NCBI Build 35	17	42692948	ITGB3

6747	-	806	C/T	0	391484	rs4531377	Human NCBI Build 35	10	129679774	PTPRE
6748	-	4296	C/T	1	391487	rs4636306	Human NCBI Build 35	9	129576571	PTGES-ENSG00000198665
6749	-	2512	C/T	1	391488	rs4640769	Human NCBI Build 35	5	35178082	PRLR
6751	-	2996	C/T	0	391493	rs4659167	Human NCBI Build 35	1	117433587	ENSG00000134258
6752	-	2883	C/T	1	391495	rs4683147	Human NCBI Build 35	3	45923268	LZTFL1-CCR9
6753	-	1697	C/T	0	391497	rs4705374	Human NCBI Build 35	5	149131512	PPARGC1B
6754	-	4543	C/T	1	391498	rs4716761	Human NCBI Build 35	7	156890536	PTPRN2
6755	-	5597	C/T	0	391499	rs4740203	Human NCBI Build 35	9	130666362	ABL1
6756	-	3734	C/T	0	391502	rs4769058	Human NCBI Build 35	13	30231431	ALOX5AP
6757	-	4732	C/T	0	391505	rs4781019	Human NCBI Build 35	16	10911651	MHC2TA
6758	-	2309	C/T	0	391506	rs4786370	Human NCBI Build 35	16	3053899	MMP25-ENSG0000008517
6759	-	503	C/T	0	391510	rs4807015	Human NCBI Build 35	19	5182135	PTPRS
6761	-	3017	C/T	0	391512	rs4809846	Human NCBI Build 35	20	49534504	NFATC2
6762	-	890	C/T	0	391513	rs4837405	Human NCBI Build 35	9	129585328	PTGES-ENSG00000198665
6763	-	4183	C/T	1	391514	rs4867897	Human NCBI Build 35	5	169245797	DOCK2
6764	-	3237	C/T	0	391515	rs4872077	Human NCBI Build 35	8	23114133	TNFRSF10A-ENSG00000147457
6765	-	4490	C/T	0	391521	rs494154	Human NCBI Build 35	1	224886418	TRIM11-ENSG00000198504
6766	-	2121	C/T	0	391522	rs4953274	Human NCBI Build 35	2	45994646	PRKCE
6767	-	4	C/T	0	391523	rs4964483	Human NCBI Build 35	12	105601524	RFX4
6768	-	5369	C/T	0	391524	rs4966008	Human NCBI Build 35	15	97020968	IGF1R
6769	-	4324	C/T	1	391526	rs496888	Human NCBI Build 35	1	12167072	TNFRSF1B
6770	-	3479	C/T	0	391528	rs4987792	Human NCBI Build 35	18	59002860	BCL2
6771	-	4751	C/T	0	391529	rs499807	Human NCBI Build 35	1	193361161	CFH
6773	-	2077	C/T	0	391531	rs5355	Human NCBI Build 35	1	166427528	SELE
6774	-	578	C/T	0	391534	rs549752	Human NCBI Build 35	18	75259213	NFATC1
6775	-	725	C/T	0	391536	rs571497	Human NCBI Build 35	19	7733830	ENSG00000104938
6776	-	4250	C/T	1	391552	rs6016958	Human NCBI Build 35	20	41168175	PTPRT
6777	-	6030	C/T	1	391553	rs6020348	Human NCBI Build 35	20	48236401	CEBPB
6778	-	2087	C/T	0	391555	rs6050200	Human NCBI Build 35	20	24883748	CST7
6779	-	4534	C/T	0	391556	rs6060627	Human NCBI Build 35	20	29725820	BCL2L1
6780	-	3004	C/T	0	391558	rs6072654	Human NCBI Build 35	20	40266189	PTPRT
6781	-	3758	C/T	0	391560	rs6096453	Human NCBI Build 35	20	49562023	NFATC2
6782	-	1593	C/T	1	391570	rs626479	Human NCBI Build 35	1	2142422	PRKCZ-ENSG00000182873
6783	-	4578	C/T	0	391571	rs629772	Human NCBI Build 35	2	45837422	PRKCE
6784	-	3228	C/T	0	391577	rs6459854	Human NCBI Build 35	7	157548264	PTPRN2
6785	-	1853	C/T	0	391580	rs652741	Human NCBI Build 35	Multiple	0	
KIR2DS2-ENSG00000167633-KIR2DS1-KIR3DS1										
6786	-	3818	C/T	0	391581	rs6543514	Human NCBI Build 35	2	239832944	HDAC4
6787	-	1043	C/T	0	391582	rs6543519	Human NCBI Build 35	2	239907211	HDAC4
6788	-	3057	C/T	0	391583	rs6555879	Human NCBI Build 35	5	169323900	DOCK2
6789	-	1189	C/T	1	391586	rs6621871	Human NCBI Build 35	X	103903767	IL1RAPL2
6790	-	5067	C/T	0	391589	rs6695302	Human NCBI Build 35	1	243940734	CIAS1-ENSG00000177535
6791	-	1225	C/T	0	391590	rs6701412	Human NCBI Build 35	1	232976356	EDARADD
6792	-	3364	C/T	0	391594	rs6759676	Human NCBI Build 35	2	113552579	IL1F10
6794	-	6027	C/T	1	391598	rs6942917	Human NCBI Build 35	7	157217957	
PTPRN2-ENSG00000196590-ENSG00000196201										
6795	-	3584	C/T	1	391600	rs6970262	Human NCBI Build 35	7	55033972	EGFR
6796	-	4550	C/T	0	391603	rs706910	Human NCBI Build 35	6	112155104	FYN
6797	-	794	C/T	0	391605	rs7083371	Human NCBI Build 35	10	71515101	H2AFY2-AMID

6798	-	2222	C/T	0	391606	rs7089539	Human NCBI Build 35	10	129706236	PTPRE
6799	-	2022	C/T	0	391607	rs715605	Human NCBI Build 35	22	28964862	LIF-ENSG00000185188
6800	-	4208	C/T	0	391608	rs716984	Human NCBI Build 35	3	191806577	IL1RAP
6801	-	5720	C/T	0	391616	rs729958	Human NCBI Build 35	9	87516741	DAPK1
6802	-	5418	C/T	0	391620	rs735574	Human NCBI Build 35	22	41847902	BIK
6804	-	1289	C/T	0	391629	rs7587182	Human NCBI Build 35	2	240045076	HDAC4
6805	-	3200	C/T	1	391638	rs7722386	Human NCBI Build 35	5	150388045	TNIP1-GPX3
6806	-	4755	C/T	1	391641	rs7766495	Human NCBI Build 35	6	47304169	TNFRSF21
6807	-	2840	C/T	0	391642	rs7778866	Human NCBI Build 35	7	157532110	PTPRN2
6808	-	434	C/T	1	391643	rs7783909	Human NCBI Build 35	7	157093892	PTPRN2
6809	-	2159	C/T	0	391645	rs7793010	Human NCBI Build 35	7	30243393	CARD4
6810	-	2291	C/T	0	391648	rs7820991	Human NCBI Build 35	8	27236864	PTK2B
6811	-	1098	C/T	1	391650	rs7838114	Human NCBI Build 35	8	75098165	LY96
6812	-	4861	C/T	0	391651	rs7846038	Human NCBI Build 35	8	27418059	EPHX2
6813	-	6213	C/T	1	391654	rs7852624	Human NCBI Build 35	9	36993075	PAX5
6815	-	2539	C/T	1	391657	rs7914787	Human NCBI Build 35	10	71532660	H2AFY2-AMID
6816	-	4198	C/T	0	391659	rs7949430	Human NCBI Build 35	11	71394948	NUMA1-IL18BP
6817	-	357	C/T	0	391660	rs7979999	Human NCBI Build 35	12	66880631	IL26
6818	-	5013	C/T	0	391661	rs8066276	Human NCBI Build 35	17	58942997	ACE
6819	-	3300	C/T	0	391662	rs8078363	Human NCBI Build 35	17	59775988	PECAM1
6820	-	6260	C/T	1	391668	rs8176928	Human NCBI Build 35	16	3646186	DNASE1-TRAP1
6821	-	802	C/T	0	391673	rs841718	Human NCBI Build 35	12	55779263	NAB2-STAT6
6822	-	5233	C/T	1	391676	rs867186	Human NCBI Build 35	20	33228215	PROCR
6823	-	4696	C/T	0	391678	rs8679	Human NCBI Build 35	1	222855289	PARP1
6824	-	5407	C/T	1	391679	rs868966	Human NCBI Build 35	1	222312833	EPHX1
6825	-	669	C/T	0	391685	rs874536	Human NCBI Build 35	18	8323852	PTPRM
6826	-	2494	C/T	0	391687	rs879576	Human NCBI Build 35	22	15963800	IL17R
6827	-	4433	C/T	0	391690	rs890862	Human NCBI Build 35	19	7184604	INSR
6828	-	3981	C/T	0	391694	rs896841	Human NCBI Build 35	11	76709955	PAK1
6829	-	4195	C/T	1	391697	rs908518	Human NCBI Build 35	2	112393857	MERTK
6830	-	2469	C/T	0	391699	rs913782	Human NCBI Build 35	9	87369751	DAPK1
6832	-	5880	C/T	0	391702	rs919396	Human NCBI Build 35	5	39196080	FYB
6833	-	1614	C/T	1	391703	rs922182	Human NCBI Build 35	15	62064695	ENSG00000035664
6834	-	5196	C/T	0	391708	rs9277341	Human NCBI Build 35	6	33147603	HLA-DPB1-HLA-DPA1
6835	-	3922	C/T	1	391712	rs9314259	Human NCBI Build 35	8	22996545	TNFRSF10C
6836	-	6208	C/T	0	391716	rs9350502	Human NCBI Build 35	6	74500695	CD109
6837	-	2381	C/T	0	391718	rs938213	Human NCBI Build 35	3	112796544	CD96-ZBED2
6838	-	296	C/T	0	391720	rs9462735	Human NCBI Build 35	6	41754817	TFEB
6839	-	4045	C/T	0	391721	rs948346	Human NCBI Build 35	18	8287072	PTPRM
6840	-	4542	C/T	1	391723	rs952784	Human NCBI Build 35	8	57046643	LYN
6841	-	4423	C/T	1	391724	rs9607623	Human NCBI Build 35	22	37942376	PDGFB
6842	-	1243	C/T	1	391725	rs9611791	Human NCBI Build 35	22	41143653	ENSG00000167087
6843	-	4464	C/T	0	391727	rs9783669	Human NCBI Build 35	17	28689	
ENSG00000187869-ENSG00000189315-ENSG00000197262										
6844	-	1729	C/T	1	391728	rs981292	Human NCBI Build 35	9	87386917	DAPK1
6845	-	1590	C/T	1	391731	rs9836399	Human NCBI Build 35	3	123294501	CD86
6846	-	3748	C/T	0	391732	rs9857	Human NCBI Build 35	5	10733547	DAP-ENSG00000164236
6847	-	5012	C/T	0	391733	rs9865102	Human NCBI Build 35	3	188918869	BCL6
6848	-	495	C/T	0	391739	rs10001565	Human NCBI Build 35	4	15398842	ENSG00000109743

6850	-	2172	C/T	0	391741	rs1004148	Human NCBI Build 35	18	75289538	NFATC1
6851	-	3726	C/T	1	391749	rs10204137	Human NCBI Build 35	2	102426730	IL1RL1
6852	-	1100	C/T	0	391756	rs10412864	Human NCBI Build 35	19	14348289	CD97
6853	-	4804	C/T	0	391758	rs10426828	Human NCBI Build 35	19	13967989	RFX1
6854	-	2747	C/T	0	391760	rs1045261	Human NCBI Build 35	12	6799898	LEPREL2-CD4
6855	-	3343	C/T	0	391763	rs1048122	Human NCBI Build 35	6	32821576	HLA-DQA2
6856	-	5606	C/T	0	391764	rs10488631	Human NCBI Build 35	7	128188134	IRF5-TNPO3
6857	-	2307	C/T	0	391766	rs10493423	Human NCBI Build 35	1	67549179	IL12RB2
6858	-	80	C/T	1	391767	rs10495927	Human NCBI Build 35	2	46264150	PRKCE
6860	-	3648	C/T	0	391769	rs10502368	Human NCBI Build 35	18	8287998	PTPRM
6861	-	6139	C/T	0	391771	rs10507	Human NCBI Build 35	6	37250400	PIM1
6862	-	4187	C/T	1	391773	rs1050922	Human NCBI Build 35	11	60541928	CD6
6863	-	4178	C/T	1	391775	rs10512202	Human NCBI Build 35	9	90715530	SYK
6864	-	745	C/T	1	391781	rs1054685	Human NCBI Build 35	19	19595539	EDG4
6865	-	3910	C/T	0	391784	rs10739757	Human NCBI Build 35	9	129587464	PTGES-ENSG00000198665
6866	-	3649	C/T	0	391785	rs10745682	Human NCBI Build 35	12	93190378	PLXNC1
6867	-	36	C/T	1	391788	rs10840	Human NCBI Build 35	17	38419943	VAT1-IFI35
6868	-	1757	C/T	0	391791	rs1086840	Human NCBI Build 35	11	36483422	TRAF6
6869	-	1030	C/T	0	391798	rs10903034	Human NCBI Build 35	1	24226211	IL28RA
6870	-	6290	C/T	0	391799	rs10915971	Human NCBI Build 35	1	222815380	none
6871	-	2178	C/T	0	391800	rs10926870	Human NCBI Build 35	1	232331939	ENSG00000143669
6872	-	3357	C/T	1	391801	rs10941583	Human NCBI Build 35	5	42727485	GHR
6873	-	4069	C/T	0	391803	rs11016053	Human NCBI Build 35	10	129761785	PTPRE
6874	-	3771	C/T	1	391804	rs11054724	Human NCBI Build 35	12	12237160	LRP6-BCL2L14
6875	-	6180	C/T	1	391805	rs11090819	Human NCBI Build 35	22	44947025	PPARA
6876	-	3202	C/T	0	391810	rs11259403	Human NCBI Build 35	10	6612231	PRKCQ
6877	-	5783	C/T	0	391815	rs1144911	Human NCBI Build 35	3	10209065	IRAK2
6878	-	3031	C/T	0	391819	rs1152592	Human NCBI Build 35	14	63745851	SYNE2-ESR2
6879	-	6398	C/T	1	391821	rs1155708	Human NCBI Build 35	3	30661744	TGFBR2
6880	-	4334	C/T	1	391824	rs11634241	Human NCBI Build 35	15	97076539	IGF1R
6881	-	4211	C/T	0	391827	rs11665501	Human NCBI Build 35	18	46489084	MAPK4
6882	-	2313	C/T	0	391828	rs11697017	Human NCBI Build 35	20	40522208	PTPRT
6883	-	3465	C/T	0	391831	rs11747314	Human NCBI Build 35	5	43268068	CCL28-ENSG00000177453
6884	-	842	C/T	0	391835	rs11808475	Human NCBI Build 35	1	161544311	PBX1
6885	-	6191	C/T	0	391836	rs11810173	Human NCBI Build 35	1	232158596	ENSG00000143669
6886	-	3866	C/T	0	391844	rs12125166	Human NCBI Build 35	1	151395202	ADAR
6887	-	1693	C/T	0	391845	rs12204904	Human NCBI Build 35	6	6152946	F13A1
6888	-	5517	C/T	0	391849	rs12407354	Human NCBI Build 35	1	29435383	PTPRU
6889	-	1023	C/T	1	391851	rs12456630	Human NCBI Build 35	18	8327540	PTPRM
6890	-	1726	C/T	0	391853	rs1248696	Human NCBI Build 35	10	79286611	DLG5
6891	-	6282	C/T	1	391854	rs12497324	Human NCBI Build 35	3	32323345	CKLFSF8
6892	-	3893	C/T	1	391859	rs12598	Human NCBI Build 35	16	66783016	NFATC3
6893	-	3592	C/T	0	391863	rs1268371	Human NCBI Build 35	14	92721745	MOAP1-C14orf109
6895	-	3277	C/T	0	391866	rs12772113	Human NCBI Build 35	10	97958138	BLNK
6896	-	3476	C/T	1	391867	rs1293764	Human NCBI Build 35	12	111888399	OAS2
6897	-	747	C/T	0	391871	rs13204446	Human NCBI Build 35	6	6208241	F13A1
6898	-	1768	C/T	0	391872	rs1322055	Human NCBI Build 35	9	114749139	TNFSF8
6900	-	4145	C/T	0	391878	rs13360222	Human NCBI Build 35	5	156459969	HAVCR2
6901	-	6175	C/T	0	391879	rs13383830	Human NCBI Build 35	2	70969961	CD207

6902	-	5055	C/T	0	391880	rs13414769	Human NCBI Build 35	2	239938051	HDAC4
6903	-	778	C/T	0	391887	rs1398873	Human NCBI Build 35	15	97213628	IGF1R
6904	-	2025	C/T	0	391888	rs1399629	Human NCBI Build 35	2	239994212	HDAC4
6905	-	4977	C/T	1	391890	rs1419135	Human NCBI Build 35	X	103950789	IL1RAPL2
6906	-	667	C/T	1	391892	rs1434262	Human NCBI Build 35	9	8693733	PTPRD
6907	-	4131	C/T	0	391902	rs15251	Human NCBI Build 35	5	149756425	TCOF1-CD74
6908	-	1277	C/T	0	391903	rs1531695	Human NCBI Build 35	18	58999803	BCL2
6909	-	3443	C/T	1	391908	rs1542130	Human NCBI Build 35	15	62005498	ENSG00000035664
6911	-	3306	C/T	0	391919	rs1589241	Human NCBI Build 35	4	142922694	IL15
6912	-	2058	C/T	0	391922	rs161827	Human NCBI Build 35	1	7916300	TNFRSF9
6913	-	3615	C/T	1	391925	rs16832307	Human NCBI Build 35	1	157461925	CD48
6914	-	6177	C/T	0	391927	rs17057255	Human NCBI Build 35	8	27417158	EPHX2
6915	-	4014	C/T	0	391929	rs1733448	Human NCBI Build 35	11	129253947	NFRKB
6916	-	4640	C/T	0	391930	rs174376	Human NCBI Build 35	6	112015058	C6orf4
6917	-	2497	C/T	1	391931	rs1760118	Human NCBI Build 35	9	90741760	SYK
6918	-	4797	C/T	0	391934	rs1770552	Human NCBI Build 35	1	161331815	PBX1-ENSG00000197613
6919	-	1783	C/T	0	391937	rs179007	Human NCBI Build 35	X	12669979	TLR7
6920	-	1742	C/T	0	391939	rs1800609	Human NCBI Build 35	9	130760738	ABL1
6921	-	5291	C/T	0	391945	rs1860334	Human NCBI Build 35	17	59366834	SCN4A-CD79B
6922	-	2068	C/T	0	391947	rs1878075	Human NCBI Build 35	1	162358613	ALDH9A1-MGST3
6923	-	5937	C/T	0	391953	rs1942958	Human NCBI Build 35	18	8021623	PTPRM
6924	-	4480	C/T	0	391954	rs1946612	Human NCBI Build 35	19	46459827	HNRPUL1-AXL
6925	-	818	C/T	1	391956	rs196345	Human NCBI Build 35	10	121410912	BAG3
6926	-	6259	C/T	1	391961	rs2000137	Human NCBI Build 35	20	41214622	PTPRT
6928	-	3382	C/T	0	391969	rs2027432	Human NCBI Build 35	1	243904482	CIAS1
6929	-	935	C/T	0	391973	rs204993	Human NCBI Build 35	19	59817	
KIR2DS2-KIR2DS1-ENSG00000189013-KIR2DL4										
6930	-	3071	C/T	0	391974	rs2051684	Human NCBI Build 35	16	24078476	PRKCB1
6932	-	3091	C/T	0	391978	rs2064205	Human NCBI Build 35	6	136999357	MAP3K5
6933	-	3548	C/T	0	391983	rs2069830	Human NCBI Build 35	7	22540377	IL6-ENSG00000179428
6934	-	5359	C/T	0	391985	rs2070682	Human NCBI Build 35	7	100370702	SERPINE1
6935	-	6333	C/T	0	391986	rs2070936	Human NCBI Build 35	2	232401936	PTMA
6936	-	2959	C/T	0	391988	rs2072070	Human NCBI Build 35	17	29710119	CCL13-CCL1
6937	-	1866	C/T	1	391995	rs2100291	Human NCBI Build 35	8	22430496	PPP3CC-PIWIL2
6938	-	4126	C/T	0	391996	rs210431	Human NCBI Build 35	X	104751078	IL1RAPL2
6939	-	283	C/T	1	392000	rs2156875	Human NCBI Build 35	6	31425326	HLA-B
6940	-	2918	C/T	0	392001	rs2168672	Human NCBI Build 35	2	160877117	ITGB6
6943	-	3116	C/T	0	392008	rs2227714	Human NCBI Build 35	7	100375344	SERPINE1
6944	-	1292	C/T	0	392009	rs2229231	Human NCBI Build 35	9	21067641	IFNB1
6946	-	2048	C/T	0	392014	rs2232346	Human NCBI Build 35	3	53867870	IL17RB
6947	-	2770	C/T	0	392015	rs2232566	Human NCBI Build 35	12	47249136	LALBA
6948	-	2825	C/T	0	392016	rs2232571	Human NCBI Build 35	20	36407498	LBP
6949	-	69	C/T	1	392018	rs2232610	Human NCBI Build 35	20	36428885	LBP
6950	-	247	C/T	0	392019	rs2232615	Human NCBI Build 35	20	36431162	LBP
6951	-	498	C/T	0	392020	rs2234256	Human NCBI Build 35	6	41234633	TREML1-ENSG00000095970
6952	-	1847	C/T	0	392021	rs2236380	Human NCBI Build 35	10	6509823	PRKCQ
6953	-	3566	C/T	1	392022	rs2240827	Human NCBI Build 35	7	38092676	TRGV9
6954	-	489	C/T	1	392029	rs2259397	Human NCBI Build 35	1	204456974	CD34
6956	-	2505	C/T	1	392034	rs2268015	Human NCBI Build 35	12	6193078	CD9

6957	-	5115	C/T	0	392038	rs2271986	Human NCBI Build 35	12	116123593	NOS1
6958	-	1397	C/T	0	392043	rs2274618	Human NCBI Build 35	1	143024928	ITGA10
6959	-	2762	C/T	0	392045	rs2275254	Human NCBI Build 35	1	111574016	ENSG00000134216
6960	-	2611	C/T	0	392047	rs2282151	Human NCBI Build 35	5	140004675	NDUFA2-IK-ENSG00000113119
6961	-	1649	C/T	0	392049	rs2284031	Human NCBI Build 35	22	35645580	CSF2RB
6962	-	3088	C/T	0	392055	rs2290714	Human NCBI Build 35	10	97959684	BLNK
6963	-	2035	C/T	0	392057	rs2292606	Human NCBI Build 35	2	219991268	PTPRN-DNAJB2
6964	-	4292	C/T	0	392064	rs2302685	Human NCBI Build 35	12	12193165	LRP6-BCL2L14
6965	-	4072	C/T	0	392069	rs2335852	Human NCBI Build 35	7	157399792	PTPRN2
6966	-	2868	C/T	0	392070	rs235249	Human NCBI Build 35	1	12192497	TNFRSF1B
6967	-	3494	C/T	0	392071	rs2364306	Human NCBI Build 35	3	58629135	FAM3D
6968	-	5412	C/T	0	392075	rs2414132	Human NCBI Build 35	15	50193950	BCL2L10
6969	-	5740	C/T	0	392076	rs2422910	Human NCBI Build 35	20	3557652	ATRN
6970	-	3352	C/T	0	392078	rs2465811	Human NCBI Build 35	12	69276321	PTPRB
6971	-	2965	C/T	0	392082	rs249916	Human NCBI Build 35	5	141988572	FGF1
6972	-	4505	C/T	0	392093	rs261020	Human NCBI Build 35	5	169231620	DOCK2
6973	-	5054	C/T	1	392097	rs2664017	Human NCBI Build 35	4	48070814	TEC
6976	-	3168	C/T	1	392100	rs2667975	Human NCBI Build 35	8	57067684	LYN
6977	-	4204	C/T	0	392108	rs273506	Human NCBI Build 35	19	18082647	IL12RB1-MAST3
6978	-	2664	C/T	0	392111	rs2753982	Human NCBI Build 35	20	3558738	ATRN
6980	-	4681	C/T	0	392115	rs2808426	Human NCBI Build 35	1	27684350	G1P3
6981	-	4690	C/T	0	392116	rs2812357	Human NCBI Build 35	9	34645436	GALT-ENSG00000137070
6982	-	58	C/T	1	392117	rs281414	Human NCBI Build 35	19	10311285	ICAM3
6983	-	5893	C/T	0	392119	rs2815807	Human NCBI Build 35	6	36220401	MAPK13
6984	-	3262	C/T	1	392120	rs2819332	Human NCBI Build 35	1	43674373	PTPRF
6985	-	2660	C/T	1	392121	rs2834167	Human NCBI Build 35	21	33562658	IL10RB-IFNAR2
6986	-	5445	C/T	1	392124	rs2850760	Human NCBI Build 35	18	59117803	BCL2
6987	-	5596	C/T	0	392126	rs2860580	Human NCBI Build 35	6	30014670	HLA-A-HLA-G
6988	-	4763	C/T	0	392131	rs290255	Human NCBI Build 35	9	90731212	SYK
6989	-	5401	C/T	1	392132	rs2908700	Human NCBI Build 35	12	9895915	ENSG00000110852
6990	-	1735	C/T	1	392133	rs2909888	Human NCBI Build 35	5	75959063	F2RL2-IQGAP2
6991	-	3623	C/T	0	392138	rs2991215	Human NCBI Build 35	9	90707660	SYK
6992	-	1595	C/T	1	392141	rs3019548	Human NCBI Build 35	11	60505515	CD6
6993	-	1850	C/T	0	392142	rs3020729	Human NCBI Build 35	2	86923951	CD8A
6994	-	6037	C/T	0	392143	rs3024505	Human NCBI Build 35	1	203328299	IL10
6995	-	5696	C/T	0	392150	rs30461	Human NCBI Build 35	19	44480955	IL29
6996	-	6159	C/T	0	392152	rs307253	Human NCBI Build 35	11	13466193	PTH
6997	-	3207	C/T	0	392155	rs3087326	Human NCBI Build 35	6	31582150	MICB
6998	-	5269	C/T	0	392156	rs3091237	Human NCBI Build 35	17	29621916	CCL7
6999	-	3632	C/T	0	392157	rs3092924	Human NCBI Build 35	X	135465966	ENSG00000102245
7000	-	5331	C/T	1	392158	rs3093040	Human NCBI Build 35	1	110182466	CSF1
7001	-	6070	C/T	0	392159	rs3094165	Human NCBI Build 35	6	29941520	HLA-G
7002	-	1569	C/T	0	392161	rs310244	Human NCBI Build 35	1	65017898	JAK1
7003	-	3271	C/T	0	392162	rs3107156	Human NCBI Build 35	1	2092792	PRKCZ
7004	-	2707	C/T	0	392163	rs3118865	Human NCBI Build 35	9	87553631	DAPK1
7005	-	3268	C/T	0	392165	rs3136614	Human NCBI Build 35	10	6045680	IL15RA
7006	-	5630	C/T	0	392167	rs3138039	Human NCBI Build 35	17	29676863	CCL8
7007	-	2033	C/T	1	392173	rs3179771	Human NCBI Build 35	6	33161555	HLA-DPB1
7008	-	3316	C/T	0	392177	rs331418	Human NCBI Build 35	18	7806276	PTPRM

7009	-	4747	C/T	0	392181	rs353630	Human NCBI Build 35	11	35144767	CD44
7010	-	2289	C/T	1	392186	rs368686	Human NCBI Build 35	5	179949250	SCGB3A1
7011	-	4081	C/T	0	392189	rs3733593	Human NCBI Build 35	4	15530994	CD38
7012	-	4559	C/T	0	392190	rs3734483	Human NCBI Build 35	6	3060525	RIPK1-ENSG00000137274
7013	-	144	C/T	0	392194	rs3743713	Human NCBI Build 35	9	35600912	ENSG00000196186-TESK1-CD72
7014	-	1541	C/T	0	392195	rs3749737	Human NCBI Build 35	5	38969169	OSMR
7016	-	5002	C/T	0	392200	rs3764276	Human NCBI Build 35	16	29580704	SPN-ENSG00000198106
7017	-	1285	C/T	0	392203	rs3769684	Human NCBI Build 35	2	204410265	CD28
7018	-	2538	C/T	1	392207	rs3782040	Human NCBI Build 35	11	117681307	CD3E
7019	-	189	C/T	0	392209	rs3785817	Human NCBI Build 35	17	39779191	GRN
7021	-	2092	C/T	0	392213	rs3789587	Human NCBI Build 35	1	50978495	FAF1
7022	-	4395	C/T	1	392215	rs3791549	Human NCBI Build 35	2	239845278	HDAC4
7023	-	2787	C/T	0	392217	rs3794766	Human NCBI Build 35	17	23146048	NOS2A
7024	-	322	C/T	1	392218	rs3794900	Human NCBI Build 35	18	46500325	MAPK4
7025	-	3654	C/T	0	392220	rs3808817	Human NCBI Build 35	9	130775614	ABL1
7026	-	3839	C/T	0	392222	rs3809863	Human NCBI Build 35	17	42740011	ITGB3
7027	-	4233	C/T	0	392228	rs3824344	Human NCBI Build 35	9	36990687	PAX5
7028	-	1250	C/T	0	392229	rs3826717	Human NCBI Build 35	19	54671705	FLT3LG
7029	-	1141	C/T	1	392231	rs3829612	Human NCBI Build 35	17	75775997	CARD14
7030	-	4835	C/T	0	392239	rs3924245	Human NCBI Build 35	9	89258948	SEMA4D
7031	-	4674	C/T	0	392243	rs4054760	Human NCBI Build 35	3	3126668	IL5RA
7032	-	4988	C/T	0	392248	rs4149623	Human NCBI Build 35	12	6320839	TNFRSF1A
7033	-	3582	C/T	0	392250	rs4245275	Human NCBI Build 35	18	54536418	MALT1
7034	-	4393	C/T	0	392252	rs4253763	Human NCBI Build 35	22	44943119	PPARA
7035	-	237	C/T	0	392255	rs4307328	Human NCBI Build 35	8	42258577	IKBKB
7036	-	577	C/T	0	392259	rs4381241	Human NCBI Build 35	1	50619459	FAF1
7037	-	1064	C/T	1	392260	rs438421	Human NCBI Build 35	19	18037086	IL12RB1
7038	-	2622	C/T	0	392261	rs4456611	Human NCBI Build 35	18	58961432	BCL2
7039	-	2972	C/T	0	392263	rs4499341	Human NCBI Build 35	19	7151990	INSR
7041	-	5081	C/T	1	392266	rs4559463	Human NCBI Build 35	1	222302847	EPHX1
7042	-	1482	C/T	0	392268	rs4608765	Human NCBI Build 35	4	87616447	MAPK10
7043	-	4584	C/T	0	392270	rs4655358	Human NCBI Build 35	1	211056104	PTPN14
7044	-	3855	C/T	0	392271	rs4656937	Human NCBI Build 35	1	157638326	CD244
7045	-	5340	C/T	0	392272	rs4683235	Human NCBI Build 35	3	46476935	LTF
7046	-	5011	C/T	1	392274	rs470119	Human NCBI Build 35	22	49257058	SC02-ECGF1
7047	-	34	C/T	0	392278	rs4746955	Human NCBI Build 35	10	71519684	H2AFY2-AMID
7048	-	1605	C/T	1	392280	rs4752805	Human NCBI Build 35	11	47974931	PTPRJ
7049	-	4342	C/T	0	392282	rs4760648	Human NCBI Build 35	12	46566932	VDR
7050	-	3466	C/T	0	392283	rs4761585	Human NCBI Build 35	12	93043143	PLXNC1
7051	-	4777	C/T	0	392284	rs4761590	Human NCBI Build 35	12	93076279	PLXNC1
7052	-	2192	C/T	0	392288	rs479448	Human NCBI Build 35	19	7737061	ENSG00000104938
7053	-	1730	C/T	0	392292	rs4802113	Human NCBI Build 35	19	46432735	AXL
7054	-	4314	C/T	0	392295	rs4812639	Human NCBI Build 35	20	40797926	PTPRT
7055	-	3414	C/T	0	392297	rs484256	Human NCBI Build 35	15	31982609	AVEN
7056	-	6043	C/T	0	392303	rs4880158	Human NCBI Build 35	9	137080516	C9orf86-TRAF2
7057	-	1438	C/T	0	392306	rs4941189	Human NCBI Build 35	18	59058907	BCL2
7058	-	1623	C/T	0	392308	rs4953251	Human NCBI Build 35	2	45906237	PRKCE
7059	-	975	C/T	0	392312	rs4977163	Human NCBI Build 35	14	105922818	IGHA1
7060	-	2070	C/T	1	392314	rs4987835	Human NCBI Build 35	18	58957195	BCL2

7061	-	1063	C/T	1	392317	rs513349	Human NCBI Build 35	6	33649697	BAK1
7062	-	969	C/T	1	392320	rs530878	Human NCBI Build 35	6	33659492	BAK1-ENSG00000197251
7063	-	5019	C/T	1	392322	rs535000	Human NCBI Build 35	20	40965705	PTPRT
7064	-	5646	C/T	1	392325	rs565042	Human NCBI Build 35	17	44932838	NGFR
7066	-	4279	C/T	0	392329	rs5743621	Human NCBI Build 35	4	38620821	TLR1
7067	-	2266	C/T	0	392332	rs5744496	Human NCBI Build 35	5	66521040	LY64
7068	-	4283	C/T	0	392335	rs586457	Human NCBI Build 35	10	6537428	PRKCQ
7069	-	4154	C/T	1	392336	rs587198	Human NCBI Build 35	10	6571155	PRKCQ
7070	-	3001	C/T	1	392338	rs5953073	Human NCBI Build 35	X	47250600	ELK1-PFC
7071	-	550	C/T	0	392339	rs5962969	Human NCBI Build 35	X	103710266	IL1RAPL2
7072	-	4820	C/T	0	392341	rs6013195	Human NCBI Build 35	20	49541069	NFATC2
7073	-	4567	C/T	0	392342	rs6021231	Human NCBI Build 35	20	49525694	NFATC2
7074	-	1892	C/T	0	392344	rs6063533	Human NCBI Build 35	20	48592806	PTPN1
7075	-	4687	C/T	0	392345	rs608139	Human NCBI Build 35	2	45789207	PRKCE
7076	-	1138	C/T	0	392349	rs6124418	Human NCBI Build 35	20	40192864	PTPRT
7077	-	5268	C/T	1	392350	rs6128	Human NCBI Build 35	1	166294562	SELP
7078	-	372	C/T	0	392358	rs6497698	Human NCBI Build 35	16	23820535	PRKCB1
7079	-	551	C/T	0	392364	rs6531670	Human NCBI Build 35	4	38657588	TLR6
7080	-	2569	C/T	0	392365	rs6544868	Human NCBI Build 35	2	46168317	PRKCE
7081	-	3235	C/T	0	392367	rs6550497	Human NCBI Build 35	3	37681271	ITGA9
7082	-	5695	C/T	0	392368	rs6559331	Human NCBI Build 35	9	88837423	C9orf47
7083	-	3956	C/T	0	392370	rs6579757	Human NCBI Build 35	5	149141630	PPARGC1B
7084	-	4557	C/T	0	392371	rs658347	Human NCBI Build 35	1	204447319	CD34
7085	-	918	C/T	0	392372	rs6621980	Human NCBI Build 35	X	104609716	IL1RAPL2
7086	-	1238	C/T	1	392376	rs6664730	Human NCBI Build 35	1	233042929	LGALS8-ENSG00000119285
7087	-	3391	C/T	0	392379	rs6672288	Human NCBI Build 35	1	203673141	C4BPA
7088	-	3480	C/T	0	392382	rs6706275	Human NCBI Build 35	2	240001871	HDAC4
7089	-	2086	C/T	0	392387	rs6743504	Human NCBI Build 35	2	46160403	PRKCE
7091	-	2106	C/T	1	392392	rs6780036	Human NCBI Build 35	3	37833414	ITGA9
7092	-	3163	C/T	0	392395	rs6868503	Human NCBI Build 35	5	169428629	DOCK2
7093	-	2099	C/T	0	392397	rs6879630	Human NCBI Build 35	5	169412008	DOCK2
7094	-	3834	C/T	0	392398	rs6880589	Human NCBI Build 35	5	156393018	HAVCR1
7095	-	3847	C/T	0	392399	rs688881	Human NCBI Build 35	5	169186359	DOCK2
7096	-	2441	C/T	0	392404	rs6944306	Human NCBI Build 35	7	157229968	
PTPRN2-ENSG00000196590-ENSG00000196201										
7097	-	605	C/T	0	392405	rs6968292	Human NCBI Build 35	7	157056499	PTPRN2-ENSG00000197192
7098	-	3384	C/T	1	392406	rs6990733	Human NCBI Build 35	8	27460054	EPHX2
7100	-	5749	C/T	0	392413	rs705866	Human NCBI Build 35	7	99609936	PILRB
7101	-	2953	C/T	0	392417	rs7094103	Human NCBI Build 35	10	71529174	H2AFY2-AMID
7103	-	2513	C/T	1	392429	rs7193473	Human NCBI Build 35	16	65157980	CKLF
7104	-	6262	C/T	1	392432	rs7220026	Human NCBI Build 35	17	3587629	ITGAE
7105	-	1379	C/T	0	392433	rs7240932	Human NCBI Build 35	18	75275634	NFATC1
7106	-	2592	C/T	0	392434	rs7250851	Human NCBI Build 35	19	56938133	FPR1
7107	-	929	C/T	0	392435	rs7252525	Human NCBI Build 35	19	59500426	ENSG00000170866
7108	-	572	C/T	0	392436	rs726302	Human NCBI Build 35	12	64912424	IRAK3
7109	-	5579	C/T	0	392437	rs7300972	Human NCBI Build 35	12	107519730	SELPLG
7110	-	4011	C/T	1	392439	rs7341507	Human NCBI Build 35	7	99595966	PILRB
7111	-	169	C/T	0	392440	rs7367066	Human NCBI Build 35	1	3826912	DFFB-ENSG00000198912
7112	-	5741	C/T	1	392443	rs738299	Human NCBI Build 35	22	36233515	CARD10

7113	-	665	C/T	0	392445	rs741326	Human NCBI Build 35	2	70970490	CD207
7114	-	885	C/T	0	392450	rs749174	Human NCBI Build 35	11	67109829	GSTP1
7115	-	5069	C/T	0	392451	rs7506506	Human NCBI Build 35	18	54509469	MALT1-ENSG00000182288
7116	-	4891	C/T	1	392455	rs7555183	Human NCBI Build 35	1	67572648	IL12RB2
7117	-	711	C/T	0	392467	rs7777198	Human NCBI Build 35	7	157134398	PTPRN2
7118	-	4399	C/T	0	392469	rs785419	Human NCBI Build 35	1	32938284	YARS
7119	-	201	C/T	0	392471	rs7869951	Human NCBI Build 35	9	130618497	ABL1
7121	-	294	C/T	0	392477	rs7946009	Human NCBI Build 35	11	127892632	ETS1
7122	-	4787	C/T	0	392483	rs8076790	Human NCBI Build 35	17	38408126	IFI35-ENSG00000131469
7124	-	5188	C/T	1	392485	rs8086809	Human NCBI Build 35	18	7747761	PTPRM
7125	-	4955	C/T	1	392486	rs8090312	Human NCBI Build 35	18	75326142	NFATC1
7126	-	5784	C/T	1	392487	rs8090560	Human NCBI Build 35	18	75314143	NFATC1
7127	-	3080	C/T	0	392489	rs8106574	Human NCBI Build 35	19	6622142	TNFSF14
7128	-	626	C/T	0	392492	rs8177772	Human NCBI Build 35	10	6055063	IL15RA
7129	-	5700	C/T	0	392494	rs832502	Human NCBI Build 35	12	93177610	PLXNC1
7130	-	3429	C/T	0	392495	rs84460	Human NCBI Build 35	22	35850231	IL2RB
7131	-	2434	C/T	0	392497	rs8512	Human NCBI Build 35	11	63766661	PPP1R14B-VEGFB-FKBP2
7132	-	5950	C/T	0	392500	rs874923	Human NCBI Build 35	20	40685754	PTPRT
7133	-	421	C/T	0	392501	rs876896	Human NCBI Build 35	12	110760977	ENSG00000089022
7134	-	5277	C/T	0	392508	rs885443	Human NCBI Build 35	4	47973819	TXK-TEC
7135	-	5283	C/T	0	392511	rs902038	Human NCBI Build 35	1	161497867	PBX1
7136	-	2881	C/T	0	392512	rs907811	Human NCBI Build 35	15	97077383	IGF1R
7137	-	4945	C/T	0	392527	rs935650	Human NCBI Build 35	2	46046416	PRKCE
7138	-	4538	C/T	0	392528	rs9381299	Human NCBI Build 35	6	44319845	HSPCB
7139	-	6168	C/T	0	392529	rs942200	Human NCBI Build 35	10	6103680	IL2RA
7140	-	5760	C/T	0	392531	rs944715	Human NCBI Build 35	10	6519162	PRKCQ
7141	-	246	C/T	0	392534	rs9525641	Human NCBI Build 35	13	42046024	TNFSF11
7142	-	4196	C/T	0	392537	rs966365	Human NCBI Build 35	1	232883812	EDARADD
7143	-	6312	C/T	1	392538	rs968257	Human NCBI Build 35	14	63750038	SYNE2-ESR2
7144	-	6101	C/T	0	392545	rs9835788	Human NCBI Build 35	3	126552194	ZNF148
7145	-	1838	C/T	0	392548	rs9845076	Human NCBI Build 35	3	138198166	ENSG00000174564
7146	-	1360	C/T	0	392550	rs990750	Human NCBI Build 35	18	20290679	HRH4-ENSG00000154059
7147	-	5287	C/T	0	392558	rs9990430	Human NCBI Build 35	4	111321876	EGF
7148	-	1701	C/T	1	392560	rs1008378	Human NCBI Build 35	22	16581805	BCL2L13
7149	-	266	C/T	0	392562	rs1012672	Human NCBI Build 35	12	12176182	LRP6-BCL2L14
7150	-	598	C/T	0	392563	rs1013192	Human NCBI Build 35	5	169131681	DOCK2
7151	-	1281	C/T	1	392568	rs10232911	Human NCBI Build 35	7	157127727	PTPRN2
7152	-	694	C/T	0	392571	rs1042489	Human NCBI Build 35	17	73731801	BIRC5-ENSG00000182802
7153	-	445	C/T	1	392573	rs10484491	Human NCBI Build 35	6	137069560	MAP3K5
7154	-	5966	C/T	0	392574	rs10488140	Human NCBI Build 35	7	54912597	EGFR
7155	-	1638	C/T	1	392577	rs1049164	Human NCBI Build 35	9	90737761	SYK
7156	-	1495	C/T	1	392578	rs10495378	Human NCBI Build 35	1	232938058	EDARADD
7157	-	6324	C/T	1	392579	rs10500538	Human NCBI Build 35	16	65165690	CKLF
7158	-	4652	C/T	0	392580	rs10503077	Human NCBI Build 35	18	58947425	BCL2
7159	-	5353	C/T	0	392583	rs10511298	Human NCBI Build 35	3	112750254	CD96
7160	-	4510	C/T	0	392585	rs1051798	Human NCBI Build 35	6	31487786	MICA
7162	-	749	C/T	1	392592	rs10754339	Human NCBI Build 35	1	117402314	ENSG00000134258
7163	-	1448	C/T	1	392596	rs10845574	Human NCBI Build 35	12	12579448	DUSP16
7165	-	5270	C/T	0	392599	rs10854166	Human NCBI Build 35	19	18513844	FKBP8

7166	-	1415	C/T	0	392601	rs10868644	Human NCBI Build 35	9	87519490	DAPK1
7167	-	3751	C/T	0	392603	rs10893882	Human NCBI Build 35	11	127878946	ETS1
7168	-	1567	C/T	0	392604	rs10931936	Human NCBI Build 35	2	201969434	CASP8-ENSG00000196709
7169	-	1083	C/T	0	392605	rs10961	Human NCBI Build 35	1	220269664	TP53BP2-CAPN2
7170	-	1286	C/T	0	392610	rs11074598	Human NCBI Build 35	16	23922112	PRKCB1
7172	-	1354	C/T	0	392614	rs11167790	Human NCBI Build 35	5	142048550	FGF1
7173	-	19	C/T	0	392615	rs11242865	Human NCBI Build 35	6	356954	IRF4
7174	-	2614	C/T	0	392617	rs11249201	Human NCBI Build 35	1	24197705	IL22RA1
7175	-	4972	C/T	0	392619	rs1126534	Human NCBI Build 35	6	33145617	HLA-DPA1
7176	-	6190	C/T	0	392621	rs1136105	Human NCBI Build 35	5	149756580	TCOF1-CD74
7177	-	3192	C/T	0	392623	rs1143627	Human NCBI Build 35	2	113310618	IL1B
7178	-	5572	C/T	1	392624	rs1143643	Human NCBI Build 35	2	113304533	IL1B
7180	-	962	C/T	0	392627	rs1151523	Human NCBI Build 35	11	65421776	FOSL1-ENSG00000197847
7181	-	4460	C/T	0	392635	rs11651719	Human NCBI Build 35	17	3625193	ITGAE
7182	-	898	C/T	0	392639	rs11674483	Human NCBI Build 35	2	233887201	INPP5D
7183	-	1946	C/T	1	392640	rs11687619	Human NCBI Build 35	2	112369123	MERTK
7184	-	6501	C/T	0	392642	rs11745634	Human NCBI Build 35	5	441064	AHRR
7186	-	3744	C/T	0	392644	rs1177457	Human NCBI Build 35	12	102838594	TRA1
7187	-	3475	C/T	1	392645	rs11785444	Human NCBI Build 35	8	141774178	PTK2
7188	-	5254	C/T	0	392646	rs11791652	Human NCBI Build 35	9	88832350	C9orf47
7189	-	2822	C/T	0	392647	rs11849394	Human NCBI Build 35	14	63653563	SYNE2-ESR2
7190	-	529	C/T	0	392648	rs11881500	Human NCBI Build 35	19	14010814	IL27RA
7191	-	2639	C/T	0	392650	rs11931532	Human NCBI Build 35	4	15402035	ENSG00000109743
7192	-	5299	C/T	0	392659	rs1224147	Human NCBI Build 35	13	107754759	TNFSF13B
7193	-	3292	C/T	0	392662	rs12432194	Human NCBI Build 35	14	23705865	ISGF3G
7194	-	3827	C/T	1	392666	rs1248751	Human NCBI Build 35	3	32493743	CKLFSF6
7195	-	312	C/T	0	392667	rs1256030	Human NCBI Build 35	14	63816923	ESR2
7196	-	2851	C/T	0	392668	rs12590163	Human NCBI Build 35	14	104294570	
ENSG00000184990-ENSG00000179627										
7197	-	5723	C/T	0	392669	rs12613347	Human NCBI Build 35	2	201880818	CASP10
7198	-	3662	C/T	0	392671	rs1263546	Human NCBI Build 35	7	156964843	PTPRN2
7199	-	833	C/T	0	392673	rs12640392	Human NCBI Build 35	4	87555382	MAPK10
7200	-	5090	C/T	0	392677	rs1270942	Human NCBI Build 35	6	32026839	RDBP-BF
7201	-	3571	C/T	0	392689	rs1320534	Human NCBI Build 35	13	27539534	FLT3
7202	-	2688	C/T	0	392698	rs13400210	Human NCBI Build 35	2	86996574	CD8B1
7203	-	4098	C/T	0	392700	rs1342642	Human NCBI Build 35	6	137364906	IL20RA
7204	-	405	C/T	0	392701	rs13426503	Human NCBI Build 35	2	128129541	GPR17-LIMS2
7205	-	1684	C/T	1	392708	rs1416834	Human NCBI Build 35	1	24231966	IL28RA
7206	-	3516	C/T	0	392712	rs1436522	Human NCBI Build 35	4	87321351	MAPK10
7207	-	216	C/T	0	392716	rs1460756	Human NCBI Build 35	4	87540089	MAPK10
7208	-	4993	C/T	0	392717	rs1461567	Human NCBI Build 35	12	42450956	ENSG00000198001
7209	-	5818	C/T	0	392720	rs1473180	Human NCBI Build 35	9	87435560	DAPK1
7211	-	2379	C/T	0	392732	rs1554973	Human NCBI Build 35	9	117560366	TLR4
7212	-	2824	C/T	0	392735	rs1570054	Human NCBI Build 35	6	137143419	MAP3K5
7214	-	5102	C/T	1	392738	rs1599961	Human NCBI Build 35	4	103800754	NFKB1
7215	-	2612	C/T	0	392743	rs1618254	Human NCBI Build 35	18	65700666	CD226
7216	-	4935	C/T	0	392747	rs1662746	Human NCBI Build 35	17	39348543	ENSG00000181763
7217	-	5124	C/T	0	392748	rs1681506	Human NCBI Build 35	12	116238298	NOS1
7218	-	4290	C/T	1	392749	rs16874698	Human NCBI Build 35	6	14243373	CD83

7219	-	1646	C/T	1	392751	rs1697142	Human NCBI Build 35	5	66531603	LY64
7220	-	581	C/T	1	392757	rs174399	Human NCBI Build 35	6	112026312	C6orf4
7221	-	5533	C/T	1	392760	rs17581141	Human NCBI Build 35	1	117272078	IGSF2
7222	-	2558	C/T	0	392762	rs1760125	Human NCBI Build 35	9	90702390	SYK
7223	-	4096	C/T	0	392764	rs17684072	Human NCBI Build 35	5	179617919	MAPK9-ENSG00000183279
7224	-	1568	C/T	1	392767	rs1788242	Human NCBI Build 35	18	65696958	CD226
7225	-	3283	C/T	1	392768	rs179760	Human NCBI Build 35	16	27348784	IL21R
7226	-	5022	C/T	0	392771	rs1804488	Human NCBI Build 35	12	111818175	OAS1
7227	-	4085	C/T	0	392772	rs1805034	Human NCBI Build 35	18	58178221	TNFRSF11A
7228	-	1491	C/T	0	392776	rs1821777	Human NCBI Build 35	12	64892495	IRAK3
7230	-	3653	C/T	0	392780	rs1872978	Human NCBI Build 35	3	30671255	TGFBR2
7231	-	4825	C/T	0	392783	rs1904347	Human NCBI Build 35	3	61929413	PTPRG
7232	-	2110	C/T	0	392787	rs1927957	Human NCBI Build 35	9	35339764	UNC13B-ENSG00000196186
7233	-	571	C/T	1	392788	rs1927976	Human NCBI Build 35	9	87488187	DAPK1
7234	-	3323	C/T	0	392795	rs1973284	Human NCBI Build 35	1	240182722	AKT3
7235	-	3007	C/T	1	392796	rs1976492	Human NCBI Build 35	17	70051440	ENSG00000167850
7236	-	5972	C/T	0	392799	rs1998651	Human NCBI Build 35	1	157354381	CD84
7237	-	4374	C/T	0	392800	rs2005154	Human NCBI Build 35	9	36846828	PAX5
7238	-	5648	C/T	0	392802	rs2018414	Human NCBI Build 35	2	239995925	HDAC4
7239	-	2424	C/T	0	392807	rs2042370	Human NCBI Build 35	1	15587048	CASP9
7240	-	151	C/T	0	392808	rs2046136	Human NCBI Build 35	18	58964961	BCL2
7241	-	5758	C/T	0	392810	rs2051308	Human NCBI Build 35	18	46448639	MAPK4
7242	-	1386	C/T	0	392812	rs20541	Human NCBI Build 35	5	132023863	IL13
7243	-	4689	C/T	0	392813	rs2066802	Human NCBI Build 35	2	191700173	STAT1
7244	-	1664	C/T	0	392815	rs2069664	Human NCBI Build 35	5	75952190	F2RL2-IQGAP2
7245	-	2790	C/T	0	392818	rs2069933	Human NCBI Build 35	2	127901918	PROC
7246	-	5010	C/T	0	392819	rs2070016	Human NCBI Build 35	4	155867919	FGA
7247	-	2232	C/T	0	392821	rs2070123	Human NCBI Build 35	1	78827926	IFI44
7248	-	1099	C/T	0	392824	rs2071048	Human NCBI Build 35	2	138555329	HNMT
7249	-	5566	C/T	1	392826	rs2071554	Human NCBI Build 35	6	32892654	TAP2-HLA-DOB
7250	-	811	C/T	0	392838	rs220065	Human NCBI Build 35	10	31821010	TCF8
7251	-	2132	C/T	0	392839	rs2203229	Human NCBI Build 35	12	69418050	PTPRR
7252	-	4905	C/T	0	392840	rs221300	Human NCBI Build 35	7	156866999	PTPRN2
7253	-	3542	C/T	0	392842	rs2230097	Human NCBI Build 35	17	37607248	STAT5B
7254	-	1737	C/T	1	392848	rs2237051	Human NCBI Build 35	4	111258802	EGF
7255	-	3894	C/T	0	392851	rs223830	Human NCBI Build 35	16	56009472	CCL17
7256	-	4091	C/T	1	392854	rs2243062	Human NCBI Build 35	5	76164997	F2RL1-ENSG00000183613
7257	-	4826	C/T	1	392856	rs2247213	Human NCBI Build 35	1	217443858	HLX1
7258	-	3570	C/T	0	392857	rs2249265	Human NCBI Build 35	1	117271768	IGSF2
7259	-	3411	C/T	1	392860	rs2268140	Human NCBI Build 35	12	15585162	PTPRO
7260	-	1808	C/T	0	392864	rs2274606	Human NCBI Build 35	9	87491979	DAPK1
7261	-	5543	C/T	1	392865	rs2275416	Human NCBI Build 35	1	12188467	TNFRSF1B
7262	-	4555	C/T	0	392866	rs2277537	Human NCBI Build 35	15	39644372	TYRO3
7263	-	3932	C/T	0	392867	rs2277991	Human NCBI Build 35	19	7661716	FCER2
7264	-	6066	C/T	0	392874	rs2286461	Human NCBI Build 35	4	15639942	ENSG00000137441
7265	-	204	C/T	0	392877	rs2289539	Human NCBI Build 35	17	75766714	CARD14
7266	-	2507	C/T	0	392879	rs2290088	Human NCBI Build 35	2	239802780	HDAC4
7267	-	1621	C/T	0	392881	rs2291375	Human NCBI Build 35	3	106746819	ALCAM
7268	-	709	C/T	1	392886	rs2298749	Human NCBI Build 35	4	111039109	none

7269	-	915	C/T	1	392888	rs2303652	Human NCBI Build 35	19	47395673	ENSG00000160570
7270	-	5139	C/T	0	392890	rs2307154	Human NCBI Build 35	1	67564301	IL12RB2
7271	-	5580	C/T	0	392897	rs2381596	Human NCBI Build 35	9	37007794	PAX5
7272	-	4746	C/T	0	392899	rs2394615	Human NCBI Build 35	10	71383930	COL13A1-AMID
7273	-	3378	C/T	1	392907	rs2467009	Human NCBI Build 35	12	69503359	PTPRR
7274	-	5801	C/T	0	392917	rs260711	Human NCBI Build 35	2	109015617	EDAR
7275	-	3577	C/T	0	392919	rs261072	Human NCBI Build 35	5	169248202	DOCK2
7276	-	3768	C/T	1	392920	rs261074	Human NCBI Build 35	5	169241658	DOCK2
7277	-	1434	C/T	1	392922	rs262883	Human NCBI Build 35	5	169082756	DOCK2
7278	-	849	C/T	0	392926	rs2684781	Human NCBI Build 35	15	97227071	IGF1R
7279	-	671	C/T	1	392931	rs2723186	Human NCBI Build 35	2	113391311	IL1F7
7280	-	1462	C/T	0	392932	rs2735061	Human NCBI Build 35	6	29801917	HLA-F
7281	-	2292	C/T	1	392933	rs2736964	Human NCBI Build 35	7	38118009	TRGV9
7282	-	1421	C/T	0	392937	rs2755212	Human NCBI Build 35	13	40041148	FOXO1A
7283	-	111	C/T	0	392939	rs276504	Human NCBI Build 35	6	137394212	IL20RA
7284	-	6008	C/T	0	392942	rs2808430	Human NCBI Build 35	1	27676429	G1P3
7285	-	5827	C/T	0	392947	rs2859242	Human NCBI Build 35	1	169356521	ENSG00000117560
7286	-	5034	C/T	0	392948	rs2881039	Human NCBI Build 35	6	112194924	FYN
7287	-	838	C/T	0	392952	rs290227	Human NCBI Build 35	9	90716219	SYK
7288	-	6091	C/T	0	392953	rs290247	Human NCBI Build 35	9	90663524	SYK
7289	-	3354	C/T	0	392954	rs2904254	Human NCBI Build 35	20	48245534	CEBPB
7290	-	1706	C/T	1	392959	rs2960266	Human NCBI Build 35	7	101542563	ENSG00000160999
7291	-	3189	C/T	0	392960	rs2969971	Human NCBI Build 35	18	46360593	MAPK4
7292	-	3361	C/T	0	392966	rs3024471	Human NCBI Build 35	6	6264534 F13A1	
7293	-	1143	C/T	1	392967	rs3024513	Human NCBI Build 35	1	203425541	PIGR-IL20
7294	-	4723	C/T	0	392976	rs3138105	Human NCBI Build 35	1	155076084	CD1C
7295	-	6321	C/T	0	392977	rs3176817	Human NCBI Build 35	9	34678366	CCL19
7296	-	494	C/T	1	392984	rs3212799	Human NCBI Build 35	19	17798516	INSL3
7297	-	992	C/T	0	392985	rs3218177	Human NCBI Build 35	1	23590594	E2F2
7298	-	3446	C/T	0	392986	rs322470	Human NCBI Build 35	5	145951066	PPP2R2B
7299	-	3543	C/T	0	392988	rs34012	Human NCBI Build 35	5	141975961	FGF1
7300	-	3239	C/T	0	392990	rs3729744	Human NCBI Build 35	5	38529539	LIFR
7301	-	363	C/T	0	392991	rs3730017	Human NCBI Build 35	17	23133229	NOS2A
7302	-	4170	C/T	1	392996	rs3740107	Human NCBI Build 35	10	45243776	ALOX5
7303	-	6107	C/T	0	393001	rs3753938	Human NCBI Build 35	1	165275889	XCL1
7304	-	512	C/T	0	393007	rs3759333	Human NCBI Build 35	12	6362208	LTBR
7305	-	248	C/T	0	393009	rs3761749	Human NCBI Build 35	5	169658405	LCP2
7306	-	4666	C/T	0	393012	rs3768347	Human NCBI Build 35	1	222899480	PARP1
7307	-	1516	C/T	0	393020	rs3780901	Human NCBI Build 35	10	45237382	ALOX5
7308	-	751	C/T	1	393025	rs3786185	Human NCBI Build 35	18	75300011	NFATC1
7309	-	6380	C/T	0	393027	rs3787334	Human NCBI Build 35	20	48561427	PTPN1
7310	-	5059	C/T	0	393030	rs3790569	Human NCBI Build 35	1	67548881	IL12RB2
7311	-	4148	C/T	1	393033	rs3791523	Human NCBI Build 35	2	239824729	HDAC4
7312	-	1989	C/T	0	393034	rs3791607	Human NCBI Build 35	2	239871506	HDAC4
7314	-	1480	C/T	1	393038	rs3793832	Human NCBI Build 35	10	71342885	COL13A1-AMID
7315	-	1177	C/T	0	393039	rs3794186	Human NCBI Build 35	11	67577612	TCIRG1-CHKA
7316	-	3036	C/T	0	393041	rs3794756	Human NCBI Build 35	17	23110756	NOS2A
7317	-	5004	C/T	0	393042	rs3795327	Human NCBI Build 35	1	157271855	SLAMF6
7318	-	5241	C/T	1	393046	rs3810672	Human NCBI Build 35	X	70613928	ACRC-CXCR3

7319	-	3396	C/T	1	393049	rs3814931	Human NCBI Build 35	14	105900839	IGHA1-ENSG00000198378
7320	-	1089	C/T	1	393051	rs3820564	Human NCBI Build 35	1	233013823	LGALS8-ENSG00000182097
7321	-	3176	C/T	0	393058	rs3833302	Human NCBI Build 35	8	16082787	MSR1
7322	-	1016	C/T	0	393059	rs3843641	Human NCBI Build 35	12	93061715	PLXNC1
7323	-	1700	C/T	1	393060	rs3845461	Human NCBI Build 35	1	180263857	NCF2
7324	-	3125	C/T	1	393061	rs3847804	Human NCBI Build 35	12	93068766	PLXNC1
7325	-	3825	C/T	0	393062	rs3847813	Human NCBI Build 35	12	93101925	PLXNC1
7326	-	4340	C/T	0	393063	rs3858605	Human NCBI Build 35	12	92734686	CRADD
7327	-	4435	C/T	0	393071	rs3929715	Human NCBI Build 35	14	24146746	GZMH
7328	-	1885	C/T	0	393078	rs4151648	Human NCBI Build 35	6	32021054	C2-BF
7329	-	5041	C/T	1	393083	rs4243494	Human NCBI Build 35	6	128558911	PTPRK
7330	-	4951	C/T	1	393085	rs4253701	Human NCBI Build 35	22	44906629	PPARA
7331	-	4003	C/T	0	393086	rs4292900	Human NCBI Build 35	1	24215120	IL22RA1
7332	-	2333	C/T	0	393088	rs4301822	Human NCBI Build 35	12	55041325	APOF-STAT2
7333	-	5045	C/T	0	393089	rs4329505	Human NCBI Build 35	1	151245493	IL6R
7334	-	1113	C/T	1	393090	rs4332084	Human NCBI Build 35	8	27305375	PTK2B
7335	-	6015	C/T	1	393098	rs442155	Human NCBI Build 35	4	75216267	PPBP-PF4
7336	-	2584	C/T	0	393099	rs4519549	Human NCBI Build 35	2	75295455	TACR1
7337	-	6337	C/T	1	393102	rs4620959	Human NCBI Build 35	16	24098013	PRKCB1
7338	-	1105	C/T	0	393110	rs4716760	Human NCBI Build 35	7	156876120	PTPRN2
7340	-	2039	C/T	1	393121	rs4796	Human NCBI Build 35	3	32498781	CKLFSF6
7341	-	6164	C/T	0	393124	rs4820262	Human NCBI Build 35	22	35641609	CSF2RB
7342	-	1980	C/T	0	393127	rs4848300	Human NCBI Build 35	2	113244137	IL1A
7343	-	1496	C/T	0	393128	rs4849148	Human NCBI Build 35	2	113545753	IL1F10
7345	-	901	C/T	0	393135	rs4877368	Human NCBI Build 35	9	87459127	DAPK1
7346	-	6233	C/T	1	393137	rs4891794	Human NCBI Build 35	18	65762523	CD226
7347	-	2188	C/T	0	393138	rs4896228	Human NCBI Build 35	6	137369507	IL20RA
7348	-	4884	C/T	0	393141	rs4939999	Human NCBI Build 35	18	46427395	MAPK4
7349	-	1400	C/T	1	393142	rs4940006	Human NCBI Build 35	18	46499698	MAPK4
7350	-	2042	C/T	1	393143	rs4947979	Human NCBI Build 35	7	54969834	EGFR
7351	-	5709	C/T	1	393145	rs4953262	Human NCBI Build 35	2	45952444	PRKCE
7354	-	938	C/T	1	393154	rs5364	Human NCBI Build 35	1	166430305	SELE
7355	-	66	C/T	0	393155	rs546076	Human NCBI Build 35	8	27526128	CLU
7356	-	2450	C/T	0	393156	rs547954	Human NCBI Build 35	12	116217226	NOS1
7357	-	6363	C/T	0	393159	rs563895	Human NCBI Build 35	15	32078561	AVEN
7358	-	4830	C/T	0	393161	rs569108	Human NCBI Build 35	11	59619680	MS4A2
7359	-	6307	C/T	0	393162	rs5741883	Human NCBI Build 35	X	12683878	TLR8
7360	-	5873	C/T	0	393163	rs5742683	Human NCBI Build 35	12	101316184	IGF1
7361	-	4930	C/T	1	393165	rs5743708	Human NCBI Build 35	4	154983922	RNF175-TLR2
7362	-	649	C/T	0	393168	rs584367	Human NCBI Build 35	1	20187360	PLA2G2D
7363	-	2224	C/T	0	393172	rs5984	Human NCBI Build 35	6	6119907	F13A1
7365	-	2369	C/T	1	393177	rs6030384	Human NCBI Build 35	20	40692810	PTPRT
7366	-	2057	C/T	0	393178	rs6030489	Human NCBI Build 35	20	40877259	PTPRT
7367	-	6064	C/T	0	393179	rs6037618	Human NCBI Build 35	20	3475582	ATRN
7368	-	487	C/T	1	393180	rs6058391	Human NCBI Build 35	20	29743569	BCL2L1
7369	-	2299	C/T	0	393190	rs6126229	Human NCBI Build 35	20	49479044	NFATC2
7370	-	3376	C/T	0	393191	rs6126251	Human NCBI Build 35	20	49597547	NFATC2
7371	-	991	C/T	0	393195	rs626364	Human NCBI Build 35	3	120755573	CD80
7372	-	1785	C/T	0	393199	rs6413891	Human NCBI Build 35	1	154524772	SPAP1

7373	-	3850	C/T	0	393200	rs6432713	Human NCBI Build 35	2	162962596	IFIH1
7374	-	6547	C/T	0	393203	rs6478012	Human NCBI Build 35	9	113326439	RGS3
7375	-	140	C/T	0	393204	rs648033	Human NCBI Build 35	11	111103535	PPP2R1B-SNF1LK2
7377	-	2084	C/T	0	393208	rs6518952	Human NCBI Build 35	22	34107067	HMOX1
7378	-	2659	C/T	0	393214	rs6546951	Human NCBI Build 35	2	75195163	TACR1
7379	-	1418	C/T	0	393217	rs6568702	Human NCBI Build 35	6	112172313	FYN
7380	-	3523	C/T	0	393230	rs6719130	Human NCBI Build 35	2	102416754	IL1RL1
7381	-	1607	C/T	1	393236	rs677986	Human NCBI Build 35	10	6517273	PRKCQ
7382	-	2546	C/T	0	393241	rs6864400	Human NCBI Build 35	5	169417805	DOCK2
7383	-	3838	C/T	0	393242	rs6869584	Human NCBI Build 35	5	169124404	DOCK2
7384	-	3287	C/T	1	393246	rs6916515	Human NCBI Build 35	6	41774043	TFEB
7385	-	4267	C/T	0	393248	rs6968343	Human NCBI Build 35	7	99596031	PILRB
7386	-	6318	C/T	0	393250	rs7005312	Human NCBI Build 35	8	56968993	LYN
7387	-	133	C/T	0	393259	rs7166547	Human NCBI Build 35	15	64471444	MAP2K1
7388	-	4135	C/T	0	393265	rs7242256	Human NCBI Build 35	18	8186939	PTPRM
7389	-	6379	C/T	0	393266	rs7250425	Human NCBI Build 35	19	18062757	IL12RB1
7390	-	5363	C/T	0	393268	rs7273698	Human NCBI Build 35	20	44190230	ENSG00000101017
7391	-	508	C/T	0	393271	rs7317427	Human NCBI Build 35	13	27518563	FLT3
7392	-	6237	C/T	0	393272	rs7358628	Human NCBI Build 35	12	6200056	CD9
7393	-	6017	C/T	1	393277	rs739984	Human NCBI Build 35	3	61975357	PTPRG
7394	-	4268	C/T	0	393278	rs7411202	Human NCBI Build 35	1	3802308	DDFB
7395	-	324	C/T	0	393280	rs7507911	Human NCBI Build 35	19	7249095	INSR
7396	-	2620	C/T	1	393282	rs7523742	Human NCBI Build 35	1	240014191	AKT3
7397	-	1466	C/T	0	393283	rs7525750	Human NCBI Build 35	1	27364250	MAP3K6-SYTL1
7398	-	3645	C/T	0	393284	rs7546890	Human NCBI Build 35	1	157808465	F11R
7399	-	3505	C/T	0	393285	rs7549250	Human NCBI Build 35	1	151217409	IL6R
7400	-	3737	C/T	1	393287	rs755149	Human NCBI Build 35	20	41125669	PTPRT
7401	-	2608	C/T	0	393290	rs7568814	Human NCBI Build 35	2	160515034	LY75
7402	-	124	C/T	0	393295	rs7620372	Human NCBI Build 35	3	112391085	PVRL3
7403	-	5568	C/T	0	393296	rs7632091	Human NCBI Build 35	3	62109842	PTPRG
7404	-	1058	C/T	0	393298	rs7637925	Human NCBI Build 35	3	61998507	PTPRG
7405	-	1404	C/T	0	393310	rs7730091	Human NCBI Build 35	5	179623007	MAPK9-ENSG00000183279
7406	-	2206	C/T	0	393316	rs7759295	Human NCBI Build 35	6	41243828	ENSG00000095970
7407	-	2408	C/T	0	393320	rs7868532	Human NCBI Build 35	9	8308618	PTPRD
7408	-	5193	C/T	0	393327	rs7958372	Human NCBI Build 35	12	111398273	PTPN11
7409	-	4443	C/T	0	393329	rs8014568	Human NCBI Build 35	14	22913203	CKLFSF5-IL17E
7410	-	5819	C/T	0	393333	rs8054708	Human NCBI Build 35	16	65167378	CKLF-ENSG00000140932
7412	-	6150	C/T	0	393336	rs8072199	Human NCBI Build 35	17	23140975	NOS2A
7413	-	4874	C/T	0	393340	rs8111423	Human NCBI Build 35	19	56952166	FPRL1
7415	-	3562	C/T	0	393344	rs8177655	Human NCBI Build 35	10	6055125	IL15RA
7416	-	2036	C/T	0	393353	rs868265	Human NCBI Build 35	9	87351433	DAPK1
7418	-	2125	C/T	0	393356	rs880769	Human NCBI Build 35	5	149135070	PPARGC1B
7419	-	2117	C/T	0	393357	rs884808	Human NCBI Build 35	1	239979480	AKT3-SDCCAG8
7420	-	5319	C/T	1	393364	rs925738	Human NCBI Build 35	2	239977509	HDAC4
7421	-	5074	C/T	1	393365	rs9259269	Human NCBI Build 35	6	29965944	HLA-H-HLA-G
7422	-	1169	C/T	0	393367	rs9277464	Human NCBI Build 35	6	33161330	HLA-DPB1
7423	-	2557	C/T	1	393370	rs9304712	Human NCBI Build 35	19	56617331	SIGLEC10
7424	-	3868	C/T	1	393371	rs9313472	Human NCBI Build 35	5	169120866	DOCK2
7425	-	3885	C/T	0	393377	rs944068	Human NCBI Build 35	9	37001386	PAX5

7426	-	4908	C/T	1	393379	rs944714	Human NCBI Build 35	10	6515163	PRKCQ	
7427	-	874	C/T	1	393380	rs949963	Human NCBI Build 35	2	102228304	IL1R1	
7428	-	6315	C/T	0	393381	rs9518	Human NCBI Build 35	18	75391014		
ENSG00000186783-NFATC1-ENSG00000198662											
7429	-	2582	C/T	0	393383	rs956409	Human NCBI Build 35	1	161518457	PBX1	
7430	-	2613	C/T	1	393386	rs9620115	Human NCBI Build 35	22	41834166	BIK	
7431	-	272	C/T	0	393392	rs978436	Human NCBI Build 35	3	106712239	ALCAM	
7432	-	1411	C/T	0	393398	rs999146	Human NCBI Build 35	18	65702326	CD226	
7433	-	5370	C/T	0	393401	rs10048926	Human NCBI Build 35	3	126562870	ZNF148	
7435	-	1659	C/T	0	393406	rs1017860	Human NCBI Build 35	18	75273194	NFATC1	
7436	-	3291	C/T	0	393407	rs10193032	Human NCBI Build 35	2	73963267	STAMBP	
7437	-	5981	C/T	0	393410	rs1024723	Human NCBI Build 35	7	76880799	PTPN12	
7438	-	121	C/T	0	393413	rs1027986	Human NCBI Build 35	8	57045025	LYN	
7439	-	81	C/T	1	393414	rs10279869	Human NCBI Build 35	7	157841906	PTPRN2	
7440	-	1171	C/T	0	393416	rs103294	Human NCBI Build 35	19	59489660	ENSG00000170866	
7441	-	609	C/T	0	393417	rs1034863	Human NCBI Build 35	19	5218751	PTPRS	
7442	-	275	C/T	0	393419	rs1035798	Human NCBI Build 35	19	18092345	PIK3R2-IL12RB1-MAST3	
7443	-	364	C/T	0	393421	rs10401504	Human NCBI Build 35	19	13976718	RFX1	
7444	-	24	C/T	0	393423	rs1041067	Human NCBI Build 35	1	157270200	SLAMF6	
7445	-	2487	C/T	0	393424	rs10412973	Human NCBI Build 35	19	5171900	PTPRS	
7447	-	5756	C/T	0	393430	rs10490342	Human NCBI Build 35	2	45827703	PRKCE	
7448	-	1228	C/T	0	393431	rs10492120	Human NCBI Build 35	12	12224619	LRP6-BCL2L14	
7449	-	2717	C/T	0	393436	rs10506604	Human NCBI Build 35	12	69386830	PTPRR	
7450	-	3769	C/T	1	393439	rs10512197	Human NCBI Build 35	9	89270029	SEMA4D	
7452	-	3370	C/T	0	393442	rs1052238	Human NCBI Build 35	1	195366282	PTPRC	
7453	-	471	C/T	0	393447	rs10746820	Human NCBI Build 35	9	87452241	DAPK1	
7454	-	6361	C/T	1	393453	rs10800309	Human NCBI Build 35	1	158285213	FCGR2A	
7455	-	5284	C/T	0	393456	rs10814232	Human NCBI Build 35	9	35357861	UNC13B-ENSG00000196186	
7456	-	5447	C/T	0	393458	rs10845568	Human NCBI Build 35	12	12556513	DUSP16	
7457	-	589	C/T	0	393464	rs10949714	Human NCBI Build 35	7	157609910	PTPRN2	
7458	-	6176	C/T	0	393465	rs10958713	Human NCBI Build 35	8	42299873	IKBKB	
7459	-	191	C/T	0	393466	rs10977144	Human NCBI Build 35	9	8464233	PTPRD	
7461	-	4110	C/T	0	393472	rs11118131	Human NCBI Build 35	1	204149591	none	
7462	-	2616	C/T	0	393473	rs1114047	Human NCBI Build 35	1	218258353	DUSP10	
7463	-	1125	C/T	1	393477	rs11188660	Human NCBI Build 35	10	97947314	BLNK	
7464	-	1227	C/T	0	393481	rs1126618	Human NCBI Build 35	1	203686075	C4BPA	
7465	-	1976	C/T	0	393485	rs11548	Human NCBI Build 35	5	150387976	TNIP1-GPX3	
7466	-	1	C/T	0	393486	rs11551840	Human NCBI Build 35	4	155890922	FGG	
7467	-	454	C/T	0	393488	rs11590627	Human NCBI Build 35	1	43668213	PTPRF	
7468	-	4893	C/T	0	393489	rs11616958	Human NCBI Build 35	13	23071049	TNFRSF19	
7469	-	4398	C/T	0	393493	rs11717612	Human NCBI Build 35	3	37711867	ITGA9	
7470	-	2452	C/T	0	393494	rs11744988	Human NCBI Build 35	5	42510453	GHR	
7471	-	5288	C/T	1	393495	rs11778246	Human NCBI Build 35	8	79868027	IL7	
7472	-	1637	C/T	0	393496	rs11808756	Human NCBI Build 35	1	203422747	PIGR-IL20	
7473	-	1648	C/T	0	393498	rs11900589	Human NCBI Build 35	2	239714587	HDAC4	
7474	-	4668	C/T	0	393500	rs11934755	Human NCBI Build 35	4	48085590	TEC	
7475	-	107	C/T	0	393501	rs1194998	Human NCBI Build 35	5	146079827	PPP2R2B	
7476	-	6024	C/T	0	393505	rs12067543	Human NCBI Build 35	1	117288661	IGSF2	
7478	-	5985	C/T	0	393514	rs12422687	Human NCBI Build 35	12	105606012	RFX4	

7479	-	3635	C/T	0	393516	rs12459238	Human	NCBI	Build	35	19	16454359	CALR3
7480	-	633	C/T	0	393523	rs12625238	Human	NCBI	Build	35	20	40268036	PTPRT
7481	-	1249	C/T	1	393527	rs12698138	Human	NCBI	Build	35	7	157385079	PTPRN2
7482	-	3246	C/T	1	393532	rs12971165	Human	NCBI	Build	35	12	56111637	
ENSG00000179912-INHBC-ENSG00000198357													
7483	-	987	C/T	0	393533	rs12984043	Human	NCBI	Build	35	19	10533493	CDKN2D-ENSG00000129347
7484	-	2773	C/T	0	393535	rs1304738	Human	NCBI	Build	35	12	15397908	PTPRO
7485	-	2578	C/T	0	393538	rs13117878	Human	NCBI	Build	35	4	142956827	IL15
7486	-	2287	C/T	0	393543	rs132622	Human	NCBI	Build	35	22	34864968	APOL3
7487	-	2914	C/T	0	393544	rs132656	Human	NCBI	Build	35	22	34882266	APOL3
7488	-	3284	C/T	1	393552	rs1360741	Human	NCBI	Build	35	7	79891681	CD36
7489	-	2158	C/T	0	393554	rs1367088	Human	NCBI	Build	35	8	27318112	PTK2B
7490	-	1791	C/T	0	393557	rs1399180	Human	NCBI	Build	35	10	8138725	GATA3-ENSG00000197308
7491	-	4583	C/T	0	393558	rs1405530	Human	NCBI	Build	35	6	112204758	FYN
7492	-	6234	C/T	0	393559	rs1409986	Human	NCBI	Build	35	1	71043519	PTGER3
7493	-	307	C/T	1	393565	rs1444888	Human	NCBI	Build	35	5	38623217	LIFR
7494	-	3945	C/T	0	393567	rs1467288	Human	NCBI	Build	35	17	31413531	CCL18
7495	-	4628	C/T	0	393569	rs1471121	Human	NCBI	Build	35	2	160853809	ITGB6
7496	-	5687	C/T	0	393572	rs1475525	Human	NCBI	Build	35	9	87361775	DAPK1
7497	-	638	C/T	1	393575	rs1530389	Human	NCBI	Build	35	18	7840717	PTPRM
7498	-	1019	C/T	0	393577	rs1546713	Human	NCBI	Build	35	15	97289389	IGF1R
7499	-	6236	C/T	0	393579	rs1553316	Human	NCBI	Build	35	5	156412087	HAVCR1
7500	-	5015	C/T	0	393585	rs1571344	Human	NCBI	Build	35	1	204059323	none
7501	-	6472	C/T	1	393589	rs161031	Human	NCBI	Build	35	5	146139096	PPP2R2B
7502	-	2755	C/T	1	393592	rs164288	Human	NCBI	Build	35	1	157417546	SLAMF1
7503	-	3450	C/T	0	393595	rs16858808	Human	NCBI	Build	35	2	218854438	IL8RA
7504	-	271	C/T	0	393597	rs16871473	Human	NCBI	Build	35	5	35120404	PRLR
7505	-	4219	C/T	1	393602	rs174402	Human	NCBI	Build	35	6	112031606	C6orf4
7507	-	1580	C/T	0	393612	rs181997	Human	NCBI	Build	35	6	33008696	HLA-DMB
7508	-	2252	C/T	0	393619	rs1873423	Human	NCBI	Build	35	16	23878178	PRKCB1
7509	-	3963	C/T	0	393620	rs1875478	Human	NCBI	Build	35	5	169382623	DOCK2
7510	-	832	C/T	0	393623	rs1887415	Human	NCBI	Build	35	6	137560931	IFNGR1-ENSG00000146394
7511	-	5563	C/T	0	393624	rs1893217	Human	NCBI	Build	35	18	12799340	PTPN2
7512	-	586	C/T	0	393627	rs1933437	Human	NCBI	Build	35	13	27522294	FLT3
7513	-	600	C/T	0	393630	rs1984311	Human	NCBI	Build	35	3	37801849	ITGA9
7514	-	5293	C/T	0	393632	rs1993553	Human	NCBI	Build	35	6	6231853	F13A1
7515	-	1419	C/T	0	393639	rs2015086	Human	NCBI	Build	35	17	31415730	CCL18
7516	-	5565	C/T	0	393640	rs2020902	Human	NCBI	Build	35	1	15579666	CASP9
7518	-	1111	C/T	0	393653	rs2070970	Human	NCBI	Build	35	11	59618559	MS4A2
7519	-	3240	C/T	0	393654	rs2071368	Human	NCBI	Build	35	5	149772984	CD74
7520	-	1810	C/T	1	393656	rs2072496	Human	NCBI	Build	35	19	17807054	INSL3
7521	-	5410	C/T	1	393657	rs208220	Human	NCBI	Build	35	20	40878397	PTPRT
7522	-	2102	C/T	0	393658	rs2084428	Human	NCBI	Build	35	2	46218053	PRKCE
7523	-	1306	C/T	0	393660	rs2115819	Human	NCBI	Build	35	10	45221095	ALOX5
7524	-	1079	C/T	0	393661	rs2132847	Human	NCBI	Build	35	4	140960577	MGST2
7525	-	4302	C/T	0	393665	rs2159377	Human	NCBI	Build	35	X	12697170	TLR8
7526	-	4752	C/T	0	393671	rs2227031	Human	NCBI	Build	35	X	103830185	IL1RAPL2
7527	-	4900	C/T	0	393672	rs2227611	Human	NCBI	Build	35	1	170607124	SERPINC1
7528	-	88	C/T	0	393675	rs2230344	Human	NCBI	Build	35	3	99733676	GPR15

7529	-	556	C/T	0	393679	rs2234185	Human NCBI Build 35	6	43005052	TNRC5-ENSG00000171611
7530	-	2952	C/T	1	393683	rs2241049	Human NCBI Build 35	22	15962234	IL17R
7531	-	4631	C/T	0	393684	rs2243204	Human NCBI Build 35	5	132027393	IL13
7533	-	1944	C/T	0	393686	rs2250246	Human NCBI Build 35	12	6423277	VAMP1-TNFRSF7
7534	-	1318	C/T	0	393687	rs2250333	Human NCBI Build 35	17	4588818	CXCL16-ZMYND15
7535	-	3735	C/T	0	393688	rs2252459	Human NCBI Build 35	3	106729462	ALCAM
7536	-	1460	C/T	1	393696	rs2274617	Human NCBI Build 35	1	143024965	ITGA10
7537	-	3697	C/T	0	393703	rs228272	Human NCBI Build 35	17	34160546	PSMB3-ENSG00000056661
7538	-	5525	C/T	1	393708	rs228840	Human NCBI Build 35	20	49504665	NFATC2
7539	-	4335	C/T	0	393713	rs2291188	Human NCBI Build 35	2	239752431	HDAC4
7540	-	1241	C/T	1	393714	rs2291427	Human NCBI Build 35	10	45256230	ALOX5
7541	-	3539	C/T	0	393715	rs2292243	Human NCBI Build 35	9	33318812	NFX1-ENSG00000086065
7542	-	3933	C/T	0	393717	rs2293117	Human NCBI Build 35	15	97296236	IGF1R
7543	-	3604	C/T	0	393718	rs2295261	Human NCBI Build 35	6	47344839	TNFRSF21
7544	-	3608	C/T	1	393721	rs2299686	Human NCBI Build 35	20	42708415	ADA
7545	-	2392	C/T	0	393723	rs2301464	Human NCBI Build 35	6	112136677	FYN
7546	-	3530	C/T	0	393726	rs231726	Human NCBI Build 35	2	204566372	CTLA4
7547	-	4156	C/T	0	393728	rs2343912	Human NCBI Build 35	3	32420093	ENSG00000153551
7548	-	6258	C/T	1	393736	rs2481955	Human NCBI Build 35	13	27481581	FLT3
7549	-	5943	C/T	0	393739	rs2503006	Human NCBI Build 35	1	29382686	PTPRU-ENSG00000116353
7550	-	5049	C/T	0	393741	rs2523608	Human NCBI Build 35	6	31430538	HLA-B
7551	-	2004	C/T	0	393742	rs2542714	Human NCBI Build 35	5	39258184	FYB
7552	-	1995	C/T	0	393743	rs2549003	Human NCBI Build 35	5	131857196	IRF1
7555	-	3296	C/T	1	393749	rs260705	Human NCBI Build 35	2	109029958	EDAR
7556	-	6192	C/T	0	393752	rs2636957	Human NCBI Build 35	16	24009089	PRKCB1
7557	-	2409	C/T	1	393755	rs2681408	Human NCBI Build 35	3	123266673	CD86
7558	-	1061	C/T	0	393756	rs2692620	Human NCBI Build 35	3	120748830	CD80
7559	-	5278	C/T	1	393757	rs2707209	Human NCBI Build 35	12	6775525	CD4
7560	-	2189	C/T	0	393759	rs2734871	Human NCBI Build 35	2	136703605	ENSG00000121966
7561	-	4483	C/T	1	393760	rs2737191	Human NCBI Build 35	9	117542269	TLR4
7562	-	2511	C/T	0	393761	rs2760532	Human NCBI Build 35	1	189279448	RGS1
7563	-	4329	C/T	0	393764	rs2780923	Human NCBI Build 35	1	39913497	ENSG00000116985
7564	-	2356	C/T	0	393774	rs2838734	Human NCBI Build 35	21	45154168	ITGB2
7565	-	4382	C/T	1	393776	rs2849380	Human NCBI Build 35	18	59130340	BCL2
7566	-	1770	C/T	1	393782	rs2903289	Human NCBI Build 35	4	78887247	CXCL13
7567	-	5150	C/T	1	393784	rs294179	Human NCBI Build 35	1	22720234	C1QG-C1QB
7568	-	2194	C/T	0	393795	rs3027649	Human NCBI Build 35	X	100409622	TIMM8A-BTK
7569	-	482	C/T	0	393796	rs303212	Human NCBI Build 35	10	91151335	IFIT1
7570	-	6239	C/T	0	393801	rs312462	Human NCBI Build 35	1	1183580	ENSG00000078808-TNFRSF18-TNFRSF4
7571	-	3564	C/T	1	393802	rs3128494	Human NCBI Build 35	9	87542131	DAPK1
7572	-	5851	C/T	0	393805	rs3134063	Human NCBI Build 35	8	120028838	TNFRSF11B
7573	-	1635	C/T	0	393807	rs3136626	Human NCBI Build 35	10	6041022	IL15RA
7574	-	3138	C/T	0	393812	rs3181088	Human NCBI Build 35	1	100910729	VCAM1
7575	-	4870	C/T	0	393816	rs3212741	Human NCBI Build 35	19	17812178	INSL3
7576	-	4192	C/T	0	393817	rs323562	Human NCBI Build 35	5	40888917	CARD6
7577	-	1163	C/T	0	393819	rs331458	Human NCBI Build 35	11	36478382	TRAF6
7578	-	4614	C/T	1	393822	rs333948	Human NCBI Build 35	1	110182634	CSF1
7579	-	999	C/T	0	393823	rs333968	Human NCBI Build 35	1	110172562	CSF1
7580	-	170	C/T	0	393825	rs355689	Human NCBI Build 35	4	78864976	CXCL13

7581	-	6053	C/T	0	393828	rs3744951	Human NCBI Build 35	18	59076960	BCL2
7582	-	163	C/T	0	393831	rs3749107	Human NCBI Build 35	2	108998292	EDAR
7583	-	4996	C/T	0	393833	rs3749741	Human NCBI Build 35	5	39237825	FYB
7584	-	4089	C/T	0	393834	rs3750537	Human NCBI Build 35	9	87513285	DAPK1
7585	-	5433	C/T	0	393840	rs3756103	Human NCBI Build 35	4	185758606	IRF2
7586	-	298	C/T	0	393842	rs3758163	Human NCBI Build 35	9	36901573	PAX5
7587	-	5058	C/T	0	393845	rs3764765	Human NCBI Build 35	X	104799108	IL1RAPL2
7588	-	370	C/T	1	393846	rs3767365	Human NCBI Build 35	1	161520296	PBX1
7589	-	6288	C/T	0	393847	rs3771863	Human NCBI Build 35	2	75331369	TACR1
7590	-	6203	C/T	0	393849	rs3775173	Human NCBI Build 35	4	87312046	MAPK10
7591	-	5789	C/T	0	393850	rs3777908	Human NCBI Build 35	6	111980345	C6orf4
7592	-	2760	C/T	0	393857	rs3785380	Human NCBI Build 35	16	24134241	PRKCB1
7594	-	4487	C/T	0	393861	rs3792783	Human NCBI Build 35	5	150435925	TNIP1
7595	-	6477	C/T	1	393862	rs3792785	Human NCBI Build 35	5	150431843	TNIP1
7596	-	2319	C/T	0	393866	rs3795326	Human NCBI Build 35	1	157279429	SLAMF6
7597	-	2833	C/T	0	393867	rs379863	Human NCBI Build 35	20	42694108	ADA
7598	-	2111	C/T	0	393868	rs3804475	Human NCBI Build 35	6	6567321 LY86	
7599	-	5540	C/T	0	393869	rs3805184	Human NCBI Build 35	4	47979163	TXK-TEC
7600	-	5110	C/T	0	393871	rs3806339	Human NCBI Build 35	1	89447156	GBP5
7601	-	2785	C/T	0	393872	rs3810926	Human NCBI Build 35	9	113339454	RGS3
7602	-	2283	C/T	0	393873	rs3813728	Human NCBI Build 35	12	7132711 ENSG00000159403	
7603	-	6317	C/T	0	393876	rs3823193	Human NCBI Build 35	6	6114217 F13A1	
7604	-	6293	C/T	1	393877	rs3825258	Human NCBI Build 35	12	12170662	LRP6-BCL2L14
7605	-	2559	C/T	0	393879	rs3847800	Human NCBI Build 35	12	93048881	PLXNC1
7606	-	3926	C/T	0	393882	rs385254	Human NCBI Build 35	3	139917856	PIK3CB
7607	-	2690	C/T	0	393884	rs3866743	Human NCBI Build 35	14	63703075	SYNE2-ESR2
7608	-	762	C/T	0	393889	rs3917429	Human NCBI Build 35	1	166427603	SELE
7609	-	953	C/T	0	393890	rs3917740	Human NCBI Build 35	1	166310924	SELP
7610	-	3596	C/T	0	393892	rs3924519	Human NCBI Build 35	8	23060574	TNFRSF10D-ENSG00000147457
7611	-	3115	C/T	1	393895	rs403018	Human NCBI Build 35	16	24059121	PRKCB1
7612	-	1862	C/T	0	393897	rs4109293	Human NCBI Build 35	10	71403327	AMID
7613	-	535	C/T	0	393898	rs4129680	Human NCBI Build 35	9	89310826	SEMA4D
7614	-	3719	C/T	0	393901	rs4237162	Human NCBI Build 35	9	5516124 PDCD1LG2	
7615	-	6525	C/T	1	393903	rs4304675	Human NCBI Build 35	10	129765225	PTPRE
7616	-	4231	C/T	0	393905	rs4353229	Human NCBI Build 35	10	115479579	CASP7
7617	-	2080	C/T	1	393906	rs4358188	Human NCBI Build 35	20	36380262	BPI
7618	-	5594	C/T	0	393908	rs4409447	Human NCBI Build 35	9	8492387 PTPRD	
7619	-	3912	C/T	0	393911	rs4468690	Human NCBI Build 35	17	7881479 ALOX15B	
7620	-	4549	C/T	1	393912	rs4512021	Human NCBI Build 35	4	77311586	CXCL11-ENSG00000169253
7621	-	5899	C/T	0	393914	rs4534095	Human NCBI Build 35	8	27260515	PTK2B-ENSG00000197825
7622	-	215	C/T	0	393917	rs4607478	Human NCBI Build 35	6	6096601 F13A1	
7623	-	4184	C/T	0	393918	rs4630205	Human NCBI Build 35	10	91082686	IFIT3-LIPA
7624	-	2180	C/T	0	393924	rs4688268	Human NCBI Build 35	3	61645177	PTPRG
7625	-	583	C/T	0	393925	rs4705120	Human NCBI Build 35	5	146112172	PPP2R2B
7626	-	926	C/T	0	393927	rs4713166	Human NCBI Build 35	6	28580635	GPX6
7627	-	1716	C/T	0	393929	rs4723740	Human NCBI Build 35	7	38112844	TRGV9
7628	-	1824	C/T	0	393930	rs4724231	Human NCBI Build 35	7	43415454	STK17A
7629	-	4511	C/T	1	393931	rs4728142	Human NCBI Build 35	7	128167918	IRF5
7630	-	3883	C/T	1	393932	rs4740372	Human NCBI Build 35	9	130705293	ABL1

7631	-	5165	C/T	1	393933	rs4746937	Human NCBI Build 35	10	71384543	COL13A1-AMID
7632	-	2258	C/T	0	393935	rs4763783	Human NCBI Build 35	12	12148402	BCL2L14
7633	-	1071	C/T	1	393936	rs4764191	Human NCBI Build 35	12	15451463	PTPRO
7634	-	2418	C/T	1	393937	rs4779656	Human NCBI Build 35	15	32111895	AVEN
7635	-	2157	C/T	0	393938	rs4787327	Human NCBI Build 35	16	24020933	PRKCB1
7636	-	2689	C/T	0	393942	rs4821401	Human NCBI Build 35	22	20539126	MAPK1
7637	-	4200	C/T	0	393943	rs4821568	Human NCBI Build 35	22	35640976	CSF2RB
7638	-	4770	C/T	0	393947	rs4852708	Human NCBI Build 35	2	70975597	CD207
7639	-	1464	C/T	0	393950	rs4891790	Human NCBI Build 35	18	65741638	CD226
7640	-	2340	C/T	0	393953	rs4936770	Human NCBI Build 35	11	122434085	HSPA8
7641	-	425	C/T	1	393958	rs4953285	Human NCBI Build 35	2	46031925	PRKCE
7642	-	1302	C/T	1	393960	rs4986931	Human NCBI Build 35	1	222326321	EPHX1
7643	-	2467	C/T	0	393961	rs500766	Human NCBI Build 35	10	6590596	PRKCQ
7644	-	400	C/T	1	393964	rs520540	Human NCBI Build 35	11	102214635	MMP3
7645	-	13	C/T	0	393965	rs527004	Human NCBI Build 35	3	120751802	CD80
7646	-	525	C/T	0	393966	rs537160	Human NCBI Build 35	11	65411969	
FOSL1-FIBP-ENSG00000175602-CTSW-ENSG00000197847										
7647	-	617	C/T	0	393970	rs565798	Human NCBI Build 35	18	8125770	PTPRM
7648	-	5001	C/T	0	393972	rs5743289	Human NCBI Build 35	16	49314275	CARD15
7649	-	4644	C/T	0	393980	rs5962297	Human NCBI Build 35	X	104789158	IL1RAPL2
7650	-	939	C/T	0	393982	rs596397	Human NCBI Build 35	11	104315827	CASP4
7651	-	1844	C/T	1	393987	rs6016004	Human NCBI Build 35	20	34654572	TGIF2-SLA2
7652	-	5945	C/T	0	393990	rs605148	Human NCBI Build 35	3	61793365	PTPRG
7653	-	2506	C/T	0	393993	rs610308	Human NCBI Build 35	19	54069131	PPP1R15A
7654	-	1487	C/T	0	393994	rs6111988	Human NCBI Build 35	20	1848961	PTPNS1
7655	-	927	C/T	0	393996	rs6130062	Human NCBI Build 35	20	40223090	PTPRT
7657	-	5539	C/T	0	394000	rs6426881	Human NCBI Build 35	1	161548384	PBX1
7658	-	3273	C/T	0	394002	rs6459875	Human NCBI Build 35	7	157685617	PTPRN2
7659	-	779	C/T	0	394003	rs6461796	Human NCBI Build 35	7	2844436	CARD11
7660	-	4703	C/T	1	394007	rs6478107	Human NCBI Build 35	9	114637759	ENSG00000181634
7661	-	2675	C/T	0	394008	rs6487550	Human NCBI Build 35	12	9057044	KLRG1
7662	-	396	C/T	0	394010	rs6538447	Human NCBI Build 35	12	92599357	CRADD
7663	-	4624	C/T	1	394011	rs6544874	Human NCBI Build 35	2	46286036	PRKCE
7664	-	2223	C/T	0	394014	rs656715	Human NCBI Build 35	10	6560555	PRKCQ
7665	-	1775	C/T	0	394015	rs656801	Human NCBI Build 35	1	204466038	CD34
7666	-	4482	C/T	1	394016	rs6570102	Human NCBI Build 35	6	137149291	MAP3K5
7667	-	4858	C/T	0	394019	rs6602705	Human NCBI Build 35	10	6527434	PRKCQ
7668	-	3405	C/T	0	394021	rs6658406	Human NCBI Build 35	1	232355516	ENSG00000143669
7670	-	86	C/T	1	394024	rs66782	Human NCBI Build 35	5	39227051	FYB
7671	-	110	C/T	1	394026	rs6684310	Human NCBI Build 35	1	161536892	PBX1
7672	-	6267	C/T	0	394027	rs6686551	Human NCBI Build 35	1	117285215	IGSF2
7673	-	3968	C/T	1	394029	rs6690037	Human NCBI Build 35	1	203652224	C4BPB
7674	-	1320	C/T	0	394030	rs669661	Human NCBI Build 35	11	56904751	PRG3
7675	-	3551	C/T	0	394032	rs6711770	Human NCBI Build 35	2	160518268	LY75
7676	-	1948	C/T	1	394035	rs6731625	Human NCBI Build 35	2	152846120	STAM2
7678	-	64	C/T	0	394048	rs6883180	Human NCBI Build 35	5	41216128	C6
7679	-	5157	C/T	0	394049	rs6896011	Human NCBI Build 35	5	41208186	C6
7681	-	5311	C/T	0	394053	rs6919828	Human NCBI Build 35	6	47302576	TNFRSF21
7682	-	1305	C/T	0	394055	rs6926666	Human NCBI Build 35	6	47386744	TNFRSF21

7683	-	5583	C/T	0	394057	rs6947877	Human NCBI Build 35	7	2832618	CARD11	
7684	-	3402	C/T	0	394068	rs7036061	Human NCBI Build 35	9	35203538	UNC13B	
7685	-	681	C/T	0	394071	rs712842	Human NCBI Build 35	7	101534173	ENSG00000160999	
7686	-	2038	C/T	0	394076	rs723877	Human NCBI Build 35	19	46548726		
ENSG00000123810-ENSG00000188054-TGFB1											
7687	-	872	C/T	0	394078	rs7251802	Human NCBI Build 35	19	5175470	PTPRS	
7689	-	2318	C/T	0	394081	rs726656	Human NCBI Build 35	9	114776002	TNFSF8	
7690	-	5276	C/T	0	394082	rs7296806	Human NCBI Build 35	12	93099026	PLXNC1	
7691	-	2668	C/T	0	394087	rs7359950	Human NCBI Build 35	19	44455605	IL28A	
7693	-	1576	C/T	1	394091	rs741625	Human NCBI Build 35	12	105485577	RFX4	
7694	-	4934	C/T	1	394093	rs745986	Human NCBI Build 35	10	45198914	ALOX5	
7696	-	2570	C/T	0	394095	rs751114	Human NCBI Build 35	18	46455461	MAPK4	
7697	-	186	C/T	1	394096	rs7515714	Human NCBI Build 35	1	166439387	SELE	
7698	-	468	C/T	1	394099	rs754301	Human NCBI Build 35	5	43452031	CCL28	
7699	-	2164	C/T	1	394100	rs7552167	Human NCBI Build 35	1	24263949	IL28RA	
7700	-	672	C/T	0	394102	rs7555835	Human NCBI Build 35	1	161369438	PBX1-ENSG00000197613	
7701	-	3541	C/T	0	394106	rs7596956	Human NCBI Build 35	2	219977864	PTPRN-DNAJB2	
7702	-	374	C/T	0	394112	rs7693	Human NCBI Build 35	14	103093457	BAG5	
7703	-	4229	C/T	1	394116	rs7739273	Human NCBI Build 35	6	33866043	LEMD2-MLN	
7704	-	2632	C/T	1	394118	rs7760247	Human NCBI Build 35	6	135582862	MYB	
7705	-	2523	C/T	1	394119	rs7761118	Human NCBI Build 35	6	36176281	MAPK13-MAPK14	
7706	-	3072	C/T	0	394122	rs7862325	Human NCBI Build 35	9	114646691	ENSG00000181634	
7707	-	6246	C/T	0	394123	rs7864816	Human NCBI Build 35	9	113316444	RGS3	
7708	-	4964	C/T	0	394124	rs7872008	Human NCBI Build 35	9	8457002	PTPRD	
7709	-	278	C/T	0	394129	rs795602	Human NCBI Build 35	4	140939537	MGST2	
7710	-	1352	C/T	0	394131	rs7975791	Human NCBI Build 35	12	47699753	PRKAG1-MLL2	
7711	-	1078	C/T	0	394133	rs8036601	Human NCBI Build 35	15	89116502	BLM	
7712	-	5317	C/T	0	394136	rs8060368	Human NCBI Build 35	16	27319915	IL21R	
7713	-	43	C/T	0	394140	rs8110944	Human NCBI Build 35	19	56601633	SIGLEC10	
7714	-	5430	C/T	1	394147	rs8770	Human NCBI Build 35	6	170804163	PDCD2-TBP	
7715	-	5130	C/T	0	394152	rs888989	Human NCBI Build 35	5	150411223	TNIP1	
7716	-	3390	C/T	0	394153	rs892117	Human NCBI Build 35	19	45403173	MAP3K10	
7717	-	4312	C/T	0	394154	rs893316	Human NCBI Build 35	18	46420554	MAPK4	
7718	-	4497	C/T	1	394155	rs907806	Human NCBI Build 35	15	97162404	IGF1R	
7719	-	314	C/T	1	394156	rs908831	Human NCBI Build 35	9	137098379	C9orf86-TRAF2	
7720	-	897	C/T	0	394159	rs925736	Human NCBI Build 35	2	240039566	HDAC4	
7722	-	3738	C/T	0	394164	rs9311835	Human NCBI Build 35	3	62019648	PTPRG	
7723	-	449	C/T	0	394176	rs9442947	Human NCBI Build 35	6	74463698	CD109	
7724	-	2763	C/T	0	394178	rs9473039	Human NCBI Build 35	6	47328664	TNFRSF21	
7725	-	852	C/T	0	394179	rs9482851	Human NCBI Build 35	6	128335327	PTPRK	
7726	-	713	C/T	1	394182	rs9510787	Human NCBI Build 35	13	23103195	TNFRSF19	
7727	-	700	C/T	0	394183	rs951351	Human NCBI Build 35	17	42719806	ITGB3	
7728	-	602	C/T	0	394185	rs9562415	Human NCBI Build 35	13	42079024	TNFSF11	
7729	-	1633	C/T	0	394187	rs962928	Human NCBI Build 35	12	12544075	DUSP16	
7730	-	3841	C/T	1	394193	rs9808753	Human NCBI Build 35	21	33709182	IFNGR2	
7731	-	1059	C/T	0	394196	rs982294	Human NCBI Build 35	1	218279314	DUSP10	
7732	-	3372	C/T	0	394198	rs9828899	Human NCBI Build 35	3	112285715	PVRL3	
7733	-	2247	C/T	0	394201	rs9866754	Human NCBI Build 35	3	61555804	PTPRG	
7734	-	1066	C/T	0	394205	rs992595	Human NCBI Build 35	18	46378713	MAPK4	

7735	-	3308	C/T	0	394209	rs1003359	Human	NCBI	Build	35	6	28594801	GPX6
7736	-	461	C/T	0	394214	rs1012760	Human	NCBI	Build	35	5	38615082	LIFR
7737	-	1934	C/T	0	394215	rs1014306	Human	NCBI	Build	35	9	87387005	DAPK1
7738	-	1388	C/T	0	394216	rs1014952	Human	NCBI	Build	35	18	59701163	SERPINB2
7739	-	3959	C/T	1	394217	rs1015458	Human	NCBI	Build	35	2	239892906	HDAC4
7740	-	2067	C/T	0	394221	rs1020445	Human	NCBI	Build	35	2	46284926	PRKCE
7741	-	2818	C/T	0	394222	rs1025687	Human	NCBI	Build	35	18	46401791	MAPK4
7742	-	2357	C/T	0	394223	rs10271154	Human	NCBI	Build	35	19	60009251	
KIR2DS2-KIR2DS1-ENSG00000189013-KIR2DL4													
7743	-	2526	C/T	0	394224	rs1030176	Human	NCBI	Build	35	5	149155857	PPARGC1B
7744	-	41	C/T	1	394225	rs1031915	Human	NCBI	Build	35	5	146410036	PPP2R2B
7745	-	1265	C/T	0	394227	rs1041935	Human	NCBI	Build	35	1	233026898	LGALS8
7747	-	1255	C/T	0	394230	rs10455038	Human	NCBI	Build	35	5	122395975	PPIC
7748	-	1910	C/T	0	394234	rs10484074	Human	NCBI	Build	35	14	106074643	IGHA1
7749	-	3473	C/T	0	394237	rs10488142	Human	NCBI	Build	35	7	54970156	EGFR
7750	-	1630	C/T	1	394239	rs10489639	Human	NCBI	Build	35	1	157492600	CD48
7751	-	2082	C/T	0	394241	rs10490920	Human	NCBI	Build	35	10	89675623	ENSG00000171862
7752	-	1949	C/T	0	394245	rs10499061	Human	NCBI	Build	35	6	112288723	FYN
7753	-	6100	C/T	1	394263	rs10516781	Human	NCBI	Build	35	4	88028929	PTPN13
7754	-	6275	C/T	1	394269	rs1059513	Human	NCBI	Build	35	12	55775976	NAB2-STAT6
7756	-	949	C/T	0	394276	rs10879183	Human	NCBI	Build	35	12	69392041	PTPRR
7757	-	6480	C/T	1	394281	rs10999061	Human	NCBI	Build	35	10	71408345	AMID
7758	-	6423	C/T	0	394283	rs11057065	Human	NCBI	Build	35	12	8099511	FOXJ2-C3AR1
7759	-	6442	C/T	0	394284	rs11128731	Human	NCBI	Build	35	3	15034334	NR2C2
7760	-	6469	C/T	0	394285	rs11130660	Human	NCBI	Build	35	3	58590710	FAM3D-ENSG00000168309
7761	-	6444	C/T	0	394288	rs11217078	Human	NCBI	Build	35	11	118255531	BLR1
7762	-	6394	C/T	1	394291	rs1125465	Human	NCBI	Build	35	3	62009873	PTPRG
7763	-	6432	C/T	0	394293	rs11265909	Human	NCBI	Build	35	9	89307700	SEMA4D
7764	-	6455	C/T	1	394294	rs1131012	Human	NCBI	Build	35	17	59781521	PECAM1
7765	-	6475	C/T	0	394298	rs11569315	Human	NCBI	Build	35	20	44183831	ENSG00000101017
7766	-	6450	C/T	0	394305	rs1168975	Human	NCBI	Build	35	2	96235949	DUSP2
7767	-	6399	C/T	0	394309	rs11756545	Human	NCBI	Build	35	6	128855588	PTPRK
7768	-	6470	C/T	0	394310	rs11778166	Human	NCBI	Build	35	8	22985295	TNFRSF10B
7769	-	6481	C/T	0	394311	rs1178560	Human	NCBI	Build	35	17	3594209	ITGAE
7770	-	6430	C/T	0	394315	rs1182091	Human	NCBI	Build	35	5	169311794	DOCK2
7771	-	6471	C/T	0	394317	rs11914777	Human	NCBI	Build	35	3	32309012	CKLFSF8
7772	-	6353	C/T	0	394320	rs11995542	Human	NCBI	Build	35	8	27403288	EPHX2
7773	-	6377	C/T	0	394324	rs12067507	Human	NCBI	Build	35	1	57134532	C8B
7774	-	6351	C/T	0	394327	rs1214611	Human	NCBI	Build	35	1	164180762	CD3Z
7775	-	6367	C/T	0	394330	rs12262943	Human	NCBI	Build	35	10	97506434	ENTPD1
7776	-	5439	C/T	0	394331	rs12320259	Human	NCBI	Build	35	12	12191436	LRP6-BCL2L14
7777	-	6466	C/T	0	394337	rs12454650	Human	NCBI	Build	35	18	59018760	BCL2
7778	-	6484	C/T	1	394338	rs12457170	Human	NCBI	Build	35	18	58967816	BCL2
7779	-	6449	C/T	1	394339	rs12462812	Human	NCBI	Build	35	19	18370526	LRRC25
7780	-	6395	C/T	0	394340	rs1248671	Human	NCBI	Build	35	10	79273832	DLG5
7781	-	6491	C/T	0	394342	rs12530245	Human	NCBI	Build	35	6	136926343	MAP3K5
7782	-	6485	C/T	0	394345	rs12629304	Human	NCBI	Build	35	3	32343744	CKLFSF8
7783	-	6352	C/T	0	394348	rs12713632	Human	NCBI	Build	35	2	68306060	

ENSG00000115953-ENSG00000115946

7784	-	6385	C/T	0	394351	rs13009282	Human NCBI Build 35	2	68276129	ENSG00000115953
7785	-	6426	C/T	1	394352	rs13043	Human NCBI Build 35 3	139830686	FAIM	
7786	-	6392	C/T	0	394353	rs13118073	Human NCBI Build 35	4	47935203	TXK
7787	-	6441	C/T	1	394356	rs13184107	Human NCBI Build 35	5	55214733	IL31RA
7788	-	6422	C/T	0	394357	rs13218316	Human NCBI Build 35	6	112189727	FYN
7789	-	6461	C/T	1	394359	rs1326270	Human NCBI Build 35	1	195351343	PTPRC
7790	-	6401	C/T	1	394362	rs1327474	Human NCBI Build 35	6	137582768	IFNGR1
7791	-	6436	C/T	0	394363	rs1332180	Human NCBI Build 35	9	21403085	IFNA8
7792	-	217	C/T	0	394366	rs1343151	Human NCBI Build 35	1	67431150	IL23R
7794	-	6574	C/T	0	394375	rs1370436	Human NCBI Build 35	6	74581135	CD109
7795	-	6581	C/T	0	394380	rs1420106	Human NCBI Build 35	2	102493562	IL18RAP
7796	-	6585	C/T	1	394384	rs1437134	Human NCBI Build 35	16	68287927	NFAT5
7798	-	6593	C/T	0	394391	rs1494324	Human NCBI Build 35	1	111127883	CD53
7799	-	6594	C/T	0	394392	rs1495964	Human NCBI Build 35	1	67506839	IL12RB2
7800	-	6600	C/T	0	394397	rs1533476	Human NCBI Build 35	2	45892762	PRKCE
7801	-	6603	C/T	0	394399	rs1544653	Human NCBI Build 35	2	70966925	CD207
7802	-	6604	C/T	0	394400	rs155342	Human NCBI Build 35	5	169113487	DOCK2
7803	-	6608	C/T	0	394403	rs1573649	Human NCBI Build 35	6	32839236	HLA-DQB2
7804	-	6613	C/T	0	394408	rs16858806	Human NCBI Build 35	2	218854416	IL8RA
7805	-	6618	C/T	0	394413	rs1716	Human NCBI Build 35 17	3579585	GSG2-ITGAE	
7806	-	6622	C/T	1	394416	rs174398	Human NCBI Build 35	6	112026155	C6orf4
7807	-	6626	C/T	0	394419	rs1780355	Human NCBI Build 35	1	161313273	PBX1
7808	-	6629	C/T	0	394422	rs1799865	Human NCBI Build 35	Multiple	0	CCR2-CCR2
7809	-	6630	C/T	0	394423	rs1801274	Human NCBI Build 35	1	158292800	FCGR2A
7810	-	6639	C/T	0	394430	rs1867006	Human NCBI Build 35	12	69322657	PTPRR
7811	-	6641	C/T	0	394432	rs1867194	Human NCBI Build 35	3	107025125	CBLB
7812	-	6646	C/T	1	394436	rs1877447	Human NCBI Build 35	9	8711943	PTPRD
7813	-	6649	C/T	0	394438	rs1882545	Human NCBI Build 35	12	6755671	LAG3
7814	-	6653	C/T	0	394442	rs1892189	Human NCBI Build 35	10	97981862	BLNK
7815	-	6657	C/T	1	394446	rs1899940	Human NCBI Build 35	5	38597060	LIFR
7816	-	6661	C/T	0	394448	rs1942952	Human NCBI Build 35	18	8033347	PTPRM
7817	-	6664	C/T	0	394451	rs1956923	Human NCBI Build 35	14	24047807	CMA1
7818	-	6666	C/T	0	394453	rs1957528	Human NCBI Build 35	14	24177405	GZMB
7820	-	6670	C/T	0	394456	rs197465	Human NCBI Build 35	6	143121732	HIVEP2
7821	-	6677	C/T	0	394460	rs1996178	Human NCBI Build 35	6	332659	IRF4
7822	-	6678	C/T	0	394461	rs1996520	Human NCBI Build 35	3	61592725	PTPRG
7823	-	6680	C/T	0	394463	rs2010452	Human NCBI Build 35	3	37741319	ITGA9
7824	-	6688	C/T	1	394469	rs2028597	Human NCBI Build 35	3	107041527	CBLB
7825	-	6690	C/T	0	394471	rs2042296	Human NCBI Build 35	19	58990826	NALP12
7826	-	6695	C/T	0	394475	rs2053025	Human NCBI Build 35	5	133514399	TCF7
7827	-	6696	C/T	0	394476	rs2063724	Human NCBI Build 35	11	77810725	GAB2
7828	-	6697	C/T	0	394477	rs2067834	Human NCBI Build 35	14	63670161	SYNE2-ESR2
7829	-	6698	C/T	1	394478	rs2069657	Human NCBI Build 35	5	75953124	F2RL2-IQGAP2
7830	-	6699	C/T	0	394479	rs2070961	Human NCBI Build 35	16	28856974	CD19
7831	-	6700	C/T	0	394480	rs2071336	Human NCBI Build 35	16	11969175	TNFRSF17-ENSG00000122309
7832	-	6701	C/T	0	394481	rs2071541	Human NCBI Build 35	6	32920836	TAP1-PSMB8
7833	-	6702	C/T	0	394482	rs2071593	Human NCBI Build 35	6	31620778	ATP6V1G2-ENSG00000168593
7834	-	6705	C/T	0	394485	rs2074928	Human NCBI Build 35	19	44920719	CLC
7835	-	6706	C/T	0	394486	rs2075731	Human NCBI Build 35	Multiple	0	KIR2DS2-KIR2DS1

7836	-	6708	C/T	0	394487	rs2075732	Human NCBI Build 35	Multiple	0	KIR2DS2-KIR2DS1
7837	-	6709	C/T	1	394488	rs2075966	Human NCBI Build 35	6	111991461	C6orf4
7838	-	6710	C/T	0	394489	rs2076262	Human NCBI Build 35	6	136954910	MAP3K5
7839	-	6711	C/T	0	394490	rs210137	Human NCBI Build 35	6	33650456	BAK1
7840	-	6712	C/T	0	394491	rs2103868	Human NCBI Build 35	6	47338574	TNFRSF21
7841	-	6719	C/T	1	394497	rs2181135	Human NCBI Build 35	X	135471802	ARHGEF6-ENSG00000102245
7842	-	6721	C/T	1	394499	rs2226299	Human NCBI Build 35	21	33620794	IFNAR1
7843	-	6734	C/T	0	394508	rs2237061	Human NCBI Build 35	5	134940229	CXCL14
7844	-	6736	C/T	0	394509	rs2237258	Human NCBI Build 35	6	112112848	FYN
7845	-	6742	C/T	0	394514	rs2241384	Human NCBI Build 35	19	59541754	ENSG00000170858
7846	-	6745	C/T	1	394517	rs2243498	Human NCBI Build 35	21	33575536	IL10RB
7847	-	6748	C/T	0	394520	rs2262771	Human NCBI Build 35	4	47963876	TXK
7848	-	6751	C/T	1	394523	rs2271708	Human NCBI Build 35	5	40972298	C7
7850	-	6755	C/T	0	394527	rs2276403	Human NCBI Build 35	1	155630672	MNDA
7851	-	6760	C/T	1	394532	rs2281472	Human NCBI Build 35	14	23845686	CIDEB-LTB4R2
7852	-	6761	C/T	0	394533	rs2282921	Human NCBI Build 35	7	41511186	INHBA
7853	-	6762	C/T	1	394534	rs2284873	Human NCBI Build 35	2	162712470	DPP4
7854	-	6764	C/T	0	394536	rs2289512	Human NCBI Build 35	4	77454316	SCARB2
7855	-	6765	C/T	1	394537	rs2292391	Human NCBI Build 35	2	160584675	LY75
7856	-	6769	C/T	0	394540	rs2302688	Human NCBI Build 35	12	15564370	PTPRO
7857	-	6772	C/T	0	394543	rs2305150	Human NCBI Build 35	2	113505547	IL1F8
7858	-	6774	C/T	0	394544	rs2310992	Human NCBI Build 35	10	71493573	H2AFY2-AMID
7859	-	6779	C/T	1	394548	rs2352593	Human NCBI Build 35	4	48038695	TEC
7860	-	6781	C/T	0	394550	rs2361797	Human NCBI Build 35	19	59445355	LILRB5
7861	-	6782	C/T	0	394551	rs2378455	Human NCBI Build 35	1	218262888	DUSP10
7862	-	6785	C/T	0	394553	rs2385025	Human NCBI Build 35	1	232326268	ENSG00000143669
7863	-	6787	C/T	1	394555	rs2416810	Human NCBI Build 35	9	120864754	C5
7864	-	6793	C/T	0	394561	rs2470378	Human NCBI Build 35	12	69512747	PTPRR
7865	-	6796	C/T	0	394564	rs249537	Human NCBI Build 35	5	35125057	PRLR
7866	-	6797	C/T	0	394565	rs250092	Human NCBI Build 35	5	141958427	FGF1
7867	-	6800	C/T	0	394568	rs2523451	Human NCBI Build 35	6	31477130	MICA
7868	-	6805	C/T	0	394573	rs253854	Human NCBI Build 35	12	15531753	PTPRO
7869	-	6806	C/T	1	394574	rs2540	Human NCBI Build 35	1	233040957	LGALS8-ENSG00000119285
7870	-	6810	C/T	0	394578	rs2571375	Human NCBI Build 35	6	30053249	HCG9-HLA-G
7871	-	6812	C/T	1	394580	rs2584028	Human NCBI Build 35	12	69225335	PTPRB
7872	-	6816	C/T	0	394584	rs2614	Human NCBI Build 35	3	158643701	PTX3-VEPH1
7873	-	6818	C/T	0	394586	rs261752	Human NCBI Build 35	5	39364263	C9
7874	-	6820	C/T	0	394588	rs262882	Human NCBI Build 35	5	169083953	DOCK2
7875	-	6822	C/T	0	394590	rs2647394	Human NCBI Build 35	1	85442008	BCL10-ENSG00000162642
7876	-	6824	C/T	0	394592	rs2671272	Human NCBI Build 35	1	222321851	EPHX1
7877	-	6829	C/T	1	394597	rs2729719	Human NCBI Build 35	2	160539248	LY75
7878	-	6833	C/T	1	394600	rs2761437	Human NCBI Build 35	1	204311476	MCP
7879	-	6836	C/T	1	394603	rs2782641	Human NCBI Build 35	1	43682448	PTPRF
7880	-	6838	C/T	0	394605	rs2800775	Human NCBI Build 35	1	161368156	PBX1-ENSG00000197613
7881	-	6840	C/T	0	394607	rs2808630	Human NCBI Build 35	1	156493941	CRP
7882	-	6841	C/T	0	394608	rs2834158	Human NCBI Build 35	21	33539083	IFNAR2
7883	-	6844	C/T	0	394610	rs2853884	Human NCBI Build 35	22	30672867	YWHAH
7884	-	6845	C/T	0	394611	rs2854450	Human NCBI Build 35	1	222319312	EPHX1
7885	-	6850	C/T	0	394616	rs289838	Human NCBI Build 35	2	151948909	NMI

7886	-	6852	C/T	0	394618	rs290986	Human NCBI Build 35	9	90643091	SYK
7887	-	6854	C/T	1	394620	rs3024444	Human NCBI Build 35	6	6120173 F13A1	
7888	-	6856	C/T	0	394622	rs3024660	Human NCBI Build 35	16	27278659	IL4R
7889	-	6857	C/T	1	394623	rs3024896	Human NCBI Build 35	2	191722222	STAT4
7890	-	6859	C/T	0	394625	rs304449	Human NCBI Build 35	10	91166218	IFIT5
7891	-	6860	C/T	0	394626	rs30489	Human NCBI Build 35	5	133509366	TCF7
7892	-	6862	C/T	0	394627	rs3077	Human NCBI Build 35	6	33141000	HLA-DPA1
7893	-	6864	C/T	1	394629	rs3093009	Human NCBI Build 35	6	167519888	CCR6-ENSG00000187485
7894	-	6865	C/T	0	394630	rs3116496	Human NCBI Build 35	2	204420018	CD28
7895	-	6870	C/T	0	394634	rs3124238	Human NCBI Build 35	9	87475871	DAPK1
7897	-	6876	C/T	1	394639	rs3181115	Human NCBI Build 35	10	97618160	ENTPD1
7898	-	6877	C/T	0	394640	rs3181354	Human NCBI Build 35	9	114772727	TNFSF8
7899	-	6878	C/T	0	394641	rs3212247	Human NCBI Build 35	14	23879635	RIPK3
7900	-	6879	C/T	1	394642	rs3218295	Human NCBI Build 35	22	35857568	IL2RB
7901	-	6881	C/T	1	394644	rs34016	Human NCBI Build 35	5	141979150	FGF1
7902	-	6888	C/T	1	394649	rs357251	Human NCBI Build 35	5	38971909	OSMR-ENSG00000164327
7903	-	6889	C/T	0	394650	rs3732379	Human NCBI Build 35	3	39282260	CX3CR1
7904	-	6892	C/T	0	394652	rs3739578	Human NCBI Build 35	9	8310065	PTPRD
7905	-	6893	C/T	1	394653	rs3740720	Human NCBI Build 35	11	69731195	FADD
7906	-	6896	C/T	0	394655	rs3744483	Human NCBI Build 35	17	37719964	STAT5A-STAT3
7907	-	6903	C/T	0	394660	rs3752703	Human NCBI Build 35	12	69214883	PTPRB
7908	-	6904	C/T	0	394661	rs3753389	Human NCBI Build 35	1	157620226	CD244
7909	-	6905	C/T	1	394662	rs3753666	Human NCBI Build 35	1	222378305	
ENSG00000196187-ENSG00000143787										
7910	-	6906	C/T	0	394663	rs3755311	Human NCBI Build 35	2	191671709	STAT1
7911	-	6909	C/T	0	394666	rs3761846	Human NCBI Build 35	9	120769151	TRAF1
7912	-	6913	C/T	1	394670	rs3769683	Human NCBI Build 35	2	204404303	CD28
7913	-	6914	C/T	0	394671	rs3769823	Human NCBI Build 35	2	201948501	CASP8
7914	-	6917	C/T	0	394674	rs3775167	Human NCBI Build 35	4	87303320	MAPK10
7915	-	6920	C/T	0	394677	rs3776081	Human NCBI Build 35	5	149512300	PDGFRB
7917	-	6931	C/T	0	394688	rs3791428	Human NCBI Build 35	2	239776700	HDAC4
7918	-	6935	C/T	0	394691	rs3793825	Human NCBI Build 35	10	71357498	COL13A1-AMID
7919	-	6940	C/T	0	394694	rs3804251	Human NCBI Build 35	5	169654296	LCP2
7920	-	6943	C/T	1	394697	rs3806277	Human NCBI Build 35	1	65064951	JAK1
7921	-	6944	C/T	1	394698	rs3809676	Human NCBI Build 35	16	46053294	PHKB-ENSG00000129636
7922	-	6946	C/T	0	394700	rs3811630	Human NCBI Build 35	2	196863236	STK17B
7923	-	6948	C/T	0	394702	rs3816661	Human NCBI Build 35	15	71792653	ENSG00000103855
7924	-	6950	C/T	0	394704	rs3818346	Human NCBI Build 35	9	8511244	PTPRD
7925	-	6952	C/T	1	394706	rs3824400	Human NCBI Build 35	9	130763629	ABL1
7926	-	6955	C/T	1	394709	rs3845422	Human NCBI Build 35	1	177744628	MR1
7927	-	6958	C/T	1	394711	rs3849903	Human NCBI Build 35	9	33308588	NFX1-ENSG00000086065
7928	-	6959	C/T	0	394712	rs3849925	Human NCBI Build 35	9	36934717	PAX5
7929	-	6972	C/T	0	394724	rs3934594	Human NCBI Build 35	9	88840097	C9orf47
7931	-	6976	C/T	1	394728	rs4076201	Human NCBI Build 35	15	79359358	IL16
7932	-	6978	C/T	0	394730	rs411089	Human NCBI Build 35	1	155037898	CD1A
7933	-	6983	C/T	0	394734	rs4251424	Human NCBI Build 35	12	42440093	
ENSG00000198001-ENSG00000129317										
7934	-	6984	C/T	1	394735	rs4253755	Human NCBI Build 35	22	44935895	PPARA
7935	-	6985	C/T	0	394736	rs4312730	Human NCBI Build 35	4	48023361	TEC

7936	-	6987	C/T	0	394738	rs4327285	Human NCBI Build 35	20	40627042	PTPRT
7937	-	6990	C/T	0	394741	rs4401102	Human NCBI Build 35	17	53715836	MPO
7938	-	6991	C/T	1	394742	rs4416340	Human NCBI Build 35	3	126512569	ZNF148-ENSG00000169128
7939	-	7005	C/T	0	394754	rs4585986	Human NCBI Build 35	1	218294997	DUSP10
7940	-	7007	C/T	0	394755	rs4596504	Human NCBI Build 35	6	128538250	PTPRK
7941	-	7008	C/T	0	394756	rs4648022	Human NCBI Build 35	4	103853630	NFKB1
7942	-	7009	C/T	1	394757	rs4655692	Human NCBI Build 35	1	67403686	IL23R
7944	-	7013	C/T	0	394760	rs4673260	Human NCBI Build 35	2	204430993	CD28
7946	-	7016	C/T	0	394763	rs4682799	Human NCBI Build 35	3	45968610	CXCR6-FYC01
7947	-	7018	C/T	0	394765	rs4703508	Human NCBI Build 35	5	35224559	PRLR
7948	-	7024	C/T	0	394770	rs4750439	Human NCBI Build 35	10	6509330	PRKCQ
7949	-	7026	C/T	0	394772	rs4754	Human NCBI Build 35 4	89259871	SPP1	
7950	-	7030	C/T	0	394775	rs4778889	Human NCBI Build 35	15	79376050	IL16
7951	-	7034	C/T	0	394779	rs4798636	Human NCBI Build 35	18	8373862	PTPRM
7952	-	7037	C/T	1	394782	rs4826915	Human NCBI Build 35	X	104210970	IL1RAPL2
7953	-	7039	C/T	0	394783	rs4844106	Human NCBI Build 35	X	69139948	IGBP1
7954	-	7042	C/T	0	394786	rs4878104	Human NCBI Build 35	9	87422545	DAPK1
7955	-	7043	C/T	1	394787	rs4879806	Human NCBI Build 35	9	34565810	CNTFR
7956	-	7055	C/T	0	394798	rs4958881	Human NCBI Build 35	5	150430429	TNIP1
7957	-	7057	C/T	1	394800	rs4979928	Human NCBI Build 35	10	79290788	DLG5
7958	-	7063	C/T	0	394806	rs507445	Human NCBI Build 35	18	8086608	PTPRM
7959	-	7067	C/T	0	394810	rs5743612	Human NCBI Build 35	4	38622667	TLR1
7960	-	7068	C/T	0	394811	rs5746031	Human NCBI Build 35	1	12188281	TNFRSF1B
7961	-	7069	C/T	0	394812	rs5750113	Human NCBI Build 35	22	20544628	MAPK1
7962	-	7073	C/T	0	394815	rs585156	Human NCBI Build 35	2	45813406	PRKCE
7963	-	7074	C/T	0	394816	rs5917192	Human NCBI Build 35	X	104064565	IL1RAPL2
7964	-	7079	C/T	0	394820	rs6030548	Human NCBI Build 35	20	40952139	PTPRT
7965	-	7080	C/T	1	394821	rs6063	Human NCBI Build 35 4	155888482	FGG	
7966	-	7081	C/T	0	394822	rs6065565	Human NCBI Build 35	20	41071878	PTPRT
7967	-	7082	C/T	1	394823	rs6072869	Human NCBI Build 35	20	40832585	PTPRT
7968	-	7088	C/T	0	394828	rs6130141	Human NCBI Build 35	20	40526898	PTPRT
7969	-	7090	C/T	1	394830	rs620080	Human NCBI Build 35	11	104327387	CASP4
7970	-	7091	C/T	0	394831	rs627305	Human NCBI Build 35	1	232938692	EDARADD
7971	-	7092	C/T	0	394832	rs628777	Human NCBI Build 35	9	33305447	NFX1-ENSG00000086065
7972	-	7094	C/T	0	394833	rs636819	Human NCBI Build 35	10	6539612	PRKCQ
7973	-	7104	C/T	1	394841	rs652553	Human NCBI Build 35	1	57111643	C8B
7974	-	7109	C/T	0	394846	rs6598553	Human NCBI Build 35	15	97156732	IGF1R
7975	-	7110	C/T	0	394847	rs6601105	Human NCBI Build 35	5	179631160	MAPK9
7976	-	7111	C/T	1	394848	rs663695	Human NCBI Build 35	11	104324537	CASP4
7977	-	7112	C/T	1	394849	rs6665210	Human NCBI Build 35	1	143021867	ITGA10
7978	-	7115	C/T	1	394852	rs6675851	Human NCBI Build 35	1	240113535	AKT3
7980	-	7119	C/T	0	394856	rs6719779	Human NCBI Build 35	2	45985368	PRKCE
7981	-	7121	C/T	0	394858	rs6729733	Human NCBI Build 35	2	162732739	DPP4
7982	-	7122	C/T	0	394859	rs6729914	Human NCBI Build 35	2	220269021	INHA
7983	-	7131	C/T	0	394865	rs6763816	Human NCBI Build 35	3	173723780	TNFSF10
7984	-	7140	C/T	0	394873	rs6906021	Human NCBI Build 35	6	32734289	HLA-DQB1
7986	-	7143	C/T	0	394875	rs6916921	Human NCBI Build 35	6	31628405	ENSG00000168593
7987	-	7152	C/T	0	394883	rs7035431	Human NCBI Build 35	9	8585416	PTPRD
7988	-	7158	C/T	0	394888	rs7133464	Human NCBI Build 35	12	15462612	PTPRO

7989	-	7159	C/T	0	394889	rs714289	Human NCBI Build 35	6	33013789	HLA-DMB
7990	-	7161	C/T	0	394891	rs715891	Human NCBI Build 35	5	145966276	PPP2R2B
7991	-	7165	C/T	0	394895	rs7207017	Human NCBI Build 35	17	50834065	MMD
7992	-	7171	C/T	0	394899	rs7243985	Human NCBI Build 35	18	59140904	BCL2
7993	-	7174	C/T	0	394901	rs7276343	Human NCBI Build 35	21	41650303	FAM3B
7994	-	7176	C/T	1	394903	rs7311672	Human NCBI Build 35	12	7035375 C1S	
7995	-	7179	C/T	0	394906	rs7341312	Human NCBI Build 35	6	128391862	PTPRK
7996	-	7181	C/T	1	394908	rs735830	Human NCBI Build 35	16	3635355 DNASE1	
7997	-	7183	C/T	1	394910	rs739496	Human NCBI Build 35	12	110350379	ENSG00000111252
7998	-	7184	C/T	0	394911	rs742152	Human NCBI Build 35	22	36221249	CARD10
7999	-	7191	C/T	0	394916	rs7521521	Human NCBI Build 35	1	161469207	PBX1
8000	-	7200	C/T	0	394923	rs7574420	Human NCBI Build 35	2	160521307	LY75
8001	-	7201	C/T	1	394924	rs7576306	Human NCBI Build 35	2	201900034	CASP10
8003	-	7210	C/T	0	394931	rs7611893	Human NCBI Build 35	3	32295296	CKLFSF8
8004	-	7214	C/T	0	394934	rs7636734	Human NCBI Build 35	3	37721855	ITGA9
8005	-	7218	C/T	0	394937	rs7668374	Human NCBI Build 35	4	87465689	MAPK10
8006	-	7222	C/T	0	394941	rs7718587	Human NCBI Build 35	5	146223189	PPP2R2B
8007	-	7226	C/T	0	394944	rs7745413	Human NCBI Build 35	6	30023448	HLA-A-HLA-G
8008	-	7228	C/T	0	394946	rs7755097	Human NCBI Build 35	6	136942169	MAP3K5
8010	-	7233	C/T	0	394951	rs7854303	Human NCBI Build 35	9	5547672 PDCD1LG2	
8011	-	7234	C/T	0	394952	rs7854413	Human NCBI Build 35	9	5547708 PDCD1LG2	
8012	-	7240	C/T	1	394955	rs7900939	Human NCBI Build 35	10	129712039	PTPRE
8013	-	7247	C/T	0	394960	rs7944380	Human NCBI Build 35	11	129253532	NFRKB
8014	-	7248	C/T	0	394961	rs795593	Human NCBI Build 35	4	140965607	MGST2
8015	-	7249	C/T	1	394962	rs7957531	Human NCBI Build 35	12	12222805	LRP6-BCL2L14
8016	-	7252	C/T	0	394965	rs8033712	Human NCBI Build 35	15	62079783	ENSG00000035664
8017	-	7254	C/T	0	394967	rs8078723	Human NCBI Build 35	17	35420405	CSF3
8018	-	7258	C/T	0	394970	rs8177388	Human NCBI Build 35	11	125672684	TIRAP
8019	-	7260	C/T	0	394972	rs834835	Human NCBI Build 35	2	157013653	NR4A2
8020	-	7262	C/T	0	394974	rs8510	Human NCBI Build 35	6	36186158	MAPK13-MAPK14
8021	-	7264	C/T	1	394975	rs851016	Human NCBI Build 35	6	36137277	MAPK13-MAPK14
8022	-	7265	C/T	1	394976	rs859706	Human NCBI Build 35	1	204350665	MCP
8023	-	7267	C/T	0	394978	rs863002	Human NCBI Build 35	1	155987993	FY-IGSF4B
8024	-	7268	C/T	1	394979	rs865094	Human NCBI Build 35	16	54074733	MMP2
8025	-	7273	C/T	0	394982	rs876687	Human NCBI Build 35	3	30700649	TGFBR2
8026	-	7276	C/T	0	394985	rs886441	Human NCBI Build 35	12	46549231	VDR
8027	-	7278	C/T	0	394987	rs890860	Human NCBI Build 35	19	7179165 INSR	
8028	-	7279	C/T	0	394988	rs895497	Human NCBI Build 35	2	113479806	IL1F6
8029	-	7280	C/T	1	394989	rs896011	Human NCBI Build 35	18	75274932	NFATC1
8030	-	7286	C/T	0	394994	rs916973	Human NCBI Build 35	12	111909823	OAS2
8031	-	7288	C/T	0	394996	rs9277463	Human NCBI Build 35	6	33161285	HLA-DPB1
8032	-	7291	C/T	0	394999	rs9292571	Human NCBI Build 35	5	35181120	PRLR
8033	-	7293	C/T	0	395001	rs9307020	Human NCBI Build 35	4	87901026	PTPN13
8034	-	7295	C/T	1	395003	rs9321103	Human NCBI Build 35	6	128330473	PTPRK
8035	-	7297	C/T	1	395005	rs9368326	Human NCBI Build 35	6	21698083	SOX4
8036	-	7307	C/T	0	395014	rs9494683	Human NCBI Build 35	6	137533794	IL22RA2
8037	-	7311	C/T	1	395016	rs953549	Human NCBI Build 35	6	128751186	PTPRK
8038	-	7312	C/T	1	395017	rs9550985	Human NCBI Build 35	13	23055969	TNFRSF19
8039	-	7317	C/T	0	395020	rs9657293	Human NCBI Build 35	8	27335140	PTK2B

8040	-	7320	C/T	1	395023	rs976355	Human NCBI Build 35	16	23843808	PRKCB1
8041	-	7321	C/T	0	395024	rs9817675	Human NCBI Build 35	3	12651113	RAF1-ENSG00000198383
8043	-	7324	C/T	0	395027	rs9837923	Human NCBI Build 35	3	32253969	CKLFSF8
8044	-	7326	C/T	0	395029	rs986831	Human NCBI Build 35	20	40594892	PTPRT
8045	-	7332	C/T	0	395035	rs9949924	Human NCBI Build 35	18	54571810	MALT1
8046	-	7333	C/T	0	395036	rs997550	Human NCBI Build 35	1	29400964	PTPRU
8047	-	7337	C/T	0	395040	rs1009399	Human NCBI Build 35	2	46178921	PRKCE
8048	-	7342	C/T	0	395045	rs10158201	Human NCBI Build 35	1	210943999	PTPN14
8049	-	7346	C/T	1	395048	rs1019856	Human NCBI Build 35	3	30671820	TGFBR2
8050	-	7351	C/T	0	395053	rs10264159	Human NCBI Build 35	7	43429076	STK17A
8051	-	7362	C/T	0	395064	rs10404156	Human NCBI Build 35	19	16454329	CALR3
8052	-	7363	C/T	0	395065	rs10404318	Human NCBI Build 35	19	7198627	INSR
8053	-	7364	C/T	1	395066	rs1041250	Human NCBI Build 35	1	204044210	CR2
8054	-	7367	C/T	1	395069	rs1044141	Human NCBI Build 35	7	43437520	STK17A
8055	-	7371	C/T	1	395073	rs10488883	Human NCBI Build 35	4	111305486	EGF
8056	-	7373	C/T	0	395075	rs10489627	Human NCBI Build 35	1	67491697	IL12RB2
8058	-	7381	C/T	1	395081	rs10490831	Human NCBI Build 35	3	106856526	CBLB
8059	-	7385	C/T	0	395085	rs10494424	Human NCBI Build 35	1	161526240	PBX1
8060	-	7388	C/T	1	395088	rs10497205	Human NCBI Build 35	2	160551455	LY75
8061	-	7395	C/T	0	395093	rs10503814	Human NCBI Build 35	8	27510492	CLU
8062	-	7396	C/T	0	395094	rs10506613	Human NCBI Build 35	12	69562282	PTPRR
8063	-	7398	C/T	0	395096	rs10510691	Human NCBI Build 35	3	37500765	ITGA9
8064	-	7401	C/T	0	395099	rs10512188	Human NCBI Build 35	9	87498768	DAPK1
8065	-	7402	C/T	0	395100	rs10512747	Human NCBI Build 35	5	40877498	CARD6
8066	-	7404	C/T	0	395102	rs1051461	Human NCBI Build 35	11	59993810	MS4A1
8067	-	7408	C/T	1	395106	rs1057190	Human NCBI Build 35	12	42434526	
ENSG00000198001-ENSG00000129317										
8068	-	7411	C/T	0	395109	rs10761395	Human NCBI Build 35	9	90722452	SYK
8069	-	7413	C/T	1	395111	rs10794486	Human NCBI Build 35	15	97119058	IGF1R
8070	-	7416	C/T	1	395114	rs10829321	Human NCBI Build 35	10	129741611	PTPRE
8071	-	7417	C/T	0	395115	rs10842665	Human NCBI Build 35	12	9031154	KLRG1
8072	-	7420	C/T	0	395118	rs10861147	Human NCBI Build 35	12	102832982	TRA1
8073	-	7425	C/T	1	395122	rs10940495	Human NCBI Build 35	5	55298417	IL6ST
8074	-	7426	C/T	1	395123	rs10941412	Human NCBI Build 35	5	38954915	OSMR
8075	-	7427	C/T	0	395124	rs10975179	Human NCBI Build 35	9	5549893	PDCD1LG2
8076	-	7430	C/T	1	395126	rs10977193	Human NCBI Build 35	9	8532019	PTPRD
8078	-	7436	C/T	0	395130	rs11118832	Human NCBI Build 35	1	218272766	DUSP10
8079	-	7439	C/T	0	395132	rs11120315	Human NCBI Build 35	1	210975092	PTPN14
8080	-	7443	C/T	0	395135	rs11178485	Human NCBI Build 35	12	69594501	PTPRR
8081	-	7450	C/T	1	395140	rs11259432	Human NCBI Build 35	10	6618634	PRKCQ
8082	-	7454	C/T	0	395143	rs1149795	Human NCBI Build 35	1	50684585	FAF1
8083	-	7458	C/T	0	395147	rs11585	Human NCBI Build 35	11	33684281	CD59
8084	-	7460	C/T	1	395149	rs11636443	Human NCBI Build 35	15	50106988	MAPK6
8085	-	7464	C/T	0	395153	rs11717893	Human NCBI Build 35	3	123289515	CD86
8086	-	7465	C/T	0	395154	rs11724347	Human NCBI Build 35	4	47923023	TXK
8087	-	7467	C/T	0	395156	rs11785328	Human NCBI Build 35	8	23128201	TNFRSF10A-ENSG00000147457
8088	-	7468	C/T	0	395157	rs11785599	Human NCBI Build 35	8	22948219	TNFRSF10B
8089	-	7472	C/T	0	395161	rs11942525	Human NCBI Build 35	4	48046870	TEC
8090	-	7481	C/T	0	395168	rs12068871	Human NCBI Build 35	1	232191447	ENSG00000143669

8092	-	7500	C/T	0	395181	rs1243963	Human NCBI Build 35	10	8152248	GATA3
8093	-	7504	C/T	1	395184	rs12509560	Human NCBI Build 35	4	88050574	PTPN13
8094	-	7507	C/T	0	395186	rs1256044	Human NCBI Build 35	14	63803780	ESR2
8095	-	7516	C/T	0	395193	rs12755958	Human NCBI Build 35	1	211039175	PTPN14
8096	-	7519	C/T	1	395196	rs13063765	Human NCBI Build 35	3	126577556	ZNF148
8097	-	7521	C/T	0	395197	rs13073764	Human NCBI Build 35	3	106753240	ALCAM
8098	-	7525	C/T	0	395199	rs13106911	Human NCBI Build 35	4	142973350	IL15
8099	-	7539	C/T	0	395210	rs1332190	Human NCBI Build 35	9	21428684	IFNA1
8100	-	7541	C/T	0	395212	rs13422553	Human NCBI Build 35	2	201970865	CASP8-ENSG00000196709
8102	-	7548	C/T	0	395218	rs1380839	Human NCBI Build 35	15	62099217	ENSG0000035664
8104	-	7552	C/T	0	395221	rs1398602	Human NCBI Build 35	12	69382102	PTPRR
8105	-	7556	C/T	0	395225	rs1426060	Human NCBI Build 35	8	75081425	LY96
8106	-	7560	C/T	0	395229	rs1468673	Human NCBI Build 35	9	120889444	C5
8107	-	7561	C/T	0	395230	rs1470383	Human NCBI Build 35	12	67493429	MDM2
8108	-	7562	C/T	0	395231	rs1492347	Human NCBI Build 35	12	87428441	KITLG
8109	-	7563	C/T	1	395232	rs1503854	Human NCBI Build 35	1	157412083	SLAMF1
8110	-	7569	C/T	1	395237	rs1547668	Human NCBI Build 35	6	33883424	MLN
8111	-	7583	C/T	0	395246	rs161042	Human NCBI Build 35	5	146166067	PPP2R2B
8112	-	7584	C/T	0	395247	rs1634506	Human NCBI Build 35	17	31449476	CCL4
8113	-	7587	C/T	0	395249	rs167634	Human NCBI Build 35	5	146272767	PPP2R2B
8114	-	7597	C/T	0	395256	rs171388	Human NCBI Build 35	4	78878704	CXCL13
8115	-	7608	C/T	0	395264	rs179012	Human NCBI Build 35	X	12661219	TLR7
8116	-	7609	C/T	0	395265	rs1797580	Human NCBI Build 35	4	75677267	AREG
8117	-	7614	C/T	0	395270	rs1860187	Human NCBI Build 35	17	29626323	CCL7
8118	-	7619	C/T	0	395275	rs1879612	Human NCBI Build 35	15	97216231	IGF1R
8119	-	7620	C/T	0	395276	rs1880101	Human NCBI Build 35	3	188934311	BCL6
8120	-	7624	C/T	0	395279	rs1888016	Human NCBI Build 35	9	36948317	PAX5
8121	-	7626	C/T	0	395280	rs1890995	Human NCBI Build 35	1	214993073	ENSG0000092969
8122	-	7630	C/T	0	395282	rs1892190	Human NCBI Build 35	10	97982008	BLNK
8123	-	7636	C/T	0	395287	rs1927911	Human NCBI Build 35	9	117549608	TLR4
8124	-	7638	C/T	0	395288	rs1927962	Human NCBI Build 35	9	35377166	UNC13B-ENSG00000196186
8126	-	7641	C/T	0	395291	rs1976194	Human NCBI Build 35	16	23968950	PRKCB1
8127	-	7649	C/T	1	395297	rs2032174	Human NCBI Build 35	18	12782954	PTPN2
8128	-	7651	C/T	0	395299	rs2038526	Human NCBI Build 35	20	48619056	PTPN1
8129	-	7658	C/T	1	395304	rs2072476	Human NCBI Build 35	2	102095382	IL1R2
8130	-	7661	C/T	0	395306	rs2080390	Human NCBI Build 35	2	70969881	CD207
8131	-	7662	C/T	0	395307	rs2082100	Human NCBI Build 35	8	27328277	PTK2B
8132	-	7663	C/T	0	395308	rs2095864	Human NCBI Build 35	1	51011618	FAF1
8133	-	7677	C/T	0	395318	rs2205944	Human NCBI Build 35	20	40578759	PTPRT
8134	-	7678	C/T	0	395319	rs2216307	Human NCBI Build 35	2	75304486	TACR1
8135	-	7682	C/T	0	395322	rs2227778	Human NCBI Build 35	5	76056823	F2R-ENSG00000183613
8136	-	7684	C/T	1	395324	rs2232337	Human NCBI Build 35	3	53864408	IL17RB
8137	-	7688	C/T	0	395327	rs2236876	Human NCBI Build 35	1	169749143	TNFSF18
8138	-	7690	C/T	0	395329	rs2239186	Human NCBI Build 35	12	46555677	VDR
8139	-	7691	C/T	0	395330	rs2239196	Human NCBI Build 35	12	110335887	ENSG00000111252
8140	-	7697	C/T	0	395336	rs2244529	Human NCBI Build 35	1	166318690	SELP
8141	-	7701	C/T	0	395339	rs2260010	Human NCBI Build 35	12	119927691	OASL
8143	-	7706	C/T	1	395343	rs2273642	Human NCBI Build 35	20	49566496	NFATC2
8144	-	7709	C/T	1	395346	rs2279240	Human NCBI Build 35	11	22653466	GAS2

8145	-	7711	C/T	0	395348	rs2282797	Human NCBI Build 35	5	141970825	FGF1
8146	-	7716	C/T	1	395350	rs2288404	Human NCBI Build 35	19	7075986	INSR
8147	-	7719	C/T	0	395353	rs2293624	Human NCBI Build 35	12	102847851	TRA1
8148	-	7727	C/T	1	395359	rs2297518	Human NCBI Build 35	17	23120724	NOS2A
8149	-	7728	C/T	0	395360	rs230154	Human NCBI Build 35	20	40541534	PTPRT
8150	-	7730	C/T	1	395361	rs230158	Human NCBI Build 35	20	40547754	PTPRT
8151	-	7731	C/T	0	395362	rs2302464	Human NCBI Build 35	4	15385521	ENSG00000109743
8152	-	7735	C/T	0	395365	rs2314342	Human NCBI Build 35	9	130736916	ABL1
8153	-	7736	C/T	0	395366	rs235549	Human NCBI Build 35	20	3557912	ATRN
8154	-	7738	C/T	1	395367	rs2356350	Human NCBI Build 35	2	191828044	STAT4
8155	-	7740	C/T	0	395368	rs2365936	Human NCBI Build 35	3	61623676	PTPRG
8156	-	7743	C/T	0	395370	rs2414906	Human NCBI Build 35	15	64513305	MAP2K1
8157	-	7744	C/T	0	395371	rs2421735	Human NCBI Build 35	1	71111895	PTGER3
8158	-	7746	C/T	0	395373	rs2430608	Human NCBI Build 35	12	12120154	BCL2L14
8159	-	7750	C/T	1	395376	rs2465810	Human NCBI Build 35	12	69301547	PTPRB
8160	-	7751	C/T	0	395377	rs250103	Human NCBI Build 35	5	141966795	FGF1
8161	-	7758	C/T	0	395381	rs253156	Human NCBI Build 35	12	9897687	ENSG00000110852
8162	-	7760	C/T	0	395382	rs2535694	Human NCBI Build 35	22	16533961	BCL2L13
8163	-	7761	C/T	0	395383	rs2551919	Human NCBI Build 35	2	208255889	CREB1
8164	-	7764	C/T	1	395385	rs26120	Human NCBI Build 35	5	149212406	PPARGC1B
8165	-	7769	C/T	0	395390	rs262880	Human NCBI Build 35	5	169086328	DOCK2
8167	-	7772	C/T	0	395393	rs2661686	Human NCBI Build 35	17	73728259	BIRC5-ENSG00000182802
8168	-	7773	C/T	0	395394	rs2666986	Human NCBI Build 35	2	160568278	LY75
8169	-	7778	C/T	0	395399	rs2684953	Human NCBI Build 35	15	32093023	AVEN
8170	-	7789	C/T	0	395407	rs2737139	Human NCBI Build 35	17	3613611	ITGAE
8171	-	7794	C/T	0	395410	rs2792247	Human NCBI Build 35	1	161352444	PBX1-ENSG00000197613
8172	-	7796	C/T	0	395411	rs2792249	Human NCBI Build 35	1	161335780	PBX1-ENSG00000197613
8173	-	7798	C/T	0	395413	rs2816306	Human NCBI Build 35	1	189279702	RGS1
8174	-	7800	C/T	1	395415	rs2838738	Human NCBI Build 35	21	45168854	ITGB2
8175	-	7802	C/T	0	395417	rs2839666	Human NCBI Build 35	10	31842788	TCF8
8176	-	7808	C/T	0	395421	rs2877545	Human NCBI Build 35	1	177755262	MR1
8177	-	7810	C/T	0	395423	rs2889	Human NCBI Build 35	8	22931854	TNFRSF10B-RHOBTB2
8178	-	7814	C/T	0	395427	rs3006927	Human NCBI Build 35	1	239983440	AKT3-SDCCAG8
8179	-	7819	C/T	0	395432	rs305082	Human NCBI Build 35	16	84494479	ENSG00000140968
8180	-	7821	C/T	0	395434	rs3111394	Human NCBI Build 35	2	160840614	ITGB6
8181	-	7824	C/T	0	395437	rs3124743	Human NCBI Build 35	10	115454161	CASP7
8182	-	7826	C/T	0	395438	rs3130055	Human NCBI Build 35	6	31605378	ATP6V1G2-ENSG00000189327
8183	-	7835	C/T	0	395446	rs3218312	Human NCBI Build 35	22	35854832	IL2RB
8184	-	7838	C/T	0	395449	rs333616	Human NCBI Build 35	8	56963551	LYN
8185	-	7842	C/T	0	395453	rs346070	Human NCBI Build 35	3	11278874	HRH1
8186	-	7843	C/T	0	395454	rs347144	Human NCBI Build 35	3	32452076	ENSG00000153551
8187	-	7844	C/T	0	395455	rs353619	Human NCBI Build 35	11	35131171	CD44
8188	-	7845	C/T	0	395456	rs355680	Human NCBI Build 35	4	78837440	CXCL13
8189	-	7847	C/T	1	395458	rs360063	Human NCBI Build 35	1	222343044	EPHX1-ENSG00000196187
8190	-	7854	C/T	0	395465	rs3737606	Human NCBI Build 35	1	29451572	PTPRU
8191	-	7865	C/T	0	395474	rs3757156	Human NCBI Build 35	6	136653804	ENSG0000029363
8192	-	7873	C/T	0	395480	rs3767368	Human NCBI Build 35	1	161507032	PBX1
8193	-	7874	C/T	0	395481	rs3768067	Human NCBI Build 35	1	232299791	ENSG00000143669
8194	-	7878	C/T	0	395485	rs3770704	Human NCBI Build 35	2	208264624	CREB1

8195	-	7880	C/T	0	395487	rs3771833	Human NCBI Build 35	2	75278592	TACR1
8196	-	7889	C/T	0	395495	rs3780151	Human NCBI Build 35	9	36916028	PAX5
8197	-	7892	C/T	1	395497	rs3781870	Human NCBI Build 35	11	107481660	CUL5
8198	-	7895	C/T	0	395499	rs3789184	Human NCBI Build 35	5	169611615	LCP2-ENSG00000181538
8199	-	7896	C/T	0	395500	rs3789599	Human NCBI Build 35	1	114035360	PTPN22-RSBN1
8200	-	7898	C/T	1	395502	rs3791242	Human NCBI Build 35	2	138572492	HNMT
8201	-	7900	C/T	0	395504	rs3795175	Human NCBI Build 35	X	114066235	IL13RA2
8202	-	7901	C/T	0	395505	rs3796867	Human NCBI Build 35	4	15494817	CD38
8204	-	7907	C/T	1	395509	rs380649	Human NCBI Build 35	5	41299606	C6
8205	-	7919	C/T	0	395517	rs3861953	Human NCBI Build 35	1	169912045	TNFSF4
8206	-	7920	C/T	0	395518	rs3886999	Human NCBI Build 35	20	3525062	ATRN
8207	-	7925	C/T	1	395523	rs4074080	Human NCBI Build 35	2	45927286	PRKCE
8208	-	7936	C/T	0	395530	rs4247362	Human NCBI Build 35	17	7885267	ALOX15B
8209	-	7937	C/T	0	395531	rs4251527	Human NCBI Build 35	12	42463130	ENSG00000198001
8210	-	7942	C/T	0	395535	rs4254438	Human NCBI Build 35	19	18256537	JUND
8211	-	7950	C/T	0	395540	rs4363475	Human NCBI Build 35	1	166421032	SELE
8212	-	7951	C/T	1	395541	rs449043	Human NCBI Build 35	21	41622280	FAM3B
8213	-	7953	C/T	1	395543	rs45479	Human NCBI Build 35	2	109060483	EDAR
8214	-	7956	C/T	1	395546	rs4629793	Human NCBI Build 35	7	121210201	PTPRZ1
8215	-	7957	C/T	0	395547	rs4648808	Human NCBI Build 35	1	2073098	PRKCZ
8216	-	7959	C/T	1	395549	rs4657616	Human NCBI Build 35	1	155784159	IFI16
8217	-	7961	C/T	0	395551	rs4716836	Human NCBI Build 35	7	157248059	PTPRN2-ENSG00000196590
8218	-	7962	C/T	0	395552	rs4738412	Human NCBI Build 35	8	75078223	LY96
8219	-	7971	C/T	0	395558	rs4769873	Human NCBI Build 35	13	30210689	ALOX5AP
8220	-	7974	C/T	0	395561	rs4798593	Human NCBI Build 35	18	7761132	PTPRM
8221	-	7975	C/T	0	395562	rs480992	Human NCBI Build 35	10	6593640	PRKCQ
8222	-	7981	C/T	0	395567	rs4891384	Human NCBI Build 35	18	65775534	CD226
8223	-	7984	C/T	1	395570	rs4937338	Human NCBI Build 35	11	127855956	ETS1
8224	-	7992	C/T	0	395578	rs4988390	Human NCBI Build 35	22	41840020	BIK-ENSG00000183614
8225	-	7996	C/T	0	395582	rs527590	Human NCBI Build 35	12	116244638	NOS1
8226	-	7997	C/T	0	395583	rs5368	Human NCBI Build 35	1	166428604	SELE
8227	-	7998	C/T	0	395584	rs5484	Human NCBI Build 35	12	21422704	IAPP-SLC01A2
8228	-	7999	C/T	0	395585	rs569898	Human NCBI Build 35	2	239070355	none
8229	-	8000	C/T	0	395586	rs5702	Human NCBI Build 35	1	71043451	PTGER3
8230	-	8004	C/T	0	395589	rs5743810	Human NCBI Build 35	4	38652916	TLR6
8231	-	8006	C/T	0	395591	rs5746451	Human NCBI Build 35	22	16500574	BCL2L13
8232	-	8007	C/T	0	395592	rs588655	Human NCBI Build 35	15	32034914	AVEN
8233	-	8014	C/T	0	395599	rs6016809	Human NCBI Build 35	20	40556248	PTPRT
8234	-	8017	C/T	0	395601	rs6021183	Human NCBI Build 35	20	49455556	NFATC2
8235	-	8019	C/T	0	395603	rs6072658	Human NCBI Build 35	20	40278039	PTPRT
8236	-	8020	C/T	0	395604	rs6073000	Human NCBI Build 35	20	41210863	PTPRT
8237	-	8030	C/T	1	395612	rs6459842	Human NCBI Build 35	7	157434033	PTPRN2
8238	-	8031	C/T	0	395613	rs6459863	Human NCBI Build 35	7	157639591	PTPRN2
8239	-	8033	C/T	1	395614	rs6499235	Human NCBI Build 35	16	68180017	NFAT5
8240	-	8035	C/T	0	395616	rs6523836	Human NCBI Build 35	X	104378091	IL1RAPL2
8241	-	8038	C/T	0	395619	rs6543062	Human NCBI Build 35	2	97805657	ZAP70
8242	-	8039	C/T	1	395620	rs6550005	Human NCBI Build 35	3	30625068	TGFBR2
8243	-	8042	C/T	0	395623	rs657813	Human NCBI Build 35	3	61758210	PTPRG
8244	-	8043	C/T	0	395624	rs6584028	Human NCBI Build 35	10	97548769	ENTPD1

8245	-	8050	C/T	0	395631	rs6672195	Human NCBI Build 35	1	240285584	AKT3
8246	-	8055	C/T	1	395635	rs677759	Human NCBI Build 35	3	61700818	PTPRG-ENSG00000168370
8247	-	8056	C/T	0	395636	rs6785634	Human NCBI Build 35	3	37565140	ITGA9
8248	-	8058	C/T	0	395638	rs6793085	Human NCBI Build 35	3	3117423	IL5RA
8249	-	8059	C/T	1	395639	rs6795621	Human NCBI Build 35	3	188929195	BCL6
8250	-	8062	C/T	0	395642	rs6861890	Human NCBI Build 35	5	55221121	IL31RA
8251	-	8066	C/T	1	395645	rs6891939	Human NCBI Build 35	5	35226742	PRLR
8252	-	8067	C/T	1	395646	rs6892205	Human NCBI Build 35	5	147455579	SPINK5
8253	-	8068	C/T	0	395647	rs6904753	Human NCBI Build 35	6	137015976	MAP3K5
8254	-	8070	C/T	1	395649	rs6911594	Human NCBI Build 35	6	6108087	F13A1
8255	-	8085	C/T	0	395663	rs7175701	Human NCBI Build 35	15	79345678	IL16
8256	-	8086	C/T	0	395664	rs7189692	Human NCBI Build 35	16	11584047	ENSG00000189067
8257	-	8088	C/T	0	395665	rs7193869	Human NCBI Build 35	16	27331002	IL21R
8258	-	8089	C/T	0	395666	rs7203982	Human NCBI Build 35	16	28862361	CD19
8259	-	8092	C/T	1	395669	rs721936	Human NCBI Build 35	9	87512703	DAPK1
8260	-	8093	C/T	0	395670	rs7236492	Human NCBI Build 35	18	75321604	NFATC1
8261	-	8098	C/T	0	395675	rs7395231	Human NCBI Build 35	11	48048265	PTPRJ
8262	-	8099	C/T	0	395676	rs7400079	Human NCBI Build 35	13	23118816	TNFRSF19
8263	-	8108	C/T	0	395683	rs7505939	Human NCBI Build 35	18	7987833	PTPRM
8264	-	8113	C/T	1	395687	rs7517644	Human NCBI Build 35	1	154530101	SPAP1
8265	-	8116	C/T	0	395690	rs753302	Human NCBI Build 35	2	239850391	HDAC4
8266	-	8118	C/T	0	395692	rs753572	Human NCBI Build 35	2	46113989	PRKCE
8267	-	8122	C/T	0	395696	rs7605560	Human NCBI Build 35	2	179146009	PRKRA
8268	-	8124	C/T	0	395697	rs7627622	Human NCBI Build 35	3	33825153	PDCD6IP
8269	-	8127	C/T	0	395699	rs763361	Human NCBI Build 35	18	65682622	CD226
8270	-	8131	C/T	1	395703	rs7685696	Human NCBI Build 35	4	77496689	SCARB2
8271	-	8136	C/T	0	395707	rs7722711	Human NCBI Build 35	5	75942607	F2RL2-IQGAP2
8273	-	8143	C/T	0	395713	rs779850	Human NCBI Build 35	5	43419155	CCL28
8274	-	8144	C/T	0	395714	rs7804098	Human NCBI Build 35	7	2832699	CARD11
8275	-	8153	C/T	1	395719	rs7939247	Human NCBI Build 35	11	127831260	ETS1
8276	-	8155	C/T	0	395721	rs7962764	Human NCBI Build 35	12	69483515	PTPRR
8277	-	8156	C/T	1	395722	rs8022428	Human NCBI Build 35	14	63633366	SYNE2-ESR2
8278	-	8158	C/T	0	395723	rs8028253	Human NCBI Build 35	15	32031512	AVEN
8280	-	8162	C/T	0	395727	rs8104320	Human NCBI Build 35	19	18507897	FKBP8
8282	-	8168	C/T	1	395732	rs8177654	Human NCBI Build 35	10	6055203	IL15RA
8283	-	8172	C/T	0	395736	rs861319	Human NCBI Build 35	1	155728990	PYHIN1
8284	-	8173	C/T	0	395737	rs862996	Human NCBI Build 35	1	155981682	FY-IGSF4B
8285	-	8174	C/T	0	395738	rs863171	Human NCBI Build 35	1	7926881	TNFRSF9
8286	-	8175	C/T	0	395739	rs864058	Human NCBI Build 35	X	12665687	TLR7
8287	-	8184	C/T	1	395746	rs917998	Human NCBI Build 35	2	102526674	IL18RAP
8288	-	8189	C/T	0	395748	rs922959	Human NCBI Build 35	11	48001207	PTPRJ
8290	-	8192	C/T	0	395751	rs9296355	Human NCBI Build 35	6	41171043	NFYA
8291	-	8200	C/T	0	395758	rs9328348	Human NCBI Build 35	6	6220931	F13A1
8292	-	8204	C/T	0	395760	rs9375548	Human NCBI Build 35	6	128441350	PTPRK
8293	-	8207	C/T	0	395763	rs940806	Human NCBI Build 35	7	55053954	EGFR
8294	-	8210	C/T	0	395765	rs9482858	Human NCBI Build 35	6	128392836	PTPRK
8295	-	8213	C/T	0	395767	rs9514828	Human NCBI Build 35	13	107719374	TNFSF13B
8296	-	8217	C/T	0	395770	rs959627	Human NCBI Build 35	5	146093685	PPP2R2B
8297	-	8222	C/T	0	395775	rs9817203	Human NCBI Build 35	3	191711050	IL1RAP

8298	-	8224	C/T	1	395777	rs983798	Human NCBI Build 35	12	15435198	PTPRO
8299	-	8226	C/T	0	395778	rs9839443	Human NCBI Build 35	3	62160215	PTPRG
8300	-	8232	C/T	0	395783	rs9887672	Human NCBI Build 35	X	104802300	IL1RAPL2
8302	-	8241	C/T	0	395791	rs1004819	Human NCBI Build 35	1	67382234	IL23R
8303	-	8244	C/T	1	395794	rs1010119	Human NCBI Build 35	5	35098874	PRLR
8304	-	8245	C/T	0	395795	rs10157379	Human NCBI Build 35	1	243931640	CIAS1
8305	-	8248	C/T	0	395797	rs10247026	Human NCBI Build 35	7	157730071	PTPRN2
8306	-	8252	C/T	0	395800	rs10409243	Human NCBI Build 35	19	10193988	EDG5
8307	-	8253	C/T	1	395801	rs10432228	Human NCBI Build 35	18	65719229	CD226
8308	-	8256	C/T	0	395803	rs10447139	Human NCBI Build 35	5	35136887	PRLR
8309	-	8257	C/T	1	395804	rs1046668	Human NCBI Build 35	2	152052078	TNFAIP6
8310	-	8264	C/T	1	395810	rs10491121	Human NCBI Build 35	17	31454449	CCL4
8311	-	8266	C/T	0	395812	rs10492323	Human NCBI Build 35	12	92594467	CRADD
8312	-	8272	C/T	0	395817	rs10502415	Human NCBI Build 35	18	12799561	PTPN2
8313	-	8277	C/T	1	395821	rs10506608	Human NCBI Build 35	12	69441647	PTPRR
8314	-	8282	C/T	1	395824	rs10509637	Human NCBI Build 35	10	93577712	TNKS2
8315	-	8284	C/T	0	395826	rs10511494	Human NCBI Build 35	9	8406196	PTPRD
8316	-	8285	C/T	1	395827	rs10511496	Human NCBI Build 35	9	8459809	PTPRD
8317	-	8287	C/T	0	395828	rs10511934	Human NCBI Build 35	9	36846268	PAX5
8318	-	8288	C/T	0	395829	rs10512687	Human NCBI Build 35	5	38617019	LIFR
8319	-	8294	C/T	0	395834	rs10753420	Human NCBI Build 35	1	222817974	none
8320	-	8297	C/T	0	395836	rs10765179	Human NCBI Build 35	10	129637733	PTPRE
8321	-	8300	C/T	0	395837	rs10771925	Human NCBI Build 35	12	9643997	KLRB1
8322	-	8304	C/T	0	395841	rs10796268	Human NCBI Build 35	10	6643923	PRKCQ
8323	-	8312	C/T	0	395847	rs10872328	Human NCBI Build 35	6	128377691	PTPRK
8324	-	8314	C/T	1	395849	rs108858	Human NCBI Build 35	3	138212583	ENSG00000174564
8325	-	8315	C/T	0	395850	rs10888690	Human NCBI Build 35	1	50672542	FAF1
8326	-	8317	C/T	0	395851	rs10890795	Human NCBI Build 35	11	107386090	CUL5
8327	-	8319	C/T	0	395853	rs10901281	Human NCBI Build 35	9	130674698	ABL1
8328	-	8337	C/T	0	395865	rs11188657	Human NCBI Build 35	10	97942032	BLNK
8329	-	8338	C/T	1	395866	rs11205748	Human NCBI Build 35	1	50812063	FAF1
8330	-	8339	C/T	0	395867	rs11205760	Human NCBI Build 35	1	50886351	FAF1
8331	-	8340	C/T	1	395868	rs11209026	Human NCBI Build 35	1	67417979	IL23R
8332	-	8342	C/T	0	395870	rs11421	Human NCBI Build 35	6	32115566	TNXB-CYP21A2-C4A
8333	-	8347	C/T	0	395875	rs11583394	Human NCBI Build 35	1	203357288	IL19-PIGR
8334	-	8349	C/T	0	395877	rs11688303	Human NCBI Build 35	2	128126474	GPR17-LIMS2
8335	-	8350	C/T	0	395878	rs11709670	Human NCBI Build 35	3	62214636	PTPRG
8336	-	8353	C/T	0	395881	rs11741953	Human NCBI Build 35	5	55303571	IL6ST
8337	-	8354	C/T	0	395882	rs11743187	Human NCBI Build 35	5	43303918	CCL28-ENSG00000177453
8338	-	8361	C/T	0	395888	rs1196475	Human NCBI Build 35	7	121243174	PTPRZ1
8339	-	8362	C/T	0	395889	rs11969650	Human NCBI Build 35	6	137013714	MAP3K5
8340	-	8363	C/T	1	395890	rs12012976	Human NCBI Build 35	X	104572722	IL1RAPL2
8341	-	8365	C/T	0	395892	rs12065210	Human NCBI Build 35	1	50654805	FAF1
8342	-	8368	C/T	0	395893	rs12086220	Human NCBI Build 35	1	116806264	CD58
8343	-	8377	C/T	0	395901	rs12423041	Human NCBI Build 35	12	110787566	ENSG00000089022
8344	-	8380	C/T	0	395904	rs12478709	Human NCBI Build 35	2	162989298	IFIH1
8345	-	8381	C/T	0	395905	rs12538371	Human NCBI Build 35	7	55010229	EGFR
8346	-	8384	C/T	0	395908	rs12607710	Human NCBI Build 35	18	12877485	PTPN2
8347	-	8390	C/T	0	395912	rs1264459	Human NCBI Build 35	6	30563899	HLA-E-ENSG00000178214

8348	-	8391	C/T	1	395913	rs1268524	Human NCBI Build 35	1	157283331	SLAMF6
8349	-	8393	C/T	1	395915	rs12769331	Human NCBI Build 35	10	129630658	PTPRE
8350	-	8394	C/T	1	395916	rs13010343	Human NCBI Build 35	2	191668951	STAT1
8352	-	8396	C/T	0	395918	rs13150561	Human NCBI Build 35	4	87987116	PTPN13
8353	-	8398	C/T	0	395920	rs1316489	Human NCBI Build 35	9	87357983	DAPK1
8354	-	8399	C/T	0	395921	rs13168551	Human NCBI Build 35	5	150442831	TNIP1
8355	-	8401	C/T	1	395922	rs1317639	Human NCBI Build 35	3	61544253	PTPRG
8357	-	8405	C/T	0	395926	rs132643	Human NCBI Build 35	22	34870070	APOL3
8358	-	8407	C/T	1	395928	rs1328918	Human NCBI Build 35	9	5097394	JAK2
8359	-	8411	C/T	0	395931	rs13385656	Human NCBI Build 35	2	111604865	BCL2L11
8360	-	8415	C/T	0	395935	rs1377382	Human NCBI Build 35	4	140966930	MGST2
8362	-	8434	C/T	0	395950	rs1474335	Human NCBI Build 35	2	73978116	STAMBP
8363	-	8439	C/T	1	395954	rs1495963	Human NCBI Build 35	1	67507340	IL12RB2
8364	-	8440	C/T	1	395955	rs1508394	Human NCBI Build 35	3	62088317	ID2B-PTPRG
8365	-	8450	C/T	0	395964	rs1562724	Human NCBI Build 35	18	75270559	NFATC1
8366	-	8451	C/T	0	395965	rs1566447	Human NCBI Build 35	9	8366477	PTPRD
8367	-	8458	C/T	1	395970	rs161036	Human NCBI Build 35	5	146146571	PPP2R2B
8368	-	8459	C/T	0	395971	rs1611732	Human NCBI Build 35	6	29938987	HLA-G
8369	-	8465	C/T	0	395975	rs16929093	Human NCBI Build 35	22	49012806	
ENSG00000188989-PLXNB2-MAPK11										
8370	-	8466	C/T	0	395976	rs16938324	Human NCBI Build 35	9	21177067	IFNA4
8371	-	8472	C/T	0	395981	rs1732877	Human NCBI Build 35	12	64885411	IRAK3
8372	-	8474	C/T	0	395983	rs1736867	Human NCBI Build 35	X	104363261	IL1RAPL2
8373	-	8478	C/T	0	395987	rs1780629	Human NCBI Build 35	20	36442880	LBP
8375	-	8496	C/T	0	396000	rs1864616	Human NCBI Build 35	3	30640232	TGFBR2
8376	-	8498	C/T	0	396001	rs1873458	Human NCBI Build 35	10	71463779	AMID
8377	-	8501	C/T	1	396003	rs1878808	Human NCBI Build 35	7	2793616	CARD11
8378	-	8502	C/T	0	396004	rs1886910	Human NCBI Build 35	1	89226231	GBP1
8379	-	8504	C/T	0	396006	rs1891146	Human NCBI Build 35	6	128795564	PTPRK
8380	-	8506	C/T	0	396007	rs1894447	Human NCBI Build 35	X	104219150	IL1RAPL2
8381	-	8507	C/T	0	396008	rs1905786	Human NCBI Build 35	8	120020873	TNFRSF11B
8382	-	8509	C/T	1	396010	rs1923949	Human NCBI Build 35	1	189279367	RGS1
8383	-	8514	C/T	1	396014	rs1956926	Human NCBI Build 35	14	24041507	CMA1
8384	-	8516	C/T	1	396015	rs1979671	Human NCBI Build 35	3	46249219	CCR3
8385	-	8518	C/T	0	396017	rs1984266	Human NCBI Build 35	1	57145116	C8B
8386	-	8519	C/T	0	396018	rs1986588	Human NCBI Build 35	7	157535260	PTPRN2
8387	-	8522	C/T	0	396021	rs2042237	Human NCBI Build 35	5	169367556	DOCK2
8389	-	8532	C/T	0	396029	rs2070022	Human NCBI Build 35	4	155862553	FGA
8390	-	8535	C/T	0	396031	rs2072379	Human NCBI Build 35	16	3678888	TRAP1
8391	-	8537	C/T	0	396033	rs2075109	Human NCBI Build 35	7	54993112	EGFR
8392	-	8545	C/T	0	396039	rs2107301	Human NCBI Build 35	12	46541837	VDR
8393	-	8546	C/T	0	396040	rs2120105	Human NCBI Build 35	3	107010625	CBLB
8394	-	8548	C/T	0	396042	rs2154430	Human NCBI Build 35	21	33532357	IFNAR2
8395	-	8550	C/T	0	396043	rs2154754	Human NCBI Build 35	11	76856346	PAK1
8396	-	8555	C/T	0	396046	rs2199937	Human NCBI Build 35	18	58978769	BCL2
8397	-	8565	C/T	0	396055	rs2229360	Human NCBI Build 35	10	8156085	GATA3
8398	-	8566	C/T	0	396056	rs2230524	Human NCBI Build 35	5	66514485	LY64
8399	-	8569	C/T	0	396059	rs2232618	Human NCBI Build 35	20	36435175	LBP
8400	-	8570	C/T	1	396060	rs2236338	Human NCBI Build 35	14	24170122	GZMB

8401	-	8571	C/T	0	396061	rs2241046	Human NCBI Build 35	22	15961025	IL17R
8402	-	8574	C/T	0	396064	rs2251746	Human NCBI Build 35	1	156085133	FCER1A-ENSG00000196266
8403	-	8578	C/T	0	396067	rs2271383	Human NCBI Build 35	2	160568369	LY75
8404	-	8580	C/T	0	396069	rs2274273	Human NCBI Build 35	14	54684389	DLG7-LGALS3
8405	-	8595	C/T	0	396079	rs2292387	Human NCBI Build 35	2	160560229	LY75
8406	-	8598	C/T	0	396081	rs2295257	Human NCBI Build 35	6	47381372	TNFRSF21
8407	-	8600	C/T	0	396083	rs2301271	Human NCBI Build 35	6	32833171	HLA-DQB2
8408	-	8603	C/T	0	396085	rs2308917	Human NCBI Build 35	6	33145452	HLA-DPA1
8409	-	8604	C/T	1	396086	rs2316709	Human NCBI Build 35	3	158632949	PTX3-VEPH1
8410	-	8607	C/T	1	396088	rs2322123	Human NCBI Build 35	17	11894232	MAP2K4
8411	-	8610	C/T	0	396090	rs2327743	Human NCBI Build 35	6	136950935	MAP3K5
8412	-	8622	C/T	0	396100	rs2470371	Human NCBI Build 35	12	69505955	PTPRR
8413	-	8624	C/T	0	396101	rs248156	Human NCBI Build 35	5	135322716	LECT2
8414	-	8625	C/T	0	396102	rs2488255	Human NCBI Build 35	1	204330136	MCP
8415	-	8626	C/T	0	396103	rs249907	Human NCBI Build 35	5	146131050	PPP2R2B
8416	-	8627	C/T	1	396104	rs249923	Human NCBI Build 35	5	141995573	FGF1
8417	-	8631	C/T	0	396106	rs2524070	Human NCBI Build 35	6	31352499	HLA-C
8418	-	8639	C/T	0	396112	rs263408	Human NCBI Build 35	3	10212297	IRAK2
8419	-	8643	C/T	0	396114	rs2647396	Human NCBI Build 35	1	85450451	BCL10
8421	-	8651	C/T	0	396122	rs2715442	Human NCBI Build 35	15	97230085	IGF1R
8422	-	8654	C/T	0	396125	rs2731148	Human NCBI Build 35	14	106171256	IGHA1
8423	-	8662	C/T	1	396132	rs2792251	Human NCBI Build 35	1	161273635	PBX1
8424	-	8667	C/T	0	396136	rs2855160	Human NCBI Build 35	9	130646795	ABL1
8425	-	8672	C/T	0	396139	rs290229	Human NCBI Build 35	9	90713968	SYK
8426	-	8679	C/T	0	396143	rs2984800	Human NCBI Build 35	1	164220683	CD3Z-ENSG00000198352
8427	-	8686	C/T	0	396148	rs3024436	Human NCBI Build 35	6	6141603 F13A1	
8428	-	8689	C/T	0	396151	rs3092043	Human NCBI Build 35	20	40847822	PTPRT
8429	-	8694	C/T	0	396155	rs31535	Human NCBI Build 35	5	135308451	LECT2-ENSG00000164616
8430	-	8698	C/T	0	396159	rs3181191	Human NCBI Build 35	4	110970141	CASP6-ENSG0000005059
8431	-	8707	C/T	0	396164	rs3213710	Human NCBI Build 35	4	15393590	ENSG00000109743
8432	-	8710	C/T	0	396167	rs322468	Human NCBI Build 35	5	145959816	PPP2R2B
8433	-	8717	C/T	0	396172	rs3733236	Human NCBI Build 35	4	77281177	CXCL9
8434	-	8721	C/T	0	396174	rs3737002	Human NCBI Build 35	1	204149168	none
8435	-	8724	C/T	0	396176	rs3740286	Human NCBI Build 35	10	90741320	ENSG00000026103
8436	-	8731	C/T	1	396183	rs3760275	Human NCBI Build 35	17	50855658	MMD
8437	-	8733	C/T	0	396185	rs3764795	Human NCBI Build 35	8	143919622	GML
8438	-	8745	C/T	0	396193	rs3773982	Human NCBI Build 35	3	191762754	IL1RAP
8439	-	8749	C/T	0	396196	rs3777134	Human NCBI Build 35	5	147478212	SPINK5
8440	-	8750	C/T	1	396197	rs3783581	Human NCBI Build 35	2	113253382	IL1A
8441	-	8753	C/T	0	396200	rs3794959	Human NCBI Build 35	18	8100805	PTPRM
8442	-	8759	C/T	0	396203	rs3805221	Human NCBI Build 35	5	41001075	C7
8443	-	8782	C/T	1	396219	rs3917254	Human NCBI Build 35	2	102235036	IL1R1
8444	-	8783	C/T	1	396220	rs3917769	Human NCBI Build 35	1	166304003	SELP
8445	-	8792	C/T	1	396226	rs4129008	Human NCBI Build 35	4	38597382	TLR10
8446	-	8795	C/T	1	396229	rs4151002	Human NCBI Build 35	11	36546789	RAG1
8447	-	8804	C/T	0	396235	rs4321629	Human NCBI Build 35	4	15408649	ENSG00000109743
8448	-	8809	C/T	0	396238	rs4426449	Human NCBI Build 35	18	58193797	TNFRSF11A
8449	-	8811	C/T	0	396240	rs4461456	Human NCBI Build 35	3	32460134	ENSG00000153551
8450	-	8812	C/T	0	396241	rs4463047	Human NCBI Build 35	4	155853138	FGB-FGA

8451	-	8818	C/T	1	396244	rs4506155	Human NCBI Build 35	7	157503457	PTPRN2
8453	-	8826	C/T	1	396250	rs4646077	Human NCBI Build 35	1	15572442	CASP9
8454	-	8829	C/T	0	396253	rs4671880	Human NCBI Build 35	2	68339667	ENSG00000115953
8455	-	8837	C/T	0	396259	rs4744516	Human NCBI Build 35	9	90707039	SYK
8456	-	8840	C/T	0	396261	rs4764886	Human NCBI Build 35	12	101326179	IGF1
8457	-	8843	C/T	1	396263	rs4798613	Human NCBI Build 35	18	8162328	PTPRM
8458	-	8844	C/T	0	396264	rs4798618	Human NCBI Build 35	18	8206997	PTPRM
8459	-	8851	C/T	0	396269	rs4844591	Human NCBI Build 35	1	203888688	DAF
8460	-	8853	C/T	1	396271	rs4852019	Human NCBI Build 35	2	239756876	HDAC4
8461	-	8855	C/T	0	396273	rs4896243	Human NCBI Build 35	6	137556483	IFNGR1-ENSG00000146394
8462	-	8860	C/T	1	396277	rs4938800	Human NCBI Build 35	11	119714596	ARHGEF12
8463	-	8870	C/T	1	396287	rs5030713	Human NCBI Build 35	9	117554523	TLR4
8464	-	8885	C/T	0	396296	rs5743372	Human NCBI Build 35	7	30238275	CARD4
8465	-	8887	C/T	0	396297	rs5743509	Human NCBI Build 35	20	36373728	BPI
8467	-	8892	C/T	1	396302	rs5962469	Human NCBI Build 35	X	104205390	IL1RAPL2
8468	-	8895	C/T	0	396305	rs6030239	Human NCBI Build 35	20	40500013	PTPRT
8469	-	8902	C/T	0	396310	rs6130136	Human NCBI Build 35	20	40514660	PTPRT
8470	-	8912	C/T	0	396319	rs6498224	Human NCBI Build 35	16	11576044	ENSG00000189067
8471	-	8915	C/T	0	396321	rs6519362	Human NCBI Build 35	22	41840520	BIK-ENSG00000183614
8472	-	8918	C/T	0	396324	rs6540844	Human NCBI Build 35	1	211068773	PTPN14
8473	-	8921	C/T	1	396327	rs658230	Human NCBI Build 35	10	6548569	PRKCQ
8474	-	8923	C/T	1	396329	rs6621881	Human NCBI Build 35	X	103977006	IL1RAPL2
8476	-	8929	C/T	1	396335	rs6691070	Human NCBI Build 35	1	214905154	ENSG00000092969
8477	-	8931	C/T	0	396337	rs6712381	Human NCBI Build 35	2	201939058	CASP8
8478	-	8935	C/T	0	396340	rs6734376	Human NCBI Build 35	2	151970175	NMI
8479	-	8944	C/T	0	396348	rs6900017	Human NCBI Build 35	6	43866463	VEGF
8480	-	8950	C/T	0	396353	rs6977343	Human NCBI Build 35	7	30234031	CARD4
8482	-	8956	C/T	0	396357	rs701848	Human NCBI Build 35	10	89716725	ENSG00000171862
8483	-	8961	C/T	0	396361	rs7070505	Human NCBI Build 35	10	129663964	PTPRE
8484	-	8972	C/T	1	396369	rs720321	Human NCBI Build 35	18	59033630	BCL2
8485	-	8974	C/T	0	396371	rs721412	Human NCBI Build 35	4	111305082	EGF
8486	-	8975	C/T	1	396372	rs7226991	Human NCBI Build 35	18	58139671	TNFRSF11A
8487	-	8978	C/T	0	396375	rs730171	Human NCBI Build 35	3	37575006	ITGA9
8488	-	8979	C/T	0	396376	rs7301769	Human NCBI Build 35	12	109633746	PPP1CC
8489	-	8986	C/T	0	396382	rs743562	Human NCBI Build 35	5	131900282	IL5
8490	-	8988	C/T	0	396383	rs7530511	Human NCBI Build 35	1	67397408	IL23R
8492	-	8994	C/T	0	396388	rs7562024	Human NCBI Build 35	2	191681027	STAT1
8493	-	8995	C/T	1	396389	rs7581914	Human NCBI Build 35	2	45990615	PRKCE
8494	-	8998	C/T	0	396392	rs759170	Human NCBI Build 35	7	54929581	EGFR
8495	-	9003	C/T	0	396396	rs765086	Human NCBI Build 35	X	123236485	SH2D1A-ODZ1
8496	-	9006	C/T	0	396398	rs7663941	Human NCBI Build 35	4	15462593	CD38
8497	-	9010	C/T	0	396402	rs7731587	Human NCBI Build 35	5	169422585	DOCK2
8498	-	9012	C/T	0	396404	rs7747030	Human NCBI Build 35	6	137100859	MAP3K5
8499	-	9014	C/T	1	396406	rs7766109	Human NCBI Build 35	6	6201832	F13A1
8501	-	9017	C/T	0	396409	rs7825750	Human NCBI Build 35	8	6867213	DEFA1
8502	-	9018	C/T	1	396410	rs7870226	Human NCBI Build 35	9	5520017	PDCD1LG2
8503	-	9021	C/T	0	396413	rs7895103	Human NCBI Build 35	10	129686948	PTPRE
8504	-	9022	C/T	1	396414	rs7906717	Human NCBI Build 35	10	31754660	TCF8
8505	-	9029	C/T	1	396421	rs7972757	Human NCBI Build 35	12	10437407	KLRC4

8506	-	9030	C/T	1	396422	rs7974346	Human NCBI Build 35	12	69428260	PTPRR
8507	-	9032	C/T	0	396424	rs8063316	Human NCBI Build 35	16	55981359	CX3CL1
8508	-	9036	C/T	0	396427	rs8090532	Human NCBI Build 35	18	59452093	SERPINB3
8509	-	9042	C/T	0	396431	rs8103483	Human NCBI Build 35	19	7096374	INSR
8510	-	9044	C/T	0	396432	rs8104439	Human NCBI Build 35	19	18507932	FKBP8
8511	-	9054	C/T	0	396440	rs875423	Human NCBI Build 35	3	62221462	PTPRG
8512	-	9071	C/T	1	396449	rs917727	Human NCBI Build 35	7	120612530	FAM3C
8513	-	9084	C/T	0	396458	rs9388629	Human NCBI Build 35	6	128708442	PTPRK
8514	-	9087	C/T	0	396461	rs940928	Human NCBI Build 35	2	108972982	EDAR
8515	-	9088	C/T	0	396462	rs9428576	Human NCBI Build 35	1	239988068	AKT3-SDCCAG8
8516	-	9103	C/T	1	396474	rs9826645	Human NCBI Build 35	3	62112123	PTPRG
8518	-	9107	C/T	0	396477	rs9842934	Human NCBI Build 35	3	62247119	PTPRG
8520	-	9122	C/T	0	396488	rs1007212	Human NCBI Build 35	15	97101441	IGF1R
8521	-	9127	C/T	0	396492	rs10161389	Human NCBI Build 35	12	92643727	CRADD
8522	-	9133	C/T	0	396496	rs1021692	Human NCBI Build 35	11	22721956	GAS2
8523	-	9135	C/T	1	396498	rs10411676	Human NCBI Build 35	19	7224991	INSR
8524	-	9138	C/T	0	396500	rs10484795	Human NCBI Build 35	6	137358523	IL20RA
8525	-	9139	C/T	0	396501	rs10484798	Human NCBI Build 35	6	137512449	IL22RA2
8526	-	9145	C/T	1	396505	rs10490777	Human NCBI Build 35	3	62005807	PTPRG
8527	-	9148	C/T	0	396507	rs10494421	Human NCBI Build 35	1	161470385	PBX1
8528	-	9150	C/T	1	396508	rs10494783	Human NCBI Build 35	1	195395318	PTPRC
8529	-	9153	C/T	0	396511	rs10498475	Human NCBI Build 35	14	54682233	DLG7-LGALS3
8530	-	9155	C/T	0	396513	rs10501322	Human NCBI Build 35	11	48069499	PTPRJ
8531	-	9157	C/T	0	396515	rs10505767	Human NCBI Build 35	12	12515508	DUSP16-LOH12CR1
8532	-	9159	C/T	0	396516	rs10507393	Human NCBI Build 35	13	30225521	ALOX5AP
8533	-	9161	C/T	0	396517	rs10507486	Human NCBI Build 35	13	40084501	FOXO1A
8534	-	9164	C/T	0	396520	rs10512263	Human NCBI Build 35	9	98965626	TGFBR1
8535	-	9165	C/T	0	396521	rs10512413	Human NCBI Build 35	9	130698429	ABL1
8536	-	9167	C/T	1	396523	rs10512781	Human NCBI Build 35	5	41270400	C6
8537	-	9170	C/T	0	396526	rs1051593	Human NCBI Build 35	11	59994567	MS4A1
8538	-	9176	C/T	1	396531	rs10738979	Human NCBI Build 35	9	36879325	PAX5
8539	-	9181	C/T	0	396535	rs10811537	Human NCBI Build 35	9	21398824	IFNA8
8540	-	9184	C/T	0	396538	rs10890800	Human NCBI Build 35	11	107409856	CUL5
8541	-	9186	C/T	0	396539	rs10893883	Human NCBI Build 35	11	127879923	ETS1
8542	-	9190	C/T	0	396543	rs10933931	Human NCBI Build 35	3	109270215	CD47
8543	-	9191	C/T	1	396544	rs10937439	Human NCBI Build 35	3	191776257	IL1RAP
8545	-	9197	C/T	0	396549	rs10991925	Human NCBI Build 35	9	91257195	NFIL3
8546	-	9200	C/T	0	396552	rs11033019	Human NCBI Build 35	11	35158386	CD44
8547	-	9205	C/T	0	396556	rs11205726	Human NCBI Build 35	1	50698078	FAF1
8548	-	9209	C/T	0	396558	rs11210888	Human NCBI Build 35	1	43745723	PTPRF
8549	-	9215	C/T	0	396563	rs11466650	Human NCBI Build 35	4	38599278	TLR10
8550	-	9217	C/T	0	396564	rs11466658	Human NCBI Build 35	4	38598205	TLR10
8551	-	9224	C/T	0	396568	rs11573949	Human NCBI Build 35	8	120004782	TNFRSF11B
8552	-	9230	C/T	0	396572	rs11587909	Human NCBI Build 35	1	50762820	FAF1
8553	-	9241	C/T	1	396580	rs11751266	Human NCBI Build 35	6	128745751	PTPRK
8554	-	9243	C/T	1	396582	rs11893841	Human NCBI Build 35	2	152824060	STAM2
8555	-	9246	C/T	0	396585	rs12001295	Human NCBI Build 35	9	5508260	PDCD1LG2
8556	-	9249	C/T	0	396588	rs12033535	Human NCBI Build 35	1	155069369	CD1C
8557	-	9256	C/T	0	396593	rs1212166	Human NCBI Build 35	4	87983207	PTPN13

8558	-	9263	C/T	0	396598	rs12204754	Human NCBI Build 35	6	137575713	IFNGR1
8559	-	9267	C/T	0	396602	rs12306807	Human NCBI Build 35	12	15363621	PTPRO
8560	-	9272	C/T	1	396604	rs12340431	Human NCBI Build 35	9	87414007	DAPK1
8561	-	9273	C/T	0	396605	rs12364480	Human NCBI Build 35	11	119870238	ARHGEF12-ENSG00000197316
8562	-	9274	C/T	0	396606	rs12434783	Human NCBI Build 35	14	63656640	SYNE2-ESR2
8563	-	9277	C/T	0	396607	rs12473396	Human NCBI Build 35	2	46008454	PRKCE
8564	-	9281	C/T	0	396610	rs12580224	Human NCBI Build 35	12	69372693	PTPRR
8565	-	9282	C/T	0	396611	rs12629204	Human NCBI Build 35	3	61695482	PTPRG
8566	-	9283	C/T	1	396612	rs12663543	Human NCBI Build 35	6	135559307	MYB
8567	-	9284	C/T	0	396613	rs1266828	Human NCBI Build 35	6	52216021	IL17F
8568	-	9285	C/T	0	396614	rs12678503	Human NCBI Build 35	8	16027542	MSR1
8569	-	9287	C/T	0	396616	rs1270629	Human NCBI Build 35	14	92716162	MOAP1-C14orf109
8570	-	9288	C/T	0	396617	rs12821887	Human NCBI Build 35	12	10445946	KLRC4
8571	-	9290	C/T	0	396618	rs1292627	Human NCBI Build 35	6	128815641	PTPRK
8572	-	9293	C/T	0	396621	rs1327575	Human NCBI Build 35	10	101942506	CHUK
8573	-	9295	C/T	0	396623	rs13332786	Human NCBI Build 35	16	45968704	ENSG00000129636
8574	-	9296	C/T	1	396624	rs1347068	Human NCBI Build 35	15	64513571	MAP2K1
8575	-	9297	C/T	0	396625	rs1379700	Human NCBI Build 35	1	240235443	AKT3
8576	-	9302	C/T	0	396629	rs1411479	Human NCBI Build 35	1	177738587	MR1
8577	-	9307	C/T	0	396632	rs1423001	Human NCBI Build 35	5	147430048	SPINK5
8578	-	9308	C/T	0	396633	rs1443614	Human NCBI Build 35	18	7835629	PTPRM
8579	-	9310	C/T	0	396634	rs1446519	Human NCBI Build 35	2	113538679	IL1F10-IL1F5
8580	-	9316	C/T	0	396640	rs1500336	Human NCBI Build 35	9	8396003	PTPRD
8581	-	9317	C/T	0	396641	rs1511723	Human NCBI Build 35	8	56965733	LYN
8582	-	9322	C/T	0	396645	rs1555498	Human NCBI Build 35	6	137367540	IL20RA
8583	-	9325	C/T	1	396647	rs1561261	Human NCBI Build 35	18	46395655	MAPK4
8584	-	9326	C/T	0	396648	rs1562303	Human NCBI Build 35	2	113498623	IL1F6-IL1F8
8587	-	9330	C/T	0	396652	rs158688	Human NCBI Build 35	9	90738409	SYK
8588	-	9333	C/T	0	396654	rs1681626	Human NCBI Build 35	11	47972972	PTPRJ
8589	-	9334	C/T	0	396655	rs1718067	Human NCBI Build 35	11	33716246	CD59-FBX03
8590	-	9337	C/T	1	396657	rs1800	Human NCBI Build 35	3	37780866	ITGA9
8591	-	9338	C/T	0	396658	rs1841957	Human NCBI Build 35	12	10453292	KLRC4
8592	-	9339	C/T	0	396659	rs1858878	Human NCBI Build 35	15	89081058	BLM
8593	-	9340	C/T	0	396660	rs1865761	Human NCBI Build 35	18	65690372	CD226
8594	-	9343	C/T	1	396662	rs1867828	Human NCBI Build 35	2	113484851	IL1F6
8595	-	9348	C/T	0	396667	rs192802	Human NCBI Build 35	11	13472770	PTH
8596	-	9349	C/T	0	396668	rs1941030	Human NCBI Build 35	11	59982334	MS4A1
8597	-	9353	C/T	0	396670	rs1956917	Human NCBI Build 35	14	24050332	CMA1
8598	-	9355	C/T	0	396672	rs1962589	Human NCBI Build 35	15	97154292	IGF1R
8599	-	9359	C/T	0	396676	rs1984547	Human NCBI Build 35	17	22987444	LGALS9
8600	-	9360	C/T	0	396677	rs1990525	Human NCBI Build 35	4	15097292	C1QTNF7
8601	-	9362	C/T	1	396679	rs1995830	Human NCBI Build 35	15	79300099	IL16
8602	-	9370	C/T	0	396686	rs2034598	Human NCBI Build 35	16	45559127	DNAJA2-ENSG00000129635
8603	-	9374	C/T	1	396690	rs2048607	Human NCBI Build 35	12	69497704	PTPRR
8604	-	9376	C/T	0	396692	rs2051324	Human NCBI Build 35	18	65701339	CD226
8605	-	9381	C/T	0	396697	rs2066804	Human NCBI Build 35	2	191667265	STAT1
8606	-	9383	C/T	0	396699	rs2069718	Human NCBI Build 35	12	66836429	IFNG
8607	-	9387	C/T	0	396702	rs2072370	Human NCBI Build 35	12	6215341	CD9
8608	-	9405	C/T	0	396717	rs2191312	Human NCBI Build 35	7	38140499	TRGV9

8609	-	9407	C/T	0	396719	rs2205945	Human NCBI Build 35	20	40489698	PTPR
8610	-	9410	C/T	0	396721	rs2227621	Human NCBI Build 35	1	170603463	SERPINC1
8611	-	9412	C/T	0	396723	rs2239908	Human NCBI Build 35	17	23749392	SARM1-ENSG00000076351
8612	-	9417	C/T	1	396727	rs2275560	Human NCBI Build 35	1	161261324	PBX1
8613	-	9429	C/T	0	396738	rs2305971	Human NCBI Build 35	12	93105768	PLXNC1
8615	-	9440	C/T	0	396746	rs2361355	Human NCBI Build 35	12	93132497	PLXNC1
8616	-	9442	C/T	0	396747	rs2365736	Human NCBI Build 35	12	93066386	PLXNC1
8617	-	9443	C/T	0	396748	rs2400228	Human NCBI Build 35	5	146049791	PPP2R2B
8618	-	9446	C/T	1	396751	rs2491393	Human NCBI Build 35	1	203688654	C4BPA
8619	-	9447	C/T	0	396752	rs2515406	Human NCBI Build 35	2	113538399	IL1F10-IL1F5
8620	-	9449	C/T	1	396754	rs2518144	Human NCBI Build 35	12	8650712	AICDA
8621	-	9453	C/T	0	396757	rs259896	Human NCBI Build 35	5	169292344	DOCK2
8622	-	9454	C/T	0	396758	rs261004	Human NCBI Build 35	5	169269201	DOCK2
8623	-	9456	C/T	0	396759	rs261076	Human NCBI Build 35	5	169236950	DOCK2
8624	-	9457	C/T	1	396760	rs262929	Human NCBI Build 35	6	37252382	PIM1
8626	-	9466	C/T	0	396767	rs2744119	Human NCBI Build 35	6	22390710	PRL
8627	-	9468	C/T	0	396769	rs2796821	Human NCBI Build 35	1	214974216	ENSG00000092969
8628	-	9469	C/T	0	396770	rs2800791	Human NCBI Build 35	1	161295083	PBX1
8629	-	9471	C/T	1	396772	rs2820579	Human NCBI Build 35	1	156733059	SLAMF9-IGSF9
8630	-	9474	C/T	0	396774	rs2930047	Human NCBI Build 35	5	10748526	DAP-ENSG00000164236
8631	-	9480	C/T	0	396777	rs3025035	Human NCBI Build 35	6	43859337	VEGF
8632	-	9481	C/T	0	396778	rs3092921	Human NCBI Build 35	X	135468520	ARHGEF6-ENSG00000102245
8633	-	9486	C/T	0	396781	rs3123592	Human NCBI Build 35	1	2119719	PRKCZ
8634	-	9489	C/T	0	396783	rs3136594	Human NCBI Build 35	3	173713286	TNFSF10
8635	-	9490	C/T	1	396784	rs3136618	Human NCBI Build 35	10	6041702	IL15RA
8636	-	9495	C/T	0	396788	rs3181030	Human NCBI Build 35	1	155033364	CD1A
8637	-	9496	C/T	0	396789	rs3188795	Human NCBI Build 35	4	15526954	CD38
8638	-	9497	C/T	1	396790	rs319152	Human NCBI Build 35	5	146187649	PPP2R2B
8639	-	9499	C/T	0	396791	rs320302	Human NCBI Build 35	1	240087776	AKT3
8640	-	9500	C/T	1	396792	rs3219053	Human NCBI Build 35	1	222881289	PARP1
8641	-	9501	C/T	0	396793	rs3219132	Human NCBI Build 35	1	222861110	PARP1
8642	-	9503	C/T	1	396795	rs33871	Human NCBI Build 35	12	9899164	ENSG00000110852
8643	-	9504	C/T	0	396796	rs34303	Human NCBI Build 35	5	67589583	PIK3R1
8644	-	9506	C/T	0	396798	rs347134	Human NCBI Build 35	3	32414789	ENSG00000153551
8645	-	9512	C/T	0	396802	rs3729908	Human NCBI Build 35	16	24138749	PRKCB1
8646	-	9519	C/T	0	396807	rs3739784	Human NCBI Build 35	9	87445648	DAPK1
8647	-	9520	C/T	0	396808	rs3740082	Human NCBI Build 35	10	35542539	CREM
8648	-	9522	C/T	1	396809	rs3750769	Human NCBI Build 35	10	71529872	H2AFY2-AMID
8649	-	9531	C/T	0	396818	rs3771827	Human NCBI Build 35	2	75273519	TACR1
8650	-	9534	C/T	0	396821	rs3773999	Human NCBI Build 35	3	191716540	IL1RAP
8651	-	9545	C/T	0	396830	rs3793744	Human NCBI Build 35	10	97597256	ENTPD1
8652	-	9551	C/T	0	396834	rs3803071	Human NCBI Build 35	12	93201348	PLXNC1-ENSG00000173588
8653	-	9561	C/T	1	396842	rs3853683	Human NCBI Build 35	18	59482212	SERPINB3
8654	-	9562	C/T	0	396843	rs3855625	Human NCBI Build 35	10	71349283	COL13A1-AMID
8655	-	9563	C/T	1	396844	rs3863222	Human NCBI Build 35	6	6219083	F13A1
8656	-	9566	C/T	0	396847	rs3917406	Human NCBI Build 35	1	166433936	SELE
8657	-	9570	C/T	0	396851	rs4255740	Human NCBI Build 35	15	64559061	MAP2K1
8658	-	9573	C/T	1	396854	rs433243	Human NCBI Build 35	6	137379969	IL20RA
8659	-	9577	C/T	1	396857	rs4407980	Human NCBI Build 35	9	36942743	PAX5

8660	-	9582	C/T	0	396862	rs4515770	Human NCBI Build 35	1	240012954	AKT3
8661	-	9590	C/T	0	396868	rs4686554	Human NCBI Build 35	3	191756520	IL1RAP
8662	-	9601	C/T	0	396877	rs4804103	Human NCBI Build 35	19	7186389	INSR
8663	-	9610	C/T	0	396884	rs4846349	Human NCBI Build 35	1	218300412	DUSP10
8664	-	9618	C/T	0	396889	rs4895830	Human NCBI Build 35	6	128475654	PTPRK
8666	-	9630	C/T	0	396899	rs524149	Human NCBI Build 35	18	20292322	HRH4-ENSG00000154059
8667	-	9633	C/T	0	396901	rs555244	Human NCBI Build 35	9	35291140	UNC13B-ENSG00000196186
8669	-	9636	C/T	0	396904	rs5743809	Human NCBI Build 35	4	38653080	TLR6
8670	-	9638	C/T	0	396906	rs5744169	Human NCBI Build 35	1	1375130	TLR5
8671	-	9639	C/T	0	396907	rs5745297	Human NCBI Build 35	5	10733997	DAP-ENSG00000164236
8672	-	9640	C/T	0	396908	rs5746214	Human NCBI Build 35	3	12619753	RAF1
8673	-	9641	C/T	0	396909	rs5766741	Human NCBI Build 35	22	44925709	PPARA
8674	-	9643	C/T	0	396911	rs582666	Human NCBI Build 35	1	232925149	EDARADD
8675	-	9650	C/T	0	396917	rs6016710	Human NCBI Build 35	20	40242258	PTPRT
8676	-	9651	C/T	0	396918	rs602383	Human NCBI Build 35	1	71103667	PTGER3
8677	-	9653	C/T	0	396919	rs6030390	Human NCBI Build 35	20	40707077	PTPRT
8678	-	9654	C/T	0	396920	rs603052	Human NCBI Build 35	3	61765300	PTPRG
8679	-	9656	C/T	0	396921	rs6030669	Human NCBI Build 35	20	41208284	PTPRT
8680	-	9657	C/T	0	396922	rs6054	Human NCBI Build 35	4	155847213	FGB-FGA
8681	-	9659	C/T	1	396923	rs6081121	Human NCBI Build 35	20	1837858	PTPNS1
8682	-	9661	C/T	1	396925	rs6093765	Human NCBI Build 35	20	41027589	PTPRT
8683	-	9664	C/T	0	396928	rs6102967	Human NCBI Build 35	20	40702735	PTPRT
8684	-	9666	C/T	0	396930	rs622721	Human NCBI Build 35	1	71125345	PTGER3
8685	-	9672	C/T	0	396933	rs631968	Human NCBI Build 35	10	6515302	PRKCQ
8686	-	9675	C/T	0	396936	rs641320	Human NCBI Build 35	3	139830655	FAIM
8687	-	9677	C/T	0	396938	rs644183	Human NCBI Build 35	18	8113197	PTPRM
8688	-	9678	C/T	1	396939	rs6445247	Human NCBI Build 35	3	61980695	PTPRG
8689	-	9682	C/T	0	396940	rs6445255	Human NCBI Build 35	3	62025319	PTPRG
8690	-	9683	C/T	0	396941	rs6446309	Human NCBI Build 35	4	5133239	ENSG00000170891
8691	-	9684	C/T	0	396942	rs6449195	Human NCBI Build 35	4	15491083	CD38
8692	-	9685	C/T	1	396943	rs6450354	Human NCBI Build 35	5	55195555	IL31RA
8693	-	9689	C/T	0	396947	rs6478108	Human NCBI Build 35	9	114638257	ENSG00000181634
8694	-	9694	C/T	0	396952	rs6567002	Human NCBI Build 35	18	54494262	MALT1
8695	-	9696	C/T	0	396954	rs6580448	Human NCBI Build 35	5	146418228	PPP2R2B
8696	-	9700	C/T	0	396958	rs6685648	Human NCBI Build 35	1	15570501	CASP9
8698	-	9708	C/T	1	396966	rs6740343	Human NCBI Build 35	2	105963996	NCK2
8699	-	9712	C/T	0	396970	rs6791765	Human NCBI Build 35	3	107026726	CBLB
8701	-	9718	C/T	1	396976	rs6817630	Human NCBI Build 35	4	88066595	PTPN13
8702	-	9722	C/T	0	396979	rs6890504	Human NCBI Build 35	5	169161475	DOCK2
8703	-	9728	C/T	0	396985	rs703193	Human NCBI Build 35	6	136651043	ENSG0000029363
8704	-	9731	C/T	0	396988	rs706127	Human NCBI Build 35	9	33293900	NFX1-ENSG0000086065
8705	-	9736	C/T	0	396991	rs710891	Human NCBI Build 35	16	3650098	DNASE1-TRAP1
8706	-	9737	C/T	0	396992	rs7111546	Human NCBI Build 35	11	22786333	GAS2
8707	-	9738	C/T	0	396993	rs7131826	Human NCBI Build 35	12	93048788	PLXNC1
8708	-	9740	C/T	0	396994	rs713330	Human NCBI Build 35	11	35180521	CD44
8709	-	9744	C/T	0	396998	rs7192187	Human NCBI Build 35	16	66689610	NFATC3
8710	-	9746	C/T	1	396999	rs7205935	Human NCBI Build 35	16	66709658	NFATC3
8711	-	9751	C/T	0	397003	rs7304935	Human NCBI Build 35	12	92723753	CRADD
8712	-	9752	C/T	1	397004	rs7316037	Human NCBI Build 35	12	63133078	XPOT-TBK1

8713	-	9754	C/T	0	397006	rs7349397	Human NCBI Build 35	2	46164938	PRKCE
8715	-	9757	C/T	0	397009	rs7431531	Human NCBI Build 35	3	106681064	ALCAM
8716	-	9758	C/T	0	397010	rs747726	Human NCBI Build 35	12	12561494	DUSP16
8717	-	9762	C/T	0	397014	rs7523198	Human NCBI Build 35	1	240028307	AKT3
8718	-	9765	C/T	1	397017	rs7541867	Human NCBI Build 35	1	89225558	GBP1
8719	-	9767	C/T	0	397019	rs7550432	Human NCBI Build 35	1	161554494	PBX1
8720	-	9771	C/T	0	397023	rs7601374	Human NCBI Build 35	2	160579557	LY75
8721	-	9780	C/T	0	397031	rs7679010	Human NCBI Build 35	4	47924813	TXK
8722	-	9795	C/T	0	397043	rs7808907	Human NCBI Build 35	7	128178035	IRF5
8723	-	9798	C/T	0	397044	rs7870456	Human NCBI Build 35	9	8444921	PTPRD
8724	-	9799	C/T	0	397045	rs7955573	Human NCBI Build 35	12	69467017	PTPRR
8725	-	9802	C/T	1	397047	rs7962629	Human NCBI Build 35	12	7037031	C1S
8726	-	9805	C/T	1	397049	rs7998462	Human NCBI Build 35	13	27572026	FLT3
8727	-	9807	C/T	0	397050	rs8021840	Human NCBI Build 35	14	106029993	IGHA1
8728	-	9812	C/T	1	397054	rs8063132	Human NCBI Build 35	16	23797562	PRKCB1
8729	-	9819	C/T	0	397059	rs8091305	Human NCBI Build 35	18	12860870	PTPN2
8730	-	9826	C/T	0	397065	rs8553	Human NCBI Build 35	12	93203786	PLXNC1-ENSG00000173588
8731	-	9827	C/T	0	397066	rs856114	Human NCBI Build 35	1	155711887	PYHIN1
8732	-	9829	C/T	0	397068	rs882763	Human NCBI Build 35	8	120013632	TNFRSF11B
8733	-	9836	C/T	1	397075	rs9292618	Human NCBI Build 35	5	35914269	IL7R
8734	-	9838	C/T	1	397077	rs9325024	Human NCBI Build 35	5	146185979	PPP2R2B
8735	-	9839	C/T	0	397078	rs934328	Human NCBI Build 35	3	30682748	TGFBR2
8736	-	9840	C/T	0	397079	rs935672	Human NCBI Build 35	2	45957610	PRKCE
8738	-	9843	C/T	0	397082	rs9429940	Human NCBI Build 35	1	204051307	CR2
8739	-	9850	C/T	0	397089	rs976530	Human NCBI Build 35	3	106643091	ALCAM
8740	-	9855	C/T	1	397093	rs9924271	Human NCBI Build 35	16	68237722	NFAT5
8741	-	9858	C/T	0	397095	rs10095917	Human NCBI Build 35	8	56992814	LYN
8742	-	9859	C/T	0	397096	rs10114470	Human NCBI Build 35	9	114627326	ENSG00000181634
8743	-	9861	C/T	1	397098	rs1015704	Human NCBI Build 35	3	191821114	IL1RAP
8744	-	9867	C/T	0	397103	rs10421474	Human NCBI Build 35	19	44926848	CLC
8745	-	9868	C/T	0	397104	rs1048318	Human NCBI Build 35	14	59829480	PPM1A
8746	-	9873	C/T	0	397108	rs10492196	Human NCBI Build 35	12	66903062	IL26
8747	-	9881	C/T	0	397116	rs10513854	Human NCBI Build 35	3	191788576	IL1RAP
8748	-	9883	C/T	0	397117	rs10519901	Human NCBI Build 35	15	32066560	AVEN
8749	-	9886	C/T	0	397119	rs10774603	Human NCBI Build 35	12	109618667	PPP1CC
8750	-	9887	C/T	0	397120	rs10777588	Human NCBI Build 35	12	93180840	PLXNC1
8751	-	9889	C/T	0	397122	rs10798918	Human NCBI Build 35	1	32945074	YARS
8752	-	9890	C/T	0	397123	rs10826945	Human NCBI Build 35	10	31702492	TCF8
8753	-	9903	C/T	0	397136	rs11120276	Human NCBI Build 35	1	203707597	C4BPA
8754	-	9904	C/T	0	397137	rs11120748	Human NCBI Build 35	1	203912936	DAF
8755	-	9909	C/T	0	397141	rs11167950	Human NCBI Build 35	5	146339639	PPP2R2B
8756	-	9919	C/T	0	397149	rs1157	Human NCBI Build 35	3	106778151	ALCAM
8757	-	9920	C/T	0	397150	rs11650072	Human NCBI Build 35	17	42748664	ITGB3
8758	-	9921	C/T	0	397151	rs11653322	Human NCBI Build 35	17	3635731	ITGAE
8759	-	9922	C/T	1	397152	rs1165672	Human NCBI Build 35	12	102822225	TRA1
8760	-	9926	C/T	0	397155	rs11780345	Human NCBI Build 35	8	23107911	TNFRSF10A-ENSG00000147457
8761	-	9928	C/T	0	397156	rs11807851	Human NCBI Build 35	1	155142167	CD1E
8762	-	9931	C/T	1	397159	rs11865790	Human NCBI Build 35	16	45991035	ENSG00000129636
8763	-	9932	C/T	1	397160	rs11874504	Human NCBI Build 35	18	8147247	PTPRM

8764	-	9935	C/T	0	397162	rs1204672	Human NCBI Build 35	1	204432827	CD34
8765	-	9936	C/T	0	397163	rs1205961	Human NCBI Build 35	6	22393991	PRL
8766	-	9943	C/T	0	397169	rs12120762	Human NCBI Build 35	1	195431450	PTPRC
8767	-	9946	C/T	0	397171	rs1213392	Human NCBI Build 35	10	35470291	CREM
8768	-	9948	C/T	0	397173	rs12155083	Human NCBI Build 35	7	38085111	TRGV9
8769	-	9962	C/T	1	397185	rs12520276	Human NCBI Build 35	5	42600319	GHR
8770	-	9964	C/T	0	397187	rs12546391	Human NCBI Build 35	6	31783276	C6orf21-BAT5-LY6G6E
8771	-	9965	C/T	0	397188	rs1256063	Human NCBI Build 35	14	63771970	ESR2
8772	-	9971	C/T	0	397194	rs13081408	Human NCBI Build 35	3	106781069	ALCAM
8773	-	9976	C/T	0	397198	rs13307	Human NCBI Build 35 2	160485503	LY75	
8774	-	9977	C/T	0	397199	rs1333635	Human NCBI Build 35	9	90645961	SYK
8775	-	9981	C/T	0	397202	rs1343409	Human NCBI Build 35	X	103949950	IL1RAPL2
8776	-	9989	C/T	0	397210	rs1444903	Human NCBI Build 35	5	41240060	C6
8777	-	9990	C/T	1	397211	rs1457233	Human NCBI Build 35	2	160822476	ITGB6
8778	-	9994	C/T	0	397215	rs1470598	Human NCBI Build 35	2	46181218	PRKCE
8779	-	9996	C/T	0	397216	rs1473822	Human NCBI Build 35	9	8716153	PTPRD
8780	-	9997	C/T	0	397217	rs150110	Human NCBI Build 35	6	167482177	CCR6-ENSG00000187485
8781	-	9998	C/T	0	397218	rs1508402	Human NCBI Build 35	3	62133458	PTPRG
8782	-	10000	C/T	0	397220	rs1536800	Human NCBI Build 35	9	5045434	JAK2
8783	-	10002	C/T	0	397222	rs1564280	Human NCBI Build 35	4	861505	GAK
8784	-	10003	C/T	0	397223	rs1569922	Human NCBI Build 35	1	67376984	IL23R
8785	-	10005	C/T	1	397225	rs161039	Human NCBI Build 35	5	146159224	PPP2R2B
8786	-	10006	C/T	0	397226	rs1611133	Human NCBI Build 35	6	29917361	HLA-G
8787	-	10018	C/T	0	397235	rs1770555	Human NCBI Build 35	1	161304289	PBX1
8788	-	10019	C/T	0	397236	rs1786704	Human NCBI Build 35	11	125670967	TIRAP
8789	-	10023	C/T	0	397239	rs1805671	Human NCBI Build 35	12	9054861	KLRG1
8790	-	10024	C/T	0	397240	rs1813323	Human NCBI Build 35	1	222807566	LIN9
8791	-	10036	C/T	0	397250	rs1927978	Human NCBI Build 35	9	87547092	DAPK1
8792	-	10037	C/T	0	397251	rs1935130	Human NCBI Build 35	6	128823604	PTPRK
8793	-	10040	C/T	0	397254	rs2024303	Human NCBI Build 35	12	8165032	ENSG00000111729
8794	-	10042	C/T	0	397256	rs2031904	Human NCBI Build 35	9	5077087	JAK2
8795	-	10047	C/T	0	397261	rs2071223	Human NCBI Build 35	X	100415692	BTB
8796	-	10049	C/T	0	397263	rs2097461	Human NCBI Build 35	22	27516433	XBP1
8797	-	10050	C/T	0	397264	rs2107561	Human NCBI Build 35	3	61968576	PTPRG
8798	-	10051	C/T	0	397265	rs2112593	Human NCBI Build 35	5	179633209	MAPK9
8799	-	10053	C/T	0	397266	rs2125443	Human NCBI Build 35	5	146209621	PPP2R2B
8800	-	10054	C/T	0	397267	rs2163057	Human NCBI Build 35	3	32514492	CKLFSF6
8801	-	10057	C/T	0	397269	rs2196425	Human NCBI Build 35	12	92614546	CRADD
8803	-	10061	C/T	0	397271	rs2238984	Human NCBI Build 35	X	100445946	BTB
8804	-	10062	C/T	0	397272	rs2238986	Human NCBI Build 35	X	100437808	BTB
8805	-	10064	C/T	0	397274	rs2243191	Human NCBI Build 35	1	203404352	IL19-PIGR
8806	-	10068	C/T	0	397277	rs2281389	Human NCBI Build 35	6	33167774	HLA-DPB1-ENSG00000172899
8807	-	10072	C/T	1	397279	rs2290706	Human NCBI Build 35	2	160851843	ITGB6
8808	-	10073	C/T	1	397280	rs2291326	Human NCBI Build 35	12	93151413	PLXNC1
8809	-	10075	C/T	0	397282	rs2300161	Human NCBI Build 35	1	71148277	PTGER3
8810	-	10078	C/T	0	397284	rs2305560	Human NCBI Build 35	2	198191294	HSPD1-ENSG00000115541
8811	-	10082	C/T	0	397287	rs2346878	Human NCBI Build 35	2	46834521	SOC5
8812	-	10083	C/T	0	397288	rs2374626	Human NCBI Build 35	12	105506029	RFX4
8813	-	10086	C/T	0	397291	rs2394180	Human NCBI Build 35	6	29913178	HLA-G

8814	-	10087	C/T	0	397292	rs239932	Human NCBI Build 35	6	167385092	CCR6-ENSG00000187485
8815	-	10088	C/T	0	397293	rs2421826	Human NCBI Build 35	11	35187181	CD44
8816	-	10089	C/T	1	397294	rs244418	Human NCBI Build 35	16	68180263	NFAT5
8817	-	10091	C/T	0	397296	rs2455314	Human NCBI Build 35	5	40975048	C7
8818	-	10095	C/T	1	397298	rs249522	Human NCBI Build 35	5	35096076	PRLR
8819	-	10097	C/T	0	397300	rs2534575	Human NCBI Build 35	7	38144714	TRGV9-ENSG00000198117
8820	-	10098	C/T	1	397301	rs2535704	Human NCBI Build 35	22	16549212	BCL2L13
8821	-	10102	C/T	0	397304	rs2584019	Human NCBI Build 35	12	69318052	PTPRB-PTPRR
8822	-	10114	C/T	0	397312	rs2684811	Human NCBI Build 35	15	97271086	IGF1R
8823	-	10118	C/T	1	397315	rs2902366	Human NCBI Build 35	11	43312977	API5
8824	-	10121	C/T	0	397318	rs3024536	Human NCBI Build 35	16	27260214	IL4R
8825	-	10124	C/T	1	397321	rs3093003	Human NCBI Build 35	6	167523885	CCR6-ENSG00000187485
8826	-	10125	C/T	0	397322	rs310202	Human NCBI Build 35	1	65061565	JAK1
8827	-	10127	C/T	1	397323	rs3117600	Human NCBI Build 35	4	75096847	CXCL1
8828	-	10129	C/T	0	397325	rs3181367	Human NCBI Build 35	9	114746232	TNFSF8
8829	-	10130	C/T	1	397326	rs319217	Human NCBI Build 35	5	146234086	PPP2R2B
8830	-	10138	C/T	0	397333	rs3730293	Human NCBI Build 35	5	55286484	IL6ST
8832	-	10140	C/T	0	397335	rs3736812	Human NCBI Build 35	11	35164827	CD44
8833	-	10142	C/T	0	397336	rs3739798	Human NCBI Build 35	9	98994367	TGFBR1
8834	-	10149	C/T	0	397343	rs3768761	Human NCBI Build 35	2	46229481	PRKCE
8835	-	10151	C/T	0	397345	rs3773983	Human NCBI Build 35	3	191762568	IL1RAP
8836	-	10157	C/T	0	397350	rs3797143	Human NCBI Build 35	5	10805181	DAP
8837	-	10160	C/T	0	397353	rs3799488	Human NCBI Build 35	6	137561473	IFNGR1-ENSG00000146394
8838	-	10162	C/T	0	397355	rs3806338	Human NCBI Build 35	1	89447335	GBP5
8839	-	10163	C/T	1	397356	rs3808847	Human NCBI Build 35	9	5499091	PDCD1LG2
8840	-	10167	C/T	0	397358	rs3845978	Human NCBI Build 35	3	158642396	PTX3-VEPH1
8841	-	10169	C/T	0	397360	rs3851513	Human NCBI Build 35	6	6219160	F13A1
8842	-	10170	C/T	0	397361	rs3862271	Human NCBI Build 35	1	50667017	FAF1
8843	-	10185	C/T	0	397374	rs4294603	Human NCBI Build 35	12	69337485	PTPRR
8845	-	10189	C/T	0	397378	rs4475344	Human NCBI Build 35	6	128387184	PTPRK
8847	-	10195	C/T	0	397384	rs4744514	Human NCBI Build 35	9	90690316	SYK
8848	-	10196	C/T	0	397385	rs4786430	Human NCBI Build 35	16	3673735	TRAP1
8849	-	10211	C/T	1	397398	rs4912486	Human NCBI Build 35	3	185569671	POLR2H-THPO
8850	-	10212	C/T	0	397399	rs4934538	Human NCBI Build 35	10	35512156	CREM
8852	-	10220	C/T	0	397407	rs527866	Human NCBI Build 35	15	32004828	AVEN
8853	-	10221	C/T	0	397408	rs533612	Human NCBI Build 35	11	111102652	PPP2R1B-SNF1LK2
8854	-	10223	C/T	0	397410	rs558863	Human NCBI Build 35	5	39378775	C9
8855	-	10224	C/T	0	397411	rs5743236	Human NCBI Build 35	11	43304898	API5
8856	-	10232	C/T	0	397418	rs6051962	Human NCBI Build 35	20	3517391	ATRN
8857	-	10238	C/T	0	397423	rs626707	Human NCBI Build 35	18	8132437	PTPRM
8858	-	10240	C/T	0	397425	rs628764	Human NCBI Build 35	18	20295192	HRH4
8859	-	10246	C/T	0	397430	rs6424410	Human NCBI Build 35	1	71096701	PTGER3
8860	-	10248	C/T	1	397431	rs6437999	Human NCBI Build 35	3	112852163	CD96
8861	-	10249	C/T	0	397432	rs6445252	Human NCBI Build 35	3	61981230	PTPRG
8862	-	10254	C/T	0	397435	rs6494711	Human NCBI Build 35	15	66161081	PIAS1
8863	-	10258	C/T	0	397437	rs649598	Human NCBI Build 35	18	8040886	PTPRM
8864	-	10262	C/T	0	397441	rs6533492	Human NCBI Build 35	4	111401849	EGF-ELOVL6
8865	-	10263	C/T	0	397442	rs6544852	Human NCBI Build 35	2	45935022	PRKCE
8866	-	10268	C/T	0	397446	rs6598048	Human NCBI Build 35	11	266012	NALP6

8867	-	10269	C/T	0	397447	rs6602354	Human NCBI Build 35	10	6052307	IL15RA	
8868	-	10271	C/T	0	397449	rs6663177	Human NCBI Build 35	1	164223212		CD3Z-ENSG00000198352
8869	-	10279	C/T	0	397456	rs6803618	Human NCBI Build 35	3	138106489		NCK1-ENSG00000181882
8870	-	10283	C/T	0	397459	rs6822478	Human NCBI Build 35	4	87433539		MAPK10
8871	-	10295	C/T	0	397470	rs706713	Human NCBI Build 35	5	67558478		PIK3R1
8872	-	10297	C/T	0	397471	rs7088062	Human NCBI Build 35	10	129688985		PTPRE
8873	-	10301	C/T	0	397475	rs7159462	Human NCBI Build 35	14	63828629		ESR2
8874	-	10306	C/T	0	397478	rs719195	Human NCBI Build 35	3	62029848		PTPRG
8875	-	10307	C/T	0	397479	rs7195648	Human NCBI Build 35	16	23996368		PRKCB1
8876	-	10309	C/T	0	397481	rs728010	Human NCBI Build 35	12	10444534		KLRC4
8877	-	10316	C/T	0	397487	rs743811	Human NCBI Build 35	22	34117528		MCM5-HMOX1
8879	-	10320	C/T	0	397490	rs7496452	Human NCBI Build 35	15	79293169		IL16
8880	-	10323	C/T	0	397493	rs755340	Human NCBI Build 35	17	75784819		CARD14
8881	-	10325	C/T	0	397494	rs7583215	Human NCBI Build 35	2	102312572		IL1RL2
8882	-	10326	C/T	0	397495	rs759169	Human NCBI Build 35	7	54928845		EGFR
8883	-	10330	C/T	1	397498	rs7626555	Human NCBI Build 35	3	33840616		PDCD6IP
8884	-	10331	C/T	0	397499	rs763586	Human NCBI Build 35	1	23605339		E2F2
8885	-	10336	C/T	0	397504	rs7714146	Human NCBI Build 35	5	55253515		IL31RA
8886	-	10338	C/T	0	397506	rs7732013	Human NCBI Build 35	5	35192289		PRLR
8887	-	10341	C/T	1	397507	rs7745598	Human NCBI Build 35	6	3044417	RIPK1	
8888	-	10342	C/T	0	397508	rs7763349	Human NCBI Build 35	6	6547183	LY86	
8889	-	10343	C/T	1	397509	rs7770797	Human NCBI Build 35	6	6566961	LY86	
8890	-	10344	C/T	1	397510	rs7777968	Human NCBI Build 35	7	157579816		PTPRN2
8891	-	10346	C/T	1	397512	rs7810486	Human NCBI Build 35	7	142523948		CASP2-ENSG00000173568
8892	-	10354	C/T	0	397519	rs7929685	Human NCBI Build 35	11	77763301		GAB2
8893	-	10358	C/T	0	397522	rs7982100	Human NCBI Build 35	13	107756366		TNFSF13B
8894	-	10359	C/T	0	397523	rs800292	Human NCBI Build 35	1	193373890		CFH
8895	-	10360	C/T	0	397524	rs8024103	Human NCBI Build 35	15	71796617		ENSG00000103855
8896	-	10363	C/T	1	397526	rs8083946	Human NCBI Build 35	18	59056901		BCL2
8897	-	10365	C/T	0	397528	rs8094421	Human NCBI Build 35	18	7850388	PTPRM	
8898	-	10371	C/T	0	397533	rs865569	Human NCBI Build 35	12	93151571		PLXNC1
8899	-	10376	C/T	1	397535	rs876688	Human NCBI Build 35	3	30700780		TGFBR2
8900	-	10379	C/T	1	397538	rs907715	Human NCBI Build 35	4	123892658		IL21
8901	-	10384	C/T	0	397543	rs9313473	Human NCBI Build 35	5	169152577		DOCK2
8902	-	10385	C/T	0	397544	rs9313476	Human NCBI Build 35	5	169336666		DOCK2
8903	-	10386	C/T	1	397545	rs932880	Human NCBI Build 35	13	23086039		TNFRSF19
8904	-	10387	C/T	0	397546	rs933226	Human NCBI Build 35	22	30668401		YWHAH
8905	-	10393	C/T	0	397551	rs948562	Human NCBI Build 35	11	58104341		CNTF-LPXN
8906	-	10398	C/T	0	397555	rs9928466	Human NCBI Build 35	16	45780919		ENSG00000129636
8907	-	10401	C/T	0	397558	rs1003061	Human NCBI Build 35	1	220334734		TP53BP2
8908	-	10403	C/T	0	397560	rs10088780	Human NCBI Build 35	8	42290214		IKKBK
8909	-	10404	C/T	0	397561	rs1011692	Human NCBI Build 35	7	121153962		PTPRZ1
8910	-	10405	C/T	1	397562	rs10163540	Human NCBI Build 35	18	8132163	PTPRM	
8912	-	10409	C/T	0	397566	rs1025963	Human NCBI Build 35	5	38601396		LIFR
8913	-	10410	C/T	1	397567	rs1029508	Human NCBI Build 35	3	61928141		PTPRG
8914	-	10413	C/T	0	397570	rs10475933	Human NCBI Build 35	5	169622825		LCP2
8915	-	10414	C/T	0	397571	rs1048135	Human NCBI Build 35	2	151964924		NMI
8916	-	10419	C/T	0	397575	rs10493149	Human NCBI Build 35	1	50682496		FAF1
8917	-	10425	C/T	0	397579	rs10504554	Human NCBI Build 35	8	75082267		LY96

8918	-	10431	C/T	0	397583	rs10507033	Human NCBI Build 35	12	93107600	PLXNC1
8919	-	10432	C/T	1	397584	rs10510655	Human NCBI Build 35	3	32382486	CKLFSF8
8920	-	10437	C/T	0	397588	rs10514611	Human NCBI Build 35	16	84512743	ENSG00000140968
8921	-	10438	C/T	0	397589	rs10515574	Human NCBI Build 35	5	145952286	PPP2R2B
8922	-	10443	C/T	0	397592	rs10776483	Human NCBI Build 35	4	38597606	TLR10
8923	-	10446	C/T	0	397595	rs10833818	Human NCBI Build 35	11	22773148	GAS2
8924	-	10447	C/T	1	397596	rs10846175	Human NCBI Build 35	12	15475891	PTPRO
8925	-	10452	C/T	0	397601	rs11086031	Human NCBI Build 35	19	16448528	CALR3-EPS15L1
8926	-	10460	C/T	1	397607	rs1112756	Human NCBI Build 35	12	69357254	PTPRR
8927	-	10463	C/T	0	397609	rs11205783	Human NCBI Build 35	1	51030125	FAF1
8928	-	10470	C/T	0	397615	rs11630608	Human NCBI Build 35	15	64532191	MAP2K1
8930	-	10483	C/T	0	397626	rs12078213	Human NCBI Build 35	1	51010310	FAF1
8931	-	10485	C/T	0	397628	rs12097550	Human NCBI Build 35	1	193683749	CFHL5
8932	-	10488	C/T	0	397631	rs12187493	Human NCBI Build 35	5	38537664	LIFR
8933	-	10492	C/T	1	397634	rs12346650	Human NCBI Build 35	9	98943653	TGFBR1
8934	-	10496	C/T	0	397638	rs1255955	Human NCBI Build 35	14	63618777	SYNE2-ESR2
8935	-	10501	C/T	0	397643	rs12744132	Human NCBI Build 35	17	6856125	
ENSG00000141498-ENSG00000161939-ALOX12										
8937	-	10510	C/T	0	397651	rs13392494	Human NCBI Build 35	2	113455906	IL1F9
8938	-	10512	C/T	1	397653	rs13435	Human NCBI Build 35	5	179594298	MAPK9
8939	-	10518	C/T	0	397658	rs1368982	Human NCBI Build 35	9	8685998	PTPRD
8940	-	10523	C/T	0	397662	rs1441438	Human NCBI Build 35	8	79804324	IL7
8941	-	10526	C/T	1	397664	rs1514346	Human NCBI Build 35	6	334630	IRF4
8942	-	10527	C/T	0	397665	rs1534809	Human NCBI Build 35	3	61844304	PTPRG
8944	-	10535	C/T	0	397672	rs1738548	Human NCBI Build 35	11	33708979	CD59
8945	-	10536	C/T	0	397673	rs1744066	Human NCBI Build 35	6	137370727	IL20RA
8946	-	10539	C/T	0	397676	rs17827158	Human NCBI Build 35	2	160501857	LY75
8947	-	10543	C/T	0	397680	rs1896795	Human NCBI Build 35	15	78045391	BCL2A1
8948	-	10556	C/T	0	397691	rs2042772	Human NCBI Build 35	2	160487565	LY75
8949	-	10557	C/T	0	397692	rs2053005	Human NCBI Build 35	15	64491503	MAP2K1
8950	-	10558	C/T	1	397693	rs2069698	Human NCBI Build 35	5	75952643	F2RL2-IQGAP2
8952	-	10565	C/T	1	397699	rs2143511	Human NCBI Build 35	20	48578076	PTPN1
8953	-	10567	C/T	0	397700	rs2161148	Human NCBI Build 35	5	169189578	DOCK2
8954	-	10571	C/T	0	397703	rs2201150	Human NCBI Build 35	3	46233906	CCR3
8955	-	10573	C/T	0	397704	rs221247	Human NCBI Build 35	7	156827004	PTPRN2
8956	-	10575	C/T	0	397705	rs2234978	Human NCBI Build 35	10	90761809	ENSG0000026103
8957	-	10581	C/T	0	397708	rs2270238	Human NCBI Build 35	12	10353783	KLRD1
8958	-	10585	C/T	0	397710	rs2273650	Human NCBI Build 35	14	34940549	NFKBIA
8959	-	10587	C/T	1	397712	rs2275992	Human NCBI Build 35	11	58135000	CNTF
8960	-	10590	C/T	1	397714	rs2284033	Human NCBI Build 35	22	35858534	IL2RB
8961	-	10592	C/T	0	397716	rs2302759	Human NCBI Build 35	16	49385102	ENSG00000083799
8962	-	10593	C/T	1	397717	rs2303067	Human NCBI Build 35	5	147461148	SPINK5
8963	-	10595	C/T	1	397719	rs2327742	Human NCBI Build 35	6	136925861	MAP3K5
8964	-	10596	C/T	0	397720	rs2352974	Human NCBI Build 35	3	49865617	
ENSG00000164076-ENSG00000183763										
8965	-	10597	C/T	0	397721	rs2384280	Human NCBI Build 35	10	35344868	CUL2
8966	-	10598	C/T	1	397722	rs2384285	Human NCBI Build 35	10	35377222	CUL2
8967	-	10599	C/T	1	397723	rs238691	Human NCBI Build 35	20	3437857	ATRN
8968	-	10600	C/T	0	397724	rs2399047	Human NCBI Build 35	3	106700338	ALCAM

8969	-	10602	C/T	0	397726	rs2459611	Human NCBI Build 35	2	191764693	STAT4
8970	-	10603	C/T	0	397727	rs2461489	Human NCBI Build 35	8	22426198	PPP3CC-PIWIL2
8971	-	10605	C/T	0	397728	rs2469749	Human NCBI Build 35	8	22413543	PPP3CC-PIWIL2
8972	-	10607	C/T	0	397730	rs256946	Human NCBI Build 35	5	114959509	TICAM2
8973	-	10610	C/T	1	397733	rs2668022	Human NCBI Build 35	8	57039605	LYN
8974	-	10611	C/T	0	397734	rs267531	Human NCBI Build 35	3	37564997	ITGA9
8975	-	10616	C/T	0	397738	rs2717428	Human NCBI Build 35	12	69287924	PTPRB
8976	-	10617	C/T	0	397739	rs2725827	Human NCBI Build 35	11	76763590	PAK1
8977	-	10620	C/T	0	397742	rs2797409	Human NCBI Build 35	1	114042244	PTPN22-RSBN1
8978	-	10626	C/T	0	397747	rs2890818	Human NCBI Build 35	9	8610137	PTPRD
8979	-	10637	C/T	1	397758	rs351540	Human NCBI Build 35	8	16056665	MSR1
8980	-	10638	C/T	0	397759	rs351572	Human NCBI Build 35	8	16065839	MSR1
8981	-	10643	C/T	0	397761	rs353612	Human NCBI Build 35	11	35136227	CD44
8982	-	10646	C/T	0	397763	rs35767	Human NCBI Build 35	12	101378036	IGF1
8983	-	10648	C/T	0	397765	rs3729959	Human NCBI Build 35	5	55301046	IL6ST
8984	-	10652	C/T	1	397768	rs3740961	Human NCBI Build 35	11	36466647	TRAF6
8985	-	10654	C/T	1	397770	rs3751436	Human NCBI Build 35	13	40033038	FOXO1A
8986	-	10655	C/T	0	397771	rs3754097	Human NCBI Build 35	1	195377116	PTPRC
8987	-	10656	C/T	1	397772	rs3754230	Human NCBI Build 35	1	232152624	ENSG00000143669
8988	-	10660	C/T	1	397774	rs3759465	Human NCBI Build 35	13	107719731	TNFSF13B
8989	-	10672	C/T	1	397785	rs3804797	Human NCBI Build 35	3	3104632	IL5RA
8990	-	10674	C/T	0	397787	rs3821318	Human NCBI Build 35	2	75298966	TACR1
8991	-	10676	C/T	0	397789	rs3828016	Human NCBI Build 35	20	1865290	PTPNS1
8992	-	10682	C/T	1	397795	rs3924523	Human NCBI Build 35	2	45907001	PRKCE
8993	-	10683	C/T	0	397796	rs3927911	Human NCBI Build 35	18	59084606	BCL2
8994	-	10684	C/T	1	397797	rs395967	Human NCBI Build 35	5	38878716	OSMR
8995	-	10688	C/T	0	397801	rs4233337	Human NCBI Build 35	1	89348968	GBP2
8996	-	10690	C/T	0	397803	rs4264601	Human NCBI Build 35	2	45920736	PRKCE
8997	-	10694	C/T	1	397806	rs4365846	Human NCBI Build 35	5	42583012	GHR
8998	-	10698	C/T	1	397809	rs4604670	Human NCBI Build 35	1	210969879	PTPN14
8999	-	10705	C/T	0	397816	rs4688659	Human NCBI Build 35	3	61671155	PTPRG
9000	-	10710	C/T	0	397819	rs4705449	Human NCBI Build 35	5	146320034	PPP2R2B
9001	-	10712	C/T	0	397821	rs4761223	Human NCBI Build 35	12	69286671	PTPRB
9002	-	10714	C/T	0	397823	rs478582	Human NCBI Build 35	18	12825976	PTPN2
9003	-	10715	C/T	0	397824	rs4789073	Human NCBI Build 35	17	70043973	
ENSG00000167850-ENSG00000178789										
9004	-	10719	C/T	0	397828	rs4851004	Human NCBI Build 35	2	102468055	IL18R1
9005	-	10724	C/T	0	397833	rs4891793	Human NCBI Build 35	18	65745841	CD226
9006	-	10725	C/T	0	397834	rs4926873	Human NCBI Build 35	1	51115616	FAF1
9007	-	10728	C/T	0	397835	rs4937333	Human NCBI Build 35	11	127835730	ETS1
9009	-	10735	C/T	0	397840	rs517736	Human NCBI Build 35	11	104398767	CASP1
9010	-	10738	C/T	0	397842	rs550942	Human NCBI Build 35	11	58150730	CNTF
9011	-	10748	C/T	0	397851	rs5992801	Human NCBI Build 35	22	16568261	BCL2L13
9012	-	10751	C/T	0	397854	rs602756	Human NCBI Build 35	10	6506286	PRKCQ
9013	-	10753	C/T	0	397856	rs6067805	Human NCBI Build 35	20	49568498	NFATC2
9014	-	10758	C/T	1	397861	rs624035	Human NCBI Build 35	3	120739769	CD80
9015	-	10762	C/T	0	397864	rs6432708	Human NCBI Build 35	2	162717355	DPP4
9016	-	10763	C/T	1	397865	rs6441929	Human NCBI Build 35	3	45899795	LZTFL1-CCR9
9017	-	10768	C/T	0	397870	rs6495554	Human NCBI Build 35	15	79335436	IL16

9018	-	10771	C/T	0	397872	rs6506522	Human NCBI Build 35	18	7627325	PTPRM	
9019	-	10772	C/T	0	397873	rs6506557	Human NCBI Build 35	18	8193406	PTPRM	
9020	-	10784	C/T	0	397885	rs6701416	Human NCBI Build 35	1	204204258	none	
9021	-	10785	C/T	0	397886	rs6720896	Human NCBI Build 35	2	233868584	INPP5D	
9022	-	10792	C/T	0	397892	rs6770096	Human NCBI Build 35	3	32971513	CCR4	
9023	-	10793	C/T	0	397893	rs6861025	Human NCBI Build 35	5	156451675	HAVCR2	
9024	-	10795	C/T	1	397895	rs6887169	Human NCBI Build 35	5	43243995	CCL28-ENSG00000177453	
9025	-	10802	C/T	0	397899	rs695172	Human NCBI Build 35	1	78823883	IFI44-ENSG00000137959	
9026	-	10806	C/T	1	397903	rs7023146	Human NCBI Build 35	9	5030163	JAK2-ENSG00000183276	
9027	-	10809	C/T	0	397906	rs706781	Human NCBI Build 35	10	6126391	IL2RA	
9028	-	10812	C/T	0	397908	rs7083579	Human NCBI Build 35	10	6560590	PRKCQ	
9029	-	10817	C/T	0	397912	rs728440	Human NCBI Build 35	4	103809447	NFKB1	
9030	-	10819	C/T	1	397914	rs7311199	Human NCBI Build 35	12	69268374	PTPRB	
9031	-	10820	C/T	0	397915	rs736637	Human NCBI Build 35	X	104296315	IL1RAPL2	
9032	-	10825	C/T	0	397920	rs7526293	Human NCBI Build 35	1	151257282	IL6R	
9033	-	10827	C/T	0	397921	rs7541057	Human NCBI Build 35	1	232186381	ENSG00000143669	
9034	-	10832	C/T	0	397926	rs7635078	Human NCBI Build 35	3	112771229	CD96	
9035	-	10837	C/T	0	397931	rs7684686	Human NCBI Build 35	4	111333289	EGF-ELOVL6	
9036	-	10840	C/T	0	397934	rs7712778	Human NCBI Build 35	5	42730064	GHR	
9037	-	10845	C/T	0	397938	rs7894459	Human NCBI Build 35	10	31651262	TCF8	
9038	-	10848	C/T	0	397941	rs8001054	Human NCBI Build 35	13	23138331	TNFRSF19	
9040	-	10854	C/T	0	397946	rs834254	Human NCBI Build 35	5	39220308	FYB	
9041	-	10860	C/T	0	397950	rs854685	Human NCBI Build 35	17	31343239	CCL15	
9042	-	10869	C/T	0	397956	rs9307016	Human NCBI Build 35	4	87539615	MAPK10	
9044	-	10871	C/T	0	397958	rs9320379	Human NCBI Build 35	6	112291314	FYN	
9045	-	10874	C/T	0	397961	rs9324536	Human NCBI Build 35	8	141947596	PTK2	
9046	-	10876	C/T	0	397963	rs9372885	Human NCBI Build 35	6	128517784	PTPRK	
9048	-	10879	C/T	0	397966	rs948337	Human NCBI Build 35	18	7619802	PTPRM	
9049	-	10880	C/T	0	397967	rs9514827	Human NCBI Build 35	13	107717404	TNFSF13B	
9050	-	10886	C/T	0	397972	rs987849	Human NCBI Build 35	12	46540943	VDR	
9051	-	10889	C/T	1	397974	rs9928102	Human NCBI Build 35	16	24011478	PRKCB1	
9052	-	10892	C/T	0	397977	rs10029671	Human NCBI Build 35	4	87910082	PTPN13	
9053	-	10894	C/T	0	397978	rs1003854	Human NCBI Build 35	21	44534535	AIRE	
9054	-	10905	C/T	0	397987	rs1016364	Human NCBI Build 35	11	129250082	NFRKB	
9055	-	10906	C/T	0	397988	rs1017119	Human NCBI Build 35	9	120887092	C5	
9056	-	10907	C/T	0	397989	rs10173099	Human NCBI Build 35	2	191692838	STAT1	
9057	-	10911	C/T	0	397993	rs1039559	Human NCBI Build 35	4	38654162	TLR6	
9058	-	10915	C/T	0	397997	rs10482750	Human NCBI Build 35	1	214944431	ENSG00000092969	
9059	-	10916	C/T	0	397998	rs10484323	Human NCBI Build 35	6	6217185	F13A1	
9060	-	10917	C/T	0	397999	rs10485692	Human NCBI Build 35	20	40443978	PTPRT	
9061	-	10921	C/T	0	398002	rs10493763	Human NCBI Build 35	1	85439239	BCL10-ENSG00000162642	
9062	-	10926	C/T	1	398005	rs10494420	Human NCBI Build 35	1	161414774	PBX1	
9063	-	10932	C/T	0	398011	rs10515522	Human NCBI Build 35	5	142738587	NR3C1	
9064	-	10933	C/T	0	398012	rs1057523	Human NCBI Build 35	7	43443563	STK17A	
9065	-	10943	C/T	0	398019	rs10800584	Human NCBI Build 35	1	195412624	PTPRC	
9066	-	10948	C/T	0	398024	rs10929956	Human NCBI Build 35	2	160540122	LY75	
9067	-	10950	C/T	0	398025	rs10953502	Human NCBI Build 35	7	105486382	PBEF1	
9068	-	10951	C/T	0	398026	rs10977210	Human NCBI Build 35	9	8568261	PTPRD	
9069	-	10952	C/T	0	398027	rs11008510	Human NCBI Build 35	10	31835218	TCF8	

9070	-	10954	C/T	0	398028	rs11054941	Human NCBI Build 35	12	12548462	DUSP16
9071	-	10957	C/T	0	398030	rs11077405	Human NCBI Build 35	17	74481477	LGALS3BP
9072	-	10961	C/T	0	398033	rs11129773	Human NCBI Build 35	3	37830118	ITGA9
9073	-	10962	C/T	0	398034	rs11217861	Human NCBI Build 35	11	119793270	ARHGEF12
9074	-	10964	C/T	0	398036	rs11247375	Human NCBI Build 35	15	97169263	IGF1R
9075	-	10965	C/T	1	398037	rs11574780	Human NCBI Build 35	5	55279795	IL6ST-ENSG00000176534
9076	-	10967	C/T	1	398039	rs1181333	Human NCBI Build 35	12	12256796	LRP6-BCL2L14
9077	-	10975	C/T	1	398043	rs12088788	Human NCBI Build 35	1	154545333	SPAP1
9078	-	10976	C/T	0	398044	rs12125732	Human NCBI Build 35	1	50848123	FAF1
9079	-	10980	C/T	1	398047	rs12259	Human NCBI Build 35	15	39658784	TYRO3
9080	-	10982	C/T	0	398048	rs12280964	Human NCBI Build 35	11	48017402	PTPRJ
9081	-	10983	C/T	0	398049	rs12375663	Human NCBI Build 35	9	8442875	PTPRD
9082	-	10987	C/T	0	398052	rs12621378	Human NCBI Build 35	2	152820685	STAM2
9083	-	10996	C/T	1	398058	rs12749729	Human NCBI Build 35	1	218271891	DUSP10
9084	-	11001	C/T	1	398062	rs1320172	Human NCBI Build 35	3	61544793	PTPRG
9086	-	11007	C/T	0	398067	rs1340521	Human NCBI Build 35	1	161267213	PBX1
9087	-	11009	C/T	1	398069	rs1359120	Human NCBI Build 35	9	8460974	PTPRD
9088	-	11012	C/T	0	398071	rs1409837	Human NCBI Build 35	6	112302304	FYN
9089	-	11014	C/T	0	398073	rs1421001	Human NCBI Build 35	9	87388867	DAPK1
9090	-	11019	C/T	1	398076	rs1499243	Human NCBI Build 35	11	22752540	GAS2
9091	-	11020	C/T	0	398077	rs1500318	Human NCBI Build 35	9	8351445	PTPRD
9093	-	11024	C/T	1	398081	rs1523475	Human NCBI Build 35	3	188926912	BCL6
9094	-	11025	C/T	0	398082	rs1529047	Human NCBI Build 35	3	99734717	GPR15
9096	-	11030	C/T	1	398085	rs1552031	Human NCBI Build 35	15	57758824	BNIP2
9097	-	11032	C/T	0	398087	rs1599313	Human NCBI Build 35	4	87492303	MAPK10
9099	-	11037	C/T	0	398092	rs168568	Human NCBI Build 35	5	38960673	OSMR
9100	-	11038	C/T	0	398093	rs1738288	Human NCBI Build 35	6	128629940	PTPRK
9101	-	11044	C/T	1	398097	rs1822814	Human NCBI Build 35	5	38602162	LIFR
9102	-	11049	C/T	0	398100	rs1849553	Human NCBI Build 35	1	51030026	FAF1
9103	-	11052	C/T	0	398102	rs1862628	Human NCBI Build 35	5	42758885	GHR
9104	-	11055	C/T	0	398104	rs1877448	Human NCBI Build 35	9	8686410	PTPRD
9105	-	11056	C/T	0	398105	rs1893489	Human NCBI Build 35	18	46449659	MAPK4
9106	-	11058	C/T	0	398107	rs1927914	Human NCBI Build 35	9	117544279	TLR4
9107	-	11061	C/T	0	398110	rs1970559	Human NCBI Build 35	1	114089190	PTPN22
9108	-	11065	C/T	0	398114	rs2025818	Human NCBI Build 35	10	6604583	PRKCQ
9109	-	11066	C/T	0	398115	rs2041466	Human NCBI Build 35	11	22769111	GAS2
9110	-	11072	C/T	1	398120	rs210434	Human NCBI Build 35	X	104756073	IL1RAPL2
9111	-	11073	C/T	0	398121	rs2111850	Human NCBI Build 35	2	162716786	DPP4
9112	-	11079	C/T	0	398125	rs2227306	Human NCBI Build 35	4	74972090	IL8
9113	-	11080	C/T	0	398126	rs2227751	Human NCBI Build 35	5	76049264	F2R-ENSG00000183613
9114	-	11086	C/T	0	398131	rs2253084	Human NCBI Build 35	9	130651327	ABL1
9115	-	11087	C/T	0	398132	rs2256385	Human NCBI Build 35	1	71160498	PTGER3
9116	-	11094	C/T	1	398137	rs2275993	Human NCBI Build 35	11	58136563	CNTF
9117	-	11097	C/T	0	398139	rs2279965	Human NCBI Build 35	4	47917176	TXK
9118	-	11099	C/T	0	398141	rs2288720	Human NCBI Build 35	12	97599938	APAF1
9119	-	11100	C/T	0	398142	rs2291332	Human NCBI Build 35	12	93123606	PLXNC1
9120	-	11105	C/T	1	398147	rs2383190	Human NCBI Build 35	9	21432958	IFNA1
9121	-	11112	C/T	0	398152	rs2583999	Human NCBI Build 35	12	69298785	PTPRB
9122	-	11116	C/T	0	398155	rs2701653	Human NCBI Build 35	12	64868152	IRAK3

9123	-	11124	C/T	0	398162	rs2808470	Human NCBI Build 35	1	203675582	C4BPA
9125	-	11129	C/T	0	398167	rs2989836	Human NCBI Build 35	9	91260916	NFIL3
9126	-	11139	C/T	0	398176	rs352678	Human NCBI Build 35	1	157489747	CD48
9127	-	11145	C/T	0	398181	rs3737445	Human NCBI Build 35	11	111130776	PPP2R1B
9128	-	11146	C/T	0	398182	rs3743781	Human NCBI Build 35	16	49388757	ENSG00000083799
9129	-	11147	C/T	0	398183	rs3750478	Human NCBI Build 35	9	21156077	IFNA21
9130	-	11153	C/T	0	398188	rs3765259	Human NCBI Build 35	6	137031976	MAP3K5
9131	-	11154	C/T	0	398189	rs3766404	Human NCBI Build 35	1	193383489	CFH
9133	-	11158	C/T	0	398193	rs3811021	Human NCBI Build 35	1	114068705	PTPN22-RSBN1
9134	-	11160	C/T	0	398194	rs3816018	Human NCBI Build 35	5	149488668	PDGFRB
9135	-	11163	C/T	1	398197	rs3826619	Human NCBI Build 35	18	58166730	TNFRSF11A
9136	-	11167	C/T	1	398201	rs3924714	Human NCBI Build 35	12	69543564	PTPRR
9137	-	11170	C/T	0	398203	rs401694	Human NCBI Build 35	5	35098375	PRLR
9138	-	11175	C/T	0	398208	rs4389322	Human NCBI Build 35	2	204631340	ICOS
9139	-	11176	C/T	0	398209	rs444556	Human NCBI Build 35	5	39149695	FYB
9140	-	11180	C/T	0	398212	rs45758	Human NCBI Build 35	6	137383376	IL20RA
9141	-	11182	C/T	0	398214	rs4650092	Human NCBI Build 35	1	71036027	PTGER3
9142	-	11184	C/T	0	398216	rs4688645	Human NCBI Build 35	3	61595936	PTPRG
9143	-	11186	C/T	0	398217	rs4696483	Human NCBI Build 35	4	154976860	TLR2
9144	-	11188	C/T	1	398219	rs4705442	Human NCBI Build 35	5	146110111	PPP2R2B
9145	-	11191	C/T	0	398222	rs4761528	Human NCBI Build 35	12	92692971	CRADD
9146	-	11193	C/T	0	398224	rs4812661	Human NCBI Build 35	20	41008537	PTPRT
9147	-	11195	C/T	0	398226	rs4851531	Human NCBI Build 35	2	102107127	IL1R2
9148	-	11198	C/T	1	398228	rs4855617	Human NCBI Build 35	3	109278787	CD47
9149	-	11204	C/T	0	398232	rs4953418	Human NCBI Build 35	2	46896278	SOC5
9150	-	11205	C/T	0	398233	rs4966036	Human NCBI Build 35	15	97247272	IGF1R
9151	-	11210	C/T	0	398238	rs5742667	Human NCBI Build 35	12	101325945	IGF1
9152	-	11213	C/T	0	398241	rs585881	Human NCBI Build 35	10	6598275	PRKCQ
9153	-	11214	C/T	0	398242	rs5992795	Human NCBI Build 35	22	16561359	BCL2L13
9154	-	11216	C/T	1	398243	rs6016945	Human NCBI Build 35	20	41136299	PTPRT
9155	-	11220	C/T	0	398247	rs622373	Human NCBI Build 35	11	119762055	ARHGEF12
9156	-	11226	C/T	0	398249	rs6435068	Human NCBI Build 35	2	201901954	CASP10
9157	-	11229	C/T	1	398252	rs6442322	Human NCBI Build 35	3	12664858	RAF1-ENSG00000198383
9158	-	11230	C/T	0	398253	rs6447614	Human NCBI Build 35	4	47908885	TXK
9159	-	11231	C/T	1	398254	rs6451413	Human NCBI Build 35	5	39173137	FYB
9160	-	11232	C/T	0	398255	rs6461781	Human NCBI Build 35	7	2824616	CARD11
9161	-	11235	C/T	0	398258	rs6533491	Human NCBI Build 35	4	111388391	EGF-ELOVL6
9162	-	11241	C/T	0	398262	rs6673237	Human NCBI Build 35	1	232367170	ENSG00000143669
9163	-	11246	C/T	0	398267	rs6868333	Human NCBI Build 35	5	179620378	MAPK9-ENSG00000183279
9164	-	11254	C/T	0	398273	rs7016131	Human NCBI Build 35	8	27269556	PTK2B
9165	-	11257	C/T	0	398275	rs704341	Human NCBI Build 35	3	61923776	PTPRG
9166	-	11258	C/T	0	398276	rs705853	Human NCBI Build 35	1	157589760	LY9
9167	-	11262	C/T	0	398279	rs716221	Human NCBI Build 35	1	155116945	CD1B
9168	-	11266	C/T	0	398283	rs722973	Human NCBI Build 35	18	8197445	PTPRM
9169	-	11267	C/T	0	398284	rs7302235	Human NCBI Build 35	12	46579105	VDR
9170	-	11272	C/T	0	398288	rs7309888	Human NCBI Build 35	12	69340682	PTPRR
9171	-	11274	C/T	0	398290	rs7428824	Human NCBI Build 35	3	106625222	ALCAM
9172	-	11275	C/T	0	398291	rs7513168	Human NCBI Build 35	1	111124954	CD53
9173	-	11279	C/T	1	398294	rs7528924	Human NCBI Build 35	1	67401057	IL23R

9174	-	11286	C/T	0	398300	rs7653452	Human NCBI Build 35	3	109263096	CD47
9175	-	11287	C/T	0	398301	rs7686447	Human NCBI Build 35	4	78888511	CXCL13
9176	-	11293	C/T	0	398306	rs790635	Human NCBI Build 35	1	67395507	IL23R
9177	-	11294	C/T	0	398307	rs7907161	Human NCBI Build 35	10	71467806	AMID
9178	-	11295	C/T	0	398308	rs7939646	Human NCBI Build 35	11	77789261	GAB2
9179	-	11300	C/T	0	398312	rs8063584	Human NCBI Build 35	16	45841478	ENSG00000129636
9180	-	11303	C/T	0	398315	rs8084255	Human NCBI Build 35	18	46398752	MAPK4
9181	-	11309	C/T	0	398320	rs856075	Human NCBI Build 35	1	155779971	IFI16
9182	-	11310	C/T	0	398321	rs856111	Human NCBI Build 35	1	155709910	PYHIN1
9183	-	11319	C/T	0	398328	rs926288	Human NCBI Build 35	20	41247578	PTPRT
9184	-	11322	C/T	1	398330	rs9282648	Human NCBI Build 35	3	123321048	CD86
9185	-	11324	C/T	0	398332	rs9372313	Human NCBI Build 35	6	112248783	FYN
9186	-	11326	C/T	1	398334	rs9402845	Human NCBI Build 35	6	137131215	MAP3K5
9187	-	11327	C/T	0	398335	rs9463314	Human NCBI Build 35	6	47326730	TNFRSF21
9188	-	11329	C/T	0	398337	rs952033	Human NCBI Build 35	3	62071131	PTPRG
9189	-	11333	C/T	0	398341	rs978763	Human NCBI Build 35	1	157486852	CD48-ENSG00000198698
9190	-	11337	C/T	0	398343	rs9822989	Human NCBI Build 35	3	61889361	PTPRG
9191	-	11343	C/T	1	398349	rs9956880	Human NCBI Build 35	18	7637297	PTPRM
9192	-	11346	C/T	0	398352	rs10089107	Human NCBI Build 35	8	141767633	PTK2
9193	-	11348	C/T	0	398353	rs1013306	Human NCBI Build 35	9	87386695	DAPK1
9194	-	11356	C/T	0	398358	rs1048037	Human NCBI Build 35	4	15123714	C1QTNF7
9195	-	11375	C/T	0	398373	rs10881975	Human NCBI Build 35	10	93570624	TNKS2
9196	-	11376	C/T	0	398374	rs10899377	Human NCBI Build 35	11	76828869	PAK1
9197	-	11377	C/T	0	398375	rs10901294	Human NCBI Build 35	9	130762306	ABL1
9198	-	11378	C/T	0	398376	rs10972388	Human NCBI Build 35	9	35219091	UNC13B-ENSG00000196186
9199	-	11380	C/T	0	398378	rs11039489	Human NCBI Build 35	11	47985100	PTPRJ
9200	-	11381	C/T	0	398379	rs11085954	Human NCBI Build 35	19	15455019	ENSG00000161031
9201	-	11383	C/T	0	398381	rs11120277	Human NCBI Build 35	1	203707965	C4BPA
9202	-	11391	C/T	0	398388	rs11558237	Human NCBI Build 35	12	109625253	PPP1CC
9203	-	11399	C/T	0	398394	rs11852361	Human NCBI Build 35	15	89127103	BLM
9204	-	11406	C/T	0	398398	rs12001671	Human NCBI Build 35	9	8547948	PTPRD
9205	-	11407	C/T	0	398399	rs12041056	Human NCBI Build 35	1	67339281	IL23R
9206	-	11410	C/T	0	398402	rs12089041	Human NCBI Build 35	1	51093615	FAF1
9207	-	11413	C/T	0	398404	rs12114599	Human NCBI Build 35	8	16023670	MSR1
9208	-	11415	C/T	0	398406	rs12210179	Human NCBI Build 35	6	22407025	PRL
9209	-	11418	C/T	0	398408	rs12269373	Human NCBI Build 35	10	101962368	CHUK
9210	-	11426	C/T	0	398415	rs1321382	Human NCBI Build 35	X	104333204	IL1RAPL2
9211	-	11429	C/T	0	398418	rs1420620	Human NCBI Build 35	4	88012232	PTPN13
9212	-	11433	C/T	0	398421	rs1500317	Human NCBI Build 35	9	8348567	PTPRD
9213	-	11436	C/T	1	398423	rs1579564	Human NCBI Build 35	9	8694007	PTPRD
9214	-	11437	C/T	0	398424	rs161803	Human NCBI Build 35	1	7910055	TNFRSF9
9215	-	11438	C/T	0	398425	rs1639150	Human NCBI Build 35	16	3687205	TRAP1
9216	-	11440	C/T	0	398427	rs1738289	Human NCBI Build 35	6	128638991	PTPRK
9217	-	11447	C/T	0	398434	rs2029091	Human NCBI Build 35	2	68389599	ENSG00000115953
9218	-	11450	C/T	0	398437	rs2064501	Human NCBI Build 35	6	137519516	IL22RA2
9219	-	11453	C/T	0	398440	rs2069779	Human NCBI Build 35	4	123731502	ENSG00000109471
9220	-	11454	C/T	0	398441	rs2072449	Human NCBI Build 35	12	8101904	FOXJ2-C3AR1
9221	-	11460	C/T	0	398447	rs216151	Human NCBI Build 35	5	149428620	CSF1R
9222	-	11467	C/T	0	398453	rs2287291	Human NCBI Build 35	2	162961463	IFIH1

9223	-	11472	C/T	0	398458	rs2301378	Human NCBI Build 35	X	103836866	IL1RAPL2
9224	-	11479	C/T	0	398464	rs2461491	Human NCBI Build 35	8	22417197	PPP3CC-PIWIL2
9225	-	11489	C/T	0	398472	rs2709360	Human NCBI Build 35	2	208240847	CREB1
9226	-	11490	C/T	0	398473	rs2719230	Human NCBI Build 35	8	57050632	LYN
9227	-	11498	C/T	0	398479	rs2885373	Human NCBI Build 35	3	191829170	IL1RAP
9228	-	11508	C/T	0	398488	rs347156	Human NCBI Build 35	3	32443220	ENSG00000153551
9229	-	11510	C/T	1	398490	rs367632	Human NCBI Build 35	5	156538237	ITK
9230	-	11511	C/T	0	398491	rs37389	Human NCBI Build 35	5	35120937	PRLR
9231	-	11516	C/T	0	398494	rs3772558	Human NCBI Build 35	3	106725377	ALCAM
9232	-	11530	C/T	0	398506	rs4085784	Human NCBI Build 35	6	128744182	PTPRK
9233	-	11532	C/T	1	398508	rs4129632	Human NCBI Build 35	9	87452690	DAPK1
9234	-	11537	C/T	0	398513	rs4385206	Human NCBI Build 35	5	122402896	PPIC
9235	-	11540	C/T	0	398515	rs4465172	Human NCBI Build 35	1	210997274	PTPN14
9236	-	11541	C/T	0	398516	rs4487072	Human NCBI Build 35	2	201833804	CFLAR
9237	-	11542	C/T	0	398517	rs4487330	Human NCBI Build 35	4	87372545	MAPK10
9238	-	11547	C/T	1	398521	rs4657370	Human NCBI Build 35	1	161395685	PBX1
9239	-	11550	C/T	0	398523	rs4665124	Human NCBI Build 35	2	160528888	LY75
9240	-	11553	C/T	1	398524	rs4812688	Human NCBI Build 35	20	41243626	PTPRT
9241	-	11556	C/T	1	398526	rs4952787	Human NCBI Build 35	2	46006124	PRKCE
9242	-	11558	C/T	0	398528	rs4957343	Human NCBI Build 35	5	40730827	PTGER4
9244	-	11570	C/T	1	398539	rs5916940	Human NCBI Build 35	X	104706702	IL1RAPL2
9245	-	11571	C/T	1	398540	rs5917190	Human NCBI Build 35	X	104053380	IL1RAPL2
9246	-	11578	C/T	0	398547	rs6517664	Human NCBI Build 35	21	41626853	FAM3B
9247	-	11579	C/T	0	398548	rs6550109	Human NCBI Build 35	3	32266207	CKLFSF8
9248	-	11582	C/T	1	398549	rs661968	Human NCBI Build 35	15	32048361	AVEN
9249	-	11586	C/T	0	398553	rs6668388	Human NCBI Build 35	1	232259945	ENSG00000143669
9250	-	11587	C/T	0	398554	rs6675945	Human NCBI Build 35	1	155715417	PYHIN1
9251	-	11589	C/T	0	398556	rs683762	Human NCBI Build 35	11	76759698	PAK1
9253	-	11600	C/T	0	398566	rs720305	Human NCBI Build 35	5	146414339	PPP2R2B
9254	-	11601	C/T	0	398567	rs723177	Human NCBI Build 35	1	158382729	FCGR2B
9255	-	11607	C/T	0	398572	rs746106	Human NCBI Build 35	9	8485044	PTPRD
9257	-	11624	C/T	0	398587	rs7820086	Human NCBI Build 35	8	75103065	LY96
9258	-	11625	C/T	1	398588	rs7830593	Human NCBI Build 35	8	23000640	TNFRSF10C
9259	-	11627	C/T	0	398590	rs7854004	Human NCBI Build 35	9	120833129	C5
9260	-	11629	C/T	1	398592	rs7962555	Human NCBI Build 35	12	15485996	PTPRO
9261	-	11631	C/T	1	398594	rs8004842	Human NCBI Build 35	14	63843145	ESR2
9262	-	11632	C/T	0	398595	rs8010715	Human NCBI Build 35	6	32024379	C2-RDBP-BF
9263	-	11635	C/T	0	398598	rs8078439	Human NCBI Build 35	17	11983357	MAP2K4
9264	-	11639	C/T	1	398602	rs864106	Human NCBI Build 35	12	93140025	PLXNC1
9265	-	11642	C/T	0	398605	rs917787	Human NCBI Build 35	7	76835517	PTPN12
9266	-	11649	C/T	0	398610	rs9310938	Human NCBI Build 35	3	30634123	TGFBR2
9267	-	11650	C/T	1	398611	rs9311833	Human NCBI Build 35	3	61968706	PTPRG
9268	-	11652	C/T	1	398613	rs9333353	Human NCBI Build 35	9	21401631	IFNA8
9269	-	11655	C/T	0	398615	rs9375543	Human NCBI Build 35	6	128352833	PTPRK
9270	-	11660	C/T	1	398619	rs980455	Human NCBI Build 35	4	103776144	NFKB1
9271	-	11665	C/T	0	398623	rs10250971	Human NCBI Build 35	18	75387055	
ENSG00000186783-NFATC1-ENSG00000198662										
9272	-	11670	C/T	0	398627	rs1033125	Human NCBI Build 35	9	8637808	PTPRD
9273	-	11680	C/T	1	398633	rs10498658	Human NCBI Build 35	6	3049695	RIPK1

9274	-	11681	C/T	1	398634	rs10503144	Human NCBI Build 35	1	220326366	TP53BP2
9275	-	11684	C/T	1	398637	rs10805347	Human NCBI Build 35	4	15517108	CD38
9276	-	11696	C/T	0	398646	rs11608799	Human NCBI Build 35	12	15429064	PTPRO
9277	-	11701	C/T	1	398650	rs12066633	Human NCBI Build 35	1	152521417	DAP3-ENSG00000125459
9278	-	11703	C/T	0	398652	rs12116643	Human NCBI Build 35	1	193704840	CFHL5
9279	-	11738	C/T	0	398679	rs2000636	Human NCBI Build 35	11	59977523	MS4A1
9280	-	11742	C/T	0	398682	rs2078035	Human NCBI Build 35	6	28596013	GPX6
9281	-	11743	C/T	0	398683	rs2193875	Human NCBI Build 35	3	191804158	IL1RAP
9282	-	11744	C/T	0	398684	rs2227484	Human NCBI Build 35	12	66934196	IL22
9283	-	11746	C/T	0	398686	rs2243010	Human NCBI Build 35	5	76153524	F2RL1-ENSG00000183613
9284	-	11751	C/T	1	398691	rs2273405	Human NCBI Build 35	1	222430876	ENSG00000143768
9285	-	11753	C/T	1	398693	rs2289545	Human NCBI Build 35	5	39223278	FYB
9286	-	11763	C/T	0	398702	rs2457996	Human NCBI Build 35	4	75221570	CXCL5-PPBP
9287	-	11779	C/T	0	398712	rs2847286	Human NCBI Build 35	18	12807815	PTPN2
9288	-	11780	C/T	0	398713	rs2877098	Human NCBI Build 35	7	41516534	INHBA
9289	-	11782	C/T	0	398715	rs291329	Human NCBI Build 35	2	239880676	HDAC4
9290	-	11785	C/T	0	398718	rs3176800	Human NCBI Build 35	12	9797756	CD69
9291	-	11788	C/T	0	398721	rs33998	Human NCBI Build 35	5	141949111	FGF1
9292	-	11794	C/T	0	398725	rs3741792	Human NCBI Build 35	12	12161227	LRP6-BCL2L14
9294	-	11797	C/T	0	398728	rs3768072	Human NCBI Build 35	1	232342756	ENSG00000143669
9295	-	11800	C/T	1	398731	rs3773651	Human NCBI Build 35	3	30693536	TGFBR2
9296	-	11802	C/T	0	398733	rs3785378	Human NCBI Build 35	16	24134526	PRKCB1
9297	-	11811	C/T	0	398738	rs4143029	Human NCBI Build 35	1	116760372	CD58
9298	-	11814	C/T	0	398740	rs4440487	Human NCBI Build 35	6	128543849	PTPRK
9299	-	11818	C/T	0	398743	rs4688291	Human NCBI Build 35	3	62246456	PTPRG
9300	-	11819	C/T	0	398744	rs4688640	Human NCBI Build 35	3	61569809	PTPRG
9301	-	11822	C/T	1	398746	rs4800573	Human NCBI Build 35	18	20313668	HRH4
9302	-	11827	C/T	1	398749	rs4938802	Human NCBI Build 35	11	119734199	ARHGEF12
9303	-	11830	C/T	1	398752	rs4968199	Human NCBI Build 35	17	7388922	TNFSF12
9304	-	11837	C/T	0	398759	rs636833	Human NCBI Build 35	11	60492356	CD6
9305	-	11841	C/T	1	398762	rs6450355	Human NCBI Build 35	5	55214028	IL31RA
9306	-	11843	C/T	0	398763	rs6473118	Human NCBI Build 35	8	79864238	IL7
9307	-	11855	C/T	0	398771	rs6769017	Human NCBI Build 35	3	61910845	PTPRG
9308	-	11858	C/T	0	398773	rs6854208	Human NCBI Build 35	4	87426355	MAPK10
9309	-	11860	C/T	1	398774	rs6873877	Human NCBI Build 35	5	41211181	C6
9310	-	11862	C/T	0	398776	rs6931769	Human NCBI Build 35	6	128685222	PTPRK
9311	-	11873	C/T	0	398783	rs7129944	Human NCBI Build 35	11	119804917	ARHGEF12
9312	-	11874	C/T	1	398784	rs7162087	Human NCBI Build 35	15	89145732	BLM
9313	-	11875	C/T	0	398785	rs7165366	Human NCBI Build 35	15	97185196	IGF1R
9314	-	11877	C/T	0	398786	rs7171854	Human NCBI Build 35	15	31956694	AVEN
9316	-	11880	C/T	0	398788	rs7373528	Human NCBI Build 35	3	37725628	ITGA9
9317	-	11885	C/T	0	398792	rs7552221	Human NCBI Build 35	1	232289925	ENSG00000143669
9318	-	11892	C/T	0	398798	rs7796348	Human NCBI Build 35	7	157098551	PTPRN2
9319	-	11896	C/T	0	398802	rs8043421	Human NCBI Build 35	15	39662243	TYRO3
9320	-	11901	C/T	0	398805	rs851010	Human NCBI Build 35	6	36149409	MAPK13-MAPK14
9321	-	11903	C/T	0	398806	rs8539	Human NCBI Build 35	2	198187524	HSPD1-ENSG00000115541
9322	-	11906	C/T	0	398809	rs884618	Human NCBI Build 35	1	151414230	ADAR
9323	-	11910	C/T	0	398812	rs918608	Human NCBI Build 35	5	41188446	C6
9324	-	11912	C/T	1	398813	rs924140	Human NCBI Build 35	7	45736354	IGFBP3

9325	-	11914	C/T	0	398814	rs9288803	Human NCBI Build 35	3	106614698	ALCAM
9326	-	11916	C/T	1	398816	rs9288817	Human NCBI Build 35	3	106922212	CBLB
9327	-	11917	C/T	1	398817	rs9319410	Human NCBI Build 35	13	27489318	FLT3
9328	-	11918	C/T	0	398818	rs932272	Human NCBI Build 35	7	30286399	CARD4
9329	-	11921	C/T	0	398821	rs9532580	Human NCBI Build 35	13	40142260	FOXO1A
9330	-	11927	C/T	1	398826	rs982764	Human NCBI Build 35	10	90759978	ENSG00000026103
9331	-	11935	C/T	1	398832	rs10212473	Human NCBI Build 35	3	33847988	PDCD6IP
9332	-	11940	C/T	0	398837	rs10497213	Human NCBI Build 35	2	160789110	ITGB6
9333	-	11943	C/T	0	398840	rs10512764	Human NCBI Build 35	5	41193097	C6
9334	-	11946	C/T	0	398842	rs10814123	Human NCBI Build 35	9	34551808	CNTFR
9335	-	11947	C/T	0	398843	rs10814229	Human NCBI Build 35	9	35336385	UNC13B-ENSG00000196186
9336	-	11954	C/T	0	398850	rs11190430	Human NCBI Build 35	10	101974535	CHUK
9337	-	11956	C/T	1	398851	rs11205756	Human NCBI Build 35	1	50857373	FAF1
9338	-	11957	C/T	1	398852	rs1156793	Human NCBI Build 35	9	8368662	PTPRD
9340	-	11966	C/T	0	398858	rs1253626	Human NCBI Build 35	1	232943257	EDARADD
9341	-	11980	C/T	1	398868	rs1500324	Human NCBI Build 35	9	8367235	PTPRD
9342	-	11991	C/T	1	398877	rs1788230	Human NCBI Build 35	18	65684054	CD226
9345	-	11998	C/T	0	398883	rs1924	Human NCBI Build 35	7	79936049	CD36
9346	-	11999	C/T	0	398884	rs1945738	Human NCBI Build 35	11	104334372	CASP4
9347	-	12006	C/T	1	398889	rs2013214	Human NCBI Build 35	17	11898778	MAP2K4
9348	-	12018	C/T	1	398899	rs2288739	Human NCBI Build 35	12	97547231	APAF1
9349	-	12024	C/T	0	398904	rs2300939	Human NCBI Build 35	9	120891271	C5
9350	-	12026	C/T	1	398905	rs2302975	Human NCBI Build 35	5	67605235	PIK3R1
9351	-	12036	C/T	0	398913	rs2562754	Human NCBI Build 35	15	78042264	BCL2A1
9352	-	12038	C/T	1	398914	rs261597	Human NCBI Build 35	5	169176420	DOCK2
9353	-	12047	C/T	0	398922	rs320344	Human NCBI Build 35	1	240192077	AKT3
9354	-	12049	C/T	0	398924	rs3736509	Human NCBI Build 35	11	107473994	CUL5
9355	-	12053	C/T	0	398927	rs3780150	Human NCBI Build 35	9	36897255	PAX5
9356	-	12057	C/T	1	398930	rs3796870	Human NCBI Build 35	4	15487801	CD38
9357	-	12059	C/T	1	398932	rs3815997	Human NCBI Build 35	12	97573491	APAF1
9358	-	12061	C/T	0	398934	rs391463	Human NCBI Build 35	5	38923537	OSMR
9359	-	12062	C/T	0	398935	rs394447	Human NCBI Build 35	8	16092517	MSR1
9360	-	12063	C/T	0	398936	rs417708	Human NCBI Build 35	21	41639532	FAM3B
9361	-	12068	C/T	0	398940	rs4442186	Human NCBI Build 35	9	8690193	PTPRD
9362	-	12076	C/T	0	398948	rs4664463	Human NCBI Build 35	2	162975472	IFIH1
9363	-	12078	C/T	0	398950	rs4688666	Human NCBI Build 35	3	61899485	PTPRG
9364	-	12086	C/T	0	398955	rs4878669	Human NCBI Build 35	9	36922342	PAX5
9365	-	12091	C/T	0	398959	rs5951303	Human NCBI Build 35	X	100441785	BTB
9366	-	12092	C/T	0	398960	rs601032	Human NCBI Build 35	3	139832030	FAIM
9367	-	12095	C/T	0	398962	rs611596	Human NCBI Build 35	1	89433883	GBP5
9368	-	12096	C/T	0	398963	rs6130305	Human NCBI Build 35	20	41226191	PTPRT
9369	-	12100	C/T	0	398967	rs6523800	Human NCBI Build 35	X	103932049	IL1RAPL2
9370	-	12101	C/T	0	398968	rs6523819	Human NCBI Build 35	X	104131186	IL1RAPL2
9371	-	12107	C/T	0	398972	rs6763419	Human NCBI Build 35	3	62192561	PTPRG
9372	-	12109	C/T	0	398974	rs6889164	Human NCBI Build 35	5	156399356	HAVCR1
9373	-	12117	C/T	1	398981	rs7117238	Human NCBI Build 35	11	77717907	GAB2
9374	-	12122	C/T	0	398985	rs7304487	Human NCBI Build 35	12	15368950	PTPRO
9375	-	12126	C/T	0	398989	rs7619647	Human NCBI Build 35	3	106975976	CBLB
9377	-	12134	C/T	1	398995	rs7769070	Human NCBI Build 35	6	128469242	PTPRK

9378	-	12138	C/T	0	398997	rs7834266	Human NCBI Build 35	8	22954349	TNFRSF10B
9379	-	12148	C/T	0	399006	rs8024123	Human NCBI Build 35	15	97142392	IGF1R
9380	-	12160	C/T	1	399018	rs9398869	Human NCBI Build 35	6	128783169	PTPRK
9381	-	12162	C/T	0	399020	rs957077	Human NCBI Build 35	4	142937421	IL15
9382	-	12164	C/T	0	399022	rs9878820	Human NCBI Build 35	3	139868113	PIK3CB
9383	-	12165	C/T	1	399023	rs9886768	Human NCBI Build 35	9	8665366	PTPRD
9384	-	12167	C/T	0	399025	rs9991664	Human NCBI Build 35	4	111222137	EGF
9385	-	12170	C/T	0	399027	rs10078717	Human NCBI Build 35	5	39217144	FYB
9386	-	12171	C/T	0	399028	rs1022506	Human NCBI Build 35	6	135553280	MYB
9387	-	12173	C/T	0	399030	rs10408844	Human NCBI Build 35	19	7195884	INSR
9388	-	12180	C/T	1	399037	rs10772273	Human NCBI Build 35	12	10428840	KLRC4
9389	-	12185	C/T	0	399039	rs10964969	Human NCBI Build 35	9	21337959	IFNA6
9390	-	12191	C/T	0	399044	rs12348522	Human NCBI Build 35	9	8633259	PTPRD
9391	-	12197	C/T	0	399048	rs13230419	Human NCBI Build 35	7	79953936	CD36
9392	-	12202	C/T	0	399051	rs1392519	Human NCBI Build 35	9	8364083	PTPRD
9393	-	12203	C/T	1	399052	rs1417900	Human NCBI Build 35	6	128846741	PTPRK
9394	-	12205	C/T	0	399053	rs1441586	Human NCBI Build 35	11	59612604	MS4A2
9395	-	12212	C/T	1	399060	rs1697938	Human NCBI Build 35	5	40890439	CARD6
9396	-	12218	C/T	1	399065	rs1876680	Human NCBI Build 35	5	54370181	GZMK
9397	-	12221	C/T	1	399067	rs2070715	Human NCBI Build 35	5	142004440	FGF1
9398	-	12227	C/T	0	399072	rs2300287	Human NCBI Build 35	12	15621948	PTPRO
9399	-	12229	C/T	0	399073	rs2305268	Human NCBI Build 35	3	139866771	PIK3CB
9400	-	12233	C/T	0	399077	rs2589523	Human NCBI Build 35	4	87290381	MAPK10
9401	-	12236	C/T	1	399079	rs2709359	Human NCBI Build 35	2	208240643	CREB1
9402	-	12238	C/T	0	399081	rs2787337	Human NCBI Build 35	9	114163782	ORM1
9403	-	12239	C/T	0	399082	rs2853559	Human NCBI Build 35	12	46569072	VDR
9404	-	12244	C/T	0	399087	rs367153	Human NCBI Build 35	5	156543424	ITK
9405	-	12245	C/T	0	399088	rs3729734	Human NCBI Build 35	5	38563065	LIFR
9406	-	12250	C/T	0	399092	rs3866741	Human NCBI Build 35	14	63691985	SYNE2-ESR2
9407	-	12251	C/T	0	399093	rs3887125	Human NCBI Build 35	11	56906803	PRG3-PRG2
9408	-	12252	C/T	0	399094	rs4235652	Human NCBI Build 35	5	35245096	PRLR
9409	-	12254	C/T	0	399096	rs4292454	Human NCBI Build 35	5	42659002	GHR
9410	-	12255	C/T	1	399097	rs4406737	Human NCBI Build 35	10	90749704	ENSG0000026103
9411	-	12256	C/T	0	399098	rs4511593	Human NCBI Build 35	17	7396260	TNFSF12
9412	-	12257	C/T	0	399099	rs4573107	Human NCBI Build 35	6	128463455	PTPRK
9413	-	12259	C/T	0	399101	rs4961234	Human NCBI Build 35	8	141910063	PTK2
9414	-	12262	C/T	1	399103	rs519086	Human NCBI Build 35	1	89436666	GBP5
9415	-	12266	C/T	0	399107	rs6093581	Human NCBI Build 35	20	40221249	PTPRT
9416	-	12269	C/T	0	399110	rs6573549	Human NCBI Build 35	14	63791402	ESR2
9417	-	12289	C/T	0	399123	rs7861140	Human NCBI Build 35	9	8575188	PTPRD
9418	-	12292	C/T	0	399125	rs8008134	Human NCBI Build 35	14	54577273	SOCS4
9419	-	12293	C/T	0	399126	rs8044842	Human NCBI Build 35	16	45829377	ENSG00000129636
9420	-	12294	C/T	1	399127	rs8084791	Human NCBI Build 35	18	8002208	PTPRM
9421	-	12298	C/T	1	399130	rs888163	Human NCBI Build 35	12	15552708	PTPRO
9422	-	12308	C/T	0	399139	rs11644557	Human NCBI Build 35	16	45751552	ENSG00000129636
9423	-	12309	C/T	0	399140	rs1165694	Human NCBI Build 35	12	102843482	TRA1
9424	-	12312	C/T	0	399143	rs13428968	Human NCBI Build 35	2	157018121	NR4A2
9425	-	12316	C/T	1	399145	rs1380846	Human NCBI Build 35	15	62015209	ENSG0000035664
9426	-	12320	C/T	0	399148	rs1633292	Human NCBI Build 35	1	155754292	PYHIN1

9427	-	12324	C/T	1	399152	rs1935836	Human NCBI Build 35	1	114021214	PTPN22-RSBN1
9428	-	12329	C/T	1	399156	rs2043498	Human NCBI Build 35	7	157313691	PTPRN2
9429	-	12332	C/T	0	399158	rs2066870	Human NCBI Build 35	4	155888938	FGG
9430	-	12334	C/T	0	399160	rs212714	Human NCBI Build 35	2	32371999	CARD12
9431	-	12344	C/T	1	399166	rs3767747	Human NCBI Build 35	1	195395759	PTPRC
9432	-	12346	C/T	1	399167	rs3774932	Human NCBI Build 35	4	103781378	NFKB1
9433	-	12349	C/T	0	399170	rs4421217	Human NCBI Build 35	6	128559785	PTPRK
9434	-	12353	C/T	0	399173	rs4953255	Human NCBI Build 35	2	45915735	PRKCE
9435	-	12356	C/T	0	399176	rs6102926	Human NCBI Build 35	20	40662152	PTPRT
9436	-	12365	C/T	0	399184	rs7233012	Human NCBI Build 35	18	66134435	SOCS6
9437	-	12378	C/T	0	399193	rs900328	Human NCBI Build 35	4	111432504	EGF-ELOVL6
9438	-	12385	C/T	0	399199	rs10799128	Human NCBI Build 35	1	29424615	PTPRU
9439	-	12386	C/T	1	399200	rs10815924	Human NCBI Build 35	9	8674624	PTPRD
9440	-	12392	C/T	0	399206	rs12603036	Human NCBI Build 35	17	11884426	MAP2K4
9441	-	12398	C/T	1	399211	rs1952586	Human NCBI Build 35	14	63829172	ESR2
9442	-	12403	C/T	0	399216	rs2210909	Human NCBI Build 35	1	154557921	SPAP1
9443	-	12405	C/T	0	399217	rs2275646	Human NCBI Build 35	10	93576695	TNKS2
9444	-	12406	C/T	1	399218	rs2306664	Human NCBI Build 35	12	93155695	PLXNC1
9445	-	12408	C/T	0	399220	rs2418736	Human NCBI Build 35	16	66712363	NFATC3
9446	-	12409	C/T	1	399221	rs251037	Human NCBI Build 35	3	61947662	PTPRG
9447	-	12415	C/T	0	399225	rs3752689	Human NCBI Build 35	2	179138120	PRKRA
9448	-	12416	C/T	0	399226	rs4832316	Human NCBI Build 35	2	86956371	CD8B1
9449	-	12417	C/T	0	399227	rs6469783	Human NCBI Build 35	8	120008446	TNFRSF11B
9450	-	12420	C/T	0	399230	rs706716	Human NCBI Build 35	5	67584198	PIK3R1
9451	-	12428	C/T	0	399234	rs7824121	Human NCBI Build 35	8	57084226	LYN
9452	-	12429	C/T	1	399235	rs914925	Human NCBI Build 35	9	90664348	SYK
9453	-	12434	C/T	0	399240	rs11054707	Human NCBI Build 35	12	12192761	LRP6-BCL2L14
9454	-	12439	C/T	0	399244	rs2111227	Human NCBI Build 35	16	46044318	ENSG00000129636
9455	-	12440	C/T	0	399245	rs2161612	Human NCBI Build 35	5	39142857	FYB-ENSG00000182977
9456	-	12441	C/T	0	399246	rs223531	Human NCBI Build 35	10	31780097	TCF8
9457	-	12453	C/T	0	399257	rs6523794	Human NCBI Build 35	X	103784547	IL1RAPL2
9458	-	12458	C/T	1	399260	rs6752136	Human NCBI Build 35	2	239946561	HDAC4
9459	-	12459	C/T	0	399261	rs718403	Human NCBI Build 35	12	12188223	LRP6-BCL2L14
9460	-	12461	C/T	1	399262	rs7430600	Human NCBI Build 35	3	112339473	PVRL3
9461	-	12464	C/T	1	399265	rs961292	Human NCBI Build 35	6	128792790	PTPRK
9462	-	12468	C/T	1	399268	rs1046675	Human NCBI Build 35	2	152061906	TNFAIP6
9463	-	12478	C/T	0	399275	rs1372558	Human NCBI Build 35	12	69301067	PTPRB
9464	-	12480	C/T	0	399277	rs1553457	Human NCBI Build 35	1	157461622	CD48
9465	-	12482	C/T	0	399278	rs2159011	Human NCBI Build 35	17	11965208	MAP2K4
9466	-	12484	C/T	1	399280	rs2482705	Human NCBI Build 35	9	91262057	NFIL3
9467	-	12490	C/T	0	399286	rs706911	Human NCBI Build 35	6	112156745	FYN
9468	-	12494	C/T	0	399290	rs925585	Human NCBI Build 35	15	97133010	IGF1R
9469	-	12502	C/T	0	399295	rs3809915	Human NCBI Build 35	18	12876163	PTPN2
9470	-	12505	C/T	0	399298	rs1265742	Human NCBI Build 35	12	109477841	ENSG00000196850
9471	-	1094	G/T	0	389128	rs11465333	Human NCBI Build 35	7	75046093	CCL26
9472	-	1215	G/T	0	389133	rs11574570	Human NCBI Build 35	19	59866821	ENSG00000186818
9473	-	1439	G/T	0	389142	rs11880097	Human NCBI Build 35	19	52515711	C5R1
9475	-	1542	G/T	0	389150	rs12459996	Human NCBI Build 35	19	46448746	AXL
9476	-	1653	G/T	0	389158	rs1268514	Human NCBI Build 35	10	79248298	DLG5

9477	-	2503	G/T	0	389196	rs16896257	Human NCBI Build 35	6	29963797	HLA-H-HLA-G
9478	-	2685	G/T	0	389203	rs1797647	Human NCBI Build 35	12	12143345	BCL2L14
9479	-	2696	G/T	0	389204	rs1802470	Human NCBI Build 35	1	158002009	APOA2-NDUFS2-FCER1G
9481	-	2886	G/T	0	389217	rs1893806	Human NCBI Build 35	18	59135944	BCL2
9482	-	2932	G/T	0	389220	rs1946	Human NCBI Build 35	12	107185845	CMKLR1
9483	-	4113	G/T	0	389280	rs2239301	Human NCBI Build 35	16	3056257	ENSG00000008517
9484	-	4280	G/T	1	389287	rs2246614	Human NCBI Build 35	11	609789	IRF7-ENSG00000099834
9486	-	5047	G/T	1	389319	rs2295259	Human NCBI Build 35	6	47380648	TNFRSF21
9487	-	5238	G/T	0	389329	rs2303112	Human NCBI Build 35	19	7672866	FCER2
9489	-	5326	G/T	0	389335	rs2306190	Human NCBI Build 35	19	14023676	IL27RA-ENSG00000187867
9490	-	5628	G/T	0	389348	rs2481082	Human NCBI Build 35	1	157796742	F11R
9491	-	5682	G/T	0	389350	rs2517897	Human NCBI Build 35	6	29908080	HLA-G
9492	-	6217	G/T	0	389386	rs3218171	Human NCBI Build 35	1	23592770	E2F2
9493	-	6309	G/T	0	389391	rs352142	Human NCBI Build 35	3	52241422	PTK9L
9494	-	6364	G/T	0	389396	rs366122	Human NCBI Build 35	5	169628189	LCP2-ENSG00000198424
9495	-	6598	G/T	0	389411	rs3748263	Human NCBI Build 35	12	115777158	HRK
9496	-	6831	G/T	0	389441	rs3811046	Human NCBI Build 35	2	113387609	IL1F7
9497	-	6868	G/T	0	389444	rs3813063	Human NCBI Build 35	17	75790449	CARD14
9498	-	7308	G/T	0	389502	rs4864872	Human NCBI Build 35	4	54993212	PDGFRA
9499	-	7310	G/T	1	389503	rs4880018	Human NCBI Build 35	9	36833844	PAX5
9500	-	7625	G/T	0	389554	rs6498130	Human NCBI Build 35	16	10917651	MHC2TA
9503	-	8164	G/T	1	389644	rs899729	Human NCBI Build 35	16	87229281	IL17C-ENSG00000158545
9505	-	8249	G/T	1	389660	rs9525639	Human NCBI Build 35	13	42030879	TNFSF11
9506	-	8278	G/T	1	389665	rs9657979	Human NCBI Build 35	1	7929356	TNFRSF9
9507	-	8323	G/T	0	389676	rs9951088	Human NCBI Build 35	18	46405476	MAPK4
9508	-	8366	G/T	0	389682	rs1005099	Human NCBI Build 35	3	188923208	BCL6
9509	-	8371	G/T	1	389684	rs1007889	Human NCBI Build 35	22	22563797	MIF
9510	-	8577	G/T	0	389719	rs11097099	Human NCBI Build 35	4	87465734	MAPK10
9511	-	8767	G/T	0	389767	rs1420624	Human NCBI Build 35	4	88036821	PTPN13
9512	-	8789	G/T	0	389774	rs1550002	Human NCBI Build 35	9	8694192	PTPRD
9513	-	8801	G/T	1	389776	rs1562653	Human NCBI Build 35	2	46108583	PRKCE
9515	-	8886	G/T	0	389798	rs1803306	Human NCBI Build 35	19	60017267	
KIR2DS2-ENSG00000167633-KIR2DS1-KIR3DS1-ENSG00000189013-KIR2DL4										
9516	-	8958	G/T	0	389808	rs196014	Human NCBI Build 35	16	23897101	PRKCB1
9518	-	9073	G/T	0	389831	rs2112703	Human NCBI Build 35	5	169059675	DOCK2
9519	-	9109	G/T	1	389839	rs2227447	Human NCBI Build 35	5	148738220	IL17B
9520	-	9143	G/T	1	389847	rs2231449	Human NCBI Build 35	11	117691515	CD3E
9521	-	9146	G/T	0	389849	rs2239455	Human NCBI Build 35	X	47240934	PFC
9522	-	9208	G/T	0	389859	rs2256721	Human NCBI Build 35	1	111574994	ENSG00000134216
9523	-	9220	G/T	0	389863	rs2272300	Human NCBI Build 35	12	51873735	ITGB7
9527	-	9588	G/T	0	389930	rs3181139	Human NCBI Build 35	3	173710607	TNFSF10
9528	-	9600	G/T	0	389932	rs3213119	Human NCBI Build 35	5	158676366	IL12B
9529	-	9796	G/T	1	389961	rs3761548	Human NCBI Build 35	X	48874612	FOXP3
9531	-	9916	G/T	1	389978	rs3789204	Human NCBI Build 35	6	41362719	TREM1
9532	-	10065	G/T	0	389999	rs3817614	Human NCBI Build 35	11	129240887	NFRKB
9533	-	10852	G/T	0	390116	rs6750782	Human NCBI Build 35	2	160517968	LY75
9534	-	10858	G/T	0	390118	rs6764042	Human NCBI Build 35	3	46034143	XCR1
9535	-	11278	G/T	0	390193	rs8119860	Human NCBI Build 35	20	49520170	NFATC2
9536	-	11321	G/T	1	390200	rs858550	Human NCBI Build 35	1	164211423	CD3Z

9537	-	11363	G/T	0	390210	rs883966	Human NCBI Build 35	9	36983868	PAX5
9539	-	11539	G/T	1	390233	rs962859	Human NCBI Build 35	21	33569993	IL10RB
9540	-	11551	G/T	0	390236	rs9658372	Human NCBI Build 35	12	116179027	NOS1
9541	-	11580	G/T	0	390240	rs9906989	Human NCBI Build 35	17	37709372	STAT5A
9542	-	11614	G/T	0	390244	rs998584	Human NCBI Build 35	6	43865874	VEGF
9543	-	11717	G/T	0	390264	rs1042506	Human NCBI Build 35	19	60568923	IL11-ENSG00000180024
9544	-	11863	G/T	0	390295	rs10949683	Human NCBI Build 35	7	157285192	PTPRN2
9545	-	11871	G/T	0	390297	rs11113062	Human NCBI Build 35	12	105520137	RFX4
9546	-	11888	G/T	0	390302	rs11188664	Human NCBI Build 35	10	97952507	BLNK
9547	-	11958	G/T	0	390314	rs11541191	Human NCBI Build 35	19	54069230	PPP1R15A
9548	-	11972	G/T	0	390317	rs11574845	Human NCBI Build 35	10	104146373	NFKB2
9549	-	11974	G/T	0	390318	rs11575245	Human NCBI Build 35	12	55023518	IL23A-STAT2
9552	-	12127	G/T	1	390346	rs12302046	Human NCBI Build 35	12	8574988	ENSG00000166523
9553	-	12395	G/T	0	390395	rs1538773	Human NCBI Build 35	1	240000723	AKT3
9554	-	12454	G/T	0	390405	rs1615402	Human NCBI Build 35	5	40894217	CARD6
9555	-	12495	G/T	0	390413	rs1683564	Human NCBI Build 35	19	810214	ELA2-DF
9556	-	12534	G/T	0	390420	rs17088980	Human NCBI Build 35	8	23112849	TNFRSF10A-ENSG00000147457
9557	-	4421	G/T	0	390440	rs182832	Human NCBI Build 35	8	56953415	LYN
9558	-	5300	G/T	0	390446	rs1892808	Human NCBI Build 35	3	37621949	ITGA9
9559	-	1333	G/T	0	390454	rs2048767	Human NCBI Build 35	2	239897005	HDAC4
9560	-	2286	G/T	0	390489	rs2236350	Human NCBI Build 35	14	23700850	ISGF3G
9561	-	5676	G/T	0	390499	rs2241147	Human NCBI Build 35	16	54100823	MMP2-ENSG00000087253
9562	-	4462	G/T	0	390549	rs2295612	Human NCBI Build 35	1	157429776	SLAMF1
9563	-	1452	G/T	0	390568	rs244073	Human NCBI Build 35	20	42688109	ADA
9564	-	3458	G/T	0	390569	rs2480678	Human NCBI Build 35	1	164175081	CD3Z
9565	-	2805	G/T	0	390578	rs2701880	Human NCBI Build 35	13	40048505	FOXO1A
9566	-	426	G/T	0	390583	rs2744902	Human NCBI Build 35	1	71219562	PTGER3
9568	-	3276	G/T	1	390626	rs3212723	Human NCBI Build 35	19	17815215	INSL3
9569	-	5667	G/T	0	390641	rs3738760	Human NCBI Build 35	1	110178852	CSF1
9570	-	2863	G/T	1	390643	rs3745568	Human NCBI Build 35	19	6641613	C3
9571	-	4052	G/T	0	390651	rs3756712	Human NCBI Build 35	5	362096	AHRR
9572	-	4699	G/T	0	390666	rs3788150	Human NCBI Build 35	21	45158230	ITGB2
9573	-	4375	G/T	0	390673	rs3793833	Human NCBI Build 35	10	71340290	COL13A1-AMID
9574	-	5050	G/T	0	390675	rs3799558	Human NCBI Build 35	6	6129818	F13A1
9575	-	4471	G/T	0	390691	rs3821231	Human NCBI Build 35	2	128126032	GPR17-LIMS2
9576	-	3522	G/T	0	390695	rs3825390	Human NCBI Build 35	12	109439129	ENSG00000196850
9577	-	3568	G/T	0	390717	rs4252336	Human NCBI Build 35	14	75502382	TGFB3
9578	-	2837	G/T	0	390738	rs457414	Human NCBI Build 35	3	10177884	IRAK2
9579	-	869	G/T	1	390793	rs6102760	Human NCBI Build 35	20	40355020	PTPRT
9580	-	4220	G/T	0	390796	rs612392	Human NCBI Build 35	7	157200090	
PTPRN2-ENSG00000196590-ENSG00000196201										
9581	-	5186	G/T	0	390797	rs6133	Human NCBI Build 35	1	166297004	SELP
9582	-	4886	G/T	1	390798	rs6184	Human NCBI Build 35	5	42755101	GHR
9583	-	2830	G/T	0	390814	rs6587082	Human NCBI Build 35	17	19228069	MFAP4-MAPK7
9584	-	2321	G/T	0	390817	rs6621944	Human NCBI Build 35	X	104262237	IL1RAPL2
9585	-	2010	G/T	1	390818	rs6707930	Human NCBI Build 35	2	113453861	IL1F9
9586	-	735	G/T	1	390819	rs671329	Human NCBI Build 35	20	3563027	ATRN
9587	-	4288	G/T	0	390824	rs6808835	Human NCBI Build 35	Multiple	0	CCRL2-ENSG00000188268
9588	-	2876	G/T	0	390833	rs704856	Human NCBI Build 35	1	164212698	CD3Z

9589	-	5680	G/T	0	390843	rs7230967	Human NCBI Build 35	18	54537900	MALT1
9590	-	4890	G/T	0	390851	rs7259731	Human NCBI Build 35	19	59533544	ENSG00000170858
9591	-	6028	G/T	0	390878	rs7687648	Human NCBI Build 35	4	185946422	CASP3-ENSG00000164306
9592	-	4575	G/T	0	390880	rs770087	Human NCBI Build 35	12	88247241	DUSP6
9594	-	5961	G/T	0	390949	rs954440	Human NCBI Build 35	10	91056269	IFIT2-LIPA
9595	-	1311	G/T	0	390952	rs9607272	Human NCBI Build 35	22	20460952	MAPK1
9596	-	4214	G/T	0	390968	rs10125894	Human NCBI Build 35	9	8356757	PTPRD
9597	-	1513	G/T	0	390976	rs10413421	Human NCBI Build 35	19	15443973	ENSG00000161031
9598	-	3204	G/T	0	390999	rs10521209	Human NCBI Build 35	16	49313210	CARD15
9599	-	6248	G/T	0	391011	rs10784411	Human NCBI Build 35	12	63142194	TBK1
9600	-	1374	G/T	0	391017	rs10914611	Human NCBI Build 35	1	32909689	YARS-ENSG00000162522
9601	-	3174	G/T	0	391041	rs11593766	Human NCBI Build 35	10	115447254	CASP7
9602	-	76	G/T	1	391047	rs11715522	Human NCBI Build 35	3	39298167	CX3CR1
9603	-	2746	G/T	0	391071	rs12401994	Human NCBI Build 35	1	157294735	SLAMF6
9604	-	4105	G/T	0	391112	rs1398603	Human NCBI Build 35	12	69361567	PTPRR
9605	-	1153	G/T	0	391134	rs1638006	Human NCBI Build 35	18	75389794	
ENSG00000186783-NFATC1-ENSG00000198662										
9606	-	5794	G/T	0	391142	rs1709851	Human NCBI Build 35	2	240059915	HDAC4
9607	-	4974	G/T	0	391153	rs1806465	Human NCBI Build 35	7	157368860	PTPRN2
9608	-	3811	G/T	0	391198	rs2072561	Human NCBI Build 35	19	51217707	PGLYRP1-ENSG00000104983
9609	-	5275	G/T	0	391220	rs2227551	Human NCBI Build 35	10	75339196	C10orf55-PLAU
9610	-	3939	G/T	1	391224	rs2228468	Human NCBI Build 35	3	42882116	CCBP2
9611	-	5078	G/T	0	391237	rs2238154	Human NCBI Build 35	12	110345205	
ENSG00000111252-ENSG00000196824										
9612	-	673	G/T	0	391252	rs2270132	Human NCBI Build 35	15	89152872	BLM
9613	-	5523	G/T	1	391298	rs2401398	Human NCBI Build 35	12	9795946	CD69
9614	-	5546	G/T	1	391310	rs2494514	Human NCBI Build 35	1	156609774	ENSG00000158714
9615	-	2895	G/T	0	391344	rs2898716	Human NCBI Build 35	2	239785165	HDAC4
9616	-	6323	G/T	0	391371	rs32574	Human NCBI Build 35	5	149199079	PPARGC1B
9617	-	2185	G/T	0	391388	rs3736907	Human NCBI Build 35	1	117272971	IGSF2
9618	-	3983	G/T	0	391401	rs3753658	Human NCBI Build 35	1	222319421	EPHX1
9619	-	855	G/T	0	391403	rs3755547	Human NCBI Build 35	2	160824299	ITGB6
9620	-	6130	G/T	0	391423	rs3784381	Human NCBI Build 35	15	62236892	SNX22-PPIB
9621	-	3178	G/T	0	391428	rs3796504	Human NCBI Build 35	1	157393622	SLAMF1
9622	-	6157	G/T	0	391429	rs3797111	Human NCBI Build 35	5	10738185	DAP-ENSG00000164236
9623	-	54	G/T	0	391438	rs3804250	Human NCBI Build 35	5	169655475	LCP2
9624	-	362	G/T	0	391442	rs3813627	Human NCBI Build 35	19	54858462	
ENSG00000126461-BCL2L12-IRF3										
9625	-	5493	G/T	0	391486	rs4595639	Human NCBI Build 35	12	69599986	PTPRR
9626	-	5365	G/T	0	391527	rs4977686	Human NCBI Build 35	9	21189680	ENSG00000137026
9627	-	4489	G/T	1	391535	rs551238	Human NCBI Build 35	7	99966179	EPO
9628	-	404	G/T	0	391538	rs5743869	Human NCBI Build 35	11	1284328	TOLLIP
9629	-	112	G/T	0	391546	rs5946040	Human NCBI Build 35	X	114070746	IL13RA2
9630	-	4217	G/T	1	391562	rs6111968	Human NCBI Build 35	20	1845045	PTPNS1
9632	-	4937	G/T	0	391588	rs6660233	Human NCBI Build 35	1	157286236	SLAMF6
9633	-	1349	G/T	0	391599	rs6945706	Human NCBI Build 35	7	157117454	PTPRN2
9634	-	3940	G/T	0	391601	rs699738	Human NCBI Build 35	1	117023189	CD2
9635	-	4285	G/T	0	391630	rs759167	Human NCBI Build 35	7	54901993	EGFR
9636	-	5119	G/T	0	391632	rs760458	Human NCBI Build 35	21	45153345	ITGB2

9638	-	3741	G/T	0	391640	rs7747167	Human NCBI Build 35	6	74487394	CD109
9639	-	4182	G/T	0	391664	rs8112883	Human NCBI Build 35	19	7130320	INSR
9641	-	2428	G/T	0	391669	rs833060	Human NCBI Build 35	6	43843127	VEGF
9642	-	3179	G/T	0	391696	rs908262	Human NCBI Build 35	2	239953776	HDAC4
9643	-	3713	G/T	0	391714	rs932859	Human NCBI Build 35	1	204084275	none
9644	-	3248	G/T	0	391742	rs1004420	Human NCBI Build 35	1	32398795	LCK
9645	-	4730	G/T	0	391744	rs10084647	Human NCBI Build 35	22	41112814	ENSG00000167087
9646	-	3067	G/T	1	391751	rs1021720	Human NCBI Build 35	9	8390610	PTPRD
9647	-	3389	G/T	0	391770	rs10502416	Human NCBI Build 35	18	12812702	PTPN2
9648	-	1982	G/T	1	391818	rs11466043	Human NCBI Build 35	16	3234259	MEFV
9649	-	3311	G/T	0	391829	rs11721	Human NCBI Build 35	1	1192554	TNFRSF4-ENSG00000078808
9650	-	5159	G/T	0	391868	rs12978323	Human NCBI Build 35	19	46447878	AXL
9651	-	159	G/T	0	391883	rs1375341	Human NCBI Build 35	2	46040918	PRKCE
9652	-	1050	G/T	0	391897	rs1499242	Human NCBI Build 35	11	22750385	GAS2
9653	-	2316	G/T	0	391899	rs1519553	Human NCBI Build 35	4	142996831	IL15
9654	-	5063	G/T	1	391901	rs1522984	Human NCBI Build 35	2	45852230	PRKCE
9656	-	2806	G/T	0	391936	rs1788279	Human NCBI Build 35	11	63045225	LGALS12-ENSG00000184999
9657	-	158	G/T	0	391952	rs1941421	Human NCBI Build 35	11	104458106	CASP1
9658	-	3128	G/T	0	391975	rs2056626	Human NCBI Build 35	1	164152083	CD3Z
9659	-	4354	G/T	0	392025	rs2243115	Human NCBI Build 35	3	161188982	IL12A
9660	-	3098	G/T	1	392041	rs2274065	Human NCBI Build 35	1	180291361	NCF2
9661	-	120	G/T	0	392052	rs2288523	Human NCBI Build 35	19	60394722	BRSK1-PTPRH
9662	-	5911	G/T	0	392063	rs2302009	Human NCBI Build 35	7	75043649	CCL26
9663	-	3065	G/T	1	392065	rs2304060	Human NCBI Build 35	5	149481944	PDGFRB
9664	-	5889	G/T	0	392067	rs2305820	Human NCBI Build 35	2	160819803	ITGB6
9666	-	2142	G/T	0	392134	rs291333	Human NCBI Build 35	2	239881630	HDAC4
9667	-	2076	G/T	0	392140	rs30084	Human NCBI Build 35	5	169208420	DOCK2
9668	-	1184	G/T	1	392164	rs3135499	Human NCBI Build 35	16	49323628	CARD15
9669	-	4047	G/T	0	392166	rs3136677	Human NCBI Build 35	17	29707671	CCL13-CCL1
9670	-	4602	G/T	0	392172	rs3176777	Human NCBI Build 35	12	9806272	CD69
9671	-	3683	G/T	0	392183	rs355974	Human NCBI Build 35	16	65224138	CKLFSF4
9672	-	1908	G/T	0	392193	rs3740677	Human NCBI Build 35	11	77605684	USP35-GAB2
9673	-	6273	G/T	0	392291	rs4801893	Human NCBI Build 35	19	56957884	FPRL1
9674	-	6047	G/T	0	392302	rs4880023	Human NCBI Build 35	9	36858848	PAX5
9676	-	4218	G/T	0	392326	rs5743295	Human NCBI Build 35	16	49323164	CARD15
9677	-	44	G/T	1	392333	rs582384	Human NCBI Build 35	2	45808088	PRKCE
9678	-	5707	G/T	0	392348	rs6096431	Human NCBI Build 35	20	49486048	NFATC2
9679	-	1549	G/T	1	392357	rs6494458	Human NCBI Build 35	15	62058148	ENSG00000035664
9680	-	4697	G/T	0	392359	rs6504224	Human NCBI Build 35	17	59793415	PECAM1
9681	-	5192	G/T	0	392369	rs6567274	Human NCBI Build 35	18	58188780	TNFRSF11A
9682	-	2846	G/T	0	392373	rs6621985	Human NCBI Build 35	X	104626699	IL1RAPL2
9683	-	952	G/T	1	392378	rs6669161	Human NCBI Build 35	1	211094863	PTPN14-ENSG00000181931
9684	-	3794	G/T	0	392389	rs6762192	Human NCBI Build 35	3	58601115	FAM3D
9685	-	2209	G/T	0	392391	rs6769925	Human NCBI Build 35	3	62139979	PTPRG
9686	-	1904	G/T	1	392402	rs6921588	Human NCBI Build 35	6	167464808	CCR6-ENSG00000187485
9687	-	4243	G/T	1	392410	rs7043489	Human NCBI Build 35	9	5013604	JAK2
9688	-	138	G/T	0	392419	rs7105163	Human NCBI Build 35	11	107451181	CUL5
9689	-	2440	G/T	0	392430	rs7199551	Human NCBI Build 35	16	23941146	PRKCB1
9690	-	4851	G/T	1	392442	rs737812	Human NCBI Build 35	22	28963664	LIF-ENSG00000185188

9691	-	2002	G/T	0	392448	rs745697	Human NCBI Build 35	1	220342577	TP53BP2
9692	-	643	G/T	0	392453	rs7517847	Human NCBI Build 35	1	67393690	IL23R
9693	-	3557	G/T	1	392454	rs7518199	Human NCBI Build 35	1	151220492	IL6R
9694	-	3856	G/T	0	392458	rs759159	Human NCBI Build 35	7	54953609	EGFR
9695	-	740	G/T	0	392465	rs7757915	Human NCBI Build 35	6	135585620	MYB
9696	-	3095	G/T	0	392466	rs7776191	Human NCBI Build 35	6	112289927	FYN
9697	-	3677	G/T	0	392470	rs7859849	Human NCBI Build 35	9	8660737	PTPRD
9698	-	432	G/T	0	392478	rs798037	Human NCBI Build 35	1	117020280	CD2
9699	-	3100	G/T	1	392490	rs8123	Human NCBI Build 35 17	4583314	CXCL16-ENSG00000161920	
9700	-	603	G/T	0	392493	rs821426	Human NCBI Build 35	1	150095145	PGLYRP3
9701	-	5436	G/T	1	392525	rs9324672	Human NCBI Build 35	5	150400249	TNIP1
9703	-	1543	G/T	1	392540	rs9729550	Human NCBI Build 35	1	1175165	TNFRSF18
9704	-	2928	G/T	0	392567	rs10208860	Human NCBI Build 35	2	75283243	TACR1
9705	-	746	G/T	0	392582	rs1050580	Human NCBI Build 35	6	36171794	MAPK13-MAPK14
9706	-	4226	G/T	0	392593	rs10758268	Human NCBI Build 35	9	34562767	CNTFR
9709	-	4532	G/T	0	392625	rs11465772	Human NCBI Build 35	1	67346546	IL23R
9710	-	1154	G/T	0	392629	rs11547274	Human NCBI Build 35	16	30273069	CD2BP2-ENSG00000169221
9711	-	5750	G/T	0	392630	rs11553986	Human NCBI Build 35	3	61703558	PTPRG-ENSG00000168370
9712	-	2349	G/T	0	392641	rs1172665	Human NCBI Build 35	9	90734059	SYK
9714	-	1533	G/T	0	392665	rs12466402	Human NCBI Build 35	2	46085688	PRKCE
9715	-	1260	G/T	0	392687	rs13196774	Human NCBI Build 35	6	6216613	F13A1
9716	-	264	G/T	1	392693	rs132653	Human NCBI Build 35	22	34881323	APOL3
9717	-	3895	G/T	0	392703	rs1360238	Human NCBI Build 35	9	5504372	PDCD1LG2
9718	-	3576	G/T	1	392706	rs1398101	Human NCBI Build 35	3	32320703	CKLFSF8
9719	-	1214	G/T	0	392727	rs1532800	Human NCBI Build 35	17	70048774	ENSG00000167850
9720	-	306	G/T	0	392753	rs17038766	Human NCBI Build 35	12	105657598	RFX4
9721	-	341	G/T	0	392759	rs17561	Human NCBI Build 35 2	113253454	IL1A	
9722	-	827	G/T	0	392805	rs2037955	Human NCBI Build 35	7	30285189	CARD4
9723	-	6279	G/T	0	392809	rs2051203	Human NCBI Build 35	3	37815088	ITGA9
9724	-	1499	G/T	1	392811	rs2052490	Human NCBI Build 35	5	149158366	PPARGC1B
9725	-	1585	G/T	0	392828	rs2073335	Human NCBI Build 35	14	24045001	CMA1
9726	-	1237	G/T	0	392833	rs2153906	Human NCBI Build 35	1	117463558	ENSG00000134258
9727	-	1139	G/T	0	392861	rs2269423	Human NCBI Build 35	19	18089331	PIK3R2-IL12RB1-MAST3
9729	-	5109	G/T	1	392882	rs2292018	Human NCBI Build 35	5	38882311	OSMR
9730	-	1493	G/T	0	392885	rs2298455	Human NCBI Build 35	6	30814340	FLOT1-DDR1-IER3
9731	-	2186	G/T	0	392898	rs2392685	Human NCBI Build 35	X	104223377	IL1RAPL2
9732	-	5766	G/T	1	392903	rs2448051	Human NCBI Build 35	12	12135761	BCL2L14
9733	-	1988	G/T	0	392914	rs2584665	Human NCBI Build 35	17	44925181	NGFR
9734	-	1986	G/T	1	392935	rs2740762	Human NCBI Build 35	7	55035551	EGFR
9735	-	1772	G/T	0	392940	rs2779252	Human NCBI Build 35	17	23155497	NOS2A
9737	-	190	G/T	1	392949	rs2887501	Human NCBI Build 35	8	79881135	IL7
9738	-	3027	G/T	0	392971	rs3093494	Human NCBI Build 35	X	154796819	IL9R
9739	-	3863	G/T	0	393000	rs3751149	Human NCBI Build 35	12	119916682	OASL-ENSG00000157895
9740	-	5743	G/T	0	393004	rs3756242	Human NCBI Build 35	4	15462271	CD38
9741	-	4783	G/T	1	393019	rs3779633	Human NCBI Build 35	8	27320162	PTK2B
9742	-	622	G/T	1	393035	rs3792285	Human NCBI Build 35	3	123302276	CD86
9743	-	3359	G/T	0	393053	rs3824872	Human NCBI Build 35	11	45862181	CRY2-MAPK8IP1
9744	-	6446	G/T	0	393055	rs3828149	Human NCBI Build 35	1	43719889	PTPRF
9745	-	4720	G/T	0	393057	rs3829382	Human NCBI Build 35	13	27475688	FLT3

9746	-	4245	G/T	0	393064	rs3859503	Human NCBI Build 35	19	58986212	NALP12
9747	-	5118	G/T	0	393076	rs4149246	Human NCBI Build 35	8	27439818	EPHX2
9748	-	5626	G/T	0	393079	rs4151660	Human NCBI Build 35	6	32026997	RDBP-BF
9750	-	3679	G/T	0	393151	rs522807	Human NCBI Build 35	1	12158505	TNFRSF1B
9751	-	4885	G/T	0	393153	rs535630	Human NCBI Build 35	11	59618108	MS4A2
9752	-	2402	G/T	0	393160	rs566416	Human NCBI Build 35	11	118264820	BLR1
9753	-	2442	G/T	0	393167	rs578169	Human NCBI Build 35	11	104366853	CASP5
9754	-	4599	G/T	0	393173	rs5992628	Human NCBI Build 35	22	15969624	IL17R
9755	-	3871	G/T	1	393184	rs606954	Human NCBI Build 35	18	8338401	PTPRM
9756	-	891	G/T	0	393186	rs6072793	Human NCBI Build 35	20	40618938	PTPRT
9757	-	3133	G/T	1	393187	rs6072926	Human NCBI Build 35	20	41052261	PTPRT
9758	-	914	G/T	0	393209	rs652641	Human NCBI Build 35	Multiple	0	
KIR2DS2-ENSG00000167633-KIR2DS1-KIR3DS1										
9759	-	2268	G/T	1	393212	rs6540433	Human NCBI Build 35	1	204041790	CR2
9760	-	518	G/T	1	393221	rs6602392	Human NCBI Build 35	10	6118085	IL2RA
9761	-	4952	G/T	1	393237	rs6794523	Human NCBI Build 35	3	3082691	IL5RA
9762	-	6116	G/T	0	393264	rs7227507	Human NCBI Build 35	18	7758602	PTPRM
9763	-	6090	G/T	1	393281	rs7517289	Human NCBI Build 35	1	157914963	DEDD
9764	-	3263	G/T	0	393297	rs763405	Human NCBI Build 35	6	6564697	LY86
9765	-	309	G/T	0	393312	rs7742662	Human NCBI Build 35	6	74547723	CD109
9766	-	743	G/T	0	393335	rs8069945	Human NCBI Build 35	17	24428097	MYO18A
9767	-	2390	G/T	0	393349	rs863454	Human NCBI Build 35	1	164220457	CD3Z-ENSG00000198352
9768	-	4513	G/T	0	393355	rs877440	Human NCBI Build 35	20	40672332	PTPRT
9769	-	2865	G/T	1	393363	rs922870	Human NCBI Build 35	6	6138755	F13A1
9770	-	227	G/T	1	393387	rs9658356	Human NCBI Build 35	12	116186738	NOS1
9772	-	879	G/T	0	393408	rs10223418	Human NCBI Build 35	6	37253501	PIM1
9773	-	1240	G/T	0	393409	rs1022650	Human NCBI Build 35	6	112233448	FYN
9774	-	3041	G/T	0	393411	rs1024748	Human NCBI Build 35	7	54902548	EGFR
9775	-	4728	G/T	0	393415	rs1032425	Human NCBI Build 35	1	29396221	PTPRU
9776	-	3710	G/T	1	393445	rs1058200	Human NCBI Build 35	11	35158489	CD44
9778	-	3890	G/T	0	393460	rs10860862	Human NCBI Build 35	12	101288539	IGF1
9779	-	4151	G/T	0	393462	rs10914539	Human NCBI Build 35	1	32384734	LCK-ENSG00000183615
9781	-	2501	G/T	0	393490	rs11690399	Human NCBI Build 35	2	113456490	IL1F9
9782	-	1931	G/T	0	393499	rs11929280	Human NCBI Build 35	3	112342878	PVRL3
9783	-	2437	G/T	0	393553	rs1366234	Human NCBI Build 35	19	7118817	INSR
9784	-	2136	G/T	1	393563	rs1429638	Human NCBI Build 35	4	75102965	CXCL1
9785	-	1226	G/T	0	393576	rs1539019	Human NCBI Build 35	1	243926342	CIAS1
9786	-	287	G/T	0	393591	rs164207	Human NCBI Build 35	3	32520695	CKLFSF6
9787	-	2290	G/T	0	393600	rs170364	Human NCBI Build 35	16	55967435	CX3CL1
9788	-	1309	G/T	1	393609	rs1800563	Human NCBI Build 35	6	137568992	IFNGR1
9789	-	4713	G/T	0	393638	rs2013826	Human NCBI Build 35	9	90670834	SYK
9790	-	955	G/T	0	393649	rs2066816	Human NCBI Build 35	12	55036270	APOF-STAT2
9791	-	5505	G/T	1	393668	rs2187999	Human NCBI Build 35	14	105845710	IGHA1
9792	-	1505	G/T	1	393673	rs2227612	Human NCBI Build 35	1	170607058	SERPINC1
9793	-	3388	G/T	0	393680	rs2235938	Human NCBI Build 35	1	29453216	PTPRU
9794	-	1310	G/T	0	393694	rs2271146	Human NCBI Build 35	5	169634968	LCP2-ENSG00000198424
9795	-	4346	G/T	0	393695	rs2273863	Human NCBI Build 35	1	233032319	LGALS8
9796	-	5683	G/T	0	393698	rs2276645	Human NCBI Build 35	2	97788570	ZAP70
9797	-	3463	G/T	1	393720	rs2296135	Human NCBI Build 35	10	6034700	IL15RA

9798	-	2265	G/T	0	393754	rs2681401	Human NCBI Build 35	3	123325817	CD86
9799	-	1773	G/T	0	393767	rs2796820	Human NCBI Build 35	1	214969842	ENSG00000092969
9800	-	1000	G/T	0	393769	rs2817864	Human NCBI Build 35	1	71215126	PTGER3
9801	-	5975	G/T	0	393779	rs2855812	Human NCBI Build 35	6	31580699	MICB
9802	-	2767	G/T	0	393786	rs2990510	Human NCBI Build 35	1	193752315	F13B
9803	-	4598	G/T	0	393798	rs311312	Human NCBI Build 35	1	204013936	CR2
9804	-	4600	G/T	0	393803	rs3128917	Human NCBI Build 35	6	33167974	HLA-DPB1-ENSG00000172899
9805	-	2009	G/T	0	393815	rs3212220	Human NCBI Build 35	5	158686773	IL12B
9806	-	1539	G/T	0	393818	rs324058	Human NCBI Build 35	5	40997651	C7
9807	-	906	G/T	0	393826	rs3733475	Human NCBI Build 35	4	185770259	IRF2
9808	-	4817	G/T	0	393835	rs3750768	Human NCBI Build 35	10	71529753	H2AFY2-AMID
9809	-	2838	G/T	0	393848	rs3773958	Human NCBI Build 35	3	191792305	IL1RAP
9810	-	6390	G/T	0	393864	rs3793740	Human NCBI Build 35	10	133642662	BNIP3
9811	-	820	G/T	1	393900	rs419137	Human NCBI Build 35	1	193428532	CFH
9812	-	25	G/T	1	393949	rs4878111	Human NCBI Build 35	9	87469883	DAPK1
9813	-	1077	G/T	0	393955	rs4952774	Human NCBI Build 35	2	45933032	PRKCE
9814	-	765	G/T	1	393973	rs5744222	Human NCBI Build 35	12	56431423	CDK4-MARCH9-SAS
9815	-	685	G/T	1	393984	rs598425	Human NCBI Build 35	3	106743488	ALCAM
9816	-	14	G/T	1	393991	rs606289	Human NCBI Build 35	10	6601253	PRKCQ
9817	-	1217	G/T	1	394025	rs6682987	Human NCBI Build 35	1	211042715	PTPN14
9818	-	148	G/T	1	394046	rs6878328	Human NCBI Build 35	5	38617770	LIFR
9819	-	5922	G/T	0	394059	rs696763	Human NCBI Build 35	5	39377102	C9
9820	-	422	G/T	0	394085	rs7307228	Human NCBI Build 35	12	8579342	ENSG00000166523
9821	-	930	G/T	0	394109	rs7632357	Human NCBI Build 35	3	32967207	CCR4
9822	-	715	G/T	0	394120	rs7777757	Human NCBI Build 35	7	38078459	TRGV9
9823	-	393	G/T	1	394128	rs795592	Human NCBI Build 35	4	140966250	MGST2
9824	-	4277	G/T	0	394169	rs9400489	Human NCBI Build 35	6	112093487	FYN
9825	-	3918	G/T	0	394194	rs9808938	Human NCBI Build 35	3	61524608	PTPRG
9826	-	730	G/T	0	394195	rs9809501	Human NCBI Build 35	3	12630689	RAF1-ENSG00000198383
9827	-	911	G/T	0	394208	rs10025248	Human NCBI Build 35	4	75106454	CXCL1
9828	-	4669	G/T	0	394219	rs1016140	Human NCBI Build 35	1	116788589	CD58
9829	-	255	G/T	1	394228	rs1041973	Human NCBI Build 35	2	102413986	IL1RL1
9830	-	2037	G/T	1	394242	rs10491118	Human NCBI Build 35	17	31338999	CCL15
9831	-	3925	G/T	0	394260	rs10515576	Human NCBI Build 35	5	146120172	PPP2R2B
9832	-	861	G/T	0	394270	rs1065489	Human NCBI Build 35	1	193441431	CFH
9834	-	6350	G/T	0	394297	rs11544516	Human NCBI Build 35	1	232972679	EDARADD
9835	-	6413	G/T	0	394303	rs11651242	Human NCBI Build 35	17	16795271	TNFRSF13B-ENSG00000170160
9836	-	6348	G/T	0	394355	rs131794	Human NCBI Build 35	22	49261896	ECGF1
9837	-	6576	G/T	1	394376	rs1370482	Human NCBI Build 35	18	46352772	MAPK4
9838	-	6615	G/T	1	394410	rs1697143	Human NCBI Build 35	5	66516825	LY64
9839	-	6636	G/T	0	394427	rs1843939	Human NCBI Build 35	7	2837162	CARD11
9840	-	6672	G/T	0	394457	rs197721	Human NCBI Build 35	3	37485040	ITGA9
9841	-	6684	G/T	0	394466	rs2024832	Human NCBI Build 35	6	112296405	FYN
9842	-	6728	G/T	0	394503	rs2228672	Human NCBI Build 35	1	166297923	SELP
9843	-	6737	G/T	0	394510	rs2238985	Human NCBI Build 35	X	100438118	BTk
9844	-	6746	G/T	0	394518	rs2243600	Human NCBI Build 35	21	33645531	IFNAR1
9845	-	6756	G/T	0	394528	rs2278326	Human NCBI Build 35	5	38917110	OSMR
9847	-	6791	G/T	0	394559	rs244935	Human NCBI Build 35	5	133483956	TCF7
9849	-	6834	G/T	0	394601	rs276513	Human NCBI Build 35	6	137404431	IL20RA

9850	-	6884	G/T	0	394646	rs351555	Human NCBI Build 35	8	16048607	MSR1
9851	-	6937	G/T	0	394692	rs379527	Human NCBI Build 35	19	6627442 C3	
9852	-	6961	G/T	0	394714	rs3858604	Human NCBI Build 35	12	92720114	CRADD
9853	-	6967	G/T	0	394719	rs3907130	Human NCBI Build 35	18	46403011	MAPK4
9854	-	6970	G/T	0	394722	rs3917407	Human NCBI Build 35	1	166433774	SELE
9856	-	6977	G/T	0	394729	rs410469	Human NCBI Build 35	2	32388643	CARD12
9857	-	7023	G/T	0	394769	rs4742095	Human NCBI Build 35	9	5435990 ENSG00000120217	
9858	-	7031	G/T	0	394776	rs4787676	Human NCBI Build 35	16	23964387	PRKCB1
9859	-	7032	G/T	0	394777	rs4796955	Human NCBI Build 35	18	12252402	CIDEA
9860	-	7045	G/T	0	394789	rs4880050	Human NCBI Build 35	9	36989024	PAX5
9861	-	7047	G/T	1	394791	rs489806	Human NCBI Build 35	2	239835710	HDAC4
9862	-	7061	G/T	0	394804	rs5025708	Human NCBI Build 35	6	30063178	HLA-G
9863	-	7065	G/T	0	394808	rs566435	Human NCBI Build 35	2	239858598	HDAC4
9864	-	7075	G/T	1	394817	rs6021233	Human NCBI Build 35	20	49528840	NFATC2
9865	-	7083	G/T	0	394824	rs6072947	Human NCBI Build 35	20	41075425	PTPRT
9866	-	7108	G/T	1	394845	rs6593206	Human NCBI Build 35	7	54954319	EGFR
9867	-	7134	G/T	0	394868	rs6787964	Human NCBI Build 35	3	61639986	PTPRG
9868	-	7144	G/T	1	394876	rs6918223	Human NCBI Build 35	6	32830510	HLA-DQB2
9869	-	7162	G/T	0	394892	rs7168213	Human NCBI Build 35	15	97047858	IGF1R
9870	-	7272	G/T	0	394981	rs871335	Human NCBI Build 35	15	97297469	IGF1R
9871	-	7281	G/T	0	394990	rs905155	Human NCBI Build 35	5	169406903	DOCK2
9872	-	7282	G/T	1	394991	rs911248	Human NCBI Build 35	1	57104530	C8B
9873	-	7329	G/T	0	395032	rs9877854	Human NCBI Build 35	3	120728437	CD80-C3orf1
9874	-	7344	G/T	1	395047	rs10191412	Human NCBI Build 35	2	45923596	PRKCE
9875	-	7350	G/T	0	395052	rs1025547	Human NCBI Build 35	9	8654838 PTPRD	
9876	-	7356	G/T	1	395058	rs1035191	Human NCBI Build 35	4	88034436	PTPN13
9877	-	7360	G/T	0	395062	rs1038679	Human NCBI Build 35	1	161431380	PBX1
9879	-	7453	G/T	1	395142	rs1147611	Human NCBI Build 35	10	106015248	GSTO1-ENSG00000065621
9881	-	7517	G/T	0	395194	rs12959396	Human NCBI Build 35	18	58190289	TNFRSF11A
9882	-	7518	G/T	0	395195	rs12999858	Human NCBI Build 35	2	191737353	STAT4
9883	-	7522	G/T	0	395198	rs13082242	Human NCBI Build 35	3	62093530	PTPRG
9884	-	7533	G/T	0	395205	rs132660	Human NCBI Build 35	22	34886736	APOL3
9885	-	7538	G/T	1	395209	rs13320692	Human NCBI Build 35	3	61943056	PTPRG
9886	-	7544	G/T	0	395214	rs1350790	Human NCBI Build 35	3	99738082	GPR15
9887	-	7554	G/T	0	395223	rs1417806	Human NCBI Build 35	1	155792264	IFI16
9888	-	7564	G/T	0	395233	rs1519602	Human NCBI Build 35	2	196853298	STK17B
9889	-	7567	G/T	0	395235	rs1531842	Human NCBI Build 35	5	10728766	DAP-ENSG00000164236
9890	-	7591	G/T	0	395251	rs16840956	Human NCBI Build 35	1	193709346	CFHL5
9891	-	7593	G/T	0	395252	rs1686172	Human NCBI Build 35	1	161414048	PBX1
9892	-	7633	G/T	0	395285	rs1896270	Human NCBI Build 35	2	160484246	LY75-ENSG00000136539
9893	-	7642	G/T	0	395292	rs197729	Human NCBI Build 35	3	37470850	ITGA9
9894	-	7654	G/T	1	395301	rs2069714	Human NCBI Build 35	12	66837311	IFNG
9895	-	7666	G/T	0	395310	rs2105960	Human NCBI Build 35	6	30561768	HLA-E-ENSG00000178214
9896	-	7679	G/T	0	395320	rs2227607	Human NCBI Build 35	1	170612409	SERPINC1
9897	-	7695	G/T	0	395334	rs2241116	Human NCBI Build 35	2	102461783	IL18R1
9898	-	7767	G/T	0	395388	rs2619508	Human NCBI Build 35	3	10190950	IRAK2
9899	-	7774	G/T	0	395395	rs2667976	Human NCBI Build 35	8	57067277	LYN
9900	-	7784	G/T	0	395403	rs2717434	Human NCBI Build 35	12	69294814	PTPRB
9901	-	7790	G/T	0	395408	rs2784250	Human NCBI Build 35	1	217448788	HLX1

9902	-	7793	G/T	0	395409	rs2784253	Human NCBI Build 35	1	217451192	HLX1
9903	-	7809	G/T	0	395422	rs2882694	Human NCBI Build 35	6	74574401	CD109
9904	-	7816	G/T	1	395429	rs3024304	Human NCBI Build 35	6	6267874 F13A1	
9905	-	7861	G/T	0	395471	rs3754565	Human NCBI Build 35	2	46296000	PRKCE
9906	-	7864	G/T	0	395473	rs3754934	Human NCBI Build 35	2	201957613	CASP8
9907	-	7871	G/T	0	395478	rs3766364	Human NCBI Build 35	1	157425212	SLAMF1
9908	-	7881	G/T	0	395488	rs3771836	Human NCBI Build 35	2	75292607	TACR1
9909	-	7887	G/T	1	395493	rs3775180	Human NCBI Build 35	4	87336326	MAPK10
9910	-	7897	G/T	0	395501	rs3790558	Human NCBI Build 35	1	67489042	IL12RB2
9911	-	7902	G/T	0	395506	rs379707	Human NCBI Build 35	5	39155480	FYB
9913	-	7922	G/T	0	395520	rs3917812	Human NCBI Build 35	1	166297030	SELP
9914	-	7966	G/T	0	395555	rs4761466	Human NCBI Build 35	12	93071828	PLXNC1
9915	-	7976	G/T	0	395563	rs4812626	Human NCBI Build 35	20	40757927	PTPRT
9916	-	7986	G/T	1	395572	rs4941195	Human NCBI Build 35	18	59121016	BCL2
9917	-	8027	G/T	0	395609	rs6414248	Human NCBI Build 35	3	112365016	PVRL3
9918	-	8041	G/T	0	395622	rs656598	Human NCBI Build 35	1	57122166	C8B
9919	-	8046	G/T	1	395627	rs6659011	Human NCBI Build 35	1	51133349	FAF1
9920	-	8054	G/T	0	395634	rs6764198	Human NCBI Build 35	3	62092225	PTPRG
9921	-	8102	G/T	0	395678	rs740862	Human NCBI Build 35	16	3629679 DNASE1	
9922	-	8103	G/T	0	395679	rs7408803	Human NCBI Build 35	19	60417222	BRSK1-PTPRH
9923	-	8114	G/T	0	395688	rs7518582	Human NCBI Build 35	1	161433702	PBX1
9924	-	8121	G/T	1	395695	rs7604285	Human NCBI Build 35	2	204644430	ICOS
9925	-	8138	G/T	0	395709	rs7740786	Human NCBI Build 35	6	128667526	PTPRK
9926	-	8145	G/T	1	395715	rs7856850	Human NCBI Build 35	9	8536095 PTPRD	
9927	-	8146	G/T	0	395716	rs7871590	Human NCBI Build 35	9	8575378 PTPRD	
9928	-	8165	G/T	0	395729	rs8111710	Human NCBI Build 35	19	7243583 INSR	
9929	-	8183	G/T	0	395745	rs916839	Human NCBI Build 35	17	31461494	CCL4
9930	-	8186	G/T	0	395747	rs921183	Human NCBI Build 35	2	46202067	PRKCE
9931	-	8195	G/T	0	395753	rs9302671	Human NCBI Build 35	16	54079226	MMP2
9932	-	8212	G/T	0	395766	rs950880	Human NCBI Build 35	2	102391080	IL1RL1
9933	-	8229	G/T	0	395781	rs9868266	Human NCBI Build 35	3	112820859	CD96
9935	-	8346	G/T	1	395874	rs11574696	Human NCBI Build 35	4	110976511	CASP6
9936	-	8355	G/T	0	395883	rs11749976	Human NCBI Build 35	5	41204248	C6
9937	-	8358	G/T	0	395886	rs1181334	Human NCBI Build 35	12	12258855	LRP6-BCL2L14
9938	-	8374	G/T	0	395898	rs12337907	Human NCBI Build 35	9	21209601	ENSG00000137026
9939	-	8378	G/T	0	395902	rs12458537	Human NCBI Build 35	18	54488276	MALT1
9940	-	8389	G/T	0	395911	rs12640238	Human NCBI Build 35	4	77489736	SCARB2
9941	-	8397	G/T	1	395919	rs13157656	Human NCBI Build 35	5	41000609	C7
9942	-	8406	G/T	0	395927	rs1327449	Human NCBI Build 35	1	71049946	PTGER3
9943	-	8433	G/T	1	395949	rs1474159	Human NCBI Build 35	1	218283134	DUSP10
9944	-	8436	G/T	0	395951	rs1489330	Human NCBI Build 35	1	161426748	PBX1
9945	-	8447	G/T	0	395961	rs1550713	Human NCBI Build 35	3	106902676	CBLB
9946	-	8483	G/T	0	395990	rs1803256	Human NCBI Build 35	7	79948001	CD36
9948	-	8491	G/T	0	395995	rs184236	Human NCBI Build 35	10	91169275	IFIT5
9949	-	8493	G/T	0	395997	rs1860264	Human NCBI Build 35	3	45898089	LZTFL1-CCR9
9950	-	8508	G/T	1	396009	rs1918309	Human NCBI Build 35	12	93198996	PLXNC1
9951	-	8510	G/T	0	396011	rs1935131	Human NCBI Build 35	6	128875755	PTPRK
9952	-	8527	G/T	0	396024	rs20514	Human NCBI Build 35	9	8352230 PTPRD	
9953	-	8560	G/T	1	396050	rs2218660	Human NCBI Build 35	2	46259443	PRKCE

9954	-	8561	G/T	0	396051	rs222601	Human NCBI Build 35	X	104410901	IL1RAPL2
9955	-	8568	G/T	0	396058	rs2232548	Human NCBI Build 35	12	9877182 KLRF1	
9956	-	8584	G/T	0	396073	rs2284552	Human NCBI Build 35	21	33565952	IL10RB
9957	-	8647	G/T	0	396118	rs2684768	Human NCBI Build 35	15	97188944	IGF1R
9958	-	8656	G/T	1	396126	rs2735592	Human NCBI Build 35	1	85455762	BCL10
9959	-	8666	G/T	0	396135	rs2853887	Human NCBI Build 35	22	30678448	YWHAH
9960	-	8671	G/T	0	396138	rs2893089	Human NCBI Build 35	1	89342742	GBP2
9961	-	8685	G/T	0	396147	rs3024409	Human NCBI Build 35	6	6168293 F13A1	
9962	-	8712	G/T	1	396168	rs34081	Human NCBI Build 35 19	11392272	EPOR-ENSG00000198003	
9963	-	8726	G/T	1	396178	rs3747414	Human NCBI Build 35	X	12699069	TLR8
9964	-	8732	G/T	1	396184	rs3763613	Human NCBI Build 35	9	34574319	CNTFR
9965	-	8741	G/T	0	396190	rs3771848	Human NCBI Build 35	2	75311085	TACR1
9966	-	8742	G/T	0	396191	rs3771891	Human NCBI Build 35	2	152043693	TNFAIP6
9967	-	8748	G/T	0	396195	rs3775596	Human NCBI Build 35	4	143007419	IL15
9968	-	8762	G/T	0	396205	rs3816997	Human NCBI Build 35	12	92473254	SOCS2
9969	-	8814	G/T	0	396242	rs4476230	Human NCBI Build 35	17	50826104	MMD
9970	-	8831	G/T	0	396254	rs4693144	Human NCBI Build 35	4	87632435	MAPK10
9971	-	8834	G/T	0	396256	rs4706552	Human NCBI Build 35	6	74489933	CD109
9972	-	8849	G/T	1	396267	rs4803455	Human NCBI Build 35	19	46543349	TGFB1
9973	-	8850	G/T	0	396268	rs4804592	Human NCBI Build 35	19	11386395	EPOR
9974	-	8852	G/T	0	396270	rs4846479	Human NCBI Build 35	1	214986805	ENSG00000092969
9975	-	8859	G/T	0	396276	rs4936682	Human NCBI Build 35	11	111134953	PPP2R1B
9976	-	8872	G/T	1	396288	rs503922	Human NCBI Build 35	3	139806534	FAIM
9977	-	8875	G/T	0	396290	rs514191	Human NCBI Build 35	11	76735406	PAK1
9978	-	8881	G/T	0	396294	rs558788	Human NCBI Build 35	11	59608654	MS4A2
9979	-	8890	G/T	1	396300	rs579461	Human NCBI Build 35	9	35288717	UNC13B-ENSG00000196186
9980	-	8917	G/T	1	396323	rs6532244	Human NCBI Build 35	4	77483057	SCARB2
9981	-	8928	G/T	0	396334	rs6687859	Human NCBI Build 35	1	71074608	PTGER3
9982	-	8957	G/T	0	396358	rs7019643	Human NCBI Build 35	9	36905243	PAX5
9983	-	8970	G/T	1	396368	rs7172206	Human NCBI Build 35	15	31962532	AVEN
9984	-	8992	G/T	0	396386	rs7543038	Human NCBI Build 35	1	161455493	PBX1
9985	-	9039	G/T	0	396429	rs8098294	Human NCBI Build 35	18	65701755	CD226
9986	-	9059	G/T	1	396444	rs893315	Human NCBI Build 35	18	46391182	MAPK4
9987	-	9069	G/T	0	396448	rs907190	Human NCBI Build 35	1	222873461	PARP1
9988	-	9083	G/T	0	396457	rs9381530	Human NCBI Build 35	6	47304549	TNFRSF21
9989	-	9093	G/T	0	396467	rs962409	Human NCBI Build 35	1	85444962	BCL10
9990	-	9097	G/T	0	396469	rs969262	Human NCBI Build 35	20	40717809	PTPRT
9991	-	9100	G/T	1	396472	rs9811776	Human NCBI Build 35	3	106995958	CBLB
9992	-	9104	G/T	0	396475	rs9827569	Human NCBI Build 35	3	188935184	BCL6
9993	-	9120	G/T	0	396486	rs10033029	Human NCBI Build 35	4	88042975	PTPN13
9994	-	9124	G/T	0	396490	rs10124570	Human NCBI Build 35	9	130756548	ABL1
9995	-	9126	G/T	0	396491	rs1012674	Human NCBI Build 35	12	15595692	PTPRO
9996	-	9129	G/T	1	396493	rs1016536	Human NCBI Build 35	6	170814194	PDCD2
9998	-	9188	G/T	0	396541	rs10925116	Human NCBI Build 35	1	232888919	EDARADD
9999	-	9189	G/T	0	396542	rs10926960	Human NCBI Build 35	1	232369451	ENSG00000143669
10000	-	9199	G/T	0	396551	rs11002310	Human NCBI Build 35	10	79266036	DLG5
10001	-	9214	G/T	0	396562	rs11465804	Human NCBI Build 35	1	67414547	IL23R
10002	-	9221	G/T	1	396566	rs1153942	Human NCBI Build 35	1	220277480	TP53BP2
10003	-	9231	G/T	1	396573	rs1165687	Human NCBI Build 35	12	102836660	TRA1

10004	-	9257	G/T	0	396594	rs12122697	Human NCBI Build 35	1	50755264	FAF1
10006	-	9294	G/T	0	396622	rs1329575	Human NCBI Build 35	9	36966563	PAX5
10007	-	9299	G/T	0	396627	rs1396500	Human NCBI Build 35	5	54359712	GZMK
10008	-	9303	G/T	0	396630	rs1420103	Human NCBI Build 35	2	102407150	IL1RL1
10009	-	9306	G/T	0	396631	rs1422993	Human NCBI Build 35	5	147484013	SPINK5
10010	-	9312	G/T	0	396636	rs1470323	Human NCBI Build 35	18	7978643	PTPRM
10011	-	9318	G/T	0	396642	rs1539041	Human NCBI Build 35	10	93567121	TNKS2
10012	-	9327	G/T	0	396649	rs1566734	Human NCBI Build 35	11	48101951	PTPRJ
10013	-	9331	G/T	0	396653	rs1664983	Human NCBI Build 35	18	7652457	PTPRM
10014	-	9347	G/T	0	396666	rs1916661	Human NCBI Build 35	18	59726100	SERPINB2
10015	-	9352	G/T	0	396669	rs1941134	Human NCBI Build 35	18	7588656	PTPRM
10016	-	9358	G/T	0	396675	rs1983973	Human NCBI Build 35	9	87397556	DAPK1
10017	-	9367	G/T	0	396683	rs2026880	Human NCBI Build 35	21	44489758	DNMT3L-ENSG00000160223
10018	-	9398	G/T	0	396712	rs2170007	Human NCBI Build 35	10	62217575	CDC2
10019	-	9420	G/T	0	396730	rs2282348	Human NCBI Build 35	1	177759582	MR1
10020	-	9422	G/T	1	396732	rs2285934	Human NCBI Build 35	12	111814240	OAS1
10021	-	9470	G/T	0	396771	rs281508	Human NCBI Build 35	2	46322858	PRKCE
10022	-	9484	G/T	0	396780	rs310209	Human NCBI Build 35	1	65057637	JAK1
10023	-	9517	G/T	0	396806	rs3739577	Human NCBI Build 35	9	8394987	PTPRD
10024	-	9523	G/T	0	396810	rs3756416	Human NCBI Build 35	5	43419259	CCL28
10025	-	9535	G/T	1	396822	rs3774965	Human NCBI Build 35	4	103882128	NFKB1
10026	-	9539	G/T	0	396824	rs3780138	Human NCBI Build 35	9	36875406	PAX5
10027	-	9543	G/T	0	396828	rs3789576	Human NCBI Build 35	1	50657547	FAF1
10028	-	9560	G/T	1	396841	rs3853188	Human NCBI Build 35	4	77466759	SCARB2
10029	-	9568	G/T	0	396849	rs4149252	Human NCBI Build 35	8	27452028	EPHX2
10030	-	9604	G/T	0	396879	rs4812644	Human NCBI Build 35	20	40822372	PTPRT
10031	-	9608	G/T	1	396882	rs4812682	Human NCBI Build 35	20	41220578	PTPRT
10032	-	9614	G/T	0	396886	rs4879686	Human NCBI Build 35	9	33333397	NFX1
10033	-	9621	G/T	1	396891	rs4922624	Human NCBI Build 35	11	22715067	GAS2
10035	-	9631	G/T	0	396900	rs537727	Human NCBI Build 35	11	104445414	CASP1
10036	-	9649	G/T	0	396916	rs599437	Human NCBI Build 35	11	76748047	PAK1
10037	-	9697	G/T	0	396955	rs6604724	Human NCBI Build 35	1	220305306	TP53BP2
10038	-	9727	G/T	1	396984	rs6966279	Human NCBI Build 35	7	38142788	TRGV9
10039	-	9729	G/T	0	396986	rs7042528	Human NCBI Build 35	9	130716271	ABL1
10040	-	9742	G/T	1	396996	rs7151976	Human NCBI Build 35	14	64073644	HSPA2
10042	-	9810	G/T	0	397052	rs8031079	Human NCBI Build 35	15	66188636	PIAS1
10043	-	9814	G/T	0	397055	rs8073827	Human NCBI Build 35	17	42699661	ITGB3
10044	-	9817	G/T	1	397057	rs8088915	Human NCBI Build 35	18	59469169	SERPINB3
10045	-	9830	G/T	0	397069	rs884205	Human NCBI Build 35	18	58205837	TNFRSF11A
10046	-	9862	G/T	0	397099	rs10187908	Human NCBI Build 35	2	46040109	PRKCE
10047	-	9863	G/T	0	397100	rs10215288	Human NCBI Build 35	7	79909612	CD36
10048	-	9870	G/T	0	397106	rs10490422	Human NCBI Build 35	2	162741920	DPP4
10049	-	9874	G/T	1	397109	rs1049329	Human NCBI Build 35	7	156831304	PTPRN2
10050	-	9876	G/T	1	397111	rs10500204	Human NCBI Build 35	19	7133963	INSR
10051	-	9884	G/T	0	397118	rs10758412	Human NCBI Build 35	9	36884656	PAX5
10052	-	9894	G/T	0	397127	rs10861638	Human NCBI Build 35	12	105513513	RFX4
10053	-	9899	G/T	0	397132	rs10977218	Human NCBI Build 35	9	8574683	PTPRD
10054	-	9914	G/T	0	397145	rs1126057	Human NCBI Build 35	5	146315917	PPP2R2B
10055	-	9918	G/T	0	397148	rs11546488	Human NCBI Build 35	6	30561979	HLA-E-ENSG00000178214

10056	-	9949	G/T	0	397174	rs12156014	Human NCBI Build 35	8	141922700	PTK2
10057	-	9951	G/T	0	397176	rs12259337	Human NCBI Build 35	10	106010210	GSTO1
10058	-	9953	G/T	0	397177	rs12334538	Human NCBI Build 35	8	27400277	EPHX2
10059	-	9961	G/T	0	397184	rs12493137	Human NCBI Build 35	3	61684030	PTPRG
10060	-	9988	G/T	0	397209	rs1432443	Human NCBI Build 35	15	64506236	MAP2K1
10061	-	9993	G/T	0	397214	rs1468674	Human NCBI Build 35	12	9639549	KLRB1
10062	-	10007	G/T	1	397227	rs162299	Human NCBI Build 35	6	167437268	CCR6-ENSG00000187485
10063	-	10014	G/T	0	397233	rs1735685	Human NCBI Build 35	10	31846049	TCF8
10064	-	10027	G/T	1	397243	rs186493	Human NCBI Build 35	16	3229332	MEFV-ZNF200
10065	-	10070	G/T	0	397278	rs2288726	Human NCBI Build 35	12	97586855	APAF1
10066	-	10077	G/T	0	397283	rs2302267	Human NCBI Build 35	X	12645235	TLR7
10067	-	10120	G/T	0	397317	rs2940944	Human NCBI Build 35	5	42524899	GHR
10068	-	10175	G/T	0	397365	rs3924513	Human NCBI Build 35	11	127870403	ETS1
10069	-	10179	G/T	0	397368	rs4130485	Human NCBI Build 35	18	8251221	PTPRM
10070	-	10186	G/T	0	397375	rs4320092	Human NCBI Build 35	3	191843717	IL1RAP
10072	-	10201	G/T	0	397389	rs4812663	Human NCBI Build 35	20	41042528	PTPRT
10075	-	10267	G/T	0	397445	rs6573766	Human NCBI Build 35	14	23921886	NFATC4
10076	-	10270	G/T	0	397448	rs6602398	Human NCBI Build 35	10	6122959	IL2RA
10077	-	10273	G/T	1	397451	rs6670720	Human NCBI Build 35	1	232265887	ENSG00000143669
10078	-	10278	G/T	1	397455	rs6795773	Human NCBI Build 35	3	139922537	PIK3CB
10079	-	10286	G/T	0	397462	rs6839501	Human NCBI Build 35	4	47907792	TXK
10080	-	10305	G/T	0	397477	rs7179346	Human NCBI Build 35	15	89139164	BLM
10081	-	10335	G/T	0	397503	rs768600	Human NCBI Build 35	2	75207393	TACR1
10082	-	10353	G/T	0	397518	rs7921727	Human NCBI Build 35	10	115435174	CASP7
10083	-	10391	G/T	0	397550	rs9427838	Human NCBI Build 35	1	189767052	SSA2
10084	-	10397	G/T	0	397554	rs957708	Human NCBI Build 35	4	75688054	AREG
10085	-	10411	G/T	1	397568	rs1032129	Human NCBI Build 35	8	120021081	TNFRSF11B
10086	-	10417	G/T	0	397573	rs10490695	Human NCBI Build 35	2	105963513	NCK2
10087	-	10424	G/T	0	397578	rs10503574	Human NCBI Build 35	8	16028961	MSR1
10088	-	10449	G/T	1	397598	rs10889677	Human NCBI Build 35	1	67437141	IL23R
10089	-	10466	G/T	0	397612	rs11466649	Human NCBI Build 35	4	38599291	TLR10
10090	-	10491	G/T	0	397633	rs12252639	Human NCBI Build 35	10	35457788	CREM
10091	-	10506	G/T	0	397647	rs13031237	Human NCBI Build 35	2	61047780	REL
10092	-	10537	G/T	0	397674	rs174642	Human NCBI Build 35	16	45861136	ENSG00000129636
10093	-	10555	G/T	1	397690	rs2027993	Human NCBI Build 35	17	23731073	SARM1
10094	-	10570	G/T	0	397702	rs2197209	Human NCBI Build 35	3	107050855	CBLB
10095	-	10625	G/T	0	397746	rs2885370	Human NCBI Build 35	3	191759697	IL1RAP
10096	-	10627	G/T	0	397748	rs3019561	Human NCBI Build 35	11	60500429	CD6
10097	-	10645	G/T	0	397762	rs355960	Human NCBI Build 35	16	65244211	CKLFSF4
10098	-	10650	G/T	0	397766	rs3730556	Human NCBI Build 35	12	67502788	MDM2
10099	-	10665	G/T	0	397778	rs3775296	Human NCBI Build 35	4	187372916	TLR3
10101	-	10680	G/T	0	397793	rs3917289	Human NCBI Build 35	2	102240429	IL1R1
10102	-	10709	G/T	1	397818	rs4698370	Human NCBI Build 35	4	15015213	C1QTNF7
10103	-	10717	G/T	0	397826	rs4799055	Human NCBI Build 35	18	75282991	NFATC1
10104	-	10722	G/T	0	397831	rs487273	Human NCBI Build 35	18	12843458	PTPN2
10105	-	10739	G/T	0	397843	rs5741880	Human NCBI Build 35	X	12647073	TLR7
10106	-	10742	G/T	0	397846	rs5747347	Human NCBI Build 35	22	16620087	BID
10107	-	10743	G/T	0	397847	rs582052	Human NCBI Build 35	10	6509161	PRKCQ
10108	-	10747	G/T	0	397850	rs5988198	Human NCBI Build 35	X	114074563	IL13RA2

10109	-	10749	G/T	0	397852	rs5999704	Human NCBI Build 35	22	20503345	MAPK1
10110	-	10782	G/T	0	397883	rs6694672	Human NCBI Build 35	1	193677446	CFHL5
10111	-	10787	G/T	1	397888	rs6722418	Human NCBI Build 35	2	45787490	PRKCE
10112	-	10805	G/T	0	397902	rs702275	Human NCBI Build 35	9	5436388	ENSG00000120217
10113	-	10824	G/T	0	397919	rs7522020	Human NCBI Build 35	1	195369510	PTPRC
10115	-	10834	G/T	0	397928	rs7649363	Human NCBI Build 35	3	37579730	ITGA9
10116	-	10836	G/T	0	397930	rs7660964	Human NCBI Build 35	4	87874788	PTPN13
10117	-	10838	G/T	0	397932	rs7706055	Human NCBI Build 35	5	142012664	FGF1
10118	-	10861	G/T	0	397951	rs858545	Human NCBI Build 35	1	164193049	CD3Z
10119	-	10872	G/T	0	397959	rs9321119	Human NCBI Build 35	6	128819664	PTPRK
10120	-	10888	G/T	0	397973	rs9882766	Human NCBI Build 35	3	126441217	ZNF148
10121	-	10891	G/T	1	397976	rs10019269	Human NCBI Build 35	4	87563332	MAPK10
10122	-	10897	G/T	0	397980	rs1009977	Human NCBI Build 35	14	54672755	LGALS3
10123	-	10904	G/T	0	397986	rs10155140	Human NCBI Build 35	4	75087569	PF4V1
10124	-	10910	G/T	0	397992	rs1036583	Human NCBI Build 35	3	106564738	ALCAM
10125	-	10924	G/T	0	398003	rs10494134	Human NCBI Build 35	1	111571954	ENSG00000134216
10126	-	10938	G/T	0	398016	rs1078859	Human NCBI Build 35	1	232238066	ENSG00000143669
10127	-	10966	G/T	0	398038	rs11667351	Human NCBI Build 35	19	54147966	BAX
10128	-	10968	G/T	0	398040	rs11916852	Human NCBI Build 35	3	191863298	IL1RAP
10129	-	10971	G/T	1	398042	rs12082477	Human NCBI Build 35	1	51013074	FAF1
10130	-	10990	G/T	0	398054	rs1268656	Human NCBI Build 35	14	63717399	SYNE2-ESR2
10131	-	10991	G/T	0	398055	rs12721582	Human NCBI Build 35	17	37736992	STAT3
10133	-	11004	G/T	1	398065	rs13384232	Human NCBI Build 35	2	73999365	STAMBP
10134	-	11068	G/T	0	398117	rs2054724	Human NCBI Build 35	12	93145333	PLXNC1
10135	-	11091	G/T	0	398134	rs2259094	Human NCBI Build 35	10	93612303	TNKS2
10136	-	11104	G/T	1	398146	rs2325704	Human NCBI Build 35	1	155722237	PYHIN1
10137	-	11119	G/T	0	398157	rs273479	Human NCBI Build 35	14	23848800	LTB4R-CIDEB-LTB4R2
10138	-	11181	G/T	1	398213	rs4602134	Human NCBI Build 35	18	7967007	PTPRM
10139	-	11211	G/T	0	398239	rs5744048	Human NCBI Build 35	X	12689755	TLR8
10140	-	11223	G/T	0	398248	rs6414769	Human NCBI Build 35	4	15478187	CD38
10141	-	11236	G/T	0	398259	rs653973	Human NCBI Build 35	18	7787536	PTPRM
10142	-	11288	G/T	0	398302	rs7688526	Human NCBI Build 35	4	15400712	ENSG00000109743
10143	-	11289	G/T	0	398303	rs7701605	Human NCBI Build 35	5	42686227	GHR
10144	-	11290	G/T	0	398304	rs7701642	Human NCBI Build 35	5	43430535	CCL28
10146	-	11325	G/T	0	398333	rs9387045	Human NCBI Build 35	6	112268696	FYN
10147	-	11331	G/T	0	398339	rs975074	Human NCBI Build 35	1	169745424	TNFSF18
10148	-	11339	G/T	0	398345	rs9943268	Human NCBI Build 35	1	203680500	C4BPA
10149	-	11349	G/T	0	398354	rs10214916	Human NCBI Build 35	6	167513495	CCR6-ENSG00000187485
10150	-	11379	G/T	0	398377	rs10981818	Human NCBI Build 35	9	113388263	RGS3
10151	-	11404	G/T	0	398396	rs11962214	Human NCBI Build 35	6	128582041	PTPRK
10152	-	11412	G/T	1	398403	rs12089749	Human NCBI Build 35	1	51018350	FAF1
10153	-	11427	G/T	1	398416	rs1377470	Human NCBI Build 35	11	76728362	PAK1
10154	-	11446	G/T	0	398433	rs2009434	Human NCBI Build 35	7	38055406	TRGV9
10155	-	11469	G/T	0	398455	rs2289779	Human NCBI Build 35	5	38562985	LIFR
10156	-	11477	G/T	0	398462	rs2382723	Human NCBI Build 35	X	69156774	IGBP1
10157	-	11505	G/T	0	398485	rs3181166	Human NCBI Build 35	7	142503735	CASP2-ENSG00000178826
10158	-	11507	G/T	1	398487	rs3211820	Human NCBI Build 35	7	79923116	CD36
10159	-	11513	G/T	0	398492	rs3739527	Human NCBI Build 35	9	27516480	IFNK-ENSG00000120162
10160	-	11529	G/T	0	398505	rs4017732	Human NCBI Build 35	1	157593628	LY9

10161	-	11576	G/T	1	398545	rs6490814	Human NCBI Build 35	13	23147957	TNFRSF19
10162	-	11592	G/T	0	398559	rs6914136	Human NCBI Build 35	6	136643588	ENSG00000029363
10163	-	11595	G/T	0	398562	rs6984608	Human NCBI Build 35	8	56990235	LYN
10164	-	11613	G/T	1	398578	rs7612628	Human NCBI Build 35	3	62126488	PTPRG
10165	-	11647	G/T	0	398608	rs9291926	Human NCBI Build 35	5	67635412	PIK3R1
10166	-	11663	G/T	0	398621	rs9944249	Human NCBI Build 35	15	39634468	TYRO3
10167	-	11685	G/T	1	398638	rs10811505	Human NCBI Build 35	9	21198723	IFNA10-ENSG00000137026
10168	-	11729	G/T	0	398672	rs1909757	Human NCBI Build 35	9	8395674	PTPRD
10169	-	11734	G/T	1	398676	rs1967446	Human NCBI Build 35	6	136638981	ENSG00000029363
10170	-	11737	G/T	1	398678	rs1994276	Human NCBI Build 35	8	120020700	TNFRSF11B
10171	-	11752	G/T	0	398692	rs2278342	Human NCBI Build 35	12	69235100	PTPRB
10172	-	11758	G/T	0	398697	rs2357479	Human NCBI Build 35	14	63862517	ESR2
10173	-	11770	G/T	0	398706	rs264863	Human NCBI Build 35	5	168992855	DOCK2
10174	-	11776	G/T	1	398710	rs2719237	Human NCBI Build 35	8	57089416	LYN
10176	-	11828	G/T	1	398750	rs4940741	Human NCBI Build 35	18	54512757	MALT1-ENSG00000182288
10177	-	11834	G/T	0	398756	rs594454	Human NCBI Build 35	1	71142489	PTGER3
10178	-	11869	G/T	1	398781	rs7095398	Human NCBI Build 35	10	91075587	IFIT3-LIPA
10179	-	11889	G/T	0	398795	rs7656411	Human NCBI Build 35	4	154985260	RNF175-TLR2
10181	-	11915	G/T	0	398815	rs9288815	Human NCBI Build 35	3	106908600	CBLB
10182	-	11928	G/T	0	398827	rs983751	Human NCBI Build 35	10	90736673	ENSG00000026103
10183	-	11938	G/T	1	398835	rs10455097	Human NCBI Build 35	6	74550153	CD109
10184	-	11951	G/T	0	398847	rs11056560	Human NCBI Build 35	12	15609804	PTPRO
10185	-	11993	G/T	0	398879	rs1860235	Human NCBI Build 35	4	15635220	ENSG00000137441
10186	-	12008	G/T	0	398890	rs2017242	Human NCBI Build 35	4	48045522	TEC
10187	-	12029	G/T	0	398907	rs2332096	Human NCBI Build 35	3	123303833	CD86
10189	-	12043	G/T	0	398919	rs3109808	Human NCBI Build 35	1	204336872	MCP
10190	-	12064	G/T	0	398937	rs4251431	Human NCBI Build 35	12	42440957	
ENSG00000198001-ENSG00000129317										
10191	-	12070	G/T	0	398942	rs4561893	Human NCBI Build 35	4	87932051	PTPN13
10192	-	12075	G/T	0	398947	rs4657378	Human NCBI Build 35	1	161531469	PBX1
10193	-	12082	G/T	0	398952	rs4760821	Human NCBI Build 35	12	69489807	PTPRR
10194	-	12085	G/T	0	398954	rs4852983	Human NCBI Build 35	2	73970549	STAMBP
10195	-	12090	G/T	0	398958	rs5743317	Human NCBI Build 35	4	187378908	TLR3
10196	-	12108	G/T	0	398973	rs6877536	Human NCBI Build 35	5	39181010	FYB
10197	-	12113	G/T	1	398977	rs7013397	Human NCBI Build 35	8	16008976	MSR1
10198	-	12184	G/T	0	399038	rs10922153	Human NCBI Build 35	1	193710272	CFHL5
10199	-	12195	G/T	0	399046	rs1263572	Human NCBI Build 35	7	156929342	PTPRN2
10200	-	12241	G/T	0	399084	rs2918415	Human NCBI Build 35	5	142725156	NR3C1
10201	-	12267	G/T	0	399108	rs6151510	Human NCBI Build 35	15	57759664	BNIP2
10202	-	12268	G/T	1	399109	rs636842	Human NCBI Build 35	15	32055908	AVEN
10203	-	12288	G/T	0	399122	rs7857730	Human NCBI Build 35	9	5074049	JAK2
10204	-	12299	G/T	0	399131	rs896771	Human NCBI Build 35	7	157595602	PTPRN2
10205	-	12322	G/T	0	399150	rs1923143	Human NCBI Build 35	1	155081027	CD1C
10206	-	12335	G/T	0	399161	rs2381301	Human NCBI Build 35	9	35212453	UNC13B-ENSG00000196186
10207	-	12341	G/T	1	399163	rs2709402	Human NCBI Build 35	2	208246483	CREB1
10208	-	12347	G/T	1	399168	rs4253890	Human NCBI Build 35	1	210998217	PTPN14
10209	-	12354	G/T	0	399174	rs4957384	Human NCBI Build 35	5	39242184	FYB
10210	-	12397	G/T	0	399210	rs1768358	Human NCBI Build 35	6	128620465	PTPRK
10211	-	12399	G/T	1	399212	rs2026431	Human NCBI Build 35	10	6550460	PRKCQ

10213	-	12407	G/T	0	399219	rs2364482	Human NCBI Build 35	12	6372392	LTBR	
10214	-	12426	G/T	0	399233	rs7809114	Human NCBI Build 35	7	157663985		PTPRN2
10215	-	12451	G/T	0	399255	rs4748127	Human NCBI Build 35	10	6616887	PRKCQ	
10216	-	12467	G/T	1	399267	rs10282832	Human NCBI Build 35	8	75103860		LY96
10217	-	12477	G/T	0	399274	rs1256045	Human NCBI Build 35	14	63799513		ESR2
10218	-	12507	G/T	0	399300	rs2288730	Human NCBI Build 35	12	97568982		APAF1

Appendix 6 Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting

Definition of Adverse Event

AE Definition
<ul style="list-style-type: none">• An AE is any untoward medical occurrence in a patient or clinical study subject, temporally associated with the use of study treatment, whether or not considered related to the study treatment.• NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment.

Events <u>Meeting</u> the AE Definition
<ul style="list-style-type: none">• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (e.g., ECG, radiological scans, vital signs measurements), including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the Investigator (i.e., not related to progression of underlying disease).• Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency and/or intensity of the condition.• New condition detected or diagnosed after study treatment administration even though it may have been present before the start of the study.• Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment or a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an intentional overdose taken with possible suicidal/self-harming intent. Such overdoses should be reported regardless of sequelae.• Clinically significant change in objective findings (e.g., laboratory, ECG, physical examination) should be considered an AE ONLY if it meets the following criteria:<ul style="list-style-type: none">○ Associated with accompanying symptoms; and/or○ Requires medical/surgical interventions; and/or○ Leads to a change in study treatment dosing or discontinuation from the study, significant additional concomitant drug treatment or other therapy; and/or○ Leads to any of the outcomes included in the definition of an SAE• "Lack of efficacy" or "failure of expected pharmacological action" per se will not be reported as an AE or SAE. Such instances will be captured in the efficacy assessments. However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be reported as AE or SAE if they fulfil the definition of an AE or SAE.

Events **NOT** Meeting the AE Definition

- Any clinically significant abnormal laboratory findings or other abnormal safety assessments which are associated with the underlying disease, unless judged by the Investigator to be more severe than expected for the subject's condition.
- The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the subject's condition.
- Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that leads to the procedure is the AE.
- Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospital).
- Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the start of the study that do not worsen.

Definition of a Serious Adverse Event

If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions are met (e.g., hospitalization for signs/symptoms of the disease under study, death due to progression of disease).

An SAE is defined as any untoward medical occurrence that, at any dose:

Results in death

Is life-threatening

meaning an event in which the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe.

Requires hospitalization or prolongation of existing hospitalization

In general, hospitalization signifies that the subject has been detained (usually involving at least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician's office or outpatient setting. Complications that occur during hospitalization are AEs. If a complication prolongs hospitalization or fulfills any other serious criteria, the event is serious. When in doubt as to whether "hospitalization" occurred or was necessary, the AE should be considered serious.

Hospitalization for elective treatment of a pre-existing condition that did not worsen from baseline is not considered an AE.

Results in persistent disability/incapacity

which means a substantial disruption of a person's ability to conduct normal life functions; this definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (e.g., sprained ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial disruption.

Is a congenital anomaly/birth defect
<p>Is an important medical event</p> <p>such as medical events that may not be immediately life-threatening or result in death or hospitalization but, based on appropriate medical and scientific judgement, may jeopardize the subject or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These events should usually be considered serious.</p> <p>Examples of such events include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug dependency or drug abuse. Meeting laboratory criteria for drug induced liver injury (DILI) is also considered an important medical event. Suspected transmission of an infectious agent (pathogenic or nonpathogenic) via the study treatment is an SAE.</p> <p>Although pregnancy, overdose, cancer, and suspected DILI are not always serious by regulatory definition, these events must be handled as SAEs if they meet the definitions as specified in the protocol (see Section 8.7.5 Pregnancy, Section 8.8 Treatment of Overdose, and Section 7.1 Discontinuation of Study Treatment for Individual Subjects [DILI]). A study endpoint (such as all-cause mortality) for which an occurrence is considered <i>related</i> to study treatment should be reported as an SAE (e.g., death is an endpoint, if death occurred due to anaphylaxis, anaphylaxis must be reported as an SAE) (see below for reporting details).</p>

Hospitalizations <u>NOT</u> Meeting the SAE Definition in Arbutus clinical studies
<ul style="list-style-type: none"> • A visit to the emergency room or other hospital department <24 hours, that does not result in admission (unless considered an important medical or life-threatening event) • Elective surgery, planned prior to signing the ICF • Admissions as per protocol for a planned medical/surgical procedure or routine health assessment requiring admission for baseline/trending of health status (e.g., routine colonoscopy) • Medical/surgical admission other than to remedy ill health and planned prior to entry into the study. Appropriate documentation is required in these cases • Admission encountered for another life circumstance that carries no bearing on health status and requires no medical/surgical intervention (e.g., lack of housing, economic inadequacy, caregiver respite, family circumstances, administrative reason)

Recording and Follow-up of Adverse Events and/or Serious Adverse Events

AE and SAE Recording

- All SAEs will be collected and be recorded in the CRF from the signing of the ICF until the last Post-Treatment Follow-up visit. The description of the AE will include the onset date, duration, date of resolution, severity (see below), seriousness, and Investigator's assessment of relationship to the study treatment
- When an AE/SAE occurs, it is the responsibility of the Investigator to review all documentation (e.g., hospital progress notes, laboratory reports, and diagnostics reports) related to the event.
- The Investigator will then record all relevant AE/SAE information in the CRF, and on the SAE Report Form when an SAE is being reported.
- The initial report of an SAE should include the following information, at a minimum:
 - Study name or number
 - Subject number
 - Event description (including date of the event onset, outcome and reason for it being considered serious)
 - Name of the investigational product (including drug dose and administration dates)
 - Preliminary assignment of causality
 - Person reporting event (include site name or number)
 - Dated signature of the Investigator or sub-/co-Investigator

It is **not** acceptable for the Investigator to send photocopies of the subject's medical records to the Pharmacovigilance (PV) department (the CRO) in lieu of completion of the SAE Report Form.

- There may be instances when copies of medical records for certain cases are requested by the CRO PV department. In this case, all subject identifiers, except for the subject number, will be redacted on the copies of the medical records before submission to the CRO PV department.
- The Investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE.

Assessment of Severity (Intensity)
<ul style="list-style-type: none"> • The Investigator will assess intensity for each AE and SAE reported during the study using the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS Table) . • Changes in severity should be documented in the medical record to allow assessment of the duration of the event at each level of severity. • AEs characterized as intermittent require documentation of the start and stop of each incidence. • When changes in the intensity of an AE occur more frequently than once a day, the maximum intensity for the experience that day should be noted. If the intensity category changes over a number of days, then those changes should be recorded separately (with distinct onset dates).
Assessment of Causality
<ul style="list-style-type: none"> • The Investigator is obligated to use clinical judgment to assess the relationship between study treatment and each occurrence of each AE/SAE. • “Not Related” should be assessed when a causal relationship between study treatment administration and AE is <i>not considered a reasonable possibility</i>. The observed AE can be reasonably explained by an alternative cause such as underlying disease, concurrent medication or co-morbidity; or a causal association is considered unreasonable. • “Related” should be assessed when there is a reasonable possibility that the study drug caused the AE, rather than using only because a relationship cannot be ruled out. The temporal relationship, biological plausibility and absence of confounding with the underlying disease, co-morbidities or other medications make a causal relationship a reasonable possibility. • The Investigator will also consult the IB and/or Product Information, for marketed products, in making his/her assessment. • For each AE/SAE, the Investigator <u>must</u> document in the medical notes that s/he has reviewed the AE/SAE and has provided an assessment of causality. • There may be situations in which an SAE has occurred and the Investigator has minimal information to include in the initial report to the CRO PV department. However, it is very important that the Investigator always assess causality for every event before the initial transmission of the SAE data to the CRO PV department. The Investigator may change his/her opinion of causality in light of follow-up information and send a SAE follow-up report or amend the SAE Report Form with the updated causality assessment. • The causality assessment is one of the criteria used when determining regulatory reporting requirements.

Follow-up of AEs and SAEs

- The Investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations as medically indicated or as requested by the CRO PV department to elucidate the nature and/or causality of the AE or SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals.
- If a subject dies during participation in the study or during a recognized follow-up period, the Investigator will provide the CRO PV department with a copy of any post-mortem findings including histopathology.
- New or updated information will be recorded in the originally completed CRF.
- The Investigator will submit any updated SAE data to the Sponsor within 24 hours of receipt of the information.

Reporting of Serious Adverse Events

SAE Reporting to the CRO PV Department

- The primary mechanism for reporting an SAE to the CRO PV department will be e-mailing the SAE Report form to the CRO in addition to updating details in the CRF within 24 hours of knowledge of the event.
- If the electronic system is unavailable for more than 24 hours, then the site will use the paper SAE data collection tool.
- The site will enter the SAE data into the electronic system as soon as it becomes available, within 24 hours.
- After the study is completed at a given site, the electronic data collection tool will be taken off-line to prevent the entry of new data or changes to existing data.
- If a site receives a report of a new SAE from a study subject or receives updated data on a previously reported SAE after the electronic data collection tool has been taken off-line, then the site can report this information on a paper SAE form.

Contacts for SAE reporting can be found in the Safety Management Plan.

Appendix 7 Pharmacokinetic Sampling for AB-729 in Study AB-729-201

Visit	Period	Cohort	Timepoint Relative to Dose (hours)	AB-729 Plasma PK Sample
Day 1	Lead-In Treatment Period	all subjects	pre-dose ^a	X
			0.5 hours	X
			1 hours	X
			2 hours	X
			4 hours	X
			6 hours	X
Week 24	Lead-In Treatment Period	all subjects	pre-dose ^a	X
			0.5 hours	X
			1 hours	X
			2 hours	X
			4 hours	X
			6 hours	X
Week 32	Consolidation Treatment Period	Cohort A1 Cohort B1	pre-dose ^a	X
			0.5 hours	X
			1 hours	X
			2 hours	X
			4 hours	X
			6 hours	X
Week 40	Consolidation Treatment Period	Cohort A1	pre-dose ^a	X
			0.5 hours	X
			1 hours	X
			2 hours	X
			4 hours	X
			6 hours	X

a. Pre-dose sample will be collected within 60 minutes prior to dosing of AB-729.

Appendix 8 Schedule of Activities for Early Termination (Lead-in Period only)

Table 13. Schedule of Activities for Early Termination (Lead-in Period only)

Assessment	Early Termination Follow Up		
	Weeks 4 ^a , 8, 12, 16, 20, 24 ^b	Weeks 36 and 48 (EOS) ^c	Notes
Concomitant medications	X	X	
Physical examination	X	X	Targeted PEs may be completed at any study visit based on any reported changes to the subject's health.
Vital signs	X	X	BP, HR, RR, and temp to be performed pre-dose, when applicable.
ECG	X*	X	*Weeks 12 and 24 only.
Clinical laboratory tests	X	X	Includes clinical chemistry, hematology, coagulation tests, serology, and urine as specified in Appendix 4 , and are to be completed after an overnight fast of 8 hrs.
Pregnancy test (WOCBP only)	X	X	If the urine test is positive or not interpretable, a serum/plasma pregnancy test is to be conducted.
Quantitative HBsAg	X	X	
HBsAg Ultrasensitive	X	X	To be assessed only if quantitative HBsAg result is <LLOQ
Quantitative HBsAb	X*	X	*Sample to be collected at Week 12 only.
Quantitative HBV DNA	X*	X	*Samples to be collected at Weeks 8, 16, and 24 only.
Quantitative HBV RNA	X	X	
Quantitative HBcrAg	X*	X	*Samples to be collected at Weeks 8, 16, and 24 only.
Qualitative HBeAg	X*	X	*Samples to be collected at Weeks 8, 16, and 24 only.
Quantitative HBeAg	X*	X	*Samples to be collected at Weeks 8, 16, and 24 only. To be assessed only if positive result obtained with HBeAg qualitative test.
Qualitative HBeAb	X*	X	*Sample to be collected at Week 12 only.
HBsAg isoforms	X*	X	*Samples to be collected at Weeks 8, 16, and 24 only.
Resistance Sample	X	X	Samples will be stored and analyzed only if defined criteria for non-response or rebound met (Appendix 10).

Assessment	Early Termination Follow Up		
	Weeks 4 ^a , 8, 12, 16, 20, 24 ^b	Weeks 36 and 48 (EOS) ^c	Notes
Immune biomarker/cytokines sample	X*	X	Unscheduled samples will be collected in the event of any unexpected safety finding. *Collected at Weeks 4, 8, 12 and 20 only.
PBMCs	X*	X	. Unscheduled samples will be collected in the event of any unexpected safety finding. *Collected at Weeks 4, 8, 12 and 20 only.
Drug dispensing/ accountability	X	X	Subjects will record all doses in a dosing diary, which will be reviewed at each study visit.
Record AEs	X	X	Will be collected from the time of the start of study treatment through the last Post-Treatment F/U visit.
Record SAEs	X	X	Will be collected from the signing of the ICF through the last Post-Treatment F/U visit and followed until resolution of any event.

Abbreviations: AEs = adverse events; BP = blood pressure; ECG = electrocardiogram; EOS = end of study; F/U = follow up; HBcrAg = hepatitis B virus core-related antigen; HBeAb = hepatitis B virus e-antibody; HBeAg = hepatitis B virus e-antigen; HBsAb = hepatitis B virus surface antibody; HBsAg = hepatitis B virus surface antigen; HBV = hepatitis B virus; HR = heart rate; hrs = hours; ICF = informed consent form; NA = nucleos(t)ide analogue; PBMCs = peripheral blood mononuclear cells; PD = pharmacodynamic; PE = physical exam; PK = pharmacokinetic; RR = respiration rate; SAE = serious adverse event; temp = temperature; WOCBP = women of childbearing potential.

- First follow up visit will occur 4 weeks after the date the subject terminated from the study during the Lead-In Period.
- Visit windows are ± 5 days.
- Visit windows are ± 7 days.

Appendix 9 NA Retreatment Criteria and Follow up Schedule of Activities

For subjects who discontinued NA therapy per protocol (see Section 4.4), resumption of NA therapy should occur if any of the following scenarios occur and after discussion with the Sponsor Medical Monitor:

- Persistent ALT elevations $\geq 2 \times$ baseline, AND $\geq 2 - 5 \times$ ULN, AND HBV DNA > 2000 IU/mL for 12 weeks
- Persistent ALT elevations $\geq 2 \times$ baseline, AND $\geq 5 - 10 \times$ ULN, AND HBV DNA > 2000 IU/mL for 4 weeks
- HBV DNA $> 20,000$ IU/mL regardless of ALT level, confirmed by repeat
- ALT $> 10 \times$ ULN, confirmed by repeat
- ALT $>$ baseline and $>$ ULN, AND:
 - increased direct or total bilirubin $\geq 2 \times$ ULN and $\geq 2 \times$ baseline confirmed by repeat, OR
 - INR increase of ≥ 0.5 from baseline, confirmed by repeat.

Subjects who restart NA therapy will be assessed at minimum every 2 weeks until clinically stable (i.e., ALT and HBV DNA declining on 2 consecutive visits) and will be followed for 24 weeks total via unscheduled visits as needed prior to study discharge (Table 14). The Sponsor Medical Monitor should be consulted regarding when the subject is felt to be clinically stable, at which time visits may be reduced to monthly. More frequent visits may also be conducted if the subject's clinical status worsens.

Table 14. Schedule of Activities for Subjects who Restart NA Therapy

Assessment	Visit 1 ^a (Week 2)	Visit 2 ^a (Week 4)	Remaining Visits ^b (every 2 weeks until clinically stable, then every 4 weeks until Week 24/EOS)	Notes
Concomitant medications	X	X	X	
Physical examination	X	X	X	Targeted PEs may be completed at any study visit based on any reported changes to the subject's health.
Vital signs	X	X	X	BP, HR, RR, and temperature.
Clinical Laboratory tests	X	X	X	Includes clinical chemistry, hematology, coagulation tests, serology, and urinalysis as specified in Appendix 4, and are to be completed after an overnight fast of ≥ 8 hrs
Pregnancy test (WOCBP only)	X		X*	If the urine test is positive or not interpretable, a serum/plasma pregnancy test is to be conducted. *Every 8 weeks until study discharge

Assessment	Visit 1 ^a (Week 2)	Visit 2 ^a (Week 4)	Remaining Visits ^b (every 2 weeks until clinically stable, then every 4 weeks until Week 24/EOS)	Notes
Quantitative HBV DNA	X	X	X	Local testing can be performed in addition to central lab testing to facilitate more rapid results.
Quantitative HBsAg	X	X	X	If HBsAg becomes <LLOQ an unscheduled HBsAb sample may be obtained
Quantitative HBV RNA	X	X	X	
Quantitative HBcrAg	X	X	X	
Record AEs	X	X	X	
Record sAEs	X	X	X	

Abbreviations: AEs = adverse events; BP = blood pressure; ECG = electrocardiogram; EOS = end of study; F/U = follow up; HBcrAg = hepatitis B virus core-related antigen; HBsAb = hepatitis B virus surface antibody; HBsAg = hepatitis B virus surface antigen; HBV = hepatitis B virus; HR = heart rate; hrs = hours; NA = nucleos(t)ide analogue; PE = physical exam; PK = pharmacokinetic; RR = respiration rate; SAE = serious adverse event; temp = temperature; WOCBP = women of childbearing potential.

a. Visit windows are ± 3 days.

b. Visit windows are ± 3 days of visits are every 2 weeks, ± 5 days if visits are every 4 weeks.

Appendix 10 Resistance Monitoring Plan

The probability of selection of pre-existing resistant variants during AB-729 treatment is anticipated to be low. The AB-729 target site is highly conserved, at $\geq 99.4\%$ amongst 9,098 HBV genotype A-H sequences available in the hepatitis B virus database (HBVdb). Preclinical *in vitro* activity assessments of the most commonly occurring nucleotide mismatches within the AB-729 HBV target site suggest that AB-729 is able to retain activity against these HBV variants. Given that the target site of AB-729 differs from the known HBV target sites for NA and capsid inhibitor agents and does not overlap with the HBsAg open reading frame (thus negating any impact on approved vaccine epitopes), there is a reasonable expectation that resistant variants to any of these drug modalities will remain susceptible and most likely respond to treatment with the other drugs in a combination treatment setting. Consistent with this expectation, resistant variants against NAs or capsid inhibitor agents were susceptible to inhibition by AB-729 in a cell culture model of HBV. In the clinical setting, the risk of viral resistance emerging to AB-729 is decreased significantly in a combination treatment context where NAs effectively arrest viral replication.

To monitor for selection of resistant variants to AB-729, samples from all subjects undergoing AB-729 treatment will be collected at baseline and different timepoints during treatment and follow-up, and where feasible, next-generation sequencing (NGS) analyses conducted to assess the AB-729 HBV target site sequence in subjects at baseline or who experience a non-response to AB-729 treatment (defined as $<0.3 \log_{10}$ reduction in HBsAg after 24 weeks of dosing) or who show a rebound in either HBsAg (defined as $\geq 0.5 \log_{10}$ IU/mL change above nadir) or HBV DNA (defined as $\geq 1 \log_{10}$ IU/mL change above nadir or quantifiable HBV DNA after being undetectable) during repeat dosing of AB-729. Where feasible, given limitations on the sensitivity of the assay selected, HBV genotypes of baseline and on-therapy non-response or rebound samples will be determined by sequencing and phylogenetic analysis. Changes in the nucleotide sequence of the AB-729 HBV target site present in on-treatment or follow-up samples will be compared to the AB-729 target site nucleotide sequence in the baseline sample for each subject identified as showing a non-response or who experience a rebound during AB-729 treatment.

HBV viral variants with mismatches in the AB-729 HBV target site identified from subjects with on-therapy non-response or rebound will be cloned into a representative HBV genome background and susceptibility to AB-729 activity will be tested in cell culture systems, such as an HBV plasmid transient transfection model.

A listing of the virological assessments to be conducted for AB-729-201, along with detailed assay descriptions, is provided below.

An overview of the next generation sequencing approach for resistance assessment is provided below.

Virological Assessments in AB-729-201

A listing of the virological assessments to be conducted in AB-729-201 is provided in [Table 15](#).

Detailed assay descriptions and available performance characteristics are provided in the indicated locations for assays that are not currently FDA-approved.

Table 15. Virological Assessments

HBV Marker	Assay	Product Number	Assay Description and Performance Characteristics
HBsAg (Quantitative)	Roche cobas Elecsys HBsAg II quant II	P/N: 07027443119	Roche cobas HBsAg II quant II Information Sheet
HBsAg (Quantitative, Ultra-sensitive)	Abbott Architect HBsAg Next Research Use Only Assay	Not applicable	Sickinger 2020_Abbott Architect HBsAg Next Assay
HBV DNA	Roche cobas HBV 6800	P/N: 07000979190	FDA Approved
HBcrAg	Fujirebio Lumipulse G	231715	Lumipulse G HBcrAg Information Sheet
HBeAg (Qualitative)	Roche cobas Elecsys HBeAg Immunoassay	P/N: 11820583122	FDA Approved
HBeAg (Quantitative)	Roche cobas Elecsys HBeAg Immunoassay	Not applicable	Roche Quantitative HBeAg in Serum Validation Summary
Anti-HBs (Quantitative)	Advia Centaur aHBs2	4670661	FDA Approved
HBeAg Ab (Qualitative)	Roche Elecsys anti-HBe	P/N: 07026838190	FDA Approved
Anti-HBc IgM	Advia Centaur HBc IgM	00504619	FDA Approved
HBsAg Isoforms	Abbott Research Use Only Assay	Not applicable	Rodgers et al., Poster 0675
HBV RNA	Abbott Research Use Only Assay	Not applicable	Anderson M et al., Poster P13
HBsAg Immune Complex	Abbott Research Use Only Assay	Not applicable	To be provided
HBV Genotype	To be identified	To be identified	To be identified

Resistance Assessment: Next Generation Sequencing Approach


To monitor selection of resistant variants to AB-729, samples from all subjects undergoing AB-729 treatment will be collected at baseline and different timepoints during treatment and follow-up. Where feasible, next-generation sequencing will be conducted to assess the AB-729 HBV target site sequence in subjects at baseline or who experience a non-response to AB-729 treatment (defined as $<0.3 \log_{10}$ reduction in HBsAg after 24 weeks of dosing) or who show a rebound in either HBsAg (defined as $\geq 0.5 \log_{10}$ IU/mL change above nadir) or HBV DNA (defined as $\geq 1 \log_{10}$ IU/mL change above nadir or quantifiable HBV DNA after being undetectable) during repeat dosing of AB-729. Viral nucleic acids will be isolated from plasma K₂EDTA samples and used as a template for polymerase chain reaction (PCR) amplification using primers flanking the AB-729 target site, located at least 100 base pairs away from the 5' and 3' ends of the AB-729 target site (i.e. spanning at least positions 1479 to 1679 of the HBV genome as referenced by accession no. EU939600.1; the EcoRI restriction enzyme site is designated as position 1). The resulting amplicons will be used to prepare Nextera XT libraries and sequenced using the Illumina MiSeq platform. Summary statistics reports for each sequence run will be generated that will include the total number of reads, quality scores, average read length as well as trimming parameters. A detailed NGS protocol, including sample preparation and performance characteristics of the Illumina platform, will be communicated to the Food and Drug Administration (FDA) prior to submission of sequencing data.

An overview of the bioinformatics sequence analysis approach is depicted in [Figure 3](#).

Mapping of sequence reads will be conducted to representative HBV genomic sequences for each genotype ([Table 16](#)).

Sequence variant calling will be determined by comparison to the fully matched AB-729 target site (defined as complementary to antisense strand positions 2-18). Frequency tables of AB-729 target site nucleotide variants identified at $\geq 1\%$ sequence-read frequency and raw NGS data in FASTQ format will be submitted to the FDA. Summary tables identifying AB-729 target site nucleotide variants identified at $\geq 15\%$ sequence-read frequency will be provided. The procedures for submission of NGS data to the FDA will be as referenced in the published FDA guidance.[\[38\]](#) Further details of the bioinformatics sequence analysis pipeline, including algorithm parameter settings and rationale, will be included in submissions of sequence data to the FDA.

Figure 3. Overview of Bioinformatics Sequence Analysis Approach



Abbreviation: QC = quality control.

Table 16. HBV Genotype Reference Sequences for Read Mapping

HBV Genotype	Genbank Accession No.
A	X02763
B	AB219428
C	GQ924620
D	AF121240
E	AB106564
F	AY090458
G	AF160501
H	FJ356716
I	EU833891

Elecsys HBsAg II quant II

cobas[®]

REF



SYSTEM

07027443119

07027443500

100

cobas e 801

English

System information

Short name	ACN (application code number)
HBSAGQ2	10055

Intended use

Immunoassay for the in vitro quantitative determination of hepatitis B surface antigen (HBsAg) in confirmed HBsAg positive human serum and plasma. Assay results, in conjunction with HBV DNA quantification and clinical information, may be used as an aid to monitor treatment of individuals with chronic hepatitis B.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on the **cobas e 801** immunoassay analyzer.

Note

Please note that the catalogue number appearing on the package insert retains only the first 8 digits of the licensed 11-digit catalogue number: 07027443190 for the Elecsys HBsAg II quant II. The last 3 digits -190 have been replaced by -119 for logistic purposes.

Summary

The hepatitis B surface antigen (HBsAg), a polypeptide of varying size, is a component of the external envelope of the hepatitis B virus (HBV) particle.^{1,2} In addition to the intact infectious viral particles, the blood of persons infected with HBV contains large amounts of non-infectious particles which consist only of an outer coat containing HBsAg.³ After infection, HBsAg is the first immunological marker detectable in serum and is usually present weeks to months before the onset of clinical symptoms and the appearance of other biochemical markers.⁴ In the case of acute HBV infection with recovery, HBsAg is detectable in serum for up to 6 months after its appearance.⁴ If HBsAg persists for more than 6 months after acute hepatitis, the presence of chronic hepatitis B (CHB) infection must be assumed.

Classifying the stage of CHB infection is essential for identifying patients who require treatment and monitoring, as well as assessing the likelihood of responding to treatment and risk of progression to more severe liver disease.^{5,6,7} A CHB patient with elevated aminotransferase levels, high HBV DNA viral load, and histological abnormalities will be considered for therapy and two different treatment strategies are applicable: treatment of finite duration with pegylated interferon alpha or long-term treatment with nucleoside/nucleotide analogs (NUCs).⁵ Monitoring HBsAg levels, in addition to HBV DNA, before^{8,9} and during pegylated interferon-based therapy can help physicians to predict the likely response and implement the response-guided therapy algorithms, as recommended in the guidelines, to achieve the optimal outcome, which is sustained HBsAg loss with or without seroconversion to anti-HBs.^{5,6,8,9,10,11} There is also some evidence suggesting that HBsAg quantification may have value for monitoring response to NUC therapy and identifying patients able to achieve a sustained response after terminating treatment.^{3,12,13,14,15} This is based on the suggestion that HBsAg levels decline during antiviral therapy with NUCs reflecting an improvement in the degree of host immune control of the virus, with lower HBsAg levels at end of treatment being associated with continued remission.^{11,16,17} However, further studies in larger cohorts are required.

For patients in the immune clearance phase of CHB, HBV DNA levels have traditionally been used to determine the disease progression risk. However, HBsAg monitoring can provide additional information and distinguish true inactive carriers (HBV DNA < 2000 IU/mL and HBsAg < 1000 IU/mL), who are at the lowest risk of progression from those at a higher risk of developing cirrhosis or hepatocellular carcinoma (HCC). An HBsAg level ≥ 1000 IU/mL in hepatitis B 'e' antigen negative patients with HBV DNA < 2000 IU/mL has been identified as an independent risk factor for progression to HCC.^{5,6,11,18,19,20}

Test principle

Sandwich principle. Total duration of assay: 18 minutes.

- 1st incubation: 30 µL of sample, two biotinylated monoclonal anti-HBsAg antibodies, and a mixture of monoclonal anti-HBsAg antibody and polyclonal anti-HBsAg antibodies labeled with a ruthenium complex^{a)} form a sandwich complex.
- 2nd incubation: After addition of streptavidin-coated microparticles, the complex becomes bound to the solid phase via interaction of biotin and streptavidin.

- The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell II M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.
- Results are determined via a calibration curve which is instrument-specifically generated by 2-point calibration and a master curve provided via the **cobas** link.

a) Tris(2,2'-bipyridyl)ruthenium(II)-complex (Ru(bpy)₃²⁺)

Reagents - working solutions

The **cobas e** pack (M, R1, R2) is labeled as HBSAGQ2.

M Streptavidin-coated microparticles, 1 bottle, 6.4 mL:
Streptavidin-coated microparticles 0.72 mg/mL; preservative.

R1 Anti-HBsAg-Ab~biotin, 1 bottle, 7.2 mL:
Two biotinylated monoclonal anti-HBsAg antibodies (mouse)
> 0.5 mg/L; phosphate buffer 100 mmol/L, pH 7.5; preservative.

R2 Anti-HBsAg-Ab~Ru(bpy)₃²⁺, 1 bottle, 6.3 mL:
Monoclonal anti-HBsAg antibody (mouse), polyclonal anti-HBsAg antibodies (sheep) labeled with ruthenium complex > 1.5 mg/L; phosphate buffer 100 mmol/L, pH 8.0; preservative.

HBSAGQ2 Cal1 Negative calibrator 1, 2 bottles of 1.3 mL each:
Human serum, buffered, pH 6.5; preservative.

HBSAGQ2 Cal2 Positive calibrator 2, 2 bottles of 1.3 mL each:
HBsAg approximately 50 IU/mL in human serum, buffered, pH 6.5; preservative.

HBSAGQ2 Dil HepB **cobas e** pack with 2 bottles of 12.1 mL each and 1 bottle of 21 mL:
Human serum negative for HBsAg and anti-HBs, buffered, pH 6.5; preservative.

Precautions and warnings

For in vitro diagnostic use.

Exercise the normal precautions required for handling all laboratory reagents. Disposal of all waste material should be in accordance with local guidelines. Safety data sheet available for professional user on request.

All human material should be considered potentially infectious.

The calibrators and HBSAGQ2 Dil HepB have been prepared exclusively from the blood of donors tested individually and shown to be free from HBsAg (HBSAGQ2 Cal1 and HBSAGQ2 Dil HepB only) and antibodies to HCV and HIV.

The testing methods used assays approved by the FDA or cleared in compliance with the European Directive 98/79/EC, Annex II, List A.

The serum containing HBsAg (HBSAGQ2 Cal2) was inactivated using β-propiolactone and UV-radiation.

However, as no inactivation or testing method can rule out the potential risk of infection with absolute certainty, the material should be handled with the same level of care as a patient specimen. In the event of exposure, the directives of the responsible health authorities should be followed.^{21,22}

Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).

Reagent handling

The reagents (M, R1, R2, Dil HepB) in the kit are ready-for-use and are supplied in **cobas e** packs.

Calibrators

The calibrators are supplied ready-for-use in bottles compatible with the system.

Unless the entire volume is necessary for calibration on the analyzer, transfer aliquots of the ready-for-use calibrators into empty snap-cap bottles (CalSet Vials). Attach the supplied labels to these additional bottles. Store the aliquots at 2-8 °C for later use.

Elecsys HBsAg II quant II



Perform **only one** calibration procedure per aliquot.

All information required for correct operation is available via the **cobas** link.

Storage and stability

Store at 2-8 °C.

Do not freeze.

Store the **cobas e** pack **upright** in order to ensure complete availability of the microparticles during automatic mixing prior to use.

Stability of the cobas e packs (M, R1, R2, Dil HepB):	
unopened at 2-8 °C	up to the stated expiration date
on the cobas e 801 analyzer	16 weeks

Stability of the calibrators:	
unopened at 2-8 °C	up to the stated expiration date
after opening at 2-8 °C	16 weeks
on the cobas e 801 analyzer at 20-25 °C	use only once

Store calibrators **upright** in order to prevent the calibrator solution from adhering to the snap-cap.

Specimen collection and preparation

Only the specimens listed below were tested and found acceptable.

Serum collected using standard sampling tubes or tubes containing separating gel.

Li-heparin, Na-heparin, K₂-EDTA and Na-citrate plasma.

Criterion: Slope 0.9 - 1.1 + intercept within $\leq \pm 0.5$ IU/mL + coefficient of correlation ≥ 0.95 .

Stable for 6 days at 20-25 °C, 14 days at 2-8 °C, 6 months at -20 °C (± 5 °C). The samples may be frozen 6 times.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Do not use heat-inactivated samples.

Do not use samples and controls stabilized with azide.

Ensure the samples and calibrators are at 20-25 °C prior to measurement.

Due to possible evaporation effects, samples and calibrators on the analyzers should be analyzed/measured within 2 hours.

Materials provided

See "Reagents – working solutions" section for reagents.

- 2 x 6 bottle labels

Materials required (but not provided)

- [REF 07143745190](#), PreciControl HBsAg II quant II, 15 x 1.3 mL
- [REF 11776576322](#), CalSet Vials, 2 x 56 empty snap-cap bottles
- General laboratory equipment
- cobas e** 801 analyzer

Accessories for the **cobas e** 801 analyzer:

- [REF 06908799190](#), ProCell II M, 2 x 2 L system solution
- [REF 04880293190](#), CleanCell M, 2 x 2 L measuring cell cleaning solution
- [REF 07485409001](#), Reservoir Cups, 8 cups to supply ProCell II M and CleanCell M
- [REF 06908853190](#), PreClean II M, 2 x 2 L wash solution
- [REF 05694302001](#), Assay Tip/Assay Cup tray, 6 magazines x 6 magazine stacks x 105 assay tips and 105 assay cups, 3 wasteliners
- [REF 07485425001](#), Liquid Flow Cleaning Cup, 2 adaptor cups to supply ISE Cleaning Solution/Elecsys SysClean for Liquid Flow Cleaning Detection Unit
- [REF 07485433001](#), PreWash Liquid Flow Cleaning Cup, 1 adaptor cup to supply ISE Cleaning Solution/Elecsys SysClean for Liquid Flow Cleaning PreWash Unit
- [REF 11298500316](#), ISE Cleaning Solution/Elecsys SysClean, 5 x 100 mL system cleaning solution

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. **Pre-dilution of samples is mandatory according to the test algorithm (see "Dilution" section).** Refer to the appropriate operator's manual for analyzer-specific assay instructions.

Resuspension of the microparticles takes place automatically prior to use.

Place the cooled (stored at 2-8 °C) **cobas e** pack on the reagent manager. Avoid foam formation. The system automatically regulates the temperature of the reagents and the opening/closing of the **cobas e** pack.

Calibrators:

Place the calibrators in the sample zone.

Read in all the information necessary for calibrating the assay.

Calibration

Traceability: This method has been standardized against the NIBSC standard (code number: 00/588; WHO Second International Standard for HBsAg, subtype adw2, genotype A; IU/mL).

The predefined master curve is adapted to the analyzer using HBSAGQ2 Cal1 and HBSAGQ2 Cal2.

Calibration frequency: Calibration must be performed once per reagent lot using HBSAGQ2 Cal1, HBSAGQ2 Cal2 and fresh reagent (i.e. not more than 24 hours since the **cobas e** pack was registered on the analyzer).

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Renewed calibration is recommended as follows:

- after 12 weeks when using the same reagent lot
- after 28 days when using the same **cobas e** pack on the analyzer
- as required: e.g. quality control findings outside the defined limits

Quality control

For quality control, use PreciControl HBsAg II quant II.

Controls for the various concentration ranges should be run individually at least once every 24 hours when the test is in use, once per **cobas e** pack, and following each calibration.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

If necessary, repeat the measurement of the samples concerned.

Follow the applicable government regulations and local guidelines for quality control.

Calculation

The analyzer automatically calculates the analyte concentration (IU/mL) based on the measurement of HBSAGQ2 Cal1 and HBSAGQ2 Cal2. In case of a manual pre-dilution, the dilution factor needs to be accounted for manual calculation of the final result.

Limitations - interference

The effect of the following endogenous substances and pharmaceutical compounds on assay performance was tested. Interferences were tested up to the listed concentrations and no impact on results was observed.

Endogenous substances

Compound	Concentration tested
Bilirubin	≤ 684 μ mol/L or ≤ 40 mg/dL
Hemoglobin	≤ 0.311 mmol/L or ≤ 500 mg/dL
Intralipid	≤ 2000 mg/dL
Biotin	≤ 164 nmol/L or ≤ 40 ng/mL
Rheumatoid factors	≤ 1200 IU/mL
Albumin	≤ 7.0 g/dL

Criterion: For concentrations of 0.05-1 IU/mL the deviation is ≤ 0.2 IU/mL. For concentrations of 1-130 IU/mL the recovery is 80-120 %.

Elecsys HBsAg II quant II



Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.

No high-dose hook effect was found with the Elecsys HBsAg II quant II assay up to a concentration of 250000 IU/mL when samples were analyzed according to instructions for use (predilution 1:900).

Pharmaceutical substances

In vitro tests were performed on 16 commonly used pharmaceuticals. No interference with the assay was found.

In addition, the following special drugs used in hepatitis B therapy were tested. No interference with the assay was found.

Special drugs

Drug	Concentration tested mg/L
Peginterferon alfa-2a	≤ 0.036
Peginterferon alfa-2b	≤ 1.6
Lamivudine	≤ 300
Adefovir	≤ 10
Entecavir	≤ 1.0
Telbivudine	≤ 600
Tenofovir	≤ 245

In rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. These effects are minimized by suitable test design.

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

Limits and ranges

Measuring range

Measuring range for pre-diluted samples:

45-117000 IU/mL for 900-fold diluted samples.

Values below the measuring range are reported as < 45 IU/mL.

Values above the measuring range are reported as > 117000 IU/mL.

1350-3510000 IU/mL for 27000-fold diluted samples.

Values below the measuring range are reported as < 1350 IU/mL.

Values above the measuring range are reported as > 3510000 IU/mL.

Measuring range for undiluted samples:

0.05-130 IU/mL (defined by the Limit of Detection and the maximum of the master curve).

Values below the Limit of Detection are reported as < 0.05 IU/mL.

Values above the measuring range are reported as > 130 IU/mL.

Lower limits of measurement

Limit of Blank and Limit of Detection

Limit of Blank = 0.03 IU/mL

Limit of Detection = 0.05 IU/mL

The Limit of Blank and Limit of Detection were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17-A2 requirements.

The Limit of Blank is the 95th percentile value from $n \geq 60$ measurements of analyte-free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples. The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

Dilution

Initial onboard dilution of 1:900 with HBSAGQ2 Dil HepB is mandatory for every sample. Therefore every sample should first be run with a dilution step of 1:900 ordered by the user and performed by the analyzer.

After dilution by the analyzer, the software automatically takes the dilution into account when calculating the sample concentration.

If a result is found within the measuring range 45-117000 IU/mL for 900-fold diluted samples no further dilution is necessary.

If a result is found < 45 IU/mL for 900-fold diluted samples, the sample has to

be run undiluted and should be found within 0.05-130 IU/mL.

If a result is found > 117000 IU/mL for 900-fold diluted samples the sample has to be run with a dilution step 1:27000 ordered by the user and performed by the analyzer.

A dilution algorithm can be performed automatically (see section "cobas e flows").

cobas e flows

cobas e flows are procedures programmed into the system to enable a fully automated sequence of measurements and the calculation of assay combinations to perform decision algorithms.

A **cobas e flow** is available to automatically perform an initial 1:900 sample dilution and calculate the assay result. In case the result is found above the extended measuring range, another dilution of the sample is carried out (1:27000) and another result is calculated. In case the initial result is found below the extended measuring range, another measurement is carried out without dilution of the sample and the result is reported.

Expected values

Note: Where indicated, data have been generated using the Elecsys HBsAg II quant assay. Since the reagents (M, R1, R2) of the Elecsys HBsAg II quant assay are the same as those of the Elecsys HBsAg II quant II assay (only the controls and calibrators have been modified) the data generated with the Elecsys HBsAg II quant assay are transferable to the Elecsys HBsAg II quant II assay and no new data needed to be generated.

From 611 samples obtained from a multicenter evaluation the following values have been reported with the Elecsys HBsAg II quant assay.

IU/mL	MCE (n = 611)	% of total
< 1	17	2.78
1-< 10	20	3.27
10-< 100	35	5.73
100-< 1000	127	20.8
1000-< 10000	239	39.1
10000-< 100000	147	24.1
100000-< 1000000	26	4.26

The final result was determined from the first measurement in 70.0 % of the samples with 1:100 dilution and 86.5 % of the samples with a 1:400 dilution.

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

Specific performance data

Representative performance data on the analyzer is given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined using Elecsys reagents, samples and controls in a protocol (EP05-A3) of the CLSI (Clinical and Laboratory Standards Institute): 2 runs per day in duplicate each for 21 days (n = 84). The following results were obtained:

cobas e 801 analyzer					
		Repeatability ^{b)}		Intermediate precision ^{c)}	
Sample	Mean IU/mL	SD IU/mL	CV %	SD IU/mL	CV %
Human serum 1	0.103	0.002	2.0	0.003	2.6
Human serum 2	44.0	0.433	1.0	0.927	2.1
Human serum 3	304	5.37	1.8	8.84	2.9
PC ^{d)} HBsAg II quant II 1	3.33	0.035	1.1	0.072	2.2
PC HBsAg II quant II 2	78.5	0.747	1.0	1.69	2.2
PC HBsAg II quant II 3	72.1	1.69	2.3	2.11	2.9

b) Repeatability = within-run precision

c) Intermediate precision = between-run precision


d) PC = PreciControl

Elecsys HBsAg II quant II



Method comparison

A comparison of the Elecsys HBsAg II quant II assay (y) with the Elecsys HBsAg II quant assay (x) using 288 serum samples gave the following correlations:



x: Elecsys HBsAg II quant assay
y: Elecsys HBsAg II quant II assay

Passing/Bablok²³
 $y = 1.01x - 0.00$
 $r = 0.997$

The sample concentrations were between 0 and 50000 IU/mL.

A comparison of the Elecsys HBsAg II quant II assay (REF 07027443190 (cobas e 801 analyzer; y) with the HBsAg II quant II assay, (REF 07143737190 (cobas e 601 analyzer; x) gave the following correlations (IU/mL):

Number of serum samples measured: 214

Passing/Bablok²³ Linear regression
 $y = 1.02x + 0.202$ $y = 0.987x + 297$
 $r = 0.975$ $r = 0.996$

The sample concentrations were between 0.000 and 122022 IU/mL.

Quantitation of potentially cross reactive samples

1285 samples containing potentially interfering substances were tested with the Elecsys HBsAg II quant assay comprising specimens:

- containing antibodies against HAV, HCV, HIV, HTLV, CMV, EBV, HSV, Rubella, Parvo virus, VZV, Toxoplasma gondii, Treponema pallidum
- containing autoantibodies (ANA, SLE), elevated titers of rheumatoid factor or HAMA antibodies
- positive for Mumps, Measles, Malaria
- after vaccination against HBV and influenza
- from patients with monoclonal gammopathy and multiple myeloma/lymphoma, patients undergoing dialysis or patients suffering from alcoholic liver disease
- from pregnant women

No results were found ≥ 0.05 IU/mL.

Quantitation of HBV mutants

A total of 50 samples comprising different HBsAg mutations were tested with the Elecsys HBsAg II quant assay. Results of observed concentrations are displayed.

Mutant panel	Elecsys HBsAg II quant (IU/mL) ^{e)}
Native mutant panel (strains displaying amino acid substitutions either linked to vaccine resistance, resistance to therapy with human HB immunoglobulin or impaired HBsAg reactivity)	< 0.05 (n = 2) 0.05-324 (n = 17)
Recombinant mutant panel	> 0.05-6.9 (n = 31)

e) Observed concentrations with HBV mutants might differ compared to competitor assays and are a characteristic of the individual assays.

Seroconversion panels

18 seroconversion panels were analyzed with the Elecsys HBsAg II quant assay. In all panels the Elecsys HBsAg II quant assay showed a significant increase in concentration upon seroconversion correlated to the shift as it is detectable in qualitative screening assays. Observed concentrations ranged from < Limit of Detection for negative samples, and 0.058-92300 IU/mL for conversion (confirmed positive) samples.

References

- Seeger C, Zoulim F, Mason WS. Hepadnaviruses. In: Field's Virology, Knipe DM, Howley RM (eds), 2007 5th edition, Lippincott Williams and Wilkins, Philadelphia, USA. Chapter 76, pp2977-3029.
- Lee JM, Ahn SH. Quantification of HBsAg: basic virology for clinical practice. World J Gastroenterol 2011;17:283-289.
- Liaw YF. Clinical utility of hepatitis B surface antigen quantification in patients with chronic hepatitis B: a review. Hepatology 2011;54:E1-E9.
- Liaw YF, Chu CM. Hepatitis B infection. Lancet 2009;373:582-592.
- European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
- Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531-561.
- Lok ASF, McMahon B. Chronic hepatitis B: update 2009. AASLD Practice Guidelines. Available at: http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/Chronic_Hep_B_Update_2009%208_24_2009.pdf (accessed January 2013).
- Piratvisuth T, Marcellin P, Popescu M, et al. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen positive patients. Hepatol Int 2013;7:429-436.
- Marcellin P, Bonino F, Yurdaydin C, et al. Hepatitis B surface antigen levels: association with 5 year response to peginterferon alfa-2a in hepatitis B e antigen-negative patients. Hepatol Int 2013;7:88-97.
- Sonneveld MJ, Hansen BE, Piratvisuth T, et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013;58:872-880.
- Martinot-Peignoux M, Lapalus M, Asselah T, et al. The role of HBsAg quantification for monitoring natural history and treatment outcomes. Liver Int 2013;33 Suppl1:125-132.
- Janssen HLA, Sonneveld MJ, Brunetto MR. Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B? Gut 2012;61:641-645.
- Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 – a core report. J Hepatol 2011;55:1121-1131.
- Wang CC, Tseng TC, Wang PC, et al. Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients. J Formos Med Assoc Epub ahead of print Aug 1 2013.
- Liang Y, Jiang J, Su M, et al. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacol Ther 2011;34:344-352.
- Tseng T-C, Kao J-H. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. J Gastroenterol 2013;48:13-21.
- Pérez-Cameo C, Pons M, Esteban R. New therapeutic perspectives in


- HBV: when to stop NAs. Liver Int 2014;34 Suppl 1:146-153.
18. Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012;142:1140-1149.
 19. Chen CJ, Lee MH, Liu J, et al. Quantitative serum levels of hepatitis B virus DNA and surface antigen are independent risk predictors of hepatocellular carcinoma. Hepatology 2011;54:881A (abstract 1095).
 20. Tseng TC, Liu CJ, Yang HC, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology 2013;57:441-450.
 21. Occupational Safety and Health Standards: Bloodborne pathogens. (29 CFR Part 1910.1030). Fed. Register.
 22. Directive 2000/54/EC of the European Parliament and Council of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work.
 23. Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 1988 Nov;26(11):783-790.

For further information, please refer to the appropriate operator's manual for the analyzer concerned, the respective application sheets, the product information and the Method Sheets of all necessary components (if available in your country).

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Symbols


Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see <https://usdiagnostics.roche.com> for definition of symbols used):

CONTENT	Contents of kit
SYSTEM	Analyzers/Instruments on which reagents can be used
REAGENT	Reagent
CALIBRATOR	Calibrator
	Volume after reconstitution or mixing
GTIN	Global Trade Item Number

COBAS, COBAS E, ELECSYS and PRECICONTROL are trademarks of Roche. INTRALIPID is a trademark of Fresenius Kabi AB.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.
© 2017, Roche Diagnostics

 Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com





Performance characteristics of the high sensitivity Alinity i & ARCHITECT HBsAg Next Qualitative/Confirmatory assays

Eva Sickinger^{a,*}, Hans-Bertram Braun^a, Tobias Meyer^a, Kathrin Schmid^a, David Daghfal^b, Michael Oer^a, Jan Schultess^a

^a Abbott GmbH, Max-Planck-Ring 2, 65205 Wiesbaden-Delkenheim, Germany

^b Abbott Diagnostics, Abbott Park, IL 60064, USA

ARTICLE INFO

Article history:

Received 20 December 2019

Received in revised form 6 March 2020

Accepted 6 March 2020

Available online 10 March 2020

Keywords:

Hepatitis B virus

HBsAg

Acute and late infection

Sensitivity

ABSTRACT

Despite improvement in vaccinations, Hepatitis B remains a major health concern due to the difficulty of prevention even in low endemic areas such as Europe. In this report we describe the performance characteristics of the new HBsAg Next Qualitative and HBsAg Next Confirmatory assays designed for blood screening and diagnostic purposes on the Alinity i and ARCHITECT fully automated systems.

The new assays were evaluated in comparison to the ARCHITECT HBsAg Qualitative II and Confirmatory assays on seroconversion, analytical sensitivity, and mutant panels along with testing of over 400 clinical positive samples demonstrating excellent improvements in sensitivity. Additionally, specificity was shown to be improved with testing of over 6000 donors and 240 diagnostic specimens. Overall, the Alinity i & ARCHITECT HBsAg Next assays have taken a step forward in improving the detection of Hepatitis B virus.

© 2020 Elsevier Inc. All rights reserved.

1. Introduction

Although vaccination programs for Hepatitis B have been available since 1982 (WHO Hepatitis B key facts, 2019), viral hepatitis is still one of the 10 main causes of death, with Hepatitis B and C causing 96% of all hepatitis mortality (Global Hepatitis Report, 2017).

Transmission of hepatitis B virus (HBV) has been close to impossible to prevent mainly in high endemic areas, where it occurs either perinatally from mother to child at birth or through infected blood. Detection of infected mothers is of major importance as children infected during the first year of life have the highest incidence of developing chronic infection, i.e. 80–90% (Hyams, 1995), potentially leading to severe outcomes. Even in low endemic areas like Europe the incidence of acute HBV infection is increasing due to increased immigration and mass population influxes (Coppola et al., 2015; Hampel et al., 2016).

Hepatitis B surface antigen (HBsAg) is the first and most important antigenic marker for early and late acute as well as chronic infection detection (Kuhns et al., 2019a; Yang et al., 2016).

Although assays for HBsAg detection have been constantly improved (Enjalbert et al., 2014; Mortensen et al., 2016; Candotti and Laperche, 2018; Gerlich et al., 2018), there is still a need for higher sensitivity assays, to avoid false negatives in the diagnostic as well as transfusion settings, due to escape mutants, new genotypes, reactivation and occult infection.

Sensitivity is often obtained at the cost of diminished specificity. Especially in the blood bank setting higher sensitivity should not compromise specificity, to avoid time-consuming and expensive confirmatory testing, as well as delays in reporting results and unnecessary donor deferrals (Popp et al., 2011). NAT testing is more sensitive but also brings with it higher costs and the need for specialized equipment/facilities that are frequently prohibitive in developing countries. Therefore, sensitive HBsAg assays approaching mini-pool NAT sensitivity (Lou et al., 2018) could be an alternative especially in developing countries due to cost-effectiveness or in low prevalence areas.

In this report, we describe the performance characteristics of the new HBsAg Next Qualitative and HBsAg Next Confirmatory assays designed for blood screening and diagnostic purposes on the Alinity i and ARCHITECT fully automated random-access analyzers in comparison to the current on-market ARCHITECT HBsAg Qualitative II/Confirmatory assays.

2. Materials and methods

2.1. Testing sites

Testing was performed at one external site, i.e. Sanquin National Screening Laboratory, Amsterdam, Netherlands and internally at the research laboratories of Abbott GmbH, in Wiesbaden, Germany

* Corresponding author. Tel.: +49-6122-58-1381; fax: +49-6122-58-1473.

E-mail address: eva.sickinger@abbott.com (E. Sickinger).

2.1.1. Assay principle

The HBsAg Next assay is a one-step chemiluminescent microparticle immunoassay (CMIA) assay that has been built to run on both the Abbott Alinity i and the ARCHITECT i Systems.

The Alinity i system is part of a family of next generation Abbott automated analyzer systems for use with immunoassays. The Abbott ARCHITECT i analyzer system is the predecessor of the Alinity i system. The assay detects the qualitative presence of HBsAg and is calibrated/traceable to the World Health Organization (WHO) Second International Standard for HBsAg (subtype adw2, genotype A, NIBSC Code 00/588). Seventy-five microliters of the sample (serum or plasma) is mixed with antibody coated microparticles, specimen diluent and an Acridinium labeled conjugate in the first step of the assay. A series of washes including the use of an ancillary wash buffer ensues after an eighteen-minute incubation at 37 °C. Following the wash cycles, pre-trigger and trigger are added and the chemiluminescent signal is measured in relative light units (RLUs). The assay has a time to first result of 29 minutes and a throughput of up to 200 tests per hour on the ARCHITECT and Alinity i systems.

The ARCHITECT and Alinity HBsAg Next Confirmatory assay both consist of two single tests (referred to as C1 and C2) that are one-step pre-treatment immunoassays.

C1: Sample and Pre-Treatment 1 diluent are combined and incubated. The HBsAg present in the sample is neutralized by a Sheep anti-HBs in Pre-Treatment 1 diluent. An aliquot of the pretreated sample, anti-HBs coated paramagnetic microparticles, assay specific diluent and anti-HBs acridinium-labeled conjugate are combined and incubated. Any remaining non-neutralized HBsAg present binds to the anti-HBs coated microparticles and to the anti-HBs acridinium labeled conjugate. The neutralized HBsAg is blocked from forming a sandwich with acridinium-labeled anti-HBs conjugate and anti-HBs coated microparticles. Following a wash cycle, pre-trigger and trigger solutions are added. The resulting chemiluminescent reaction is measured as RLUs. There is a direct relationship between the amount of non-neutralized HBsAg in the sample and the RLUs detected by the ARCHITECT i or Alinity i System optics.

C2: Sample and Pre-Treatment 2 diluent are combined. Pre-Treatment 2 diluent does not contain Sheep anti-HBs and will not neutralize HBsAg present in the sample. Otherwise the C2 reaction follows a similar flow as C1. There is a direct relationship between the amount of HBsAg in the sample and the RLUs detected by the ARCHITECT or Alinity i System optics.

If the signal for the non-neutralized sample (incubated with Pre-Treatment 2 diluent) result is greater than or equal to the cutoff of 0.70 S/CO and the RLU of the neutralized sample (incubated with Pre-Treatment 1 diluent) is reduced by at least 50% compared to the non-neutralized sample, the sample is considered confirmed positive for HBsAg.

2.2. Specimens and Testing procedures

2.2.1. Seroconversion sensitivity

Seroconversion sensitivity was evaluated on a panel consisting of consecutive bleeds from 32 seroconverting donors obtained from commercial vendors. Testing was performed on Alinity i HBsAg Next Qualitative and ARCHITECT HBsAg Qualitative II.

2.2.2. Analytical sensitivity

Analytical Sensitivity of the ARCHITECT and Alinity i HBsAg Next Qualitative and Confirmatory assays was evaluated on the 2nd and 3rd WHO International standards for HBsAg, subtype adw2, genotype A, NIBSC code: 00/588 and NIBSC code 12/226, respectively.

The standards were reconstituted with distilled water and diluted with recalcified normal human plasma to a target stock concentration of 1000 mIU/mL. Further dilutions were prepared by combining the stock and recalcified normal human plasma to the target concentrations

of 0, 3, 5, 8, 10, 15, 20, and 40 mIU/mL. Dilutions were tested on multiple reagent lots and instruments and a minimum of 4 replicates each. For each instrument and reagent lot combination, the mean sample to cut-off (S/CO) values were calculated for each dilution. A least squares linear regression analysis was performed by regressing the mean S/CO values versus the target concentrations across the dilutions.

2.2.3. Clinical sensitivity

Clinical sensitivity was evaluated, by testing 450 samples known to be HBsAg positive and HBV NAT positive from acute ($n = 12$) and chronic ($n = 94$) phases of infection as well as from undefined infection stage ($n = 344$), all sourced from a variety of commercial suppliers.

Testing was performed on ARCHITECT and Alinity i HBsAg Next Qualitative and Confirmatory compared to ARCHITECT HBsAg Qualitative II and Confirmatory. However, testing could not be completed for all specimens on Alinity i HBsAg Next due to sample depletion (total $n=444$).

2.2.4. Mutant panel

Further sensitivity testing was completed on a total of 167 mutant panel specimens consisting of 71 recombinant mutant samples, 2 wild type controls and 94 native mutant samples collected through Abbott's Global Viral Surveillance Program (Harris et al., 2017; Rodgers et al., 2017).

All recombinant HBsAg mutant samples had amino acid sequences representing native mutants of hepatitis B surface antigen (Lou et al., 2018). Only 4 of the 165 mutant samples shared the same mutation pattern. 151 of these samples contained at least one substitution or insertion in the region spanning aa 120–145 within the 'a' determinant of the s antigen. 42 of the samples had single substitutions, 32 had double substitutions, 86 had 3 to a maximum of 18 substitutions or insertions, and 6 had insertions following aa 122 or 123 of the s antigen. Thirty-nine samples contained mutants Gln-129-His, Met-133-Leu, Asp-144-Ala, Gly-145-Arg, and Thr-123-Ala or insertion mutants 122NT, 122RA, P142L+G145R, P142S+G145R. The mutants had been diluted to a target of about 2 S/CO in the ARCHITECT HBsAg Qualitative II assay using negative human plasma.

2.2.5. Clinical specificity

Clinical specificity of the ARCHITECT HBsAg Next Qualitative assay in a blood bank population was evaluated on 6618 donor specimens (collected in 3300 serum and 3318 plasma tubes) in comparison to ARCHITECT HBsAg Qualitative II.

The Alinity i HBsAg assay was evaluated in a separate study using 6718 donor specimens (collected in 3181 serum and in 3537 plasma tubes). These specimens were obtained from 3 blood banks located in Amsterdam, Netherlands; München, Germany; and Mainz, Germany. Clinical specificity in a diagnostic setting was evaluated on a population of 240 serum and plasma specimens from hospitalized patients obtained from a commercial supplier.

2.2.6. Within assay sample carryover

Within sample carryover was evaluated by testing a high positive specimen at a concentration $\geq 125,000$ IU/mL followed by a high negative specimen testing at ~ 0.76 S/CO. The testing was carried out for 10 iterations.

2.3. Instrument configuration

Induction Heating, a system enhancement technology to preserve sample integrity, must be installed on the ARCHITECT i2000SR and the Alinity i Systems to run the Alinity i & ARCHITECT HBsAg Next Qualitative/Confirmatory assays.

3. Results

3.1. Seroconversion sensitivity

In 25 of 32 panels (78%) the number of days to the first repeat reactive and confirmed result was less for Alinity i HBsAg Next Qualitative compared to ARCHITECT HBsAg Qualitative II. For the remaining 7 panels, the investigational and comparator assay showed no difference in the number of days to the first repeatedly reactive and confirmed result. For Alinity i HBsAg Next Qualitative, the mean number of days to the first repeat reactive and confirmed result was 31.8 versus 38.3 for ARCHITECT HBsAg Qualitative II. For HBV NAT, the mean number of days to the first repeat reactive and confirmed result was 23.9 (Table 1). A second calculation was performed excluding panels 6272 and 11000, since they are known to be probable vaccine breakthrough seroconverters (Keating et al., 2014) and thus not representative of typical seroconversion in primary acute infection. Without these panels, the mean number of days to the first repeat reactive and confirmed result is 32.2 for Alinity i HBsAg Next Qualitative, 36.8 for ARCHITECT HBsAg Qualitative II and 25.5 for HBV ID-NAT.

Table 1
Alinity i HBsAg Next Qualitative seroconversion sensitivity.

Panel ID	Total n panel members	Days until first detection (n members detected)		
		HBV NAT	Alinity i	ARCHITECT
6271	5	0 (5)	0 (5)	7 (3)
6272	25	0 (25)	51 (14)	94 (7)
6273	6	3 (5)	14 (3)	14 (3)
6275	7	0 (7)	0 (7)	7 (5)
6277	11	21 (9)	26 (8)	33 (6)
6278	10	0 (10)	4 (9)	8 (8)
6279	7	12 (6)	19 (4)	26 (2)
6281	12	0 (10)	7 (8)	13 (7)
6282	14	0 (14)	12 (11)	14 (10)
6284	19	36 (11)	43 (9)	50 (7)
6285	16	31 (10)	38 (8)	40 (7)
6286	9	22 (8)	29 (6)	29 (6)
6290	12	0 (12)	14 (8)	14 (7)
9074	20	52 (8)	66 (5)	70 (4)
11000	9	0 (9)	3 (8)	26 (3)
11001	8	33 (6)	44 (4)	44 (4)
11002	6	0 (6)	0 (6)	7 (4)
11003	8	133 (5)	133 (5)	142 (3)
11006	17	19 (12)	35 (7)	42 (6)
11007	14	15 (10)	29 (6)	34 (5)
11008	18	51 (10)	62 (7)	69 (5)
11012	6	0 (6)	8 (4)	18 (3)
11013	35	230 (11)	239 (9)	244 (8)
11014	12	35 (5)	37 (4)	51 (3)
11017	14	25 (9)	34 (7)	40 (6)
11026	16	25 (9)	36 (6)	39 (5)
11029	13	21 (9)	32 (6)	35 (5)
13867/3482	30	0 (15)	0 (14)	0 (13)
1807/3463	25	0 (21)	4 (19)	4 (18)
43527/3453	26	0 (24)	0 (24)	0 (21)
26022/14518	30	0 (9)	0 (10)	7 (7)
0994/3457	23	0 (23)	0 (23)	4 (22)
Mean days	N/A	23.9	31.8	38.3
n Panel members detected of total		339/483	274/483	214/483

The days until detection of first reactive bleed of each panel is provided in the table above. The total number of bleeds detected of a panel is outlined in brackets. Although first bleed detection might be the same, this number of bleeds detected can be different between assays, e.g. panel 13867/3482, as early and late bleeds are counted.

3.2. Analytical sensitivity

For Alinity i and ARCHITECT HBsAg Next Qualitative analytical sensitivity values of 4.50 to 5.97 mIU/mL and 4.62 to 6.14 mIU/mL, respectively, have been obtained when using the WHO 2nd International Standard across reagent lots. The Alinity i and ARCHITECT HBsAg Next Qualitative assays were about 4-fold more sensitive compared to ARCHITECT HBsAg Qualitative II with an analytical sensitivity of 17.00 to 22.00 mIU/mL across reagent lots.

Using the WHO 3rd International Standard, the analytical sensitivity was assessed to be between 4.15 and 5.11 mIU/mL for ARCHITECT HBsAg Next Qualitative and between 4.35 and 5.24 mIU/mL for Alinity i HBsAg Next Qualitative across reagent lots. For the ARCHITECT HBsAg Qualitative II assay, analytical sensitivity on the 3rd WHO International Standard was not measured in this study.

3.3. Clinical sensitivity

The clinical sensitivity was determined to be 100.00% for both investigational Alinity i and ARCHITECT HBsAg Next Qualitative assays for the three sample categories tested. In comparison, the ARCHITECT HBsAg Qualitative II assay achieved an overall sensitivity of 99.78% (Table 2). This is due to one discordant HBsAg NAT positive specimen, which was found to be repeat reactive and confirmed on ARCHITECT HBsAg Next with an initial S/CO result of 4.99 and also repeat reactive and confirmed on Alinity i with an initial S/CO results of 5.57, but nonreactive on the comparator assay ARCHITECT HBsAg Qualitative II with an S/CO result of 0.77.

3.4. Mutants

Mutant specimens were better detected with the Alinity i and ARCHITECT HBsAg Next Qualitative assay. S/CO results of more than 100 were observed for single panel members that were detected at about 2 S/CO in the comparator assay with an on average 7-fold increase in S/CO values over the ARCHITECT HBsAg Qualitative II assay (Fig. 1). The new HBsAg Next Confirmatory assay showed a more efficient neutralization of mutant specimens as compared to the respective ARCHITECT HBsAg Qualitative II confirmatory assay (Fig. 2).

3.5. Clinical specificity on blood donors and diagnostic specimens

The ARCHITECT and Alinity i HBsAg Next Qualitative assays were assessed to have comparable specificity of 99.95% and 99.96%, respectively, on blood donations, and both 100% specificity on a diagnostic population. The predecessor assay ARCHITECT HBsAg Qualitative II showed a slightly lower specificity of 99.92% on blood donors, but also 100% on diagnostic specimens (Table 3). The S/CO distribution in the specificity populations is outlined in Table 4.

3.6. Within assay sample carryover

Alternating high positive specimen and elevated nonreactive specimens were tested for 10 iterations. The difference between the protected sample (nonreactive specimen not exposed to replicates of the positive sample prior to testing) and the unprotected sample (run immediately after an extremely high positive HBsAg specimen) had an absolute bias of 0.08 S/CO (confidence interval: 0.02 to 0.13) for a high nonreactive sample running at 0.76 S/CO.

4. Discussion

Although current HBsAg assays exhibit relatively high sensitivities there is a continuous need to improve sensitivity of these HBV assays, to avoid false negative results on early and late acute specimens, and to enable earlier detection of vaccine breakthrough mutants, occult

Table 2
Comparison of Clinical Sensitivity of ARCHITECT/ Alinity i HBsAg Next Qualitative and ARCHITECT HBsAg Qualitative II

Assay	Category	N	RR	Sensitivity %	95% Confidence interval
ARCHITECT HBsAg Next Qualitative	Acute HBV Infection	12	12	100.00 (12/12)	(73.54–100.00)
	Chronic HBV Infection	94	94	100.00 (94/94)	(96.15–100.00)
	HBsAg Positive	344	344	100.00 (344/344)	(98.93–100.00)
	Overall	450	450	100.00 (450/450)	(99.18–100.00)
ARCHITECT HBsAg Qualitative II (Comparator)	Acute HBV Infection	12	12	100.00 (12/12)	(73.54–100.00)
	Chronic HBV Infection	94	94	100.00 (94/94)	(96.15–100.00)
	HBsAg Positive	344	343	99.71 (343/344)	(98.39–99.99)
	Overall	450	449	99.78 (449/450)	(98.77–99.99)
Alinity i HBsAg Next Qualitative	Acute HBV Infection	11	11	100.00 (11/11)	(71.51–100.00)
	Chronic HBV Infection	92	92	100.00 (92/92)	(96.07–100.00)
	HBsAg Positive	341	341	100.00 (341/341)	(98.92–100.00)
	Overall	444*	444	100.00 (444/444)	(99.17–100.00)

RR = Repeatedly Reactive

* 6 samples could not be evaluated on the Alinity platform due to insufficient sample volume.

infections and viral reactivation (Kuhns et al., 2019a). Improved acute infection detection is especially important in regions where NAT evaluation is not available and/or affordable (Martin et al., 2012; Stramer et al., 2012; Vermeulen et al., 2013) to further reduce the detection window during acute HBV infection.

Since the introduction of HBsAg assays, the challenge has been to provide the highest possible sensitivity without compromising specificity. Maintaining this balance is critical in the blood bank setting, as high specificity is needed to avoid time-consuming confirmatory testing, as well as to eliminate delays in reporting and releasing results and avoiding unnecessary donor deferrals as well as uncertainty for donors, resulting in stress (Jonas et al., 2005). Specific care was given to

reducing non-specific background and noise levels in the new HBsAg Next assays by introducing new rare reagents and buffer systems as well as upgrading and improving hardware systems to complement the heightened sensitivity of the assays.

As a result of these modifications to the reagents and instrument systems the analytical sensitivity of the new HBsAg Next assays on the Alinity i / ARCHITECT was increased about 4-fold compared to the on-market already very sensitive ARCHITECT HBsAg Qualitative II assay. The increased analytical sensitivity enables better clinical diagnostic and screening sensitivity, mutant detection and seroconversion sensitivity. During clinical sensitivity testing, one incremental pick up was observed in one HBsAg NAT positive specimen, which was detected at 5.57 S/CO (Alinity i HBsAg Next) and 4.99 S/CO (ARCHITECT HBsAg Next) but was high non-reactive at 0.77 S/CO on ARCHITECT HBsAg Qualitative II.




Fig. 1. Comparison of mutant specimen detection (S/CO results) between Alinity i HBsAg Next Qualitative and ARCHITECT HBsAg Qualitative II. Results ranged from 1.69 to 225.07 S/CO in the Alinity i HBsAg Next Qualitative assay and from 1.35 to 10.13 S/CO in the ARCHITECT HBsAg Qualitative II




Fig. 2. Comparison of mutant neutralization capacity between Alinity i HBsAg Next Qualitative and ARCHITECT HBsAg Qualitative II.

Table 3

Comparison of Clinical Specificity of ARCHITECT/ Alinity i HBsAg Next Qualitative and ARCHITECT HBsAg Qualitative II

Assay	Category	N	IR (% of Total)	RR (% of Total)	Conf. positive (% of RR)	Specificity %	95% Confidence interval
ARCHITECT HBsAg Next Qualitative	Blood Donors Serum	3300	6 (0.18)	1 (0.03)	0 (0.00)	99.97 (3299/3300)	(99.83–100.00)
	Blood Donors Plasma	3318	10 (0.30)	2 (0.06)	0 (0.00)	99.94 (3316/3318)	(99.78–99.99)
	Total BD	6618	16 (0.24)	3 (0.05)	0 (0.00)	99.95 (6615/6618)	(99.87–99.99)
	Diagnostics	240	2 (0.83)	1 (0.42)	1 (100.00)	100.00 (239/239)	(98.47–100.00)
ARCHITECT HBsAg Qualitative II	Blood Donors Serum	3300	3 (0.09)	0 (0.00)	0 (0.00)	100.00 (3300/3300)	(99.89–100.00)
	Blood Donors Plasma	3318	8 (0.24)	5 (0.15)	0 (0.00)	99.85 (3313/3318)	(99.65–99.95)
	Total BD	6618	11 (0.17)	5 (0.08)	0 (0.00)	99.92 (6613/6618)	(99.82–99.98)
	Diagnostics	240	1 (0.42)	1 (0.42)	1 (100.00)	100.00 (239/239)	(98.47–100.00)
Alinity i HBsAg Next Qualitative	Blood Donors Serum	3181	4 (0.13)	3 (0.09)	0 (0.00)	99.91 (3178/3181)	(99.72–99.98)
	Blood Donors Plasma	3537	2 (0.06)	2 (0.06)	2 (100.00)	100.00 (3535/3535)	(99.90–100.00)
	Total BD	6718	6 (0.09)	5 (0.07)	2 (40.00)	99.96 (6713/6716)	(99.87–99.99)
	Diagnostics	240	1 (0.42)	1 (0.42)	1 (100.00)	100.00 (239/239)	(98.47–100.00)

IR = Initially Reactive, RR = Repeatedly Reactive, Conf. positive = Number of confirmed positive specimens by the corresponding Confirmatory assays, BD = blood donors.

Seventy-one recombinant mutant samples and 94 native mutant samples were evaluated, including mutants that specifically occur in regions with known mutational propensity. The mutants tested included thirty-nine samples with well documented mutations such as Gln-129-His, Met-133-Leu, Asp-144-Ala, Gly-145-Arg, and Thr-123-Ala or insertion mutants 122NT, 122RA, P142L+G145R, P142S+G145R. Furthermore, mutations at each of AA 121 through 124 and AA 112 through 117 are represented in the panel, as well as point mutations for more than half of AAs 187 to 207 mutations. Overall, mutants were detected on average about 7-fold higher with ARCHITECT / Alinity i HBsAg Next versus the ARCHITECT HBsAg Qual II assay.

Vermeulen et al. reported the first known case of transfusion-transmitted HBV infection by blood screened using individual-donation (ID)-NAT (Vermeulen et al., 2012). There are three stages where high assay sensitivity is needed: the first window period (pre-HBsAg & NAT), the second window period (post-HBsAg & NAT) and third window is in occult infection, as these donations are infectious. Alinity i HBsAg Next Qualitative seroconversion sensitivity was improved on average by approximately 6.5 days over the ARCHITECT HBsAg Qualitative II assay (maximum 43 days in one case) and was on average 7.9 days behind HBV ID-NAT. Excluding vaccine breakthrough panels 6272 and 11000, seroconversion sensitivity is improved on average by approximately 4.6

days (maximum 14 days in one case) compared to ARCHITECT HBsAg Qual II and is 6.7 days behind ID-NAT. Nevertheless, the HBsAg Next assays exhibit sensitivity approaching that of mini-pool NAT (Lou et al., 2018). As already published by Kuhns et al., 2019a, the HBsAg Next Qualitative assays exhibit improved early acute seroconversion sensitivity but also for late acute specimens, as exhibited by the testing of panels 13867–3482, 1807–3463, 26022–14518, and 43527–3453. These assays also demonstrate improvements in detection of HBsAg in vaccine breakthrough cases as exemplified by Panel 6272 and 11000 (Kuhns et al., 2019b). In both panels, the Alinity i HBsAg Next assay has significantly improved sensitivity, despite the presence of anti-HBs antibodies which frequently mask the presence of infection.

Assays launched so far exhibit either increased sensitivity or better specificity thus compromising one or the other. Specificity numbers for HBsAg assays vary. Package Insert data show initial/repeat specificity numbers of 99.51/ 99.91% for Siemens ADVIA Centaur Hepatitis B surface Antigen II (Atellica IM Hepatitis B surface Antigen II (HBsII) (Siemens) Package Insert: Rev. 02, 2017–12), 99.91/ 99.98% for Roche Cobas Elecsys HBsAg II (Elecsys HBsAg II (Roche Cobas) Package Insert: Rev. 2018-06, V 1.0) and 99.89/ 99.91% for ARCHITECT HBsAg Qualitative II (ARCHITECT HBsAg Qualitative II Package Insert: G3-4444/R05, 2013) respectively for blood donor specimen testing. The initial/ repeat specificity

Table 4

S/CO distribution in specificity populations.

Assay	Category	N	SD	Mean S/CO
ARCHITECT HBsAg Next Qualitative	Blood Donors Serum	3300	0.074	0.26
	Blood Donors Plasma	3318	0.064	0.23
	Total BD	6618	0.070	0.25
	Diagnostics	240	0.068	0.25
ARCHITECT HBsAg Qualitative II	Blood Donors Serum	3300	0.032	0.16
	Blood Donors Plasma	3318	0.030	0.16
	Total BD	6618	0.031	0.16
	Diagnostics	240	0.034	0.18
Alinity i HBsAg Next Qualitative	Blood Donors Serum	3181	0.084	0.32
	Blood Donors Plasma	3537	0.079	0.30
	Total BD	6718	0.082	0.31
	Diagnostics	240	0.069	0.32

BD= blood donors S/CO= Sample to Cut-off SD= standard deviation.

numbers obtained for ARCHITECT and Alinity i HBsAg Next Qualitative were at 99.76/99.95% and 99.94/99.96% and indicate that increased sensitivity of these assays does not impact specificity. Diagnostic specificity as outlined in the package inserts was at 100% for Siemens ADVIA Centaur, 99.88% for Roche Cobas Elecsys, and 99.93% for ARCHITECT HBsAg Qualitative II. In our study the new HBsAg Next Qualitative assays exhibited 100% specificity.

Furthermore, specificity of these high sensitive assays is not impacted as seen by the within assay sample carryover results due to using heat induction wash technology on both platforms.

Overall, the Alinity i/ ARCHITECT HBsAg Next Qualitative assays showed significantly improved sensitivity compared to the ARCHITECT HBsAg Qualitative II assay without compromising specificity. The parallel improvement of sensitivity and neutralization capacity of the Alinity i and ARCHITECT HBsAg Next Confirmatory assays allows laboratories the use of common reagents without having to rely on alternate methods (e.g. PCR) to confirm HBsAg positive specimens. The improved sensitivity of the HBsAg Next Qualitative / Confirmatory assays significantly improves detection and confirmation of HBsAg early and late infection, and Qualitative II Package Insert: Gd in a variety of mutants, occult infections and vaccine breakthrough cases even in the presence of protective levels of Anti-HBs antibodies.

With the improved sensitivity and specificity, the HBsAg Next Qualitative / Confirmatory assays can be used in both the blood screening as well as in the diagnostic setting, to permit safe and effective detection of HBV.

Acknowledgments

The authors thank Dr. A. van Weert and E. Bakker (Sanquin, National Screening Laboratory Amsterdam) for their participation and D. Kaleve for excellent coordination of the external study, as well as all internal and external laboratory technicians for participating in this study.

Ethical approval

Not required.

Funding sources

No grants were involved in supporting this work.

Declarations of interest

All authors of this publication are employees of Abbott Laboratories.

Credit Author contribution statement

E. Sickinger: Conceptualization; Data curation; Methodology; Formal analysis; Supervision; Writing – original draft; Writing – review & editing. **H.B. Braun:** Investigation; Data curation; Formal analysis; Writing – original draft; Writing – review & editing. **T. Meyer:** Data curation; Investigation; Formal analysis; Writing – original draft; Writing – review & editing. **K. Schmid:** Investigation; Data curation; Formal analysis; Writing – review & editing. **D. Daghfal:** Formal analysis; Writing – original draft; Writing – review & editing. **M. Oer:** Formal

analysis; Writing – review & editing; Supervision; Project administration. **J. Schultess:** Formal analysis; Writing – review & editing.

References

- ARCHITECT HBsAg Qualitative II Package Insert: G3-4444/R05, 2013.
- Atellica IM Hepatitis B surface Antigen II (HBsII) (Siemens) Package Insert: Rev. 02, 2017-12.
- Candotti D, Laperche S. Hepatitis B virus blood screening: need for reappraisal of blood safety measures? *Front. Med.* 2018;5:29.
- Coppola N, Alessio L, Gualdieri L, Pisaturo M, Sagnelli C, Caprio N, et al. Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infection in undocumented migrants and refugees in southern Italy, January 2012 to June 2013. *Euro Surveill* 2015; 20:30009.
- Elecsys HBsAg II (Roche Cobas) Package Insert: Rev. 2018-06, V 1.0.
- Enjalbert F, Krysztof DE, Candotti D, Allain J-P, Stramer S. Comparison of seven hepatitis B virus (HBV) nucleic acid testing assays in selected samples with discrepant HBV marker results from United States blood donors. *Transfusion* 2014;54:2485–95.
- Gerlich WH, Glebe D, Schuttler CG. Hepatitis B viral safety of blood donations: new gaps identified. *Ann blood* 2018;3:38.
- Global Hepatitis Report. 2017. Geneva: World Health Organization; 2017. <http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en>.
- Hampel A, Solbach P, Cornberg M, Schmidt RE, Behrens GM, Jablonka A. Current seroprevalence, vaccination and predictive value of liver enzymes for hepatitis B among refugees in Germany. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 2016;59:578–83.
- Harris BJ, Holzmayr V, Qureshi H, et al. Hepatitis B Genotypes and Surface Antigen Mutants Present in Pakistani Blood Donors. *PLOS ONE*. Epub 2017. <https://doi.org/10.1371/journal.pone.0178988>.
- Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. *Clin Infect Dis.* 1995;20:992–1000.
- Jonas G, Pelzer C, Beckert C, Hausmann M, Kapprell HP. Performance characteristics of the ARCHITECT anti-HCV assay. *JCV* 2005;34:97–103.
- Keating SM, Heitman JD, Wu S, Deng X, Stramer SL, Kuhns MC, et al. Cytokine and chemokine responses in the acute phase of hepatitis B virus replication in naïve and previously vaccinated blood and plasma donors. *JID.* 2014;209:845–54.
- Kuhns MC, Holzmayr V, McNamara AL, Sickinger E, Schultess J, Cloherty GA. Improved detection of early acute, late acute, and occult Hepatitis B infections by an increased sensitivity HBsAg assay. *JCV* 2019a;118:1–46.
- Kuhns MC, McNamara AL, Holzmayr V, Cloherty GA. Molecular and serological characterization of hepatitis B vaccine breakthrough infections in serial samples from two plasma donors. *Virology Journal* 2019b;16:43. <https://doi.org/10.1186/s12985-019-1154-4>.
- Lou S, Taylor R, Pearce S, Kuhns M, Leary T. An ultra-sensitive Abbott ARCHITECT assay for the detection of hepatitis B virus surface antigen (HBsAg). *JCV* 2018; 105:18–25.
- Martin L, Stramer S, Kuhns M, Schlauder G. Correlation of improved hepatitis B surface antigen detection limits with hepatitis B virus DNA nucleic acid test yield in blood donations. *Transfusion* 2012;52:2201–8.
- Mortensen E, Kamali A, Schirmer PL, Lucero-Obusan C, Winston CA, Oda G, et al. Are current screening protocols for chronic hepatitis B virus infection adequate? *DMID* 2016; 85:159–67.
- Popp C, Krams D, Beckert C, Buening C, Queirós L, Piro L, Luciani M, Roebbecke M, Kapprell HP. HBsAg blood screening and diagnosis: performance evaluation of the ARCHITECT HBsAg qualitative and ARCHITECT HBsAg qualitative confirmatory assays *DMID* 2011; 70: 479–485.
- Rodgers MA, Vallari AS, Harris B, et al. Identification of rare HIV-1 Group N, HBV AE, and HTLV-3 strains in rural South Cameroon. *Virology* 2017;504:141–51.
- Stramer S, Zou S, Notari E, Foster G, Krysztof D, Musavi F, et al. Blood donation screening for hepatitis B virus markers in the era of nucleic acid testing: are all tests of value? *Transfusion* 2012;52:440–6.
- Vermeulen M, Dickens C, Lelie N, Walker E, Coleman C, Keyter M, et al. Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk. *Transfusion* 2012;52:880–92.
- Vermeulen M, Coleman C, Mitchell J, Reddy R, Van Drimmelen H, Fickett T, et al. Sensitivity of individual-donation and minipool nucleic acid amplification test options in detecting window period and hepatitis B virus infections. *Transfusion* 2013;53: 2459–66.
- WHO Hepatitis B key facts. <https://www.who.int/news-room/fact-sheets/detail/hepatitis-b>, 2019.
- Yang R, Song G, Guan W, Wang Q, Liu Y, Wei L. The Lumipulse G HBsAg-Quant assay for screening and quantification of the hepatitis B surface antigen. *J. of Virol. Methods* 2016;228:39–47.

RUO

Read this insert carefully before performing the assay and make sure you are using the most recent version of the package insert. The reliability of assay procedures other than those described in this package insert cannot be guaranteed.

CL0008 R02

For research use only.
Not for use in diagnostic procedures.

READ HIGHLIGHTED CHANGES: Revised March 2020

Chemiluminescent Enzyme Immunoassay Reagent

Lumipulse® G HBcrAg Immunoreaction Cartridges set

■ NAME

Lumipulse G HBcrAg Immunoreaction Cartridges set
(Also referred to as 'HBcrAg Cartridges set' in this package insert)

■ INTENDED USE

For Research Use Only, with the LUMIPULSE G System for the quantitative detection of Hepatitis B virus core-related antigen in serum or plasma.

■ SUMMARY AND EXPLANATION OF THE ASSAY

Acute hepatitis B and chronic hepatitis B are conditions directly caused by HBV infection. The amount of HBV is significantly altered in the natural course of chronic hepatitis B. Furthermore, the amount of HBV correlates with its infectivity and patient prognosis. To measure HBV in liver tissue, detection of HBeAg, HBsAg or HBV-DNA in blood is commonly used. However, these methods contain methodological limitations. HBeAg cannot be detected when HBeAg forms immune complex with HBeAb. HBV-DNA detection methods are more cumbersome and time-consuming procedures. Antiviral agents such as lamivudine, adefovir dipivoxil or entecavir; inhibit DNA synthesis and release of enveloped virus particles, containing HBV-DNA. Therefore, HBV-DNA assays may show negative results even when HBV is present in liver tissue. The method of cccDNA (covalently closed circular DNA) analysis in liver biopsy specimens is effective, but as this is highly invasive it is not always preferred.

Lumipulse G HBcrAg assay is a novel CLEIA for the quantification of HBV. This assay is easy-to-use, does not use an invasive sample, has a wide measurement range and a high sensitivity. Three HBV correlated proteins are detected with this kit: 1)HBeAg, 2)HBsAg and 3)HBV pre-core protein (also known as p22cr). Different reports³⁻⁷ suggest that these HBV core-related proteins are present in blood of patients under treatment with antiviral agents and can be used to measure the amount of HBV in liver tissue as a complementary tool in the follow-up of patients with hepatitis B for the monitoring and possible discontinuation of treatment.

■ PRINCIPLES OF THE PROCEDURE

Lumipulse G HBcrAg is an assay system, including a set of immunoassay reagents, for the quantitative detection of HBcrAg in specimens based on CLEIA technology by a two-step immunoassay method on the LUMIPULSE G System

<Reaction protocol; 2-step mode>

Pretreatment of specimen

<This is a manual step>

HBcrAg in specimens are added to the pretreatment solution (containing detergent). Anti-HBcrAg antibody in specimens is inactivated in this step.

Reagent/Specimen Set

First reaction

Core-related antigens in specimens specifically binds to anti-HBcr antibodies on the particles, and antigen-antibody immunocomplexes are formed. 120 µL of pre-treated specimen or HBcrAg calibrator is pipetted to 230 µL of anti-HBcr antibodies-coated particles. Reaction solution is incubated at 37°C for 10 minutes after stirring.

Washing

Particles are washed and rinsed to remove unbound materials.

Second Reaction

Alkaline phosphatase(ALP)-labeled anti-HBcr antibodies specifically binds to HBcrAg of the immunocomplexes on the particles, and additional immunocomplexes are formed. 250µL of enzyme-labeled antibodies and antibody-coated particles are mixed. Reaction Solution is incubated at 37 °C for 10 minutes.

Washing

The particles are washed and rinsed to remove unbound materials.

Enzyme reaction

Substrate Solution is added and mixed with the particles. AMPPD contained in the Substrate Solution is dephosphorylated by the catalysis of ALP indirectly conjugated to particles.

Luminescence Measurement

Luminescence (at a maximum wavelength of 477 nm) is generated by the cleavage reaction of dephosphorylated AMPPD. The luminescent signal reflects the amount of HBcrAg.

AMPPD: 3-(2'-spiroadamantane)-4-methoxy-4-(3'-phosphoryloxy) phenyl-1, 2-dioxetane disodium salt

■ MATERIALS PROVIDED

Lumipulse G HBcrAg Immunoreaction Cartridges set:

IRC SET **REF** 231715

1. Lumipulse G HBcrAg Immunoreaction Cartridges: **IRC**

3 x 14 Tests

1)Antibody-Coated Particle Solution

(Liquid when used, 230 µL/Immunoreaction Cartridge)


Contains anti-HBcrAg monoclonal antibody (HB44, HB61, HB114)-coated particles, protein stabilizers (bovine) and chemical stabilizers in 0.2 M sodium chloride/Tris buffer. This solution contains gelatin and turns into gel at 15°C or lower. Preservative: sodium azide.

2)Enzyme-Labeled Antibody Solution

(Liquid, 350 µL/Immunoreaction Cartridge)

Contain alkaline phosphatase (ALP)-labeled anti-HBcrAg monoclonal antibody (HB91), ALP-labeled anti-HBcrAg monoclonal antibody (HB 110) and protein stabilizers

(bovine and rabbit) and chemical stabilizers in 0.037 M sodium chloride/Tris buffer. Preservative: sodium azide



2. Lumipulse G HBcrAg Calibrators: **CAL** Liquid, 1 x 2 Concentrations
HBcrAg Calibrator 0 kU/mL (1 x 1.5 mL)
HBcrAg Calibrator 10000 kU/mL (1 x 1.5 mL)
3. Lumipulse G HBcrAg Pretreatment solution: Liquid, 1 x 8 mL

■ MATERIALS REQUIRED BUT PROVIDED SEPARATELY

1. **Lumipulse G Substrate Solution:** Liquid, 6 x 50 mL **REF** 231166
6 x 100 mL **REF** 231197
Contains 0.2 mg/mL AMPPD as a substrate in diethanolamine buffer with a chemical stabilizer. Preservative: sodium azide.
2. **Lumipulse G Wash Solution:** Concentrate, 1 x 1000 mL **REF** 231173
3. **Sampling tips for LUMIPULSE SYSTEM** (rack packed): 10 x 96 tips **REF** 231579
Ready to use for G1200.
4. **Soda lime for LUMIPULSE SYSTEM:** 6 x 2 tubes **REF** 231562
Ready to use.

■ MATERIALS REQUIRED BUT NOT PROVIDED

1. Purified water
2. Control materials; refer to •QUALITY CONTROL
3. Micropipettes
4. Recommended sample cups: refer to the LUMIPULSE G System Operation Manual and SPECIMEN COLLECTION AND PREPARATION section.
5. Plastic microcup (Maximum volume of 0.3 mL or more).
6. Incubator for pre-treatment: pre-treatment reaction is processed at 56-64 °C.

■ WARNINGS AND PRECAUTIONS

For research use only.

1. SAFETY PRECAUTIONS

Please refer to the Safety Data Sheet (SDS) and product labelling for information on potentially hazardous components. The most recent SDS version is available on the website www.fujirebio.com.



Warning:
Pretreatment Solution

Hazard statements

H315 Causes skin irritation.

H319 Causes serious eye irritation.

EUH032 Contact with acids liberates very toxic gas.

EUH210 Safety data sheet available on request.

Precautionary statements

- | | |
|----------------|--|
| P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
| P302+P352 | IF ON SKIN: Wash with plenty of soap and water. |
| P305+P351+P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
| P332+P313 | If skin irritation occurs: Get medical advice/attention. |
| P337+P313 | If eye irritation persists: Get medical advice/attention. |
| P362+P364 | Take off contaminated clothing and wash it before reuse. |

2. PRECAUTIONS FOR HANDLING

- 1) No given tests can completely guarantee that infected materials are absent. To avoid risk of infection when using human specimens, wear disposable gloves to avoid direct contact to them, do not perform pipetting by mouth and follow appropriate biosafety practice.
- 2) The following reagents contain sodium azide as a preservative. Avoid contact with skin, eyes, or mouth.
Wash Solution: 1.0% (w/v) (before dilution)
Substrate Solution: 0.05% (w/v)
Antibody-Coated Particle Solution: 0.1 % (w/v)
Enzyme-Labeled Antibody Solution: 0.1 % (w/v)
Calibrators: 0.1% (w/v)
- 3) Lumipulse G Substrate Solution is an alkaline solution (pH 10). Handle carefully to avoid contact with skin, eyes, or mouth.
- 4) In the event of accidental contact of any reagent with skin, eyes, or mouth immediately rinse thoroughly with water and seek medical attention if necessary.

3. PRECAUTIONS FOR USE

- 1) Read through this package insert and the LUMIPULSE G System Operation Manual. Follow their instructions. Incorrect use of the reagents, instrument, or other consumables may result in unreliable data or accident hazard.
- 2) The HBcrAg Cartridges set (HBcrAg Cartridges/ HBcrAg Calibrators), Substrate Solution and Wash Solution are packed separately.
- 3) The HBcrAg Cartridges can be stored on-board the LUMIPULSE G System for a maximum of 30 days.
- 4) Do not use expired reagent.
- 5) To ensure measurement accuracy, always use freshly purified water.
- 6) Avoid using the reagents which may have been stored in an improper way.
- 7) Use new sampling tips and new sample cups as specified by the LUMIPULSE G System. Refer to the LUMIPULSE G System Operation Manual.
 - a. If large amounts of bubbles are present in the HBcrAg Calibrators, use a new calibrator bottle. Bubbles in a sample tube may cause sampling errors.
 - b. Bring the calibrators to room temperature (15-25 °C). Mix the calibrators by gentle inversion.
 - c. Start the HBcrAg assay immediately after sample setup to avoid evaporation of the specimen or HBcrAg Calibrators.
 - d. Avoid removing the Substrate Solution until it is time to replace it. The Substrate Solution cannot be used if it is contaminated with ALP. Use new gloves when replacing the Substrate Solution.

- e. Replace the soda lime on the LUMIPIJLSE G System according to the LUMIPLJLSE G System Operation Manual.

4. PRECAUTIONS FOR WASTE

- 1) The reagents contain sodium azide as a preservative, as previously described (See 2. PRECAUTIONS FOR HANDLING). Follow any applicable regulations for disposal. If flushing down the drain, use generous amount of water when discarding to prevent the formation of explosive metal azides.
- 2) Handle any medical waste produced by this assay in compliance with waste-related regulations in each country or region.
- 3) When any liquid such as specimen or assay waste is splashed, wipe and disinfect the whole area with an appropriate disinfectant such as sodium hypochlorite or glutaric aldehyde.

■ STORAGE INSTRUCTIONS

Store the following reagents at 2-10 °C.

DO NOT FREEZE.

1. Lumipulse G HBcrAg Immunoreaction Cartridges set
2. Lumipulse G Substrate Solution
3. Lumipulse G Wash Solution

When stored and handled properly, reagents remain stable until the expiration date. Refer to the expiration date shown on the immediate container labels.

■ INSTRUMENT

The reagents are designed for a fully automated chemiluminescent enzyme immunoassay (CLEIA) on the LUMIPULSE G System. Refer to the LUMIPULSE G System Operation Manual for further information.

■ REAGENT PREPARATION

1. Lumipulse G HBcrAg Cartridges

HBcrAg Cartridges are filled with Antibody-Coated Particle Solution and Enzyme-Labeled Antibody Solution. Peel off the transparent film from the Immunoreaction Cartridge case before installing the case for measurement.

2. Lumipulse G HBcrAg Calibrators

Bring to room temperature (15-25 °C). Mix the calibrators by gentle inversion. Pipette 200µL of calibrators into plastic tube and proceed to the manual pre-treatment step. Dispense the required amount of pre-treated calibrators into the sample cup, taking into account the dead volume which is at least 100 µL when using recommended sample cups with the LUMIPULSE G System.

3. Lumipulse G Substrate Solution

Use as is. Refer to the LUMIPULSE G System Operation Manual for installing into the LUMIPULSE G System and the package insert of Lumipulse G Substrate Solution for general information. Ensure the substrate cap seal is properly installed to avoid air entering the system.

4. Lumipulse G Wash Solution

Wash solution is concentrated. When using, dilute 10 x with purified water and mix thoroughly. The diluted Wash Solution shall be brought to room temperature (15-25 °C). Refer to the LUMIPULSE G System Operation Manual for loading into the LUMIPULSE G System and the package insert of Lumipulse G Wash Solution for general information.

5. HBcrAg pre-treatment solution

Bring to room temperature (15-25 °C) until deposition of detergent have been disappeared completely. Mix the pre-treatment solution evenly and confirm deposition is not precipitating at the bottom of the bottle. If mixing is not complete, deposition will be attached to the bottom of the bottle. Pre-treatment solution with this deposition cannot be used.

■ SPECIMEN COLLECTION AND PREPARATION

1. Specimens are brought to room temperature before pre-treatment. Dispense 150µL of specimens into plastic tubes. Add 150µL of HBcrAg Pre-Treatment solution to the plastic tubes and mix. Incubate at 60 +/-4 °C for 30 minutes and then leave the tube at room temperature for approximately 5minutes. After this measure the sample with Lumipulse G1200. Do not mix pre-treated specimens. Detergent in pre-treatment solution is likely to form bubbles and cause sampling error.

2. HBcrAg Calibrators are brought to room temperature before pretreatment. Dispense 200µL of Calibrators into plastic tubes. Add 200µL of HBcrAg Pre-Treatment solution to the plastic tubes and mix. Incubate at 60 +/-4 °C for 30 minutes and then leave the tube at room temperature for approximately 5minutes. After this measure the sample with Lumipulse G.

Do not mix pre-treated calibrators. Detergent in pre-treatment solution is likely to form bubbles and cause sampling error.

3. It is recommended to use fresh specimens.
4. Specimens may be stored at -20 °C.
5. Avoid successive freezing and thawing of specimens. Do not perform freeze/thaw cycle 6 or more times.
6. Measurements may be affected by erythrocytes, fibrin, or other unspecified precipitates or debris contained in specimens. Centrifuge specimens and/or remove these to ensure accurate results.
7. Avoid using heat-inactivated specimens.
8. Handle specimens carefully to avoid cross-contamination.
9. Human serum or plasma collected in dipotassium EDTA, sodium citrate, sodium heparin anticoagulant tubes may be used in the Lumipulse G HBcrAg. Follow the manufacturer's instructions for use. If the blood collection tubes other than the above are used, each laboratory should validate their applicability to the Lumipulse G HBcrAg.
10. Dispense pre-treated serum or plasma to the sample containers. Refer to the LUMIPULSE G System Operation Manual for the recommended sample cups and sample tubes.
11. The Lumipulse G HBcrAg uses 130 µL of pre-treated specimen. The dead volume is at least 100 µL and 250 µL when using recommended sample cups and sample tubes with the LUMIPULSE G System respectively. Therefore, the total sample volume required per assay is over 230 µL for sample cups and 380 µL for sample tubes. The size of the sample tubes for the LUMIPULSE G System is described in the LUMIPULSE G System Operation Manual.
12. When shipped, package and label specimens in compliance with any applicable regulations for the transport of clinical specimens and infectious substances.

■ ASSAY PROCEDURE

1. Refer to the LUMIPULSE G System Operation Manual and place the specimens and reagents needed for measurement in the specified locations.
2. Enter the assay requests of HBcrAg Calibrators and specimens.
3. Before starting the assay, confirm that the required amounts of HBcrAg Cartridges, Substrate Solution, diluted Wash Solution and Sampling tips are set on the LUMIPULSE G System.
4. Press the START key to start the measurement.

■ CALIBRATION

1. Required Calibrators
Lumipulse G HBcrAg Calibrators.
2. Calibration Procedure
Refer to 'REAGENT PREPARATION'. For subsequent procedures follow the LUMIPULSE G System Operation Manual.
3. When to calibrate
Calibration is performed in the following cases:
 - 1) On the first assay of the Lumipulse G HBcrAg
 - 2) When the HBcrAg Cartridges or substrate solutions are replaced with a different lot.
 - 3) When quality control results fall out of the range.
 - 4) When 30 days have elapsed since the previous calibration. Update the calibration data whenever needed.

4. The calibrator must be tested in duplicate.

■ RESULTS

The HBcrAg concentration of a specimen is automatically calculated from the luminescent signal, which is also automatically created from the calibration data.

1. Unit calculation
The result is indicated with the unit of kU/mL and LogU/mL in the LUMIPULSE G System. Substitute the value into LogU/mL. 1kU/mL is equal to 3LogU/mL

2. Measurement Range
3.0 LogU/mL - 7.0 LogU/mL (1.0 - 10000.0 kU/mL) Be careful that the LUMIPULSE G System may indicate down to 0.1 kU/mL of HBcrAg, which is out of the measurement range.

■ QUALITY CONTROL

1. Quality Control Material Preparation

Use control materials with at least two levels (e.g. negative or nonreactive and positive or reactive).

2. Quality Control Procedure

Refer to the package insert of control materials. Refer to Internal Quality Control Testing for further information! It is recommended to conduct Quality Control Testing at least once every 24 hours.

■ BIBLIOGRAPHY

1. Mizogami M, et al - Available only in Japanese
2. Sung JY, et al - Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. *Gastroenterology* 128: 1890-1897, 2005.
3. Kimura T, et al - Hepatitis B virus DNA-negative Dane particles lack core protein but contain a 22-kDa precore protein without C-terminal Arginine-rich domain. *Journal of Biological Chemistry*, 280: 21713-21719, 2005.
4. Kimura T, et al - Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. *Journal of Clinical Microbiology*, 40: 439-445, 2002.
5. Kimura T, et al - New enzyme immunoassay for detection of hepatitis B virus core antigen (HBcAg) and relation between levels of HBcAg and HBV DNA. *Journal of Clinical Microbiology*, 41: 1901-1906, 2003.
6. Rokuhara A, et al - Hepatitis B virus core and core-related antigen quantification in Chinese patients with chronic genotype B and C hepatitis B virus infection. *Journal of Gastroenterology and Hepatology*, 20: 1726-1730, 2005.
7. Tanaka E, et al - Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance. *Liver International*, 26: 90-96, 2006.
8. Nisizono I, et al - Rapid and sensitive chemiluminescent enzyme immunoassay for measuring tumor markers. *Clinical Chemistry*, 37: 1339-1644, 1991.

■ CONTACT



Fujirebio Inc.
2-1-1 Nishishinjuku, Shinjuku-ku, Tokyo 163-0410
Japan
TEL: +81-3-6279-0899

Distributor Fujirebio US Inc.
205 Great Valley Parkway, Malvern,
PA 19355 USA
Toll Free: +1 844-544-FRUS (3787)
TEL: +1 610-240-3800
FAX: +1 484-930-0543
Customersupport.US@fujirebio.com

Lumipulse is a registered trademark of Fujirebio Inc. in Japan and in Other countries.








Valencia, CA, USA

Assay Validation Report

Validation of an Electro-chemiluminescence Immunoassay by Roche for the Evaluation of Quantitative Hepatitis Be Antigen (HBeAg) in Serum on the Roche Cobas e411 Analyzer (S/N. AE1066-19)


This validation has been reviewed and performance of this method considered acceptable for patient testing

	Name and Title	Signature	Date
Authored by	David Strickler Ph.D. Senior Scientist Technical Services		17-SEP-2019
Reviewed by	Charlie Fix Global Director Scientific Harmonization		17 Sep 2019
Reviewed by	Nasrin Ramazani Director Laboratory Operations		19-Sept-2019
Reviewed by	Sona Manoukian Manager Chemistry/Special Chemistry		17 Sep 2019
Approved by	Marc Edwards, MD, MBA Senior Medical Director North America		19-Sept-2019
QA Review by	Héctor Alberto Repetto, BSc, CQA, MBA Manager Quality Assurance		

Q2CL_AP_280255VD.100.1

**Valencia, CA, USA****Assay Validation Report****Validation of an Electro-chemiluminescence Immunoassay by Roche for the Evaluation of Quantitative Hepatitis Be Antigen (HBeAg) in Serum on the Roche Cobas e411 Analyzer (S/N. AE1066-19)**

This validation has been reviewed and performance of this method considered acceptable for patient testing

	Name and Title	Signature	Date
Authored by	David Strickler Ph.D. Senior Scientist Technical Services		
Reviewed by	Charlie Fix Global Director Scientific Harmonization		
Reviewed by	Nasrin Ramazani Director Laboratory Operations		
Reviewed by	Sona Manoukian Manager Chemistry/Special Chemistry		
Approved by	Marc Edwards, MD, MBA Senior Medical Director North America		
QA Review by	Héctor Alberto Repetto, BSc, CQA, MBA Manager Quality Assurance		11 SEP 2018

Q2CL_AP_280255VD.100.1

Table of Contents

1.	Objective	4
2.	Assay Principle	4
3.	Materials and Method	4
3.1.	Sample/Specimen Description.....	4
3.2.	Materials	5
3.3.	Equipment.....	6
3.4.	FDA Status.....	6
3.5.	Method	6
3.6.	Reagent Preparation.....	6
4.	Assay Validation Parameters	6
4.1.	Precision.....	7
4.1.1	1x20 Intra-assay Precision	7
4.1.2	5x5 Inter-assay Precision	7
4.2.	Accuracy.....	7
4.2.1	Recovery of QC Samples	7
4.2.2	Matrix Specific Correlation Studies	8
4.3.	AMR Studies.....	8
4.3.1	AMR/Calibration Validation.....	8
4.3.2	Linearity of Dilution	9
4.4	Reference Range Verification	9
4.5	Stability	9
4.6	Carryover	9
4.7	Exceptional Conditions	10
5.	Documentation and Archiving	10
6.	Responsibilities	10
7.	Results.....	11
7.1	Precision.....	11
7.1.1	1x20 Intra-assay Precision	11

7.1.2	5x5 Inter-assay Precision	12
7.2	Accuracy	13
7.2.1	Recovery of QC Samples	13
7.2.2	Matrix Specific Correlation Studies	14
7.3	AMR Studies.....	17
7.3.1	AMR/Calibration Validation.....	17
7.3.2	Linearity of Dilution	18
7.4	Summary	19
7.5	Deviations/Exceptional Conditions.....	21
7.6	Recommendations	21
8.	Definitions and Abbreviations	21
8.1	Definitions.....	21
8.2	Abbreviations.....	23
9	References:	24

1. Objective

The objective of this study was to validate the performance characteristics of a Roche Electro-chemiluminescence Immunoassay for the quantitative determination of Hepatitis Be Antigen (HBeAg) in Serum at Q² Solutions Valencia on the Roche Cobas e411 Analyzer (S/N. AE1066-19).

2. Assay Principle

The HBeAg is an electrochemiluminescence immunoassay and uses monoclonal anti-HBe antibodies (mouse) for the HBeAg determination. This assay employs a sandwich principle with a total duration of 18 minutes.

1st incubation: HBe antigen from 35 µL sample, a biotinylated monoclonal HBeAg specific antibody, and a monoclonal HBeAg-specific antibody labelled with a ruthenium complex form a sandwich complex.

2nd incubation: After addition of streptavidin-coated microparticles, the complex becomes bound to the solid phase via interaction of biotin and streptavidin. The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell/ProCell M/ProCell II M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.

Results are determined automatically by the software by comparing the electrochemiluminescence signal obtained from the reaction product of the sample with the signal of the cut-off value previously obtained by calibration. The generated measuring signals in the form of cut-off index (COI) corresponds to the HBeAg concentration. HBeAg Quantitative is reported in IU/mL. The COI result from analyzer will be converted to a result in IU/mL

3. Materials and Method

3.1. Sample/Specimen Description

For the purpose of the Precision studies, one level of Roche Elecsys HBeAg Negative and one level of Roche Elecsys HBeAg Positive controls (Negative Lot# 370148, Positive Lot# 370149 Exp. 31-Jul-20) and one level of BioRad VIROTROL HBeAg (Lot# 113590 Exp. 28-Feb-20) control were used on the Roche Cobas e411 Analyzer (S/N. AE1066-19).

For the purpose of the Patient Correlation studies, forty anonymized serum samples (numbered C1 – C40) spanning the AMR as much as possible were prepared from anonymized remnant samples known to be positive for HBeAg, collected in the Quest Diagnostics Nichols Institute San Juan Capistrano laboratory and run using the Roche Elecsys HBeAg reagent. The samples were split into two aliquots at the Q² Solutions Valencia laboratory and one set was shipped to the Q² Solutions Singapore laboratory with both sets stored at or below -60°C.

For the purpose of the Analytical Measurement Range (AMR) Studies, a high unknown patient sample was used and assigned a target value by analyzing the unknown in duplicate. Serial dilutions were performed down to 100 – 150% of the manufacturer's low AMR limit of 0.142 IU/mL. The concentrations of quantitative serum HBeAg were 41.037, 20.519, 8.207, 4.104, 0.410, 0.205, and 0.137 IU/mL.

3.2. Materials

The materials used during the assay validation are given Table 1.

Table 1: Materials

Material	Preparation	Producer	Storage	Stability
<u>Validation Reagent:</u> Roche Elecsys HBeAg Catalog#: 11820583122 Lot: 33448505 Exp: 30-Nov-19	Ready for Use	Available from Roche Diagnostics UK	Refrigerated (2-8°C)	Unopened: (Up to expiration date at 2-8°C) On-system: (8 weeks at 2-8°C)
<u>Calibrator:</u> Roche Anti-HBeAg CalSet Levels 1 and 2 Catalog#: 11820583122 Lot: 33448505 Exp: 30-Nov-19	Ready for Use	Available from Roche Diagnostics UK	Refrigerated (2-8°C)	Unopened: (Up to expiration date at 2-8°C) Opened: (8 weeks at 2 - 8°C) On-system: (Up to 5 hours at 20 - 25°C)

Production Controls: PreciControl HBeAg (Positive and Negative) Catalog#: 11876376122 Lot: Negative 370148 Positive 370149 Exp: 31-Jul-20	Ready for Use	Available from Roche Diagnostics UK	Refrigerated (2-8°C)	Unopened: (Up to expiration date at 2-8°C) Opened: (8 weeks at 2 to 8°C) On-system: (Up to 6 hours at 20 to 25°C)
Production Control: BioRad VIROTROL HBeAg Catalog#: 00144 Lot: 11350 Exp: 28-Feb-20	Ready for Use	BioRad Laboratories	Refrigerated (2-8°C)	Unopened: (Up to expiration date at 2-8°C) Opened: (Up to 60 days at 2 to 8°C)

3.3. Equipment

Roche Cobas e411 Analyzer (S/N. AE1066-19).

3.4. FDA Status

Laboratory Developed Test (LDT).

3.5. Method

The method used in the validation was competitive chemiluminescent immunoassay, and assay manufacturer was Roche Diagnostics.

The validation studies listed below was performed in accordance with the guidelines listed in the Q2 Solutions Standard Operating Procedures:

- Q2 Solutions "Validation of Analytical Methods for Research Use" - Q2 Solutions eSOP Q2CL_OP_240032 Revision 3.
- Q2 Solutions "HBeAg Quantitative Assay on Roche Cobas E Analyzers" eSOP# Q2CL_AP_280255 Version 2 – September 2019.

3.6. Reagent Preparation

Materials were prepared as per manufacturer package insert and summarized [Table 1](#).

4. Assay Validation Parameters

The purpose of this assay validation is to describe the process and requirements of an infectious disease assay for serum quantitative HBeAg validation on the Roche Cobas e411 Analyzer (S/N. AE1066-19). The following studies were performed to evaluate precision, accuracy, and analytical measuring range (AMR).

The current Q² Solutions method for serum quantitative HBeAg assay on the Roche Cobas e411 Analyzer utilizes an 10.0% “Maximum Allowable Error”. Based on these guidelines, a Maximum Allowable Error of 10.0% is recommended for this assay and will be used as acceptance criteria to accept the studies performed in the validation.

4.1. Precision

One level of Roche Elecsys HBeAg Negative and one level of Roche Elecsys HBeAg Positive controls and one level of BioRad VIROTROL HBeAg control (listed in [Table 1](#)) intended for use in production was used for precision and accuracy (Section [4.2](#)) studies.

Precision was considered acceptable if the CV (%) is less than, or equal to the Maximum Allowable Error of 10.0%.

4.1.1 1x20 Intra-assay Precision

One level of Roche Elecsys HBeAg Negative, one level of Roche Elecsys HBeAg Positive, and one level of BioRad VIROTROL HBeAg controls were measured twenty times each for serum quantitative HBeAg in a single run (n = 20) on the Roche Cobas e411 Analyzer (S/N. AE1066-19).

Intra-assay precision was considered acceptable if the intra-assay %CV is within the Maximum Allowable Error of 10.0% stated in the Technical Method for quantitative HBeAg for established methods.

4.1.2 5x5 Inter-assay Precision

One level of Roche Elecsys HBeAg Negative, one level of Roche Elecsys HBeAg Positive, and one level of BioRad VIROTROL HBeAg controls were measured five times each for serum quantitative HBeAg in five separate runs (n = 25) on the Roche Cobas e411 Analyzer (S/N. AE1066-19) over 5 days.

Targets and 2 SD ranges were compared against the manufacturers targets for the Roche Elecsys HBeAg assay for acceptance of each analytical run.

Inter-assay precision was considered acceptable if the inter-assay %CV falls within the Maximum Allowable Error of 10.0% stated in the Technical Method for the quantitative HBeAg assay for established methods.

4.2. Accuracy

4.2.1 Recovery of QC Samples

Achieved control means (combined results from Intra and Inter Precision (n=45)) were compared against the manufacturers targets. Accuracy is demonstrated if recovery is within the Maximum Allowable Error (10.0%) stated in the Technical Methods for the quantitative HBeAg assay for established methods.

4.2.2 Matrix Specific Correlation Studies

Forty serum correlation samples evenly distributed over the AMR were measured in singlet in batches of 10 over 4 independent analytical runs (minimum of 2 days) for serum quantitative HBeAg on the Roche Cobas e411 Analyzer (S/N. AE1066-19). Resulting data for correlation samples (described Section 3.1) from the Q² Solutions Valencia Roche Cobas e411 Analyzer (S/N. AE1066-19) were compared to data from the Q² Solutions Singapore Roche Cobas e411 Analyzer (S/N. 091617). The following statistical analysis and acceptance criteria were used:

1. Least squares linear regression analysis (Microsoft Excel).
2. Coefficient of correlation (r) ≥ 0.975
3. Average absolute bias.
4. Average percent bias.

The correlation study was considered acceptable if the average %bias calculated from the Linear Regression Formula was less than, or equal to, the Maximum Allowable Error of 10.0%.

4.3. AMR Studies

4.3.1 AMR/Calibration Validation

The Q² Solutions global stated AMR for the serum quantitative HBeAg assay is 0.142-50.00 IU/mL. To verify the claimed AMR on the Roche Cobas e411 Analyzer (S/N. AE1066-19), a high unknown patient sample was used and assigned a target value by analyzing the unknown in duplicate. Serial dilutions were performed down to 100 – 150% of the manufacturer's low AMR limit of 0.142 IU/mL. Seven levels of diluted and undiluted high patient sample were each measured in duplicate and the achieved results compared to the corresponding assigned target values by linear regression. Where possible the lowest non-zero standard had a concentration within 100 – 150% of the lower AMR and the highest calibrator had a concentration within 80 – 120% of the upper AMR.

The mean value, SD, %CV, Absolute Bias and %Bias versus expected were calculated for each standard.

The AMR/Calibration Validation study will be considered acceptable if the achieved values for the standards used fall within 2x Maximum Allowable Error of the target values (Based on the recommended Maximum Allowable Error for the control value closest to the calibration validation material). The achieved value for the verifiers near the low end of the reportable range (LLOQ) can be greater than 2x Maximum Allowable Error from this limit but cannot exceed 40%.

4.3.2 Linearity of Dilution

To verify that accurate results can be obtained on diluted samples for serum quantitative HBeAg on the Roche Cobas e411 Analyzer (S/N. AE1066-19), a manual dilution study was performed. Four serum samples were prepared using previously analyzed patient samples with concentrations values of approximately 40 – 49 IU/mL.

Per the Q² Solutions eSOP (Q2CL_AP_280255), samples with quantitative HBeAg concentrations above the upper AMR limit of 50.00 IU/mL will be run manually diluted (1:80) on the Roche Cobas e411 Analyzer (S/N. AE1066-19). The upper CRR for the Roche Elecsys Quantitative HBeAg assay on the platform is 4000.00 IU/mL.

All four serum samples were manually diluted (1:80) and were tested along with undiluted samples in duplicate. Achieved results on the manually diluted samples were corrected for the dilution and values compared against the undiluted result of each sample to calculate the mean value, Absolute Bias, and %Bias versus expected (undiluted) sample. Results were considered acceptable if the bias observed was less than or equal to the proposed Maximum Allowable Error of 10.0%.

4.4 Reference Range Verification

HBeAg is an infectious disease and therefore the expected result would be “<0.142 IU/mL” for the quantitative HBeAg immunoassay.

4.5 Stability

Per the information provided by Roche Diagnostics, Quantitative HBeAg is stable in stored serum for the following time periods:

7 days at 20 to 25°C

11 days at 2 to 8°C

3 months at or below -15°C

4.6 Carryover

A carryover study was not performed. The Roche Cobas e411 instrument uses disposable pipette tips and sample cups, however the sample is aspirated into a common measuring cell from where potential carryover could occur. The Roche Cobas e411 (S/N. AE1066-19) was previously evaluated for potential carryover from samples containing unusually high levels of Troponin T. No carryover was observed. From this carryover study, it can be assumed that the instrument’s ability to prevent any significant carryover applies to other similar assays using the same instrument.

4.7 Exceptional Conditions

There were no exceptional conditions that occurred during the course of the assay validation execution.

5. Documentation and Archiving

Raw data was recorded in daily worksheets. The Senior Medical Director (or designee(s)) will have final review before this validation report is issued.

6. Responsibilities

The assay validation experiments were performed by Allison Gray, Senior Laboratory Associate. Data was reported by David Strickler, Senior Scientist. Review and approval were performed by Charlie Fix, Global Director Scientific Harmonization, Nasrin Ramazani, Laboratory Operations Director, and Sona Manoukian, Automated Chemistry Manager, and Héctor Alberto Repetto, QA Manager. Final review and approval were performed by Marc Edwards MD, MBA, Senior Medical Director.

7. Results

This assay validation document was prepared upon completion of the assay validation study. The raw data are documented in this Assay Validation Report as well as all of the performance characteristics, statistical analyses, summary and conclusions for quantitative HBeAg quantification in serum using the Roche Cobas e411 Analyzer (S/N. AE1066-19).

Results are reported in IU/mL throughout the Assay Validation Report.

7.1 Precision

7.1.1 1x20 Intra-assay Precision

One level of Roche Elecsys HBeAg Negative control, one level of Roche Elecsys HBeAg Positive control, and one level of BioRad VIROTROL HBeAg control material (given in [Table 1](#)) were each analyzed twenty times within one run for serum quantitative HBeAg on the Roche Cobas e411 Analyzer (S/N. AE1066-19). Data and achieved %CVs are given in Table 2.

Table 2: *1x20 Intra-assay Precision Data

Intra-assay Precision (Within-Run)			
Replicate	Roche Elecsys HBeAg Negative (IU/mL)	Roche Elecsys HBeAg Positive (IU/mL)	BioRad VIROTROL HBeAg (IU/mL)
1	0.027	2.82	0.240
2	0.027	2.97	0.244
3	0.029	2.86	0.240
4	0.029	2.86	0.226
5	0.026	2.93	0.218
6	0.024	2.81	0.233
7	0.031	2.83	0.238
8	0.028	2.87	0.240
9	0.028	2.85	0.233
10	0.027	2.78	0.226
11	0.028	2.78	0.238
12	0.026	2.85	0.238
13	0.029	2.81	0.238
14	0.027	2.81	0.235
15	0.028	2.81	0.218
16	0.028	2.74	0.235
17	0.029	2.85	0.242
18	0.030	2.79	0.233
19	0.029	2.85	0.242
20	0.028	2.81	0.235
n	20	20	20
Mean	0.028	2.83	0.235
SD	0.002	0.05	0.007
CV%	5.5%	1.8%	3.1%
Acceptance Criteria	10.0%	10.0%	10.0%
Pass/Fail	Pass	Pass	Pass

*Analysis date: 04-Sep-2019

The serum HBeAg results on the Roche Cobas e411 Analyzer (S/N. AE1066-19) were acceptable for the intra-precision study, with observed imprecision (CV%) for the Roche Elecsys HBeAg Negative, Roche Elecsys HBeAg Positive and BioRad VIROTROL HBeAg QC levels within the Maximum Allowable Error acceptance criteria of 10.0%.

7.1.2 5x5 Inter-assay Precision

One level of Roche Elecsys HBeAg Negative control, one level of Roche Elecsys HBeAg Positive control, and one level of BioRad VIROTROL HBeAg control material given in [Table 1](#) were analyzed five times each in five unique runs for serum quantitative HBeAg on the Roche Cobas e411 Analyzer (S/N. AE1066-19). Data and achieved %CVs are given for the Roche Elecsys HBeAg Negative, Roche Elecsys HBeAg Positive, and BioRad VIROTROL HBeAg QC Levels, in Tables 3 through Table 5 respectively.

Table 3: * Roche Elecsys HBeAg Negative Inter-Assay Precision

Negative Inter-assay Precision (Between-Run)						Summary	
Replicate/Run	1	2	3	4	5	Max Allowable Error	10.0%
1	0.031	0.029	0.028	0.029	0.028	Grand Mean	0.030
2	0.030	0.029	0.030	0.032	0.030	Pooled Intra-SD	0.001
3	0.031	0.029	0.032	0.032	0.032	Pooled Intra-CV%	4.7%
4	0.030	0.030	0.032	0.030	0.028	Pass/Fail	Pass
5	0.027	0.029	0.030	0.030	0.029	Overall Mean	0.030
Mean	0.030	0.029	0.030	0.031	0.029	Overall SD	0.001
Intra-SD	0.002	0.000	0.002	0.002	0.002	Overall %CV	4.7%
%CV	5.7%	1.4%	5.7%	5.2%	5.5%	Pass/Fail	Pass

*Analysis dates: Run 1, 16-Jul-2019; Run 2, 17-Jul-2019; Run 3, 18-Jul-2019; Run 4, 29-Jul-2019; Run 5, 30-Jul-2019

Table 4: * Roche Elecsys HBeAg Positive Inter-Assay Precision

Positive Inter-assay precision (Between-Run)						Summary	
Replicate/Run	1	2	3	4	5	Max Allowable Error	10.0%
1	3.05	2.91	2.92	3.16	2.93	Grand Mean	3.00
2	3.00	2.93	2.95	3.08	3.07	Pooled Intra-SD	0.09
3	2.59	2.99	3.01	2.99	3.03	Pooled Intra-CV%	3.1%
4	3.08	3.01	3.10	3.03	3.18	Pass/Fail	Pass
5	3.00	2.98	2.98	3.02	3.07	Overall Mean	3.00
Mean	2.94	2.97	2.99	3.06	3.06	Overall SD	0.11
Intra-SD	0.20	0.04	0.07	0.07	0.09	Overall %CV	3.7%
%CV	6.9%	1.4%	2.3%	2.1%	3.0%	Pass/Fail	Pass

*Analysis dates: Run 1, 16-Jul-2019; Run 2, 17-Jul-2019; Run 3, 18-Jul-2019; Run 4, 29-Jul-2019; Run 5, 30-Jul-2019

Table 5: * BioRad VIROTROL HBeAg Inter-Assay Precision

VIROTROL Inter-assay precision (Between-Run)						Summary	
Replicate/Run	1	2	3	4	5	Max Allowable Error	10.0%
1	0.224	0.222	0.222	0.226	0.229	Grand Mean	0.228
2	0.224	0.224	0.222	0.233	0.224	Pooled Intra-SD	0.005
3	0.226	0.229	0.231	0.233	0.222	Pooled Intra-CV%	2.0%
4	0.229	0.224	0.233	0.229	0.226	Pass/Fail	Pass
5	0.229	0.224	0.222	0.244	0.238	Overall Mean	0.228
Mean	0.226	0.225	0.226	0.233	0.228	Overall SD	0.005
Intra-SD	0.002	0.002	0.006	0.007	0.006	Overall %CV	2.4%
%CV	1.0%	1.1%	2.4%	2.9%	2.6%	Pass/Fail	Pass

*Analysis dates: Run 1, 29-Aug-2019; Run 2, 30-Aug-2019; Run 3, 02-Sep-2019; Run 4, 03-Sep-2019; Run 5, 04-Sep-2019

Template No.: Q2CL_TP_240038 Revision 2

Reference: Q2CL_AP_280255

Effective Date: 15Sep2018

Copyright © 2017, 2018 Q Squared Solutions Holdings LLC. All rights reserved. The contents of this document are Confidential and Proprietary to Q Squared Solutions Holdings LLC. Unauthorized use, disclosure or reproduction is strictly prohibited.

The serum HBeAg results on the Roche Cobas e411 Analyzer (S/N. AE1066-19) were acceptable for the inter-precision study, with observed imprecision (CV%) for the Roche Elecsys HBeAg Negative, Roche Elecsys HBeAg Positive and BioRad VIROTROL HBeAg QC levels within the Maximum Allowable Error acceptance criteria of 10.0%.

The serum HBeAg results on the Roche Cobas e411 Analyzer (S/N. AE1066-19) for the Roche Elecsys HBeAg Negative, Roche Elecsys HBeAg Positive, and BioRad VIROTROL HBeAg Controls were acceptable for the precision study, with intra- and inter-precision within the Maximum Allowable Error acceptance criteria of 10.0%. The results of the precision studies were acceptable.

7.2 Accuracy

7.2.1 Recovery of QC Samples

Combined means for the Roche Elecsys HBeAg Negative, Roche Elecsys HBeAg Positive, and BioRad VIROTROL HBeAg Control material listed in [Table 1](#), obtained from the intra- and inter-precision studies (n=45) were compared to the manufacturer's or Q² Solutions acceptability targets. For the BioRad VIROTROL HBeAg control the target mean was established by including all 25 data point values obtained from the inter-assay precision study and calculating the mean and 2 standard deviation control range (HBeAg Quantitative Assay on Roche Cobas E Analyzers) eSOP #Q2CL_AP_280255 Revision 2)). The achieved mean and bias calculated on the Roche Cobas e411 Analyzer (S/N. AE1066-19) for each QC level are summarized Table 6.

Table 6: *QC Recovery Data

Overall-assay Precision & Accuracy			
Levels	Roche Elecsys Negative (IU/mL)	Roche Elecsys Positive (IU/mL)	BioRad VIROTROL HBeAg (IU/mL)
n	45	45	45
Manufacturer's or Q ² Solutions Target Mean	0.031	3.13	0.228
Q ² Solutions Valencia Overall Mean	0.029	2.93	0.231
%Bias	-6.5%	-6.4%	1.3%
Acceptance criteria	10.0%	10.0%	10.0%
Pass/Fail	Pass	Pass	Pass

*Analysis dates: Roche 06-Jul-2019 – 30-Jul-2019 BioRad 29-Aug-2019 – 03-Sep-2019

For the evaluation of accuracy using the Roche Elecsys HBeAg Negative, Roche Elecsys HBeAg Positive, and BioRad VIROTROL HBeAg Control material, mean values achieved in Q² Solutions Valencia for all three levels of QC materials for the serum quantitative HBeAg assay on the Roche Cobas e411 Analyzer (S/N. AE1066-19) % bias vs. established manufacturer's targets were all within the Maximum Allowable Error acceptance criteria of 10.0%. Acceptable recovery of the Roche Elecsys HBeAg Negative, Roche Elecsys HBeAg Positive, and BioRad VIROTROL HBeAg QC material was demonstrated.

7.2.2 Matrix Specific Correlation Studies

Forty serum samples were assayed for quantitative HBeAg in singlicate on both the Q² Solutions Valencia Roche Cobas e411 Analyzer (S/N. AE1066-19) and on the Q² Solutions Singapore Roche Cobas e411 Analyzer (S/N. 091617). Results obtained from this correlation study (n = 40) are summarized in [Tables 7](#) through [8](#). Because of the large amount of data above the AMR, the data was re-examined using the patient samples with results above the AMR (>50.00 IU/mL).

-The remainder of this page left intentionally blank -

Table 7: All Correlation Data

ALL DATA				
Specimen	X	Y	Y-X	%(Y-X)/X
	Singapore Roche Cobas e411	Valencia Roche Cobas e411	Bias	%Bias
	(S/N. 091617)	(S/N. AE1066-19)		
	(IU/mL)	(IU/mL)		
C1	61.61	69.80	8.19	13.3%
C2	1.53	1.62	0.10	6.4%
C3	465.31	516.82	51.50	11.1%
C4	1.23	1.60	0.37	29.7%
C5	307.47	374.96	67.49	21.9%
C6	88.98	105.41	16.43	18.5%
C7	317.02	369.19	52.17	16.5%
C8	4.34	5.20	0.86	19.8%
C9	428.90	479.52	50.62	11.8%
C11	380.95	402.71	21.76	5.7%
C12	9.74	8.76	-0.98	-10.0%
C15	446.89	514.37	67.49	15.1%
C16	14.15	15.91	1.76	12.4%
C18	465.09	527.69	62.60	13.5%
C19	331.22	375.18	43.96	13.3%
C20	346.76	302.36	-44.40	-12.8%
C21	151.00	164.95	13.94	9.2%
C22	39.32	43.67	4.35	11.1%
C23	451.77	489.07	37.30	8.3%
C24	331.45	347.43	15.98	4.8%
C25	3.37	3.78	0.42	12.4%
C26	48.80	57.90	9.10	18.7%
C27	0.88	0.98	0.10	11.3%
C28	21.87	15.92	-5.94	-27.2%
C29	171.58	137.55	-34.03	-19.8%
C30	77.61	86.54	8.92	11.5%
C31	0.50	0.56	0.05	10.1%
C32	291.04	252.68	-38.36	-13.2%
C33	396.49	453.04	56.55	14.3%
C34	184.33	216.67	32.35	17.5%
C35	282.38	260.15	-22.23	-7.9%
C36	259.07	266.04	6.97	2.7%
C37	269.73	284.86	15.13	5.6%
C38	193.85	185.77	-8.08	-4.2%
C39	453.55	510.92	57.37	12.7%
C40	377.84	430.81	52.97	14.0%
n	36	36	Avg. %Bias	
Mean	213.27	230.01	7.9%	
SD	170.67	189.66	PASS	
Slope	1.102			
Intercept	-5.017			
r	0.992			
Total Allowable Error		15.0%		
AMR		0.142-50.00 IU/mL		
Sample ID	Dates of Analysis			
	Singapore	Valencia		
C1 - C10	28-Aug-19	9-Aug-19		
C11 - C20	28-Aug-19	12-Aug-19		
C21 - C30	29-Aug-19	13-Aug-19		
C31 - C40	30-Aug-19	14-Aug-19		
Samples below the Lower AMR <0.142 IU/mL				
C10	0.04	0.03	-0.01	-14.40%
C13	0.02	0.03	0.01	67.40%
C14	0.02	0.04	0.02	98.00%
C17	0.02	0.03	0.01	26.20%





Table 8: Data Within The AMR



Within The AMR				
Specimen	X	Y	Y-X	%(Y-X)/X
	Singapore Roche Cobas e411 (S/N. 091617) (IU/mL)	Valencia Roche Cobas e411 (S/N. AE1066-19) (IU/mL)	Bias	%Bias
C2	1.53	1.62	0.10	6.4%
C4	1.23	1.60	0.37	29.7%
C8	4.34	5.20	0.86	19.8%
C12	9.74	8.76	-0.98	-10.0%
C16	14.15	15.91	1.76	12.4%
C22	39.32	43.67	4.35	11.1%
C25	3.37	3.78	0.42	12.4%
C26	48.60	47.90	-0.90	-1.8%
C27	0.88	0.98	0.10	11.3%
C28	21.87	25.92	4.05	18.5%
C31	0.50	0.56	0.05	10.1%
n	11	11	Avg. %Bias	
Mean	13.25	14.17	7.0%	
SD	16.75	17.44	PASS	
Slope	1.036			
Intercept	0.443			
r	0.995			

Total Allowable Error	15.0%
AMR	0.142-50.00 IU/mL

Sample ID	Dates of Analysis	
	Singapore	Valencia
C1 - C10	28-Aug-19	9-Aug-19
C11 - C20	28-Aug-19	12-Aug-19
C21 - C30	29-Aug-19	13-Aug-19
C31 - C40	30-Aug-19	14-Aug-19

Sample above the Upper AMR >50.00 IU/mL				
C1	61.61	69.80	8.19	13.30%
C3	465.31	516.82	51.51	11.10%
C5	307.47	374.96	67.49	21.90%
C6	88.98	105.41	16.43	18.50%
C7	317.02	369.19	52.17	16.50%
C9	428.90	479.52	50.62	11.80%
C11	380.95	402.71	21.76	5.70%
C15	446.89	514.37	67.49	15.10%
C18	465.09	527.69	62.6	13.50%
C19	331.22	375.18	43.96	13.30%
C20	346.76	302.36	-44.4	-12.80%
C21	151.00	164.95	13.94	9.20%
C23	451.77	489.07	37.3	8.30%
C24	331.45	347.43	15.98	4.80%
C29	171.58	137.55	-34.03	-19.80%
C30	77.61	86.54	8.92	11.50%
C32	291.04	652.60	361.64	124.30%
C33	396.49	653.04	256.54	64.70%
C34	184.33	216.67	32.35	17.50%
C35	282.38	560.15	277.77	98.40%
C36	259.07	266.04	6.97	2.70%
C37	269.73	384.86	115.13	42.70%
C38	193.85	185.77	-8.08	-4.20%
C39	453.55	810.92	357.38	78.80%
C40	377.84	830.81	452.97	119.90%

Samples below the Lower AMR <0.142 IU/mL				
C10	0.04	0.03	-0.01	-14.40%
C13	0.02	0.03	0.01	67.40%
C14	0.02	0.04	0.02	98.00%
C17	0.02	0.03	0.01	26.20%



Results for the serum quantitative HBeAg assay from the Q² Solutions Valencia Roche Cobas e411 Analyzer (S/N. AE1066-19) vs. Q² Solutions Singapore Roche Cobas e411 Analyzer (S/N. 091617) (All Data) at Q² Solutions Valencia demonstrated acceptable agreement between the two instrument platforms. An R² value of 0.983 and an average bias of +7.9% was achieved which met the acceptance criteria of 10.0%.

Results for the serum quantitative HBeAg assay from the Q² Solutions Valencia Roche Cobas e411 Analyzer (S/N. AE1066-19) vs. Q² Solutions Singapore Roche Cobas e411 Analyzer (S/N. 091617) (Data Within The AMR) at Q² Solutions Valencia demonstrated acceptable agreement between the two instrument platforms. An R² value of 0.991 and an average bias of +7.0% was achieved which met the acceptance criteria of 10.0%.

The Q² Solutions Valencia laboratory Roche Cobas e411 Analyzer (S/N. AE1066-19) has demonstrated acceptable agreement of serum quantitative HBeAg results when compared against the Q² Solutions Singapore Roche Cobas e411 Analyzer (S/N. 091617). The acceptance criteria for Accuracy were met.

7.3 AMR Studies

7.3.1 AMR/Calibration Validation


A high unknown patient sample was used and assigned a target value by analyzing the unknown in duplicate. Serial dilutions were performed down to 100 – 150% of the manufacturer's low AMR limit of 0.142 IU/mL. Seven levels of diluted and undiluted high patient sample given in [Table 1](#) were each measured in duplicate within one run (for each, n = 2) on the Roche Cobas e411 Analyzer (S/N. AE1066-19) at Q² Solutions Valencia. Data and achieved Mean, %CV, absolute, and % biases are summarized in Table 9 and [Figure 1](#).

Table 9: *Analytical Measurement Range (AMR)

Level	Target	Rep 1	Rep 2	Mean	CV%	Absolute Bias	% Bias	Acceptance (± 2x Max Error %)	Pass/Fail
Neat	41.037	41.514	40.559	41.037	1.6%	0.000	0.0%	20.0%	Pass
1:2	20.519	19.219	19.125	19.172	1.6%	-1.347	-6.6%	20.0%	Pass
1:5	8.207	7.419	7.206	7.313	1.6%	-0.895	-10.9%	20.0%	Pass
1:10	4.104	3.836	3.770	3.803	1.2%	-0.301	-7.3%	20.0%	Pass
1:100	0.410	0.404	0.420	0.412	2.7%	0.002	0.5%	20.0%	Pass
1:200	0.205	0.218	0.218	0.218	0.0%	0.013	6.3%	20.0%	Pass
1:300	0.137	0.151	0.149	0.150	0.9%	0.013	9.5%	20.0%	Pass

*Analysis date: 22-Aug-2019

Figure 1: AMR Validation



The serum quantitative HBeAg assay performed on the Roche Cobas e411 Analyzer (S/N. AE1066-19) produced acceptably accurate and linear results throughout the Q² Solutions AMR (0.142 – 50.00 IU/mL) with all results meeting the acceptance criteria when compared to the expected target. Linear regression analysis showed acceptable agreement for Roche Cobas e411 Analyzer ($y = 0.993x - 0.287$, $R^2 = 0.999$). The achieved bias at all levels was within acceptable limits.

The Q² Solutions Valencia laboratory was able to demonstrate acceptable linearity throughout the Q² Solutions AMR of 0.142 – 50.00 IU/mL for the serum quantitative HBeAg assay on the Roche Cobas e411 Analyzer (S/N. AE1066-19).

7.3.2 Linearity of Dilution

To verify that accurate results can be obtained on diluted samples, a manual dilution study was performed using four serum samples with endogenous serum quantitative HBeAg levels with concentrations values of approximately 40 – 49 IU/mL. The four samples were diluted 1:80 and tested with undiluted (neat) sample in duplicate.

The achieved results were calculated by multiplying by the 1:80 dilution factor and compared against the undiluted result for the respective sample to calculate the % Bias as shown in [Table 10](#). Results were considered acceptable if the observed %Bias is within the acceptance criteria of 20.0%.

Table 10: *Linearity of Dilution

Sample ID	Dilution	Rep 1	Rep 2	Mean	% Bias	PASS/FAIL
S1	1 (Neat)	44.6	44.1	44.4	N/A	N/A
	80 (Manual)	49.6	51.2	50.4	13.6%	PASS
S2	1 (Neat)	48.8	44.7	46.8	N/A	N/A
	80 (Manual)	50.4	54.4	52.4	12.1%	PASS
S3	1 (Neat)	40.8	42.8	41.8	N/A	N/A
	80 (Manual)	39.2	39.2	39.2	-6.2%	PASS
S4	1 (Neat)	46.5	46.0	46.3	N/A	N/A
	80 (Manual)	42.4	44.0	43.2	-6.6%	PASS

*Analysis date: 22-Aug-2019

Linearity of dilution was demonstrated for achieved %Biases within the Acceptance Criteria ($\pm 20.0\%$) for maximum dilutions up to 1:80 for the quantitative HBeAg assay.

Samples testing above the upper AMR of 50.00 IU/mL for serum quantitative HBeAg may be diluted up to a maximum dilution of 1:80 and results as high as 4000.00 IU/mL reported after multiplying by the dilution factor.

AMR = 0.142 – 50.00 IU/mL

CRR = 0.142 – 4000.00 IU/mL

7.4 Summary

Table 11: Summary

Parameter	Acceptance Criteria	Observed Result
1x20 Intra-assay Precision	Roche Elecsys HBeAg Negative, Roche Elecsys HBeAg Positive and BioRad VIROTROL HBeAg Intra-assay within the Maximum Allowable Error of 10.0% stated in the Technical Method for the serum quantitative HBeAg assay.	Roche Cobas e411 Analyzer (S/N. AE1066-19) %CV Roche Elecsys HBeAg Negative Control: 5.5% %CV Roche Elecsys HBeAg Positive Control: 1.8% %CV BioRad VIROTROL HBeAg Control: 3.1%
5x5 Inter-assay Precision	Roche Elecsys HBeAg Negative, Roche Elecsys HBeAg Positive and BioRad VIROTROL HBeAg Inter-assay within the Maximum Allowable Error of 10.0% stated in the Technical Method for the serum quantitative HBeAg assay.	Roche Cobas e411 Analyzer (S/N. AE1066-19) %CV Roche Elecsys HBeAg Negative Control: 4.7% %CV Roche Elecsys HBeAg Positive Control: 3.7% %CV BioRad VIROTROL HBeAg Control: 2.4%

Recovery of QC Samples	Roche Elecsys HBeAg Negative, Roche Elecsys HBeAg Positive and BioRad VIROTROL HBeAg %Bias within the Maximum Allowable Error of 10.0% stated in the Technical Method for the serum quantitative HBeAg assay.	Roche Cobas e411 Analyzer (S/N. AE1066-19) %CV Roche Elecsys HBeAg Negative Control: -6.5% %CV Roche Elecsys HBeAg Positive Control: -6.4% %CV BioRad VIROTROL HBeAg Control: +1.3%
Correlation Study	Slope = 1.00 +/- 0.15 $r \geq 0.975$ Average %Bias $\leq 10.0\%$	Valencia Roche Cobas e411 Analyzer (S/N. AE1066-19) vs. Singapore Roche Cobas e411 Analyzer (S/N. 091617) (All Data) Slope: 1.102 r : 0.992 Average Bias: +7.9% Valencia Roche Cobas e411 Analyzer (S/N. AE1066-19) vs. Singapore Roche Cobas e411 Analyzer (S/N. 091617) (Within the AMR) Slope: 1.036 r : 0.995 Average Bias: +7.0%
AMR/ Calibration Validation	Each calibrator %Bias should be $\pm 2x$ Maximum Allowable Error of 10.0% of the target except at the LLOQ where $\leq 40\%$ is acceptable stated in the Technical Method for the serum quantitative HBeAg assay.	Roche Cobas e411 Analyzer (S/N. AE1066-19) %Bias Neat: 0.0% at 41.037 IU/mL %Bias 1:2: -6.6% at 20.519 IU/mL %Bias 1:5: -10.9% at 8.207 IU/mL %Bias 1:10: -7.3% at 4.104 IU/mL %Bias 1:100: +0.5% at 0.410 IU/mL %Bias 1:200: +6.3% at 0.205 IU/mL %Bias 1:300: +9.5% at 0.137 IU/mL AMR = 0.142-50.00IU/mL
Linearity of Dilution	Absolute %Bias $\leq 20\%$	Roche Cobas e411 Analyzer (S/N. AE1066-19) Manual Dilution Dilution 1 %Bias: +13.6% Dilution 2 %Bias: +12.1% Dilution 3 %Bias: -6.2% Dilution 4 %Bias: -6.6% Maximum Dilution Verified = 1:80 CRR = 0.142-4000.00 IU/mL

The assay validation for serum quantitative HBeAg demonstrated acceptable performance for precision, accuracy, and analytical measurement range studies on the Roche Cobas e411 Analyzer (S/N. AE1066-19) at Q² Solutions Valencia in accordance with the Assay Validation Plan.

7.5 Deviations/Exceptional Conditions

No deviations/Exceptional conditions from the validation plan were encountered during the course of the validation execution.

7.6 Recommendations

It is recommended that the Roche Cobas e411 Analyzer (S/N. AE1066-19) be used when analyzing levels of quantitative HBeAg in serum at Q² Solutions Valencia.

The results obtained during this validation study demonstrate that there are no clinically or statistically significant differences in serum quantitative HBeAg results produced on Roche Cobas e411 Analyzer (S/N. AE1066-19) at Q² Solutions Valencia when compared to the Q² Solutions Singapore Roche Cobas e411 Analyzer (S/N. 091617) at Q² Solutions Valencia.

The method can be used for pharmaceutical studies requiring the testing of patient samples for quantitative HBeAg in serum at Q² Solutions Valencia.

8. Definitions and Abbreviations

8.1 Definitions

Accuracy Closeness of the mean test results obtained by the method to the known true value of the analyte expressed as percent accuracy.

Accuracy (%): $\text{measured value/nominal value} \times 100$

Analytical Measuring Range (AMR): The range of results produced by a test system that a method can directly measure on the specimen without any dilution, concentration or any other pretreatment not part of the usual assay process, producing results that lie within the lowest limit of quantitation (LLOQ) and the upper linearity limits. Also known as the Direct Reportable Range or Linear Range or Dynamic Range.

Analytical Method:	The methodology or assay being verified to demonstrate it is suitable for its intended purpose.
Bias:	Deviation of a value from the nominal value
Calibration Standard:	A sample for which the analyte concentration is known.
Calibration Validation:	A study evaluating at least three levels of known (assayed or diluted) standards across the AMR for that analyte to verify the accuracy of a test.
Critical Reagents, Materials, or Instrumentation:	Specific components necessary to execute the method that, if substituted with similar components, may significantly alter the relevant performance characteristics of the method. Equivalency of substituted components must be demonstrated as acceptable through a documented qualification study or through re-validation of the method using "Validation of Analytical Methods" Q2CL_OP_240032.
Exceptional Condition:	Any impact/event that occurs during the course of the validation that impacts the validation outcome. This may be, but is not limited to, impact deviations from the approved method, validation acceptance criteria failures, multiple invalid results indicating a systematic problem.
Maximum Allowable %CV:	the maximum %CV that is to be used for QC acceptance criteria when both verifying new platforms for existing methods and new lots of QC material. Also used as "Maximum Allowable Error" for acceptance of bias in various accuracy studies.
Method Validation:	The process to confirm an Analytical Method performs as expected in the laboratory environment and is comparable to manufacturer claim(s). The primary location/originating laboratory must perform accuracy and precision over a period of time. Secondary locations must perform a split sample correlation with the primary location using "Technology Transfer of Analytical Methods" Q2CL_OP_240031.

Precision:	the closeness of agreement between a series of measurements obtained from multiple sampling of the same homogenous samples under the same prescribed conditions. Note: precision is not typically represented by a numerical value but is expressed quantitatively in terms of imprecision: the SD or %CV of the results in a set of replicate measurements. Also referred to as imprecision where the higher the imprecision, the higher the SD or %CV.
Quality Control (QC):	Quality Control sample is a neat or spiked sample in biological matrix which is used to monitor the performance of a bioanalytical method. The QC is adopted to assess the integrity and validity of the results of the samples analyzed in any batch.
Standard Deviation:	a statistic used to describe the distribution or spread in the data in a population (that is shown to have the shape of a normal Gaussian curve). SD squared gives a term called variance.
Maximum Allowable Error:	the amount of error that can be tolerated without compromising the clinical utility of the analytical result, or the maximum amount of error allowed for successful performance in proficiency testing.

8.2 Abbreviations

AMR	Analytical Measurement Range
CV	Coefficient of Variation
FDA	Food and Drug Administration
QC	Quality Control
SD	Standard Deviation
SOP	Standard Operating Procedure

9 References:

Product insert and relevant documentation regarding this assay validation summary.

- 9.1 Q² Solutions “Validation of Analytical Methods for Research Use” - Q² Solutions eSOP Q2CL_OP_240032 Revision 3.
- 9.2 Roche Diagnostics HBeAg Reagent (HBeAg) Kit Insert 2019-02 V1.0.
- 9.3 Q² Solutions “HBeAg Quantitative Assay on Roche Cobas E Analyzers” eSOP# Q2CL_AP_280255 Version 2 – September 2019.

0675 HBV surface antigen large and middle isoform composition are proportional to total HBsAg

MA Rodgers¹, AS Vallari¹, J Gersch¹, D Mbanya^{2,3}, Kaptue L⁴, Sauleda Oliveras S⁵, PA Shah⁶, TP Leary¹, GJ Dawson¹, DTY Lau⁶, GA Cloherty¹


¹Infectious Diseases Research, Abbott Diagnostics, Abbott Park IL, USA, ²University of Yaounde I, Yaounde, Cameroon, ³University of Bamenda, Bamenda, Cameroon, ⁴Universite des Montagnes, Bangangte, Cameroon, ⁵Banc de Sang I Teixits, Barcelona, Spain, ⁶Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School,

Contact Information:
Mary Rodgers
Abbott Diagnostics
100 Abbott Park Rd
Abbott Park IL 60064-6015
Email: mary.rodgers@abbott.com

Background

Diagnostic markers are needed to stratify HBV patients to determine an appropriate treatment plan. The relative abundances of isoforms of HBV surface antigen (HBsAg) have been proposed as novel biomarkers for staging infections and monitoring patients on therapy (Pfefferkorn et al, 2018). To evaluate the utility of HBsAg isoforms as HBV biomarkers, we developed prototype assays that specifically detect L-HBsAg (large) and M-HBsAg (middle) products of the S gene and determined the isoform composition of clinical specimens.

Figure 1. HBsAg isoforms




The PreS1, PreS2, and S open reading frames encode for HBV L-HBsAg, M-HBsAg, and S-HBsAg as depicted in panel A. The isoform compositions of non-infectious subviral particles and infectious Dane particles is shown in panel B. These ratios were established by a silver stained gel of particles purified from a single donor in 1984 (Heerman et al, 1984).

Methods

Prototype HBsAg isoform assays were developed on a fully automated chemiluminescent immunoassay instrument. Antibodies directed against the “a” determinant loop shared by all isoforms were coated on the solid phase to capture HBsAg-containing particles. Total (S-HBsAg), L-HBsAg, and M-HBsAg were detected with acridinium conjugated isoform-specific antibodies. Antibody specificity was confirmed by Western blot and assay specificity was confirmed using recombinant S-HBsAg and purified Dane particles. Three seroconversion panels, serial samples from HBeAg positive patients in the US on nucleoside analog (NA) therapy, and 284 HBsAg positive plasma donations from Cameroon, Spain, and the USA were evaluated with the prototype assays to determine isoform composition.

Figure 2. Prototype assay format




The format is shown in panel A and the isoform specificity of the detection antibodies was previously confirmed by immunoblots (Mimms et al, 1990) and is reproduced in panel B. Clones used in this study are in blue boxes.

Results

Table 1. Specificity controls


	L-HBsAg			M-HBsAg			Total HBsAg		
	RLU	S/N	% total	RLU	S/N	% total	RLU	S/N	IU/ml
Recombinant S-HBsAg	53	0.96	NA	50	0.96	NA	366859	6551	53
Purified Dane virions	733	13.33	0.15	183	3.52	0.04	488113	8716	81
Normal human plasma	55	1	NA	52	1	NA	56	1	0

Figure 3. Seroconversion panels




HBsAg positive specimens from acute/resolving (a and b) and chronic (c) seroconversion panels are shown. Dashed lines indicate 2.0 S/N, the assay cutoff for L-HBsAg, M-HBsAg, and Total HBsAg. Data are presented as signal to noise (S/N, left) or percentage of total HBsAg S/N (right) for timepoints with positive isoform S/N.

Figure 5. HBeAg comparison with isoform levels



Single timepoint specimens were categorized as HBeAg positive or negative and tested for HBsAg isoform levels (a) and DNA viral load (b).

Figure 4. Isoform composition of serial bleeds from patients on NA therapy.



The S/N (left) and percent baseline S/N (right) for total HBsAg, L-HBsAg, and M-HBsAg are plotted on the left y-axis and nucleic acid loads (RNA and DNA) are plotted on the right y-axis for three patients on NA therapy (a-c). Patient S3 became HBsAg negative after the last timepoint plotted and was HBeAg positive for all plotted timepoints. Patient E16 was HBeAg negative for the entire timecourse and E11 became HBeAg negative on bleed 5.

Figure 6. Single timepoint specimens





Figure 7. HBsAg isoform ratios



The L-HBsAg (A) and M-HBsAg (C) S/N for single timepoint specimens are compared to total HBsAg levels and DNA levels (B and C). HBeAg positive specimens are shown as red circles and HBeAg negative specimens are shown as black squares.

Conclusions

- Automated HBsAg isoform specific research assays were developed.
- The most reliable unit of measure was signal to noise (S/N). An isoform specific standard will be required for quantitative detection and inter-assay comparisons.
- The levels of L-HBsAg and M-HBsAg were proportional to total HBsAg in longitudinal samples from seroconversion panels and patients on NA therapy, despite fluctuations in other markers.
- Overall, the levels of isoforms followed the expected pattern: total > M > L
- A wide variability in isoform composition between different patients was observed in all sample types tested.
- L-HBsAg and M-HBsAg do not appear to provide an additional diagnostic benefit beyond the total HBsAg test for disease staging or monitoring response to treatment in routine clinical settings.

References

1. Pfefferkorn M, Bohm S, Schott T, et al. Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers. *Gut*. Nov 2018;67(11):2045-2053.
2. Heermann KH, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich WH. Large surface proteins of hepatitis B virus containing the pre-s sequence. *J Virol*. Nov 1984;52(2):396-402.
3. Mimms LT, Floreani M, Tyner J, et al. Discrimination of hepatitis B virus (HBV) subtypes using monoclonal antibodies to the PreS1 and PreS2 domains of the viral envelope. *Virology*. Jun 1990;176(2):604-619.
4. Invernizzi F, Vigano M, Grossi G, Lampertico P. The prognosis and management of inactive HBV carriers. *Liver Int*. Jan 2016;36 Suppl 1:100-104.

Financial Disclosures

This study was funded in part by Abbott Laboratories. MAR, AV, JG, MCK, TPL, GD, and GAC are employees and shareholders of Abbott Laboratories.

1. Background

Hepatitis B virus pregenomic RNA (HBV pgRNA) has been proposed as a potential circulating biomarker for the activity of covalently closed circular DNA (cccDNA) that is present in infected hepatocytes of HBV patients. HBV RNA is of particular interest in patients who are on nucleos(t)ide analog therapy as HBV DNA is generally low or undetectable in these patients [1]. There are an increasing number of studies [2-4] showing the utility of HBV RNA quantitation in monitoring the effectiveness of both experimental and standard of care therapies and it is being investigated as an endpoint for clinical trial effectiveness and therapy removal. We have previously reported on the development of a fully automated dual-target, quantitative assay for the measurement of HBV pgRNA (v1.0) with a lower limit of quantitation (LLOQ) of 1.65 log U/mL (~152 copies/mL) [5]. Here we report on a modified assay (v2.0) with increased overall precision, sensitivity (15-fold), and a limit of detection of ~10 HBV RNA copies/mL. Quantitated HBV RNA levels with the v2.0 assay were indistinguishable from v1.0.

2. Methods

- A Research Use Only (RUO) fully automated real-time PCR assay for the detection and quantitation of HBV RNA (v1.0) was developed for the Abbott m2000 (Abbott Molecular Diagnostics, Des Plaines, IL, USA) platform and previously described [5]. Briefly, targets in conserved regions of the HBV x and core genes are used to ensure robust detection in the presence of mutations, and the assay is standardized against a WHO secondary DNA standard. An internal control is included to detect PCR interference. Assay LLOQ was measured by Probit analysis to be 1.65 log U/mL (~152 copies/mL) using a 0.2 mL sample volume input and 95% detection threshold.
- Modifications were made to the reagent formulation, cycling parameters, and sample input volumes (0.6 mL) which improve analytical performance. Performance (linearity, sensitivity, standard deviation, and concordance) of the new assay (v2.0) was compared to v1.0. A patient sample with high levels of HBV RNA was selected from which a panel of 11 serial dilutions into negative human plasma was made. Target HBV RNA concentrations ranged from 1.00E6 log U/mL (~3.41E6 copies/mL) down to 3.13 U/mL (~10-11 copies/mL) and either 3 or 20 replicates at each dilution were tested with both assays. Longitudinal samples from 3 on-therapy patients were also tested.


Table 1: Comparison of precision and reported results with v1.0 and v2.0

Expected Concentration (log U/mL)	v1.0 Stdev (log U/mL)	v2.0 Stdev (log U/mL)	Δ v1.0-v2.0 Reported Result (log U/mL)
6.00	0.13	0.07	0.05
5.00	0.04	0.03	0.25
4.00	0.13	0.04	-0.05
3.00	0.13	0.03	0.01
2.30	0.20	0.04	-0.05
2.00	0.21	0.06	0.00
1.70	0.28	0.09	-0.14

Standard deviation is lower with v2.0 and reported results are within v1.0 standard deviation


3. Results

Figure 1. HBV RNA serial dilution panel shows increased sensitivity of v2.0 compared to v1.0




An HBV clinical sample was serially diluted to the expected concentrations shown on the x-axis and tested with (A) HBV RNA v1.0 and (B) HBV RNA v2.0 with the measured concentrations reported on the y-axis. Numbers above each concentration indicate the number of positive detections at each tested concentration.

Figure 2. HBV RNA v2.0 Linearity and comparison of reported results from v1.0 and v2.0



(A) Reported HBV RNA v2.0 results show strong linearity across the dynamic range of the assay. (B) Comparison of v1.0 and v2.0 quantitated HBV RNA results showing reported results are indistinguishable between the two versions.

Figure 3. HBV RNA v2.0 enhances detection and increases granularity in low copy longitudinal samples



Longitudinal HBV RNA results from 3 individual patients who were tested with HBV RNA v1.0 (green) and v2.0 (blue). Horizontal lines indicate v1.0 and v2.0 limits of detection.

4. Conclusions

- HBV RNA v2.0 is ~15 fold more sensitive than v1.0 and detected 100% (20/20) of tested replicates at 10 copies/mL concentration.
- Reported results are linear ($R^2=0.9995$) across the dynamic range of the v2.0 assay.
- Results reported by v2.0 are within the standard deviation of those reported by v1.0 showing good concordance between assay versions.
- Increased sensitivity of the HBV RNA v2.0 (0.6 mL) assay yields tangible increases in detected and quantifiable results in low RNA copy samples from patients on therapy.
- Increased precision of HBV RNA v2.0 leads to more granular visibility into HBV RNA changes in longitudinal samples.

Author Affiliations

¹Abbott Laboratories, Abbott Park, IL

²Abbott Molecular Diagnostics, Des Plaines, IL

³bioMONTR® Labs, Cary, NC

Contact Information:

Mark Anderson

100 Abbott Park Road

Abbott Park, IL 60064

Email: mark.anderson6@abbott.com

References

- Cloherty G, Butler E, Kuhns M. Serum Hepatitis B Virus RNA as a Potential Diagnostic Biomarker During Chronic Hepatitis B Virus Infection. *Clin Liver Dis*. **2019** Mar 29;13(3):90-92. doi: 10.1002/clid.774.
- Wu Y, Wen J, Tang G, Zhang J, Xin J. On-treatment HBV RNA dynamic predicts entecavir-induced HBeAg seroconversion in children with chronic hepatitis B. *J Infect*. **2021** Aug;30 S0163-4453(21)00447-3. doi: 10.1016/j.jinf.2021.08.044.
- Jarenlapnopparat A, Chayanupatkul M, Tangkijvanich P. Novel viral markers and the prediction of off-treatment relapse in chronic hepatitis B patients: A systematic review. *J Gastroenterol Hepatol*. **2021** Sep;36(9):2349-2362. doi: 10.1111/jgh.15516.
- Wang X, Chi X, Wu R, Xu H, Gao X, Yu L, Liu L, Zhang M, Tan Y, Niu J, Jin Q. Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment. *Virol J*. **2021** Jan 6;18(1):4. doi: 10.1186/s12985-020-01471-2.
- Butler EK, Gersch J, McNamara A, et al. Hepatitis B Virus Serum DNA and RNA Levels in Nucleos(t)ide Analog-Treated or Untreated Patients During Chronic and Acute Infection. *Hepatology* **2018**; 68(6): 2106-17.

Financial Disclosures

This study was funded in part by Abbott Laboratories. MA, MS, LD, KCL, and GC are employees and shareholders of Abbott Laboratories.

AM and DM are employees and owners of bioMONTR® Labs

Appendix 11 Protocol Amendment History

Clinical Study Protocol Amendment 1 – Summary of Changes

AB-729-201

AB-729 Subcutaneous Injection

**A RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY INVESTIGATING AB-729,
NUCLEOS(T)IDE ANALOGUE AND PEGYLATED INTERFERON ALFA-2A
TREATMENT IN SUBJECTS WITH CHRONIC HEPATITIS B INFECTION**

Initial Protocol; Version 1.0: 30 June 2021
Amendment 1; Version 2.0: 01 November 2021

Confidential Information of Arbutus Biopharma Corporation

PROTOCOL AMENDMENT SUMMARY OF CHANGES

All revisions from the original protocol (Version 1 dated 30 June 2021) to this protocol amendment 1 (Version 2.0 dated 01 November 2021) are described below. The corresponding specific changes to the protocol text are shown in a tracked-changes version of the protocol.

REVISION NO. 1:	Revised the Medical Monitor as well as the Sponsor's signatory.
General Description of Changes and Rationale:	<p>The Executive Director (Karen Sims, MD, PhD) title changed and is now Vice President, Clinical Development. The following text replaced the original wording:</p> <p>Name: Karen Sims, MD, PhD Title: Vice President, Clinical Development Arbutus Biopharma Corporation</p>
Protocol Section Affected:	Sponsor Approval Signatures page
REVISION NO. 2:	Clarified the discontinuation criteria for discontinuation of NA.
General Description of Changes and Rationale:	<p>The discontinue NA treatment criteria has been revised as below:</p> <ul style="list-style-type: none">• Alanine aminotransferase (ALT) $<2 \times$ upper limit normal (ULN), and• Undetectable HBV DNA, and• At least one of the following:<ul style="list-style-type: none">○ HBsAg undetectable (via conventional assay) for at least 24 weeks after the end of last dose of AB-729 treatment○ HBsAg <100 IU/mL at two consecutive visits at least 24 weeks after the end of last dose of AB-729 treatment○ HBsAb positive for at least 24 weeks after the end of last dose of AB-729 treatment
Protocol Section Affected:	Synopsis; 4.1 Overall Design; 4.4 Nucleos(t)ide Discontinuation Criteria.
REVISION NO. 3:	Clarified that PBMC collections are preferred to be prior to administration of AB-729 or Peg-IFN α -2a.

General Description of Changes and Rationale:	The Schedule of Activities was revised to include the following: <i>All laboratory assessments including clinical laboratory tests (safety assessments), virology, biomarker and PBMC collections should be drawn pre-dose (AB-729 or Peg-IFNα-2a) when applicable</i>
Protocol Section Affected:	1.3 Schedule of Activities.
REVISION NO. 4:	Clarified the follow-up visit schedules for early termination prior to Week 24
General Description of Changes and Rationale:	The Schedule of Activity tables were revised to include Early Termination visits, as well as a new Appendix added for the Schedule of Activities for Early Termination for the Lead-in Period.
Protocol Section Affected:	1.3 Schedule of Activities, Appendix 8.
REVISION NO. 5:	The upper limit of BMI was increased from ≤ 35 kg/m ² to ≤ 38 kg/m ² for inclusion into the study.
General Description of Changes and Rationale:	The inclusion criteria below for BMI was increased from ≤ 35 kg/m ² to ≤ 38 kg/m ² given prior experience with AB-729 and to allow more participant access to the study. 1. Body mass index (BMI) ≥ 18 kg/m ² and ≤ 38 kg/m ² .
Protocol Section Affected:	5.1 Inclusion Criteria
REVISION NO. 6:	An exclusion criterion was added for central nervous system disease per the Peg-IFN α -2a label.
General Description of Changes and Rationale:	Subjects will be excluded with known epilepsy or central nervous system dysfunction.
Protocol Section Affected:	5.2 Exclusion criteria

REVISION NO. 7:	The exclusion criterion for any known or suspected hypersensitivity or previous severe reactions was revised to include biologics such as vaccines.
General Description of Changes and Rationale:	<p>The exclusion criterion was revised as follows:</p> <p>Any known or suspected hypersensitivity or previous severe reactions to any of the constituents of AB-729 or Peg-IFNα-2a, <i>to biologics such as vaccines</i>, or a history of previous severe hypersensitivity reactions (i.e., anaphylaxis, Stevens-Johnson Syndrome, toxic epidermal necrolysis).</p>
Protocol Section Affected:	5.2 Exclusion criteria
REVISION NO. 8:	The exclusion criterion for poorly controlled diabetes mellitus subjects was clarified
General Description of Changes and Rationale:	<p>The exclusion criterion was revised as follows:</p> <p>Poorly controlled diabetes mellitus with whole blood hemoglobin A1c (HbA1c) $\geq 7.5\%$ or <i>and/or</i> Screening fasting plasma glucose of ≥ 126 mg/dL, confirmed by repeat</p>
Protocol Section Affected:	5.2 Exclusion criteria
REVISION NO. 9:	The exclusion criterion for any known or suspected hypersensitivity or previous severe reactions was revised to include biologics such as vaccines.
General Description of Changes and Rationale:	<p>The exclusion criterion was revised as follows:</p> <p>Previous <i>serious adverse events or Grade 4 adverse events due to prior</i> treatment with Peg-IFNα-2a are exclusionary.</p>
Protocol Section Affected:	5.2 Exclusion criteria
REVISION NO. 10:	Assessments and study visits were clarified for subjects who restart NA therapy

General Description of Changes and Rationale:	The table of Schedule of Activities for Subjects who Restart NA Therapy was revised to clarify study assessments and study visits.
---	--

Protocol Section Affected:	Appendix 9
----------------------------	------------

REVISION NO.11:	Corrections for typographical errors and omissions.
------------------------	---

General Description of Changes and Rationale:	The purpose of the changes is to correct typographical errors and to correct minor omission in the text.
--	--

Clinical Study Protocol Amendment 2 – Summary of Changes

AB-729-201

AB-729 Subcutaneous Injection

**A RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY INVESTIGATING AB-729,
NUCLEOS(T)IDE ANALOGUE AND PEGYLATED INTERFERON ALFA-2A
TREATMENT IN SUBJECTS WITH CHRONIC HEPATITIS B INFECTION**

Initial Protocol; Version 1.0: 30 June 2021
Amendment 1; Version 2.0: 01 November 2021
Amendment 2; Version 3.0: 17 June 2022

Confidential Information of Arbutus Biopharma Corporation

PROTOCOL AMENDMENT SUMMARY OF CHANGES

All revisions from the protocol amendment 1 (Version 2.0 dated 01 November 2021) to this protocol amendment 2 (Version 3.0 dated 17 June 2022) are described below. The corresponding specific changes to the protocol text are shown in a tracked-changes version of the protocol.

REVISION NO. 1: The visit schedule for Cohorts A1 and A2 was corrected to coincide with the Week 124 duration and the visit schedule for Cohorts B1 and B2 was also corrected to coincide with the Week 112 duration.

General Description of Changes and Rationale: The visit number was corrected for Cohorts A1 and A2 to the following: Subjects randomized to Cohorts A1 and A2 will have between 19 (through Week 100) and 28 32 (through Week 124) visits depending on whether they qualify for NA discontinuation. The visit number was corrected for Cohorts B1 and B2 to the following: Subjects randomized to Cohorts B1 and B2 will have between 16 (through Week 88) and 25 29 (through Week 112) visits depending on whether they qualify for NA discontinuation.

Protocol Section Affected: Synopsis, Section 4.1.2

REVISION NO. 2: The criteria for resuming NA therapy during the second follow-up period was revised.

General Description of Changes and Rationale: The following revisions were made to the criteria for resuming NA therapy:
Resumption of NA therapy during the second follow-up period should occur ~~in if any of the following situations~~ *scenarios occur* after discussion with the Sponsor Medical Monitor:

- Persistent ALT elevations $\geq 2 \times$ baseline, AND $\geq 2 - 5 \times$ ULN, AND HBV DNA > 2000 IU/mL for 12 weeks
- Persistent ALT elevations $\geq 2 \times$ baseline, AND $\geq 5 - 10 \times$ ULN, AND HBV DNA > 2000 IU/mL for 4 weeks
- *HBV DNA $> 20,000$ IU/mL regardless of ALT level, confirmed by repeat*
- ALT $> 10 \times$ ULN confirmed by repeat
- ALT $>$ baseline and $>$ ULN, AND:

- increased direct *or total* bilirubin $\geq 2 \times \text{ULN}$ and $\geq 2 \times >1.5 \text{ mg/dL}$ (~~or $>25 \mu\text{mol/L}$~~) from baseline confirmed by repeat, OR
- ~~increased~~ INR ~~from~~ *increase of* ≥ 0.5 from baseline, confirmed by repeat.

Protocol Section Affected: Section 4.4, Section 8.6, and Appendix 9

REVISION NO. 3: The requirement for HAV and HEV antibodies at screening were removed.

General Description of Changes and Rationale: Virology screening parameters for HAV and HEV are no longer required due to the occurrence of false-positives in cases of low clinical suspicion and confounding of the HAVAb test by prior vaccination and both tests by prior/resolved infection. Assessment of acute HAV or HEV infection will be made via clinical assessment of symptoms and liver function testing.

Protocol Section Affected: Table 1, Section 8.5.5.1, and Table 12

REVISION NO. 4: Two inclusion criteria were revised. The first was that the age was increased to include up to and including 60 years of age. Secondly, the NA therapy was revised to include switching criteria for TDF and TAF prior to Screening.

General Description of Changes and Rationale: Criterion #1 was revised to: Subjects must be 18 (or other appropriate age of consent) to ~~50~~ 60 years of age, inclusive. Criterion #8 was revised to: Subjects must have been receiving either TAF, TDF (or equivalent), or ETV consistently for ≥ 12 months prior to Day 1 and are willing to continue with the same NA treatment through the final study visit (*switching from TDF to TAF or vice versa at least 28 days prior to dosing Day 1 is permitted*). ~~Switching of NA therapy during this window (between 12 months prior to Day 1 and the final study visit) is not permitted.~~

Protocol Section Affected: Section 5.1

REVISION NO. 5: Two exclusion criteria were revised. The first was streamlining laboratory data for ANA, ASMA, and anti-LKM1 titers. The second was to revise AFP to $>10 \text{ ng/mL}$ from $>100 \text{ ng/mL}$

General Description of Changes and Rationale:	<p>Criterion #15 was revised to: Laboratory data (<i>such as positive ANA plus positive ASMA and/or anti-LKM1, confirmed by repeat</i>) and/or clinical signs or symptoms suggestive of autoimmune hepatitis., confirmed by repeat:</p> <p>a. ANA titer \geq 1:80 AND</p> <p>b. ASMA titer \geq 1:80, OR</p> <p>c. Anti-LKM1 titer \geq 1:40.</p> <p>Criterion #16 was revised to: AFP >100 ng/mL. For subjects with AFP results of 50 to 100 ng/mL, historical documentation of a liver ultrasound, computed tomography scan, or magnetic resonance imaging scan performed within 3 months prior to the first dose of study treatment to rule out HCC or other malignancy or liver abnormality must be provided</p>
Protocol Section Affected:	Section 5.2
REVISION NO. 6:	The complete and targeted physical examination schedule was added to coincide with the Schedule of Activities
General Description of Changes and Rationale:	A complete physical examination is required at Screening. A targeted physical examination can occur after Day 1 and will be based on any changes to the subject's health since the last visit.
Protocol Section Affected:	Table 1, Section 8.5.1
REVISION NO. 7:	Quantitative HBV DNA testing was clarified to include both local and central laboratory testing.
General Description of Changes and Rationale:	Quantitative HBV DNA testing can be performed locally in addition to central laboratory testing to facilitate more rapid results.
Protocol Section Affected:	Table 14
REVISION NO. 8:	A reference was updated to the Resistance Monitoring Plan.
General Description of Changes and Rationale:	The reference for the HBV RNA marker was updated to include a more recent citation.
Protocol Section Affected:	Appendix 11

REVISION NO. 9:	Resistance samples and PBMC samples are required.
General Description of Changes and Rationale:	The optional language was removed for resistance samples and PBMC samples since they are required.
Protocol Section Affected:	Table 1, Table 2, Table 3, Table 4, Table 5, and Table 13
REVISION NO. 10:	Additional secondary endpoints were added to the following objective that evaluates the proportion of subjects who experience clinical and/or viral relapse in the follow-up period after discontinuing NA therapy.
General Description of Changes and Rationale:	<p>The following 2 secondary endpoints were added to the following objective that evaluates the proportion of subjects who experience clinical and/or viral relapse in the follow-up period after discontinuing NA therapy</p> <ul style="list-style-type: none">• Proportion of subjects who have HBV DNA <LLOQ at each timepoint after discontinuation of NA therapy• Proportion of subjects who have HBsAg <100 IU/mL or <10 IU/mL at each timepoint after discontinuation of NA therapy
Protocol Section Affected:	Synopsis, Section 3
REVISION NO. 11:	Corrections for typographical errors and omissions.
General Description of Changes and Rationale:	The purpose of the changes is to correct typographical errors and to correct minor omission in the text.

INVESTIGATOR SIGNATURE PAGE

Study Protocol Number: AB-729-201

Study Title: A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects with Chronic Hepatitis B Infection

INVESTIGATOR'S STATEMENT

I understand that all information concerning the product supplied to me by Arbutus Biopharma Corporation (Arbutus) or their designee, in connection with this study and not previously published, is confidential information. This information includes the Investigator's Brochure, protocol (and applicable amendments), Case Report Forms, Pharmacy Manual, Study's PK/Laboratory Manual, and basic scientific data.

I will conduct the study per the protocol and I understand that any changes to the protocol must be approved in writing by Arbutus or their designee and by the IRB/EC before implementation, except where necessary to eliminate apparent immediate hazards to the study participants.

I confirm that I will report all adverse events following the regulations referenced in the protocol.

I confirm that I will conduct this study in conformance with the principles of the Declaration of Helsinki, Good Clinical Practices, and local law and regulations.

I confirm that I am informed of the need for records retention and that no data will be destroyed without the written consent of Arbutus.

By my signature below, I hereby attest that I have read, understood, and agree to abide by all conditions, instructions, and restrictions contained in this protocol (version as per page footer).

Investigator's Name (printed)

Investigator's Signature

Date